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Tigecycline, in vitro studies
P801
Addition of a biocatalytic oxygen-reducing agent
may be required in the absence of fresh media
(<12 hours old) when testing tigecycline using
broth microdilution
T. Stevens, B. Johnson, S. Bouchillon, J. Johnson, D. Hoban,
M. Dowzicky, P. Bradford (Schaumburg, Pearl River, USA)
Objectives: Tigecycline (TGC), a newglycylcycline antimicrobial
in development has demonstrated excellent in vitro activity
against Gram-positive and -negative pathogens. Recent reports
suggest that TGC MIC values, against some organisms, may be
elevated if broth used in microdilution panels is (>12 hours old
(aged). The NCCLS has tentatively recommended that testing of
TGC be performed in broth that is (<12 hours old (fresh). This
study looks at the difference between panels using fresh broth,
aged broth and broth with a biocatalytic oxygen-reducing agent
(BORA) added to compensate for any potential broth differences.
Materials and Methods: Testing was performed on approxi-
mately 120 organisms including: E. coli; K. pneumoniae;
M. catarrhalis; S. epidermidis; and S. pneumoniae. The BORA used
in this study is Oxyrase for Broth at 2% concentration. TIG
microdilution panels evaluated in this study include: panels and
aged broth without oxyrase (Aged); panels and aged broth with
oxyrase (AO); panels and freshbrothwithout oxyrase (Fresh); and
panels and fresh broth with oxyrase (FO). Panels and aged broth
were prepared by Microscan. Fresh broth was prepared inter-
nally. Each organism was tested on all four panel types. Quality
controls were performed using NCCLS approved ATCC strains.
Results: Combined test results showed an MIC correlation
(with in 1 log2 dilution) as follows: 97.5% between Fresh/AO;
85.6% between Fresh/Aged; 94.3% between FO/AO; and 87.9%
between FO/Aged. Quality controls ranges for FO, Fresh and
AO were all in compliance, but Aged panels were out of range
29.3% of the time.
Conclusion: The addition of a BORA to aged broth produced
results equivalent to fresh broth without a BORA.
P802
Global in vitro antibacterial activity of tigecycline
against methicillin-resistant and methicillin-
sensitive Staphylococcus aureus isolates from the
Tigecycline Evaluation Surveillance Trial (TEST)
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban,
M. Hackel, M. Person, M. Dowzicky (Schaumburg, Collegeville,
USA)
Objectives: Despite the introductionof newantimicrobials to treat
resistant gram-positive bacteria, Staphylococcus aureus continues to
be a therapeutic challenge for the clinician. Glycylcyclines are
showing the promise of signiﬁcant activity against many gram-
positive pathogens including methicillin-resistant S. aureus. Tige-
cycline, the ﬁrst glycylcycline to enter clinical trials, has shown
excellent activity against Staphylococcus spp. This study was
initiated to evaluate the in vitro activity of tigecycline as compared
with those of 9 comparator agents (ampicillin, amoxicillin-clavul-
anic acid, imipenem, ceftriaxone, levoﬂoxacin, minocycline, vanco-
mycin, linezolid, piperacillin-tazobactam) against S. aureus
including methicillin-resistant Staphylococcus aureus (MRSA) and
methicillin-sensitive Staphylococcus aureus (MSSA) from multi-
national evaluation centres in the TEST program.
Methods: A total of 1245 clinical isolates were identiﬁed to the
species level at each of 15 sites in 8 countries and conﬁrmed by the
central laboratory. Isolates were collected between January 2004
andNovember 2004.MICsweredeterminedby eachparticipating
laboratory using supplied broth microdilution panels from Dade
MicroScan. All testing was performed according to NCCLS
guidelines and manufacturer’s instructions.
Results: The MICs of tigecycline ranged from 0.06 to 1 mcg/mL
for all isolates of S. aureus. Tigecycline’s MIC50/MIC90 of 0.12/
0.25 mcg/mL, respectively, againstMSSAwassimilar to imipenem
and minocycline and 4/8 fold lower than the remaining compar-
ative agents. Tigecycline’s MIC50/MIC90 of 0.25/0.5 mcg/mL,
respectively, against MRSA was 8/4 fold lower than vancomycin,
2/4 fold lower thanminocycline and 4/8 fold lower than linezolid.
All isolates of S. aureus were inhibited by tigecycline at an MIC of
1 mcg/mL regardless of methicillin phenotype.
Conclusion: The in vitro activity of tigecycline was comparable
in all S. aureus tested regardless of methicillin phenotype.
Tigecycline activity against MRSA was more potent than all
antimicrobial agents tested in this study including imipenem,
minocycline, linezolid, and vancomycin.
P803
Tigecycline Evaluation Surveillance Trial (TEST)
– global in vitro antibacterial activity against
selected species of Enterobacteriaceae
B. Johnson, S. Bouchillon, T. Stevens, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, USA)
Background: Rapid increasing resistance in nosocomial patho-
gens has always been a challenge for clinicians and hospital
infection control. Tigecycline, a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent
expanded broad spectrum activity against most species of
Enterobacteriaceae as well as Gram positives, atypicals and
anaerobes. The TEST program determined the in vitro activity of
tigecycline compared to amikacin, ampicillin, imipenem, cefep-
ime, ceftazidime, ceftriaxone, levoﬂoxacin, minocycline and
piperacillin/tazobactam against members of Enterobacteriaceae
(mainly E. coli, Klebsiella spp., Enterobacter spp., and Serratia spp.)
collected from hospitals in North America, Europe and Asia.
Methods: A total of 3204 clinical isolates of Enterobacteriaceae
were identiﬁed to the species level at each participating site and
conﬁrmed by the central laboratory. Isolates were collected
throughout 2004. Minimum Inhibitory Concentration (MICs)
were determined by the local laboratory using broth microdi-
lution panels and interpreted according to NCCLS guidelines.
Results: Tigecycline’s activity was equivalent to imipenem
presenting a MIC50/MIC90 of 0.25/1 mcg/mL against all
strains of Enterobacteriaceae. In comparison to other antimicro-
bials tested, the MIC90 of 1 mcg/mL for tigecycline was also the
lowest being 8 fold lower than commonly prescribed broad
spectrum antimicrobials such as ceftriaxone, levoﬂoxacin, and
minocycline and 16 fold lower than ceftazidime and piperacil-
lin/tazobactam. The frequency of ESBL production among
K. pneumoniae and E. coli was found to be 10.3% and 2.2%,
respectively. Tigecycline inhibited >98% of all E. coli and
K. pneumoniae ESBL producers at an MIC of 2 mcg/mL.
Approximately 20% of Enterobacter spp. and Serratia spp.
presented resistance to third generation cephalosporins (ceftaz-
idime and ceftriaxone) suggestive of AmpC-type resistance.
Tigecycline also inhibited a majority of these isolates with an
MIC90 of 2 mcg/mL.
Conclusion: Tigecyclines in vitro activity was comparable to
the activity of a broad spectrum antimicrobial, carbapenem
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(imipenem), and greater than other commonly prescribed broad
spectrum agents tested in this study. The presented data suggest
that tigecycline may be an effective therapeutic option against
both susceptible strains of Enterobacteriaceae and multi-drug
resistant strains regardless of degree or type of resistance.
P804
Tigecycline Evaluation Surveillance Trial
(TEST) – in vitro antibacterial activity against
selected species of Enterobacteriaceae in the
United States
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban,
M. Hackel, M. Person, M. Dowzicky (Schaumburg, Collegeville,
USA)
Background: Tigecycline, a member of a new class of anti-
microbials (glycylcyclines), has been shown to have a potent
expanded broad spectrum activity against most species of
Enterobacteriaceae as well as gram-positive, atypicals and
anaerobes. The TEST program determined the in vitro activity
of tigecycline compared to amikacin, ampicillin, imipenem,
cefepime, ceftazidime, ceftriaxone, levoﬂoxacin, minocycline
and piperacillin/tazobactam against isolates of Enterobacteria-
ceae collected from hospitals across the USA.
Methods: A total of 2446 clinical isolates, collected in 2004, were
identiﬁed to the species level at each participating site and
conﬁrmed by the central laboratory. Minimum Inhibitory
Concentration (MICs) were determined by the local laboratory
using broth microdilution panels and interpreted according to
NCCLS guidelines.
Results: The efﬁcacy of all broad spectrum antimicrobial agents
still remain highly active against Enterobacteriaceae in theUnited
States. The susceptibility rates for amikacin, cefepime, ceftazi-
dime, ceftriaxone, imipenem, levoﬂoxacin, minocycline and
piperacillin/tazabactam are 99.3%, 97.5%, 89%, 92.2%, 98.8%,
85.5%, 85.7% and 91.8%, respectively. Tigecycline’s activity was
similar to imipenem presenting a MIC50/MIC90 of 0.25/1 mcg/
ml against all strains of Enterobacteriaceae. The frequency of
ESBL production amongK. pneumoniae andE. coliwas found to be
8.5% and 2.2%, respectively. Tigecycline successfully inhibited
>98% of all E. coli and K. pneumoniae ESBL producers at a MIC of
2 mcg/ml. It was also noticed unusual resistance to imipenem in
29 of these isolates. While still under more detailed analysis,
preliminarydatahave shown that tigecyclinepresented aMIC50/
MIC90 of 1/2 mcg/ml against these multi-resistant isolates.
Conclusion: Most of broad spectrum antimicrobial agents still
remain active against Enterobacteriaceae from the US. Tigecy-
cline’s activity was comparable to the activities of broad
spectrum antimicrobials and with greater activity against most
ESBL and AmpC producing isolates. Tigecycline also showed in
vitro activity against isolates that were intermediate or resistant
to imipenem, which in many instances is considered as a last
therapeutic option. The presented data suggest that tigecycline
may be an effective and reliable therapeutic option against both
susceptible strains of Enterobacterieaceae and multi-drug resist-
ant strains regardless of degree or type of resistance.
P805
Tigecycline Evaluation Surveillance Trial (TEST)
– In vitro antibacterial activity against
Gram-positive and Gram-negative pathogens
in the United States
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban,
M. Hackel, M. Person, M. Dowzicky (Schaumburg,
Collegeville, USA)
Background: Tigecycline, a member of a new class of antimicro-
bials (glycylcyclines), has been shown to have potent expanded
broad spectrum activity against most commonly encountered
Gram-positive and Gram-negative species, including anaerobic
pathogens responsible for community and hospital infections. The
TEST program determined the in vitro activity of tigecycline
compared to amikacin, ampicillin, imipenem, cefepime, ceftazi-
dime, ceftriaxone, levoﬂoxacin, minocycline and piperacillin/
tazobactam against gram negative rods in addition to linezolid,
penicillin and vancomycin for the gram positive species. Isolates
were collected fromhospitals in theUnited States throughout 2004.
Methods: A total of 4100 clinical isolates were identiﬁed to the
species level at each participating site and conﬁrmed by the cen-
tral laboratory. Minimum Inhibitory Concentration (MICs) were
determined by the local laboratory using supplied broth micro-
dilution panels and interpreted according to NCCLS guidelines.
Results: As shown in the table below, tigecycline’s activity was
similar to imipenem against Enterobacteriaceae. It inhibited
multi-resistant ESBL and AmpC producers with a MIC equal or
lesser than 2 mcg/ml. Tigecycline also showed in vitro activity
with a MIC90 2 mcg/ml against 29 imipenem resistant Entero-
bacteriaceae strains. Although similar to other classes of broad
spectrum antimicrobial agents against non-fermenters, tigecy-
cline was especially active against Acinetobacter spp. with the
lowest MIC90 of 2 mcg/ml. Tigecycline inhibited S. aureus with
MIC90 of 0.25 mcg/ml for both MSSA and MRSA isolates.
Against enterococci, tigecycline’s MIC90 was consistent regard-
less of vancomycin susceptibility.
Conclusion: Tigecycline’s in vitro activity was comparable or
greater than most commonly prescribed broad spectrum anti-
microbials. The presented data suggest that tigecycline may be
an effective and reliable therapeutic option against both sus-
ceptible common gram-positive and gram-negative pathogens,
including multi-drug resistant strains regardless of degree or
type of resistance.
Table for P805
Enterobacteriaceae (n=2,446) P. aeruginosa (n=390) Acinetobacter spp. (n=261) S. aureus (n=494) Enterococcus spp. (n=509)
Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90
Tigecycline 0.03–16 0.250 1 0.25–>16 16 >16 0.03–4 0.5 2 0.03–1 0.12 0.25 0.3–0.5 0.06 0.12
Amikacin 0.5–>64 2 4 £0.5–>64 4 8 £0.5–>64 4 32
Ampicillin 0.5–>32 >32 >32 4–>32 >32 >32 £0.5–>32 >32 >32 0.06–>16 16 >16 0.25–>16 1 >16
Cefepime 0.5–>32 0.5 1 £0.5–>32 8 32 £0.5–>32 16 >32
Ceftazidime 8–>32 8 16 £8–>32 £8 32 £8–>32 32 >32
Ceftriazone 0.06–>64 0.06 8 £0.06–>64 >64 >64 £0.06–64 64 >64 0.5–>64 8 >64 1–>64 >64 >64
Imipenem 0.12–>16 0.5 1 0.25–>16 1 8 £0.06–>16 0.5 16 0.12–>16 0.250 16 0.25–>16 1 >16
Levoﬂoxacin 0.008–>8 0.06 8 £0.008–>8 2 >8 0.015–>8 8 >8 0.06–>32 1 >32 0.5–>32 32 >32
Minocycline 0.5–>16 2 8 £0.5–>16 >16 >16 £0.5–>16 1 8 0.25–>8 0.25 0.25 0.25–>8 8 >8
Pip/tazobactam 0.06–>128 1 16 0.12–>128 4 128 £0.06–>128 32 >128 0.25–>16 4 >16 0.5–>16 2 >16
Penicillin 0.06–>8 >8 >8 0.5–>8 2 >8
Linezolid 0.5–4 2 2 0.5–>8 2 2
Vancomycin 0.25–4 0.5 1 0.25–>32 1 >32
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P806
Tigecycline Evaluation Surveillance Trial (TEST)
– In vitro antibacterial activity against Gram-
positive and Gram-negative pathogens in Europe
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban,
M. Hackel, M. Person, M. Dowzicky (Schaumburg, Collegeville, USA)
Background: Tigecycline, a member of a new class of anti-
microbials (glycylcyclines), has been shown to have potent
expanded broad spectrum activity against most commonly
encountered species responsible for community and hospital
acquired infections. The TEST program determined the in vitro
activity of tigecycline compared to amikacin, ampicillin, imipe-
nem, cefepime, ceftazidime, ceftriaxone, levoﬂoxacin, minocy-
cline, and piperacillin/tazobactam against gram negative rods
in addition to linezolid, penicillin, and vancomycin for the gram
positive species. Isolates were collected from hospitals located in
Germany, Italy, Spain, and United Kingdom throughout 2004.
Methods: A total of 1064 clinical isolates were identiﬁed to the
species level at eachparticipatingsite andconﬁrmedby the central
laboratory. Minimum Inhibitory Concentration (MICs) were
determined by the local laboratory using supplied broth micro-
dilution panels and interpreted according to NCCLS guidelines.
Results: As shown in the table below, tigecycline’s activity was
similar to imipenem against Enterobacteriaceae. It inhibited
multi-resistant ESBL and AmpC producers with MICs equal or
lesser than 2 mcg/ml. Although similar to other classes of broad
spectrum antimicrobial agents against glucose non-fermenters,
tigecycline was especially active against Acinetobacter spp.
presenting the lowest MIC90 of 1 mcg/ml. Tigecycline inhibited
S. aureus with a MIC90 of 0.25 mcg/ml regardless of sensitivity
or resistance to methicillin. The same results were noticed
against enterococci where tigecycline’s MIC90 of 0.25 mcg/ml
was consistent regardless of vancomycin susceptibility.
Conclusion: Tigecycline’s in vitro activity was comparable to or
greater than most commonly prescribed antimicrobials. The
presented data suggest that tigecycline may be an effective and
reliable therapeutic option against both aerobic gram-positive
and aerobic gram-negative bacteria, including multi-drug resist-
ant strains regardless of degree or type of resistance.
P807
Tigecycline Evaluation Surveillance Trial (TEST)
– In vitro antibacterial activity against Gram-
positive and Gram-negative pathogens in Asia
B. Johnson, S. Bouchillon, T. Stevens, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, USA)
Background: Tigecycline, a member of a new class of antimicro-
bials (glycylcyclines), has been shown to have potent expanded
broadspectrumactivityagainstmost commonlyencountered spe-
cies responsible for community and hospital acquired infections.
The TEST program determined the in vitro activity of tigecycline
compared to amikacin, ampicillin, imipenem, cefepime, ceftazi-
dime, ceftriaxone, levoﬂoxacin, minocycline and piperacillin/
tazobactam against gram negative rods in addition to linezolid,
penicillin and vancomycin for the gram positive species. Isolates
were collected from hospitals located in Asia throughout 2004.
Methods: Atotal of 424 clinical isolateswere identiﬁed to the spe-
cies level at each participating site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentration (MICs) were
determined by the local laboratory using supplied broth micro-
dilution panels and interpreted according to NCCLS guidelines.
Results: Tigecycline’s activity was similar to imipenem against
EnterobacteriaceaewithMIC50/MIC90of0.25/1 mcg/ml.Resist-
ance to third generation cephalosporin was found in 63.2% of E.
coli and 77.8% of K. pneumoniae consistent with ESBL phenotype.
Tigecycline inhibited ESBL and AmpC producers with MICs
equal or lesser than1 mcg/ml.Althoughsimilar to other classesof
broad spectrumantimicrobial agents against glucosenon-fermen-
ters, tigecycline was especially active against Acinetobacter spp.
presenting the lowest MIC90 of 1 mcg/ml. Tigecycline success-
fully inhibited S. aureuswithMIC90 of 0.25 mcg/ml regardless of
sensitivity or resistance to methicillin. Same phenomenon was
noticed against enterococci where tigecycline’s MIC90 of 0.12
mcg/ml was consistent regardless of vancomycin susceptibility.
Conclusion: Tigecycline’s in vitro activity was comparable to or
greater than most commonly prescribed antimicrobials. The
presented data suggest that tigecycline may be an effective and
reliable therapeutic option against both aerobic gram-positive
and aerobic gram-negative bacteria, including multi-drug resist-
ant strains regardless of degree or type of resistance.
P808
Tigecycline Evaluation Surveillance Trial (TEST)
– European in vitro antibacterial activity against
selected species of Enterobacteriaceae
B. Johnson, S. Bouchillon, T. Stevens, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, USA)
Background: Tigecycline, a member of a new class of antimicro-
bials (glycylcyclines), has been shown to have potent expanded
broad spectrum activity against most species of Enterobacteria-
ceae as well as gram-positive, atypicals and anaerobes. The TEST
program determined the in vitro activity of tigecycline compared
to amikacin, ampicillin, imipenem, cefepime, ceftazidime, ceftri-
axone, levoﬂoxacin, minocycline and piperacillin/tazobactam
against isolates of Enterobacteriaceae collected from hospitals in
Germany, Italy, Spain and United Kingdom.
Methods: A total of 627 clinical isolates, collected in 2004, were
identiﬁed to the species level at each participating site and
conﬁrmed by the central laboratory. Minimum Inhibitory
Concentration (MICs) were determined by the local laboratory
Table for P806
Enterobacteriaceae (n=627) P.aeruginosa (n=101) Acinetobacter spp. (n=74) S. aureus (n=116) Enterococcus spp. (n=146)
Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90
Tigecycline 0.03–4 0.250 1 0.5–>16 8 >16 £0.008–4 0.25 1 0.06–0.5 0.12 0.25 0.03–0.5 0.12 0.250
Amikacin 0.5–32 2 4 £0.5–16 4 8 £0.5–>64 4 >64
Ampicillin 1–>32 >32 >32 4–>32 >32 >32 £0.5–>32 >32 >32 0.06–>16 16 >16 0.25–>16 1 >16
Cefepime 0.5–>32 0.5 4 1–>32 4 32 £0.5–>32 16 >32
Ceftazidime 8–>32 8 32 £8–>32 £8 32 £8–>32 32 >32
Ceftriazone 0.06–>64 0.06 16 4–>64 >64 >64 0.12–>64 >64 >64 0.5–>64 4 >64 4–>64 >64 >64
Imipenem 0.25–4 0.5 1 0.5–>16 1 16 0.12–>16 0.5 16 0.12–>16 0.25 >16 0.25–>16 1 >16
Levoﬂoxacin 0.008–>8 0.06 8 0.03–>8 1 >8 0.015–>8 4 >8 0.06–16 0.25 8 0.25–>32 8 >32
Minocycline 0.5–>16 2 8 2–>16 >16 >16 £0.5–16 1 8 0.25–8 0.25 0.5 0.25–>8 8 >8
Pip/tazobactam 0.12–>128 1 8 £0.25–>128 4 128 £0.06–>128 16 >128 0.25–>16 0.5 >16 1–>16 4 >16
Penicillin 0.06–>8 >8 >8 1–>8 4 >8
Linezolid 1–4 2 4 1–>4 2 2
Vancomycin 0.5–2 1 1 0.5–2 1 2
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using supplied broth microdilution panels and interpreted
according to NCCLS guidelines.
Results: It was observed that the in vitro activity of all broad
spectrum antimicrobial agents still remains highly active against
Enterobacteriaceae in Europe. The susceptibility rates for amika-
cin, cefepime, ceftazidime, ceftriaxone, imipenem, levoﬂoxacin,
minocycline,andpiperacillin/tazobactamare99.8%,94.6%,84.8%,
87.6%, 100%, 86.1%, 84.5%, and 92.2%, respectively. Tigecycline’s
activity was similar to the most effective antimicrobial agent,
imipenem (100% susceptibility) presenting a MIC50/MIC90 of
0.25/1 mcg/ml against all strains of Enterobacteriaceae. The fre-
quency of ESBL production among K. pneumoniae and E. coliwas
found to be 21.7% and 2.4%, respectively. Tigecycline inhibited
100%of all ESBLproducingE. coli at aMIC of 0.5 mcg/ml and at a
MIC of 4 mcg/ml for ESBL producing K. pneumoniae. Approxi-
mately 30% of Enterobacter spp. and 6% of Serratia marcescens
presented resistance to third generation cephalosporins (ceftazi-
dime and ceftriaxone) suggestive of AmpC-type resistance.
Conclusion: Most of the broad spectrum antimicrobial agents
still remain active against European representatives of Entero-
bacteriaceae. Tigecycline’s in vitro activity was comparable to
the activities of all broad spectrum antimicrobials with greater
activity against ESBL and AmpC producing isolates with a MIC
90 of 2 mcg/ml. The presented data suggest that tigecycline may
be an effective and reliable therapeutic option against both
susceptible strains of Enterobacterieaceae and multi-drug resist-
ant strains regardless of degree or type of resistance.
P809
Tigecycline Evaluation Surveillance Trial
(TEST) – Global in vitro antibacterial activity
against Gram-positive and Gram-negative
pathogens
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban,
M.Hackel,M. Person,M.Dowzicky (Schaumburg, Collegeville, USA)
Background: Tigecycline, a member of a new class of anti-
microbials (glycylcyclines), has been shown to have potent
expanded broad spectrum activity against most commonly
encountered species responsible for community and hospital
acquired infections. The TEST program determined the in vitro
activity of tigecycline compared to amikacin, ampicillin, imipe-
nem, cefepime, ceftazidime, ceftriaxone, levoﬂoxacin, minocy-
cline, and piperacillin/tazobactam against gram negative rods
in addition to linezolid, penicillin, and vancomycin for the gram
positive species. Isolates were collected from hospitals in North
America, Europe and Asia throughout 2004.
Methods: A total of 6383 clinical isolates were identiﬁed to the
species level at eachparticipatingsite andconﬁrmedby the central
laboratory. Minimum Inhibitory Concentration (MICs) were
determined by the local laboratory using supplied broth micro-
dilution panels and interpreted according to NCCLS guidelines.
Results: As shown in the table below, tigecycline’s activity was
similar to imipenem against Enterobacteriaceae. It inhibited
multi-resistant ESBL and AmpC producers with a MIC equal or
lesser than 2 mcg/ml. Although similar to other classes of broad
spectrum antimicrobial agents against non-fermenters, tigecy-
cline was especially active against Acinetobacter spp. demonstra-
ting the lowest MIC90 of 2 mcg/ml. Tigecycline successfully
inhibited S. aureus with MIC90 of 0.25 mcg/ml regardless of
sensitivity or resistance to methicillin. The same results were
noticed against enterococci. Tigecycline’s MIC90 was consistent
regardless of vancomycin susceptibility.
Conclusion: Tigecycline’s in vitro activity was comparable to or
greater than most commonly prescribed antimicrobials. The
presented data suggest that tigecycline may be an effective and
reliable therapeutic option against both aerobic gram-positive
and aerobic gram-negative bacteria, including multi-drug resist-
ant strains regardless of degree or type of resistance.
P810
Tigecycline Evaluation Surveillance Trial (TEST)
– Global in vitro antibacterial activity against
selected species of Enterococcus spp.
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban,
M. Hackel, M. Person, M. Dowzicky (Schaumburg, Collegeville,
USA)
Background: Resistance to glycopeptides in enterococci was
ﬁrst recognized in the late 1980s, and since then has been a major
challenge to clinicians and infection control. Tigecycline, a
member of a new class of antimicrobials (glycylcyclines), has
been shown to have potent expanded broad spectrum activity
against most commonly encountered species responsible for
community and hospital acquired infections. The TEST program
determined the in vitro activity of tigecycline compared to
vancomycin, linezolid, ampicillin, imipenem, ceftriaxone, levo-
ﬂoxacin, minocycline, penicillin and piperacillin/tazobactam
against members of Enterococcus spp. collected from hospitals in
North America, Europe and Asia.
Methods: A total of 685 clinical isolates of Enterococcus spp. were
identiﬁed to the species level at each participating site and con-
ﬁrmed by the central laboratory. Isolates were collected through-
out 2004. Minimum Inhibitory Concentration (MICs) were
determined by the local laboratory using supplied broth micro-
dilution panels and interpreted according to NCCLS guidelines.
Results: Of 437 E. faecalis evaluated, resistance to vancomycin in
15 (3.4%) isolates was observed. These isolates were all suscept-
ible to linezolid and tigecycline. Tigecycline presented the lowest
MIC50/MIC90 (0.06/0.12 mcg/ml) among all antimicrobial
agents evaluated. Among 248 E. faecium, 50 (20.2%)were resistant
to vancomycin, of which three isolates were also resistant to
linezolid. Tigecycline also presented the lowest MIC50/MIC90
of 0.03/0.06 mcg/ml. Five isolates of vancomycin susceptible
Table for P809
Enterobacteriaceae (n=3,804) P. aeruginosa (n=449) Acinetobacter spp. (n=612) S. aureus (n=733) Enterococcus spp. (n=785)
Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90
Tigecycline 0.03–16 0.250 1 0.06–>16 8 >16 0.008–4 1 2 0.03–1 0.12 0.25 0.3–0.5 0.06 0.12
Amikacin 0.5–>64 2 4 £0.5–>64 4 8 0.5–>64 8 >64
Ampicillin 0.5–>32 >32 >32 4–>32 >32 >32 8–>32 >32 >32 0.06–>16 16 >16 0.25–>16 1 >16
Cefepime 0.5–>32 0.5 2 £0.5–>32 4 32 0.5–>32 32 >32
Ceftazidime 8–>32 8 16 £8–>32 £8 32 8–>32 >32 >32
Ceftriazone 0.06–>64 0.06 8 £0.06–>64 >64 >64 0.12–>64 >64 >64 0.5–>64 8 >64 1–>64 >64 >64
Imipenem 0.12–>16 0.5 1 0.25–>16 1 8 0.25–>16 1 16 0.12–>16 0.25 >16 0.25–>16 1 >16
Levoﬂoxacin 0.008–>8 0.06 8 £0.008–>8 2 >8 0.15–>8 >8 >8 0.06–>32 0.5 >32 0.25–>32 32 >32
Minocycline 0.5–>16 2 8 £0.5–>16 >16 >16 0.5–>16 1 8 0.25–>8 0.25 0.5 0.25–>8 8 >8
Pip/tazobactam 0.06–>128 1 16 0.12–>128 4 128 0.06–>128 64 >128 0.25–>16 2 >16 0.5–>16 4 >16
Penicillin 0.06–>8 >8 >8 0.5–>8 4 >8
Linezolid 0 5–4 2 2 0.5–>8 2 2
Vancomycin 0.25–4 1 1 0.25–>32 1 >32
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E. faecalis and one vancomycin susceptible E. faecium were non-
susceptible to linezolid. No abnormal resistance phenotype was
observed in other Enterococcus species tested.
Conclusion: Tigecycline’s in vitro activity was comparable to or
greater than most commonly prescribed antimicrobials. The pre-
sented data suggest that tigecycline may be an effective and reli-
able therapeutic option against Enterococcus spp. includingmulti-
drug resistant strains regardless of degree or type of resistance.
P811
Tigecycline Evaluation Surveillance Trial (TEST)
– Global in vitro antibacterial activity against
selected species of glucose non-fermenting
organisms
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban,
M. Hackel, M. Person, M. Dowzicky (Schaumburg, Collegeville, USA)
Background: Glucose non-fermenting gram negative rods are
known to be highly resistant in hospital settings and have
always been a challenge for clinicians and hospital infection
control. The degree or type of resistance may be due to several
sophisticated mechanisms such as production of broad spec-
trum beta-lactamases, efﬂux pumps and altered membrane
permeability, inactivating most classes of antimicrobials that are
available for treatment (cephalosporins, carbapenems, amino-
glycosides, ﬂuoruquinolones). Tigecycline, a member of a new
class of antimicrobials (glycylcyclines), has been shown to have
potent expanded broad spectrum activity against most species
of Enterobacteriaceae and selected species of non-fermenters, as
well as Gram positives, atypicals and anaerobes. The TEST
program determined the in vitro activity of tigecycline com-
pared to amikacin, ampicillin, imipenem, cefepime, ceftazidime,
ceftriaxone, levoﬂoxacin, minocycline and piperacillin/tazobac-
tam against members of Acinetobacter spp. and Pseudomonas
aeruginosa collected from hospitals in North America, Europe
and Asia.
Methods: A total of 2513 non-fermenting clinical isolates were
identiﬁed to the species level at each participating site and con-
ﬁrmed by the central laboratory. Isolates were collected through-
out 2004. Minimum Inhibitory Concentration (MICs) were
determined by the local laboratory using supplied broth micro-
dilution panels and interpreted according to NCCLS guidelines.
Results: The cephalosporins were ineffective towards A. bau-
mannii (n = 424). Tigecycline showed the lowest MICs against
A. baumannii with a MIC50/MIC90 of 0.5/2 mcg/ml, outper-
forming amikacin, 74.3% inhibition MIC50/MIC90 4/64, imipe-
nem, 79.5% MIC50/MIC90 0.5/16, and minocycline, 85.4%
MIC50/MIC90 1/8. Similar ﬁndings were found in other species
of the Acinetobacter genus.
Conclusion: The presented data suggest that tigecycline may be
an effective and reliable therapeutic option against strains of
Acinetobacter spp., including multi-drug resistant strains regard-
less of degree or type of resistance.
P812
United States in vitro antibacterial activity of
tigecycline against methicillin-resistant and
methicillin-sensitive Staphylococcus aureus
isolates from the Tigecycline Evaluation
Surveillance Trial (TEST)
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban,
M.Hackel,M.Person,M.Dowzicky (Schaumburg,Collegeville,USA)
Objective: Despite the introduction of new antimicrobials to
treat resistant gram-positive bacteria, Staphylococcus aureus
continues to be a therapeutic challenge for the clinician.
Glycylcyclines are showing the promise of signiﬁcant activity
against many Gram-positive pathogens including methicillin-
resistant S. aureus. Tigecycline, the ﬁrst glycylcycline to enter
clinical trials, has shown excellent activity against Staphylococcus
spp. This study was initiated to evaluate the in vitro activity of
tigecycline as compared with those of 9 comparator agents
(ampicillin, amoxicillin-clavulanic acid, imipenem, ceftriaxone,
levoﬂoxacin, minocycline, vancomycin, linezolid, piperacillin-
tazobactam) against S. aureus including methicillin-resistant
Staphylococcus aureus (MRSA) and methicillin-sensitive Sta-
phylococcus aureus (MSSA) from 23 US centres in the TEST
program.
Methods: A total of 794 clinical isolates were identiﬁed to the
species level at each of participating sites and conﬁrmed by the
central laboratory. Isolates were collected throughout 2004.
MICs were determined by each participating laboratory using
broth microdilution panels from Dade Microscan. All testing
was performed and interpreted according to NCCLS guidelines
and manufacturer’s instructions.
Results: Among the 794 isolates, 389 (49.0%) were found to be
resistant to methicillin (MRSA). Besides the cross resistance of
MRSA isolates to imipenem, ceftriaxone, penicillin, ampicillin,
and piperacillin/tazobactam, it was observed a high rate of non-
susceptibility to levoﬂoxacin (74.9%). No resistance was
observed against vancomycin and linezolid. The MICs of
tigecycline ranged from 0.03 to 1 mcg/mL for all isolates of S.
aureus, and tigecycline presented the lowest MIC50/MIC90 of
0.12/0.25 mcg/ml against MRSA isolates, being several folds
lower than all the comparator agents. The MSSA isolates
showed the expected proﬁle of high resistance to ampicillin
and penicillin. The only unusual pattern was the 20.4% non-
susceptibility to levoﬂoxacin. Tigecycline’s MIC50/MIC90 of
0.12/0.12 was also the lowest among all MSSA isolates.
Conclusion: The in vitro activity of tigecycline was comparable
in all S. aureus tested regardless of methicillin phenotype.
Tigecycline activity against MRSA was more potent than all
antimicrobial agents tested in this study including imipenem,
minocycline, linezolid, and vancomycin.
P813
Tigecycline Evaluation Surveillance Trial (TEST)
– United States in vitro antibacterial activity
against selected species of Enterococcus spp.
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban,
M. Hackel, M. Person, M. Dowzicky (Schaumburg,
Collegeville, USA)
Background: Resistance to glycopeptides in enterococci was
ﬁrst recognized in the late 1980s, and since then has been a major
challenge to clinicians and infection control. Tigecycline, a
member of a new class of antimicrobials (glycylcyclines), has
been shown to have potent expanded broad spectrum activity
against most commonly encountered species responsible for
community and hospital acquired infections. The TEST program
determined the in vitro activity of tigecycline compared to
vancomycin, linezolid, ampicillin, imipenem, ceftriaxone, levo-
ﬂoxacin, minocycline, penicillin and piperacillin/tazobactam
against members of Enterococcus spp. collected from hospitals in
the USA.
Methods: A total of 509 clinical isolates were identiﬁed to the
species level at each participating site and conﬁrmed by the
central laboratory. Isolates were collected throughout 2004.
Minimum Inhibitory Concentration (MICs) were determined by
the local laboratory using broth microdilution panels and
interpreted according to NCCLS guidelines.
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Results: Of 276 E. faecalis evaluated, it was observed resistance
to vancomycin in 8 (4.5%) isolates. These isolates were all
susceptible to linezolid and tigecycline. Tigecycline presented
the lowest MIC50/MIC90 (0.06/0.12 mcg/ml) among all anti-
microbial agents evaluated. As a typical proﬁle of E. faecalis,
ﬂuoroquinolone (levoﬂoxacin) and tetracycline (minocycline)
had limited activities against this species. Among 144 E. faecium,
35 (24.3%) were resistant to vancomycin, of which three isolates
were also resistant to linezolid. Tigecycline also presented the
lowest MIC50/MIC90 of 0.06/0.12 mcg/ml. Five isolates of
vancomycin susceptible E. faecalis and one vancomycin suscept-
ible E. faecium were non-susceptible to linezolid. No abnormal
resistance phenotype was observed in other Enterococcus species
tested.
Conclusion: Tigecycline’s in vitro activity was comparable to or
greater than most commonly prescribed antimicrobials. The
presented data suggest that tigecycline may be an effective and
reliable therapeutic option against Enterococcus spp. including
multi-drug resistant strains regardless of degree or type of
resistance.
P814
Tigecycline Evaluation Surveillance Trial (TEST)
– United States in vitro antibacterial activity
against selected species of glucose
non-fermenting organisms
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban,
M. Hackel, M. Person, M. Dowzicky (Schaumburg, Collegeville,
USA)
Background: Glucose non-fermenting Gram negative rods are
known to be highly resistant in hospital settings and have
always been a challenge for clinicians and hospital infection
control. The degree or type of resistance may be due to several
sophisticated mechanisms such as production of broad spec-
trum beta-lactamases, efﬂux pumps and altered membrane
permeability, inactivating most classes of antimicrobials that are
available for treatment (cephalosporins, carbapenems, amino-
glycosides, ﬂuoruquinolones). Tigecycline, a member of a new
class of antimicrobials (glycylcyclines), has been shown to have
potent expanded broad spectrum activity against most species
of Enterobacteriaceae and selected species of non-fermenters, as
well as Gram positives, atypicals and anaerobes. The TEST
program determined the in vitro activity of tigecycline com-
pared to amikacin, ampicillin, imipenem, cefepime, ceftazidime,
ceftriaxone, levoﬂoxacin, minocycline and piperacillin/tazobac-
tam against members of Acinetobacter spp. and Pseudomonas
aeruginosa collected from hospitals in the United States.
Methods: A total of 1687 clinical isolates were identiﬁed to the
species level at each participating site and conﬁrmed by the
central laboratory. Isolates were collected throughout 2004.
Minimum Inhibitory Concentration (MICs) were determined by
the local laboratory using broth microdilution panels and
interpreted according to NCCLS guidelines.
Results: Tigecycline’s activity against P. aeruginosa showed a
MIC90 of (16 mcg/ml. Towards A. baumannii (n = 849), which
cephalosporins were ineffective, Tigecycline showed the lowest
MIC50/MIC90 of 0.5/2 mcg/ml outperforming amikacin
MIC50/MIC90 4/32, imipenem MIC50/MIC90 0.5/16 and
minocycline MIC50/MIC90 1/8. Similar ﬁndings were found
in other species of Acinetobacter genus.
Conclusion: The presented data suggest that tigecycline may be
an effective and reliable therapeutic option against strains of
Acinetobacter spp., including multi-drug resistant strains regard-
less of degree or type of resistance.
P815
European in vitro antibacterial activity of
tigecycline against methicillin-resistant and
methicillin-sensitive Staphylococcus aureus
isolates from the Tigecycline Evaluation
Surveillance Trial (TEST)
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban,
M. Hackel, M. Person, M. Dowzicky (Schaumburg, Collegeville,
USA)
Objective: Despite the introduction of new antimicrobials to
treat resistant gram-positive bacteria, Staphylococcus aureus
continues to be a therapeutic challenge for the clinician.
Glycylcyclines are showing the promise of signiﬁcant activity
against many gram-positive pathogens including methicillin-
resistant S. aureus. Tigecycline, the ﬁrst glycylcycline to enter
clinical trials, has shown excellent activity against Staphylococcus
spp. This study was initiated to evaluate the in vitro activity of
tigecycline as compared with those of 9 comparator agents
(ampicillin, amoxicillin-clavulanic acid, imipenem, ceftriaxone,
levoﬂoxacin, minocycline, vancomycin, linezolid, piperacillin-
tazobactam) against S. aureus including methicillin-resistant
Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylo-
coccus aureus (MSSA) from 5 European centres in the TEST
program.
Methods: A total of 216 clinical isolates were identiﬁed to the
species level at each of participating sites and conﬁrmed by the
central laboratory. Isolates were collected throughout 2004.
MICs were determined by each participating laboratory using
broth microdilution panels from Dade Microscan. All testing
was performed and interpreted according to NCCLS guidelines
and manufacturer’s instructions.
Results: Among the 216 isolates, 76 (35.2%) were found to be
resistant to methicillin (MRSA). Besides the cross resistance of
MRSA isolates to imipenem, ceftriaxone, penicillin, ampicillin,
and piperacillin/tazobactam, it was observed that all of MRSA
isolates were also non-susceptible to levoﬂoxacin. No resistance
was observed against vancomycin and linezolid. The MICs of
tigecycline ranged from 0.06 to 0.5 mcg/mL for all isolates of
S. aureus, and tigecycline presented the lowest MIC50/MIC90
of 0.25/0.25 mcg/mL against MRSA isolates, being several folds
lower than all the comparator agents. The MSSA isolates showed
the expected proﬁle of high resistance to ampicillin and penicil-
lin. Opposite to MRSA isolates, MSSA presented very little
resistance to levoﬂoxacin (2.5%). Tigecycline’s MIC50/MIC90 of
0.12/0.25 was also the lowest among all MSSA isolates.
Conclusion: The in vitro activity of tigecycline was comparable
in all S. aureus tested regardless of methicillin phenotype.
Tigecycline activity against MRSA was more potent than all
antimicrobial agents tested in this study including imipenem,
minocycline, linezolid, and vancomycin.
P816
Tigecycline Evaluation Surveillance Trial (TEST)
– European in vitro antibacterial activity against
selected species of Enterococcus spp.
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban,
M. Hackel, M. Person, M. Dowzicky (Schaumburg, Collegeville,
USA)
Background: Resistance to glycopeptides in enterococci was
ﬁrst recognized in the late 1980s, and since then has been a major
challenge to clinicians and infection control. Tigecycline, a
member of a new class of antimicrobials (glycylcyclines), has
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been shown to have potent expanded broad spectrum activity
against most commonly encountered species responsible for
community and hospital acquired infections. The TEST program
determined the in vitro activity of tigecycline compared to
vancomycin, linezolid, ampicillin, imipenem, ceftriaxone, levo-
ﬂoxacin, minocycline, penicillin and piperacillin/tazobactam
against members of Enterococcus spp. collected from hospitals in
Germany, Italy, Spain and United Kingdom.
Methods: A total of 146 clinical isolates were identiﬁed to the
species level at each participating site and conﬁrmed by the
central laboratory. Isolates were collected throughout 2004.
Minimum Inhibitory Concentration (MICs) were determined by
the local laboratory using broth microdilution panels and
interpreted according to NCCLS guidelines.
Results: Of 82 E. faecalis evaluated, resistance to vancomycin in 3
(3.6%) isolates was observed. These isolates were all susceptible
to linezolid and tigecycline. Tigecycline presented the lowest
MIC50/MIC90 (0.12/0.25 mcg/ml) among all antimicrobial
agents evaluated. Among 40 E. faecium, 1 (5.0%) was resistant
to vancomycin. Tigecycline also presented the lowest MIC50/
MIC90 of 0.03/0.06 mcg/ml. No abnormal resistance phenotype
was observed in other Enterococci species tested.
Conclusion: Tigecycline’s in vitro activity was comparable to or
greater than most commonly prescribed antimicrobials. The
presented data suggest that tigecycline may be an effective and
reliable therapeutic option against Enterococcus spp. including
multi-drug resistant strains regardless of degree or type of
resistance.
P817
Tigecycline Evaluation Surveillance Trial (TEST)
– European in vitro antibacterial activity against
selected species of glucose non-fermenting
organisms
S. Bouchillon, T. Stevens, B. Johnson, J. Johnson, D. Hoban, M.
Hackel, M. Person, M. Dowzicky (Schaumburg, Collegeville, USA)
Background: Glucose non-fermenting gram negative rods are
known to be highly resistant in hospital settings and have
always been a challenge for clinicians and hospital infection
control. The degree or type of resistance may be due to several
sophisticated mechanisms such as production of broad spec-
trum beta-lactamases, efﬂux pumps and altered membrane
permeability, inactivating most classes of antimicrobials that are
available for treatment (cephalosporins, carbapenems, amino-
glycosides, ﬂuoruquinolones). Tigecycline, a member of a new
class of antimicrobials (glycylcyclines), has been shown to have
potent expanded broad spectrum activity against most species
of Enterobacteriaceae and selected species of non-fermenters, as
well as Gram positives, atypicals and anaerobes. The TEST
program determined the in vitro activity of tigecycline com-
pared to amikacin, ampicillin, imipenem, cefepime, ceftazidime,
ceftriaxone, levoﬂoxacin, minocycline and piperacillin/tazobac-
tam against members of Acinetobacter spp. and Pseudomonas
aeruginosa collected from hospitals in Germany, Italy, Spain, and
United Kingdom.
Methods: A total of 826 clinical isolates were identiﬁed to the
species level at each participating site and conﬁrmed by the
central laboratory. Isolates were collected throughout 2004.
Minimum Inhibitory Concentration (MICs) were determined by
the local laboratory using broth microdilution panels and
interpreted according to NCCLS guidelines.
Results: Tigecycline’s activity against P. aeruginosa showed a
MIC90 of (16 mcg/ml. The cephalosporins were ineffective
towards A. baumannii (n = 552). Tigecycline showed the lowest
MICs against A. baumannii MIC50/MIC90 of 0.25/1 mcg/ml,
outperforming amikacin MIC50/MIC90 4/>64, imipenem
MIC50/MIC90 0.5/16 and minocycline MIC50/MIC90 1/8. Sim-
ilar ﬁndings were found in other species of Acinetobacter genus.
Conclusion: The presented data suggest that tigecycline may be
an effective and reliable therapeutic option against strains of
Acinetobacter spp., including multi-drug resistant strains regard-
less of degree or type of resistance.
P818
Antimicrobial activity of tigecycline tested
against bacterial pathogens from intensive
care units
H. Sader, T. Fritsche, R. Jones (North Liberty, USA)
Objectives: To evaluate the antimicrobial activity of tigecycline
(TIG) and selected antimicrobials against bacterial pathogens
isolated from patients hospitalized in intensive care units (ICUs)
worldwide.
Methods: A total of 7129 were consecutively collected in >70
medical centres located in North America (3164), South America
(1465), Europe (2428) and the Asia–Australia region (72). The
isolates were collected from (no. of isolates/%): bloodstream
(5349/75%), respiratory tract (746/10%), skin/soft tissue (323/
5%), and urinary tract (182/3%) infections in the 2000–2004
period, and susceptibility tested by NCCLS broth microdilution
methods.
Results: The antimicrobial activity of TIG and the frequency of
occurrence of bacterial pathogens are summarized in the Table:
All Gram-positive pathogens (4817) were inhibited at <1 mg/L
of TIG. Resistance (R) to oxacillin was detected in 43% of SA and
84% of CoNS, and R to vancomycin was detected in 19% of
enterococci. TIG was very active against Enterobacteriaceae
(ENT; 1468) with a MIC90 <1 mg/L, except for Serratia spp. 10%
of E. coli and 30% of Klebsiella spp. showed an ESBL phenotype
while 28% of Enterobacter spp. were R to ceftazidime. 14% of
ENT showed R to ciproﬂoxacin. TIG and trimethoprim/sulfa-
methoxazole were the most active compounds against S. malto-
philia (MIC90, 2 and 1 mg/L respectively). TIG was also highly
active against ASP (MIC90, 1 mg/L), but PSA showed decreased
S to TIG (MIC90, 16 mg/L). Non-S to imipenem (MIC, >8 mg/L)
was observed in 16% of ASP and 31% of PSA isolates.
Conclusions: Isolates from ICU patients showed high rates of
antimicrobial R. The most alarming problems detected were
vancomycin R among enterococci, ESBL mediated beta-lactam R
and ﬂuoroquinolone R among ENT, and carbapenem R among
PSA and ASP. TIG exhibited potent in vitro activity against the
vast majority of clinically important pathogenic bacteria (except
PSA) isolated from ICU patients and may represent an excellent
option for the treatment of infections in this clinical environ-
ment.
MIC (mg/L) Cumulative % inhibited at (mg/L):
Organism (no. tested/% of total) 50% 90% 0.25 0.5 1 2 4
S. aureus (SA; 2,370/33) 0.25 0.5 85 99 100 - -
Enterococci (1, 082/15) £0.12 0.25 92 >99 100 - -
Coag-neg staphylococci (CoNS; 997/14) 0.25 0.5 74 97 100 - -
P. aeruginosa (PSA; 549/8) 8 16 <1 1 2 6 20
E. coli (533/8) 0.25 0.5 87 99 100 - -
Kiebsiella spp. (388/5) 0.5 1 35 79 93 98 100
Enterobacter spp. (285/4) 0.5 1 21 75 91 96 >99
b-haemolytic streptococci (143/2) £0.12 £0.12 100 - - - -
Acinetobacter spp, (ASP; 134/2) 1 2 21 37 67 96 99
S. pneumoniae (118/2) £0.12 £0.12 100 - - - -
Total (7,129) 0.25 2 68 84 89 91 94
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P819
Potency and spectrum of tigecycline tested
against an international collection (1999–2003) of
bacterial pathogens producing skin and soft
tissue infections
T. Fritsche, H. Sader, M. Stilwell, R. Jones (North Liberty, USA)
Objective: Tigecycline (TIG) is the sentinel representative of the
glycylcycline class to be developed as a parenteral agent
targeting bacterial pathogens responsible for pneumonia, intra-
abdominal sepsis and SSTI. The aim of this study was to
evaluate the activity and potency of TIG when tested against a
large collection of bacterial pathogens causing SSTI.
Methods: Consecutive, non-duplicate bacterial isolates (3,421
strains)were collected from 1999 to 2003 frompatients with docu-
mented community-acquired or nosocomial SSTI in >70 medical
centres participating in the TIG surveillance program in North
America (38.6%), Europe (54.0%), Latin America (3.7%) and the
Asia–Paciﬁc region (3.7%). All isolates were tested using NCCLS
broth microdilution methods against TIG and representative
comparator agents used for empiric and directed therapy of SSTI.
Results: SSTI pathogen rank order (top ten), potency and
cumulative inhibition rates for TIG are in the Table: All SA,
streptococci, enterococci, CoNS, KSP and EC were inhibited by
£2 mg/L of TIG, along with 98% of ASP and 96% of ENT. The
broad-spectrum of activity exhibited by TIG included tetracyc-
line resistant subsets as well as MRSA, VRE, and ESBL-produ-
cing strains. Only PM and PSA isolates were less susceptible
(MIC90 values at 8 and 16 mg/L, respectively).
Conclusions: Among the top ten-ranked pathogens producing
SSTI, 94% of isolates were inhibited by £2 mg/L of TIG and 98%
were inhibited by £4 mg/L (the current NCCLS breakpoint for
tetracyclines). TIGmay represent awelcome choice among newer
parenteral agents for the common Gram-positive and negative
pathogens producing serious SSTI given in vitro testing results,
thus warranting continued investigation for this indication.
P820
Tigecycline activity tested against 22,950
bloodstream infection isolates worldwide
R. Jones, H. Sader, M. Stilwell, T. Fritsche (North Liberty, USA)
Objective: To assess the activity of tigecycline (formerly
GAR936), a novel glycylcycline, against recent bloodstream
infection (BSI) pathogen isolates from six continents. Frequency
of clinical occurrence of these pathogens was determined and
their antibiograms assessed using NCCLS reference broth
microdilution methods.
Methods: A total of 22,950 strains were tested by the M7–A6
(2003) method with interpretations from M100–S14 (2004). A
tigecycline susceptible (S) breakpoint was deﬁned as £2 mg/L
for comparison purposes only, although £4 mg/L has been used
for tetracyclines. The rank order of pathogens was: S. aureus (SA;
34.2%), coagulase-negative staphylococci (CoNS; 14.1%), E. coli
(EC; 13.2%), enterococci (ENT; 12.7%), Klebsiella spp. (KSP;
5.3%), P. aeruginosa (PSA; 4.0%), Enterobacter spp. (EBS; 2.9),
beta-haemolyticstreptococci (BST; 2.8%); S. pneumoniae (SPN;
2.4%), and viridans group streptococci (VgS; 1.6%). More than 20
comparison agents were tested including tetracycline (TC) and
ciproﬂoxacin (CIP).
Results: BSI pathogens (Gram-positive and Enterobacteriaceae)
tested against tigecycline are shown in the table. Tigecycline was
consistently active against TC-resistant (R) strains (89–100% S
versus 45–90%). MIC50:% S results for other BSI species were:
P. mirabilis (4 mg/L:10), Acinetobacter spp. (0.5 mg/L:77), Serratia
spp. (1 mg/L:81), S. maltophilia (1 mg/L:77) and indole-positive
Proteae (1 mg/L:54). Tigecycline exhibited a broader spectrum
of activity against BSI isolates when compared to CIP, TC, older
aminoglycosides and imipenem. Tigecycline was not active
against PSA (MIC50, 8 mg/L; 4.0% of BSI isolates).
Conclusions: Tigecycline exhibited a wide spectrum of antimi-
crobial potency versus BSI isolates collected worldwide. Serious
infections in nosocomial environments should beneﬁt from
tigecycline among the investigational Phase 3 agents focused on
R strains.
P821
Evaluation of the in vitro activity of tigecycline
against Gram-negative anaerobic bacteria
A. Katsandri, J. Papaparaskevas, A. Pantazatou,
L.S. Tzouvelekis, G.L. Petrikkos,N.J. Legakis,A.Avlamis on behalf
of The Hellenic Study Group on Gram-Negative Anaerobic Bacteria
Objectives: The evaluation of the in vitro activity of tigecycline
in comparison to tetracycline, penicillin, piperacillin ( tazobac-
tam, cefoxitin, clindamycin, metronidazole and imipenem
against recently isolated Gram-negative anaerobic bacteria.
Materials and methods: A total of 185 Gram-negative anaerobic
clinical strains (116 Bacteroides fragilis group, 20 other Bacteroides
spp. non-fragilis, 34 Prevotella spp. and 15 miscellaneous)
isolated during the period 11/2002–11/2004 were tested using
the E-test and the agar dilution methods on brucella agar plates
supplemented with 5% horse blood, vitamin K1 and hemin.
Incubation in a ChelLab Anaerobic Chamber was performed for
48 hours. Interpretation of the results was according to NCCLS
guidelines. For quality control the strains B. fragilis ATCC25285
and B. thetaiotaomicron ATCC29741 were used.
Results: Overall MIC90 to tigecycline, tetracycline, penicillin,
piperacillin + tazobactam, cefoxitin, clindamycin, metronidaz-
ole and imipenem were 8, 128, 256, 2, 64, 256, 1 and 0.5 mg/L,
respectively, whereas MIC50 were 0.5, 16, 32, 0.125, 8, 1, 0.5 and
0.064 mg/L, respectively. Bacteroides fragilis group MIC90 were
8, 256, 256, 4, 128, 256, 1 and 0.5 mg/L, respectively, whereas
MIC50 were 0.5, 16, 64, 0.25, 16, 1, 0.5 and 0.064 mg/L,
respectively. At the tigecycline MIC90 concentration of 8 mg/
L the compound inhibited a higher percentage of isolates than
clindamycin, cefoxitin or tetracycline (which inhibited 76, 56 and
45% of the isolates, respectively). Only one strain was resistant
to imipenem (MIC > 32 mg/L), having a tigecycline MIC of 8
mg/L. In addition, six of the eight strains with a metronidazole
MIC > 16 mg/L had a tigecycline MIC < 1 mg/L.
Conclusions: In general, tigecycline showed better in vitro
activity than clindamycin, cefoxitin, tetracycline or penicillin
against Gram-negative anaerobic bacteria and somewhat lower
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activity than imipenem, metronidazole or piperacillin + tazobac-
tam. Nevertheless, among most metronidazole and imipenem
resistant isolates tigecyclinedisplayedgoodactivity. The results of
this in-vitro evaluation show that tigecycline should be consid-
ered as a possible alternative for the treatment of mixed aerobic–
anaerobic infections. Members of the Hellenic Study Group on
Gram-Negative Anaerobic Bacteria are: A. Avlamis, C. Koutsia-
Karouzou, C. Kontou-Kastelanou, A. Pangalis, E. Papafrangas,
E. Trika-Grafakos, H. Malamou-Ladas and A. Vogiatzi
P822
Effect of medium type, age and aeration on the
MICs of tigecycline and other tetracyclines
R. Hope, M. Warner, D.M. Livermore (London, UK)
Objectives: To ascertain the variation between MICs of tigecy-
cline determined in broth and agar, and by NCCLS and BSAC
methods. To assess the effect of adding tigecycline to themedium
one day before use and of usingmedia that had been aged for one
week before addition of tigecycline and inoculation.
Method: MICs for 96 non-fastidious bacteria and 20 streptococci
were determined in Mueller–Hinton broth (MHB), Mueller–
Hinton agar (MHA), Iso-Sensitest broth (ISB) or Iso-Sensitest agar
(ISA). Fresh antibiotic stock solutions (tigecycline, tetracycline
andminocycline)were incorporated into bulkmedia by rolling, to
minimise aeration. Preparation conditions otherwise were as fol-
lows: (a) freshly-prepared media, antibiotic added upon cooling,
then inoculated; (b) freshly-prepared media, antibiotic added
uponcoolingthenstoredfor1 daybeforeinoculationand(c)media
stored for 7 days before addition of the antibiotic and inoculation.
Results: MICs in fresh MHB (the NCCLS reference method)
were taken as a standard. For all the tetracyclines, these MICS
were 0–2 doubling dilutions higher than on MHA or ISA (BSAC
reference method), or in ISB. Media with tetracyclines added a
day before use gave raised MICs, though rarely by more than
one dilution. Tigecycline MICs were increased in 7–day-old
MHB or ISB. This effect was greatest (2–3 dilutions) for the most
susceptible strains (MIC £ 0.5 mg/L) and was absent for the
resistant organisms (MIC ‡ 8 mg/L); it did not occur in agar.
Minocycline MICs were not raised in aged media, and tetracyc-
line MICs were only marginally affected. The addition of blood
to the MHB largely abrogated the effect on tigecycline MIC, as
did boiling the broth prior to adding the antibiotic.
Conclusion: The raised MICs of tigecycline in aged broth
probably reﬂect inactivation by dissolved oxygen. This accords
with lack of any MIC increase in newly boiled (i.e. degassed)
MHB or on aged agar (which is boiled to melt before use). The
effect of blood may be to add to the reducing capacity, protecting
the tigecycline. At a practical level, broth MIC methods for
tigecycline (e.g. the NCCLS reference method) require, freshly
prepared or steamed medium; this is not a concern if agar
dilution methods are used, such as that of the BSAC.
Sexually transmitted diseases
P823
Prevalence of Chlamydia trachomatis and
Neisseria gonorrhoeae in native and immigrant
population (AmBITS study) in Barcelona (Spain)
M.Villa ,M.Valls ,A.Andreu ,M. Saravanya, E. Loureiro, B. Sanz,
E. Arellano, P. Saladie´, M. Meron˜o, G. Codina (Barcelona, E)
Objectives: Assess the prevalence and the epidemiological
characteristics of C. trachomatis and N. gonorrhoeae infection
among patients attended in a sexually transmitted infection unit
(STD) and in people who practice prostitution in the street.
Methods: 837 urine specimens (ﬁrst-void), obtained from
people, with or without symptoms, visited in the STD clinic
and in a non-governmental organization (Ambit Dona), were
studied from January 2002 to July 2003. The 342 male and 495
female were distributed in age groups (<20, 20–40, >40 years),
and geographic origin: Spain (Sp) 196, South America 292,
Magreb 57, Africa 88, East Europe 95, West Europe 29, and
others 80. Detection of chlamydia and gonococci was performed
with a standardised multiplex PCR Cobas amplicor assay.
Results: The overall prevalence of C. trachomatis was 4.4%,
without differences regarding age and sex. The prevalence was
3.6% in native population and 4.7% in immigrant population,
without signiﬁcant differences regarding geographic origin:
South America 3.8%, Magreb 1.6%, Africa 3.4%, East Europe
1.1%, West Europe 10.3%, others 2.5%. The overall prevalence of
N. gonorrhoeae was 4.1%. In the native population was 4.4%,
without differences regarding age and sex. The prevalence was
4.1% in the immigrant population, with no differences regarding
geographic origin: South America 0.04%, Magreb 5.3%, Africa
0%, East Europe 5.3%, West Europe 6.9%, others 5%. The risk of
transmission associated to the geographical origin was estima-
ted with the odds ratio (OR), resulting for chlamydia: South
America/Sp: 1.07, Magreb/Sp: 0.50, Africa/Sp: 0.95, East
Europe/Sp: 3.18, West Europe/Sp: 3.12, others/Sp: 1.04 and
for gonococci: South America/Sp: 1.01, Magreb/Sp: 1.31,
Africa/Sp: 0.13, East Europe/Sp: 1.31, West Europe/sp: 1.74,
others/Sp: 3.02.
Conclusion: The prevalence ofC. trachomatiswas 4.4% and forN.
gonorrhoeae 4.1%. The highest OR for chlamidia and for gonococci
were detected in the East andWest European population. On the
contrary, the African and South American countries display a
similar risk of transmission compared to native population.
P824
Epidemic spread of at least one
prolyliminopeptidase-negative Neisseria
gonorrhoeae strain in Denmark
A. Friis-Møller, L. Berthelsen, U. Germer, H. Krogdahl,
H. Fredlund, M. Unemo (Hvidovre, Copenhagen, DK; O¨rebro, S)
Since the year 2002 isolates of prolyliminopeptidase (PIP)-
negative Neisseria gonorrhoeae (GC) have been diagnosed in
Denmark especially from men, who have sex with men. Species
conﬁrmation of GC is commonly based on enzymatic reactions
in commercial kits such as API NH, RapID NH, Gonocheck II
and Neisseria PET, which among other reactions rely on a
biochemical identiﬁcation of the enzyme prolyliminopeptidase.
Objectives: To phenotypically and genotypically characterize a
selection of PIP-negative GC isolates in Denmark and to
investigate the possibility of a spread of one or several PIP-
negative strain in the Danish community from 2002 to 2004.
Methods: Twenty-ﬁve PIP-negative GC isolated in Denmark
from 23 male patients between 2002 and 2003 were genetically
characterized by means of DNA sequencing of the entire porB
gene and pulsed-ﬁeld gel electrophoresis (PFGE) with the
restriction enzymes SpeI and BglII. Phylogenetic tree was
constructed with TREECON v1.3b by using neighbor-joining
method. Phenotypic characterization was performed by serovar
determination of the 25 isolates and antibiotic susceptibility
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testing of all Danish GC strains isolated in 2002–2004 (n = 953).
Clinical and epidemiological data were obtained when possible.
Results: The 25 PIP-negative GC isolates were all designated as
serovar IB-4 and similar MIC values were identiﬁed in the
antibiograms of these isolates ﬁngerprints were identiﬁed using
SpeI and three using BglII among the 25 IB-4 isolates. Four
distinguishable PFGE . However, all these isolates differed by
less than six bands in both ﬁngerprints. The phylogenetic tree
analysis of the porB1b sequences, suggested that these minor
differences represented the ongoing evolution of the same
strain. During the period Jan. 2002 to Nov. 2004 the proportions
of PIP-neg GC per year in Denmark were 15/332, 47/261 and
27/360, respectively, and the PIP-neg GC infected mostly men
(only 5 women). The antibiograms of all Danish isolates 2002–
2004 indicate a spread of at least one PIP-neg GC strain.
Conclusions: The results of the present study indicate a
circulation of at least one N. gonorrhoeae prolyliminopeptidase-
negative strain in the Danish homosexual community. An
increased awareness for PIP-negative N. gonorrhoeae, which
create large problems in diagnosis using e.g. API NH, RapID
NH, Gonocheck II or Neisseria PET, is essential.
P825
A new recombinant antigen haemagglutination
test for the serological diagnosis
of syphilis
N. Chepurchenko, T. Ulanova, V. Puzyrev, L. Loginova,
A. Burkov, A. Obriadina (Nizhniy Novgorod, RUS)
Introduction: Passive Treponema pallidum hemagglutination
(HA) – the routine treponemal test has equal sensitivity with
the ﬂuorescent treponemal antibody absorption (FTA-ABS) test
and with the enzyme immunoassay (EIA) in later stages of
syphilis, but some studies have indicated that it is less sensitive
in the primary stage of the disease. The use of recombinant
T. pallidum antigens instead of a poorly deﬁned mixture of
antigens from wild-type T. pallidum has the potential for
improving the sensitivity of hemagglutination test.
Objectives: The purpose of this study was to evaluate the
diagnostic relevance of 4 recombinant proteins that efﬁciently
model the antigenic epitope(s) of the Treponema pallidum proteins.
Methods: Four full-length recombinant proteins (TmpA, 47, 17,
15 kDa) were expressed in E. coli and then used individually to
develop the hemagglutination test (HT) for the detection of anti-
Treponema pallidum (anti-TP) activity in serum specimens. Serum
samples (N = 267) from patients with clinically proven syphilis
in various stages of the disease (primary (N = 36), secondary
(N = 70), latent (N = 161)) and from normal blood donors
(N = 505) were tested. 24 samples from patients with primary
syphilis, 21 samples from patients with secondary and 17
samples from patients with latent stage were tested initially with
commercially available hemagglutination test based on mixture
of Treponema pallidum antigens (HTTP). All specimens were
additionally tested for speciﬁc antibodies by commercially
available enzyme immunoassay (EIA).
Results: The sensitivity of the HT for the detection of anti-TP
activity in human serum specimens varied from 38.9% to 97.2%
with primary syphilis sera, from 87.1% to 100% with secondary,
and from 96.9% to 98.1% with latent stage sera for each protein.
The TmpA was found as the most immunoreactive when serum
samples from patients with untreated syphilis were tested. The
sensitivity of TmpA HT was identical to those of the HTTP in
cases of untreated secondary and latent syphilis and signiﬁcantly
higher with specimens from primary stage of disease. The overall
speciﬁcity and sensitivity of the TmpA HT were comparable to
those of EIA 99% and 99.6%; 98% and 99.6% respectively.
Conclusions: The results of this study indicate that the TmpA
HT may be a reasonable alternative to the routine hemagglu-
tination test and the ELISA as a conﬁrmatory test for syphilis.
P826
Use of treponema + VDRL ViraBlot test as a
useful all in one conﬁrmatory assay for
Treponema pallidum antibodies
A. Kostoula, G. Vrioni, C. Bobogianni, C. Stergiopoulou,
E. Papantoniou, S. Levidiotou (Ioannina, GR)
Objectives: As detection of Treponema pallidum subsp. pallidum
by dark-ﬁeld microscopy or direct immunoﬂuorescence is
possible only in the early stages of the disease, serology has
become the method of choice for syphilis diagnosis. Except for
conventional treponemal tests, the T. pallidum Western immu-
noblot assay has also been used as an alternative conﬁrmatory
assay for T. pallidum antibodies. The aim of the present study
was the use of a multiparameter immunoassay, which simulta-
neously detects treponemal speciﬁc and lipoid antibodies, for
the conﬁrmation of syphilis antibodies.
Methods: A total of 86 serum specimens were tested including,
56 reactive sera from patients with documented treponemal
infection; a speciﬁcity panel of 10 sera from normal subjects, 10
sera with Rapid Plasma Reagin (RPR) reactivity (FTA-ABS and
TPHA negative), 5 Leptospira IgM serology-positive sera and 5
Borrelia burgdorferi IgG or IgM serology-positive sera. All serum
sampleswere testedwith conventional syphilis tests according to
the manufacturers instructions: RPR, Venereal Disease Research
Laboratory (VDRL), T. pallidum haemagglutination (TPHA) at a
serum dilution of 1:80, ﬂuorescent T. pallidum absorption (FTA-
ABS) and IgM capture enzyme immunoassay (EIA). Subse-
quently, the results were compared to those of the Treponema +
VDRL ViraBlot IgG, IgM test (Viramed, Labor – Diagnostika), a
immunoassay for the qualitative detection of speciﬁc IgG or IgM
antibodies to T. pallidum using the speciﬁc treponemal proteins
p47, p44.5, p17 and p15, and the quantitative determination of
VDRL reaction on one nitrocellulose strip.
Results: Treponema + VDRL ViraBlot IgG and IgM tests con-
ﬁrmed the results for 56 serum specimens positive for T. pallidum
antibodies: reactive VDRL band and at least two clear bands from
p47, p44.5, p17 orp15 for IgG treponemal antibodies or at least one
clear band p47, p17 or p15 for IgM treponemal antibodies. The 10
RPR reactive sera were VDRL ViraBlot reactive, but Treponema
ViraBlot speciﬁc antibodies negative. None of the remaining sera
reacted in tests with the Treponema + VDRL ViraBlot assay.
Conclusions: The Treponema + VDRL ViraBlot assay combining
the necessary serologic markers in one test strip (i.e. speciﬁc and
non-speciﬁc treponemal antigens) is a useful conﬁrmatory test
for syphilis because it increases the reliability of syphilis
diagnosis with respect to current conventional techniques.
P827
The great imitator: syphilis with predominant
acute severe hepatic involvement
R. Manfredi, S. Sabbatani, L. Attard, D. Pocaterra,
F. Chiodo (Bologna, I)
Introduction: The liver involvement of syphilis is known since
over 400 years, and proves particularly frequent in the rare
congenital form. When secondary syphilis is of concern, >70% of
patients (p) has a negligible or mild alteration of liver enzymes,
while episodes with predominant or apparently isolated acute
hepatitis are exceedingly rare.
Case reports: Two male p (one with concurrent HIV disease),
were hospitalized with an initial diagnosis of acute hepatitis, on
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thegroundof a signiﬁcant increase of serum transaminiases (up to
2200 and 900 U/L of GPT, respectively), frank jaundice, elevated
bilirubin (up to 11.7 and 9.6 mg/dL, respectively), and evident
rise of serum alkaline phosphatase and gamma-GT. Clinical
history did not show risk factors for viral hepatitis, and all labor-
atory examinations for major and minor hepatotropic viruses
proved negative, as well as autoimmmune, dysmetabolic, or
drug-induced liver damage. Repeated ultrasonography detected
increased liver and spleen dimensions, in absence of other abnor-
malities. In the second p, histopathologic study performed after
liver biopsy, showed an aspeciﬁc cholestatic hepatopathy, amod-
erate granulocyte and lympho-mononocyte intralobular inﬁltrate,
appreciable necrotic foci, and a mild portal ﬁbrosis (Knodell
score 5). Only syphilis serology, performed despite the absence of
signiﬁcant history or clinical clues, allowed to recognize an
IGM positive serology associated with TPHA titres ranging from
1:1250 and 1:680, respectively. Speciﬁc chemotherapy (i.v. peni-
cillin G at 24 MU daily for 7 days, followed by 12 MU/day in the
second p),led to a complete resolution of hepatic involvement,
associated with an improvement of serology after 1 month.
Discussion: While in the majority of episodes of syphilis liver
involvement remains missed or subclinical, an early diagnosis of
syphilis with predominant hepatic disease remains an unre-
solved problem of differential diagnosis, due to the rare
occurrence of isolated organ involvement compared with typical
syphilis signs and symptoms, and the aspeciﬁc clinical, histo-
pathological, and imaging picture (Jozsa L,Acta Hepatogast-
roenterol 1977;24:344–7; Young MF, J Clin Gastroenterol
1992;15:174–6). During the recent recrudescence of syphilis in
Italy, a diagnostic suspicion should be maintained by Clinicians
who face an apparent acute icteric hepatitis, and syphilis
serology should be included among initial laboratory workout.
P828
The great imitator: syphilis with predominant
meningoencephalitic features
R. Manfredi, S. Sabbatani, D. Pocaterra, F. Chiodo (Bologna, I)
Introduction: A signiﬁcant recrudescence of syphilis was
observed in recent years, not contained by prophylactic meas-
ures against HIV and other STDs. Meningeal and meningoen-
cephalitic involvement may occur also in early stages of syphilis,
thus posing problems of differential diagnosis.
Case reports: A young woman and an HIV-infected male
developed a syphilis with predominant meningoencephalitis
expression. In the ﬁrst p, based on an isolated positive Borrelia
burgdorferi serology (later deemed as a cross-reaction), early cef-
triaxone was started, due to a suspected neurological Lyme
disease. Also after the diagnosis of neurosyphilis (on the ground
of positive CSF serology), antimicrobial therapy was left un-
changed for 3 weeks at ourDay-Hospital facilities, until complete
clinical-microbiological cure. A second, HIV-infected p was
hospitalized owing to mild fever lasting 2 weeks, associated
with cephalalgia and anxiety.The favorable virological-immuno-
logical status (CD4 + count 439 cells/lL and undetectable HIV
viraemia, under an effectiveHAART regimen), didnot exclude all
searchs for possible HIV-related disorders.Although serum
examination detected a potential latent syphilis (isolated positive
serum Treponema pallidum IgG, TPHA 1:640,IgG-positive RPR,
andmute history for syphilis), onlyCSF examination disclosed an
increased cell content (50/lL), alteredbrain-bloodbarrier indexes
with increased intrathecal Ig synthesis, and frank VDRL,TPHA
(1:1520), and borderline T. pallidum IgM serology.Penicillin G at
24 MU/day for 14 days led to a slow resolution of neurological
signs and symptoms, and a tendency to improvement of speciﬁc
CSF-serum syphilis serology during subsequent controls.
Discussion: Focusing on differential diagnosis, a luetic etiology
should not be underestimated, when facing young p suffering
from a meningoencephalitis of unclear origin.Our cases were
characterized by a young age (34 and 44 years, respectively),
when compared with usual mean age of tertiary neurosyphilis.
In absence of suggestive history and other syphilis signs, the
diagnosis was achieved only after the retrieval of elevated
syphilis serology positivity on both CSF and serum, together
with some clinical signs, such as seizures, altered mentation,
cognitive abnormalities, and anisochoria in the ﬁrst p, and
persisting headache and anxiety in the second p. Our experience
with ceftriaxone (started in the ﬁrst p when neuroborreliosis
was suspected), was favorable like that with high-dose i.v.
penicillin G.
P829
Comparison of the genomes of pathogenic
treponemes, Treponema pallidum ssp. pallidum,
ssp. pertenue and Treponema paraluiscuniculi
D. Smajs, P. Matejkova, M. Strouhal, S.J. Norris,
G.M. Weinstock (Brno, CZ; Houston, USA)
Objectives: Genomes of closely related treponemes, Treponema
pallidum ssp. pallidum (strains Nichols and SS14) and Treponema
pallidum ssp. pertenue (Gauthier, Samoan D) were compared
with the genome of Treponema paraluiscuniculi using genomic
techniques. T. pallidum ssp. pallidum is the causative agent of a
highly invasive human disease syphilis, T. pallidum ssp. pertenue
is the causative agent of yaws and T. paraluiscuniculi is not
pathogenic to humans.
Methods: DNA microarray containing PCR products of all
annotated ORFs of the strain Nichols was used for hybridization
of labelled treponemal genomic DNA. In addition, whole
genome ﬁngerprinting was used to study treponemal genomes.
PCR-ampliﬁed regions of genomic DNA were digested with
BamH I, EcoR I, Hind III, or their combinations.
Results: After labelling of chromosomal DNA using random
hexamers and hybridization to the DNA microarray, at least 15
T. paraluiscuniculi genes showed signiﬁcantly lower signals
when compared to signals of T. pallidum ssp. pallidum. These
genes were clustered at least in ﬁve chromosomal regions and
comprised tpr genes and genes encoding hypothetical proteins
in their vicinity. No signiﬁcant differences were observed when
strains T. pallidum ssp. pertenue were compared to the Nichols
and SS14 strains indicating high degree of sequence homology
between pallidum and pertenue subspecies. PCR ampliﬁcation
and subsequent restriction analysis of the complete genomes of
the strains Nichols, SS14 and Gauthier revealed 1 absent
restriction site in SS14 and Gauthier. When compared to Nichols
genome, 8 and 34 differences in the target restriction sites and 1
and 8 detectable deletions/insertions were found in the genome
of Samoan D and T. paraluiscuniculi, respectively.
Conclusions: Presented data indicate close relationship of
T. pallidum ssp. pallidum and ssp. pertenue on the DNA level
with a relative distance from the T. paraluiscuniculi genome.
Restriction proﬁles appear to be strain-speciﬁc rather than
subspecies-speciﬁc.
P830
Sexually transmitted diseases in an area of Spain
J.L. Prada, F. Moreno, A. Del Arco, J. Aguilar, N. Montiel,
J. De La Torre, J.M. Arango (Marbella, E)
Introduction: The incidence in sexually transmitted diseases
(STD) in our region is unknown. Several factors suggest an
increment in this frequency.
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Objectives: To study the clinical proﬁle and incidence of STD in
our area.
Method: Retrospective and descriptive study of all the patients
with STD diagnosis in Costa del Sol area among janury-2000 and
september-2004. Our Microbiology Unit is the reference labor-
atory for an area in the south of Spain with a population of
300.000 inhabitants. Data from Microbiology Lab Database were
analysed. We excluded hepatitis, herpes, papilomavirus and
HIV.
Results: We have detected 145 cases of infection by Treponema
pallidum (Tp), Neisseria gonorrhoeae (Ng) and Chlamydia tracho-
matis (Ct). The average age was 36 years (19–85) and 69.7% were
males. Tp is the main cause with 102 cases (70.3%), Ng 32 cases
(22.1%) and 11 Ct (7.6%). Mean age was 39, 31 and 28 years
respectively and the rate of males 69.7%, 90.1% and 9.1%
respectively. By years from 2000 to 2004 the cases respectively
were 24, 18, 35, 24 and 44, the average of age 40, 39, 36, 36 and
34 years, Tp cases 20, 13, 26, 15 and 28, Ng cases 4, 4, 6, 8 and 10,
and Ct cases 0, 1, 3, 1 and 6. 70.3% of total cases were diagnosed
in the Primary Care System, the remains in the Hospital: 11.8%
by General Internal Medicine, 10.3% by Gynecology, 1.4% by
Dermatology, and 6.2% by other departments. The Ct diagnosis
was made by Gynecology in 81.8%. Internal Medicine made Tp
diagnosis in 15.7% and Ct in 9.1%.
Conclusions: We have observed a trend to increase the STD
incidence and a decrease in diagnosis-age (from 40 to 34 years of
average in the last 4 years). Males were principally affected
(69.7%). The STD diagnosis was made particularly in the
Primary Care Level.
P831
One-step detection and identiﬁcation of human
papillomavirus genotypes in Bulgarian women
with cytologically normal cervical smears
Z. Kalvatchev, P. Draganov, D. Georgiev, A. Gancheva (Soﬁa,
BG)
Objectives: The cervical human papillomavirus (HPV) infec-
tion is common among young sexually active women. Because
the cytology tests have some limitations, including up to 30%
false-negative results, molecular techniques are increasingly
used for identiﬁcation of HPV-induced cell changes in the
cervix. The polymerase chain reaction (PCR) for HPV diagnos-
tics was successfully introduced recently in Bulgaria. However
limited data on speciﬁc prevalence and determinants of sub-
clinical HPV infections are available. In this study we designed a
multiplex primers PCR system for simultaneous identiﬁcation of
the most common low- and high-risk HPVs in women with
cytologically normal cervical smears.
Materials & methods: DNA from 102 cervical cell samples from
women aged between 18 and 40 years with normal Pap smear
tests was extracted by standard procedure and studied for HPV
presence. Six type-speciﬁc primer sets for E6 HPV gene were
used in a single-tube reaction for detection and identiﬁcation of
HPV-6, -11, -16, -18, -31, and -33. Respective controls and
statistic analysis were included.
Results: The overall HPV DNA prevalence was 23.5% (24/102).
Ten of the HPV positive women (41.6%) were infected with
high-risk (HPV-16 or HPV-18) virus types; eight (33.3%) with
low-risk types (HPV-6 or HPV-11), and six (25%) were infected
with both high- and low-risk types (3 HPV-6/-16; 2 HPV-6/-18
or 1 HPV-6/-33). HPV prevalence among women younger than
23 years was 58.3% (14/24). For low-risk types the peak
prevalence was observed in women between 35–40 years.
Besides age, there was a positive association between the
detection rates of HPV infection and number of sexual partners
and oral contraceptive use.
Conclusion: The used technique is simple, economic, rapid and
reliable for screening studies of HPV infections. The prevalence
of HPV in cytologically normal Bulgarian women is similar to
the reported in other countries. Our ﬁndings suggest that
molecular techniques for HPV detection might be useful as an
adjunct to Pap smear screening.
P832
Group B streptococci carriage in pregnant women
M. Nishimura, G. Martı´nez, A. Meier, A. Oltoff, M. Pizzuto,
E. Cecchini (La Plata, RA)
Objective: To determine Group B streptococci (GBS) carriage in
pregnant women and its effects in delivery and newborn.
Methods: Retrospective and prospective observational study of
1504 pregnant women, the majority belonging to low income
level. They were attended in a Mother to Child Hospital (Dr.
Ollier) in the neighborhood of Buenos Aires city. Data for
identiﬁcation, gynecology and obstetrics history, microbiological
ﬁndings, prophylaxis, route of delivery, and newborn status
were recorded. They were screened for carriage of GBS: samples
of cervix, fundus of vagina and anorectal area were performed
between 35–37 weeks of pregnancy.EPI Info 6 was used to
process the collected information.
Results: The study included 5100 clinical records of pregnant
women. One thousand and ﬁve hundred four (29.5%) were
screened with gestational age over 35 weeks. Seventy-eight per
cent were aged 11–30 years (11–20 = 26% and 21–30 = 52%).
First pregnancy was in 23.8%. Overall carriage was 11%
(n = 162). Seventy seven per cent of colonized women was 11–
30 years old and 24% younger than 21. There was not statistical
difference in carriage among age groups. The events observed in
GBS carriers were: premature delivery 4.4%, early rupture of
membranes 16.7% (p 0.01 vs. no carriers). Children born from
GBS carriers were alive in 99.0% (2 death fetus) and 3.3% (n = 5)
had sepsis with isolation of GBS in two. GBS carriage was
associated with sexually transmitted infections in 2% (p 0.1 vs.
without colonization). Mothers of the ill newborns had not risk
factors for colonization with GBS.
Conclusions: GBS carriage and the incidence of GBS sepsis
were according the literature data 5–35% and 0.7–3.7%, respect-
ively. It has to be emphasized: (1) routine universal screening
must be performed for all pregnant women, (2) use of antibiotic
prophylaxis in all colonized, (3) use of antibiotic prophylaxis in
all with no performed obstetrics controls. These measures
prevent mother-to-infant transmission of GBS. It ranges between
29–72% and incidence of GBS sepsis diminishes approximately
86% with antibiotic prophylaxis use.
P833
Mixed infections of the female low genital tract
C. Panagou, J. Spiliopoulou, A. Meletiou, E. Zagotzidou,
D. Patili, M.-E. Alexandrou, A. Vogiatzi (Athens, GR)
Objective: The aim of this study was to determine the preval-
ence of the most common sexually transmitted pathogens in
symptomatic and asymptomatic women.
Materials and methods: A number of 1284 women, aged 16–
70 years, were examined for a period of 1 year. They were
divided in three age groups: group A: 16–19 years (n = 62),
group B: 20–50 years (n = 1090) and group C: 51–70 years
(n = 132). Vaginal and cervical specimens for aerobic-anaerobic
culture, a wet mount preparation and a Gram stained smear
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were examined. Mycoplasmas were determined by use of a
commercially available system (Lioﬁlchem s.r.l, Italy) and C.
trachomatis antigen by DIF (Cellabs Pty Ltd, Australia).
Results: Of 1284 specimens, 1121 were positive. The isolated
species in each age group are summarized in Table 1. In 818
cases of lower genital tract (LGT) infection, only one species was
isolated. In all three age groups, Mycoplasmas were the most
commonly identiﬁed. In particular, the species of the isolated
pathogens were: (1) Group A (n = 43): Mycoplasmas 52%,
Streptococcus spp 24%, Candida spp 8%, C. trachomatis 8% and
anaerobes 8%, (2) Group B (n = 691): Mycoplasmas 65.26%,
Candida spp 15.14%, Streptococcus spp 8.44%, B. vaginosis
(B.V) ( anaerobes 7.45%, C. trachomatis 3.22% and T. vaginalis
0.49%, (3) Group C (n = 84): Mycoplasmas 57.14%, Streptococcus
spp 24.49% and Candida spp 12.25%. In 303 women a mixed
infection was found. Especially in group B, Mycoplasmas + B.V
(n = 93), Mycoplasmas + Candida spp (n = 83), Mycoplas-
mas + Streptococcus spp (n = 21), Mycoplasmas + T. vaginalis
(n = 12), and Candida spp + C. trachomatis (n = 12) were isolated.
In 39 women of this group a mixed infection with three species
was found. From 818 women with positive cultures, 562
(68.70%) were symptomatic, while in 256 asymptomatic
women (31.20%), sexually transmitted pathogens were identi-
ﬁed. Noticeably 40.58% and 37.5% of the infected women with
Candida spp and C. trachomatis respectively, presented no
symptoms.
Conclusions: (1) The rate of mixed LGT infections was 27.02%
(2) Asymptomatic infections were 31.20% (3) All teenagers in
group A were symptomatic.
P834
Ureaplasma MBA size variants in woman with
spontaneous preterm delivery
J. Spergser, A. Witt, L. Petricevic, P. Husslein, A.M. Hirschl,
R. Rosengarten (Vienna, A)
Objectives: Despite colonization of the lower urogenital tract,
ureaplasmas reach the upper genital tract only in a subpopu-
lation of women, and only in some of these individuals
symptoms like preterm delivery ensue. While some studies
indicated that certain serovars are more frequently implicated
with particular diseases, others have suggested that size vari-
ability of the multiple banded antigen (MBA) may contribute to
ureaplasmal pathogenesis. To address these hypotheses, vaginal
and placental samples from women with spontaneous preterm
delivery were tested for ureaplasma species, serovars and MBA
size variants.
Methods: Placenta/amnion specimens and corresponding vagi-
nal samples from women that delivered via caesarean section
less than 34 weeks of pregnancy were collected. Samples were
examined for ureaplasma species and serovars by cultivation
and PCR assays. To determine MBA size variants, PCR with
primers amplifying the non-repetitive and the C-terminal repeat
region of the MBA gene were performed.
Results: Out of 100 cases examined so far, 32 placenta/amnion
specimens and 40 corresponding vaginal samples were positive
for ureaplasmas by cultivation and PCR. While ureaplasma
positive samples from the lower genital tract were carrying
U. parvum (100%) and U. urealyticum (50%), colonization of the
placenta/amnion was restricted to U. parvum which was only
recovered from women with preterm labor or preterm PROM. In
contrast, ureaplasmas were not detected in samples from
women with HELLP syndrome, IUGR and preeclampsia. As
opposed to some previous studies, particular serovars were not
implicated in adverse pregnancy outcome. However, signiﬁcant
differences between number and lengths of MBA PCR products
among placental and vaginal ureaplasma isolates were obvious.
Ureaplasma isolates from placenta/amnion membranes gave
shorter PCR products than did corresponding vaginal isolates
and while a majority of vaginal ureaplasma isolates were
composed of multiple size variants, placental isolates were
predominantly restricted to a singular MBA size variant.
Conclusion: OnlyU. parvumwas found to be frequently present
in the placenta/amnion of women with preterm delivery and
certain serovars were not more frequently implicated with
particular diseases. In addition, MBA size variation represents
an additional level of phenotypic and genetic variability beyond
the serovar category which may provide an important contri-
bution to ureaplasmal pathogenesis.
P835
Use of kanamicin in the topical therapy of aerobic
vaginitis
G. Tempera, G. Bonﬁglio, E. Cammarata, S. Corsello,
A. Cianci (Catania, Paterno`, I)
Objectives: Demonstrate the efﬁcacy of the topical therapy with
kanamicin in a new pathology called aerobic vaginitis (AV).
Methods: Eighty-one patients with clinical diagnosis of AV in
accordance to Donders’s criteria, have been included in the
study. The presence at least of four of the following symptoms
were taken as diagnosis of AV: objective abnormal yellow
vaginal discharge, foul smell (but negative to KOH test),
elevated vaginal pH (>5), abundant vaginal leukocytes and
lactobacillary grade IIa, IIb and III in accordance to Donder’s
classiﬁcation. Other characteristics such as vaginal dyspareunia,
vulva-vaginal itching, cervical erosion as well as the isolament
of vaginal microorganisms were also documented. The patients
were randomised treated, 45 with kanamycin (100 mg vaginal
ovules per 6 days, consecutively) whereas, 36 with meclocycline
(35 mg vaginal ovules per 6 days, consecutively). The patients
were visited before starting the study, 1–2 days and 30 days
after the end of the study.
Results: At the ﬁrst follow-up the patients showed different
level of symptoms reduction. Particularly, reduction of presence
of leukocytes, burning of vaginal mucosa and itching were
statistically signiﬁcant in the group treated with kanamycin with
respect to the group treated with meclocycline. Moreover, there
was also a reduction of isolament of Enterobacteriaeae (97%) in
the group treated with kanamycin versus 76% treated with
meclocycline. At the second follow-up, vaginal homeostasis
(normalisation of pH and presence of lactobacilli) was demon-
strated only in kanamycin treated group.
Conclusion: Our data suggested that the topic use of kanamy-
cin could be considered a speciﬁc antibiotic for the therapy of
this new pathology.
GROUP A
(n = 55)
GROUP B
(n = 951)
GROUP C
(n = 115)
Microorganisms N % N % N %
Mycoplasmas 31 (46.27) 679 (55.29) 76 (52.05)
Candida spp 14 (20.89) 229 (18.66) 17 (11.64)
BV+ anaerobes 3 (4.49) 163 (13.27) 19 (13.01)
C. trachomatis 5 (7.46) 48 (3.91) 3 (2.06)
T. vaginalis 0 22 (1.79) 7 (4.79)
Streptococcus spp 14 (20.89) 87 (7.08) 24 (16.45)
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P836
Comparison of Gram stain and culture for the
characterisation of vaginal microﬂora
R. Verhelst, H. Verstraelen, G. Claeys, G. Verschraegen,
M. Temmerman, M. Vaneechoutte (Ghent, B)
Objectives: Establishing the identity of Lactobacillus species
colonizing the vagina of women is of importance, because
clinical studies have demonstrated an association between the
presence of H2O2-producing strains of Lactobacillus and a
decreased prevalence of bacterial vaginosis (BV). Recently,
culture based studies using molecular identiﬁcation methods
showed that L. crispatus and L. jensenii are the most common
species of vaginal lactobacilli and that colonization by these
species was positively associated with a lower frequency of BV.
Here were report that L. crispatus can be distinguished from
other lactobacilli using Gram staining of vaginal smears.
Methods: Several approaches were used to characterize 515
vaginal microﬂora samples obtained from 197 pregnant women
at three time points in pregnancy: 1/Gram stained smears from
vaginal swabs, scored according to modiﬁed Ison and Hay
criteria; 2/identiﬁcation of cultured isolates obtained after
anaerobic culture, identiﬁed using tDNA PCR; and 3/species
speciﬁc PCR for Atopobium vaginae and Gardnerella vaginalis.
Grade I specimens, representing a normal microﬂora, were
further characterized as grade Ia when only L. crispatus cell
types were present, grade Ib when other Lactobacillus cell types
were present, grade Iab when both L. crispatus and other
lactobacilli were present and grade Ic when either gram-positive
rods, small and short, or irregularly shaped gram-positive rods,
with clubbing, curved edges and irregular staining (diphteroid
cell types) were seen.
Results: Out of the 515 samples, 86.4% showed a normal
vaginal microﬂora (grade I), 8.9% were grade II, 3.7% grade III
and 1.0% grade IV. Based on the presence of different Lactoba-
cillus species, grade I specimens were further characterized as
grade Ia (36.4%), grade Ib (40.9%), grade Iab (13.5%) and grade
Ic (8.5%). This classiﬁcation was supported by the ﬁnding that
out of respectively 86.0% and 76.6% of grade Ia and Iab
specimens L. crispatus was cultured while this species was
present in only 13.1% and 2.6% of respectively Ib and Ic
specimens. In addition, 55.1% of grade Ic specimens contained
Biﬁdobacterium spp.
Conclusion: Further reﬁnement of Gram stain based grading of
vaginal smears is possible by distinguishing additional classes
of normal microﬂora. These categories of Gram scores may
facilitate and improve future studies regarding the interpret-
ation of clinical data and therapeutic outcome.
P837
Isolation of Gardnerella vaginalis from semen
C. Marne, P. Palacia´n, Y. Martı´n, A. Betra´n,
M.J. Revillo (Zaragoza, E)
Objectives: The importance of the isolation of Gardnerella
vaginalis in bacterial vaginosis is well known. The involvement
in male urogenital infection is uncertain, probably due to low
rate of isolation for inadequated specimens process. The
objective of this study is to evaluate the possible pathogenic
rol of G. vaginalis in male urogenital pathology.
Methods: Over a 3-year period (Oct 01–Sep 04) 1318 semen
specimens were cultured, according to the Meares–Stamey
method, using semen instead of prostatic ﬂuid. Samples were
cultured onto blood and chocolate agar, with microaerophylic
incubation up to 48 h. Isolation of signiﬁcative colony numbers
of pinpoint growth, with negative or scanty growth in urethral
and vesical urine, was evaluated. Grampositive difteroid coco-
bacilli, catalase negative with diffuse betahaemolysis in Vagi-
nalis agar was reported as G. vaginalis. Conﬁrmation of the
results with new samples was recommended.
Results: G. vaginalis was isolated in high counts from semen of
7 patients. Results were conﬁrmed with second samples in 3 of
them. Age range was 28–61 years. Diagnostic was chronic
prostatitis in 4 patients, orchitis in 1 and infertility in 2. Four
semen samples were also positive for Ureaplasma urealyticum.
Chlamydia investigation was negative in all 7 patients. Vaginal
exudate was investigated in two couples with the same results
(both positive for G. vaginalis and one also for U. urealyticum).
Conclusions: 1. Repeated isolation of G. vaginalis in semen from
patients with urologic pathology, according to Meares–Stamey
critheria, indicates the probable pathogenic rol. 2. In our
experience, we do not consider necessary routine use of selective
media for G. vaginalis. Blood and chocolate agar with microae-
rophylic incubation support good growth of this species.
Selective media can be used latter for identiﬁcation of the
isolates. 3. Due to lack of information, our patients were treated
empirically by temptative antibiogram results and antibiotic
penetration in the prostatic gland. 4. According to bibliography
revised, in extravaginal isolates metronidazole is not recom-
mended. 5. Association observed between G. vaginalis and
U. urealyticum suggest treatment active against both species.
6. The same microbiological investigations must be performed in
the couple, for simultaneous treatment and prevention of
relapses. 7. G. vaginalis should also be considered in men as
sexually transmitted disease.
P838
Seminal microﬂora of healthy young men in
relation to sexual experience
S. Tu¨rk, P. Korrovits, K. Ausmees, M. Punab, R. Ma¨ndar (Tartu,
EST)
Semen is a recommended specimen in diagnosing of prostatitis.
At the same time it also reﬂects normal genital tract microﬂora.
Although its composition may be affected by the sexual activity,
there are no data regarding the changes in genital tract
microﬂora during the sexual debut.
Objective: To identify possible associations between sexual
experience and the reproductive tract inﬂammatory parameters
and microﬂora in healthy young men.
Methods: A total of 72 healthy men aged 17–22 years were
included and divided into 3 groups based on their sexual
experience (virgins n = 13, monogamous n = 11 and polygam-
ous n = 48). A semen sample of each subject was assessed for
basic semen parameters (semen volume, sperm concentration,
sperm motility), white blood cell (WBC) counts and quantitative
cultures for aerobic, microaerobic and anaerobic bacteria, and
possible correlations between the type of sexual experience,
WBC counts and seminal microﬂora were calculated.
Results: Basic semen parameters were similar in all groups.
5.5% of men had high (>1 M/ml) and 19.4% of men had medium
(0.2–1 M/ml) semen WBC counts. There were no correlations
between the type of sexual experience and semenWBC counts. In
comparison to sexually active men in virgin subjects the total
microbial counts in semen (4.4 vs 5.0 log CFU p < 0.05) and the
number of different species (3 vs 5, p ¼ 0.05) were lower,
however, no differences between mono- and polygamous men
were found. There was a positive correlation between the total
microbial concentrations and number of different species
(r = 0.54; p < 0.0001). Staphylococci, Corynebacterium seminale,
other coryneforms, gamma- and alpha-haemolytic streptococci
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and peptostreptococci were the most prevalent organisms. No
signiﬁcant differences in microﬂora were observed between the
groups yet the Gram-negative anaerobic rods were more often
seen in sexually experienced men than in virgins. The subjects
with highWBC counts (>1 M/ml) tended to have higher number
of different microorganisms than the rest of themen (median 7 vs
4, p = 0.05).
Conclusions: The sexual debut is associated with the enrich-
ment of seminal microﬂora but not with the inﬂux of WBC or
changes in basic seminal parameters. Strong positive correlation
can be observed between the total microbial concentration and
the number of different species in semen.
P839
Sexually transmitted infections among registered
female sex workers in Athens
A. Nicoloudi, T. Vlachou, C. Giannakakis, E. Zagotzidou,
D. Patili, A. Terzi, M.-E. Alexandrou (Athens, GR)
Objectives: 1. To assess the prevalence of ST pathogens among
registered asymptomatic sex workers. 2. To compare patterns of
STDs among Greek and immigrant sex workers.
Materials and Methods: A number of 442 asymptomatic
prostitutes, aged 20–55 years (Group A) were examined for
STIs, as well as a control group of 192 asymptomatic women of
the same age (Group B) who attended the out patients
gynaecology dpt of our Hospital, during 2-year period. Vaginal
and endocervical samples were examined microscopically for
T. vaginalis, yeast, clue cells and N. gonorrhoeae and cultured for
aerobic and anaerobic bacteria.C. trachomatis was detected with
DIF (Cellabs Pty Ltd, Australia).
Results: Of the 442 samples of Group A and 192 of Group B, ST
pathogens were found in 171 (38.6%) and 68 (35.4%) respect-
ively. Among STDs, in Group A, B. vaginosis (43.7%) was
observed to be the most common in Greek and immigrant
prostitutes, followed by Candida spp (34.2%), S. agalactiae (19.8%)
and N. gonorrhoeae in 3 cases. Candida spp were isolated in
higher rate (42.3%) in immigrant than in Greek prostitutes
(26,2%). In Group B, Candida spp (45.6%) and BV (42.6%) were
move often found, followed by S. agalactiae (11.8%). Not one case
of N. gonorrhoeae was recorded. C. trachomatis was detected in 14
(3.2%) and 6 (3.6%) women of Group A and B, respectively. The
prevalence of asymptomatic Chlamydial infection in Group A
was 3.2% (0.8% for Greeks and 5.8% for immigrants). No
obvious difference was observed in Group B: 3.6% (2.7% for
Greeks and 4.5% for immigrants).
Conclusions: 1. BV (43.7%) was the most common infection in
the STDs of female registered sex workers in Athens. 2. The
prevalence of Candida spp (42.3%) was considered higher among
immigrant prostitutes than Greek. 3. C. trachomatis was detected
in signiﬁcantly higher rate (5.8%) in immigrant sex workers than
in Greek (0.8%).
P840
High rates of genital Mycoplasma infection in
female of reproductive age
J. Spiliopoulou, C. Panagou, A. Meletiou, E. Zagotzidou,
D. Patili, A. Terzi, M.-E. Alexandrou (Athens, GR)
Objective: Mycoplasma can be isolated with considerable fre-
quency from the female urogenital tract and are thought to
cause various syndromes such as nongonococcal urethritis,
pelvic inﬂammatory disease or infertility. The aim of this study
was to evaluate the incidence of Mycoplasma infection and other
common sexually transmitted pathogens in women of repro-
ductive age.
Material and methods: Vaginal and cervical specimens were
collected from 1090 women, aged between 20 and 50 years, who
referred to our outpatients gynaecology department during a
12-month period. Every woman was tested for the presence of
Mycoplasma, Chlamydia trachomatis, Trichomonas vaginalis, Can-
dida and Gardnerella vaginalis. Aerobic and anaerobic culture, a
wet mount preparation and a Gram stained smear were
examined. The identiﬁcation of Mycoplasma and sensitivity test
was performed using the Mycoplasma system (Lioﬁlchem s.r.l,
Italy). The detection of C. trachomatis was performed using DIF
(Cellabs Pty Ltd, Australia).
Results: 951 out of 1090 women examined (87.25%) had a
positive vaginal or cervical culture. The species of isolated
pathogens were:Mycoplasma (679), Candida spp (229), Gardnerella
vaginalis ( anaerobes (163), C. trachomatis (48), T. vaginalis (22),
Streptococcus spp (87). In 691 women (72.66%) only one species
was identiﬁed. Mycoplasma were the most frequently isolated
microorganisms (65.26%) followed by Candida spp (15.14%),
Streptococcus spp (8.44%), Gardnerella vaginalis ( anaerobes
(7.45%), C. trachomatis (3.22%) and T. vaginalis (0.49%). In 221
women (23.24%) a mixed infection was found. In particular,
Mycoplasma + Gardnerella vaginalis (n = 93), Mycoplasma + Can-
dida spp (n = 83), Mycoplasma + Streptococcus spp (n = 21),
Mycoplasma + T. vaginalis (n = 12), and Candida spp + C. tracho-
matis (n = 12) were isolated. Three species were present in
39 women (4.1%).
Conclusions: In our study group, there is a high prevalence of
genital Mycoplasma (55.29%). Noticeably, Mycoplasma coexists
with Gardnerella vaginalis and Candida spp in elevated rates
(79.64%). Based on these ﬁndings, a more thorough examination
for sexually transmitted pathogens might have clinical signiﬁ-
cance, in this setting of female population.
P841
Comparison of culture with the polymearase
chain reaction for detection of Ureaplasma
urealyticum in endocervical specimens
S. Najar Peerayeh, S.D. Siadat (Tehran, IR)
Objective: Ureaplasma urealyticum is associated with infection of
the genitourinary tract, reproductive failure, and neonatal
morbidity and mortality. The objective of this study was to
compare PCR and cultivation methods to determine the inci-
dence of U. urealyticum infection in infertile women.
Methods: Duplicate endocervical swab samples were taken
from 312 infertile women. DNA was extracted by Cadieux
method. Genus-speciﬁc (MGSO & GSO) and species-speciﬁc (U4
&U5) primers were used for detection of U. aurelyticum by PCR,
and culture was done with liquid–solid methods in U broth and
U agar media.
Results: U. urealyticum was detected in 26.2% specimen by both
culture and PCR methods. 12.5% samples were PCR positive as
well as culture positive, 23.7% were positive only by PCR, and
2.5% were positive only by culture. By using culture as the
reference method, the PCR had a sensitivity of 82.9%. Overall
agreement between results obtained by culture and PCR was
47.5%. No difference was detected on the incidence of U. urea-
lyticum by age and with other clinical symptoms or signs.
Conclusion: PCR is a sensitive and reliable method for the
detection of U. urealyticum in endocervical secretions. Detection
by PCR (1–2 days) is more rapid than culture (2–5 days)
however the use of molecular microbiologic techniques is
likely to increase of the detection of U. urealyticum among
infertile patients.
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P842
Aetiologies of 121 cases of male genital ulcers
examined in the microbiology laboratory of the
central army hospital in Algiers from 1990 to 2003
M. Naim, D. Tiouit, A. Chabani, W. Amhis (Algiers, DZ)
Objectives: To determine the etiologies of the male genital
ulcers examined in the microbiology laboratory of the military
hospital and to know their respective frequency from 1990 to
2003.
Methods: Each patient addressed to our laboratory for a genital
ulceration is interrogated and examined carefully by a physician
microbiologist. Once over the semiotic analysis of the lesion
(aspect, number, consistency, pain, ade´nopathy, etc.) we sys-
tematically practice: Dark ﬁeld microscopy to search for Trepo-
nema pallidum.The microscopic exam after staining of Gram
associated to the setting up in culture adapted to the isolation of
Haemophilus ducreyi (GC agar +1% of Hemoglobin +1% of
Isovitalex +5% of serum of fœtal veal +3 lg/ml of Vancomy-
cine).The direct Immunoﬂuorescence with monoclonal antibod-
ies for the research of antigens of the herpes simplex virus type 1
and 2 (Monoﬂuokit herpes,Biorad *). The serologies for the
Syphilis (VDRL and TPHA), for the HIV (ELISA), for Chlamydia
trachomatis (Microimmunoﬂuorescence). When the clinical and/
or epidemiological context is in favour of another etiology we
practice the appropriate tests (search DONOVANS bodies on
the lesion biopsy smear after Warthin–Starry staining or Giemsa
for Donovanosis and skin scrapping for Scabies).
Results: In total on 121 ulcerations examined, 103 (85%) have
been diagnosed with precision but 18 (15%) remained undeter-
minate. The 103 positive cases are divided as follows: Haemo-
philus ducreyi = 76 (73.78%), Treponema pallidum = 11 (10.67%),
Calymmatobacterium granulomatis = 4 (3.88%), Herpes simplex
virus = 4 (3.88%), Sarcoptes scabiei hominis 3 = (2.91%), Candida
albicans = 2 (1.94%), Staphylococcus aureus = 2 (1.94%) and Chla-
mydia trachomatis = 1(0.97%). We did not ﬁnd any association
with HIV
Conclusion: Our results recover the same usual etiologies in the
genital ulcers but in different proportions in relation to other
regions of the world. So in our country as in the other emerging
countries and notably African ones it is the soft Chancroid that
predominates extensively, whereas one knows that in the
developed countries that is the genital herpes which is the
most frequent etiology. All the cases of Donovanosis diagnosed
in our laboratory come from Tamanrasset city, southern Algeria,
border with endemic sub-Saharan African countries for this
illness and other tropical infections. The cases of undeterminate
etiology can be explained on the one hand by the possible non
infectious causes that we did not search for and on the other
hand by the insufﬁciency of our diagnostic means that we
intend to improve very shortly with the acquirement in 2005 of
the whole technology of the molecular biology.
P843
Inﬂuence of chlamydial cervicitis on vaginal
microbiocenosis
M. Romanik, I. Wilk, B. Wiechula, A. Ekiel, D. Friedek,
G. Martirosian (Katowice, PL)
Chlamydia trachomatis is the predominant causative agent of
pelvic inﬂammatory disease and, as a result of damage of the
fallopian tubes, accounts for up to half of all ectopic pregnancies.
Infection with C. trachomatis can inﬂuence on vaginal microﬂora.
Association between C. trachomatis, urogenital mycoplasmas and
bacterial vaginosis (BV) was described recently. Vaginal dis-
charge based on changes in a vaginal ecosystem (decreasing
number of Lactobacillus spp. and increasing number of Mobilun-
cus spp., Gardnerella vaginalis, Prevotella spp., Peptostreptococcus
spp., Mycoplasma hominis and others) appears to be a major
cause of BV. The aim of this study was to evaluate the inﬂuence
of chlamydial cervicitis on vaginal microbiocenosis and BV.
Under investigation were 122 sexually active non-pregnant
women aged from 18 to 40 years with diagnosed cervicitis by
cytological examination and presence of muco-purulent dis-
charge. Fifty ﬁve women were included in studied group – with
conﬁrmed C. trachomatis cervicitis and 67 women – in control
group (with non-chlamydial/non-gonococcal cervicitis). BV was
diagnosed using Amsel and Nugent (0–3 negative; 4–6 interme-
diate; 7–10 positive) criteria. By using Amsel criteria BV was
suggested in 11% and 6% correspondingly among women in
studied and control group. By using Nugent criteria BV was
suggested correspondingly in 5.5% and 3%. These differences
were not statistically signiﬁcant and can be explained by the
presence of muco-purulent discharge among studied women.
Among women with chlamydial cervicitis statistically fre-
quently were observed large morphotypes of Lactobacillus spp.
and intermediate Nugent score. We did not observe signiﬁcant
differences in occurrence of Corynebacterium spp., Staphylococcus
spp., Streptococcus spp. (GBS), Gram-negative Enterobacteria-
ceae, Pseudomonas spp. and urogenital mycoplasmas. Further
studies require for evaluation of inﬂuence of chlamydial
cervicitis on BV.
Helicobacter
P844
Identiﬁcation system for Helicobacter species
based on 16S and 23S rRNA gene polymorphisms
A. Gonza´lez, Y. Moreno, P. Piqueres, J. Herna´ndez,
M.A. Ferru´s (Valencia, E)
Objectives: Helicobacter pylori is recognized as an important
human pathogen but the differentiation of the species by classical
phenotypicmethods is really difﬁcult. Therefore the objective of this
study was the development of an identiﬁcation method for
Helicobacter species based on PCR-restriction fragment length
polymorphism(PCR-RFLP)analysisof the16Sand23SrRNAgenes.
Methods: H. pylori NCTC 11637, H. pullorum NCTC 13153,
H. fennelliae NCTC 11612, H. cinaedi NCTC 12423, and 31strains
isolated from gastric biopsies were cultured on 10% (v/v) horse
blood agar at 37C under microaerobic conditions. DNA was
extracted by the cetyltrimethyl-ammonium bromide (CTAB)
method. The primers used in this study to amplify a 1004-bp
fragment of the 16S rRNA were CAM16S1a (5¢ AATACA-
TGCAAGTCGAACGA 3¢) and CAM16S1b (5¢ TTAACCC-
AACATCTCACGAC 3¢). To amplify an internal 2.6 kbp
fragment of the 23S rRNA gene primers LS1 (5¢ GGATTTCC-
GAATGGGGCAACCC 3¢) and LS2 (5¢ GTTTCGTGCTTA-
GATGCTTTC 3¢) were used. Restriction endonucleases were
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selected by computer analysis using Reb sites (http://rebase.
neb.com). DdeI and HpaII were used to digest 16S rRNA and
23S rRNA fragments respectively. The digestion mixture inclu-
ded 10 ll of the PCR product with 10 U of the restriction
endonuclease and was incubated at 37C for 3.5 hours. 12 ll of
the digested product were analysed electrophoretically at 90 V
for 3 hours with 2% (w/v) agarose gel.
Results: The internal region of the 16S rRNA gene was
ampliﬁed in all the strains. The digestion of the amplicon with
DdeI generated 3 different speciﬁc patterns, one for H. pylori,
another for H. pullorum and H. cianedi, and the last one for
H. fennelliae. The PCR-RFLP scheme failed to differentiate
H. cianedi from H. pullorum. A 2.6 kbp PCR product of the 23S
rRNA was ampliﬁed in all the strains, and the digestion of the
amplicon with HpaII generated 4 different proﬁles, one for each
one of the species studied. All of the 31 clinical isolated strains
were identiﬁed as H. pylori by both PCR-RFLP assays.
Conclusion: PCR-RFLP analysis of 16S and 23S rRNA gene
sequences allows for easy and quickly differentiating related
Helicobacter species.
P845
Genotyping of H. pylori using DNA extracted
from faeces
C. Williams, G. Mackay (Glasgow, UK)
Background: Helicobacter pylori causes peptic ulceration and is
linked to the development of gastric cancer. Despite this little is
known about the nature of transmission of this organism. It is
likely that spread occurs in early life but whether this is within
families or between peer groups is unclear. Until recently, it was
only possible to type the organism from cultures derived from
gastric biopsies. This required an endoscopy to be performed
meaning that epidemiological studies on children were not
possible. We have developed a method to detect H. pylori DNA
in faeces and have extended this to perform non-invasive typing
using a Line Probe Assay (LIPA).
Objectives: To extract and type H. pylori DNA from the faeces
of family groups.
Methods: Children referred for breath testing were used as the
index cases and faecal donations collected from parents and
siblings in 7 families. DNA was extracted from faecal samples
and analysed using a Line Probe Assay ( LBP H. pylori virulence
strips, Labo Biomedical Products, The Netherlands).
Results: H. Pylori genotypes were obtained from 17 out of 19
faecal samples analysed. 16 out of 17 were positive for the s1a
region of the vacA gene. The m1 m2a region was present in all
members of 3 families and 3 other individuals. There was no
pattern to the distribution of the cagA gene.
Conclusions: This pilot study conﬁrms the potential for LIPA
analysis to provide data on the type of H. pylori present in family
groups. In the 7 families studied there were no clear patterns
that suggested whether transmission occurred from parents or
peers and further studies using a larger number of families
would be required.
P846
Multiple analyses of different regions of the 16S
rRNA gene increase the diagnostic efﬁciency of
PCR-DGGE technique for Helicobacter spp.
W. Abu Al-Soud, I.-S. Ouis, A˚. Ljungh, T. Wadstro¨m (Lund, S)
Objectives: Since the ﬁrst identiﬁcation of Helicobacter pylori
by Warren and Marshal in 1983, members of the genus
Helicobacter increased to more than 26 species, which have
been detected in human and animals. The construction of
species speciﬁc PCR assays is difﬁcult due to the close
relatedness between different Helicobacter species. The PCR-
DGGE technique was developed for the identiﬁcation of
Helicobacter colonization. The aim of this study was to investi-
gate the effect of multiple regions of the 16 rRNA gene on the
diagnostic efﬁciency PCR-DGGE.
Methods: DNA was extracted from 40 Helicobacter strains,
which represent 20 Helicobacter species. Ampliﬁcation of
~1.2 kb of helicobacter 16S rDNA, which contains V3 and V6-7
regions, was done using previously published Helicobacter
genus speciﬁc primers C97 and C05. The PCR product can be
used as a template for two Helicobacter genus PCR assays, the
v6-7 regions 16S rDNA was ampliﬁed using the primers 1FC254
and 2RC686, the v-3 region was ampliﬁed using the primers
BSF917 and BSR1114 published at (http://rrna.uia.ac.be/
primers). DGGE analysis of the V3 and V6-7 regions was
performed on 9% polyacrylamide gels containing urea and
formamide gradient from 20–40% or 15–30%, respectively.
Electrophoresis was performed in a DCode electrophoresis
unit (BioRad) at constant voltage (200 V) at 60C for 4 hours.
Results: DGGE analysis of two regions of Helicobacter
16SrRNA gene showed mobility patterns that allowed discrim-
ination of most Helicobacter species except those which are
closely related such as H. pullorum–H. pametensis, H. ganmani–H.
rodentium and H. bizozeroni–H. felis–H. salmonis.
Conclusions: Helicobacter species are widely distributed in the
gastrointestinal tract of mammals, birds and other animals. The
PCR-DGGE technique has proven to be an easy, inexpensive
and efﬁcient tool for the identiﬁcation of Helicobacter species
and for the detection of colonisation by more than one
Helicobacter species, without the need for species-speciﬁc PCR
assays. In addition, the diagnostic efﬁciency of this technique
was increased by analysis of multiple regions of the 16S rRNA
gene.
P847
Helicobacter spp. in chronic pancreatitis,
pancreatic adenoma and pancreas cancer
H.-O. Nilsson, U. Stenram, I. Ihse, T. Wadstro¨m (Lund, S)
Objectives: Helicobacter spp. efﬁciently colonise various hostile
habitats such as the stomach, colon and biliary tract of animals
and man. With the exception of H. pylori, many Helicobacter
spp. are difﬁcult to culture. Nucleic acid based detection has
thus become a method of choice for analysis of Helicobacter spp.
in chronic inﬂammatory gastrointestinal (GI) tract diseases and
cancers. Pancreatic exocrine cancer, with few established risk
factors and very poor prognosis, is a common cause of cancer
death. Previously, serological studies found an association
between H. pylori and pancreas cancer (PC).
Methods: Pancreatic tumour specimens of patients with PC
(n = 40), tissues of chronic pancreatitis (n = 6), pancreatic
adenoma (n = 8), and benign pancreatic tissue of patients with
cancers of the choledochus, colon and duodenum (n = 6), were
analysed by semi-nested Helicobacter-speciﬁc 16S rDNA PCR.
Stomach (n = 23) and gallbladder (n = 12) specimens of the
PC-patients were also analysed. PCR-products (360–400 bp)
were characterized by DNA-sequence analysis.
Results: The Helicobacter spp. PCR was positive in 19 of 40
(47.5%) pancreas cancer patients, and in the pancreas in 4 of 6
(66.7%) patients with chronic pancreatitis. Adenoma and pan-
creas tissues of other GI-tract cancers, as well as gallbladder
specimens, were all negative. Four of 23 (17.4%) stomach
samples of the PC-patients were Helicobacter positive with
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sequences homologues to H. bilis by BLASTn analysis.
DNA-sequencing of 13 PCR-products ampliﬁed in PCs were
closely related to H. pylori (n = 9), H. ﬂexispira sp. (n = 3) and
H. cinaedi (n = 1). Two pancreatitis PCR-products matched
H. pylori.
Conclusions: Helicobacter spp. were common in PC compared
with benign pancreatic tissue.
P848
Helicobacter pylori infection and low IgG
immunoglobulin
S. Kokkinou, K. Pavlou, A. Varouta, J. Villiotou,
K. Papaefstathiou, A. Moutsopoulou, E. Papafrangas (Halandri
Athens, Athens, GR)
It is established that Helicobacter Pylori (Hp) may cause
haematological disturbances such as iron malabsorption and
Idiopathic Thrombocytopenic Purpura (ITP). The aim of this
study is to show that Hp is involved in human disease in a
more complicated way, producing an abnormal immunologic
proﬁle.
Patients and methods: This work reports the presence of a
signiﬁcant low value of IgG immunoglobulin in 52 pts suffering
from unidentiﬁed iron deﬁciency (ID)or iron deﬁciency anemia
(IDA coexisting with megaloblastic anemia(MA), in 12 leuko-
penic pts and in 3 more pts having thrombocytosis, ITP and
polycythemia respectively. The ratio Male/Female was 25/42,
and their age ranged from14–80 years. In the blood examination
there was a10-fold titre of Hp-IgG type antibody in all, while in
23 there was also a high titre of Hp-IgA type using ELISA
technique. The histopathological examination of an antral
biopsy showed diffuse corpus gastritis, atrophic gastritis and
achlorydria secondary to Hp infection that take place in gastric
area.
Results: 52 pts had unidentiﬁed ID or IDA coexisted with
megaloblastic anemia. Serum iron, transferrin saturation, serum
ferritin and B12levels were found to be signiﬁcantly low. All of
them had also Hp infection. Their anemia existed for more than
10 years, was unresponsive to treatment and recurrent in nature.
Twelve pts with undeﬁned eukopenia (L:3.3 · 109/l) lasting for
at least 8 years, had also an Hp infection. All of our pts had a
signiﬁcantly low value of IgG immunoglobulin. Mean value
ranged from 551 to 868 mg/dl(normal value:850–1517 mg/dl).
They subjected to eradication therapy. All but one responded
well.
Conclusions: (1) Hp infection was found to coincide with ID,
IDA, MA and leukopenia. (2) The normalization of haemato-
logical parameters after eradication started 6 months later. (3)
The essential mechanism between the Hp infection and low IgG
is unclear and its value remains low and after the eradication
therapy. (4) Studies with larger samples should be done for a
better evaluation of the Hp infection and it’s involvement in
human disease. (5) Hp infection acts in a catabolic way for the
humans. It must be considered to search for it in haematological
conditions of undeﬁned origin.
P849
Helicobacter pylori from the dyspeptic patients in
Thailand: diagnosis, antimicrobial susceptibility
and correlation to clinical outcomes
C. Chomvarin, P. Kulsuntiwong, P. Mairiang,
C. Kulabkhow (Khon Kaen, TH)
Objectives: To evaluate methods for routine clinical diagnostic
use of Helicobacter pylori infection of gastric biopsies, to study the
correlation of H. pylori infection to the clinical outcomes and to
study antimicrobial susceptibility by disk agar diffusion in
Thailand.
Methods: Gastric biopsies, obtained from 210 patients under-
went at the endoscopy unit of Srinagarind Hospital, Faculty of
Medicine, Khon Kaen University, were diagnosed by culture,
rapid urease test (RUT, Pronto dry) and histological examina-
tion. A true positive criteria was indicated when culture or both
RUT and histology tests were positive. One hundred and ﬁfteen
isolates of H. pylori isolates were tested for six antimicrobial
agents by disk agar diffusion method.
Results: The H. pylori infection rate was 44.3% (93/210). The
sensitivity vs. speciﬁcity of the culture, RUT and histology were
88.2% and 100%, 95.7% and 98.3%, and 96.8% and 59.8%
respectively. The prevalence of H. pylori in gastritis (GT),
duodenal ulcer (DU) and gastric ulcer (GU); and gastric cancer
(GCA) patients were 41.2%, 57.9% and 70.6%, respectively. The
chi-squared test showed that GCA patients were signiﬁcantly
more often infected with H. pylori than GT patients. The
resistance of 115 H. pylori isolates to single antimicrobial agent
as metronidazole (MTZ), clarithromycin (CLR),ciproﬂoxacin
(CIP), amoxycillin (AML), and tetracycline (TE) were detected
in 21.7, 0, 5.2, 1.7 and 0 percent, respectively. The combination
resistance to MTZ & CLR, MTZ & CIP, MTZ & AML, MTZ & TE;
and CLR & CIP were detected in 1.7, 1.7, 0.8, 1.7 and 0.8 percent,
respectively. The 2.5 per cent of H. pylori isolates were resistance
to three or more antimicrobial agents.
Conclusion: RUT method was highly sensitive and speciﬁc and
appropriate for routine laboratory use. The correlation of the
GCA patients to H. pylori infection was signiﬁcant difference
compared to GT patients. The high resistance rate to metroni-
dazole indicated that the effective for eradication of H. pylori by
metronidazole should be considered in the clinical management
of H. pylori infection.
P850
Use of an indirect immunoﬂuorescence test for
the detection of CagA in H. pylori
C. Scherer (Essen, D)
Objectives: The cytotoxin associated gene (cagA) of H. pylori is
a frequently discussed virulence factor which codes for a 128-
kDa cytotoxin associated antigen (CagA). The cagA-gene is
usually detected by PCR methods. Publications about pheno-
typic methods for the detection of CagA are rare. Aim of our
investigation was to compare a slightly modiﬁed, recently
published indirect immunoﬂuorescence test (iIFT) for the
detection of CagA with commonly used PCR assays.
Methods: H. pylori ATCC 43504 (cagA+/CagA+) was used as
positive control strain, ATCC 51932 (cagA+/CagA+) as negative
control strain. Nineteen clinical isolates of H. pylori were
examined for their CagA- and cagA-status. CagA was detected
by iIFT using monoclonal anti-CagA-antibody from mice, which
were visualised for immunoﬂuorescence microscopy with
FITC-conjugated anti-mouse-antibody from rabbits. DNA was
extracted by a standard phenol–chlorophorm procedure after
proteinase K treatment of the cells from a 4-day old culture. 7
primer pairs and their published protocols were used: F1/B1
and D008/R008 as the most described primer pairs and further
ﬁve primer pairs. All tests were performed in duplicate.
Results: 4 from 19 (22%) strains were CagA positive in the iIFT,
and also cagA positive in each PCR. 13 from 19 (68%) strains
were negative in the iIFT. 10 from these 13 were cagA-negative
in each PCR and 3 showed varying results in the PCR-assays. 2
from 19 ( 10%) strains could not be interpreted by iIFT, both
showed varying results in the PCR-assays.
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Conclusion: The iIFT might be a simple to use tool in the
determination of the cagA-status, since it showed no false
positive result in neither tested PCR. The differing results in iIFT
and PCR suggest that genotypic positive strains may not always
express CagA in vitro and maybe also not in vivo. Therefore the
CagA-iIFT may be an interesting parameter for the determin-
ation of strain virulence in addition to PCR-assays.
P851
Evaluation of ELISA serology for the primary
diagnosis of Helicobacter pylori infection in
Turkish dyspeptic patients: a prospective study
from a developing country
B. Kocazeybek, Y. Erzin, S. Altun, A. Dobrucali, M. Aslan,
S. Erdamar, A. Dirican (Istanbul, TR)
Aim: Hp is recognized as an important human pathogen by
virtue of it’s association with peptic ulcer disease, gastric cancer
and gastric lymphoma and the high prevalence of infection
worldwide. Both invasive and noninvasive tests are available to
diagnose Hp infection but there is still no single gold standard.
The aim of the present study was to evaluate the diagnostic
accuracy of a commercially available anti-Hp IgG ELISA kit for
the primary diagnosis of Hp infection.
Materials and methods: A total of 185 patients who were
referred to our endoscopy unit were included. According to our
gold standard, a patient was classiﬁed as being Hp(+) if the
culture and/or both histology, rapid urease test were positive
and as Hp()) only if all of these tests remained negative.
Standard methods were used to calculate sensitivity, speciﬁcity,
predictive values of positive and negative results and 95%
conﬁdence intervals of these values.
Results: After excluding patients with discordant results131 of
152 patients (86%) were Hp (+). The sensitivity, speciﬁcity and
diagnostic accuracy of the IgG-ELISA were 97%, 67%, 93%
respectively.
Conclusion: Due to it’s lack for speciﬁcity, we conclude that
quantitative anti-Hp ELISA test may not be a suitable alternative
for primary diagnosis of Hp in our country, where the
prevalence of infection is still very high.
P852
Comparison of two different stool antigen tests
for the primary diagnosis of Helicobacter pylori
infection in Turkish dyspeptic patients
B. Kocazeybek, Y. Erzin, S. Altun, A. Dobrucali, M. Aslan,
S. Erdamar, A. Dirican (Istanbul, TR)
Aim: To assess the reliability of two different enzyme immu-
noassays in detecting the Helicobacter pylori(Hp) status in stool
specimens of Turkish dyspeptic patients.
Materials and methods: 151 patients [74 with non-ulcer dys-
pepsia(NUD), 64 with duodenal ulcer(DU),13 with gastric
cancer]who were admitted to the endoscopy unit of Istanbul
University, Cerrahpasa Medical Faculty for upper gastrointes-
tinal endoscopy due to dyspepsia were enrolled in the study. Hp
infection was conﬁrmed in all patients by histology, rapid urease
test(RUT) and culture. A patient was classiﬁed as being
Hp-positive if the culture alone or both histology, RUT were
positive in the absence of a positive culture and as negative only
if all of these tests remained negative. Stool samples of patients
were obtained in order to assess the reliability of a monoclonal
(FemtoLab H. pylori, Connex, Martinsried, Germany) and a
polyclonal (Premier Platinum HpSA, Meridian Diagnostics Inc.,
Cincinnati, USA) stool antigen test and to compare their
diagnostic accuracies. The v2 test was used for statistical
comparison of the values.
Results: Using a cutoff 0.19 for FemtoLab H. pylori and 0.16 for
Premier Platinum HpSA the sensitivity, speciﬁcity, positive
predictive value (PPV), negative predictive value (NPV) and
diagnostic accuracy of the former and latter tests were 93%, 90%,
98%, 68%, 93% and 84 %, 67%, 94%, 40%, 81% respectively. The
sensitivity, speciﬁcity, NPV and diagnostic accuracy of the
former test were signiﬁcantly superior to the latter one’s (v2 =
3.98; p < 0.05 for sensitivity and v2 = 15.67; p = 0.000 for
speciﬁcity, v2 = 15.78; p = 0.000 for NPV and v2 = 6.37;
p = 0.012 for diagnostic accuracy). The bacterial load did not
affect the sensitivity of both tests.
Conclusions: The monoclonal FemtoLab H. pylori, using a
cutoff 0.19 is a very sensitive, speciﬁc and easy to perform
diagnostic tool for the primary diagnosis of Hp infection in
Turkish, dyspeptic patients.
P853
Evaluation of two different enzyme
immunoassays for detection of Helicobacter
pylori in stool specimens of Turkish dyspeptic
patients after eradication therapy
B. Kocazeybek, Y. Erzin, S. Altun, S. Saribas, A. Dobrucali,
M. Aslan, S. Erdamar, A. Dirican (Istanbul, TR)
Aim: To assess the reliability of two different enzyme immu-
noassays(EIAs) in detecting the Hp status in stool specimens of
Turkish, dyspeptic patients in the post-treatment period.
Materials and methods: 48 patients with non-ulcer dyspep-
sia(NUD) who were positive for Hp underwent a one week
regimen of triple therapy. Stool samples of patients were
obtained 2–6 weeks and 13C-urea breath test(UBT) was per-
formed 6 weeks after eradication therapy in order to assess the
reliability of a monoclonal (FemtoLab H. pylori, Connex,
Martinsried, Germany) and a polyclonal (Premier Platinum
HpSA, Meridian Diagnostics Inc., Cincinnati, USA) stool antigen
test and to compare their diagnostic accuracies. The v2 and
Fisher’s exact tests were used for statistical comparison of the
values.
Results: Using a cutoff 0.19 for FemtoLab H. pylori and 0.16 for
Premier Platinum HpSA the sensitivity, speciﬁcity, positive
predictive value (PPV), negative predictive value (NPV) and
diagnostic accuracy of the former and latter tests were 93%, 67%,
56%, 96%, 75%versus 87%, 33%, 37%, 85%, 50%2 weeks and 93%,
88%, 78%,97%, 90%versus67%,70%, 50%, 82%,69%6 weeksafter
completion of eradication therapy, respectively. Both at the 2nd
and 6th weeks in the post-treatment period the diagnostic
accuracy of FemtoLab H. pylori was signiﬁcantly superior to
Premier Platinum’s (75%versus 50%, v2 = 6.4 ;p = 0.011, and 90%
versus 69%, v2 = 6.316; p = 0.012 respectively).
Conclusions: The monoclonal FemtoLab H. pylori, using a
cutoff 0.19 is sensitive and speciﬁc enough to monitor Hp
infection in Turkish, dyspeptic patients 6 weeks after completion
of eradication therapy.
P854
Helicobacter pylori cag pathogenity island genes
cagA, cagE and vacA subtypes in Turkish
dyspeptic patients
B. Kocazeybek, Y. Erzin, V. Koksal, S. Erdamar, S. Altun,
A. Dobrucali (Istanbul, TR)
Objectives: Although more than %50 of the world’s population
is infected with Helicobacter pylori(Hp), only a minority of
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carriers develop serious gastroduodenal diseases. So, it is
important to deﬁne whether strains with speciﬁc genotype are
associated with the clinical outcome. The aim of this study was
to determine the distribution of the cagA, cagE and vacA
subtypes of Hp in patients with various gastroduodenal diseases
in Turkey, and to explore the association between genotype and
the clinical outcome of infection.
Methods: 93 strains of Hp were isolated from cultures and
pathological archives of 30 patients with non-ulcer dyspepsia
(NUD), 30 with duodenal ulcer(DU) and 33 with gastric
carcinoma. The cagA, cagE and vacAs1a/s1b, m1/m2 genotypes
were determined by polymerase chain reaction methodology.
Results: There were no statistically signiﬁcant difference among
three different clinical outcomes according to the positive rates
of vacA s1b, s2 and vacA m1/m2. But the positive rates of vacA
s1a, cagA and cagE were 66.7% (20/30), 50% (15/30) and 26.7%
(8/30) in NUD; 93.3% (28/30), 83.3% (25/30) and 66.7% (20/30)
in DU; 87.9% (29/33), 84.8% (28/33) and 81.8% (27/33) in gastric
cancer group, respectively, showing statistically signiﬁcant
difference (p = 0.015, p = 0.002, p = 0.001, respectively). The
prevalence of vacAs2 and m2 in NUD patients was higher than
that in duodenal ulcer group, but this difference was not
statistically signiﬁcant.
Conclusions: Helicobacter pylori cagA, cagE and vacAs1a geno-
types have a signiﬁcant relation with duodenal ulcer and gastric
carcinoma in Turkish population. There were no statistically
signiﬁcant association of the vacA s1b, s2 and vacA m1/m2
strains among disease groups.
P855
Clinical relevance of iceA1, iceA2 and babA2
genotypes of Helicobacter pylori in Turkish
patients with non-ulcer dyspepsia, duodenal
ulcer and gastric cancer
B. Kocazeybek, Y. Erzin, V. Koksal, S. Erdamar, S. Altun,
A. Dobrucali, A. Oner (Istanbul, TR)
Objectives: The clinical relevance of the Helicobacter pylori(Hp)
adherence factor, babA gene, and the other virulence determin-
ant, iceA gene, has not yet been determined in Turkish clinical
isolates to date. Therefore, the aim of this study was to evaluate
the prevalence of iceA1, iceA2 and babA2 Hp genotypes in
Turkish patients with non-ulcer dyspepsia(NUD), duodenal
ulcer(DU) and gastric cancer.
Methods: 30 strains were isolated from patients with NUD, 30
were isolated from individuals with DU and 33 were isolated
from patients with gastric cancer. Bacterial DNA was extracted
from cultures and Hp positive parafﬁn-embedded biopsy
samples and genotyping of iceA and babA2 was carried out
utilizing polymerase chain reaction molecular technique by
using speciﬁc primers.
Results: The iceA1, iceA2 and babA2 genotypes were detected
in 75.3% (70/93), 24.7% (23/93), 53.8% (50/93) respectively, of
the Hp strains studied. The prevalence of iceA1 in gastric cancer
patients was higher than that in NUD group, 84.8% (28/33) and
60% (18/30), respectively (p = 0.045). The prevalence of iceA2 in
NUD group was higher than that gastric cancer patients, 40%
(12/30) and 15.2% (5/33), respectively (p = 0.045). The positive
rates of babA2 were 23.3% (7/30) in NUD; 46.7% (14/30) in DU
and 87.9% (29/33) in gastric cancer group, showing statistically
signiﬁcant difference (p = 0.0001).
Conclusions: BabA2 genotype distribution was evaluated in
different gastric pathologies in Turkish population and was a
goodmarker for the presence of DU and gastric adenocarcinoma.
Thus, our current results conﬁrm previous experimental studies
indicating a central role of Hp’s adhesin and Lewis antigens in
the pathogenesis of ulcer disease and adenocarcinoma.
P856
Inﬂuences of interleukin 1B and interleukin 1RN
polymorphisms on the development of non-ulcer
dyspepsia, duodenal ulcer and gastric cancer in
Turkish population
B. Kocazeybek, Y. Erzin, V. Koksal, S. Erdamar, S. Altun,
A. Dobrucali (Istanbul, TR)
Objectives: IL-1B and IL-1RN gene polymorphisms (which
encode interleukin 1B and interleukin-1 receptor antagonist,
respectively) have been associated with development of gastric
atrophy and with increased risk of gastric carcinoma. The aim of
this study was to determine the inﬂuences of host IL-1B -31TC,
IL-1B -511CT and IL-1B RN gene polymorphisms on the
development of various gastroduodenal pathologies in 93
Helicobacter pylori (Hp) positive Turkish patients [(30 with non-
ulcer dyspepsia (NUD), 30 with duodenal ulcer (DU) and 33
with gastric cancer (GC)].
Methods: Genomic DNA was extracted from Hp positive
parafﬁn embedded gastric biopsy samples of 30 NUD, 30 DU
and 33 GC patients. IL-1B and IL-1B RN gene polymorphisms
were analysed by polymerase chain reaction-restriction frag-
ment length polymorphism. These polymorphic sites include
promoter regions of IL-1B at positions-511 (C–T transition) and -
31 (T–C transition), and IL-1 RN variable tandem repeats
(intron2 VNTR).
Results: There were no statistically signiﬁcant difference
among three clinical outcomes in the frequencies of IL-1B
-511CT + TT and IL-1B -31 TC + CC genotypes (as called
proinﬂamatory genotypes) (p = 0.161 and p = 0.077, respect-
ively). The prevalence of the proinﬂamatory IL-1B RN 1/2 + 2/
2 alleles in GC group was higher than that in NUD and DU
groups. The frequencies of IL-1B RN 1/2 + 2/2 alleles were
20.0% (6/30) in NUD; 31.0% (9/30) in DU; and 57.6% (19/33) in
GC group, showing statistically signiﬁcant differences
(p = 0.006).
Conclusions: There were no statistically signiﬁcant difference
among three clinical outcomes in the frequencies of IL-1B -
511CT + TT and IL-1B -31 TC + CC genotypes, whereas proinf-
lamatory IL-1B RN *2 allele (1/2 + 2/2) was associated with
gastric cancer in Turkey.
P857
Rapid detection of clarithromycin-resistant
Helicobacter pylori in patients with dyspeptic by
ﬂuorescent in situ hybridisation (FISH), in
comparison with E-test
M. Moosavian, S. Tajbakhsh, A. Samarbafzadeh (Ahwaz, IR)
Objectives: Isolation of H. pylori from more than 90% of the
patients with peptic ulcer have demonstrated a strong relation-
ship between these bacteria and created ulcers or dyspeptic.
Recovery of the patients will be accelerated, if clarithromycin be
added to therapeutic protocol. The objectives of this study are:
1-Rapid detection of the susceptible or resistant strains of
Helicobacter pylori to clarithromycin, in patients with dyspeptic
by FISH technique. 2-Comparison of the results of FISH &
Epsilometer test ( E-test) techniques.
Methods: Frozen – sections of gastric biopsies of 50 patients
with dyspeptic were hybridized in situ by 5 ﬂuorescent
oligonucleotide probes (FISH). The prepared slides were
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examined under a ﬂuorescent microscope, after staining with
DAPI. Also, susceptibility and resistance of isolated strains of
H. pylori to clarithromycin were determined by E-test. Both
results of E-test and FISH techniques were compared in ﬁnal.
Results: 25 out of 50 examined gastric biopsy samples were
positive for H. pylori by FISH. Out of these 25 H. pylori strains, 17
strains (68%) were susceptible, 6 strains (24%) were resistant and
2 strains (8%) were mixture of susceptible and resistance strains
to clarithromycin. This study showed no signiﬁcant different
between FISH and E-test results, in view of number in
susceptible or resistance strains.
Conclusions: Since the patient gastric biopsies are not routinely
cultured in the most of clinical laboratories, also, for isolation of
H. pylori, it is needed to enriched and selective media and the
other way, clarithromycin is an expensive drug, so, it looks like
that FISH technique is a suitable method for replacing of the
culture, antibiotic sensitivity test and or E-test method.
P858
Diagnosis of atrophic gastritis from a blood
sample
P. Douramani, S. Mavrea, A. Arkas, A. Adamopoulos,
E. Anastasakou (Athens, Paros, GR)
Introduction: The majority of gastritis is related to infectious
agents, where H. pylori is the most important and common.
H. pylori gastritis could proceed, over time, to atrophic form of
gastritis a serious disease that increases the risk of peptic ulcers
and gastric cancer. A new test panel was developed for non-
endoscopic diagnosis of atrophic antrum and corpus gastritis
from a blood sample.
Aim: To investigate whether atrophic gastritis can be diagnosed
and typed non-endoscopically if the serum levels of pepsinogen
I (S-PGI) and gastrin-17 are assayed in connection with H. pylori
testing.
Materials and methods: The study population consists of 50
selected dyspeptic outpatients with (cases) or without (con-
trols) advanced (moderate or severe atrophic gastritis) who
underwent a diagnostic gastroscopy for dyspeptic symptoms.
Of the 50 selected patients,28 (cases) had an advanced atrophic
gastritis or a resected stomach. Of these 28 cases, 4 had an
advanced antrum-limited atrophic gastritis, 6 had resected
antrum,15 had a corpus limited advanced atrophic gastritis.
Two patients had an advanced atrophic gastritis in both the
antrum and corpus (multofocal atrophic gastritis) and the
whole stomach was removed in one patient. The controls
comprise 22 patients of whom 10 had a non atrophic H. pylori
gastritis; the antrum and corpus were normal and healthy in 12
patients. The sample for postprandial gastrin -17 (S-G-17
prand) was taken 20 min after a protein drink. The S-G-17,S-
PGI and IgG class antibodies to H. pylori were determined
using ELISA methods.
Results: A low S-PGI (<25 mg/l) was found in 15 of 18 patients
(83%) with and in 2 of 32 patients (6%) without corpus atrophy.
A low S-G-17 prand (<5 pmol/l) was found in all 4 patients with
H. pylori associated antral-atrophy and in 5 of 7 patients (71%)
with resected antrum but in one of 10 patients (10%) with
H. pylori-related non-atrophic gastritis. The mean values of both
S-G-17 prand and S-PGI decreased with increasing grade of
antral and corpus atrophy respectively. Among all patients with
atrophic gastritis,24 of 28 patients (86%) had a low S-PGI and/or
a low S-G-17 prand with positive IgG H. pylori antibodies. Such
low values were found only in one of the 22 (4.6%) control
patients.
Conclusions: Low serum levels of G-17 and S-PGI are diagnos-
tic markers of atrophic antral and corpus gastritis, respectively.
A low S-G-17prand is a sigh of the multifocal or antrum-limited
atrophic gastritis in patients infected with H. pylori.
P860
Helicobacter pylori in gastric mucosa: an
ultrastructural study
E. Ozbek, A. Ozbek, H. Dursun, O. Vuraler (Erzurum, TR)
Objectives: Helicobacter pylori are extraordinary among bacteria
in their ability to colonize the human gastric mucosa, an
inhospitable acidic environment, and to stay on there for long
periods as decades in despite of host immune and inﬂammatory
responses. In this study, we aimed to research where H. pylori
are found within the stomach by transmission electron micros-
copy (TEM).
Methods: Gastroscopic biopsy samples from patients suspected
with gastritis or peptic ulcer were processed for both of PCR and
TEM. The presence of H. pylori in biopsy samples was inves-
tigated with PCR method by using speciﬁc 23 S ribosomal RNA
primers. The samples for electron microscopic examination were
ﬁxed in 3% glutaraldehyde, postﬁxed in 1% osmic acid,
dehydrated in acetone, and embedded in Araldite. Plastic
blocks of positive samples for the presence of H. pylori
conﬁrmed by PCR were cut with a Nova LKB Bromma
ultratome. Thin sections were stained with uranyl acetate and
lead citrate, and examined by using a Jeol 100 SX transmission
electron microscope.
Results: We observed that cross- and longitudinal-sectioned
H. pylori within the mucus layer overlying gastric epithelium, in
the intercellular spaces between gastric epithelial cells (ﬁgure 1),
and between two microvilli protruding from the apical surface
of an epithelial cell into the gastric lumen. Apart from the
extracellular H. pylori, we found also intravacuolar H. pylori
within the epithelial cells of the gastric mucosa. We observed
H. pylori engulfed by pseudopod-like structures at the apical
part of the epithelial cells. There were also late endosomal
vacuoles containing H. pylori within the deeper cytoplasmic
parts of the cell.
Conclusion: Although H. pylori is considered generally a non-
invasive pathogen, our electron microscopic observations prove
that H. pylori is able to invade gastric epithelial cells, and to enter
large cytoplasmic vacuoles. That H. pylori is able to be found
intracellularly might explain why the eradication of H. pylori
infection is difﬁcult with the antibiotics such as gentamicin that
cannot easily cross the eukaryotic cell membrane. Abbreviations
for ﬁgure 1: H, Helicobacter pylori; N, nucleus of a gastric
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epithelial cell; E, cross-sectioned epithelial cells; Nm, nuclear
membrane; IS, intercellular space.
Bar = 0.5 micrometre
P861
Helicobacter pylori and association with
histological ﬁndings in endoscopic biopsies
in western Greece
C. Petropoulos, E. Jelastopulu, M. Kardara,
S. Spiropoulos (Erymanthia, Patras, GR)
Objectives: There is evidence that Helicobacter pylori (H. pylori)
infection is strongly associated with gastric and duodenal
lesions in general population. In this study we reviewed
gastroscopic and histological records of patients who underwent
gastroscopy for multiple reasons in a tertiary hospital in order to
evaluate the frequency of H. pylori colonization in biopsy
specimens and to examine the association between H. pylori
infection and histological ﬁndings.
Methods: The medical records of 251 patients who presented to
the General Hospital Agios Andreas in Patras, Western Greece,
during the period 2002–03 for upper gastrointestinal complaints
and other speciﬁed symptoms were reviewed for the presence of
H. pylori. All patients have been submitted to endoscopy with
biopsy mainly of the gastric mucosa. The statistical analysis was
performed using the SPSS.
Results: Gastroscopies and biopsies were undertaken in 251
patients (149 men, 102 women; mean age 58.5, range 16–
95 years). In 140 (59.1%) of the patients dyspepsia was the
main indication for gastroscopy, followed by 44 (18.6%)
patients with anaemia, 12 (5.1%) patients with black faeces
and 11 (4.6%) patients with reﬂux. Usual macroscopic ﬁndings
were oedema (70%), hyperaemia (50%), erythema (22.3%), ulcer
(16.8%) and erosions (7.5%). The histological examination
revealed chronic gastritis in 209 (83.3%) subjects (in 39% of
mild form, in 50% of moderate and in 11% of severe form),
atrophic chronic gastritis in 8 (3.1%) and adenocarcinoma in 10
(3.9%) patients. The overall colonization of H. pylori was
detected in 80 (34.2%) subjects. In case of H. pylori positive
patients, chronic gastritis was found in 15.4% of mild form, in
61.5% of moderate and in 23.1% of severe form, whereas in
absence of H. pylori infection the histological type of chronic
gastritis was 52.5%, 43.2% and 4.3% respectively. In case of
chronic gastritis of severe form H. pylori colonization was
found in 75% (p < 0.001), whereas regarding the mild form H.
pylori presence was observed only in 14% (p < 0.001).
Conclusions: The study reveals that H. pylori infection is
strongly associated with the severe form of chronic gastritis.
Thus, for the optimal management and treatment of the
patients with gastritis a biopsy of the mucosa appears to be
necessary.
MRSA – virulence, genes, VISA and treatment
P862
Molecular analysis of methicillin-resistant
Staphylococcus aureus genes in isolates inhibited
by natural products
N.S. Mariana, N.I. Mashan, S. Zamberi, A.R. Raha,
V. Neela (Selangor, MYS)
Objective: The ultimate aim of the study is to explore
potential natural products as alternative for treatment of
infections from Staphylococcus aureus including methicillin
resistant Staphylococcus aureus (MRSA). The speciﬁc objective
of the paper is to assay for molecular changes in the genes of
MRSA isolates upon inhibition by natural products. Five genes
of MRSA isolates study include mecA, mecI and mecRI adaB
and sav1017 and the non-MRSA isolates were adaB and
sav1017 genes. The adaB gene encodes for methyltransferase
activity for DNA repair mechanism while the sav1017 is the
cell wall protein gene.
Methods: MRSA and non-MRSA isolates were obtained from
patients receiving treatment in Malaysian hospitals. These
isolates were subjected to growth in methanol extract of marine
seaweed. Inhibition assay of extract on isolates including
several genera of the gram-negative bacteria, were determined
by the disc diffusion and minimum inhibitory (MIC) methods.
Treated and untreated isolates inhibited by extract were
subjected to PCR ampliﬁcation, followed by commercial
sequencing, RT-PCR assay of the mRNA followed by sequen-
cing of the cDNA and BLASTN analysis with the GenBank
sequences.
Results: The inhibition assay of methanol extract showed
activity only in MRSA and non-MRSA isolates but not in gram
negative isolates. The nucleotide sequences changes were seen
in four genes of treated MRSA isolates which were the mecA,
mecRI, mecI and the adaB. The nucleotide changes in non-
MRSA and MRSA were only seen in the adaB gene but not the
sav1017. The BLASTN analysis showed variation in nucleotide
changes in all genes involved in MRSA phenomenon.
Conclusions: These preliminary results utilizing genomics for
study on nucleotide sequences of pathogen can aim at utilizing
the biomolecules from natural products to target the affected
nucleotides so as to inhibit growth of the organism. The research
activity has the potential of speeding up drug discovery
programme and the nucleotide changes in several genes treated
with the extract indicates the potential target sites of the extracts.
The inhibitory effect of extract on the nucleotide of some genes
remained unchanged in the PCR and RT_PCR assay, indicating
selective effect of extracts on the genes and the extracts has the
potential to be applied as antibacterial agents. Implication of the
ﬁndings is directed towards discovery of antibacterial drug
target sites, which warrants further study.
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P863
Phenotypic and genotypic characteristics of
Staphylococcus aureus strains defective in
species-speciﬁc proteins
A. Luczak, J. Krzyszton-Russjan, K. Nowak,
W. Hryniewicz (Warsaw, PL)
Objectives: The objective of this study was to characterise
phenotypically clumping factor and/or coagulase defective
S. aureus.
Methods: The study was performed on 170 S. aureus isolates
identiﬁed between 1996 and 2004 as clumping factor (CF) or free
coagulase (FC) defective by clinical microbiology laboratories
and submitted to National Institute of Public Health in Warsaw
for veriﬁcation. Reidentiﬁcation included detection of clumping
factor, coagulase, thermonuclease, and ability to ferment mann-
itol. Antimicrobial susceptibility testing was performed by disk-
diffusion method according to the NCCLS. Glycopeptides
susceptibility was determined by screening method, MIC
evaluation and population analysis. PCR reactions were per-
formed to conﬁrm the presence of species speciﬁc genes, as cfa,
cfb, coa, nuc, spa. To obtain isolates clonality, Multiple-Locus
Variable-Number Tandem Repeat Analysis (MLVA) was
applied.
Results: Based on the phenotypic reidentiﬁcation methods, 114
(67%) isolates were phenotypically defective in respect to
clumping-factor or coagulase production. All but one isolate
exhibited the presence of the genes encoding CF or FC. Seventy-
ﬁve (67%) isolates were resistant to methicilin (MRSA) and
multiresistant. Twenty-six (22.8%) isolates showed reduced
glycopeptides susceptibility in PAP. All hVISA and hGISA
isolates were MRSA and all were defective mainly in clumping-
factor production. Thirty-one different MLVA groups were
distinguished. The A and L groups were the most common and
variable. The A type was the most prevalent in hVISA/hGISA
isolates and found in 18 centres.
Conclusion: The clonal spread of S. aureus defective in species
speciﬁc proteins was revealed. The correlation between
decreased susceptibility to glycopeptides and defective species
speciﬁc proteins was observed.
P864
Detection of Panton-Valentine leucocidin and
other staphylococcal toxins using oligonucleotide
arrays
S. Monecke, R. Ehricht (Dresden, Jena, D)
Objectives: The recent outbreaks of community acquired
MRSA (cMRSA) harbouring Panton-Valentine Leucocidin
(PVL) caused serious concern worldwide. In order to screen
clinical isolates, we designed and tested an oligonucleotide
array which can detect both components of this virulence
factor, six staphylococcal superantigens and the two exfoliative
toxins as well as several resistance genes and species-speciﬁc
controls.
Methods: Twenty-two clinical isolates (two suspected cMRSA
and twenty randomly selected) from swabs obtained from a
dermatological clinic in Saxony/Germany were cultured. DNA
was isolated and subjected to a linear multiplex ampliﬁcation
incorporating biotin-labeled dUTP into the amplicon.
Hybridization of the amplicons to the array was detected
using an enzymatic precipitation reaction.
Results: In two cases of chronical furunculosis, PVL-positive
cMRSA were identiﬁed. One case was a soldier returning from a
peace mission to Kosovo where he apparently contracted the
disease, the other one was his spouse. In three other cases of
furunculosis/abscesses, PVL-positive but methicillin-suscept-
ible S. aureus were found. Staphylococcal enterotoxins were
found in four, toxic shock syndrome toxin in three isolates, and
exfoliative toxin A in one isolate. In two cases, multiple toxins
were found (PVL + tst + entC and entB + entK + entQ + etA).
Conclusions: While epidemic cMRSA strains often can pre-
sumably be identiﬁed due to their resistance proﬁle (methicillin,
tetracycline, fusidic acid), there is no easy method to detect PVL-
positive, methicillin-susceptible S. aureus. Therefore, strains
carrying PVL are more common than previously suspected.
The high prevalence of this virulence factor as well as of
other toxins found in the present study warrants further
investigations.
P865
Characterisation of methicillin-resistant
Staphylococcus aureus harbouring the
Panton-Valentine leucocidine
A. Anders, M. Kaase, S. Friedrich, S.G. Gatermann (Bochum, D)
Objectives: Until nowmethicillin-resistant Staphylococcus aureus
(MRSA) have been known only as a major problem in hospitals.
Lately, a new kind of MRSA has been described. This MRSA is
responsible for community-acquired infections (c-MRSA) and
harbours the determinant for the Panton-Valentine leucocidine
(PVL).As there are descriptions of c-MRSA possessing the PVL
throughout the world with different MLST types we wanted to
characterize eleven c-MRSA from our area possessing the gene
for Panton-Valentine leucocidine.
Methods: The isolates were found from 1999 until the summer
of 2004, the gene encoding PVL was veriﬁed by PCR.We
determined the PFGE pattern, the MLST type, the SCCmec type
and the agr allele type of the eleven isolates.
Results: So far all isolates belong to the ST 80 which has been
also described elsewhere in Germany and in France but differs
from the types found in the US (1 and 8) or in Australia (30 and
298). They possess a SCCmec element of type IVb and the agr3
allele type. All isolates were resistant to oxacillin, which was
determined by mecA PCR, and all were resistant to fusidic acid.
Only two were additionally resistant to erythromycin. No
resistance could be found to ﬂuoroquinolones.The average age
of patients was 47 years and they all had severe community-
acquired abscesses of the skin or soft tissue that caused hospital
admission.
Conclusion: MRSA cannot be longer considered as affecting
only hospitalized and elderly patients but we should also be
aware of them in community-acquired infections.
P866
Accessory gene regulator group polymorphism in
methicillin-resistant Staphylococcus aureus in
Korea: an association with clinical signiﬁcance
H.J Yoon, J.Y. Choi, J.M. Kim, D. Yong, K.W. Lee,
Y.G. Song (Seoul, KOR)
Background: Genetic variation among S. aureus strains has been
shown to be associated with pathogenic potential. Virulence
gene expression in S. aureus is controlled by regulators such as
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accessory gene regulator (agr), and its locus of S. aureus is a
quorum-sensing gene cluster of ﬁve genes (hld, agrB, agrD,
agrC, and agrA) that upregulates production of secreted
virulence factors, including the alpha-, beta-, delta-hemolysins,
and downregulates production of cell-associated virulence
factors. S. aureus strains can be divided into 4 major agr
groups (agr I-IV) on the basis of a polymorphism in agrD and
agrC. The purpose of this study is to know the proportion of agr
I, II, and III polymorphisms and to compare clinical character-
istics between group II and non-group II polymorphism of
methicillin-resistant Staphylococcus aureus (MRSA) strains in a
tertiary care teaching hospital in Korea.
Methods: Isolates were identiﬁed as S. aureus by conventional
methods. Susceptibility to methicillin was determined by the
NCCLS guideline. Agr locus was identiﬁed using restriction
fragment length polymorphisms (RFLPs) analysis of agr BDC
amplicons with DraI digestion. The factors assessed included
the patients’ demographics, comorbidities (diabetes mellitus,
congestive heart failure, peripheral vascular disease, dialysis-
dependent renal failure, cirrhosis, malignancy, and alcoholism),
infection site (central catheter-related bacteraemia, bacteraemia
of unknown origin, device, endocarditis, intraabdominal, res-
piratory, skin, urine, and ear), receipt of mechanical ventilation
and operation, the presence of nosocomial infection and treat-
ment failure, creatinine level, and mortality.
Results: A total of 18 strains from 18 MRSA-infected patients (7
males and 11 females) were evaluated. Their mean age was
50.5 ± 24.3 years old. There were 4 (22.2%), 12 (66.7%), and 2
(11.1%) strains in agr group I, II, and III polymorphism,
respectively. Only nosocomial infections were statistically sig-
niﬁcant clinical parameter according to univariate analysis
(p = 0.009) and multivariate analysis (OR, 22.0 (1.540 )
314.292); P, 0.023).
Conclusion: Agr group II was most prevalent in this study and
nosocomial infections were correlated with group II polymorph-
ism. This result suggests virulence and nosocomial spread of
MRSA strains are originated from group II polymorphism. A
recruit of more strains will increase and clarify the clinical
difference between agr groups.
P867
Distribution of toxic shock syndrome toxin-1,
exfoliative toxins and enterotoxins SEG and SEI
among methicillin-resistant Staphylococcus
aureus clonal types
V. Chini, G. Dimitracopoulos, I. Spiliopoulou (Patras, GR)
Objectives: Staphylococcus aureus produces a variety of exotox-
ins including the toxic shock syndrome toxin-1 (TSST-1), the
exfoliative toxins ETA and ETB and the enterotoxins SEG and
SEI. The SEG and SEI genes (seg and sei) coexist in the same
operon. The aim of this study was to investigate the presence of
genes encoding the TSST-1 (tst), ETA (eta), ETB (etb), SEG (seg)
and SEI (sei) among methicillin-resistant S. aureus (MRSA)
clinical isolates, in relation to their clonal types.
Methods: The MIC of oxacillin was determined by the agar
dilution method in Mueller–Hinton agar supplemented with 2%
NaCl according to the guidelines of NCCLS. PBP2a production
was investigated by a Latex agglutination test (bioMerieux) in
all S. aureus isolates with MIC >0.5 mg/L. PCR ampliﬁcation
was performed for the detection of mecA gene to the aforemen-
tioned isolates, from different patients, during 2001–2003,
resulting to 160 MRSA. The presence of tst, eta, etb, seg and
sei genes was also investigated by PCR. Clonal types were
determined by PFGE of chromosomal DNA SmaI digests.
Results: Among the 160 MRSA, 35 (22%) carried both seg and
sei genes, 24 (15%) isolates carried the tst, 2 (1%) the eta,
whereas no strains exhibited the etb gene. Precisely, during 2001
the tst gene coexisted in 12 out of 13 seg/sei-positive strains.
Eleven strains belonged to PFGE type A, whereas the other two
to type B, mainly associated with wound infections. Eight MRSA
in 2002 belonging to PFGE type A, carried tst, seg and sei. Two
more strains carrying seg/sei, belonged to PFGE type C. Two
out of 3 seg/sei-positive additional MRSA which were charac-
terized as a new clone F, carried also eta. In 2003, four MRSA
carrying the tst, seg and sei belonged to clone A, whereas 5 more
carrying the seg/sei were characterized as PFGE type C. Most
isolates were associated with wound infections and abscesses.
Conclusions: During the study period (2001–2003) the inci-
dence of the tst gene carriage among MRSA was reduced from
26% to 6%, while the seg/sei genes were almost constantly
present. The distribution of these genes was mainly associated
with strains of clonal type A, exhibiting a drift towards clone
type C predominant during the last two years.
P868
Detection of decreased susceptibility to
glycopeptides in Staphylococcus aureus using
tablet (disc) prediffusion
S.V. Nielsen, J.B. Casals (Taastrup, DK)
Objectives: The aim of the study was to develop a screening
and conﬁrmatory method to detect Staphylococcus aureus with
decreased susceptibility to glycopeptides (hVISA/VISA and
GISA).
Methods: The glycopeptide resistance of 20 Staphylococcus
aureus strains from our strain collection including well-known
resistant strains (ATCC 700788, ATCC 700789, ATCC 700698,
ATCC 700699) was examined. We compared: (i) zone sizes of
Vancomycin 5 lg and Teicoplanin 30 lg Neo-Sensitabs (Rosco
Diagnostica) when prediffused for 2 h (with disc) + 18 h (with-
out disc) on Mueller–Hinton and BHI, both media supplemen-
ted with 5% horse blood, (ii) agar dilution MICs (iii) zone sizes
around Cefoxitin 60 lg Neo-Sensitabs. The inoculum used was
McFarland 0.5 and the plates were incubated for 24 h at 35C.
Results: Regression lines were prepared and there was a good
correlation between MICs for vancomycin and teicoplanin and
the corresponding zone sizes. All hVISA/VISA/GISA strains
tested showed zones less than 15 mm with Cefoxitin 60 lg and
zones £ 21 mm (teicoplanin) and/or £ 23 mm (vancomycin) on
MH Blood Agar, corresponding to MICs > 2 lg/ml for both
antimicrobials. On BHI agar the zones were £ 17 mm (teicopla-
nin) and/or £ 21 mm (vancomycin) for the hVISA/VISA/GISA
strains corresponding toMICs > 4 lg/ml for both antimicrobials.
Conclusion: Zones obtained by agar diffusion methods using
prediffusion with Vancomycin and Teicoplanin Neo-Sensitabs
correlated with MICs and predicted hVISA/VISA/GISA strains.
For screening high resistance to Cefoxitin (zones <15 mm) may
be used to select strains for further testing in a daily routine
laboratory. The system should be evaluated further in the
routine diagnostic laboratory.
P869
High rate of vancomycin intermediate
Staphylococcus aureus among methicillin-
resistant isolates in Taiwan
J. Lu, S.-Y. Lee (Taipei, TW)
Objectives: One thousand and ﬁve hundred consecutive meth-
icillin-resistant Staphylococcus aureus (MRSA) isolates collected
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from 637 patients in the Tri-Service General Hospital in Taiwan
were screened for vancomycin resistance and isolates with
reduced susceptibility to vancomycin were further studied for
their characteristics.
Methods: Brain heart infusion agar plates containing vancomy-
cin (5 lg/mL) (BHIA-VA5) were using for vancomycin resist-
ance screening. Minimum inhibitory concentration (MIC) of
vancomycin was determined on both BHIA and the standard
Mueller–Hinton agar (MHA) on screened-positive isolates. For
strains with MICs equaled to 8 lg/mL, characteristics including
population analysis, susceptibility to triton X-100 induced
autolysis, van gene and pulsed ﬁeld gel electrophoresis
(PFGE) typing were further performed as previously described.
Results: Of the 230 isolates that grew on BHIA-VA5 plates
(15.3%, 230/1500), 43 (2.9%, 43/1500) were with a minimum
inhibitory concentration (MIC) of 8 lg/mL for vancomycin
when BHIA was used. However, when the standard MHA was
used, only 8 (0.5%, 8/1500) were conﬁrmed to be vancomycin
intermediate S. aureus (VISA). Population analysis also dis-
played a homogeneous intermediate-resistant to vancomycin
among the 8 isolates. The remaining 35 isolates were classiﬁed
as heterogeneous intermediate-resistant (28) or susceptible (7) to
vancomycin according to the deﬁnition by Hiramatsu et al. Six
of the 43 isolates were with reduced susceptibility to autolysis
which was induced by triton X-100. The 43 MRSA with reduced
susceptibility to vancomycin were isolated from 21 patients, 13
of whom had received glycopeptide treatment before the
isolation. Five patients died despite vancomycin therapy. No
enterococal vancomycin resistance genes were detected among
the 43 isolates. Pulsed-ﬁeld gel electrophoresis (PFGE) revealed
that these 43 isolates belonged to 2 PFGE types (Types A and B).
The type A was most prevalent in this survey.
Conclusion: We have demonstrated the ﬁrst VISA reports and
the high prevalence of VISA among methicillin-resistant isolates
in Taiwan.
P870
Screening for methicillin-resistant
Staphylococcus aureus with reduced
susceptibility to glycopeptide in a Belgian
hospital
Y. Glupczynski, O. Denis, C. Berhin, C. Nonhoff, A. Deplano,
Y. Degheldre, M.J. Struelens (Yvoir, Brussels, B)
Background: MRSA isolates with decreased susceptibility to
glycopeptides (GISA) have been reported worldwide since 1997.
Most strains were isolated from catheters and other foreign
bodies in patients treated with glycopeptides. We aimed to
determine the prevalence of GISA isolates in a Belgian hospital
where MRSA has been endemic for many years.
Methods: All MRSA isolates collected between 09/98 and 06/
04 were screened for reduced susceptibility to glycopeptides on
Mueller–Hinton agar and 5 mg/L teicoplanin (MH-teico) as
recommended by the CASFM. The macromethod Etest (BHI
agar, 2 McFarland (MF) inoculum, 48 h incubation) was per-
formed as secondary screening for all isolates which grew 4
colonies on MH-Teico. GISA/h-GISA phenotypes were con-
ﬁrmed by E-test MIC determination on MH agar with 0.5 MF
and 24 h incubation as well as by vancomycin (V) and
teicoplanin (T) population analysis proﬁles (PAP). All conﬁrmed
GISA/h-GISA isolates identiﬁed were compared by PFGE to
other strains identiﬁed in Belgium in order to delineate their
clonality.
Results: Among 520 MRSA strains (from 468 patients), 14
isolates showed growth on MH-Teico and 8 of these (from 7
patients) yielded a positive macromethod E-test (MIC 8 lg/ml
for V and T). Seven were conﬁrmed by PAP as h-GISA and one
as a GISA (T MIC: 32 lg/ml; V MIC: 8 lg/ml). Origins of the
isolates were: lower respiratory tract (4), urine (2) and wound
(2). All h-GISA strains had a similar antibiotic resistance
phenotype by disk diffusion (gentamicin, rifampin, erythromy-
cin, clindamycin, oﬂoxacin). By molecular analysis, the h-GISA/
GISA isolates clustered in two different PFGE groups A (n = 6)
and G (n = 1). The A PFGE group was previously described in
h-GISA isolates in Belgium. In this study, it was subdivided in 2
types, both including 3 strains. One PFGE type resulted in a
small outbreak in 3 patients during a stay in ICU. All 5 other
isolates were sporadic with no apparent geographic or temporal
relationship between cases.
Conclusion: GISA/h-GISA were found in only 7 out of 468
(1.5%) MRSA-positive patients. None of them presented with
severe infection nor had any previous known exposure to
glycopeptides. In view of the low prevalence of GISA/h-GISA in
our hospital, screening should not be performed systematically
but rather on an individual basis taking into account clinical
data and risk factors. Whenever the occurrence of GISA is
considered, Teico-MH agar appears as a suitable ﬁrst screening
approach.
P871
A case-control study to evaluate the economic
outcome of early PO linezolid in patients with
methicillin-resistant Staphylococcus aureus
infections
S. Davis, M. Shieh, D. Levine, P. McKinnon (Detroit, St. Louis,
USA)
Oral therapy with linezolid (LZD) has the potential to decrease
hospital costs and shorten length of stay of patients with Gram-
positive infections who would otherwise continue to receive IV
therapy.
Objective: To evaluate the impact of early PO conversion to
LZD in patients receiving traditional IV therapy for methicillin-
resistant S. aureus (MRSA) infections.
Methods: Patients with documented MRSA infection between
2001 and 2004 were evaluated in a matched case-control study.
Cases included patients who were converted to PO LZD from IV
Table 1 includes comparisons of cost, duration of therapy and
LOS. Predictably, patients receiving LZD in the hospital had
higher drug costs; however, a decreased LOS contributed to a
$7000 lower cost of hospitalization.
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LZD or IV vancomycin (VANC), and controls were patients who
received only IV VANC. Patients were paired in a 1:2 ratio of
cases to controls and matched based on infection type, age and
comorbidities. Demographics, antimicrobial agents, concomitant
infections, and clinical status were assessed daily from the onset
of infection through the end of treatment or hospitalization.
Antibiotic cost, length of stay (LOS), and clinical success rates
were compared between the groups.
Results: 78 patients were assessed. Demographic characteristics
were similar between groups. Average age (mean ± SD) was
46 ± 14; APACHE II (median, range) was 6 [0–22], Charlson
comorbidity score 2 [0–8], and 60% were male. 55% of patients
were treated for skin/soft tissue infection, 19% pneumonia, 13%
bone/joint infections, 11% bacteraemia, and 2% other infections.
Clinical and microbiologic outcomes were similar between
groups, with 100% clinical success at the end of therapy.
Conclusions: Oral therapy with linezolid shortens LOS decreas-
ing hospital cost of patients with MRSA infections.
P872
Linezolid vs vancomycin for the treatment of
infections caused by methicillin-resistant
Staphylococcus aureus in Japan
S. Kohno, K. Yamaguchi, N. Aikawa, Y. Sumiyama, S. Odagiri,
N. Aoki, Y. Niki, S. Watanabe, M. Furue, T. Ito, R. Croos-
Dabrera, K.J. Tack (Nagasaki, Tokyo, Kanagawa, Niigata, Okayama,
Fukuoka, JP; Ann Arbor, USA)
Objectives: To compare the efﬁcacy and safety of linezolid
(LZD) with those of vancomycin (VAN) for the treatment of
infections caused by methicillin-resistant Staphylococcus aureus
(MRSA) in Japan.
Methods: This was a randomized, open-label study conducted
in Japan. Patients with nosocomial pneumonia, complicated skin
and soft tissue infections, or sepsis syndrome, caused by MRSA,
were randomized (2:1 LZD: VAN) to receive LZD,
600 mg q12 h, or VAN, 1 g q12 h. Outcomes were evaluated at
end of therapy (EOT) and at a follow-up (FU) evaluation 7–14
days after completion of therapy.
Results: 151 patients received study drug (100 LZD, 51 VAN);
the treatment groups were similar with regards to demo-
graphics and risk factors. At EOT, clinical success rates in the
MRSA-microbiologically evaluable population were 62.9% and
50.0% for the LZD and VAN groups, respectively; microbio-
logic eradication rates were 79.0% and 30.0% in the two
groups, respectively (p < 0.0001). At FU, the clinical success
rates were 36.7% for both groups, and the microbiologic
eradication rates were 46.8%, and 36.7%, respectively. Clinical
success rates in both groups reﬂect an automatic outcome of
failure for patients receiving prohibited antimicrobials prior to
FU. Reversible anemia (13%) and thrombocyotopenia (19%)
were reported as adverse events more frequently in LZD
patients. Analysis of laboratory data showed that platelet
counts decreased more frequently in LZD patients with
recovery by FU. The mean platelet count in LZD patients
with an adverse event of thrombocytopenia was 101,000/mm3.
Signiﬁcantly low platelet counts (<50,000/mm3) were more
frequently observed in VAN patients (6 % vs 3%). No
difference was observed in mean changes in hemoglobin
levels between the treatment groups.
Conclusions: LZD is as effective as VAN for the treatment of
MRSA infections in seriously ill patients, and may be more
effective in achieving microbiologic eradication. Although
hematologic adverse events were reported more frequently in
LZD-treated patients, analysis of laboratory data showed only a
mild reversible trend toward lower platelet counts.
P873
Cost-effectiveness of linezolid versus
vancomycin in complicated skin and soft-tissue
infection due to suspected methicillin-resistant
Staphylococcus aureus infection in Germany
D. Schu¨rmann, E. De Cock, S. Sorensen, T. Baker, A. Resch,
J. Hardewig, S. Duttagupta (Berlin, D; London, UK; Bethesda,
USA; Karlsruhe, D; New York, USA)
Objectives: Linezolid, a novel antibiotic, has demonstrated
efﬁcacy in infections due to suspected or proven methicillin-
resistant Staphylococcus aureus (MRSA). Among patients with
complicated skin and soft-tissue infections (cSSTI) due to
suspected or proven MRSA, clinical cure rate was higher and
length of stay (LOS) in hospital was shorter in patients treated
with linezolid versus vancomycin (Weigelt J et al. Posters 314
and 315 presented at: The 41st Annual Meeting of the Infectious
Diseases Society of America; October 9–12, 2003; San Diego,
Calif). The objective of the present analysis was to evaluate the
cost-effectiveness of linezolid compared with vancomycin in
the treatment of cSSTI due to suspected MRSA infection from
the German perspective.
Methods: A decision-analytic model was developed to examine
the costs and outcomes of using linezolid versus vancomycin in
hospitalized patients with cSSTI in Germany. An expert panel of
German physicians experienced in treating cSSTI provided
resource-utilization data through structured interviews. Costs
frompublished sources (Rote Liste, DKG-NT, EBM)were applied
to clinical and laboratory tests, adverse events, isolation proce-
dures, intravenous (IV) or oral (linezolid only) drug treatment,
hospitalization by ward type (medical, intensive care), and
outpatient physician consultation. If appropriate, patients could
be discharged from hospital and treated in an ambulant setting.
Themodel assumed 50% of suspectedMRSApatients had proven
MRSA. Outcomes included total costs per patient, cost per death
avoided, cost per life-year gained, and cost per cure.
Results: An additional 4.4% of patients treated with linezolid
(98.4%) versus vancomycin (94.1%) were cured. Average total
cost per episode was 9352 versus 9474 for linezolid- versus
vancomycin-treated patients, giving a 121 saving per episode.
The model was sensitive to the LOS in hospital, days in
isolation, duration of oral versus IV treatment, percentage of
MRSA patients, and price of linezolid.
Conclusion: In this decision analytic model, more patients with
cSSTI due to suspected MRSA achieved clinical cure in the
linezolid group compared with the vancomycin group. Linezo-
lid was cost saving versus vancomycin for the treatment of
cSSTI. Linezolid resulted in a shorter treatment duration and
shorter LOS that offset the higher acquisition cost of linezolid
versus vancomycin in cSSTI in Germany.
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Training, scientiﬁc output in infectious disease
P874
A bibliometric analysis of worldwide trends in
research productivity in microbiology
P. Vergidis, A. Karavasiou, K. Paraschakis, I. Bliziotis,
P. Papastamataki, M. Falagas (Athens, GR)
Background: Microbiology contributes signiﬁcantly to the
understanding and control of infectious diseases and has
always been a ﬁeld of extensive research. However, the
literature lacks studies estimating the quantity and quality of
worldwide research production. We evaluated the contribution
of different world regions in research production in the ﬁeld of
Microbiology.
Methods: Using the Medline database we retrieved articles
from 64 journals included in the Microbiology category of the
Journal Citation Reports database of the Institute for Scientiﬁc
Information for the period 1995–2002. The world was divided
into 9 regions based on geographic, economic and scientiﬁc
criteria. Using an elaborate retrieval system we obtained data
on published articles from different world regions. In our
evaluation we introduced an estimate of both quantity and
quality of research produced from each world region per year
using: (1) the total number of publications, (2) the mean impact
factor of publications, and (3) the product of the above two
parameters.
Results: Data on the country of origin of the research was
available for 76,118 out of 77,080 retrieved articles (98.8%).
Western Europe exceeds all other world regions in research
production for the period studied, with USA ranking second
(table). The difference in production between these two
regions increased gradually from 1995 to 2002. However, the
mean impact factor for articles published in microbiology
journals was highest for the USA (3.34), while it was 2.79 for
Western Europe and 2.31 for the rest of the world (7 regions
combined).
Conclusions: USA and Western Europe make up a striking 78%
of the world’s research production in terms of both quantity and
quality. All world regions have increased their research pro-
duction during the period studied. The highest increase was
achieved by Asia (excluding Japan), Latin America, and Eastern
Europe.
P875
From conference abstract to full paper:
differences between data presented in
conferences and journals
E. Rosmarakis, P. Vergidis, A. Kapaskelis, K. Paraschakis,
M. Falagas (Athens, GR)
Background: On some occasions, we noted differences between
data presented in conference abstracts and subsequent pub-
lished papers. We studied the frequency and the type of these
differences in the ﬁelds of Infectious Diseases and Microbiology.
Methods: We reviewed all abstracts from the ﬁrst session of 7
out of 15 major research categories presented in the 1999 and
2000 ICAAC. For each selected pair of ICAAC abstract and
related full paper published in journals indexed by Index
Medicus, two independent investigators performed a compar-
ison of all data in the abstract and the corresponding informa-
tion in the published paper. Using Cox logistic regression
models we analysed variables for association with differences of
data.
Results: From 190 abstracts that were reviewed, 68 (35.8%)
were subsequently published as papers by March 2004. From
them, 52 referred to the same study period and population for
both the abstract and the paper. Differences between data
presented in conference abstracts and published papers were
found in 28 out of 51 pairs which were analysed further (54.9%,
95% C.I.: 41.2%–68.6%). The identiﬁed differences were related
to the numbers and/or rates of the studied patients (11/28),
numbers or rates of isolates (9/28), MICs values or Ki values (5/
28), other chemical properties of antibiotics (2/28), odds ratio
(1/28), and duration of observation (1/28). The differences were
substantial in several pairs. Time to publication of full paper
was found to be independently associated with presence of
differences (p = 0.029, OR = 2.043 per year), while the research
category, type of presentation (oral or poster), number of
publications of the presenting and last author, impact factor of
the journal, and country of origin were not.
Conclusions: While there are several explanations for the noted
differences between data presented in conference abstracts and
full papers, it is likely that the research community may
improve the accuracy of presentation of data.
P876
Worldwide trends in quantity and quality of
published articles in the ﬁeld of infectious
diseases
I. Bliziotis, K. Paraschakis, P. Vergidis, A. Karavasiou,
A. Kapaskelis, M. Falagas (Athens, GR)
Background: Trying to confront with the widespread burden of
infectious diseases, the society worldwide invests considerably
on research. However, the literature lacks studies estimating the
quantity and quality of worldwide research production. We
evaluated the contribution of different world regions in research
production in Infectious Diseases.
Methods: Using the Medline database we retrieved articles
from 38 journals included in the Infectious Diseases category of
the Journal Citation Reports database of the Institute for
Scientiﬁc Information for the period 1995–2002. The world was
Number of microbiology articles multiplied by the impact factor
of the corresponding journal.
1995 1996 1997 1998 1999 2000 2001 2002 Total
Western Europe 7,785 9,744 9,292 10,434 11,819 13,201 14,052 13,716 90,042
USA 8,297 10,061 8,331 8,792 9,680 10,748 11,142 11,286 78,337
Japan 1,346 1.348 1,716 1,710 1,794 2,153 2,138 2,268 14,472
Asia (excl. Japan) 566 752 822 924 1,081 1,209 1,589 1,740 8,683
Canada 893 985 882 982 1,019 1,067 1,098 1.268 8,195
Oceania 600 568 636 644 635 815 839 926 5,665
Latin America 330 327 432 553 520 613 808 922 4,504
Eastern Europe 234 264 305 377 386 482 687 705 3,439
Africa 135 126 131 211 238 266 359 270 1,737
Total 20,187 24,175 22,548 24,627 27,171 30,555 32,711 33,102 215,075
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divided into 9 regions based on geographic, economic and
scientiﬁc criteria. Using an elaborate retrieval system we
obtained data on published articles from different world
regions. In our evaluation we introduced an estimate of both
quantity and quality of research produced from each world
region per year using: (1) the total number of publications, (2)
the mean impact factor of publications, and (3) the product of
the above two parameters.
Results: Data on the country of origin of the research was
available for 45,232 out of 45,922 retrieved articles (98.5 %). USA
and Western Europe are by far the most productive regions
concerning publications of research articles, as displayed in the
Table. However, the rate of increase in the production of articles
was higher in the developing world regions during the study
period. The mean impact factor is highest for articles originating
in the USA (3.42), while it was 2.82 for Western Europe and 2.73
for the rest of the world (7 regions combined).
Conclusions: USA and Western Europe make up a striking 80%
of the world’s research production in Infectious Diseases in
terms of both quantity and quality. However, all world regions
present a steady increase in the production of infectious disease
articles with the developing countries displaying the highest
rate of increase.
P877
Does training physicians in good clinical practice
make a difference in quality of running clinical
trials?
M. Akova, H. Akan, I.H. Ayhan, E. Kansu, O. Akbas, C. Ari,
E. Tetik, E. Taylan (Ankara, Istanbul, TR)
Objectives: Quality of clinical trials requires the implementa-
tion of the rules of good clinical practice (GCP). However,
formal training for this purpose has been lacking both in
undergraduate and postgraduate curricula in most medical
schools in Europe. During a series of 3-days educational
programme, 4 interactive GCP courses were organized between
December 2003 and October 2004.
Methods: The programme included several informative lec-
tures covering knowledge about EU Directive 2001/20/EC and
ICH GCP Guidelines and interactive sessions with several case-
based scenarios. The faculty was composed of a pharmacologist,
an oncologist, a hematologist, an ID physician and the director
of a contract research organization. Excluding the latter, all
faculty members had administrative responsibilities in different
universities and/or goverment institutions (i.e. ethics commit-
tees). Financial support was obtained from a pharmaceutical
company. However, the sponsor had no role in organizing the
scientiﬁc content of the programme.
Results: 146 physicians including ID specialists were selected
from several university hospitals or tertiary care government
hospitals where running clinical trials has been a common
practice. Pre-training queries revealed that among the trainee
population, 30.5% never obtained an informed consent from a
patient, 47% did not randomize any patients for trials, 44% did
not run any Phase I-IV trials, 55% did not use placebo for trial
purposes and 49% did not report any serious adverse events to
local and or international authorities. A 24-question pre-and
post-course tests about basic principles of GCP and local and EU
regulations for running clinical trials were applied to determine
and compare the knowledge of the trainees on these subjects
prior and after the course. The percentage of correct answers
ranged 35–91% before, and 51–98% after the course was
completed (p < 0.01).
Conclusions: Training in GCP and other regulations about
running clinical trials may increase the awareness and know-
ledge of physicians. These educational activities will also help to
raise the quality of clinical trials.
P878
Learning appropriate use of antibiotics (PK/PD
and guidelines): a CD-ROM course for healthcare
professionals and students
E. Ampe, Y. Glupczynski, P.M. Tulkens, F. Van
Bambeke (Brussels, Mont-Godinne, B)
Objectives: In a context of growing resistance and limited
supply of new molecules, a rational use of antibiotics should be
a high priority. Our objective is to train healthcare professionals
and students in PK/PD and in a correct implementation of
guidelines, since this could help to improve antibiotic use in
both short and mid-terms.
Methods: We developed a PK/PD – guidelines course on
CD-rom, targeted to both physicians and pharmacists but also
usable by students. The course was prepared by a team of 2
pharmacists, 1 clinical microbiologist, and 1 pharmacologist.
Sources of information were (i) textbooks, review papers and
primary papers by internationally recognized experts (ii) mate-
rials presented at training workshops of the International
Society for Antiinfective Pharmacology (ISAP; www.isap.org)
during the last 3 years, (iii) national and, if not available,
international guidelines for the management of respiratory tract
or urinary tract infections.
Results: The course is organized as a series of Power Point
presentations covering in a progressive fashion the followings
topics: (1) bases in microbiology (in vitro properties of antibi-
otics); (2) pharmacokinetics (deﬁnition of the main parameters);
(3) pharmacodynamics, with (A) the concepts, (B) the methods
and pertinent models, and (C) the data, including the param-
eters to take into account to optimize the dosage of the main
antibiotic classes; (4) resistance, including (A) the main mech-
anisms and (B) the use of pharmacodynamics to avoid the
selection of resistance; (5) the appropriate use (including
appropriate dosages) of antibiotics in (A) respiratory tract and
(B) urinary tract infections.
Conclusions: This course promotes continuous education in the
pharmacology and pharmacotherapy of antibiotics, in a format
easily usable for courses and seminars to both students and
professionals.
Number of infectious disease articles multiplied by the impact
factor of the corresponding journal
1995 1996 1997 1998 1999 2000 2001 2002 Total
USA 6527 7,155 6,737 7,912 8,136 9,106 9,447 8,784 63,804
Western Europe 4,114 5,241 4,773 5,729 6,403 7,647 7,787 7,338 49,033
Asia (excl. Japan) 400 417 557 783 779 917 993 1,081 5,927
Canada 446 467 440 537 596 674 639 711 4,510
Japan 294 455 496 385 515 663 632 673 4,113
Oceania 239 343 334 392 391 548 472 434 3,153
Central and
Latin America
199 257 271 360 374 457 467 593 2,978
Africa 198 189 303 337 478 433 532 443 2,913
Eastern Europe 78 93 117 117 168 237 232 283 1,325
Total 12,495 14,617 14,028 16,552 17,840 20,682 21,201 20,341 137,756
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Pneumonia
P879
The efﬁcacy of the long-term treatment with
macrolides in patients with bronchiectasis
colonised by P. aeruginosa
M. Schmidt-Ioanas, M. Allewelt, A. Polzin, H. Lode (Berlin, D)
Background: Although macrolides have no intrinsic antipseu-
domonal activity, these drugs appear effective in controlling
infection by P. aeruginosa through mechanisms such as disrup-
tion of quorum sensing or anti-inﬂammatory effects.
Objectives: The aim of our prospective study was to evaluate
the efﬁcacy of macrolides in patients with bronchiectasis
infected and colonised by P. aeruginosa.
Methods: The study included hospitalised patients with CT
evidence of bronchiectasis and presenting an acute exacerbation
by P. aeruginosa, isolated in sputum. Microbiological ﬁndings,
clinical data and treatment recommendations were recorded at
admission and at the end of therapy. Patients completed daily
diary cards for symptoms and PEF values. Patients were
followed for 1 year.
Results: Twenty-two patients (14 men, mean age 57.3 ± 14.5)
with bronchiectasis and P. aeruginosa infection were included.
During hospital stay, patients were treated with at least two
susceptible antipseudomonal drugs, according to the antibio-
gram (usually beta-lactam plus aminoglycoside) for a period of
16.9 ± 1.6 days. An oral macrolide (azithromycin
250 mg x 3 days/week in 10 patients, clarithromycin 500 mg
daily in 12 patients) was further administrated for
4.9 ± 1.9 months. At the end of long-term therapy, 11 (50%)
patients showed no evidence of P. aeruginosa in sputum, 8
(36.3%) patients still presented P. aeruginosa in sputum and 3
(13.6%) discontinued the treatment after less that 1 month
because of adverse events. All patients had a signiﬁcant
reduction of sputum volume (83.3 ml/day before therapy vs.
22.5 ml/day at the end of therapy, p = 0.03) and of the mean
number of exacerbations during follow-up (2.4 in the previous
year vs. 1.2 in the follow-up year, p = 0.01). An increase of the
mean PEF value was also noted, although statistically not
signiﬁcant (373.2 ± 43.5 l/min before therapy vs. 489.2 ± 23.5 l/
min at the end of therapy, p = 0.3)
Conclusion: These observational ﬁndings suggest that macro-
lides may have a role in modulation of P. aeruginosa colonisation
in patients with bronchiectasis.
P880
Community-acquired pneumonia requiring
hospitalisation in young adults: clinical features,
causative organisms, and outcomes
A. Mykietiuk, J. Carratala`, N. Ferna´ndez-Sabe´, S. Padrones,
R. Verdaguer, F. Gudiol (Barcelona, E)
Objectives: There is little information on CAP requiring hospi-
talization in young adults (£ 40 years). We analysed clinical
features, causative organisms, and outcomes of CAP in this
patient population.
Methods: Prospective observational study of non-immunocom-
promised adult patients with CAP (1995–2003). Patients with
HIV infection, transplantation, and neutropenia were not inclu-
ded. For the purposes of the study, patients were divided into 2
age-groups, £ 40 years and > 40 years.
Results: We documented 1732 consecutive patients with CAP;
150 patients (8.7%) were £ 40 years and 1582 were > 40 years.
Mean patient ages were 30.3 years in the former group and
69.6 years in the latter group. Main reasons for hospitalization in
young adults were: hypoxia (PO2 < 60) 59 patients, PORT high
severity risk class (IV-V) 13 patients, empyema 9 patients, and/
or shock 7 patients. Young patients were more frequently
current smokers (63% vs 22%, p < 0.001). Comorbid conditions
were more common in older patients (20% vs 66%, p < 0.001),
mainly diabetes mellitus, COPD, and chronic heart disease.
Multilobar pneumonia was more frequent in young patients
(56% vs 32%, p < 0.001). The most common causative organisms
were Streptococcus pneumoniae (19% vs 24%, NS) and Legionella
pneumophila (9% vs 7%, NS). Atypical agents were more frequent
in young adults (11% vs 4%, p = 0.001), while Haemophilus
inﬂuenzae (2% vs 7%, p = 0.026) and gram-negative bacilli (0% vs
1.4%, NS) were rarely identiﬁed in this group. The frequency of
bacteraemia was similar in both groups (8% vs 12%, NS). ICU
admission was more frequent in young adults (13% vs 7%,
p = 0.006), but no differences were found regarding the need of
mechanical ventilation (5% vs 4%). Median LOS was shorter in
young patients (7 vs 9 days, p = 0.002). Five young patients
died; shock (2 patients) and multiorganic failure (3). Early
mortality (< 48 hours) was similar in both groups (1.4% vs
2.8%). Overall mortality (< 30 days) was higher in older patients
(3.4% vs 8.7%, p = 0.026).
Conclusions: CAP requiring hospitalization in young adults,
mainly smokers, is not uncommon, being respiratory failure the
most frequent reason for admission. S. pneumoniae and atypical
agents are the most frequent causative organisms in this group.
Although overall mortality is relatively low, a number of young
patients require ICU admission and have a complicated course.
P881
Corticosteroids in patients with severe
community-acquired pneumonia: impact on
mortality
C. Garcia Vidal, E. Calbo, C. Ferrer, V. Pascual, S. Quintana,
J. Garau (Terrassa, E)
Background: Mortality in patients with severe CAP has been
traditionally related to microorganism virulence and to host
characteristics. Recently, there has been an increasing interest
host-pathogen interaction, and inadequate immunologic
response has been shown to be associated with a higher
mortality. Immune modulation concomitant to antibiotic ther-
apy has been postulated to improve outcome. The aim of our
study was to determine the risk factors for increased mortality in
patients with severe CAP and to evaluate the impact of
administration of corticosteroids in outcome.
Methods: We reviewed the charts of all hospitalized CAP
patients in our centre between October 2001 and December 2003.
Severe CAP deﬁned by Pneumonia Severity Index (PSI) categ-
ories 4 and 5 were included. Data on demographics, comorbidity
measured by Charlson score, bacterial aetiology, the presence of
immunosuppression, COPD, ICU admission, antibiotic therapy,
use of corticosteroids and mortality were recorded.
Results: Of the 375 severe CAP patients included, 258 and
117,were categories 4 and 5, respectively. 256 patients(69%)
were treated with standard antimicrobial therapy and116
(31%) received also corticosteroids. Mean age (78 vs 77),
Charlson score (2.5 vs. 2.6), neoplasm (22% vs. 21%), HIV
(0.7% vs. 0.8%), chronic liver disease (9% vs.7%), diabetes
mellitus ( 19% vs.22%), ICU admission (4% vs. 4%),
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monotherapy (63% vs. 66%), and aetiology (S. pneumoniae 34%
vs. 36%; L. pneumophila 3% vs.2%; others 8% vs.11%; unknown
54% vs.51%) were similar. Patients receiving corticotherapy
had been exposed to another immunosuppressive treatment
more frequently (6% vs. 12%; p = 0.04), COPD was commoner
( 20% vs. 66%; p < 0.001) and mortality was higher (5% vs.
11%; p = 0.03) than in the group not treated with corticoster-
oids. In multivariate analysis, severity of disease (OR 3.1;
IC95% 1.3–7.1; p = 0.07) and the use of corticosteroids (OR 3.3;
IC 95%, 1.3–8.0;p = 0.009) were found to be related to
mortality.
Conclusions: In our experience corticosteroid treatment in
patients with severe CAP appears to be associated with higher
mortality.
P882
Use of levoﬂoxacin in community-acquired
pneumonia
J. Olalla, I. Escot, J.J. Garcı´a-Alegrı´a (Marbella, E)
Introduction and objectives: Community Acquired Pneumonia
(CAP) is a prevalent and important disease, with an important
consume of resources at Hospitals. Our aim is to study the
proﬁle of income patients with CAP diagnosis, the year of
introduction of levoﬂoxacin in our centre and compare the
length of stay in order to different antibiotics treatments,
adjusting the results by Fine’s scale.
Methods: In our hospital (a second level hospital in Marbella,
Spain) all the diagnosis at discharge are codiﬁed and included in
the hospital database, so, all the diagnosis of CAP between
September 2001 and March 2002 were collected, and clinical
reports were examined. Demographic data were registered, so
were all the parameters affecting Fine classiﬁcation, antibiotic
treatment, intensive care unit (ICU) incomes, deaths and length
of stay.
Results: 129 cases of CAP were found (86 males, 43 females),
with a mean age of 67 years (ys)-CI 95%: 64–70), no difference
between gender. 4 patients (pts) were living in a residence. 11
pts (8.5%) had a previous diagnosis of Heart Failure -HF-(mean
of age 78 vs 66, p < 0.005) and other 11 pts had Cerebrovas-
cular disease -CVD- (mean of age 80.7 vs 66, p < 0.01), 12 pts
had Chronic hepatopathy, 15 –11.5%- any form of cancer, 23–
17.8%- pts Chronic renal failure (mean of age 74 vs 66,
p = 0.049), 41 pts (32%) Chronic Obstructive Pulmonary Dis-
ease (COPD). 3 pts were admitted at ICU and 3 deaths were
registered. Blood cultures were collected in 30% of cases,
culture of sputum in 21%, Legionella antigen in urine in 13.2%.
In according with Fine’s classiﬁcation the patients were
stratiﬁed in group I (10.9%), II (16.3%), III (22.5%), IV (27.9%)
and V (22.5%). In 40% cases corresponding to Fine I and II
levoﬂoxacin was used alone, vs 19% in Fine III, IV and V
(p=0.021). When length of stay was analysed in patients Fine I
and II, the use of levoﬂoxacin was associated with a non
signiﬁcant reduction (MEAN + SE: 5.86 + 2.7 days vs 7.67 +
4.9 days), in people on groups III, IV and V use of levoﬂoxacin
do not showed any reduction of length of stay (6.67 +
5.06 days in people using levoﬂoxacin vs 6.11 + 4.5 days).
No readmissions in relationship with recurrent CAP was
registered.
Conclusions: In our experience, use of levoﬂoxacin is associ-
ated with less severe CAP, in which a non signiﬁcant reduction
in length of stay is observed.
P883
Telithromycin versus other ﬁrst-line single-agent
antibiotics in the treatment of community-
acquired pneumonia: a randomised
superiority trial
Y. Mouton, V. Thamlikitkul, R.B. Nieman, C. Janus (Tourcoing,
F; Bangkok, TH; Bridgewater, USA; Paris, F)
Objectives: Macrolides and beta-lactams are commonly recom-
mended for the treatment of outpatients with community-
acquired pneumonia (CAP). The aim of this study was to
demonstrate the superiority of the ketolide telithromycin (TEL)
to other ﬁrst-line, oral, single-agent antibiotics (comparators,
COMP) in achieving clinical cure in outpatients with mild to
moderate CAP in geographical areas of high pneumococcal
resistance (erythromycin resistance rate ‡ 30%).
Methods: Patients with clinical and radiological evidence of
CAP were randomised centrally to receive either TEL 800 mg
once daily for 7–10 days or COMP (chosen by the investigator in
accordance with local treatment guidelines/practices). Efﬁcacy
was assessed post-therapy (Days 17–21). Clinical outcomes in
this open-label trial were validated by three independent
experts who were fully blinded to treatment assigned.
Results: Of the 505 patients enrolled, 482 were included in the
modiﬁed intent to treat (mITT) and 438 in the per protocol (PP)
efﬁcacy analyses. In the COMP group, 39% of patients had
received macrolides, 44% beta-lactams and 17% ﬂuoroquinolo-
nes. Resistance to penicillin and erythromycin among Strepto-
coccus pneumoniae isolates was 28% and 31%, respectively.
Clinical cure rates in the TEL group were signiﬁcantly higher
than those in the COMP group (as shown in the following table).
TEL and COMP were similarly well tolerated.
Conclusions: In this outpatient CAP study, post-therapy clin-
ical cure rates achieved with TEL were shown to be statistically
superior to those achieved with other usual care ﬁrst-line
antibiotics – in both the mITT and PP populations, and
according to evaluations by both the investigators and blinded
experts.
P884
Changing epidemiology, clinical features, and
outcome of acute community-acquired
pneumonia among adults in India
D.D. Tariang, A. Ajaykumar, K.N. Brahmadattan, M.K. Lalitha,
N. Paul, A. Zachariah, O.C. Abraham, J.-H. Song,
D. Mathai (Vellore, IND; Seoul, KOR)
Background: Acute CAP is the third leading cause of mortality
in India. Two prospective studies from our centre identiﬁed
common causes of CAP in India to be Mycoplasma pneumoniae
[MP] and Legionella pneumophila [LP] by serology in 11% each,
and SPN in 10% by culture of respiratory secretions/blood/
Post-therapy clinical cure rates, % (n/N)
Population TEL COMP Difference
[95% Cl]
p-value
mITT (investigator’s analysis) 86.0% (208/242) 78.8% (189/240) [0.004, 0.140] 0.04
mITT (blinded experts’ analysis)a 92.1% (223/242) 85.8% (206/240) [0.008, 0.119] 0.03
PP (investigator’s analysis) 87.2% (191/219) 79.9% (175/219) [0.004, 0.142] 0.05
PP (blinded experts’ analysis)a 94.1% (206/219) 87.7% (192/219) [0.010, 0.118] 0.03
aClinical failure ¼ subsequent antibiotic for lower respiratory tract infection or CAP-related fever
post-therapy.
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pleural ﬂuid among 125 patients [pts] in the year [y] 1994; and
Chlamydia pneumoniae [CP] in 6.5% among 80 pts in y 1998.
Methods: In a 14-month prospective study ending June 2003,
100 consecutive adults hospitalized with CAP were studied for
epidemiology and mortality, and compared with data from
previous studies.
Results: Among 100 pts [age 15–84 yrs], 21 were elderly [age
> 65 yrs]. There were 63 males. Risk factors included: broncho-
pulmonary diseases (34 pts), cardiovascular (15), liver and renal
(9 each), non pulmonary neoplasms (4), and cerebrovascular
accidents (2).Cultures in 55 yielded: SPN (13) Klebsiella spp [KP]
(12); PSA (9); Haemophilus inﬂuenzae [HI] and Staphylococcus
aureus [SA] (5 each); and others (11). CP was detected serolog-
ically in 24% and LP urinary antigen was negative in all. SPN
isolates were uniformly susceptible to PCN [table 1].Mortality
was 15%. Patients infected with PSA had the highest mortality
(44.4%) > HI (40%) > KP (25%) and CP (12.5%). None infected
with SPN or SA died. Pneumonia Outcome Research Team
[PORT] risk classes I and II had low mortality (3.2%) compared
to III (18.8%), IV (22.2%), and V (63.6%). Factors signiﬁcantly
associated with mortality included: renal failure [creatinine
>1.4 mg/dL] (OR 8.3, 95% CI 1.5–44.4); tachypnea [rate >30/mt]
(OR 5.6, 95% CI 1.5–21.1); PSA associated pneumonia (OR 5.8,
95% CI 1.1–30.9). Mortality in 1994 and 1998 was 3/125 and 5/80
respectively. Initial treatment was with PCN in 28 and ﬂour-
oquinolones [FQR] in two.
Conclusion: Although SPN is the most common isolate, the
rising numbers of gram negative organisms (38%) and atypical
pathogens associated with increasing mortality stress the need
for review of initial antibiotic choice for adults with higher
PORT classes. In view of enduring susceptibility of SPN to PCN
and minimization of resistance with narrow spectrum activity,
this should be the drug of choice for SPN in India. FQR that has
a wide coverage against most respiratory pathogens including
atypicals, can be considered as an initial choice in both
hospitalized and ambulatory setting. Continued surveillance of
respiratory pathogens is needed.
P885
Fluoroquinolones in the treatment of community
and hospital-acquired Legionella pneumonia
L. Mateu, M.L. Pedro-Botet, N. Sopena, A. Garcia Cruz,
G. Tolchinsky, C. Rey-Joly, S. Ragull, M. Sabria`, D. Garcia Pares
(Badalona, E)
Background: Fluoroquinolones (FQ) are highly active against
Legionella and have been shown to be efﬁcacious in animal
models and clinical studies of patients with community and
hospital-acquired Legionella pneumonia (CALP and HALP).
Objectives: To evaluate the efﬁcacy of FQ in the treatment of
CALP and HALP requiring hospitalization.
Methods: Observational non comparative study of intravenous
followed by oral levoﬂoxacin (L) or oﬂoxacin (O) for the
treatment of patients with CALP and HALP diagnosed from
1995 to 2004 by Legionella pneumophila sg 1 urinary antigen
test (UAT) and /or isolation of Legionella spp. in respiratory
samples. Patients who previously received appropriate antibi-
otic therapy other than FQ were excluded, except in cases with
antibiotic failure.
Results: 63 patients were identiﬁed (42 patients with CALP and
21 with HALP). 62 were treated with levoﬂoxacin and 1 with
oﬂoxacin. All had a positive UAT and 2 had a positive sputum
culture. 52 (82.59%) were males with a mean age of 59.3 yr (19–
93); 30 (47.6%) were smokers, 13 (20.6%) alcoholics; 41 (65.1%)
had underlying diseases with neoplasms (14), chronic lung
disease (13), diabetes (12), chronic heart failure (8), morbid
obesity (8) and HIV infection (6), being the most prevalent; 9
(14.3%) were on immunosuppressors. Aspiration risk was
present in 5 patients (7.9%). 3 patients (4.8%) required ICU
care. Clinical manifestations included fever in 56 (88.99%),
cough in 41 (65.1%), dyspnea in 24 (38.1%), gastrointestinal
manifestations in 18 (28.6%) and neurological disorders in 24
(38.1%). Hyponatremia (Na <130/mm3) was present in 10
(15.9%), CK increase in 9 (14.3%), AST increase in 19 (30.2%)
and pO2 <60 mm Hg in 18 (28.6%). Radiological inﬁltrate was
unilobar in 52 (82.5%), with lower lobes (31) being the most
prevalent. The mean time to apyrexia was 51.9 hours (range
12–240), and 31 (49.2%) presented complications, with respira-
tory failure (26) being the most frequent. Mortality was 6.3%. No
patient developed severe adverse events.
Conclusion: Fluoroquinolones are safe and efﬁcacious for
the treatment of patients with moderate to severe Legionella
pneumonia of community and hospital origin.
P886
Single-dose azithromycin microspheres versus
7 days of levoﬂoxacin for the treatment of mild to
moderate community-acquired pneumonia in
adults
J. D’Ignazio, M.A. Camere, D.E. Lewis, D. Jorgensen (Montreal,
CAN; Lima, PE; Groton, New London, USA)
Objective: Community-acquired pneumonia (CAP) is a major
causeofmorbidity andmortalityworldwide. Inability or failure to
comply with standard antibiotic regimens, which may last up to
10 days, may result in patients receiving suboptimal antibiotic
treatment. Treatment with a single-dose antibiotic regimen
maximizes compliance with prescribed therapy. A novel micro-
sphere formulation of azithromycin makes it possible to admin-
ister more drug in a single dose while maintaining tolerability.
The objective of this study was to test the hypothesis that a single
2.0 g oral dose of azithromycinmicrospheres was as effective as a
7-day regimenof oral levoﬂoxacin 500 mg/daywhenused to treat
adult patients with mild to moderate CAP (Fine classes I, II, III).
Methods: This was a phase III, multinational, multicentre,
randomized, double-blind, double-dummy trial. The primary
endpoint was the clinical response (cure or failure) in the Clinical
Per Protocol (CPP) population at Test Of Cure (TOC) (Day 14–21).
Results: Of 427 patients randomized, 363 (85.8%) were included
in the CPP population (azithromycin microspheres, n = 174;
levoﬂoxacin, n = 189). Clinical cure was achieved in 89.7% of
azithromycin-treated patients and 93.7% of levoﬂoxacin recip-
ients (95% CI –9.7, 1.7). Clinical response was maintained at
Long-Term Follow Up (Day 28–35): no azithromycin micro-
spheres patients and only one levoﬂoxacin patient (0.6%)
relapsed. Clinical cure rates were comparable between both
Table 1 Susceptibility of SPN Isolates to commonly used
antibodies for CAP
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treatment groups for subjects with Haemophilus inﬂuenzae (inclu-
ding beta-lactamase positive and negative isolates), Moraxella
catarrhalis, Streptococcus pneumoniae, and Chlamydia pneumoniae
isolates. Clinical cure rates for subjects with Mycoplasma pneu-
moniae were lower in the azithromycin-microspheres group
71.4% (5/7) compared with the levoﬂoxacin group 100% (18/
18); however, the number of isolates in the azithromycin group
was too small for meaningful analysis of results. Most treat-
ment-related adverse events were GI in nature, with diarrhoea
more common in the azithromycin-microspheres group (12.3%
vs. 4.7%). In the majority (85%) of patients receiving azithro-
mycin microspheres, diarrhoea was limited to study Day 1 or 2.
No patients discontinued treatment due to treatment-related
adverse events.
Conclusions: A single 2.0 g dose of azithromycin micro-
spheres was as effective as a 7-day course of levoﬂoxacin
when used to treat adult outpatients with mild to moderate
CAP.
P887
Preferred ﬁrst line antibiotics in adult CAP
admitted to hospital in Spain
A.M. Martı´n-Sa´nchez, M. De-la-Rosa, R. Landı´nez, R. Dal-Re´,
J. Garau on behalf of the NACER Group
Objectives: Many guidelines have been issued for the treatment
of CAP. We wanted to assess how frequently the national
guidelines for treatment of CAP were followed in 10 Spanish
acute care hospitals in patients admitted with CAP.
Methods: Retrospective review of the charts of patients
admitted to the hospital with the diagnosis of CAP over a
1-year period (1Nov 01 to 31Oct 01) in 10 geographically
scattered hospitals in Spain. Data were available from 3233
patients.
Results: Amoxicillin/clavulanate was the most common anti-
biotic choice (79.5% was given as monotherapy and 20.4% in
association with clarithromycin). Levoﬂoxacin (93.1% given only
as monotherapy) follows closely. They were followed by third
generation cephalosporins (ceftriaxone and cefotaxime) but up
to 60% of them were given in association with clarithromycin.
Clarithromycin was used mainly as a complement to both
amoxicillin/clavulanate and cephalosporins since only 8.6% of
its 25.8% was given as monotherapy. Other antibiotics were very
uncommonly prescribed (cefepime 1.9%, and ciproﬂoxacin
1.4%).
Conclusions: 1) Monotherapy with levoﬂoxacin, followed by
amoxicillin/clavulanic acid were the most common ﬁrst line
antibiotic choices in these 10 Spanish hospitals. However,
amoxicillin/clav alone or in combination with clarithromycin
was the most common antibiotic prescribed. 2) Monotherapy
with clarithromycin was relatively uncommon (2.2%). 3) These
choices reﬂect quite well the recommendations of the different
national guidelines issued in our country in an environment of
high prevalence of resistance to penicillin and to macrolides in
S. pneumoniae in Spain and the concomitant coverage of
Legionella and other atypical pathogens.
P888
The microbiology of ABECB – potential
predictive value of clinical criteria
J. Kahn (Raritan, USA)
Objectives: To explore the relationship between speciﬁc pul-
monary disease severity criteria and the microbiology of acute
bacterial exacerbations of chronic bronchitis (ABECB).
Methods: This was a double-blind, randomized clinical trial
evaluating levoﬂoxacin 750 mg qd for 3–5 days in ABECB. All
potential subjects had to meet the ATS deﬁnition of chronic
bronchitis but only those patients with Anthonisen type 1 or 2
exacerbations (N = 763) were enrolled. Stratiﬁcation by disease
severity was determined using parameters suggested by Gross-
man: FEV1 % of predicted value, deﬁned co-morbidities, and
number of exacerbations during the previous 12 months. Because
different spectra of etiologic organismswere expectedon the basis
of the stratiﬁcation, different comparator agents were used for
uncomplicated patients (azithromycin for ﬁve days) and those
considered complicated (amoxicillin/clavulanate for ten days).
Results: Initial microbiology from all intent-to-treat patients
revealed notable differences between the two strata. Among
isolates from uncomplicated cases, 55% were the traditional triad
of S. pneumoniae, H. inﬂuenzae, and M. catarrhalis. Inclusion of
H. parainﬂuenzae raises this ﬁgure to 79%. In the complicated arm
the ﬁgures were 48% and 68%, respectively. Gram-negative bacilli,
primarily Enterobacteriaceae spp. and several Pseudomonads, rep-
resented 15% of the uncomplicated and 23% of the complicated
isolates. Microbiological eradication rates and the percentage of
organism persisting after therapy from the uncomplicated stratum
were compatiblewith theunexpectedly largenumber ofmacrolide-
resistant organisms isolated. In the complicated arm, both levoﬂ-
oxacin and amoxicillin/clavulanate had lower, but comparable,
eradication and persistence rates. Clinical efﬁcacy in microbiolog-
cally-evaluable patients was consistent with these ﬁgures.
Conclusion: While there was clearly overlap among the ﬂora
isolated from the two strata deﬁned by application of the
Grossman criteria, there was separation of the populations. This
predictive approach seems to be of value in identifying the
optimal antimicrobial regimen, especially for uncomplicated
exacerbations. Further work to deﬁne and validate predictive
clinical parameters may help optimize the choice and duration
of antimicrobial agents for ABECB.
P889
Efﬁcacy and safety of pharmacokinetically
enhanced amoxicillin/clavulanate 2000/125 mg
(PKE AMX/CA) in patients with community-
acquired pneumonia, including cases caused by
penicillin-resistant S. pneumoniae
K. Bhatt, V. Kalia, E. Berkowitz, M. Twynholm, B. Abraham-van
Parijs, R. Hodge (Collegeville, USA; Greenford, Harlow, UK)
Objectives: To evaluate the efﬁcacy and safety of PKE AMX/
CA against CAP, a common, costly respiratory illness,
Microbiological
Eradication Rate (%)
Persistent
Organisms (%)
UNCOMPLICATED
Azithromycin 82.8 17.2
Levoﬂoxacin 93.8 6.3
COMPLICATED
Amoxicillin/clavulanate 79.8 18.0
Levoﬂoxacin 81.4 18.6
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particularly cases caused by Streptococcus pneumoniae, including
penicillin-resistant (PRSP, penicillin MICs ‡2 mg/L) strains.
Methods: An open-label, non-comparative, multicentre study.
Patients with a diagnosis of CAP received oral PKE AMX/CA,
2x 1000/62.5 mg tablets twice daily, for 7 days. Patients were
required to provide a sputum sample or, if clinically indicated,
an invasive respiratory sample for bacteriological evaluation.
Positive pneumococcal urine antigen test and/or the presence of
Gram+ diplococci by direct examination of a sample smear was
added to inclusion criteria via protocol amendment. Patients
were to attend clinic at screening (Day 0), on therapy (Day 3–5),
end of therapy (EOT, Day 9–11) and follow-up (FU, Day 28–35).
Results: A total of 1903 patients were enrolled, 1888 of whom
(including 984 post-protocol amendment) received study medi-
cation and had veriﬁable efﬁcacy results (intent-to-treat [ITT]
population). Of these, 665 had ‡1 typical pathogen identiﬁed at
screening (bacteriology ITT population). The majority of patients
(58.7%) were male and the mean age was 46.5 years. Bacterio-
logical success (eradication or presumed eradication of screen-
ing pathogen) in the bacteriology ITT population at FU (primary
efﬁcacy endpoint) was 79.7% (530/665; 95% CI 76.4, 82.7) and at
EOT was 87.4% (581/665; 95% CI 84.5, 89.7). Bacteriological
success at FU against S. pneumoniae was 84.0% (331/394) in the
bacteriology ITT population, including 81.4% (35/43) of patients
with PRSP, and against Haemophilus inﬂuenzae was 79.0% (128/
162). Clinical success (resolution of signs/symptoms of CAP
such that no further antibacterial therapy was needed) and
radiological success (improvement/resolution of radiological
signs of CAP) were achieved in >77% of patients at FU and
>80% of patients at EOT. In the safety population (N = 1900),
diarrhoea was the most frequently reported adverse event (AE),
occurring in 14.3% of patients. Headache (4.6%, 87/1900) and
nausea (3.3%, 62/1900) were the only other AEs to occur in ‡3%
of patients. The majority of AEs were mild to moderate in
severity. Only 4.9% (93/1900) of patients in the ITT population
withdrew from the study due to AEs.
Conclusions: PKE AMX/CA was effective in treating CAP,
including cases caused by PRSP, and was well tolerated, with
few patients withdrawing from the study due to AEs.
P890
Comparison of cefepime and ceftazidime in
treatment of ventilator-associated pneumonia in
severe trauma patients
D. Protsenko, S. Yakovlev, B. Gelfand, A. Yaroshetskiy,
Y. Romanovsky (Moscow, RUS)
Objectives: Nosocomial pneumonia is the second most
common nosocomial infection and, along with primary bac-
teraemia, the leading cause of death from infection acquired in
the hospital. Despite the frequency of ventilator-associated
pneumonia (VAP) and the threat it poses to patient survival,
consensus on an appropriate antibiotic treatment of VAP has yet
to be established. The uncertainty is compounded by a lack of
well-controlled comparisons of speciﬁc treatment regimens and
their impact on relevant outcomes, such as morbidity, mortality,
and cost. The comparable analysis of clinical and microbiologi-
cal efﬁcacy of cefepime and a combination ceftazidime and
amikacin in the treatment of VAP in severe trauma patients was
the aim of present study.
Methods: This prospective, randomized study was approved
by the institutional review board for human research. Thirty
adult patients who admitted in ICU of an 1850-bed emergency
municipal hospital with severe trauma complicated with VAP
were included. The CPIS was used for diagnostics of VAP. A
combination of ceftazidime (2 g TID, IV) and amikacin (1 g once
daily, IV) was used as initial empiric therapy of VAP in 17
patients and monotherapy with cefepime (2 g BID, IV) – in 13
patients. These regimes of empiric therapy have been chosen
according our local microbiological monitoring and P. aeruginosa
was the prevalent pathogen of VAP. The cost-effectiveness
analysis was performed to compare both costs and outcomes of
competing regimes.
Results: There was no difference between groups in patients
mean age, average time of mechanical ventilation before onset of
VAP and CPIS. Mean APACHE II score was 23.1 in the group of
combination therapy and 24.0 in the group of monotherapy. The
positive clinical outcome was registered in 92.3% patients on
cefepime and 88.2% patients on ceftazidime plus amikacin. The
rate of eradication was 53.8 and 58.8% respectively. The
duration of effective treatment with cefepime was from 7 to
12 days (mean 8.5 days), with combination therapy – from 7 to
18 days (mean 9.1 days). The mean cost of VAP treatment with
cefepime was 452.8 Euro in comparison with 585.4 Euro when
the empiric therapy was initiated with ceftazidime and amika-
cin.
Conclusions: Cefepime in a monotherapy regimen has the
same clinical and bacteriological efﬁcacy in comparison with a
combination of ceftazidime and amikacin in VAP patients with
severe trauma but the use of cefepime results in lower costs.
P891
Inﬂuence of antibacterial protocol in multiple
trauma patients on incidence and mortality of
VAP
D. Protsenko, A. Yaroshetskiy, S. Yakovlev, B. Gelfand (Moscow,
RUS)
Objectives: The aim of present study was the evaluation of
antibacterial protocol in multiple trauma patients on incidence
and mortality of VAP.
Methods: A comparable analysis of incidence, attributive mor-
tality (chi-square test) and pathogens of VAP in multiple trauma
patients was performed during two periods: 2001 (before
introduction of protocol) and 2003 (after introduction of proto-
col) years. The developed protocol included: 1. Abandoning of
antibiotic prophylaxis of VAP; 2. Intrusion criteria of early
diagnostics of VAP; 3. Exclusion of 1st, 2nd and 3rd generation
cephalosporines , aminoglycosides and ﬂuoroquinolones as
empiric therapy of VAP; 4. Cefepime (APACHE II <20) or
carbapenems (APACHE II >20) were used as initial empiric
therapy of VAP; 5. Efﬁcacy of antibiotic treatment was evaluated
within 48 hours; 6. Carbapenems and/or vancomycin was
added if initial therapy was inefﬁcient. In the case of suspected
diagnosis of VAP microbiological analysis of bronco-alveolar
lavage ﬂuid (BAL) was performed.
Results: We analysed all 399 patients admitted to 12-bed ICU
of emergency hospital (220 pts in 2001 and 179 pts in 2003).
The incidence of VAP was 10% in 2001 (22/220) and 14% in
2003 (25/179), difference was not signiﬁcant. Attributive
mortality due to VAP was 63% (14/22) in 2001 and 24%
(6/25) in 2003, p < 0.01. In 2003 comparison with 2001 the
consumption of the following antibiotics was increased (DDD):
cefepime – from 40 to 663, imipenem – from 8 to 86,
meropenem – from 8 to 216, vancomycin – from 15 to 279. A
widespread use of broad spectrum antibiotics shifted the
structure of nosocomial pathogens. We observed decrease of
MRSA rate and signiﬁcant increase (more than 10 times) in rate
of Klebsiella pneumoniae (from 0.6 to 18.1%, most of strains were
resistant to 3rd generation cephalosporines) and in rate of
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Acinetobacter baumanii (from 1.2 to 12.3%, most of strains were
resistant to ceftazidime).
Conclusions: Introduction of strict antibacterial protocol in
patients with multiple trauma and VAP results in signiﬁcant
decrease of attributive mortality without any change in inci-
dence of VAP.
P892
Antimicrobial prophylaxis in cardiac surgery and
postoperative pneumonia rate
E. Bachinskaya, N.V. Beloborodova, S. Kuznetcova (Moscow,
RUS)
Objective: The purpose of this study was to assess the postop-
erative pneumonia rate according to antimicrobial prophylaxis
regimens in patients after cardiac surgery with cardiopulmon-
ary bypass.
Patients and methods: Cardiac surgery patients were included
(n = 86) in the retrospective study. We observed 44 patients with
postoperative pneumonia (pneumonia group) and 42 patients
without infectious complications in postoperative period. The
groups were compared by age, sex, volume of transaction,
severity of disease. In a studied period is from 2001 to 2003 two
main regimens of antimicrobial prophylaxis were used: ceftri-
axone 1–2 g IV once before operation or cefuroxime 1.5 g IV
before operation and additional dosage 0.75 mg in 2–3 hours
after surgery beginning; then prophylaxis were conducted after
operation during 48–72 hours. Data were compared by Fisher
exact; we determined about signiﬁcantly differences between
groups when p < 0.05.
Results: Preoperative prophylaxis by cefrtiaxone was adminis-
tered more often in pneumonia group than in patients without
infection complications (56.3% vs. 33.3%, NS). Ceftriaxone was
used signiﬁcantly more often in comparison to cefuroxime in
subgroup of patients with cardiopulmonary bypass less than
180 min who developed postoperative pneumonia (63.2% vs
30%, p < 0.05). During cardiopulmonary bypass longer than
180 min we did not reveal difference between antimicrobial
prophylaxis regimens.
Conclusion: Cefuroxime is more preferable than ceftriaxone for
antimicrobial prophylaxis of postoperative pneumonia in
patients after cardiac surgery with cardiopulmonary bypass
less than 180 min duration.
P893
Closed versus open tracheal suction system to
prevent ventilator-associated pneumonia
M. Lecuona, L. Lorente, M. Cuervo, M.A. Miguel, I. Montesinos,
B. Castro, S. Campos, A. Sierra (La Laguna, E)
Objective: The aim of this study was to analyze the incidence of
ventilator-associated pneumonia (VAP) using a closed tracheal
suction system (CTSS) versus an open system (OTSS).
Methods: Prospective and randomized study, between October
1, 2002 and December 31, 2003 in a 24-bed medical-surgical
Intensive Care Unit of a 650-bed tertiary hospital. Patients
requiring mechanical ventilation during more than 24 hours
were included in the study, and were randomized in two
groups: one group was suctioned with CTSS and another group
with OTSS. Throat swabs were taken at the moment of
admission and twice a week until discharge, to classify pneu-
monia in endogenous and exogenous.
Results: A total of 443 patients (210 with CTSS and 233 with
OTSS) were included. There were not signiﬁcant differences
between both groups of patients in age, sex, diagnosis groups,
mortality, number of aspirations per day and APACHE-II. No
signiﬁcant differences were found in the percentage of patients
who developedVAP (20.47% vs. 18.02%) neither in the number of
VAP per 1000mechanical ventilation-days (17.59 vs. 15.84). There
were also no differences in the VAP incidence by MV duration.
At the same time we did not ﬁnd any differences in the incidence
of exogenous VAP. Likewise, there were also no differences in
the microorganisms responsible for pneumonia. Patient cost per
day for the closed suction was more expensive than the open
suction system (11.11 ± 2.25$ vs. 2.50 ± 1.12$, p < 0.001).
Pharmacokinetics/pharmacodynamics of antibacterial drugs
P894
Pharmacokinetic/pharmacodynamic model for
the tolerability of tigecycline in healthy
volunteers
J. Passarell, A. Meagher, K. Liolios, B. Cirincione, T. Grasela,
T. Babinchak, E.J. Ellis-Grosse (Buffalo, Collegeville, USA)
Objectives: Tigecycline (T), a ﬁrst-in-class glycylcycline, is an
antimicrobial agent with demonstrated in vitro activity against
susceptible & multiple-drug resistant Gram-positive & -negative
bacteria. Similar to tetracyclines, nausea (N) & vomiting (V) are
frequently reported adverse events. Exposure-response relation-
ships & subject (subj) covariates predictive of the ﬁrst occur-
rence of N&V in healthy volunteers were evaluated.
Methods: Subj with PK data from 3 single-dose (12.5, 25, 50, 75,
100, 200, 300 mg) Phase 1 studies were pooled for analysis. N&V
(deﬁnitely, possibly, or probably related to T) reported from the
start of infusion until 24 hrs post dose were included. Subj
administered ondansetron or with severe/end-stage renal dis-
ease were excluded. Individual T exposure measures [AUC 0–
inﬁnity (AUC) and Cmax] were obtained from previously
conducted noncompartmental analyses. Covariates included
age, weight, gender, and geographic location. Logistic regres-
sion & Kaplan–Meier methods were used to evaluate the time to
ﬁrst occurrence of N&V.
Results: The dataset included 136 subj. Mean (SD) age & weight
were 38 (20) years and 74 (12) kg. Approximately 87% were
Caucasian, 84% were male, 38% were enrolled in USA & 62% in
Europe. Single N occurrences were reported in 51 (38%); V in 25
(18%) subj. 2 N or V events were reported in 4 subj. N(V) was
reported in 12% (4%) of placebo subj, 17% (0%) on T 25 mg, &
33% (0%) on T 50 mg. Females had a higher occurrence of N&V
(45% & 19%) vs males (36% & 14%). France & USA had similar
N rates (39% vs 35%); France had a much higher V rate (24% vs
10%). Most N (V) events occurred £4 hrs (£6 hrs) of T infusion
for all doses. For doses £100 mg, median duration of N&V was
<1 hr & increased dramatically for 200 & 300 mg dose groups
(<3 hrs). Most N (V) occurrences were mild [49% (20%)] & 27%
(44%) were moderate. 111 subj had PK. Final statistical model
concluded AUC & Cmax as signiﬁcant predictors of N
(p £ 0.0001, 0.0022) & V (p £ 0.0001, 0.0006). Increased expo-
sures resulted in increased events. At the median AUC (Cmax)
of 2599 ng x hr/mL (392 ng/mL) for the 50 mg dose group, N
probability was 0.26 (0.29); V probability was 0.08 (0.11).
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Conclusion: T exposure (AUC > Cmax) was a signiﬁcant pre-
dictor of the probability of N&V events in Phase 1 subj. Model
predicted rates of N&V were comparable with those seen with
the tetracycline class of antibiotics, with tolerable rates predicted
at the targeted T 50 mg q12 h dose.
P895
Dalbavancin penetration into skin supports once
weekly dosing
J.A. Dowell, M. Buckwalter, E. Seltzer, M. Stogniew,
T. Henkel (King of Prussia, USA)
Objectives: Dalbavancin is a novel, second generation lipogly-
copeptide that has been shown to have clinical efﬁcacy as a
once-weekly treatment for complicated skin and skin structure
infections (cSSSI). The dosage used in clinical studies is 1000 mg
Day 1/500 mg Day 8. In vitro studies have determined dalba-
vancin MIC90s of less than or equal to 0.06 mg/L for target
bacteria, principally staphylococci and streptococci, including
isolates resistant to other antibiotics. The plasma protein binding
of dalbavancin is 93%. As skin infections occur in extravascular
space, antibiotic concentrations are assessed in blister ﬂuid as a
measure of skin penetration and to obtain pharmacokinetic
observations that may correlate with efﬁcacy.
Methods: A Phase I, open label, single-dose study was con-
ducted in 9 healthy subjects. Subjects were administered a
1000 mg IV dose of dalbavancin. Blisters were induced by
applying 0.25% cantharidin ointment to the skin. Blister ﬂuid
was collected prior to dose, and at 12 hours, Day 3, Day 5 and
Day 7. Blood samples were collected throughout the study.
Blister ﬂuid and plasma were assayed for dalbavancin using a
validated LC-MS/MS method and pharmacokinetic parameters
were determined. Area under the concentration-time curve
(AUC) was determined for blister ﬂuid (AUCbf) and plasma
(AUCp) through the ﬁrst week. The degree of penetration into
skin was determined by AUCbf/AUCp (%).
Results: Dalbavancinwaswell toleratedwith no serious adverse
events; most adverse events were mild and self-limited. Maxi-
mum observed dalbavancin blister ﬂuid concentrations were
achieved by the ﬁrst collection (12 hours) and concentrations
were maintained above 30.3 (±4.4) mg/L through Day 7. The
mean (SD) AUCbf and AUCp were 6438 ± 1238 and 10806 ±
1926 mg h/L, respectively. Skin penetration was approximately
60%. Dalbavancin blister ﬂuid concentrations were maintained
well above MICs throughout the treatment interval, even when
considering the possible effects of protein binding.
Conclusions: Blister ﬂuid concentrations are maintained well
above MICs of cSSSI target organisms for a week following a
single dose of dalbavancin. These data support a once-weekly
regimen and are consistent with the efﬁcacy observed in clinical
studies.
P896
The safety and pharmacokinetics of dalbavancin
in subjects with renal impairment or end-stage
renal disease
J.A. Dowell, E. Seltzer, D. Krause, T. Henkel (King of Prussia,
USA)
Objectives: Dalbavancin is a novel, second generation lipogly-
copeptide antibiotic in late stage clinical development for
complicated skin and skin structure infections (cSSSI). The
weekly dosage used in clinical studies is 1000 mg Day 1/500 mg
Day 8. Since dalbavancin will likely be used in patients with
various degrees of renal impairment, it is important to
determine the safety and pharmacokinetics in this population,
as well as to evaluate if a dosage adjustment is necessary.
Methods: Single intravenous doses of 1000 mg dalbavancin
were examined in subjects with mild (CLCR of 50–79 mL/min)
and moderate (CLCR of 30–49 mL/min) renal impairment.
Doses of 500 mg dalbavancin were studied in subjects with end-
stage renal disease (ESRD; dialysis-dependent). Single doses of
500 mg and 1000 mg dalbavancin were studied in subjects with
severe renal impairment (CLCR <30 mL/min). Subjects with
normal renal function were studied and used as controls.
Pharmacokinetic data were analysed using non-compartmental
methods; parameters included maximum concentration (Cmax)
and area under the plasma concentration time curve (AUC).
Results: A total of 43 subjects received dalbavancin and were
included in the pharmacokinetic analysis (6 mild, 6 moderate, 10
severe, 6 ESRD, and 15 normal). Dalbavancin was well tolerated
in each of the renal impairment groups. The majority of adverse
events were mild or moderate in severity and unrelated to study
drug. There were no related serious adverse events. Dalbavan-
cin pharmacokinetics were similar between subjects with mild
and moderate renal impairment and subjects with normal renal
function. Concentrations in subjects with ESRD were similar to
subjects with normal renal function, indicating compensation in
renal insufﬁciency due to regular dialysis (3 times/week).
Subjects with severe renal impairment had increased concen-
trations and exposure. Concentrations were increased by no
more than 40% through the ﬁrst week post dose, but differences
continued to increase through the rest of the proﬁle. AUC was
increased almost 2-fold.
Conclusion: Dalbavancin was well tolerated in subjects with
various degrees of renal impairment. Patients with severe renal
impairment (CLCR <30 mL/min) may require a modest dosage
adjustment. No dosage adjustment is required for patients
undergoing regularly scheduled dialysis.
P897
Effect of haemodialysis on single dose
pharmacokinetics of telavancin
K. Duchin, J. Shaw, J. Seroogy, S. Barriere, R. Novack (South San
Francisco, New Orleans, USA)
Background: TLV, a novel lipoglycopeptide antibiotic with
multiple mechanisms of action, exerts rapid and concentra-
tion-dependent bactericidal activity against clinically important
gram-positive bacteria, including methicillin-resistant S. aureus.
The kidney is the primary route of elimination of TLV in man.
Phase 3 studies are ongoing in skin and skin structure infections
and hospital acquired pneumonia.
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Objective: To compare the single dose PK of TLV in subjects
maintained on hemodialysis with an aged and sex-matched
group of healthy subjects without renal dysfunction.
Methods: Six hemodialysis subjects (5 males, 1 female) received
a single 7.5-mg/kg dose of TLV intravenously over 1 hour
approximately 2–4 hours prior to a 4-hour hemodialysis session.
Six subjects (5 males, 1 female) with normal renal function
(mean creatinine clearance 94 mL/min) also received the same
dose of TLV over 1 hour. Blood and dialysate samples were
obtained at speciﬁed intervals post dose and assayed for TLV
with a validated LC/MS/MS assay. PK parameters were
determined using non-compartmental methods.
Results: Average values for plasma PK parameters for TLV in
both groups of subjects are shown below.The average (range)
clearance of TLV via dialysis was 4.6 mL/min (4.0–5.8) and the
per cent of dose removed by dialysis was 5.9% (3.0–7.6). Subjects
tolerated TLV well.
Conclusions: Dose reductions of TLV of 50% are recommended
in patients maintained on hemodialysis. Supplementation of a
TLV dose post dialysis is not needed.
P898
Pharmacokinetics and tissue penetration of
telavancin in healthy subjects
K. Duchin, H.K. Sun, J. Shaw, D. Nicolau (South San Francisco,
Hartford, USA)
Background: TLV, a novel lipoglycopeptide antibiotic with
multiple mechanisms of action, exerts rapid and concentra-
tion-dependent bactericidal activity against clinically important
gram-positive bacteria, including methicillin-resistant S. aureus.
The MIC90 for S. aureus, including MRSA and GISA, from
pooled studies is 0.5 lg/mL. Phase 3 studies are ongoing in skin
and skin structure infections and hospital acquired pneumonia.
Objectives: To determine the steady-state PK proﬁle of TLV in
plasma and skin blister ﬂuid in healthy subjects.
Methods: 8 subjects (7 males, 1 female) received three daily
doses of TLV (7.5 mg/kg) intravenously over 1 hour. Canthar-
idin ointment (0.25%) was applied to the forearms to produce 7
blisters/subject beginning 12–14 hours prior to the third dose of
TLV. Blood and blister ﬂuid samples were obtained at speciﬁed
intervals on days 3 and 4 and assayed for TLV with a validated
LC/MS/MS assay. PK parameters in both matrices were
determined using non-compartmental methods.
Results: The average values for PK parameters for TLV in
plasma and in blister ﬂuid are shown below. Mean (SD) trough
values of the ratios of concentrations of TLV in blister ﬂuid to
plasma on days 3 and 4 were 0.79 (0.2) and 0.82 (0.2),
respectively. Most subjects reported transient mild taste distur-
bance following administration of TLV.
Conclusions: Penetration of TLV was excellent into skin blister
ﬂuid and concentrations throughout the dosing interval excee-
ded the MIC90 for S. aureus.
P899
Inﬂuence of dose and infusion duration on the
time above MIC of ceftobiprole in healthy
volunteers
A.H. Schmitt-Hoffmann, B. Roos, J. Spickermann, M. Roehrle,
R. Pypstra (Basel, CH; Neu-Ulm, D)
Objective: To assess the inﬂuence of dose and infusion duration
on the plasma concentration-time proﬁles of ceftobiprole.
Methods: This study compared two different dosing regimens
in thirty six healthy volunteers. Nine male and nine female
subjects assigned to regimen A received a single 30 minute
intravenous constant rate infusion of ceftobiprole medocaril,
corresponding to 750 mg of ceftobiprole. A further nine male
and nine female subjects, assigned to regimen B, received a
single 60-minute intravenous constant rate infusion of ceftobi-
prole medocaril, corresponding to 500 mg of ceftobiprole. Blood
samples were collected immediately before start of infusion and
15 min, 30 min, 1 h, 4 h, 5 h, 6 h, 7 h, 8 h, and 24 h after start of
infusion. Plasma concentrations of ceftobiprole were quantiﬁed
using a validated speciﬁc LC-MS/MS assay.
Results: After single intravenous infusions of 750 mg equivalent
(eq) ceftobiprole for 30 minutes or 500 mg eq ceftobiprole for
60 minutes, mean Cmax-values at infusion endpoint are 57.9 lg/
mL and 34.2 lg/mL, respectively. The corresponding mean
AUC0-inf-values are 154 lg h/mL and 116 lg h/mL. Inter-
subject variability of the parameters AUC and Cmax of ceftobi-
prole is below 20%. Mean systemic clearance is 4.9 and 4.5 L/h
and mean steady-state volume of distribution is 13.7 and 11.0 L
for the 750 mg and 500 mg dosing regimen, respectively. After
infusion of 500 mg for 60 minutes or 750 mg for 30 minutes, the
TimeaboveMIC (targetMICof4 lg/mLforMethicillinResistant
Staphylococcus aureus) is 6 and 7 hours for the total plasma concen-
trations and 3.5 and 5.2 hours for the corrected unbound plasma
concentrations, respectively. With twice-daily administration of
500 mg for 60 minutes or 750 mg for 30 minutes, the proportion
of the dosing interval above the MIC of 4 lg/mL, would be
75% and 87% for the total plasma concentrations and 55% and
65% for the unbound plasma concentrations, respectively.
Conclusions: Ceftobiprole infusions of 500 mg eq for 60 min-
utes or 750 mg eq for 30 minutes, results in similar time above
target concentration of 4 lg/mL well above the minimum
efﬁcacy requirement 25–30% required for MRSA.
P900
2 hour versus 0.5 hour infusion of imipenem in
healthy volunteers
S. Jaruratanasirikul (Hat-Yai, Songkhla, TH)
Introduction: The bactericidal activity of beta-lactam antibiotics
is determined by the time that concentrations in plasma are
above the MIC (T > MIC) for the pathogens during the dosing
interval.
Objective: The aim of this study was to demonstrate the
T > MIC of imipenem when administered by 2 h infusion
compared with 0.5 h infusion.
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Methods: The study was a randomized, three-way crossover
study with 30 hours wash-out period in 8 healthy volunteers.
Each subject received imipenem in three regimens : (i) 0.5 h
infusion of 0.5 g every 6 h for 3 doses; (ii) 2 h infusion of 0.5 g
every 6 h for 3 doses; (iii) 2 h infusion of 1 g every 6 h for 3 doses.
Results:
Conclusion: The 2 h infusion of 0.5 or 1 g of imipenem both
give greater values for T > MIC than a 0.5 h infusion and that a
2 h infusion may be a useful mode of administration in tropical
countries where drug instability may prevent the use of
continuous infusion.
P901
Pharmacodynamic characterisation of LMB415
against Haemophilus inﬂuenzae in an in vitro
hollow-ﬁbre system
A. Meagher, P. Smith, A. Forrest, A. Odundele,
P. Ambrose (Buffalo, Albany, USA)
Objectives: LBM415 is a peptide deformylase inhibitor with
in vitro activity against those pathogens commonly associated
with community-acquired respiratory tract infections. The pur-
pose of these studies was to determine which pharmacokinetic-
pharmacodynamic (PK-PD) measure is most strongly associated
with drug response and to examine the relationship between
drug exposure and response for LMB415 against Haemophilus
inﬂuenzae (HI).
Methods: Two wild-type HI strains (MIC 2 and 8 mg/L) were
studied. The hollow-ﬁber system (HFS) was inoculated with
approximately 10E7–10E8 CFU/mL in log-phase growth. Simu-
lating human pharmacokinetics (t½ = 2 hours), bacteria were
exposed to escalating free drug LMB415 exposures (AUC
ranging from 0 to 200 mg · h/L) using a dose fractionation
study design and delivering drug q12 hours, q24 hours, and by
continuous infusion (CI). Serial samples were collected to
determine bacterial counts (CFU/mL) and drug concentrations.
Drug effect was quantiﬁed as the log10 ratio (LR) of the 24 hour
area under the bacterial growth/kill curves for drug and growth
control (LR = log10 AUCdrug/AUCgrowth control).
Results: Overall, the greatest activity (at 6xMIC) was seen with
the CI regimen (CI > Q12 >> Q24). Due to the short half-life,
dosing q24 hours yielded no net kill compared to baseline.
Neither per cent time above MIC, AUC:MIC ratio, nor peak:MIC
ratio could co-model the q12 and q24 hour regimens with CI
results. Separating these into 2 datasets (q12/24 vs CI), only the
AUC:MIC ratio could adequately describe the CI results (Emax
LR of (2 at an AUC:MIC ratio ‡50). The q12/24 dataset was
reasonably ﬁt by the AUC:MIC ratio and per cent time above
MIC (Emax LR of (2 to (3 at an AUC:MIC ratio ‡120 and per cent
time above MIC of ‡50–60%, respectively). The peak:MIC ratio
was not informative.
Conclusion: For intermittent dosing regimens, per cent time
above MIC and the AUC:MIC ratio adequately described drug
response. Percent time above MIC and the AUC:MIC ratio
associated with maximal decline were ‡50–60% and ‡120,
respectively. CI regimens could not be co-modeled with inter-
mittent regimens, suggesting that neither per cent time above
MIC nor the AUC:MIC ratio completely described drug effect.
Drug effect continued to increase beyond 100% time above MIC.
Q12 hour dosing had more effect than q24 hour dosing, and
would probably be an effective LBM415 regimen in humans for
HI.
P902
Pharmacodynamics of antimicrobials for the
empiric treatment of nosocomial pneumonia: a
report from the OPTAMA program
H.K. Sun, J.L. Kuti, D.P. Nicolau (Hartford, USA)
Objectives: Appropriate empiric antibiotic therapy is vital for
maximizing patient outcomes in the treatment of nosocomial
pneumonia and is dependent on the drug exposure achieved in a
patient and the causative pathogen’s MIC. The purpose of this
study was to compare the probability of achieving bactericidal
exposures for commonly used intravenous antibiotics against the
bacteria most commonly implicated in nosocomial pneumonia.
Methods: A 10,000-subject Monte Carlo simulation calculated
target attainments for cefepime (FEP), ceftazidime (CAZ),
imipenem (IPM), meropenem (MEM), piperacillin/tazobactam
(TZP), and ciproﬂoxacin (CIP) as 30-minute infusions. Bacteri-
cidal targets were free drug concentrations above the MIC for
40% of the dosing interval for IPM and MEM, 50% for FEP, CAZ
and TZP, and a total AUC/MIC ratio of 125 for CIP. MICs (in
rank order) for S. aureus, P. aeruginosa, S. pneumoniae, Klebsiella
sp., Enterobacter sp., E. coli, Serratia sp., Acinetobacter sp., P.
mirabilis and Citrobacter sp. were taken from the MYSTIC 2003
surveillance study and weighted by the prevalence of each
pathogen as the cause of nosocomial pneumonia according to
published data. A sensitivity analysis varying pathogen preval-
ence was applied. Population pharmacokinetic parameters were
taken from healthy volunteer studies. MRSA was excluded.
Results: Percent target attainments are listed in Table 1. The
sensitivity analysis revealed that when P. aeruginosa incidence
Table 1% Target attainment rates for FEP, CAZ, IMP, MEM, TZP
CIP
%T > MIC
0.5 h
infusion
2 h infusion
0.5g 1 g
16 lg/ml 21.51 (2.16) 26.85 (8.49) 51.55 (5.44)a,b
8 lg/ml 38.55(3.51) 48.04 (3.52)a 677.3 (4.50)ab
4 lg/ml 57.45(3.95) 65.41 (3.33)a 87.79 (5.63)a,b
a p < 0.05 versus 0.5 h infusion.
b p < 0.05 versus 2 h infusion of 0.5 g.
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was high, target attainments for FEP, CAZ, and TZP decreased,
but carbapenem target attainments remained the same regard-
less of pathogen prevalence.
Conclusions: Target attainments were greatest for IPM and
MEM, followed by higher doses of FEP, CAZ and TZP. Because
these antibiotic regimens provide optimal bactericidal exposure,
they would be most suitable for the empiric treatment of
nosocomial pneumonia along with an anti-MRSA antibiotic until
pathogen identiﬁcation and susceptibility results are available.
P903
Penetration of ertapenem into different
pulmonary compartments of patients undergoing
lung surgery
O. Burkhardt, J. Majcher-Peszynska, R.G. Mundkowski,
K. Borner, B. Drewelow, T. Welte (Magdeburg, Rostock, Berlin, D)
Objective: Ertapenem, a new carbapenem, is approved for the
treatment of community-acquired pneumonia, but its in vivo
penetration into lung tissue (LT), epithelial lining ﬂuid (ELF),
and alveolar cells (AC) in humans is unknown.
Methods: Fifteen adult patients undergoing thoracotomy for
suspected lung cancer were treated with 1 g intravenous
ertapenem for perioperative prophylaxis. In all patients BAL
was performed 1, 3, and 5 h after the start of ertapenem
infusion. From 12 patients normal lung tissue were sampled
simultaneously at the time of the extraction of the pulmonary
segment, lobe or lung. Blood samples were collected before, and
at different time points up to 24 h after medication, and at the
time of taking the tissue samples. Samples were analysed by a
validated HPLC method.
Results: Mean concentrations of ertapenem in plasma, ELF, and
AC were: at 1.0 h: 63.1, 4.06, 0.004 mg/L; at 3.0 h: 39.7, 2.59,
0.003 mg/L; at 5.0 h: 27.2, 2.83, 0.007 mg/L. The mean (range)
concentration in normal lung tissue was 7.60 (2.5–19.4) mg/kg of
tissue 1.5–4.5 h after infusion. After a single dose ertapenem
exhibited in plasma a mean (SD) Cmax of 90.3 (19.8) mg/L at a
median Tmax of 0.5 h, a mean (SD) terminal elimination half-life
of 6.6 (4.5) h, and an mean (SD) AUC of 591.4 (416.5) mg/L h.
No serious adverse events were observed.
Conclusions: Like in other beta-lactam antibiotics penetration
of ertapenem into AC was low. However, its concentrations in
plasma, ELF and lung tissue exceeded to a large extent of the
dosing interval the MIC90 of all important community-acquired
respiratory pathogens. These results support the clinical efﬁcacy
of ertapenem in the treatment of community-acquired pneu-
monia.
P904
Pharmacodynamic comparison of intravenous
antimicrobials against Pseudomonas aeruginosa
in Hungarian hospitals – A report from the
OPTAMA Program
E. Ludwig, D. Maglio, M. Konkoly-Thege, J. Kuti,
D. Nicolau (Budapest, HUN; Hartford, USA)
Objectives: The treatment of multi-drug resistant Pseudomonas
aeruginosa (PSA) infections is a growing problem worldwide.
Since the clinical value of antimicrobials depends on local
resistant patterns, the PD proﬁles of ﬁve Beta-lactams and
ciproﬂoxacin were evaluated using Monte Carlo simulation
against isolates collected in Hungary.
Methods: MICs for 180 nonduplicate PSA collected from 14
hospitals in Hungary were determined by E-test methodology.
A 5,000 subject Monte Carlo simulation was performed to
calculate the target attainment (TA) of obtaining bactericidal PD
exposures for standard dosing regimens of meropenem (MEM),
imipenem (IMI), ceftazidime (CTZ), cefepime (PIM), piperacil-
lin/tazobactam (TZP), and ciproﬂoxacin (CIP). Bactericidal
exposures were deﬁned as free drug concentrations above the
MIC for 40% of the dosing interval for MEM and IMI, 50% for
CTZ, PIM, and TZP, and a total drug area under the curve
(AUC) to MIC ratio of 125 for CIP. Pharmacokinetic data were
obtained from healthy volunteer studies. A TA greater than 90%
was deﬁned as optimal. In the case of poor TA, PD optimized
regimens were simulated for select agents by increasing infusion
(INF) time, dose and frequency.
Results: No regimen obtained greater than 90% TA. The highest
TA achieved with standard dosing regimens was MEM 1 g q8
and 0.5 g q6 h at 78% and 77%, followed by the CTZ 2 g q8 h at
75%, then IMI, TZP, PIM, and lastly CIP. Increasing INF, dose
and frequency for MEM, PIM and TZP all increased TA, with
the greatest TA acheived by MEM 2 g q8 h as a 3 hour INF at
88%, followed by 1 g q8 h as a 3 hour INF and TZP 4.5 g q6 h as
a 4 hour INF.
Conclusions: Given the poor TA predicted with standard
dosage regimens against these PSA, it seems prudent to evaluate
patient outcomes in this population. When empirically treating
suspected PSA infections in Hungary, alternative dosage strat-
egies such as increasing doses, frequencies or prolonging the
infusion time for the Beta-lactams along with combination
therapy is justiﬁed.
P905
Single-dose pharmacokinetics of fosfomycin
during continuous venovenous haemoﬁltration
R. Gattringer, B. Meyer, G. Heinz, C. Guttmann, P. Dittrich,
F. Thalhammer (Vienna, Graz, A)
Objective: Fosfomycin (F) is an often employed antibiotic in
critically ill patients with severe infections. Continous venove-
nous haemoﬁltration (CVVH) is an important supportive
extracorporeal renal replacement therapy in treatment of inten-
sive-care patients. This study was designed to ﬁnd out recom-
mendations of dosing F for patients undergoing CVVH.
Method: Twelve intensive care patients with acute renal failure
and suspected or proven infection were included in the study.
CVVH was performed using a polyethylene sulfone haemoﬁlter
with a membrane surface of 1.2 m2. Mean blood ﬂow rate was
153.33 + 17.23 mL/min and ultraﬁltration rate pump rate was
adjusted to 25 mL/min. All patients received a single dose of
8 g F into a central venous catheter, different from the venous
catheter used for CVVH. Blood samples were drawn from the
arterial (input) and venous (output) line of the extracorporeal
circuit before and 15, 30, 60, 90, 180, 360, 480 and 720 min after
the start of the infusion. Ultraﬁltration samples were collected at
corresponding times. F in the samples was quantitated by gas
chromatography after derivatisation. The area under the con-
centration time curve (AUC), the elimination half-life, the total
clearance and the volume of distribution were estimated. The
clearance of hemoﬁltration was also determined. The sieving
coefﬁcient and the total removal of the drug during hemoﬁltra-
tion were calculated.
Results: Peak serum concentrations were 442.78 ± 129.56 mg/L
and 338.04 ± 128.19 mg/L at the arterial port and at the
venous port, respectively. Trough serum levels were
102.10 ± 36.59 mg/L at the arterial port and 72.88 ±
35.94 mg/L at the venous port after 720 min. The mean arterial
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and venous elimination half-life was12.11 ± 5.41 and
11.77 ± 6.25 h, respectively. The mean arterial AUC0-12 was
2159.38 ± 636.92 mg * h/L and the arterial AUC0-24 2922,49 ±
795.83 mg * h/L. The mean venous AUC0-12 and AUC0-24
were 1550.23 ± 611.58 mg * h/L and 2135.32 ± 782.16 mg * h/L.
The sieving coefﬁcient was 0.71 ± 0.15, respectively. Mean total
removal of the drug was 76.79 + 6.25%. The results of calculated
clearance were 1.06 ± 0.22 L/h.
Conclusion: In conclusion a regimen of 8 g F every 12 hours
should be an appropriate amtimicrobial treatment for patients
undergoing CVVH. But because of fast resistance development
and lack of postantibiotic effects F should be combined with
antimicrobials where synergically activity was already shown.
P906
Telithromycin and azithromycin
pharmacodynamics vs. genotypically
characterised (mefA and ermB) macrolide-
resistant strains of Streptococcus pneumoniae
simulating free serum and free epithelial lining
ﬂuid concentrations
D.J. Hoban, A. Noreddin, T. Hisanaga, M. DeCorby, N. Laing,
A. Wierzbowski, G.G. Zhanel (Winnipeg, CAN)
Objectives: Telithromycin (Teli) is a new ketolide with in vitro
activity against macrolide resistant SPN. The purpose of this
study was to compare the pharmacodynamics (PD) of Teli and
azithromycin (Azi) versus macrolide-resistant SPN simulating
free serum (S) and free epithelial lining ﬂuid (ELF) concentra-
tions in an in vitro model.
Methods: Five PCR-positive mefA, one PCR-positive ermB and
a control PCR-negative mefA, ermB strain of SPN were studied.
A one compartment in vitro pharmacodynamic model was used
with starting inocula 1 · 106 CFU/ml. Teli was added to the
model simulating a dosage of 800 mg PO OD (S: free drug
Cpmax 0.7 lg/ml, t1/2 10 hr, free AUC ~4; ELF: free drug Cmax
6 lg/ml, t1/2 10 hr, free AUC ~35). Azi was added simulating a
dosage of 500/250 mg PO OD (S: free drug Cpmax 0.2 lg/ml,
t1/2 68 hr, free AUC ~2; ELF: free drug Cmax 1 lg/ml, t1/2
68 hr, free AUC ~10). Samples were obtained over 24 hours to
assess viable growth and selection of resistance.
Results: Both S and ELF Teli concentrations eradicated (low-
ered inoculum below level of detection) all PCR-positive mefA,
ermB and wild type SPN from the model within 6 hours. No
difference in the rate or extent of killing (>3 log10 reduction)
occurred between the test and control strains or between S and
ELF concentrations. Azi S and ELF concentrations eradicated
macrolide-susceptible SPN but did not eradicate macrolide-
resistant SPN regardless of resistance phenotype.
Conclusion: Both Teli and Azi eradicated macrolide-susceptible
SPN. Teli but not Azi, completely eradicated both mefA and
ermB SPN from the model with no regrowth over 24 hour. Teli
offers promise for the management of respiratory infections
caused by macrolide-resistant SPN.
P907
Postantibiotic sub-MIC and subinhibitory effects
of various antibiotics on B. anthracis
A. Athamna, M. Athamna, D.J. Bast, D. Farrell, E. Rubenstein
(Kfar Qaraa, IL; Canada, CAN; London, UK; Ramat Gan, IL)
Objective: To determine the Post Antibiotic Effect of Sub
Minimal Inhibitory Concentrations (PA-Sub MIC) and Sub
Minimal Inhibitory Concentration effect (SME) of 6 antibacterial
agents against two strains of B. anthracis.
Methods: The PA-Sub MIC and SME were determined by
exposing the bacteria to antibiotic concentrations 10 times the
MIC for 2 h at 37 C. Following repeated washings and
centrifugations to remove the antibiotic, cultures were divided
into four tubes. To three tubes, the tested antibiotic was added to
make a ﬁnal concentration of 0.5 MIC, 0.25 MIC and 0.125 MIC
to the fourth tube no antibiotic was added. Optical Density was
determined before exposure, immediately after washing and
then hourly up to 9 h. For the determination of SME, the same
procedure was performed except that the organisms were not
pre-exposed to any antibiotic. The ODs were converted to CFUs
by using a standard curve. The PA-Sub MIC was deﬁned as PA-
Sub MIC = Tpa ) C, where Tpa is the time for cultures
previously exposed to an antibiotic and then reexposed to
different sub-MICs to increase 1 log10 above the counts deter-
mined immediately after washing and C is the corresponding
time for the antibiotic unexposed control. The SME was deﬁned
as SME = Ts ) C, where Ts is the time for the cultures exposed
only to sub-MICs to increase 1 log10 above the counts deter-
mined immediately after washing and C is the corresponding
time for the unexposed control.
Results: The PAE of ciproﬂoxacin and moxiﬂoxacin on B.an-
thracis STi and Sterne strains were 3–4 h. The PA-Sub MIC of
ciproﬂoxacin (0.5 MIC) was 5 h for both strains, while moxiﬂ-
oxacin PA-Sub MIC was >8 h for both strains. Tetracycline PAE
was 1–2 h for both strains and the same result was found with
the PA-Sub MIC. Linezolid PAE was 1 h while the PA-Sub MIC
was 7 h. Penicillin PAE was 1–2 h, the PA-Sub MIC (0.5 MIC)
was >8 h. Quinoprestin–Dalfoprestin PAE and PA-Sub MIC
were 8 h. The SME of all antibiotics tested was 0 h.
Conclusion: Moxiﬂoxacin, linezolid and penicillin at PA-
SubMIC have a prolonged effect, which delayed the re-growth
of B.anthracis. Our results suggest that longer dosing intervals
may be possible for treatment of anthrax with these antibiotics.
P908
Pharmacodynamic proﬁling of cefepime in the
cerebrospinal ﬂuid of hospitalised patients
through the use of population pharmacokinetic
modelling and Monte Carlo simulation
T.P. Lodise, D.H. Rhoney, V.H. Tam, D. Parker, P.S. McKinnon,
G.L. Drusano (Albany, Detroit, Houston, St. Louis, USA)
Background: Data on the disposition of cefepime in human CSF
is limited and the ability of cefepime to achieve adequate
T > MIC for 40–100% of the dosing interval (DI) [40–100%
T > MIC] in the CSF of hospitalized patients for the range of
MICs deemed susceptible by NCCLS has not been characterized.
Methods: Serum and CSF cefepime PK data was obtained from
7 hospitalized patients with pneumonia and external ventricular
drains. The concentration-time proﬁles in serum and CSF were
modeled using a three-compartment model with zero-order
infusion and ﬁrst order elimination and transfer. The apparent
volume of the central compartment (VC), apparent volume in
the CSF (VCSF), intercompartmental transfer rate constants
(K12, K21, K13, and K31) and plasma clearance (CL) were
identiﬁed in a population PK analysis (NPAG) [table 1]. For
cefepime 2 g IV Q8 h (0.5 h infusion), a Monte Carlo Simulation
of 10,000 subjects (ADAPT II) was performed to estimate the
probability of attaining the targets of free cefepime serum
concentration (assumed 20% protein binding) and total cefepime
CSF concentration 40–100% T > MIC for MICs 0.25–8 mg/L
(table 2). CSF/serum median penetration ratio was calculated.
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Results:
Post MAP-Bayesian observed-predicted regression and r2 for
serum and CSF were as follows: (serum) observed = 0.984 ·
predicted + 2.570; r2 = 0.944. (CSF) observed = 0.785 · predic-
ted + 0.868; r2 = 0.821. The penetration of cefepime as measured
by median AUCcsf/AUC serum was 7.8% (25th–75th percen-
tiles 2.9–21.4%).
Results of Serum and CSF Target Attainment analysis for
Cefepime 2 g IV Q8H
Conclusion: In the setting of non-inﬂamed meninges, cefepime
2 g IV Q8 h does not provide adequate T > MIC in the CSF for
>80% of patients for MICs ‡0.5 mg/L. The inﬂuence of inﬂam-
mation on the calculated CSF target attainment rates is
unknown. The deﬁnitive pharmacodynamic target in the CSF
has not been elucidated and further research is needed.
P909
Application of microbiological and capillary
electrophoresis methods to
phenoxymethylpenicillin dissolution assay
W. Grzybowska, G. Pajchel, M. Zapasnik, S. Tyski (Warsaw, PL)
Objectives: Drug absorption from a solid dosage form after oral
administration depend on the release of the active substance
from the medicinal product. In some cases of drug analysis,
especially when the results of tests are out of speciﬁcation, it is
necessary to use another assay, simultaneously with the refer-
ence method. In case of phenoxymethylpenicillin tablets, the
reference method for dissolution assay is spectrophotometric
method. The aim of the study was to apply parallel microbio-
logical and capillary electrophoresis methods and compare the
results with those obtained using UV assay.
Methods: Two preparations (tablets), containing 1 00 000 IU/mg
ofpenicillinV: TaropenandOspenwere examined.Thedissolution
tests were performed at temperature 37C ± 0.5C, in phosphate
buffer pH 6.8 (900 ml for Ospen and 1000 ml for Taropen) using
baskets, rotation speed 100 rpm; samples were taken only at:
30 minute or at 10, 20 and 30 minutes in case of proﬁle of
dissolution analysis. The amount of penicillin V dissolved was
assayed spectrophotometrically at 268 nm. Hanson Research dis-
solution system and CE apparatus: Quanta 4000 of (Waters) were
used. Pharmacopoeal, microbiological agar diffusion method and
Staphylococcus aureusATCC 6538 P strain, were applied.
Results: The dissolution of penicillin V from Taropen prepar-
ation after 30 minutes was 100%, independently on method
applied. In case of Ospen tablets these values were different,
depending on the analytical assay. The statistical Fisher–Snede-
cor test for comparison of dissolution data obtained using three
methods was performed. The Fisher Fcalc. value was lower than
theoretical only in Taropen case. The dissolution proﬁles of two
examined preparations were also compared and statistically
evaluated according to the FDA method. The results of these
calculations showed that dissolution proﬁles of phenoxymeth-
ylpenicillin from Taropen and Ospen tablets differ signiﬁcantly.
Conclusion: Performed analysis proved that capillary electro-
phoresis and microbiological methods can be used alternatively
but only for determination of Taropen dissolution.
P910
Penetration of penicillin G in combination with
sulbactam into nasal tissues
U. Frank, S. Wenzler-Ro¨ttele, W. Maier, F. Knapp, R. Trittler,
H. Egle, K. Kuemmerer (Freiburg, D)
Objective: The penetration of antimicrobial agents into target
tissues is essential for treatment at the site of infection. We
investigated the distribution of penicillin G in combination with
sulbactam in human nasal tissues.
Methods: To determine the pharmacokinetics of penicillin G/
sulbactam, informed written consent was obtained from 22
patients aged between 19 and 73 years scheduled for endonasal
operations such as septoplasty and conchotomy. After infusion
of 5 m IU of penicillin G and 1 g of sulbactam, the concentra-
tions of these agents were determined in serum and various
nasal tissues such as septal mucosa, septal cartilage and bone.
Serum and nasal tissue concentrations were determined by
liquid chromatography-mass spectrometry (LC-MS).
Results: Up to 1, 2, 3, 4 and 5 hours after infusion, themean serum
concentrations of penicillin G were 114.9 lg/ml (SD ± 24.2),
54.0 lg/ml (SD ± 29.8), 33.6 (SD ± 26.9), 12.7 lg/ml (SD ± 9.6),
17.6 lg/ml (SD ± 8.2) and 2.8 lg/ml, while the mean serum
concentrationswere 17.6 lg/ml (SD ± 8.2) 24.3 lg/ml (SD ± 15.2),
9.3 lg/ml (SD ± 3.5), 3.5 lg/ml (SD ± 0.6), and 1.9 lg/ml
(SD ± 0.4). Mean penicillin G and sulbactam concentrations in
septalmucosa decreased from141.7 and 128.3 lg/g (1st hour) to 3.0
and 2.7 lg/g (5th hour), respectively. In septal cartilage, the highest
tissue concentrations were observed 2 hours after infusion, with
mean penicillin G and sulbactam concentrations of 59.4 and
80.1 lg/g, respectively. The mean penicillin G and sulbactam
concentrations in bone decreased from 31.2 and 14.8 lg/g (1st
hour) to 1.4 and 1.8 lg/g (5th hour), respectively. The regression
analysis of thedata showedthat 3 hafter administrationof thedrug
combination, the levels still exceeded the 4-fold MIC90 of methi-
cillin-susceptible Staphylococcus aureus, Streptococcus pyogenes,Mor-
axella catarrhalis and Haemophilus inﬂuenzae.
Conclusions: Our data support the use of the drug combination
in perioperative prophylaxis and the treatment of ENT (nasal
and paranasal) infections due to common bacterial pathogens.
P911
MIC vs. kill-curve based pharmacokinetic/
pharmacodynamic modelling of activities of
cefpodoxime and ceﬁxime
H. Derendorf, P. Liu, K. Rand, B. Obermann (Gainesville, USA;
Munich, D)
Objectives: Pharmacokinetic (PK)/Pharmacodynamic (PD)
modeling of antibiotics usually consists of the comparison
between plasma PK and the MIC, such as the T > MIC, Cmax/
MIC, and AUC/MIC. These indices are limited due to the innate
inaccuracy of the MIC and the fact that it does not reﬂect the
in vivo scenario where concentrations are not static but ﬂuctuate
between doses. An alternative is to use time-kill curves that
follow bacterial killing and growth as a function of time and
concentration. This study provides a systematic comparison of
MIC and kill-curve approaches to show the potential of both
methods for antibiotic evaluation. In an example, we developed
a mathematical pharmacokinetic/pharmacodynamic (PK/PD)
Cefepime Population on PK Mean (SD) Parameter Estimates
obtained by NPAG analysis
Vc (L) CL (L/h) K12 (h
-1) K21 (h
-1) K13 (h
-1) K31 (h
-1) VCSF (L)
21.1 (13.0) 6.9 (2.0) 5.4 (5.9) 7.0 (5.0) 3.4 (4.9) 14.8 (9.4) 45.1 (32.0)
2g Q 8 H T > MIC 0.25 mg/L 0.5 mg/L 1 mg/L 2 mg/L 4 mg/L 8 mg/L
(S/CSF) 0.4 DI 1.0/0.94 1.0/0.88 1.0/0.75 1.0/0.60 1.0/0.41 1.0/0.25
(S/CSF) 0.5 DI 1.0/0.92 1.0/0.85 1.0/0.71 1.0/0.55 0.99/0.37 0.99/0.23
(S/CSF) 0.6 DI 1.0/0.89 1.0/0.81 1.0/0.67 0.99/0.52 0.99/0.34 0.91/0.21
(S/CSF) 0.7 DI 1.0/0.87 1.0/0.78 1.0/0.63 0.99/0.48 0.97/0.32 0.93/0.19
(S/CSF) 1 DI 0.99/0.78 0.98/0.67 0.97/0.52 0.94/0.39 0.89/0.24 0.78/0.13
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model to integrate the in vitro antimicrobial activity with the PK
proﬁle of two oral cephalosporines at the tissue site.
Methods: Kill curves could be described with different combi-
nations of maximum kill rate (kmax), drug concentration at
half-maximum effect (EC50) and bacterial growth rate (k0) that
resulted in the same MIC in each scenario. In the experimental
part, bacterial time-kill curves of cefpodoxime and ceﬁxime
against four bacterial strains were compared in in vitro kinetic
models in which previously measured human pharmacokinetic
proﬁles of unbound antibiotic were integrated.
Results: Different combinations of kmax, EC50 and k0 can yield
the same MIC and consequently the same MIC-based index.
However, depending on the combination of PD parameters, kill
curvesmaypredictquiteoppositeoutcomes inbothscenarios.EC50
values of cefpodoxime and ceﬁxime were consistent with their
respective MIC values. Both antibiotics had similar high potency
against H. inﬂuenzae (EC50: 0.04 mg/L) and M. catarrhalis (EC50:
0.12 mg/L), while the potency of cefpodoxime against S. pneumo-
niae strains was about 10-fold higher than that of ceﬁxime (EC50s/
sensitive: 0.02 vs 0.27 mg/L; EC50s/intermediate: 0.09vs 0.69 mg/
L). Simulations showed that cefpodoxime will have higher bac-
teriological success against S. pneumoniae than ceﬁxime.
Conclusions: Simple comparison of exposure and MIC may not
be sufﬁcient to evaluate anti-infective efﬁcacy. Kill curves
provide a more detailed approach in predicting antimicrobial
effects. The developed Emax model effectively described the
pharmacodynamics of cefpodoxime and ceﬁxime. Cefpodoxime
(200 mg bid) has higher tissue penetration and antimicrobial
efﬁcacy than ceﬁxime (400 mg qd) against S. pneumoniae.
P912
Bacteriologic efﬁcacy of intravenous piperacillin/
tazobactam and ampicillin/sulbactam for infected
diabetic foot ulcers
L. Harkless, J. Boghossian, R. Pollack, W. Caputo, A. Dana,
S. Gray, D. Wu (San Antonio, Belleville, Collegeville, USA)
Objectives: To test the efﬁcacy of single-agent empiric treatment,
either intravenously administeredpiperacillin/tazobactam (TZP)
(4 g/0.5 gq8 h) or ampicillin/sulbactam (SAM) (2 g/1 gq6 h), of
moderate to severe infected foot ulcers in patients with diabetes.
Methods: In this open-label trial, 314 adults were randomized to
receive TZP or SAM for up to 21 days. Patients with polymicrobial
infections involving methicillin-resistant Staphylococcus aureus also
received vancomycin 1 g q12 h. Samples for bacteriologic evalua-
tion were taken at baseline from infected ulcers and blood to
document causative pathogen(s) and test for antimicrobial suscep-
tibility; samples were taken as clinically indicated at the end-of-
treatment and test-of-cure visits (14–21 days post-treatment). To
minimize risk of contamination, samples were to be obtained by
aspirate, curettage, or biopsy rather than by swabbing.
Results: A total of 123 of the 314 patients in the study were
bacteriologically evaluable.Themost commoncausativepathogens
in monomicrobial infections were S. aureus, Streptococcus agalactiae,
Enterococcus faecalis, and Pseudomonas aeruginosa. About 30% of
patients in each treatment arm had polymicrobic infections. The
combination of S. aureus plus S. agalactiae was most common. The
median duration of treatment was 8 days for both groups. The by-
pathogen bacteriological success rates were similar in both treat-
ment groups for S. aureus, S. agalactiae, and E. faecalis. TZP had an
eradication rate of 85.7% forP. aeruginosa; SAM is not active against
P. aeruginosa, and patients with P. aeruginosa in the SAM group
(n = 5) were discontinued from the study .
Conclusions: Previous studies have shown that TZP at a dose
of 3 g/0.375 g q6 h was effective for treatment of diabetic foot
infections. Our study conﬁrmed that less frequent administra-
tion of TZP at 4 g/0.5 g q8 h was sufﬁcient to attain bacterio-
logic success rates of 76.9% for S. aureus, 83.3% for S. agalactiae,
71.4% for E. faecalis, and 85.7% for P. aeruginosa in the
bacteriologically evaluable population. This study differed
from previous studies of infected diabetic foot ulcers, which
found gram-negative enterics to be more common than P. aeru-
ginosa as causative pathogens. However, it is consistent with
data showing that P. aeruginosa has recently become the gram-
negative pathogen most frequently isolated from soft tissue
infections in Europe, North American, and Latin America.
P913
Penetration of beta-lactamase inhibitors
tazobactam and sulbactam in severe acute
pancreatitis
S. Fo¨rster, E. Eckleben, U. Werner, U. Adam, R. Wacke, E. Klar,
B. Drewelow (Rostock, Freiburg, D)
Objectives: Despite of high standard intensive care and surgi-
cal management, acute necrotising pancreatitis is still related
with an extremely high mortality rate. This is determined by
local infectious complications, especially in necrotising areas.
Limited penetration of antimicrobial drugs in these areas is
considered to be a major cause for failure of therapy of severe
infections. Combinations of beta-lactamase inhibitors (BLI) and
beta-lactam antibiotics like broad-spectrum penicillines (BSP)
have antibacterial activity against most of the common patho-
gens in severe necrotising pancreatitis. Co-administration leads
to an increase of antibacterial activity due to an inhibition of
beta-lactamases compared to those of beta-lactam antibiotics
alone. Some BSP has been shown to penetrate rapidly and
efﬁciently into pancreatic tissue. The penetration of BLI into
inﬂamed pancreatic tissue has not been investigated yet.
Methods: Addressing the penetration capability of BLI, a
clinical trial was designed to investigate the penetration of
Tazobactam (Taz, n = 8) and Sulbactam (Sul, n = 5) in patients
with severe necrotising pancreatitis undergoing pancreas sur-
gery. Samples were taken from blood, necrotic areas of pancre-
atic tissue (PN), peripancreatic fatty tissue (PFT) and bursa
secretion (BS) following intravenous administration of 0.5 g Taz
or 1.0 g Sul. Concentrations of BLI were determined by HPLC/
UV. The aimed concentration for full enzymatic effect of BLI
should be 4 lg/mg (Taz) and 8 lg/mg (Sul), respectively.
Results: Mean plasma concentrations at 1.0 h after application
were 20.6 ± 9.58 lg/ml (Taz) and 48.6 ± 18.8 lg/ml (Sul). Cor-
responding mean concentrations were in PN 2.95 ± 0.25 lg/mg
(Taz) and 8.48 ± 0.68 lg/mg (Sul), in PFT 1.72 ± 1.09 lg/mg
(Taz) and 4.70 ± 0.88 lg/mg (Sul), in BS 8.22 ± 2.12 lg/mg (Taz)
and 14.3 ± 5.59 lg/mg (Sul). The penetration rate into PN was
14.5% (Taz) and 18.8% (Sul), into BS 44.4% (Taz) and 31.7% (Sul).
The aimed concentration for both BLI was reached or exceeded in
plasma, PN and BS but not in PFT.
Conclusion: Both BLI has been demonstrated to reach rapidly
effective inhibitory concentrations into relevant areas and
compartments of pancreatic and parapancreatic tissue. In
combination with BSP Taz and Sul either may have a potential
clinical beneﬁt in prevention and treatment of local infectious
complications of severe necrotising pancreatitis.
P914
PK/PD of beta-lactam antibiotics in experimental
urinary tract infection
D. Jensen, N. Frimodt-Moller (Copenhagen, DK)
Background: UTI is one of the most common infectious condi-
tions treated in general practice and represents a major part of
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antibiotic use in the community. It is of major importance to
know, how we treat these infections correctly, i.e. maximum
efﬁcacy with the least amount of drug in order to reduce the risk
of development of resistance.
Materials and methods: UTI was induced in anesthetized
female NMRI mice via intraurethral inoculation of 10-8 CFU of
E. coli. One day later, treatment was started with 12–24 hour
dosing schedules with 12–16 different doses of each drug
securing a wide variation of Time > MIC and AUC/MIC. 24 h
after the last dose mice were sacriﬁced and urine collected, and
the bladder and both kidneys removed. Bladder and kidneys
were homogenized before CFU determination. The drugs used
were the cephalosporins, cefuroxime (CEF, MIC = 0 3 mg/l)
and ceftriaxone (CRO, MIC = 0.094 mg/l), and the penicillin,
mecillinam (MIC = 0.1 mg/l). The PK of the drugs in serum was
determined in similar mice as well. The two cephalosporins
were studied together (CEF has a t½ of 14 min and CRO a t½ of
56 min, respectively, in mice). PD parameters were calculated
from serum total antibiotic concentrations, since protein-binding
is a minor issue in the urine, and the relation to CFU´s estimated
by the Hill-equation.
Results: All drugs reduced CFU´s in urine and kidney tissue by
3–4 logs, but little effect was found in the bladder tissue. For the
two cephalosporins combined Time > MIC in % of dosing
interval best described the correlation with CFU´s in urine (R2 =
0.69, P < 0.05) and in kidney tissue (R2 = 0.89, P < 0.05),
respectively, while no such correlation was found in the bladder
tissue, neither did AUC/MIC reveal any correlation with CFU´s
in urine or any organs. The same was found for mecillinam, i.e.
no correlation for AUC/MIC vs. CFU´s in urine or organs, while
Time > MIC % signiﬁcantly (P < 0.05) correlated with CFU´s in
urine (R2 = 0.48), and kidney tissue (R2 = 0.82), respectively. The
Time > MIC% for maximum efﬁcacy was around 30–40% for all
three antibiotics.
Conclusion: The optimal PKPD parameter for efﬁcacy of beta-
lactam antibiotics in UTI is the Time > MIC. Maximum effect is
seen for Time > MIC for 30–40% of the dosing interval, when
serum total drug concentration is used as surrogate parameter.
In humans this would call for TID dosing of mecillinam and
cefuroxime, and OD dosing for ceftriaxone.
P915
Comparative performance of different methods to
simulate drug exposure variability in a
population
V.H. Tam, G.L. Rosner (Houston, USA)
Objectives: Stochastic pharmacokinetic (PK) forecasting such as
Monte Carlo simulations (MCS) are increasingly being used to
predict the PK variability of antimicrobials in a population,
based on data from relatively few subjects. However, various
MCS approaches may signiﬁcantly differ in the accuracy and
precision of the predictions. We compared the performance of 4
different MCS approaches using a dataset with known param-
eter values and dispersion.
Methods: Concentration-time proﬁles for 10 subjects after an
intravenous bolus of 1000 mg were randomly generated using
elimination rate constant (K) 0.1 ± 0.025 h)1(mean ± SD) and
volume of distribution (V) 20 ± 5 L. Normal distribution of
parameter values and no correlation between K and V were
assumed. System noise was incorporated as a linear function of
drug concentration. Using these concentration-time proﬁles, the
best-ﬁt parameter estimates were determined by the standard
two-stage method. Four methods were subsequently used to
simulate the AUC0-inf of the population by MCS, using the
central tendency and dispersion of the following in the subject
sample: (1) K and V; (2) clearance and V; (3) dose/clearance; (4)
AUC0-inf. In each scenario, 10,000 subject simulations were
performed with ADAPT II, using normally distributed input
parameter(s) with means and variances set to the ﬁtted values.
Results: Reasonably good parameter estimates were obtained
(K = 0.101 ± 0.034 h)1; V = 18.0 ± 7.2 L). Compared to true
AUC0-inf of the population (581.1 ± 314.9 mg h/L), the simu-
lated AUC0-inf by various methods were: (1) 911.1 ± 2416, (2)
1348 ± 23510, (3) 1348 ± 23510, and (4) 713.7 ± 430.1 mg h/L,
respectively.
Conclusions: Our results suggest that various MCS approaches
may predict PK variability in a population differently. The most
realistic approach appeared to be based on the variability of
AUC0-inf in the subject sample. Our observations are consistent
with statistical principles concerning estimation. This method
did not amplify variability of the model parameters and was the
least likely to be associated with model misspeciﬁcation.
P916
In vivo mutant prevention concentration (MPC)
studies: quantiﬁcation of ﬂuoroquinolone
antibiotics in chicken liver, caecal contents and
serum
S.W. Cooles, K. Stapleton, N.G. Coldham, L.P. Randall,
M.J. Woodward (Addlestone, UK)
Objectives: Fluoroquinolone treatment of humans and animals
can rapidly select for organisms with increased resistance to
these antibiotics. Animal models are key to investigating in vivo
antibiotic concentrations that prevent selection of resistance (e.g.
the mutant prevention concentration (MPC) concept), but use of
such models requires validated procedures for extraction and
analysis of ﬂuoroquinolones from relevant tissues. Here, we
report the validation of a method to quantify the concentration
of enroﬂoxacin, and its metabolite ciproﬂoxacin, extracted from
chicken liver, caecal contents and serum following treatment
with BaytrilTM (enroﬂoxacin).
Methods: The extraction procedure described by Wiuff et al.
2002 was validated for ﬂuoroquinolone analysis, in pig tissues,
by fortiﬁcation of target matrices with enroﬂoxacin and ciproﬂ-
oxacin. Norﬂoxacin was added as an internal standard to all
samples. Samples were homogenised and extracted with aceto-
nitrile (6 ml), centrifuged and the supernatants retained for
analysis. The extracts were diluted with distilled water and
analysed by HPLC equipped with ﬂuorescence detection. The
analytes were chromatographed on a C18 reverse phase column
and eluted with an isocratic potassium phosphate buffer/
acetonitrile system.
Results: Liver samples were fortiﬁed with 0.1, 1.0 and 5.0 lg/g
enroﬂoxacin and provided recoveries of 114.5, 78.6 and 78.2%
respectively. Quantiﬁcation of ciproﬂoxacin at the 0.1 lg/g level
was not possible due to interference from sample co-extractives,
but the recoveries at 1.0 and 5.0lg/g were 73.7 and 91.1%. For
caecal content samples, enroﬂoxacin recoveries were 70.6 and
69.1% at 1.0 and 5.0lg/g respectively, and ciproﬂoxacin 65.4 and
63.3%. The recovery from serum was much higher, samples
fortiﬁed at 0.1, 1.0 and 5.0lg/mL, enroﬂoxacin and ciproﬂoxacin
yielded recoveries of 94.7, 80.9 and 86.1%, and 91.1, 85.6 and
87.9% respectively. Selected samples were also analysed by
zonal microbial growth inhibition bioassay and HPLC equipped
with MS/MS detection; the data were broadly similar between
all methods.
Conclusion: A valid method for the analysis of ﬂuoroquinolo-
nes in chicken liver, caecal content and serum has been
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established, and will be applied to in vivo MPC studies. Where
sample matrices interfere (e.g. liver, caeca), bioassay or LC-MS/
MS must be used to provide valid results.
P917
The ecological effects of norﬂoxacin and
pivmecillinam (PIV) on the periurethral and
vaginal ﬂora in women with recurrent urinary
tract infection
B. Stattin Norinder, R. Norrby, A.-C. Palmgren,
C.E. Nord (Stockholm, Solna, S)
Objectives: To compare the ecological effects on the periure-
thral and vaginal microﬂora and time to normalisation of orally
administered norﬂoxacin (NFLX) and pivmecillinam (PIV) in
women with recurrent lower UTI.
Methods: Women with recurrent lower UTI participated in a
randomized, single blind parallel multi-centre study. Twenty-
ﬁve women, aged 18–55 years, with a positive nitrite test and
symptoms (urgency, frequency, dysuria and/or suprapubic
pain) of lower UTI were included. Only patients with an UTI
caused by E. coli or Klebsiella spp were evaluated. Key exclusion
criteria were; menopause; pregnancy or breast feeding, known
hypersensitivity to study drugs, antibiotics within the preceding
month, impaired liver or kidney function, known or clinically
suspected pyelonephritis, complicated UTI and/or gastrointes-
tinal infection. Study drugs: Seven days treatment of either
NFLX 400 mg BID or PIV 400 mg TID. Samples from midstream
urine, periurethra and vagina were obtained before start of
treatment Day 1 and at two follow-ups Day 12–4 and 28–35.
Informed consent was obtained. The Ethical Review Committee
and Medical Product Agency approved the study protocol.
Results: Nineteen patients (11 NFLX and 8 PIV) fulﬁlled the
inclusion and exclusion criteria. No differences of patient
characteristics were seen between the two groups. At the initial
visit, more NFLX patients were colonized with aerobic bacteria,
although no differences were seen for anaerobic bacteria. The
E. coli strains were suppressed markedly by NFLX and PIV in
both locations. S. epidermidis increased more markedly following
PIV treatment compared to NFLX in the periurethral location. In
the PIV group E. faecalis was less frequent initially, increased at
visit 2, and returned to pre-treatment numbers at visit 3. For the
NFLX group, more patients were colonized initially with
E. faecalis, with a decrease at visit 3. Lactobacilli decreased
slightly in the periurethra in the NFLX group, whilst no changes
were seen for PIV. Bacteroides spp. decreased more markedly for
NFLX. Restoration of the pre-treatment colonization levels
occurred gradually, except for E. coli being markedly sup-
pressed by NFLX throughout the study period. The bacterio-
logical outcome of the urinary tract infection both at the short-
term and long-term follow up was successful.
Conclusions: Limited ecological effects on the microﬂora were
seen following treatment with NFLX and PIV, a beneﬁt for
antibiotics used for treatment of patients with UTI.
P918
Antibiotics inﬂuence release of IL-6 and IL-8 by
KB cells and gingival ﬁbroblasts
S. Eick, M. Lausse, S. Schwarz, P. Wachter, W. Pﬁster,
E. Straube (Jena, D)
Objectives: In general, antibiotics are used in defense against
pathogenic bacteria. Nevertheless, side effects such as immuno-
modulatory activity should be considered. The purpose of this
study was to determine the effect of antibiotics normally used in
periodontal treatment on the release of IL-6 and IL-8 by KB cells
and gingival ﬁbroblasts.
Methods: KB cells and primary gingival ﬁbroblasts were
infected with Actinobacillus actinomycetemcomitans Y4 (A.a.) and
Porphyromonas gingivalis ATCC 33277 (P.g.). The antibiotics
doxycycline, tetracycline, minocycline, metronidazole, and mox-
iﬂoxacin were added in concentrations ranging from 0.25 MIC
to 100 lg/ml. After 1, 6 and 18 h supernatants were obtained
and the levels of IL-6 and IL-8 were measured by ELISA
technique. Additionally, after 18 h the number of surviving
bacteria was enumerated.
Results: Minocycline and moxiﬂoxacin in concentrations pre-
dicted in serum as well as 100 lg/ml were effective in killing
planctonic A.a. and P.g. as well as adherent and intracellular
bacteria. Low levels of both interleukines released from KB cells
and ﬁbroblasts infected by P.g. were found only after addition of
tetracycline up to 10 lg/ml. Metronidazole, moxiﬂoxacin and
tetracycline in subinhibitory concentrations enhanced the
release of IL-6 from non-infected and A.a.-infected ﬁbroblasts
(up to 3200 pg/ml) after 18 h, contradictory 100 lg/ml tetra-
cycline and minocyline reduced the release of IL-6. IL-6 in the
supernatants of KB-cells was detectable only after addition of
100 lg/ml moxiﬂoxacin. Each 100 lg/ml of tetracycline and
minocycline suppressed totally the release of IL-6 and IL-8 from
non infected and infected ﬁbroblasts, but not from KB cells.
Metronidazole and moxiﬂoxaxin in high concentrations promo-
ted the release of IL-8.
Conclusions: Antibiotics inﬂuence the release of IL-6 and IL-8.
Besides the good antibacterial effect especially minocycline
might suppress inﬂammation. Nevertheless, the killing of
bacteria as well as a possible inhibition of virulence factors
(bacterial proteases of P.g. by tetracycline) might inﬂuence the
enhanced or reduced release of these cytokines.
Organ transplants
P919
Exceedingly infrequent infectious complications
during orthotopic liver transplantation:
tubercular peritonitis
R. Manfredi (Bologna, I)
Introduction: Tuberculosis (T) is a very infrequent complication
in patients (p) who undergo solid organ transplantation: in liver
transplant recipients a 0.9–2.3% rate has been retrieved by a
literature update. In these p T occurs within 12 months, and less
than 10% of cases are observed after a repeated transplantation.
Pulmonary localization predominates (50% of p), followed by
disseminated T (30%), while extrapulmonary T is an exceedingly
rare event, reported only nu anectdotal p descriptions. Pathoge-
netically, a T peritonitis follows disseminated infection or a
primaryTenteric localization,and isbornebya80%mortality rate.
Case report: A 57-year-old female p with a mute T personal and
familial history and normal chest X-ray, underwent liver
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transplantation 9 years ago, because of a HCV-related decom-
pensated cirrhosias. Four years later a novel graft was needed,
after the development of end-stage hepatic insufﬁciency due to
massive HCV re-infection. One year later (while of cyclosporin
treatment), abdominal pain and ascites formation prompted
admission, and M. tuberculosis sensible to all tested drugs was
repeatedly isolated from an abdominal ﬂuid with an elevated
lymphocyte-monocyte count. Associated ethambutol, isoniazid,
streptomycin and levoﬂoxacin (this one replaced by cycloserine
after 2 months), led to a complete clinical and bacteriological
cure already achieved after 3 months, although a 3-drug anti-T
treatment was continued for 1 year.
Conclusionas: In our rare case report, the selected anti-T
chemotherapy showed a successful efﬁcacy and tolerability
proﬁle, with contained untoward events despite a very critical
clinical context, due to the severity of T complication, and the
broad spectrum of problems related to graft and all associated
issues. In order to obtain an early diagnosis, an elevated clinical
suspicion should be maintained for this rare complication too,
by recommending microscopy and culture search of mycobac-
teria on ascitic ﬂuid.
P920
Nosocomial infections in the renal transplant
recipient
S.R.P.E. Dantas, R.H. Kuboyama, M. Mazzali, M.L.
Moretti (Campinas-SP, BR)
Objective: To determine the incidence of nosocomial infections
in the renal transplant recipients and risk factors associated with
urinary tract infection (UTI) and surgical site infection (SSI), in
patients hospitalized in the Hospital and Clinics of the Univer-
sidade Estadual de Campinas, Sa˜o Paulo, Brazil.
Methods: From January 2000 through December 2001, a pros-
pective cohort study was conducted to determine the rate of
bacterial nosocomial infection in renal transplant recipients. The
patients were divided in two groups according to the origin of
the allograft: cadaver or living donors. Enterobacter cloacae
strains, the most prevalent multidrug-resistant bacterial organ-
isms isolated from UTI were determined using genomic analysis
with pulsed-ﬁeld gel electrophoresis (PFGE).
Results: One hundred sixty-three patients who received renal
transplants were reviewed during the hospitalization. One
hundred and ten (67.5%) renal transplanted were from cadaver
and 53 (32.5%) from living donor. The median of length of stay
in hospital was 12 days (range, 9–75 days) from transplant of
living donor and 26 days (range, 2–28 days) from transplant of
cadaver (P < 0.0001). Twenty-one (39.6%) living donors recipi-
ents and 68 (61.8%) cadaver donors recipients had bacterial
infection episodes (P = 0.019). Post-transplant nosocomial infec-
tions diagnosed during the hospitalization were UTI (44.8%), SSI
(11%), pneumonia (6.1%), bloodstream catheter-related infection
(4.2%) and others (1.8%). Risk factors for UTI in the multivariate
analysis included cadaver donor recipient; substitution of the
initial immunosuppressive regimen; days of urinary bladder
catheterization and length of stay in hospital before the
infection. Substitution of initial protocol of the post-transplant
immunosuppressive regimen and the surgeon was also asso-
ciated with SSI. Six different E. cloacae multidrug-resistant to
antibiotics DNA proﬁles were detected in UTI of our recipients
and hospital dissemination was documented.
Conclusions: UTI was the single most important type of
hospital infection in renal transplant recipient and a signiﬁcant
difference in the incidence of UTI was found comparing living
donor and cadaver donor recipient. The high incidence of UTI in
the early period post-transplant suggested that the operative
manipulation of the urinary tract may be an important causative
factor for the development of UTI.
P921
Usefulness of CMV antigenaemia assay after
liver transplantation
H.K. Ki, K.-M. Sohn, J.-Y. Rhee, Y.-M. Wi, C.S. Moon, W.S. Oh,
K.R. Peck, N.Y. Lee, J.-H. Song (Seoul, KOR)
Objective: To evaluate the clinical manifestations of cytomeg-
alovirus (CMV) infections among the liver transplant recipients
in Samsung Medical Center.
Methods: All the recipients of liver transplantation during the
period from Jan 1996 to Aug 2003 were enrolled. Medical
records and microbiologic data for CMV infections were
reviewed retrospectively. Preemptive therapy was initiated if
CMV antigenaemia was positive (>/=3/200,000 cells) as pre-
ventive strategies for CMV infection.
Results: All the 284 enrolled patients received livers from CMV
seropositive donors, and 281 recipients (98.9%) were CMV
seropositive before transplantation. 133 recipients (46.8%) had
evidences of CMV reactivation: 125 patients were positive for
CMV antigenaemia, 15 patients for CMV culture, 14 patients for
CMV PCR, 12 patients for pathology, and 10 patients for CMV
IgM. Among the patients with CMV reactivation, 40 recipients
were symptomatic (30.1%): 12 patients had organ-speciﬁc CMV
diseases. Most of the CMV infections occurred within 180 days
after transplantation except 9 patients (6.7%). Among the
antigenaemia positive patients, the mean number of CMV
antigen-positive WBC was 19.36 per 200,000 cells (19.36 ± 37.64
cells). The mean duration of CMV antigenaemia was 8.72 days
(8.72 ± 9.99 days). Peak value of CMV antigenaemia was signi-
ﬁcantly higher (p = 0.002) in symptomatic patients compared to
asymptomatic patients (41.38 ± 61.38 vs. 9.68 ± 13.97). Duration
of CMV antigenaemia was signiﬁcantly longer (p = 0.002) in
symptomatic patients. Eleven recipients (8.3%) had experienced
recurrent episodes of CMV infection detected by CMV anti-
genaemia. Recurrence rates were higher (p < 0.001) in sympto-
matic infections. Underlying liver diseases of the recipients,
infectious complications other than CMV, rejection rates, and
survival rates were not different between symptomatic and
asymptomatic CMV infections (p > 0.05).Conclusion: About an
half of the recipients experienced CMV reactivation, mostly
within 180 days post-transplantation. Thirty percents of reacti-
vation were symptomatic. Peak value and duration of CMV
antigenaemia were signiﬁcantly higher in symptomatic infec-
tions than those in asymptomatic infections.
P922
Toxoplasma gondii infection in bone marrow
transplant recipients: the polymerase chain
reaction-blood sample combination in diagnosis
and early detection
A. Sensini, R. Castronari, C. Ferranti, T. Aloisi, F. Aversa,
F. Bistoni (Perugia, I)
Objectives: Toxoplasmosis is a rare and frequently fatal com-
plication in bone marrow transplant recipients. It presents with
local brain lesions or disseminated infection. Usually, the
diagnosis is based on histologic conﬁrmation and observation
of typical lesions on radiologic imaging, which resolve after
appropriate therapy. The aim of this study was to stress the
pivotal role of the polymerase chain reaction (PCR) in diagnosis
and early detection of Toxoplasma infection.
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Methods: From January 1999 to July 2004 two hundred and
thirteen patients underwent allogeneic peripheral blood stem
cell transplantation (PBSCT). In the presence of symptoms
suggestive of cerebral, pulmonary and disseminated Toxoplas-
ma infection, 992 biological samples (blood, serum, CSF, pleural
ﬂuid, BAL) were collected and examined by nested PCR.
Results: Fourteen cases of toxoplasmosis were identiﬁed,
having an incidence of 6.6%. Ten patients manifested cerebral
toxoplasmosis, two had pulmonary infection and two dissem-
inated. The overall mortality in this group, not necessarily due
to toxoplasmosis, was 57% (8/14). The pre-transplant recipient
serostatus was known in 9 patients: 5 were seropositive, but it is
to be noted that 4 were seronegative, whereas 5 were unknown.
MRI study was performed in 12 patients. Typical lesions were
observed in 7 patients (sensitivity: 58%). The pulmonary
toxoplasmosis occurred very early (day 9 and 10) and cerebral
toxoplasmosis from day 29 to day 240 (mean 80.4) after PBSCT.
One case of disseminated infection had CNS localization (day
21) and then pulmonary (day 42), whereas the second case had
ﬁrst pulmonary involvement (day 8) immediately followed by
CNS. Blood samples demonstrated higher sensitivity (10 PCR-
positive/12) than CSF (6 PCR-positive/11) in identiﬁcation of
the etiologic agent. All patients with toxoplasmosis were treated
with pyrimethamine and sulfadiazine.
Conclusion: The study conﬁrms the pivotal role of PCR in early
diagnosis of toxoplasmosis after PBSCT. In our experience, a
positive PCR signal in blood was an early sign of Toxoplasma
infection, therefore blood appears to be a suitable and reliable
biological sample for diagnosis. Moreover, the samples were
PCR-negative after the start of therapy and therefore PCR can be
useful to monitor the effect of treatment. Finally, our study
indicates that toxoplasmosis is a potential pathology even in
pre-transplant seronegative subjects, suggesting primary infec-
tion.
P923
Cryptosporidium associated cholangitis in a liver-
transplant patient
C. Denkinger, P. Harigopal, P. Ruiz, A. Tzakis,
L. Dowdy (Wu¨rzburg, D; Miami, USA)
Cryptosporidium parvum is a parasite of the group coccidia.
C. parvum causes self-limiting diarrhoeal illness in immunocom-
petent hosts and severe long standing diarrhoea in immuno-
compromised patients. Sclerosing cholangitis (SC) caused by
C. parvum is frequently found in HIV-infected patients. In the
transplant recipients only two case reports exist describing SC
due to C. parvum; one in an adult renal transplant patient and
the others in three children who underwent liver transplanta-
tion. We report herein the ﬁrst case of C. parvum associated
cholangitis in an adult liver transplant patient. This 52-year-old
male patient underwent a liver transplantation three years prior
to presentation. His initial transplant failed due to acute
rejection requiring retransplant within one year. The second
transplant was complicated by sepsis, tacrolimus induced
hemolytic uremic syndrome, leaving the patient hemodialysis
dependent. In 2004, he presented with pruritus, hypotension,
severe dehydration and a three-week history of severe diar-
rhoea. Endoscopic biopsy revealed numerous organisms in the
stomach and changes in the colon consistent with cryptospo-
ridiosis. Stool cultures were negative. In addition, gamma
gluytamyl transferase and alkaline phosphatase were elevated
while bilirubin and AST were normal. The patient was diag-
nosed with colitis due to cryptosporidium and treated with
azithromycin. Immunosuppression with tacrolimus was contin-
ued. The patient continued to have diarrhoea, low-grade fevers
and fatigue. Two weeks later a cholangiogram and liver biopsy
were performed. The liver biopsy revealed C. parvum lining the
ductal epithelium. SC was diagnosed. The cholangiogram
showed no sclerosing changes in the biliary tree, suggesting
an early phase of disease. Paromomycin was added to the
regimen. The patient improved, and was discharged home. We
believe this to be the ﬁrst case of SC associated with C. parvum in
an adult liver transplant recipient.
P924
Risk of human herpesvirus 6 infection in
seronegative solid organ transplant recipients
C. Cervera, M.A. Marcos, N. Benito, A. Sierra, J.C. Trullas,
F. Cofan, J.M. Salmeron, M.J. Ricart, F. Oru´s, C. Regata,
A. Moreno, T. Pumarola (Barcelona, E)
Objective: Human herpesvirus 6 (HHV-6) infection usually
occurs during the ﬁrst 2 years of life, and its prevalence is higher
than 95% in adult population. Negative serostatus for HHV-6 in
solid organ transplant recipients is a risk factor for fungal
infection, but the incidence and severity of HHV-6 infections in
seronegative patients has not been evaluated. Our objective is
evaluate prospectively seronegative HHV-6 solid organ trans-
plant patients for HHV-6 infection by means of quantitative PCR
for HHV-6.
Methods: From February to August 2004, we prospectly eval-
uated all solid organ transplant patients. Patients must have a
minimum follow-up of 3 months. Patients underwent basal
determination of IgG for HHV-6. Seronegative patients were
included for follow-up. Blood samples were obtained at 7, 14, 21,
28, 45, 60, 75, and 90 days post-transplant. For viral DNA
analysis, following DNA ampliﬁcation, it was determined by
hibridation in microplaque (Afﬁgene).
Results: In the study period, 112 patients were evaluated (58
kidney, 35 liver, 11 heart, 4 kidney and pancreas, liver and
kidney 2, pancreas 1, heart and kidney 1). Nine patients were
seronegative (7 kidney, 1 liver, and 1 heart). We analysed 67
plasma samples. All patients but one had a negative PCR for
HHV-6. The patient with primary infection had a maximum of
78,002 HHV-6 DNA copies/ml. Clinically, the patient suffered
from slight abdominal pain and discrete cholestasis in blood
analyses; no fever or serious complications were detected. He
did not receive pre-emptive treatment with Ganciclovir. No
fungal infections were detected.
Conclusion: Primary infection by HHV-6 in seronegative solid
organ transplant patients is not frequent, and in 1 patient it
appeared with slight symptoms. However, a larger study with
more seronegative patients is needed.
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P925
Development and validation of a new real-time
PCR assay for HHV-6 detection and
differentiation of HHV-6A and HHV-6B
D. Becker, S. Ziegelmaier, S. Wach, T. Laue,
T. Grewing (Hamburg, D)
Objectives: Human herpesvirus 6 (HHV-6) has been identiﬁed
as the etiologic agent of roseola infantum in infants. In adults
HHV-6 causes complications in immunocompromised patients
such as AIDS patients and transplant recipients. Two virus
variants can be distinguished: HHV-6A and HHV-6B. Several
studies have shown variant speciﬁc clinical outcome. The
objective of this work was the development of a reliable,
sensitive and speciﬁc HHV-6 detection assay, based on real-time
PCR technology, which enables the discrimination between
HHV-6A and B. This assay ought to run with the same
temperature proﬁle as the RealArt LC PCR assays for HSV1/2,
EBV, CMV and VZV (artus GmbH).
Methods: By sequence alignments, a region of the HHV-6
genome was deﬁned, which allows the speciﬁc ampliﬁcation by
real-time PCR, and discrimination between HHV-6A and B
by melting curve analysis. Assay speciﬁcity has been tested by
analysing HHV-6 A/B reference material (ABI) and cell culture
supernatant from clinical isolates. Cross reactivity was excluded
by testing DNA from related viruses and bacteria. Analytical
sensitivity was determined by probit analysis. A heterologous
PCR system was incorporated, which serves as an internal
control. A set of quantitation standards was established, for
exact quantitation of the viral load.
Results: With the RealArt HHV-6 A/B LC PCR assay artus
GmbH developed a ready-to-use assay for the detection and
distinct differentiation of HHV-6A and B. Quantitation of the
viral load within a broad linear range is possible for both
variants. Simultaneous ampliﬁcation and parallel detection of
internal control and speciﬁc sample in one reaction tube
excludes false negative results. The RealArt HHV-6 A/B LC
PCR assay has the same temperature proﬁle as the RealArt LC
PCR assays for HSV1/2, EBV, CMV and VZV. 0
Conclusion: The RealArt HHV-6 A/B LC PCR assay allows
sensitive and speciﬁc detection, as well as subtyping of HHV-6.
This leads not only to a reliable HHV-6 diagnosis, but also to a
better understanding of the role of HHV-6 variants in patho-
genesis. Due to the same temperature proﬁle, the RealArt HHV-
6 A/B PCR assay completes the RealArt LC PCR assays for the
detection of different herpes viruses. Now the parallel detection
of HSV1/2, EBV, CMV, VZV, and HHV-6 A/B is possible in a
single real-time PCR run. Thus, clinicians receive a reliable
diagnostic tool for rapid detection of herpes viruses, and
especially in transplant recipients.
P926
Quantitative CMV PCR in allogenic stem-cell
transplant patients
L. Carden˜oso, C. Blazquez, R. Rodriguez, J. Diaz-Regan˜on,
E. Lomas, P. Sanchez, R. Ca´mara (Madrid, E)
Objective: To assess the clinical value of a commercial quan-
titative plasma CMV-PCR assay (COBAS AMPLICOR CMV
MONITOR test, Roche Molecular System) in allogeneic SCT
patients by comparing the results obtained with the PCR with
those obtained with antigenaemia. To evaluate the impact of an
automatised DNA extraction method and a lower cut-off on
PCR sensibility.
Methods: All patients were monitored until day 100 post-SCT
with weekly antigenaemia and PCR. A total of 562 blood
samples from 30 patients (23 mieloablative and 7 non-mielo-
ablative; 25 HLA identical siblings and 5 from unrelated
donors) were tested prospectively. Twenty-seven CMV sero-
positive patients (or negative with a seropositive donor)
received high dose of acyclovir as prophylaxis. PCR was
considered positive when more or equal 600 DNA copies/ml
were detected. Antigenemia was considered positive when one
or more positive cells were detected (in 2x105 PMNs). Positive
samples by antigenaemia and/or PCR (n = 54 samples) were
tested retrospectively with an automatised extraction method
(MAGNAPURE).
Results: All CMV seronegative patients with a seronegative
donor (n = 3) were antigenaemia and PCR negative. Seropos-
itive patients (n = 27): 14 had a positive antigenaemia and/or
PCR, with a total of 23 CMV infection episodes. None
developed CMV disease. PCR detected 10 out of 23 CMV
episodes. Overall there were 44 positive antigenemias (belong-
ing to 13 patients): 23 were PCR+, 20 PCR negative and 1 PCR
inhibited. Only 1 patient had a positive PCR with a negative
antigenaemia. Automatised MAGNAPURE extraction
increased the sensibility of the PCR. With this method PCR
detected 19 out of 23 episodes in contrast with only 10/23 with
the manual extraction. For samples with less than 600 DNA
copies/ml a manual calculation of the number of copies was
retrospectively done (using a new cut-off of 50 copies/ml).
With this lower cut-off, PCR detected 20 out of 23 CMV
episodes. None of the negative patients by antigenaemia and/
or PCR gave a positive result with the automatised extraction
method or with the lowered cut-off PCR.
Conclusion: Quantitative CMV PCR assay showed a lower
sensibility for the detection of CMV infection in allogeneic SCT
compared with antigenaemia. Two technical modiﬁcations
increased the sensibility without a decrease in the speciﬁcity:
automatised MAGNAPURE extraction, and lowering the cut-
off.
P927
Trichosporon beigelii as a life-threatening
pathogen in bone marrow transplantation
recipients: the ﬁrst case report from Iran
S.A. Ghiasian, A.H. Maghsood (Hamedan, IR)
Patients undergoing bone marrow transplantation (BMT) are
profoundly immunosuppressed as a result of their intensive
chemotherapy and are at high risk for opportunistic fungal
infections mainly caused by Candida spp and Aspergillus spp.
Trichosporon beigelii (T. beigelii) has emerged as a life-threaten-
ing opportunistic pathogen in immunocompromised hosts.
Response to antifungal agents is poor, mortality is high and
immunological recovery is the most important factor for a
favorable outcome in patients with trichosporonosis. We
present the ﬁrst case of T. beigelii infection in patients
undergoing allogeneic BMT in Iran. A 12-year-old female
presented with aplastic anemia, cough and fever. She had
received cytotoxic drug therapy, broad spectrum antibiotics
and was neutropenic. T. beigelii was repeatedly demonstrated
by appropriate morphological and physiological characteristics
in her sputum, nose and mouth ulcers by direct microscopy
and culture, and also isolated and histopathologically recog-
nized in post-mortem from lung and liver. Trichosporonosis is
likely to be recognized more frequently than apparent from the
available reports.
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Exotic infections – I: case series
P928
Trichinella infection in Greenland
L.N. Moeller, S. Andersen, M. Melbye, E. Petersen,
C.M.O. Kapel, P. Laurberg, A. Koch (Frederiksberg, Aalborg,
Copenhagen, DK)
Objectives: Trichinellosis is a well-known problem in Green-
land. In West Greenland a number of large outbreaks took place
during the 1940’s and 1950’s, but since then only sporadic cases
have been registered. It is unknown whether the decrease in
trichinellosis cases reﬂects the general transition in Greenland
towards a more western lifestyle with less consumption of meat
from wildlife, or whether it reﬂects insufﬁcient case registration.
The objectives of the present study were to determine the
prevalence of human trichinellosis from the 1980ies to present
times in Nuuk, the capital of Greenland, and in Ammassalik
district on the east coast of Greenland, where more traditional
food is still eaten, and to evaluate if changes in lifestyle had an
effect on prevalence.
Methods: Blood samples from 86 persons collected in 1981 and
533 persons collected in 1998 in Nuuk and Ammassalik district
were tested for Trichinella-speciﬁc IgG antibodies using ELISA
and Western blot analyses. Background information was
obtained from questionnaires from the 1998 study.
Results: In 1981 the trichinellosis prevalence was 8.7% in Nuuk
and 23.8% in Ammassalik district, while the prevalence in 1998
was 5.2% in Nuuk and 19.8% in Ammassalik district. Persons
living in the settlements of Ammassalik district had higher
Trichinella-speciﬁc antibody prevalence than persons living in
the town of Tasiilaq. The following risk factors were signiﬁcant
in a univariate analysis: Ethnicity, age, place of living, dietary
habits, intake of seal meat, and hunting. A multivariate model
was constructed consisting of the variables: Ethnicity, age, place
of living, diet group, intake of seal meat, and hunting. The
variables were removed stepwise in the following order: seal
meat (p = 0.73), hunting (p = 0.36), age (p = 0.3), and ethnicity
(p = 0.16). The ﬁnal multivariate model consisted of diet group
and place of living, both being signiﬁcant. Thus, living on a
Greenlandic diet and living in the settlements in Ammassalik
district implied higher relative risk of being Trichinella seropos-
itive than living on a diet dominated by imported food items and
living in Nuuk.
Conclusion: As lifestyle in the settlements is more traditional
compared both with Tasiilaq and Nuuk, these results indicate
that the decline in human trichinellosis cases in the 19th century
most likely reﬂects the transition from traditional greenlandic
lifestyle to more western dietary habits.
P929
Study on prevalence of Toxocara cati in vagrant
cats of Sari township, Iran, 2004
M Sharif, P. Ziapoor, H. Ziaee, S. Kholami (Sari, IR)
Objectives: Toxocara cati is one of the important and prevalent
parasites in cats and common between human and animals.
Ingestion of larvae of this parasite and lack of it’s maturation in
human body , the infected persons develop visceral larvae
migrans which is known as toxocariasis. Considering the signi-
ﬁcance of transmission of this parasite in human and due to the
increase in vagrant cats in Sari township, this study was
performed in order to determine the severity and prevalence of
Toxocara cati in these cats in Sari township.
Methods: This cross sectional descriptive study was done on
100 vagrant cats (28 males and 72 females) during April to
October 2004. Sampling was done randomly at different regions
by net. The speciﬁcation of vagant cats were recorded after
hunting and were deeply anaesthetized by chloroform to
annihilate them. The intestinal content were examined for the
presence of parasites and counting of their number was done
ﬁnally after ﬁxation and staining by recommended kits of
reference book for genus and species identiﬁcation.
Results: In all, 42 (42 %) cats were infected with Toxocara cati, of
which 8(19%)were males and 34 (81%)were females. Range of
infection was 1-32 and mean severity of infection was 3.14 for
each cat. The rate of infection at the west region was more than
the other sites, and it was more in the females than males and
also it was more in immature than the mature cats.
Conclusion: Considering the merely high prevalence of this
zoonotic parasite and it’s hygienic signiﬁcance in causing
toxocariasis in human particularly in children, who are in more
contact with soil and also lack of control on vagrant cats
population, which are the potential risk factors, it is recommen-
ded to control personal and dietary hygiene and avoid storing
the garbages in unprotected wire boxes on the streets in order to
prevent the gathering of vagrant street cats.
P930
Imaging in 100 patients of pulmonary hydatid
disease; review of unusual imaging appearances
S. Zahirifard, M. Bakhshayeshkaram, M. Tahbaz,
K. Kaynama (Tehran, IR)
Objective: To evaluate the chest radiography and CT scan
characteristics of pulmonary hydatid disease.
Material and methods: 100 patients with surgically proven
pulmonary hydatid cysts were enrolled for study. We reviewed
clinical ﬁndings and imaging of patients. The radiological
features (localization, diameter, architecture, density and other
radiological signs and appearances) were determined.
Results: On CXR 124 cysts were determined. On 82 available CT
scans a total of 112 cysts were detected. No discrete cyst was
detected on 11 CXR. On 82 available CT, a total of 112 cysts were
detected and in 5 CT scans no cyst was detected. 57 cysts were
ruptured and 25 patients with ruptured cysts had hemoptysis.
Single cysts were in 63 patients while multiple cysts were in 37.
Median CT density was 24HU. Respectively, it was seen on CT
and CXRwaterlily sign in 18 and 22 patients, Air-ﬂuid level in 12
and 17 patients and cresent sign on 11 and 5 of patients. Inverse
cresent sign and calciﬁcationwere not observedonCXRsbut each
one was recorded on 4 CT scans. On CT scan 90% of Cysts were
smooth and 89% were uniloculated. 19% of cysts were infected.
Conclusion: CT scan should be done to elucidate cystic nature
of the lung masses and for accurate localization in the preop-
erative period. In endemic regions like Iran, atypical imaging
presentation of complicated pulmonary hydatid disease such as
solid masses should be considered in differential diagnosis of
pulmonary lesions (abstract truncated at 250 words)
P931
The seroprevalence of coxiellosis in farmers and
cattle in north-eastern Turkey
S. Seyitoglu, Z. Ozkurt, U. Dinler, B. Okumus (Erzurum, TR)
Objectives: Coxiellosis is a worldwide zoonosis caused by
Coxiella burnetii. The aim of this study was to determine the
Abstracts
284
prevalence of coxiellosis in cattle and farmers in North Eastern
Turkey.
Methods: A total of 230 cattle and 92 human sera were collected
in 2003, and tested for antibodies against C.burnetii by commer-
cial ELISA test.
Results: The antibodies of C. burnetii were detected in 22
(9.56%) cattle and 18 (19.5%) healthy farmers. Seropositivity was
found in 12 of 53 (22.6%) cattle with abortion history, and 10 of
177 (5.6%) cattle without abortion history (p < 0.05). There was
correlation between animals and human seroprevalance in same
district. Thirteen of 18 farmers who were antibody positive had
seropositive animals, and there were seropositive animals in the
villages of remaining 5 cases. It was observed that seropreva-
lance of coxiellosis was higher in north districts (in animals
15.4%, in humans 32.4%), have drier and warmer climate, than
in other districts (in animals 6.5%, in humans 12.1%) both for
humans and animals (p < 0.05).
Conclusions: The study show that coxiellosis was an important
health problem both in humans and in animals in our region.
P932
An unusual case of Gramineae in sublingual
salivary gland
L. Doganci, M. Calgurel, Y. Gungen, G. Kiran (Ankara, TR)
Foreign bodies of organic nature and parasitic elements are very
rare in oral cavity and in salivary glands in humans because of
their structural and functional features. Here we report a very
interesting case, with sublingual salivary gland involvement of
Gramineae (Brachiaria spp.) which was thought to be a parasitic
life cycle in the gland.
Case: 40 y/o female teacher with a recent history of travel to
mountainswhere shedrunkandhadan exposure tounsafe spring
water. She had a strong stinging pain right after she drunk the
water in her mouth, radiating to her neck. She developed fever,
pain, lymph node swelling, difﬁculty of eating, weight lost and
remarkable eosinophilia. She also noted a self moving small
tail-like object on the oriﬁce of the sublingual salivary gland.
Removal of the object revealed an interesting unusual living
object. Then, deﬁnitive diagnosis is Gramineae (Brachiaria spp)
after parasitological and pathological consultation.
Comment: To our best knowledge, this unusual case is the ﬁrst
presented patient related to travel in our region. Differential
diagnosis has several entities including squid sperm bag sting,
marine animal larvae and nematod and trematod life stages.
P933
Evaluation of Echinococcus granulosus prevalence
using ELISA and abdominal ultrasonography in a
group of students staying in a state hostel in
Turkey
B. Arda, H. Pullukcu, T. Yamazhan, S. Tamsel, G. Demirpolat,
M. Korkmaz (Izmir, TR)
Objective: Cystic echinococcosis, caused by larval form of Ech-
inococcus granulosus is one of the most important and widely
distributed parasitic zoonotic diseases in the world. Echinococ-
cosis is a major problem in all regions of Turkey but particularly
prevalent in rural areas, where domestic livestock raising is
common. The reported epidemiologic ﬁndings are usually based
on retrospective evaluation pf surgical ﬁndings or hospital
charts. Well planned epidemiologic studies are limited. In this
study our aim was to analyse the seroprevalance of cystic
echinococosis and prevalance of lesions (with abdominal
ultrasonography) in a group of young adult university students
who were staying in a state hostel in Bornova-Izmir-Turkey.
Method: The study group consisted 750 students (360 woman,
390 men, aged 20.92 ± 1.82, min 17, max 29). Informed written
consent was received from each student and they were reques-
ted to ﬁll a questionnaire form. Blood sampling was performed
by IV puncture and sera were obtained after centrifugation. Anti
Echinococcus granulosus antibodies were detected by using ELISA
tecnique. All participants were gven an appointment for
abdominal ultrasonography.
Results: Of 750 students 99 (13.2%) were seropositive for anti
Echinococcus granulosus Ig G (table 1). A total of 250 students (49
seropositive- 201 seronegative) were performed abdominal
ultrasonography (3.5 MHZ transducer, Sonoline, Elegra-Sie-
mens). Two of 250 students (1 in liver, 1 in kidney both
seropositive) had cystic lesions and were referred to surgery.
Conclusion: Well designed epidemiologic studies about cystic
echinococcosis are lacking in Turkey. A previous study showed
seropositivity rate of 13.7% for Echinococcus granulosus. Our
ﬁndings suggest that cystic echinococcosis is prevalent in Turkey
and epidemiologic studies combining ELISA and abdominal
ultrasonograpy are warranted.
P934
Epizootiology and epidemiology of anthrax in
Eastern Turkey between 1992–2004
Z. Ozkurt, M. Parlak, R. Tastan, U. Dinler, Y.S. Saglam,
S.F. Ozyurek (Erzurum, TR)
Objective: Anthrax is an epidemic zoonosis in Eastern part of
Turkey. This study was aimed to investigate the epizootiology
and epidemiology of anthrax in this region.
Methods: Animal and human anthrax cases during 1992–2004
period were included in this study. Data were obtained formal
records of Health Directorate, Institute of Veterinary Control and
Investigation. The diagnosis of anthrax had based on clinical
ﬁndings and/or microbiological procedures, including Gram
strains and culture of materials obtained from lesions.
Results: In a 13-years period, 464 animal cases and 503 human
cases with anthrax were detected. Of 464 animal cases, 20 (4.3%)
were sheep, others (95.7%) were cattle. Most cases occurred
between July and September in both animals and humans.
Anthrax was seen most frequently in Erzurum, which is the
important centre for animal commencement.When theﬁrst 6 years
period (1992–1997) was compared with last 7 years period (1998–
2004) thenumberof animal caseswere161vs. 230andhumancases
were 234 vs. 269. An analysis of the yearly case distribution shows
that the incidence of anthrax in this region had not been changed.
Conclusion: Anthrax is an important health problem both
animals and humans in this region. The preventive measures
should be taken for decreasing the incidence of anthrax.
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P935
Molecular ecological study of B. anthracis in
Kazakhstan
Y. Sansyzbayev, A. Aikimbayev, L. Lukhnova,
T. Meka-Mechenko, V. Dubiansky, Z. Sagiyev (Almaty, KAZ)
Objectives: Anthrax is endemic in Kazakhstan and occurs
among humans at an incidence rate of 0.1 to 1 per 100,000
population per year. During the late 1990s, several epidemics
occurred associated with home slaughter of infected animals,
and a general increase in incidence was seen among animals and
humans. Historically, Kazakhstan accounted for 15% of the
anthrax cases reported from the Soviet Union; and the plains of
Central Asia may have served as the historical source of
B. anthracis for the rest of the world. In Kazakhstan, the
geographic distribution of anthrax among animals and
humans is focal and generally associated with areas considered
to be high-risk. The determinants of this focal distribution are
poorly understood. In addition, strains of B. anthracis isolated
from outbreaks within these foci have not been compared on a
molecular or pathogenic basis.
Methods: Work has been initiated to study the geographic
distribution and potential environmental preferences of
B. anthracis using geographic information system (GIS) tech-
nologies.
Results: The GIS was used to map a set of B. anthracis strains
from several outbreaks between 1997 and 2003 to evaluate
geographic patterns. The GIS is also being used to derive a
historical database of spatially explicit human and livestock
outbreaks from 1948 to 2003 for spatial analyses on the
nationwide distribution of B. anthracis. This database contains
information on the location of the anthrax incident, the year and
month of the occurrence, whether the incident involved live-
stock or human, the outcome of the disease, and biological
information about the strains.
Conclusions: Although in a preliminary stage of application,
the ArcGIS software can be used to map loci of anthrax
occurrence. In the future, these maps will be used to identify
factors that inﬂuence the occurrence and spread of the pathogen
and to prevent infection of livestock or humans. The research
described in this abstract was made possible in part by support
provided by the U.S. Defense Threat Reduction Agency (DTRA)
under the project «KB0-1950-AL-03» and administered by U.S.
Civilian Research and Development Foundation (CRDF).
P936
Structure of anthrax morbidity in Kazakhstan
A. Aikimbayev, L. Lukhnova, T. Meka-Mechenko, Y.
Pazylov (Almaty, KAZ)
Objectives: The anthrax situation in the country was unfavo-
rable from the 1950s through the 1970s. Until the 1990s, anthrax
in Kazakhstan was an occupational disease in animal husban-
dry. After 1991, the practice of raising livestock for private use
increased. This report shows that, at the same time, the
incidence of anthrax in persons involved in this practice
increased signiﬁcantly.
Methods: In order to characterize the epidemic process, we used
methods of descriptive epidemiology, using epidemiological
variables (who became ill, where and when, trends of disease by
time, sources, transmission factors of B. anthracis, and the age,
gender, and occupation of persons who become ill with anthrax).
Results: Anthrax occurs in rural areas among private owners of
livestock and their families and persons hired to assist with the
slaughter. In the last decade, 89.4% of cases of anthrax illness in
humans were caused by the slaughter of domestic livestock. Of
these cases, 62.2% were unemployed rural residents, 2.3% were
shepherds working for cooperatives, 11.7% were blue-collar
workers, 5.4% were white-collar workers, and 18.1% were
students. A single source, path and factors of transmission of
B. anthracis are typical of this type of the disease. In recent years,
the majority of cases involve infection of several persons during
the slaughter of a single diseased animal. The source of infection
is cattle in 48.2% of cases, sheep and goats in 15.7% of cases,
horses in 31.2% of cases, and soil in 4.7% of cases. The factors of
transmission of B. anthracis to humans are contact with the meat
of livestock during slaughter and butchering in 91.9% of cases,
vector-borne transmission in 2.7% of cases, and soil in 5.4% of
cases. A large number of human cases occur in July through
September.
Conclusion: In Kazakhstan today, the prevalent sub-type of
anthrax disease in humans involves non-professional activity at
home. This requires changes in the tactics of preventing the
disease. The research described in this abstract was made
possible in part by support provided by the U.S. Defense Threat
Reduction Agency (DTRA) under the project KB0-1950-AL-03
and administered by U.S. Civilian Research and Development
Foundation(CRDF).
P937
Establishment of non-productive infection
and activation of inf-alpha and -gamma gene
expression in normal lymphomonocytes
by sars-cov
C. Castilletti, L. Bordi, E. Lalle, G. Rozera, F. Poccia, C. Agrati,
I. Abbate, M.R. Capobianchi (Rome, I)
Objectives: Severe acute respiratory syndrome (SARS) is an
emerging infection caused by a novel coronavirus known as
SARS-CoV. During the early phases of the disease, the presence
of the replicative intermediates of SARS-CoV has been shown in
PBMC from patients. No information is available on the ability
of SARS-CoV to stimulate IFN induction, although IFN-gamma
may be activated in SARS patients. We investigate the capability
of SARS-CoV to give rise to a productive infection in normal
PBMC, in parallel with the ability to activate IFN-alpha and -
gamma gene expression.
Methods: Normal PBMC were infected with a MOI 0.1. Virus
progeny formation was measured at subsequent time points, by
back-titration of cell lysates on Vero cells. Cell mortality and
apoptosis were detected by trypan blue and propidium iodide
staining. In order to detect virus-speciﬁc plus- and minus-RNA
strand, total RNA extracted from SARS-CoV-infected PBMC
was retrotranscribed in the presence of the sense and antisense
primers, respectively, targeting the replicase gene. Measurement
of SARS-CoV genomic RNA was performed by quantitative Real
Time RT-PCR. IFN induction was performed by exposing PBMC
to SARS-CoV at different MOI, ranging from 0.1 to 10. Induction
of IFN-alpha and -gamma was analysed by measuring their
mRNA levels by limiting dilution RT-PCR. Sensitivity of SARS-
CoV replication to exogenous IFN-alpha and -gamma was tested
in Vero cells pre-exposed to the individual cytokines of to a
combination of both.
Results: In unstimulated PBMC, no infectious viral progeny
formation was detected up to day 13 post-infection. Neverthe-
less, minus-strand and genomic SARS-CoV RNA peaked at 24
hours post-infection. Dose dependent induction of both IFN-
alpha and IFN-gamma mRNA was observed, that was most
evident at MOI 10. A combination of these two cytokines was
shown to strongly inhibit SARS-CoV replication in Vero cells.
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Conclusions: Our results show that SARS-CoV is able to infect
normal PBMC. However, this appears to be only a transient
phenomenon, followed by a progressive disappearance of both
virus-speciﬁc RNA strands, with no infectious virus progeny
production. Moreover, SARS-CoV appears to have the intrinsic
ability to activate dose-dependently both IFN-alpha and -
gamma gene expression in PBMC cultures. Our results can be
pathogenically relevant to the inﬂammatory events occurring in
the diseased tissues that can be mediated by the endogenous
activation of INF system.
P938
Production of extracellular proteases and toxic
metabolites by Trichoderma strains isolated from
opportunistic infections
L. Kredics, J. Pakarinen, Z. Antal, M. Andersson, L. Manczinger,
M. Salkinoja-Salonen, C. Va´gvo¨lgyi, E. Nagy (Szeged, HUN;
Helsinki, FIN)
Objectives: Trichoderma species are potential candidates for
biocontrol of plant pathogenic fungi and cellulase producers of
biotechnological importance. On the other hand, they are
emerging as opportunistic pathogens of immunocompromised
and dialized patients. This study was designed to examine the
ability of 10 clinical Trichoderma isolates to produce extracel-
lular proteases and to screen them for toxicity to mammalian
cells.
Methods: Supernatants from induced liquid cultures of the
examined strains were screened for proteolytic enzyme activities
with 11 different chromogenic p-nitroaniline substrates. Tryp-
sin- and chymotrypsin-like activities were separated by Sepha-
dex G-100 column chromatography and their pH-dependence
was studied. Sperm toxicity bioassays were performed by
exposing boar sperm suspension to Trichoderma-methanol
extracts, the motility of spermatozoa was estimated by phase-
contrast microscopy. Mitochondrial membrane damage in sper-
matozoa was studied by epiﬂurescence microscopy using the
JC-1/propidium iodide staining.
Results: The production of trypsin-like, chymotrypsin-like and
chymoelastase-like protease activities was common among the
examined strains. Separation of trypsin- and chymotrypsin-like
activities by column chromatography revealed, that both
systems are complex consisting of several isoenzymes. Relat-
ively high activity levels were detected between pH 5 and 9
suggesting that the different isoenzymes have different pH
characteristics. More than 90% of the spermatozoa were motile
in a non-exposed control sample and in a sample exposed to 5
microliter of methanol. More than 90% of the spermatozoa
were immotile in samples exposed to T. longibrachiatum
UAMH 9515, ATCC 201044, CM382 and T. harzianum CBS
102174 in a concentration of 1.25 mg biomass ml-1, indicating
that these strains produce heat-stable substances toxic to
sperm cells. These four strains were found to inhibit the
motility of boar spermatozoa even at a low concentration (50%
reduction of motility in the case of 5 microgramm ml)1 of
extended boar sperm) and to induce dissipation of mitoch-
ondrial membrane potential. Other studied strains had no
toxic effect.
Conclusions: Production of extracellular proteolytic enzymes
and toxic metabolites are among the potential virulence factors
of Trichoderma strains as emerging fungal pathogens. This
work was supported by grants F037663 of the Hungarian
Scientiﬁc Research Fund and 53305 of the Academy of
Finland.
P939
Occurrence of scabies in patients and in the staff
of healthcare facilities
K. Zitek (Prague, CZ)
Objectives: Scabies is an itching dermatosis which continues to
be a frequent health problem. Long-term follow-up of the
epidemiological situation conﬁrms a thirty-year cycle for which
there is no satisfactory explanation.
Methods: Standard methodology of diagnostics is based on a)
subjective sensations in the patient b) objective dermatological
ﬁnding c) positive epidemiological history d) laboratory dem-
onstrations of causative agent e) remission of symptoms upon
speciﬁc therapy. Cases of scabies diagnosed and reported by
dermatologists nationwide are included by the public health
service in the central system EPIDAT (NIPH, Prague).
Results: The last two documented epidemic waves of scabies
affecting the Czech Republic peaked in 1970 and in 1993.
Speciﬁc morbidity is the highest among persons 15–24 years of
age (it closely connected with sexual activity-the source of
infestation in 60% of adults was a sexual partner and that is
conﬁrmed by an almost identical trend in reported scabies
morbidity and fresh cases of syphilis in 1965–1999 years), but the
morbidity trend has been falling sharply after the year 1993.
However, morbidity in persons over 65 years of age has been
gradually rising over recent years. Group epidemics (86) have
been repeatedly reported in such facilities as departments of
gerio-psychiatry, institutions for long-term chronic patients, old
folks homes, social care institutes and charity facilities. That
occurs in bed-ridden subjects hospitalized on a long-term basis,
the mentally retarded and the superannuated, in whom the
scabies is of a nosocomial character. The affected staff of
healthcare institution is very often the source of further
transmission to others, namely to immobile patients, as well as
to especially vulnerable individuals under higher risk of
infection. Analysis of the reported cases revealed a 13% share
of healthcare workers in this infection. Under greater risk are
senior nurses (62%), junior nurses (21%), auxiliary paramedical
staff (13%)and the last of all physicians (4%). Scabies as an
occupational disease occurs almost exclusively in the healthcare
sector.
Conclusions: Scabies poses on increased risk for the younger
population (active scabies) and the elderly population (passive
scabies). It poses a great occupational risk in the paramedical
healthcare staff carrying out nursing or managing services. It is
necessary to consistently observe preventive and repressive
epidemiological measures in the population.
P940
Fire ants, the new public health problem in Iran
K. Akbarzadeh, M. Nateghpour, S. Tirgari (Tehran, IR)
Ants are probably the most successful of all insects. They are
present almost in all countries and all places. A few of them can
bite, sting and squirt formic acid. Formica ruﬁbarbis and a few the
others are secondary hosts of Dicrocoelium dentriticum in Iran.
But the newest public health problem depending on ants in the
country is biting and stinging of ﬁre ant Pachycondyla sennaa-
rensis (Formicidae; Hymenoptera) in south and southeastern Iran.
Ecology, biology and morphology of P. sennaarensis were
considered in Iranshahr County (southeast of Iran) where has
been much infected because of the ant. According to the survey
over 92% of questioned individuals had bitten at least once with
the ant. Usually the effects of the stings are mild but this ant is
capable of multiple stinging and this can induce annoyance
people especially in children.
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P941
A survey on the geographical distribution of soft
and hand ticks in Buyer Ahmad and Dena cities,
Kohgilouye and Boyer Ahmad province, Iran
M. Shayeghi, N. Piazak, A. Khoramro, S. Moosakazemi (Tehran,
IR)
Objective: Tick play as important role in diseases transmission
to human being. Different tick-borne diseasea including borrel-
iasis, CCHF have been reported from iran.
Method: An attempt was made to determine the fauna and
geographical distribution of soft and hard ticks in this area from
October 2002 until April 2004. About 10% of the villages were
selected randomly and tick collection was carried out using
standard method. Ticks were collected from indoor resting and
hiding places in 70 villages as well as inside stables, rodent
borrows, on sheep, lamps, goat and cattel by monthly in each
season.
Result: 3382 ticks were collected and identiﬁed using national
systematic key. The copmosition and frequencies of them were
as follows: Ornithodoros lahorensis (11%), Argas persicus (23.12%),
Rhipicephalus bursa (4.3%), Rhipicephalus sanguines (1.53%), Haem-
aphysialis concinna (9.6%), Haemaphysialis sulcata (26.8%), Haem-
aphysialis punctata (1.54%), Hyaloma schulzei (8.16%), Hyaloma
marginatum (7.21%), Hyaloma dentriticum (3.08%), Hyaloma asiat-
icum(1.53%).
Conclusion: Distribution and ferquency of tlck was differ in
various season and location.
P942
Evaluation of the use of saliva to soothe blood-
sucking arthropod bites
R. Romano, F. Curtale, F. Benvegnu’, R. Zamburlini, V. Ascoli,
M. Coluzzi (Rome, Portogruaro, I)
Objectives: Our study is based on the working hypothesis that
a new category of medically important bloodsucking arthro-
pods, promoter arthropods (Coluzzi M et al, 2002, Parassito-
logia 44:123) is involved in the transmission of human herpes
virus type 8 (HHV-8). This ﬁts well with epidemiological
evidences such as i) the prevalence of non-sexual intra-familial
horizontal transmission (Mbulaiteye SM et al, 2003, J Infect Dis
187:1780), and ii) the possible role of human saliva, the only
body ﬂuid in which HHV-8 DNA is detectable (Dedicoat M et al,
2004, J Infect Dis 190:1068). The conditions for HHV-8 transmis-
sion are met when i) a child’s skin responds to the bite of a
blood-sucking arthropods, and ii) an HHV-8-seropositive
mother (or caregiver) attempting to relieve the child’s itching
and to reduce scratching applies her infective saliva to the bite’s
site. The use of saliva is a traditional behavioural practice in sub-
Saharan Africa, for healing with herbal leaves crushed and
mixed with saliva and for medical practices and in the
premastication of food (Wojcicki JM, 2003, Br J Cancer
89:2016). The human behaviour associated with the transfer of
saliva from parents to infants and the use of herbal leaves
treated with saliva in relation to arthropod bite could be a risk
factor for HHV-8 infection and perhaps other infections too
(such as the hepatitis B virus).
Methods: To evaluate to what extent saliva is used to heal
insect bites on children’s and adolescents skin, we draw up a
questionnaire directed at students of elementary and interme-
diate school. Two groups were tested, one from Italy (a school
near Rome, Latium, and schools in Veneto) and one from a
sub-Saharan African country known for high transmission levels
(Uganda, between Kampala and Entebbe by Lake Victoria).
Results: The frequencies of the use of saliva were not signiﬁ-
cantly different in Latium (12.5%) and in Veneto (14.6%) so that
an average frequency of 13.5% (96 / 712) has been compared
with the frequency of 74.8% (119 / 159) from Uganda
(P << .0001). The frequencies in the two groups are related
also to a different cultural and economic development and
improvement in hygiene.
Conclusion: We suggest that blood-sucking promoter arthro-
pods can play a role in the spread of HHV-8 infection
particularly in Africa. Therefore, a behavioural change limiting
the use of saliva on the skin and to prepare herbal leaves, could
be an attempt to control the spread of HHV-8 infection.
P943
C-reactive protein and reduced glutathione in
cerebrospinal ﬂuid of patients with tick-borne
encephalitis
I. Zeltina, A. Broduza, V. Sondore, N. Sevastjanova,
B. Rozentale (Riga, LV)
Background: Prognosis of tick-borne encephalitis (TBE) is very
difﬁcult to appoint. Although the serious TBE virus-host cell
interactions are involved in the development of pathological
process, correlation of standard laboratory ﬁndings with clinical
course and outcome of disease is problematic. The inﬂammatory
and antioxidant changes in the cerebrospinal ﬂuid (CSF) also are
controversial in different CNS damages including TBE.
Aim of study – To ﬁnd out in CSF some baseline markers of
inﬂammation and redox status for the estimation of develop-
ment tendences and clinical course of pathological process in
TBE.
Patients and methods: 60 patients with meningeal and men-
ingoencephalitic form of TBE treated at the Infectology Center of
Latvia were included in this study. Diagnosis of TBE was
conﬁrmed by ELISA, Enzygnost, Anti-TBE IgM in blood and/or
CSF. Traditional clinical criteria were used for the characteriza-
tion of TBE severity degree. Some nontraditional lab methods
were used: C-reactive protein (CRP) (immunoturbidimetrically)
and reduced glutathione (GSH) concentration (colorimetrically)
detection in CSF.
Results: Concentration of CRP in CSF was signiﬁcantly higher
in TBE patients in acute phase (5.55 ± 1.0 mg/l; n = 34) than in
reconvalescence (2.41 ± 0.5 mg/l; n = 26), P = 99%. CRP and
GSH in about 50% of TBE cases in CSF was under detectable
values. The second part of TBE patients demonstrated tendency
of the increasing of GSH during acute stage of disease
(1.64 ± 0.20 mg%; n = 32) if compared with reconvalescence
(1.41 ± 0.20 mg%; n = 24), P = 61%. No statistically signiﬁcant
differences of CRP and GSH concentrations in CSF were found
in cases of moderate meningitis form of TBE if compared to
severe meningoencephalitic form of TBE.
Conclusion: 1) Analysis of data obtained from patients with
TBE gives evidence of substantial CRP and GSH changes in CSF
in dependence on disease stage, but not on its severity degree. 2)
These objective biochemical data from CSF investigation give
proof that there are no separately moderate and severe TBE
cases in clinic: they have to be interpreted always as equally
severe. 3) The origin of CRP and GSH in CSF is unknown
(production in CNS and/or from blood due to blood-brain
barrier permeability increasing?).
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P944
Vibrio cholerae is transported to water bodies by
adult, ﬂying chironomids
M. Broza, H. Gancz, M. Halpern, Y. Kashi (Haifa, IL)
Background: Cholera is a severe disease caused by Vibrio
cholerae. The natural reservoir of this aquatic pathogenic bacter-
ium is referred to as the aquatic environment. Our group
showed that egg masses of the non-biting midge Chironomidae
spp. (Diptera) harbour V. cholerae and provide nutrient source
for their multiplication, thereby offering a new natural reservoir
for the cholera bacterium.
Objective: The presence of viable V. cholerae on ﬂying adult
chironomids will suggest that V. cholerae can be carried through
the air to other water bodies by the adult ﬂying insects and
hence a new route of infestation of water sources by the bacteria
is suggested.
Methods: In ﬁeld studies chironomid egg masses and adults
were simultaneously collected from the same environment. In
addition fresh, drinking quality water was left exposed or netted
in the vicinity of adult chironomid hatching foci. The exposed
water was monitored for chironomid egg masses and V. cholerae
presence. In the laboratory those experiments were repeatedwith
V. cholerae O9 tagged with Green Fluorescent Protein.
Results: To date, more then 30 V. cholerae serogroups have been
isolated from chironomids egg masses and adults. In the ﬁeld
experiments, a clear-cut connection between netting and V. chol-
erae absencewas noted implying that a relationship exist, between
entrance of large invertebrate to water bodies and presence of
V. cholerae in that water. In the laboratory experiments, the GFP
tagged bacteria were found on the outer surface of the adult
chironomid, in locations prone to microbial attachment.
Conclusions: The evidence shown here suggests that aerial
transport of V. cholerae by chironomids ﬂying adults is feasible
and does lead to V. cholerae contamination of unprotected water
bodies.
P945
Intracellular survival of Vibrio cholerae O1 El Tor
strains in environmental protozoa- Acanthamoeba
castellanii may induce bacterial phenotypic
alterations
G. Sandstro¨m, A. Weintraub, H. Abd (Stockholm, S)
Objectives: Cholera is a severe and potentially life-threatening
diarrheal disease caused by certain spices of the gram-negative
bacterium Vibrio cholerae. Many millions of cases of cholera
occur annually, in epidemic and pandemic forms due to
V. cholerae O1 and O139, and also sporadically due to non-O1
and non-O139 V. cholerae strains. In this context, the survival of
V. cholerae in nature is of interest from an epidemiological
perspective. Although the natural reservoirs for survival and
multiplication of V. cholerae are far from compeletly disclosed,
our previous study has shown that free-living amoebae can be
reservoirs for the seventh-pandemic V. cholerae O1 El Tor- Inaba
strain N16961, which can survive and grow intracellularly in
Acanthamoeba castellanii.The aim of this study was to examine the
ability of different strains of V. cholerae O1 El Tor to grow and
survive in Acanthamoeba castellanii, and to examine whether
intra-amoebic survival of bacteria alter their pattern of resistance
and sensitivity to different antibiotics.
Methods: V. cholerae O1 El Tor strains were co-cultured with
A. castellanii for more than two weeks. The interaction between
thesemicroorganismswas followedbyviable counts of alone- and
co-cultivated microorganisms. Intra-amoebic growth and
localization of each bacterial strain were estimated by gentamicin
assay, viable count, microscopy, and PCR to detect cholera toxin
gene and amoebic 18s RNA gene disclosing symbiont-host
association.
Results: The results show that examined V. cholerae O1 El Tor
strains multiplied and survived inside trophozoites and cysts of
A. castellanii. The bacterial internalization was in cytoplasmic
compartment of the amoebae cells. The relation between these
microorganisms in co-cultures could be classiﬁed as symbiosis,
since presence of the amoebae enhanced growth of bacterial
strains, and presence of the bacteria did not affect amoebic
growth. The intra-amoebic survival of bacteria did not alter their
pattern of resistance and sensitivity to different antibiotics such
as ampicillin, gentamicin, and tetracycline.
Conclusions: This study shows a facultative intracellular beha-
viour of examined V. cholerae O1 El Tor strains, which is in
contrast to the general held view, which considers the bacterium
to be extracellular microorganisms. The clinical importance of
free-living amoebae is their possible role as Trojan horse.
P946
Genetic variability among serotype G4 human
rotavirus strains circulating in Palermo in the
period 1985–2003
G.M. Giammanco, S. De Grazia, V. Martella, C. Colomba,
A Cascio, S. Arista (Palermo, Bari, Messina, I)
The genetic variation of VP7 and VP4 antigenic proteins was
studied in 38 G4 strains recovered in Palermo from 1985 to 2003.
VP7 sequence analysis showed that 14 strains, recovered during
1999–2003, though cross-reacting with G4-ST3:1 MAb, belonged
in fact to genotype G9 and were 99% identical to G9 strains
recovered in Palermo from 1999. Sequence comparison of 23 G4
strains grouped them into three sublineages (Ia to Ic) containing
respectively viral strains collected in 1990–1994, 1995 and 1999–
2003. Amino acid sequences were well conserved within each
sublineage and a peculiar single amino acid insertion was
observed in the variable region 4 of all sublineage Ic strains.
Both G4 and G9 Italian strains exhibited P[8] genotype and their
VP4-encoding sequences clustered in previously deﬁned lineages
following a temporal distribution: strains collected in 1989–1993
fell within lineage P[8]-1, while those recovered in 1995–2003
clustered in lineage P[8]-3. The variety of their deduced amino
acid sequences enabled us to describe, respectively, two (1A and
1B) and six (3A–3F) different patterns of substitutionswith regard
to lineage P[8]-1 and P[8]-3 reference strains. Comparison of VP7
and VP4 gene sequences of Italian and European G4 strains
indicates that different G4P[8] populations have been circulating
in Europe over the years and that the latest Italian strains aremore
closely related to recent isolates from other countries than to the
reference vaccinal ST3 strain. These results will help increase
knowledge about G4 rotavirus epidemiology and evolution, and
might be useful for future rotavirus vaccine formulation.
P947
Detection of rotavirus, adenoviruses and
astrovirus in gastroenteritis cases among young
children, ﬁrst experience with adenovirus
identiﬁcation by PCR and microplate
hybridisation assay
C. Christaki, G. Vrioni, E. Priavali, C. Gartzonika, V. Papatolis,
S. Levidiotou (Ioannina, GR)
Objectives: The aim of the present study was the detection of
Rotavirus, Adenovirus and Astrovirus in stool samples from
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young children hospitalized with acute gastroenteritis and
Adenovirus species identiﬁcation.
Methods: Stool specimens were collected from 684 young
children, hospitalised in the University Hospital of Ioannina
(NW Greece) from April 2002 to November 2004. The detection
of Rota (group A), Adeno (all human serotypes) and Astroviruses
antigens (seven human serotypes) was performed by Enzyme
Immunoassay method (DAKO IDEIA Rotavirus, Adenovirus
and Astrovirus Tests, respectively). All specimens positive for
Adenoviruses were conﬁrmed and identiﬁed by a PCR-micro-
plate hybridization assay (PCR Adenovirus Consensus, Argene,
Biosoft), which used Adenovirus genus-speciﬁc primers and one
generic and six species-speciﬁc probes deﬁned in the VA RNA
gene. According to our results: Rotavirus was detected in 63
cases (9.2%), Adenovirus in 15 cases (2.2%) and Astrovirus in 15
cases (2.2%). PCR Adenovirus Consensus assay identiﬁed the
Adenovirus species from all the 15 cases: Adenovirus species F
(enteric Adenovirus serotype 40 / 41) in 11 cases (1.6%),
Adenovirus species C in 2 cases (0.3%) and Adenovirus species
A in 2 cases (0.3%). Rotavirus gastroenteritis presented a
seasonal distribution in spring, while Adenovirus and Astrovi-
rus gastroenteritis presented no seasonality.
Conclusions: Rotavirus gastroenteritis was signiﬁcantly more
common than Adenovirus and Astrovirus infections in young
children in our territory. PCR Adenovirus Consensus technique
was a useful method for the identiﬁcation of Adenovirus in stool
specimens. Eventhought enteric Adenoviruses 40 / 41 (species F)
caused the majority of acute gastroenteritis due to Adenovirus,
non-enteric serotypes (species A and C) were occasionally
involved in the aetiology of acute diarrhoea. The study contin-
ues with the examination of great number of specimens and
patients for the investigation of more useful and speciﬁc results.
P948
Immigrant inpatients from 1999 until today:
‘pressure’ exerted over infectious disease wards
R. Manfredi (Bologna, I)
Objective: Foreign individuals ofﬁcially living in Bologna and
province are 39186 with predominant origin from Northern
Africa (31.5%), Eastern Europe (22%), and Far East (12%). The
temporal trend of admissions of patients coming from outside of
the European Union was examined according to a broad series
of variables.
Methods: Through the electronic databases of our Hospital
located in a metropolitan area of Northern Italy, informations
related to all foreign patients (p) hospitalized or followed by
Day-Hospital centres have been collected from January 1999 up
to March 31, 2004. After recording all discharge diagnosis-
related group (DRG) codes we focused attention on those
regarding Infectious Diseases.
Results: Overall discharges were 339051, with 6670 regarding
foreign p:a prevalence of the female sex (64.4%) was noticed. In
49.6% of foreign p,the mean age ranged from 20 to 35 years. The
rate of foreigners compared with overall admitted p varied from
0.3 of year 1999 to a. maximum of 0.47% of year 2002. A major
involvement was borne by Obstetrics-Gynecology (39.3%),
Internal Medicine (13.1%), Specialistic Surgery (7.3%), Special-
istic Medicine and Pediatrics (7.3% each), and Emergency
Medicine (7.1%). When considering Infectious Disease-related
DRGs, tuberculosis (142 cases), HIV-AIDS (25), chronic viral
hepatitis and related complications (22), septicemia, central
nervous system infection, and acute viral hepatitis (12 episodes
each), were the most frequent discharge codes followed by other
Infectious Disease DRGs (72 cases). The duration of admission of
foreign p was very short (1–3 days) in 42.1% of cases,while it
reached 4–7 days in 22.6% of p,and 8–14 days in 11.2% of cases,
while the mean hospitalization time at Infectious Diseases ward
was 8.6 ± 3.2 days (p < .002). Even 549 hospitalizations ended
with voluntary discharge which occurred during the ﬁrst day of
admission in 61.8% of p.
Discussion: Our pilot study demostrates that the need for
health care expressed by foreign p is increasingly frequent and
covers a very broad spectrum of disorders with Infectious
Diseases-associated illnesses gaining a increasing role through
time. A signiﬁcant problem is represented by the tendency to
very short duration of hospitalization for foreign p, often ending
with voluntary discharge while admissions carried out at our
specialized Infectious Disease ward are signiﬁcantly more
prolonged, although they are expected to give an increased
beneﬁt in terms of effective management.
P949
Change of the characteristics of natural focuses of
plague and microbiological properties of plague
microbes as a result of consequences of the
natural calamity on Aral Sea
A. Nematov, A. Mustanov, G. Bazarova (Tashkent, UZB)
Enzootics of plague as that of any other transmissible feral herd
[feral nidal] infection are determined by the interaction of a
disease’s causative agent and its warm-blooded carriers under
speciﬁc ecological environment.
Introduction and objectives: Change of the characteristics of
natural focuses of plague and microbiological properties of
plague microbes as a result of consequences of the natural
calamity on Aral Sea.
Methods: Conventional microbiological research methods were
used, when studying microbiological properties of 116 strains of
plague microbe from Kyzylkum natural focuses of plague
isolated from rodents, ticks and ﬂeas.
Results: Strains from the Kyzylkum natural focuses of plague
have all determinants of virulence, show characteristics that
allow attributing them to the continental variety, i.e. glycerin
digestion, do not ferment rhamnose and decompose arabinose;
they have nutrient need that is typical for the strains from the
Central Asian desert focus. There are differences in the need for
amino acid leucine, whereas strains from Ustyurt and Gissar
focuses are dependant on it. Out of 116 strains from the
Kyzylkum natural focus only 8 turned out to be dependant on
luecine. There were identiﬁed stains from the Kyzylkum natural
focus that had essentially different properties as compared to
the majority of isolated cultures, in particular, those can not
synthesize fraction 1 of the plague agent; have growth factor of
different nature, i.e. lower dependence on phenylalanine. Plague
bacteria strains circulating in rodent populations in the Kyzyl-
kum natural focus are characterized by low virulence in white
mice and guinea-pig, although they have all the determinants of
virulence. When studying resistance to antibiotics, there were
identiﬁed strains non-susceptible to streptomycin (5%).
Conclusions: Thus, studying the properties of the causative
agent of plague is of great importance for solving problems of
natural focuses and understanding patterns of ﬂuctuations in
the epizootic situation in a certain territory. This understanding
is an integral part of determining the epidemic potential of
natural focuses, and is used in organizing epidemiological
surveillance of the infection.
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Infection and immunopathology
P950
Amyloid peptide beta 1–40 enhances the action of
Toll-like receptor-2 and -4 agonists but
antagonizes Toll-like receptor-9 induced
inﬂammation in primary mouse microglial cell
cultures
M. Lotz, S. Ebert, H. Esselmann, J. Wiltfang, J. Gerber,
R. Nau (Gottingen, Erlangen, D)
Objectives: Toll-like receptors (TLR) play a key role in the
recognition of products from virtually all classes of pathogenic
organisms. Amyloid peptides also can stimulate the innate
immune system. For this reason, we hypothetized that bacterial
compounds and amyloid peptides may jointly stimulate the
innate immune system.
Methods: The interaction of endogenous and exogenous stimu-
lators of innate immunity was examined in primary cultures of
mouse microglial cells after application of deﬁned Toll-like
receptor (TLR) agonists [lipopolysaccharide (LPS) (TLR4), the
synthetic lipopeptide tripalmytoyl-cysteinyl-seryl-(lysyl)3-lysine
(Pam3Cys) (TLR2) and single-stranded unmethylated Cytosine-
guanosine (CpG) oligodesoxynucleotide (TLR9)] alone and in
combination with amyloid beta peptide (Abeta) 1–40. Supern-
atants from stimulated glial cultures and unstimulated controls
were analysed for nitric oxide (NO), tumor necrosis factor-alpha
(TNF-alpha) and interleukin-10 (IL-10) production.
Results: Co-administration of Abeta1–40 with LPS or Pam3Cys
led to an additive release of NO and TNF-alpha. In contrast, co-
application of Abeta1–40 with CpG led to a substantial decrease
of NO and TNF-alpha release compared to stimulation with
CpG alone. CpG was the only compound investigated, which
induced the release of the anti-inﬂammatory cytokine IL-10.
Conclusion: The additive effect of LPS and Pam3Cys and Abeta
may be one reason for the clinical deterioration frequently
observed in patients with Alzheimer‘s disease during infections.
The substantial decrease of NO and TNF-alpha release after
CpG and Abeta application compared to stimulation with CpG
alone suggests that not all microbial products enhance the
stimulatory effect of Abeta on innate immunity. The cause for
the divergent behaviour after activation of TLR9 versus stimu-
lation of TLR2 and TLR4 probably lies in differences of the
signaling cascade.
P951
HLA-B27 is a marker for susceptibility and
severity of reactive arthritis after Salmonella,
Shigella, and Yersinia infections but not after
Campylobacter and E. coli enteritis
P. Schiellerup, H. Locht, K.A. Krogfelt (Copenhagen, DK)
Objectives: Reactive arthritis (ReA) is a well-known complica-
tion after infections with Salmonella, Yersinia, Shigella and
Campylobacter. The presence of tissue-antigen HLA-B27 is
associated with ReA, and HLA-B27 may be a marker of a
prolonged disease course. We designed a case-case comparison
study of ReA after gastrointestinal infections caused by Salmon-
ella, Yersinia, Campylobacter, Shigella and E coli, to evaluate the
impact of HLA-B27 on attack rate and severity of ReA between
these 5 bacteria.
Methods: Between January 2001 and November 2002 consecu-
tive patients were included from the Danish Registry of
Gastrointestinal Infections, when culture positive for Salmonella,
Yersinia, Campylobacter, Shigella, or E coli. All patients were
addressed by a questionnaire. In this study ReA includes
reactive arthritis and arthralgia. Debut of pain in a previously
healthy joint was registered and patients were asked to mark
swollen or tender joints on a drawing. A VAS-scale was used for
assessment of pain caused by ReA. All patients were encour-
aged to donate blood samples for serology and HLA-B27 typing
(PCR).
Results: A total of 2106 patients returned the questionnaire
(response rate 67%). Only subjects with mono-infections were
included. The male/female ratio was 40/60. Blood samples were
obtained from 1558 (74%): Campylobacter (n = 693), Salmonella
(n = 503), E. coli (n = 213), Shigella (n = 74) and Yersinia (n = 75).
The overall prevalence of HLA-B27 was 9%, corresponding to
the rate within the Danish population. Odds ratios for contract-
ing ReA when the individual was HLA-B27 positive were;
Campylobacter 1.70 (CI: 0.89; 3.43), Salmonella 3.4 (CI: 1.83; 6.37),
E. coli 1.1 (CI: 0.23; 5.04), Shigella 33.5 (CI: 2.48; 452.78) and
Yersinia 5.1 (CI: 1.03; 25.68). Thus, HLA-B27 was signiﬁcantly
more frequent among ReA-patients with Salmonella, Yersinia,
and Shigella compared to Campylobacter and E coli. The VAS-
score for ReA was signiﬁcantly higher in the groups with
Yersinia and Salmonella. There was a signiﬁcant positive corre-
lation between VAS-score and the fractions of patients that were
HLA-B27 + .
Conclusions: This large comparative study shows that HLA-
B27 has a signiﬁcant impact on the susceptibility to contract ReA
after Salmonella, Shigella, and Yersinia, but not after Campylobacter
or E. coli. Furthermore the severity of ReA as measured by VAS
differed among bacterial species and was strongly correlated to
the presence of the HLA-B27 antigen.
P952
A shift to Gram-negative bacteria in the intestinal
microﬂora contributes to immunopathology of
acute ileitis in the Toxoplasma gondii-driven
mouse model of small intestinal inﬂammation
M. Heimesaat , A. Fischer , D. Fuchs , O. Goldenberg, H. Jahn,
I. Dunay , R. Schumann, A. Moter, D. Gescher, H. Hahn,
U. Go¨bel, S. Bereswill, O. Liesenfeld (Berlin, D)
Objectives: The normal gut microbiota triggers experimental
colitis and large intestinal manifestations of human inﬂamma-
tory bowel diseases (IBD). However, the availability of animal
models for the study of ileitis is limited. Thus, only little is
known hitherto in small intestinal IBD. Recently, parasite-
induced ileitis in the mouse, mimicking characteristics of ileitis
in human IBD, was proposed as a model for Crohn’s disease
(CD). Oral infection of susceptible C57BL / 6 mice with Toxo-
plasma gondii induces a severe Th1-type immunopathology,
which is restricted to the terminal ileum. In order to unravel the
mechanisms underlying ileitis, we used this model to monitor
microﬂora changes during ileal inﬂammation and determined
contributions of the gut microbiota to ileal disease.
Methods: C57BL / 6 mice were infected perorally with 100
cysts of T. gondii (ME49 strain). Ciproﬂoxacin, metronidazole,
ciproﬂoxacin plus metronidazole (each 50 mg / kg body
weight / d, p.o.), piperacillin plus tazobactam (200 mg/kg
body weight/d, i.p.) were applied from day 0 until day 8 after
T. gondii-infection. The ileal bacterial ﬂora was analysed on
day 8 p.i. by microbiological and molecular methods (16S
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rDNA-targeted denaturing gel electrophoresis (DGGE), sequen-
cing of clone libraries).
Results: Microbiological and molecular approaches revealed
that ileal inﬂammation leads to an increased total bacterial load
and to drastic changes in the ﬂora composition. In the acute
stage of disease, the grampositive cocci and rods - predominant in
the ilea of healthy mice - are displaced by gramnegatives,
identiﬁed as Escherichia coli and Bacteroides sp., respectively.
Antibacterial treatment (ciproﬂoxacin, metronidazole, a combi-
nation of both, or piperacillin plus tazobactam) ameliorated
disease symptoms and reduced ileal inﬂammation. This was
also seen in SPF-mice colonized by only one grampositive
bacterial species.
Conclusions: The fact that gramnegative bacteria accumulate
during acute ileitis and contribute profoundly to intestinal
inﬂammation is well in line with similar observations in
experimental colitis and in human IBD. This provides evidence
that gut ﬂora modulation is a valuable therapeutical strategy for
IBD treatment. Finally, the contribution of gut microbiota to ileal
disease supports the use of the parasite-induced small intestinal
inﬂammation as a model for IBD research.
P953
Assessment of hydroxyproline as a marker for
collagenolytic activity in neuroinﬂammatory
disorders
J. Sellner, F. Simon, D. Meli, D. Grandgirard, B. Storch-
Hagenlocher, U. Meyding-Lamade, S. Leib (Berne, CH;
Heidelberg, D)
Objectives: Pathophysiologic mechanisms that contribute to
brain injury in neuroinﬂammatory disorders include breakdown
of the blood-brain-barrier, extravasation of leukocytes, cerebral
hypoperfusion and vasculitis. Matrix-Metalloproteinases
(MMPs) including the collagenases MMP-2 and -9 are crucially
involved in all these steps. In this study we aimed to assess the
extent of in-vivo collagenolytic activity in cerebrospinal ﬂuid
(CSF) by determination of the amino acid hydroxyproline, a
major and exclusive degradation product of collagen.
Methods: Paired serum and CSF samples from patients with
bacterial meningitis (n = 11), aseptic meningitis/encephalitis
(n = 17), multiple sclerosis (n = 13), and normal CSF (n = 12)
were assessed. Degraded collagen was hydrolysed to dissolve
its major component hydroxyproline, which subsequently was
determined spectrophotometrically. CSF levels of MMP-2 and -9
were studied by gel zymography. In a rat model of pneumo-
coccal meningitis localization of collagenolytic activity was
performed by in-situ zymography with intramolecularly
quenched gelatin.
Results: Hydroxyproline in CSF from patients with bacterial
meningitis was signiﬁcantly increased compared to all studied
groups (P < 0.001) while serum hydroxyproline did not differ
signiﬁcantly between the groups. The amount of hydroxyproline
in CSF correlated signiﬁcantly with the amount of MMP-9
(r = 0.8; p < 0.001). In the rat model in-situ zymography
localized gelatinolytic activity to the subarachnoidal and
ventricular space inﬂammation and in association to cortical
lesions.
Summary & Conclusions: The study documents a signiﬁcant
increase of the collagen degradation product hydroxyproline in
CSF of patients with bacterial meningitis. The close correlation
of hydroxyproline and MMP-9 in the CSF validates the assess-
ment of hydroxyproline as an index for CSF collagenolytic
activity in neuroinﬂammatory diseases and supports a role for
collagenases in the pathogenesis of bacterial meningitis.
Staphylococcal infections
P954
Toxic shock syndrome: a diagnostic difﬁculty
S. Thomas, D. Waghorn, M. Lyons (High Wycombe, UK)
Introduction: Toxic shock syndrome (TSS), is an acute, non-
contagious systemic illness. It is caused by the toxin producing
strains of S. aureus and the b-haemolytic streptococci and can occur
in any non-immune person exposed to a TSS toxin. TSS is
commonly associated with menstruation and tampon use,
however can also be related to skin or soft tissue infections,
particularly post surgical, skeletal infections or respiratory tract
infection. TSS is often non-immunising and recurrent menstrual-
associated TSS is well-described. Literature suggests that TSS is
extremely rare, but diagnostic difﬁculties can lead to misdiag-
nosis and TSS can be fatal if left undiagnosed. We report a series
of three cases of TSS, presenting within a short period of time.
Case Reports: Case 1. 17 year old female, presented with
sudden onset collapse, diarrhoea, vomiting and abdominal
pains. She gave no history of menstruation and an initial
diagnosis of severe gastroenteritis was made. She failed to
respond to conservative management and required ITU support.
She was discharged with no ﬁrm diagnosis and re-presented one
month later with similar symptoms, when a diagnosis of
staphylococcal TSS was conﬁrmed. Case 2. 15 year old female,
presented during menses with sudden onset rash, rigors, severe
diarhhoea, vomiting and abdominal pains. She was diagnosed
with staphylococcal TSS on admission. Case 3. 28 year old
female. Presented with sudden onset severe diarrhoea,
vomiting, pyrexia and rash. She gave no history of menstru-
ation. She responded poorly to treatment, required ITU support,
high dose steroids and was eventually diagnosed with strepto-
coccal TSS.
Discussion: Diagnostic criteria for TSS include high fever,
hypotension, erythematous rash and a complicated multisystem
disfunction. Patients often require aggressive management. The
Public Health Laboratory Service reports an average of 18 cases
of diagnosed TSS in the UK per year. However, because of the
uncommon and difﬁcult nature of the diagnosis, many cases are
misdiagnosed and therefore go unreported. It is essential to
maintain a high level of suspicion for patients who are epidem-
iologically at high risk, but importantly, also the less ill patient
with suggestive symptoms who fails to meet all diagnostic
criteria but are in an at-risk group. High morbidity and mortality
has been reported for undiagnosed and untreated cases.
P955
Dressing changes under laminar ﬂow conditions
to prevent Staphylococcus aureus wound
colonisation in patients admitted to a burn centre
A.M.D. Kooistra-Smid, M.K. Nieuwenhuis, E. van Zanten,
J. Hiddingh, S.R. van Dijk, G.I.J.M. Beerthuizen, W.H.M. Vogels,
A.A. van Zwet, H.A. Verbrugh (Groningen, Rotterdam, NL)
Objectives: Staphylococcus aureus colonization and infection of
burn wounds increases morbidity and delays wound healing of
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patients suffering from burn wounds. A vulnerable moment in
the route of transmission of S. aureus is the exposed burn wound
during dressing changes. The aim of this study was to evaluate
the effect of dressing changes under laminar ﬂow conditions on
burn wound patients with regard to S. aureus colonization.
Methods: From the ﬁrst of February 2003 to the ﬁrst of June
2003, 25 patients were included in this study at our 10-bed burn
centre. In 12 of these patients the dressings were changed under
laminar ﬂow conditions. All patients were frequently screened
for S. aureus in nose, throat and burn wounds. All S. aureus
isolates were genotyped with Pulsed Field Gel Electrophoresis.
Results: At admission 17 / 25 (68%) patients had no S. aureus
colonization in their nose, throat or burn wounds. Dressing
changes under laminar ﬂow conditions were carried out on 8 /
17 patients of this group. However, 6 / 8 (75%) patients
acquired burn wound colonization with S. aureus during their
stay at the centre. Six out of 9 patients (67%) whose dressing
changes were not carried out under laminar ﬂow conditions
acquired burn wound colonization with S. aureus. A total of 12
patients acquired burn wound colonization; these patients also
acquired carriage of S. aureus in nose or throat. The same type of
S. aureus was carried in the nose or throat as well as the burn
wounds in 7 (58%) of these patients.
Conclusion: The results of this study suggest ﬁrstly that
dressing changes under laminar ﬂow conditions does not
prevent colonization of burn wounds with S. aureus, and
secondly, that the exogenous route plays an important role in
the transmission dynamics of this pathogen in burn wound
centres. Future research should be focused on this mode of
transmission of S. aureus in this special circumstance.
P956
Mupirocin prophylaxis to prevent Staphylococcus
aureus wound colonisation in patients admitted
to a burn centre
A.M.D. Kooistra-Smid, S.R. van Dijk, G.I.J.M. Beerthuizen,
W.H.M. Vogels, A.A. van Zwet, H.A. Verbrugh (Groningen,
Rotterdam, NL)
Objectives: Staphylococcus aureus (S. aureus) colonisation of burn
wounds increases morbidity and delays wound healing. Many
burn wound colonisations with S. aureus are endogenous in
nature. The aim of this study was to evaluate the effect of
eradication of nasal S. aureus with mupirocin in patients with
regard to S. aureus colonisation of their burn wounds.
Methods: From September 2000 to March 2001, 42 patients
admitted to our 10-bed burn centre were screened for S. aureus
in nose and burn wounds. Isolates were genotyped with PFGE.
All patients received nasal mupirocin at the time of admission to
the burn centre. Fifty-ﬁve patients from the same unit who were
followed from September 1997 till May 1998 and had not
received mupirocin prophylaxis served as a historical control
group.
Results: At admission 29 / 42 (69%) patients in the mupirocin
trial had no S. aureus colonisation in their burn wounds. Of this
group 25 patients were non-carriers and 4 patients were nasal
carriers of S. aureus. Seven (28%) non-carriers and 2 (50%) nasal
carriers acquired burn wound colonisation with S. aureus during
their stay at the centre. Of the historical control group, 39 (71%)
patients had no S. aureus colonisation of their burn wounds at
the time of admission. Of this group 31 patients were non-
carriers and 8 patients were nasal carriers; 18 (58%) non-carriers
and 7(88%) nasal carriers acquired S. aureus wound colonisation
during their stay. The overall probability of wound colonisation
in the patients treated with mupirocin was signiﬁcantly lower
than in the historical non-treated group (p = 0.01, chi-square test
with Yates correction).
Conclusion: The results of this study suggest that application of
nasal mupirocin to all patients upon admission to a burn centre
may reduce but not eliminate the risk of subsequent S. aureus
colonisation of burn wounds. Other measures including
improved infection control practices and eradication of exogen-
ous S. aureus reservoirs, including S. aureus carriage among
healthcare workers, may be necessary to further reduce the
incidence of S. aureus burn wound colonisation.
P957
Controlling an outbreak of Staphylococcus aureus
on a surgical ward
P.E.M. Haanen, M. van der Bijl, P.H.M. Savelkoul, E.R. van der
Vorm (Amsterdam, NL)
Objectives: In February 2004 an increase of S. aureus infections
was recognized on a surgical ward of the VU medical centre.
Also, two healthcare workers (HCW A and B) on that ward
appeared to have skin problems. After this observation, cultures
were taken and HCW A and B were relieved from patient
contact. The cultures were positive with S. aureus. The outbreak
was characterised and the S. aureus infections were monitored
by means of molecular surveillance.
Methods: From February until June 2004 the S. aureus strains
were collected from clinical and policlinic patients from the
surgical ward. The strains were characterised and compared by
Ampliﬁed Fragment Length Polymorphism (AFLP).
Results: The characterisation of the S. aureus in February
showed a cluster of identical strains in three patients and HCW
A. The strains of two patients were similar to the strain of HCW
B. Three patients had a unique strain. In the surveillance period a
total of eighteen isolates in sixteen patients were found. In the
surveillance period the epidemic-strains were found in other
patients but only in patients who have been on the ward during
the epidemic period. Two patients had an identical new isolate.
That indicates that the exchange between patients of S. aureus
may occur without notion. Another remarkable observation was
that some of the patients lost their original strain and acquired a
new isolate of S. aureus during hospitalisation.
Conclusions: A small outbreak of S. aureus could be traced to 2
HCW who proved to be carriers. Relieving them from patient
contact stopped the outbreak. Molecular surveillance is an
appropriate way to evaluate the success of measurements taken
and to underscore the importance of hygienic measures.
P958
Risk factors for S. aureus carriage in health care
workers
A. Widmer, M. Lang, R. Frei (Basel, CH)
Introduction: S. aureus (MSSA) carriage is common among
health care workers (HCWs)and might be associated with type
of care provided and other potential risk factors. Transmission
of MSSA has been observed by ’’cloud adults’’.
Objectives: To determine risk factors for MSSA carriage in
HCWs, and the percentage of methicillin-resistant S. aureus
(MRSA) in a tertiary care centre.
Methods: Retrospective review of all data of staff health
department and the microbiology laboratory. All HCWs who
were working in a high MRSA prevalence country were
routinely screened at the time they were hired by the institution.
In addition, data were generated from MRSA screenings of
HCWs if there was evidence for nosocomial transmission of
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MRSA in patients. MRSA was deﬁned as S. aureus being
oxacillin-resistant and expressing the PBP2’ and/or being
positive for the mecA gene by PCR. Data of HCWs were
collected by chart review in a case-report form that included
demographic data, work place, skin diseases and other varia-
bles. Data were compared by univariate and multiple logistic
regression analyses.
Results: A total of 3474 swabs were taken from 1217 HCWs
between Jan 1997 and Dec.2001. Data were available from 1182
HCWs:50% originated from Switzerland, 27% fromGermany, 4%
from France, and 19% from other countries. The overall preval-
ence of MSSA and MRSA was 53% and 1%, respectively. More
than one samplewas available from332 individuals: Of the repeat
samples, 38% were negative, 32% were negative, but had one
single positive culture, and 30% were consistently positive. Sex,
profession, work place, number of years at the institution was not
associated with S. aureus carriage (p > 0.2). The only signiﬁcant
risk factor for S. aureus carriage was young age, deﬁned <35years
(p = 0.02). The prevalence of MSSA increased from 51% (1997) to
63% (2001). Eight HCWswere carriers ofMRSA: theywere young
and half of the them reported skin diseases.
Conclusion: S. aureus carriage among HCWs is common: Only
young age remained a risk factor even after adjusting for other
variables. MRSA was rare among HCWs.
P959
Prevalence of nasal carriage of methicillin-
susceptible and methicillin-resistant
Staphylococcus aureus among hospital personnel
and outpatients
St. Fokas, Sp. Fokas, C. Tsamolia, M. Skoutari (Eghio, GR)
Objectives: To assess the nasal colonization of Staphylococcus
aureus among hospital staff in the absence of an epidemic and to
compare it with the nasal carrier status among outpatients,
focusing on the MRSA rate.
Methods: The study included 150 hospital personnel and 150
adults admitted to outpatient clinics of our hospital. Given that a
history of hospitalization is the most important facilitative factor
for colonization of Staphylococcus aureus we exclude individuals
with a history of hospitalization in the preceding year of our
study. The specimens were obtained with swabs from the
anterior nares-ecological niches of S. aureus- and cultured
according NCCLS guidelines. ID 32 STAPH strips were used
for identiﬁcation and conﬁrmed with Slidex Staph Plus kit (both
by biomerieux). MRSA strains detection was achieved with
Slidex MRSA Detection kit of the same company. Antibiotic
susceptibility of MRSA strains was determined with ATB
STAPH method (version 2000) according to the recommenda-
tions of the producer (biomerieux).
Results: Among hospital staff the carriage rates of MRSA and
methicillin susceptible S. aureuswere 2.7% and 20% respectively.
None of the outpatients was found to be a nasal carrier of
MRSA. In addition MSSA carriage in this group was 11%. The
prevalence of MRSA nasal carriage rate among personnel
working in the different medical wards was also examined.
The difference in the rates among personnel working in the
surgical ward, operating theaters and the rest of the staff was
statistically signiﬁcant (p < 0.001). All MRSA strains were
susceptible to oral antibiotics.
Conclusions: Although the prevalence of MRSA is low among
hospital personnel, education is needed as they are one of most
important reservoirs for nosocomial MRSA infections. The low
incidence of MRSA infections around the time of the study
suggests that with usual infection control practices MRSA
spread was avoided. All MRSA carriers were treated with
intranasal muripocin for eliminating the nasal carrier status.
Continuous monitoring of MRSA carriage is needed to avoid
nosocomial spread.
P960
Understanding the Staphylococcus aureus nasal
colonisation of HIV outpatients based on DNA
genotyping
M.C. Padoveze, R. Pedro, D. Blum-Menezes, O.J. Bratﬁch,
M.L. Moretti (Campinas Sao Paulo, BR)
AIDS patients are a special population related with high risk of
infection due to Staphylococcus aureus. Previous colonization is a
recognized predisposing factor for development of infection due
to this organism. However, nasal carriage of S. aureus in HIV-
patients is still not completely characterized.
Objectives: To describe the epidemiological features of com-
munity-acquired S. aureus nasal colonization in out care HIV-
patients based on the molecular genotypes.
Methods: HIV-outpatients without previous hospitalization
within the last two years were screened for S. aureus nasal
colonization. Three samples from each patient were collected,
and the variables associated with colonization were assessed.
Nasal carriage was classiﬁed as: absent, transient colonization or
persistent colonization. The persistent colonization was assessed
according to the molecular proﬁles performed by Pulsed-Field
Gel Electrophoresis, in: simple (same proﬁle), multiple (different
proﬁles) or combined (two with the same e and one with
different proﬁles).
Results: 111 patients were enrolled in the study. Seventy
patients (63%) had at least one culture positive for S. aureus
and 99 patients concluded three samples collection. Only one
isolate was a community acquired MRSA. The rates of colon-
ization was higher when two or more samples were taken,
ranging from 45.5% in the ﬁrst sample up to 65.6% when 3
samples were collected. HIV-patients with AIDS were more
likely to be colonized than non-AIDS patients (p=0.02). Among
the patients with S. aureus nasal carriage, 39% were transient
and 61% were persistent carriers, whose genomic subtype was:
61.5% simple, 20.5% combined and 18% multiple persistent
colonization. Previous use of antibiotics was associated with
absence of S. aureus colonization (p < 0.05).
Conclusions: HIV out care patients had high rates of oxacillin-
susceptible S. aureus nasal colonization. Regardless, the recent
literature, only one isolate was community-acquired MRSA. The
most common characteristic of colonization is simple persistent
colonization showing the same genomic proﬁle.
P961
S. aureus bacteraemia: prospective study of 238
cases (2000–2003)
R. Ban˜os, J. Go´mez, E. Garcı´a Va´zquez, J. Ruiz, J.A. Herrero,
V. Ban˜os, M. Canteras, M. Valde´s (Murcia, E)
Objectives: S. aureus bacteraemia (SAB) continues to be a major
problem related to both community-acquired and nosocomial
infection. We undertook an evaluation of a large cohort of
patients with SAB to assess features of the infection and
predictors of mortality.
Patients and Methods: 238 cases of SAB admitted to our
hospital (2000–3) were prospectively studied. All patients had at
least one positive blood culture for S. aureus and clinical
symptoms of bacteraemia. SAB was considered to be nosocomial
if the ﬁrst positive blood culture specimen was obtained > 72 h
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after admission and there was no clinical evidence of infection
on admission. Microbiological studies were carried under
standard protocols. Epidemiological and clinical characteristics,
antimicrobial treatment and outcome (relapse or mortality) were
analysed.
Results: 434 cases of SAB were identiﬁed but only 238 were
prospectively included in the study protocol. Incidence was the
highest in year 2001 (4.21 per 1000). Out of the 238 cases, 167
(70%) were male with a mean age of 51 year (SD 24.89). Mean
length of stay was 30.34 days (SD 29.54); 165 (69.3%) cases were
nosocomial. Distribution of patients according to Wards was
46.2%, 24.8%, 20.2% and 8.4% in medical wards, surgical wards,
intensive care unit and paediatric ward, respectively; 92.9% of
the cases had an underlying disease; 52% of the patients
developed complications; a primary origin of the bacteraemia
was not identiﬁed in 37% cases; 35.7% occurred in patients with
IV catheters and 16% had a cutaneous origin. 85 cases (35.7%)
were due to MRSA. Overall, treatment was inadequate in 56%%
of patients (rate of treatment inadequacy 63.3% in SAMS cases
and 42.3% in SMAR bacteraemia). Overall, 44 (18.4%) of the 238
patients with SAB died during hospitalisation. Mortality
in patients with SAMR bacteraemia was 34.11% versus 9.8% in
patients with SAMS bacteraemia.
Conclusion: The knowledge of clinical and epidemiological
factors of patients with SAB may allow to optimize its manage-
ment and to reduce morbidity and mortality.
P962
Detection and interpretation of macrolide-
lincosamide-streptogramin resistance among
Staphylococcus with Phoenix Automated
Microbiology System and BDXpert System
B. Turng, J. Sinha, M. Deal, J. Pollitt, D. Callihan, B. Brasso,
T. Wiles, J. Reuben (Sparks, USA)
Objectives: The National Committee for Clinical Laboratory
Standards (NCCLS) recently published recommendations for
the detection of macrolide-lincosamide-Streptogramin (MLSb)
resistance in Staphylococcus. These statements provide guidelines
for laboratorians to detect the MLSb resistance phenotypes in
macrolide resistant staphylococci. The Societe Francaise De
Microbiologie (SFM) and Deutsches Institut fur Normung (DIN)
have not yet implemented similar guidelines. This study
evaluated the detection and reporting of MLSb results in
Staphylococcus using the BD PhoenixTM Automated Microbio-
logy System and BDXpert System with NCCLS, SFM or DIN as
interpretative standards.
Methods: Comments regarding MLSb resistance as listed in the
NCCLS M100–S14 were converted into expert rules. Special
BDXpert rules were also constructed for the detection and
reporting of MLSb resistance when applying SFM or DIN
guidelines. A total of 177 strains of Staphylococcus (146 S. aureus,
12 S. epidermidis, and 19 coagulase-negative staphylococci)
were tested in Phoenix panels containing erythromycin (E) and
clindamycin (CC). NCCLS, SFM or DIN breakpoints were used
to interpret the Phoenix MIC results. The double disk diffusion
D-test (E and CC) was used as the reference method for the
determination of MLSb resistance phenotypes.
Results: The Phoenix E and CC MIC values were interpreted
based on the standard selected. The BDXpert rules were executed
and applicable expert messages were displayed. The Phoenix
correctly detected 38 out of 43 constitutive MLSb (cMLSb)
phenotypes as compared to the D-test results. The remaining 5
cMLSb strains were interpreted by the BDXpert as potential
inducible MLSb (iMLSb)/efﬂux phenotypes. A total of 69 iMLSb
and 22 efﬂux phenotype isolateswere all reported by the BDXpert
as iMLSb/efﬂux phenotype and the userswere alerted to perform
D-test before reporting the CC results. The CC interpretation was
suppressed in these isolates. The NCCLS, SFM, or DIN showed
identical detection and interpretation of MLSb resistant pheno-
types by the Phoenix and BDXpert systems.
Conclusions: The Phoenix and BDXpert Systems can assist
laboratories in rapid detection and accurate interpretation of
MLSb results for Staphylococcus. Special messages can be used to
communicate timely and accurate information to clinicians for
proper therapy of staphylococcal infections with MLSb resistant
phenotypes.
P963
In vitro activity of new compounds tested against
multi-drug resistant S. aureus isolated in Latin
American medical centres
A. Gales, H. Sader, D. Biedenbach, P. Strabala, R. Jones (Sao
Paulo, BR; North Liberty, USA)
Background: Oxacillin-resistant S. aureus (ORSA) isolated in
LAMCs shows high rates of co-resistance (R) with most
antimicrobial classes used in the clinical setting. We evaluated
the MDR patterns of ORSA strains collected in LAMC by the
SENTRY Antimicrobial Surveillance Program in 2003. We also
evaluated the susceptibilities (S) of new, investigational com-
pounds against these important endemic pathogens.
Methods: Among 1.437 S. aureus collected, 507 (35.3%) were R
to oxacillin. These strains were isolated from 10 LAMCs (5
countries) and tested against > 30 antimicrobials by NCCLS
broth microdilution methods. ORSA strains were grouped by
the MDR patterns for the 8 primary drugs (47).
Results: The MIC50 in mg / L / % S for the primary drugs
were: erythromycin (ERY) > 8/8; clindamycin (CC) > 8 / 13;
ciproﬂoxacin (CIP) > 8 / 8; tetracycline (TC) £ 4/61, co-trim-
oxazole (T / S) > 2 / 49, chloramphenicol (CHL) 16 / 47,
rifampin 2 / 48, gentamicin (GM) > 8 / 14; and newer agents
were: daptomycin (DAP) 0.5 / 100, dalbavancin (DAL) 0.06/-,
linezolid (LZD) 2/100, quinupristin/dalfopristin (Q / D) 0.5 /
100, teicoplanin (TEI) £ 2/100 and vancomycin (VAN) 1 / 100.
Table shows 6 MDR-ORSA patterns (77.5% of all ORSA):
Conclusions: All newer compounds (LZD, Q/D, DAP and
DAL), TEI and VAN were very active against endemic and
epidemic ORSA in LAMCs. These S. aureus having MDR
patterns (ave. R to 6 agents) will require greater use of newer
compounds particularly in Brazil.
P964
VGA-gene is responsible for the low-level
resistance to quinupristin-dalfopristin among
staphylococci in Greek hospitals
E. Petinaki, M. Maniati, Z. Bersos, V. Chini, A. Foka, A.N.
Maniatis, I. Spiliopoulou (Larissa, Patras, GR)
Objectives: Quinupristin-dalfopristin (Q–D) is widely used for
the treatment of infections caused by gram-positive cocci, except
Pattern (no.) R antibiogram Geographic distribution (%)
1 (126) All primary drugs Brazil (82%)
2 (6) CHL, CIP, CC, ER, GM Chile (66%)
3 (65) CIP, CC, ER, GM Argentina (51%). Brazil (48%)
4 (51) All, except CHL Brazil (75%)
6 (48) All, except TC Brazil (100%, 75% one site)
6 (37) CIP, CC, ER Mexico (86%)
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Enterococcus faecalis. Despite the prolonged use of streptogra-
mins in animal husbandry, a limited number of staphylococcal
isolates were found to be non susceptible worldwide. The
purpose of this study was to investigate the rates of resistance
among staphylococci to this agent in Greece, after a three year
period of usage in our hospitals.
Methods: A total of 846 staphylococci (250 S. aureus and 596
coagulase-negative staphylococci, CNS) recovered from clinical
specimens of different patients in two tertiary care Greek
hospitals (University Hospital of Larissa, University Hospital of
Patras) during 2003–2004 were investigated for their resistance
to quinupristin-dalfopristin (breakpoints for susceptibility < =
1 mg / L, resistance >4 mg / L). Identiﬁcation at species level
was performed by Gram stain, catalase and coagulase produc-
tion, and by the API Staph system. Susceptibility to various
antimicrobial agents including Q-D was assessed by disk the
diffusion method. Determination of MIC to Q-D was performed
by the E-test and agar dilution method. Isolates with MICs
greater than 1 mg / L were examined for the presence of vatA,
vatB, vatC, vga, vgaB, vgb, vgbB genes by Polymerase Chain
Reactions. The clonality of isolates was studied by PFGE of
chromosomal SmaI DNA digests.
Results: All S. aureus isolates had MICs ranging from 0.19 to
0.75 mg / L (mean value: 0.25 mg / L). Among the CNS, 579
isolates expressed MICs between 0.125–1 mg / L (mean value:
0.33 mg / L), while 17 isolates had MICs that ranged from 1.5 to
4mg / L. All these 17 isolates, including one S. haemolyticus, one
S.capitis, and ﬁfteen S. epidermidis were vga-positives and
expressed MLSB phenotype carrying the ermC-gene.
Conclusions: The presence of vga-gene, conferring resistance to
streptogramin A by a putative efﬂux mechanism is responsible
for the non-susceptibility of staphylococci to quinupristin-
dalfopristin in Greece.
P965
Dynamics of nasopharyngeal colonisation by
coagulase-negative staphylococci in patients with
resectable lung cancer during short-term
hospitalisation
A. Malm, M. Juda, R. Los, M. Sawicki, F. Furmanik (Lublin, PL)
Objectives: Coagulase negative staphylococci (CoNS) represent
a part of physiological microﬂora. However, in recent years,
they have also emerged as nosocomial pathogens of infections
associated with indwelling medical devices (e. g. pleural drains),
mainly in immuno-compromised patients. The aim of this study
was to determine dynamics of nasopharyngeal colonization by
CoNS in patients with resectable lung cancer during short-term
hospitalization, especially those receiving routinely preoperative
antimicrobial prophylaxis.
Methods: In present study CoNS species were selected from
patients divided into two groups: (I) patients who were
undergoing pulmonary resection and receiving preoperative
prophylaxis (piperacillin, cefuroxime alone or in combination
with amikacin) – prophylaxis group and (II) control group.
Throat and nasal specimens were taken from each patient twice,
in four-days interval. All isolates were identiﬁed by the
biochemical microtests API STAPH (bioMerieux) and tested
for drugs susceptibility according to NCCLS reccomendations.
Results: 187 strains of CoNS strains were selected from clinical
specimens: 137 strains from prophylaxis group and 50 strains
from control group. The most often isolated species was
Staphylococcus epidermidis with the predominated API numerical
proﬁle 6606113. A detailed analyses of the API numerical
proﬁles and resistance to antimicrobial agents indicated that
during four-days interval of hospitalization, changes in pheno-
types among CoNS colonizing nasopharynx were observed in
both groups of patients. The changes in drug resistance patterns
were found more often in prophylaxis group compared to
those in control group – 48 / 54 (88.9%) and 11 / 22 (50%),
respectively. This difference was statistically signiﬁcant
(p = 0.0007 – Chi2 test with Yates correction).
Conclusion: Our data suggest that preoperative antimicrobial
prophylaxis routinely used in patients with resectable lung
cancer may be regarded as an important factor predisposing to
changes in drug resistance patterns among CoNS isolates
colonizing nasopharynx.
P966
The susceptibility of coagulase-negative
staphylococci in a teaching hospital compared
with a secondary care hospital
J.H. Sloos, L. Dijkshoorn, N.M. Bax, A.T. Bernards, E. van Strijen,
P.H. van den Broek (Alkmaar, Leiden, NL)
Objectives: To compare the susceptibility of coagulase-negative
staphylococci (CoNS) for teicoplanine (T) and vancomycine (V)
in two hospitals, the Leiden University Medical Center (LUMC)
and Medical Center Alkmaar (MCA), in which these antibiotics
are respectively the ﬁrst choice antibiotics in serious infections
with these species.
Methods: Antibiotics tested were T, V, ciproﬂoxacin (C), mox-
iﬂoxacin (M), levoﬂoxacin (L), and linezolid (Li). Collections I
comprised 44 isolates and were from the LUMC, whereas
collection II comprised 27 isolates from the MCA. Susceptibil-
ities were determined by agar dilution on Mueller Hinton agar.
Results: In total, six different species were identiﬁed in 71
isolates, 72% of which were Staphylococcus epidermidis. In the
LUMC the species diversity was greater than in the MCA, with
ﬁve isolates of Staphylococcus haemolyticus found in the ﬁrst. No
difference between the two hospitals was found in activity of the
antibiotics tested, except for Li. The MIC90s were as follows: V 2
mg / L, T 4 mg / L, C 16 mg / L, M 2 mg / L, L 8 mg / L. Of
Li the MIC90 was 2 mg / L in the LUMC and 1 mg / L in the
MCA. According to Dutch guidelines, in total 7 / 71 isolates
were found resistant to T and 21 intermediate resistant. All
isolates were susceptible for V.
Conclusion: The ﬁrst choice glycopeptide for serious CoNS
infections, T or V, has no inﬂuence on the susceptibility of CoNS
for these antibiotics. According to Dutch guidelines, the activity
of T, C, and L against CoNS is relatively low, whereas the
activity of M and Le is in the susceptible range.
P967
Characterisation of bioﬁlm-forming
Staphylococcus epidermidis clinical isolates
D. Petrelli, C. Zampaloni, L.A. Vitali, M. Prenna, S. D’Ercole,
M.S. Pasquantonio, S. Ripa (Camerino, I)
Objective: Staphylococcus epidermidis is one of the bacterial
species mainly implicated in foreign body associated infections.
We have characterized several S.epidermidis clinical isolates for
their ability to form bioﬁlms and their resistance to antibiotics.
Methods: 76 S.epidermidis strains isolated from implantable
medical devices have been collected from hospitals of Central
Italy. Susceptibility to penicillin, methicillin, erythromycin and
tetracycline has been determined in vitro by E-test according to
NCCLS guidelines. The speciﬁc antibiotic resistance determi-
nants have been checked by PCR (blaZ, mecA, ermA, ermB,
ermC, msrA, tetK and tetM). The ability to form bioﬁlms has
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been determined: (i) by PCR, detecting genes speciﬁc for
attachment and bioﬁlm development (icaADBC operon, aap,
and atlE); (ii) by Congo Red Agar (CRA) plate test to assay the
production of polisaccaridic intercellular adhesin (PIA); (iii) by
crystal violet (CV) stain to determine the bioﬁlm biomass
development on polystyrene microtiter plates; (iv) and by CSLM
microscopy observations to investigate bioﬁlm structure.
Results: 94% of the strains under study was resistant to
penicillin, 87% to methicillin, 72% to erythromycin and 25% to
tetracycline. On the side of bioﬁlm-speciﬁc genes detection, 66%
of strains was positive to ica operon genes, 82% possessed atlE
gene, and 42% aap determinant. In 89% of the population, the
CRA test conﬁrmed the correlation between the presence of ica
genes and slime expression. The CV assay classiﬁed the quasi-
totality of our strains (97%) as bioﬁlm producers on plastic
surface. In addition, the distribution of optical density values
(OD540) obtained after CV stain, showed a signiﬁcant statistical
difference in bioﬁlm biomass development between the ica-
ADBC-positive strains and the icaADBC-negative ones. Finally,
a correlation, although not always present, has been observed
between ability of the strains to develop in a high-structureted
bioﬁlm and speciﬁc bioﬁlm-formation determinants.
Conclusions: The investigated bacterial population shows a
very high and alarming level of resistance to all tested drugs.
Although the speciﬁc determinants for bioﬁlms formation are
not always present, nevertheless all the strains are able to
develop in sessile form showing that different and not still
identiﬁed factors could work together in the formation and
organization of staphylococcal complex microbial communities.
P968
Genetic relatedness of coagulase negative
staphylococci in sternal wound colonisation and
sternal wound infection after open heart surgery
C. Balmelli, R. Hysenai, G. Senn, M. Spiess Pangrazzi,
E. Schmid, M. Turina, C. Ruef (Zurich, CH)
Objective: Coagulase-negative staphylococci (CoNS) are fre-
quently isolated in sternal wound infections (SWI) after open
heart surgery. Our study had two principal aims. First, to
establish the source and route of transmission of staphylococci
found in SWI and sternal wound colonization during interven-
tions under laminar ﬂow ventilation (LVF). Second, to assess the
source of strains found in the ultra clean area (UCA) and to
deﬁne the role of airborne transmission.
Methods: Prospective evaluation of 50 patients undergoing
elective open heart surgery. Swabs of noses and hands of HCW
involved in patient care. Swabs of noses and sternal skin of
patients before interventions. Three air samples done during
each intervention in the vicinity of the surgical site. Genotyping
of all 2413 cultured isolates of CoNS using pulsed ﬁeld gel
electrophoresis (PFGE).
Results: Two out of 50 patients developed SWI, one infection
was caused by CoNS and needed surgical revision, the second
was caused by coryneform bacteria. PFGE showed that the
CoNS originated from the hands of a supporting staff member
(SSM) who shaved the patient just before intervention. Another
CoNS strain was found in the same wound during revision, and
was traced to another SSM who took care of the patient just
before reintervention.
Five out 50 patients had intraoperative sternal wound coloniza-
tion with CoNS. None of these CoNS genotypes were observed
among isolates from patients, HCW or from the air. Most air
samples showed <10 CFU/m3. 17/216 (8%) of CoNS isolates
from the air could be traced to HCW or patients, among which
50% originated from the non-scrubbed team.
Conclusions: Analysing the origin of colonization or infec-
tion in 6 patients with CoNS isolated from the operative site,
the bacteria could only be traced in one patient who
developed an infection. Transmission most probably occurred
by direct contact. The low level of bacterial contamination in
the UCA together with the lack of correlation of genotypes
between isolates found in the UCA and in the wounds
suggest that airborne transmission does not play a major role
in the development of SWI. More than 90% of staphylococci
found in air samples were not traceable to any investigated
sources. Most probably, they originated from non swabbed
parts of the HCW’s bodies. Since 50% of the traceable
isolates from the UCA originated from non scrubbed team
members, protection of the operative site by LFV appears to
be suboptimal.
P969
Clonality of endemic methicillin-resistant
Staphylococcus epidermidis strains isolated in a
neonatal intensive care unit
N. Ben Saida, A. Ferjani, N. Sfar, J. Boukadida (Sousse, TN)
Objectives: Methicillin-resistant staphylococcus epidermis
(MRSE) is one of the important pathogen responsible for
nosocomial infections particularly in newborns. The aim of our
study was to establish if these infections are caused by
endemic clones or by incidentally occurring bacterial strains
of this ubiquitous species and to evaluate the performance of
PCR iner-IS256 as a novel method for typing MRSE strains
using pulsed-ﬁeld gel electrophoresis (PFGE) as the reference
method.
Methods: Twenty strains of MRSE (mecA+) has been collected
during the period of survey (december 2003 to september 2004)
from different pathological products of newborns hospitalized
in a neonatal intensive care unit of a public maternity hospital in
Sousse, Tunisia. Identiﬁcation of strains was done by conven-
tional procedures and the Api staph (Api-biomerieux. Sa).
Susceptibility testing to antibiotics was determined according to
CA-SFM recommendations. All strains have been characterized
by genotypage in pulsed-ﬁeld gel electrophoresis (PFGE) variety
CHEF after SmaI macrorestriction. Genomic proﬁles have been
interpreted according to criteria of Tenover (J. Clin. Microbiol
1995; 33:2223–2239). Strains were also characterized by elec-
trophoretic proﬁles obtained by PCR-based analysis of inter-
IS256 spacer polymorphisms.
Results: These MRSE represent 41.6% of the total strain of
S.epidermidis collected from the neonatology ward during the
period of survey. Majority of these strains come from blood
sample (75%), other strains from vascular catheter (5%), pus
(10%), sound (10%). 17 antibiotypes and 6 genotypic proﬁles
according Tenover criteria were individualized: type A (with 5
subtypes), type B, type C (with 1 subtypes), type D (with 1
subtypes), type E (with 2 subtypes)and type F. A total of four
PCR patterns were obtained based on the interpretation criteria
that PCR patterns exhibiting more than one band difference
were considered to represent distinct types, type 1, type2, type3,
and type4.
Conclusion: MRSE appear to be endemic and multiclonal with
a dominant clone in the neonatal intensive care unit. Our study
demonstrates that a signiﬁcant proportion of MRSE infections
may be attributable to transmission among newborns and that
certain strain can become endemic over long periods in this
setting.
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P970
Clonality of Staphylococcus haemolyticus strains
isolated in a neonatal intensive care unit
N. Ben Saida, A. Ferjani, J. Boukadida (Sousse, TN)
Objective: Methicilllin-resistant Staphylococcus haemolyticus
(MRSH) was increasingly important nosocomial pathogens
particularly in critically ill neonates. The aim of our study was
to establish if these infections are caused by endemic clone or by
incidentally occurring bacterial strains of this species.
Methods: Thirteen strains of MRSH according CA-SFM recom-
mendations and mecA+ (Murakami K. J.Clin.Microbiol 1991,
29:2240–4) has been collected during the period of survey (april
2004 to october 2004). Eleven strains come from different
pathological products of newborns hospitalized in a neonatal
intensive care unit of a public maternity hospital. Tow strains
come from paediatric and internal medicine wards were used as
control to ensure that endemic strains can be differentiated from
outbreak strains. All strains were identiﬁed with the Api-staph
method (Api bioMerieux). Strains have been characterized by
genotypage in pulsed-ﬁeld gel electrophoresis (PFGE variety
CHEF) after SmaI macrorestriction. Genomic proﬁles have been
interpreted according to Tenover criteria (J.Clin.Microbiol.1995 ;
33 :2223–2239).
Results: S. haemolyticus was quantitatively the second staphylo-
cocci (23.6 %) after S. epidermidis isolated in neonatology ward.
MRSH represent 85. 7 % of the total strains of S. haemolyticus
collected from the neonatology ward during the period of study.
The majority of the strains come from blood sample 7 (63.63%), 4
(36.36%) from pus and 1 (9%) from CSF. Eight resistant
antibiotyps proﬁles and 3 genotypic pattern according Tenover
criteria were individualized: type A, type B (with 3 subtypes),
and type C. The strains coming from paediatric ward present
pattern type B3, but strains coming from internal medicine ward
present distinct pattern.
Conclusion: MRSH is a major bacterium of nosocomial infec-
tion in neonatal intensive care unit. This bacterium is respon-
sible as shown in our study, of endemic multiclonal nosocomial
infections with a predominant clone.
P971
Staphylococcus haemolyticus bacteraemia in an
intensive care unit
M. Galie`, P. Carfagna, F. Taglietti, O. Capelli, G. Testa,
C. Santini (Rome, I)
Objectives: To analyse clinical and microbiological features of
bacteremias due to S. haemolyticus (SHB) acquired in an ICU.
Methods: All SHB in a 8-bed ICU, from Jan 2003 to Aug 2004
were retrospectively evaluated.
Results: S. haemolyticus was isolated from 21% of all positive
blood cultures and represented the 37.9% of the coagulase
negative staphylococci. Twenty-nine cases of SHB occurred
during the study period (5.6 episodes per 1000 patients-days).
All cases were hospital-acquired and occurred after a mean
hospitalisation of 24.5 days. The mean age was 68.4 years (range
20–90) and 16 patients (55.2%) were males. Twenty-eight
patients (96.5%) had a central venous catheter (cvc). All patients
received previously antimicrobial therapy. Thirteen patients
(44.8%) had polymicrobial bacteraemia. In 18 cases (62.1%) the
source of bacteraemia was the cvc. All isolates were resistant to
oxacillin and gentamicin, 94.3% and 34.3% were resistant to
ciproﬂoxacin and teicoplanin, respectively; all strains were
susceptible to vancomycin. Sixteen patients (55.2%) had sepsis,
3 (10.3%) severe sepsis, and 7 (24.7%), all polymicrobial, septic
shock.; in 3 patients (10.3%) SHB had no clinical signiﬁcance.
Twenty patients died (69%) and deaths were directly related to
SHB in 1 patient (3.4%), and partially related in 2 (6.8%). Nine
patients (31%) survived.The patient who died for SHB, devel-
oped a persistent cvc-related bacteraemia after a 6-week course
therapy for streptococcal endocarditis. S. haemolyticus become
resistant to teicoplanin during a teicoplanin-based therapy and
the patient died 47 days after the onset of bacteraemia. The 2
patients, in which death was partially related to SHB, had a
polimicrobial bacteraemia due to C. tropicalis and Enterococcus spp,
respectively, and died after 22 and 6 days respectively, for septic
shock, during adequate therapy. Among the 17 patients in
which death was not related to SHB, 15 (88.2%) received
adequate therapy that cleared the blood cultures, 2 patients
improved after the removal of cvc without antimicrobial
therapy.
Conclusions: S. haemolyticus is an emerging pathogen, respon-
sible of sepsis, frequently cvc-related; most of strains are
resistant to many antistaphylococcal agents currently used as
empiric therapy, thus constituting a clinical concern. Neverthe-
less, this pathogen shows a low virulence and is associated with
a low related mortality, probably representing a marker of
severe underlying diseases.
P972
Staphylococci from the skin of patients: changes
associated with treatment by isotretinoin
A. Thomas, R. Williams, N. Hepburn, T. Watts,
R. Dixon (Lincoln, UK)
Objectives: Isotretinoin, a retinoid has been used to treat
patients with moderate to severe acne despite the adverse
effects of mucosal surface drying and the contraindication of use
during pregnancy. In clinical practice, patients are frequently
prescribed systemic isotretinoin because they have not
responded to previous treatment with oral or topical antibiotics.
Broad-spectrum antibacterial therapy has nevertheless promo-
ted changes in the diversity and antibiotic resistance status of
the patients skin microbiota and we are studying the effect of
isotretinoin on these changes. Methods: The present study
investigated the recovery and analysis of skin organisms from 53
patients (mean age 23 y range 15–37y) before, during and after
treatment with a 16-week course of isotretinoin (1 mg / kg body
weight). The number of aerobic bacterial isolates (presumptive
Staphylococci) recovered from Baird-Parker agar from each of
three speciﬁc sites per patient were compared with age-matched
controls of healthy volunteers.
Results: Both patients and controls had generally similar
numbers of organisms on the nares, cheek and toe webs
before treatment, whereas all patients showed a signiﬁcant
reduction in Staphylococci recovered from one site during and
after 16 weeks of isotretinoin treatment. The majority of the
patients had a greater reduction (1–2 log) for the cheek site than
either nares or toe webs both of which showed minimal
reduction.
Conclusions: Preliminary results from this study show a
pronounced reduction in the number of presumptive staphylo-
cocci recovered from the treated group immediately following
isotretinoin compared to untreated controls. Since isotretinoin
has little known antibacterial activity against the Staphylococci
the observed reductions would suggest that the effect is
mediated through changes in the skin nutritional micro-envi-
ronment.
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Mechanisms of resistance in staphylococci
P973
Effect of erythromycin on the selection of
linezolid resistance in hypermutable and clinical
isolates of Staphylococcus aureus
S.E. North, M.J. Ellington, A.P. Johnson, D.M. Livermore,
N. Woodford (London, UK)
Objectives: Emergence of mutational resistance to linezolid
(lin) in Staphylococcus aureus has been associated with loss of
erythromycin resistance methylase (erm) genes, both in vivo and
in vitro. We tested the general validity of this claim, and
examined whether the emergence of lin resistance is delayed in
the presence of ery.
Methods: Six lin-susceptible S. aureus strains were used: 2
genetically-related, ery-resistant (ermC) and susceptible pairs of
EMRSA-15, also the isogenic pair RN4220 and its hypermutable
RN422mutS mutant, which harbours ermB. In 4 replicated
experiments, ery-susceptible and ery-resistant isolates were
grown on agar containing increasing concentrations of lin. In
addition, ery-resistant isolates were grown with 100 mg / L ery
and increasing concentrations of lin. The number of days for
isolates to develop the ability to grow in the presence of 6
mg / L lin was recorded. The absence of erm genes was checked
by PCR; MICs of lin and ery were determined by agar dilution,
and PFGE proﬁles of mutants were veriﬁed.
Results: Thirty-three mutants were obtained from the 4 experi-
ments; 24 from the 4 clinical EMRSA-15 isolates, 3 from RN4220
and 6 from RN422mutS. Lin-resistance emerged more slowly in
ery-resistant clinical isolates grown with lin and ery than with
the same isolates grown with lin alone: mean 20 days (SD 26.8)
to emerge on 6 mg / L lin versus 30 days (SD 18.4) in the
presence of lin and ery. Growing the hypermutable strain,
RN422mutS, in the presence of lin and ery did not delay the
emergence of lin-resistance (11 days with SD 8.7, in either case).
In the absence of ery selection, loss of erm with the emergence of
lin-resistance was only noted for one EMRSA-15 isolate in 1 of 4
experiments. All isolates grown in the presence of ery retained
erm determinants. Ery 100 mg / L did not supress growth of
ery-resistant strains and linezolid was stable within the ambit of
the long-selection experiments.
Conclusions: Growing the clinical isolates in the presence of ery
and lin slowed the emergence of lin-resistance. Thismerits further
study with lower, clinically-relevant concentrations of ery.
P974
In vitro selection of linezolid resistance in
hypermutable and wild-type Staphylococcus
aureus
S.E. North, M.J. Ellington, A.P. Johnson, D.M. Livermore,
N. Woodford (London, UK)
Objectives: Resistance to linezolid (lin) is rare, but can arise via
mutations in the 23S rRNA genes. We hypothesised (a) that
resistance would emerge preferentially in staphylococci with a
hypermutable phenotype engineered by mutations in the mutS
gene, and (b) that hypermutability might be co-selected with
linezolid resistance. MutS is part of the DNA mismatch repair
(MMR) system, which identiﬁes and corrects genome alterations
post-replication, thereby inﬂuencing the net mutation rate.
Method: Linezolid-resistant (LinR) mutants of Staphylococcus
aureus RN4220, its hypermutable mutS deletion mutant
RN4220mutS, harbouring an erythromycin resistance marker
gene (ermB), and a genetically-related pair of clinical isolates
were selected by repeated passage with increasing concentra-
tions of lin. Mutant parentage was conﬁrmed by PFGE and
susceptibility was tested by agar dilution. An ampliﬁed 694-bp
fragment of 23S rRNA genes was studied by sequencing and by
RFLP analysis. Frequencies at which LinR mutants yielded
variants resistant to fusidic acid and rifampin were calculated in
triplicate experiments.
Results: Seventeen LinR mutants (MICs 8–64 lg/ml) were
raised. Ten mutants had a G2447T mutation in their 23S rRNA
genes; 4, all from RN4220mutS, had G2576T, typically seen in
LinR gram-positive cocci from the clinic; 1 had T2504C; 2 had no
identiﬁable mutations. Curiously 5 / 7 RN4220mutS mutants
lost ermB during the course of the experiment, reverting to
macrolide susceptible. LinR mutants had mutation frequencies
for rifampicin and fusidic acid resistance comparable with those
of their parents (10–6 to 10–9), implying no co-selection of stable
hypermutability.
Conclusion: More LinR mutants were obtained from the
hypermutable (RN4220mutS) strain than from the wild type
strain, and G2576T mutants were only obtained from the
hypermutable organism. These data suggest hypermutability
facilitates the emergence of LinR, nevertheless, LinR mutants
derived from wild-type parents did not have elevated mutation
frequencies.
P975
Disproving the link between expression levels of
tcaA and mprF and clinical isolates of
glycopeptide-intermediate Staphylococcus aureus
M. Wootton, R.A. Howe, P.M. Bennett, A.P. MacGowan,
T.R. Walsh (Bristol, UK)
Objectives: The mechanism of resistance in Glycopeptide Inter-
mediate Staphylococcus aureus (GISA) and hGISA isolates is
unknown. However the inactivation of certain genes has been
shown to confer an increase in glycopeptide resistance. Two
genes, tcaA and mprF, when inactivated in GISA strains cause a
reduction in glycopeptideMIC.Overexpression of tcaA causes an
increase in teicoplanin susceptibility and so bothgenesmayplay a
role in the development of glycopeptide resistance. This study
aims to investigate the expression levels of tcaA andmprF in a set
of GISA, hGISA and glycopeptide-susceptible S. aureus (GSSA).
Methods: RNA was extracted from the following: 1 set of
clinically related (CR) GSSA and hGISA (LLA and LLE), 2 sets
of CR hGISA andGISA (PC1 and PC3, LIM1 and LIM3) harvested
during exponential phase growth (EX) and during exponential
phase growth in the presence of sub-MIC levels of vancomycin
(EXV). RNAwas extracted from a further hGISA,Mu3 andGISA,
Mu50 as well as 4 clinical GSSA strains. RT-PCR was performed
with customised primers and the products visualised by electro-
phoresis. Band intensity was taken as indicative of mRNA
quantity, and hence expression level, at time of cell harvest.
Results: The expression of tcaA is similar in all strains tested.
Each strain within the related strain sets all show similar band
intensities, despite differing glycopeptide resistance phenotype.
Both Mu3 and Mu50 also exhibited similar expression levels to
those found for all other GISA, hGISA and GSSA strains. Levels
of expression were not affected by the presence of sub-MIC
levels of vancomycin in any strain tested. Sequence analysis of
tcaA in these strains showed no mutations present as previously
thought. Expression levels of mprF were found to be strain
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speciﬁc. No difference in gene expression was found in the CR
related strain sets.
Conclusions: No reduction in expression levels of tcaA and
mprF were found to correlate with clinical strains exhibiting
higher glycopeptide resistance. Thus it it uncertain what role
tcaA ot mprF play with mediating glycopeptide resistance in
Staphylococcus aureus.
P976
Strain-speciﬁc expression levels of pbp4 exist in
isolates of glycopeptide-intermediate
Staphylococcus aureus (GISA) and hGISA
M. Wootton, R.A. Howe, P.M. Bennett, A.P. MacGowan,
T.R. Walsh (Bristol, UK)
Objectives: GISA and hGISA strains all have a characteristic
thickened cell wall with reportedly fewer cross-links. Fewer
peptidoglycan cross-links create increased D-ala-D-ala penta-
peptide termini and hence more vancomycin targets. PBP4 has
been shown to have both transpeptidase and D,D-carboxypept-
idase activity, cleaving terminal D-alanine residues from
un-cross-linked muropeptides. Reduced levels of PBP4 have
been reported in laboratory-generated GISA mutants and a few
clinical GISA strains. This study aims to investigate the
expression levels of pbp4 in a set of GISA, hGISA and
glycopeptide-susceptible S. aureus (GSSA).
Methods: RNA was extracted from the following: 1 set of
clinically related (CR) VSSA and hGISA (LLA and LLE), 2 sets of
CR hGISA and GISA (PC1 and PC3, LIM1 and LIM3) harvested
during exponential phase growth (EX), after overnight growth
(ON) and during exponential phase growth in the presence of
sub-MIC levels of vancomycin (EXV). RNAwas extracted from a
further 8 clinically unrelated (CU) GISA (including Mu50), 8 CU
hGISA (including Mu3) and 8 GSSA (EX). RT-PCR was per-
formed with customised primers and the products visualised by
electrophoresis. Band intensity was taken as indicative of
mRNA quantity at time of harvest and hence gene expression.
Results: The expression of pbp4 varies according to strain. The
band intensities of the related strain set LLA (GSSA) and LLE
(hGISA) reduce slightly with increasing intermediate vancomy-
cin resistance. However in two other CR hGISA and GISA (PC1/
PC3, LIM1/LIM3) strain sets no variation in expression was
observed. Both Mu3 and Mu50 exhibited lower pbp4 expression
than any other strain, with the presence of sub-MIC levels of
vancomycin reducing expression further. pbp4 expression was
found to be reduced in 3 other GISA and 1 other hGISA, which
showed lower band intensities than GSSA.
Conclusions: The reduced levels of PBP4 suspected to be
associated with reduced susceptibility to vancomycin in
S. aureus is not exclusive. The expression of pbp4 is reduced in
Mu50 and 3 clinical GISA, as reported previously. However 5
other GISA strains exhibit pbp4 expression levels similar to
GSSA isolates. Therefore pbp4 expression levels appear to be
strain speciﬁc and a lowered expression level is not an essential
requirement in the development of the GISA phenotype.
P977
Does vancomycin resistance emerge during the
treatment of methicillin-resistant Staphylococcus
aureus in respiratory tracts?
E.S. Kim, H.B. Kim, A. Huh, S.H. Eun, Y.S. Lee, B.N. Kim,
J.W. Jeong, D.H. Whang, B.-M. Shin, B.S. Kim, M.-D. Oh,
K. Choe (Goyang-si, Seoul, KOR)
Objectives: The prolonged use of vancomycin is known to be
the most important factor in inducing vancomycin resistance to
S. aureus. Methicillin-resistant S. aureus (MRSA) colonizing in
respiratory tracts might be chronically exposed to subtherapeu-
tic concentrations of vancomycin because the level of vancomy-
cin within pulmonary lining ﬂuids was much lower than the
concentration of serum. Despite the continuous use of vanco-
mycin MRSAs were still found to be presented in respiratory
specimens of some patients.
Methods: All MRSAs which had been continuously isolated in
respiratory specimens during vancomycin therapy were collec-
ted from Jul 2003–Mar 2004 at Seoul Paik Hospital. MRSAs were
screened on Brain Heart Infusion plates containing vancomycin
4 lg / mL (BHI-4) and 6 lg / mL (BHI-6) for vancomycin
resistance. Minimal inhibitory concentrations (MICs) were
determined by E-tests, agar dilution methods, and broth dilution
methods. The patterns of pulsed ﬁeld gel electrophoresis were
analysed.
Results: Nine patients and 27 isolates were assessed. Five
patients had pneumonia and four patients had other MRSA
infections. Twelve MRSAs were isolated from tracheal aspirates
and 15 from expectorated sputum specimens. The duration of
vancomycin use ranged from 7–22 days. Five isolates and one
isolate were cultured on BHI-4 and BHI-6, respectively; the
vancomycin MICs of these isolates revealed 3 lg / mL by
E-tests. The MICs from agar dilution methods and broth dilution
methods showed from 0.5–2 lg / mL.
Conclusion: Vancomycin resistance during the treatment of
patients did not develop.
P978
Bactericidal activity of vancomycin and
daptomycin tested against heterogeneous and
homogeneous vancomycin-intermediate S. aureus
(hVISA and VISA) strains
H. Sader, P. Rhomberg, R. Jones (North Liberty, USA)
Objective: To evaluate vancomycin (VAN) and daptomycin
(DAP) bactericidal activity tested against S. aureus strains with
decreased susceptibility to VAN (VISA and hVISA).
Methods: A total of 105 well-characterized S. aureus strains with
decreased susceptibility to VAN (88 hVISA and 17 VISA) as well
as 105 oxacillin-resistant wild-type (WT) S. aureus with VAN
MIC £ 2 mg / L (MRSA-WT; isolated in 2003) were susceptibil-
ity (S) tested by reference NCCLS broth microdilution method
against DAP and VAN. MBC values were assessed by plating
the entire volume of the broth from each well above the MIC for
each organism. The lowest concentration of antimicrobial agent
that killed ‡ 99.9% of the initial inoculum was deﬁned as the
MBC endpoint. Bactericidal action was deﬁned as a MBC/MIC
ratio £ 2 and tolerance was deﬁned as a MBC / MIC ratio ‡ 16.
Results: VAN MIC and MBC results for 3 subsets of S. aureus
strains are summarized in the Table. Only two-third of the
MRSA-WT isolates showed VAN MBC results £ 4 mg / L, and
for hVISA and VISA groups, only 19.3 and 0.0% of isolates had a
VAN MBC at £ 4 mg / L, respectively. Fourteen (13.3%), 61
(69.3%), and 17 (100.0%) strains respectively showed VAN MBC
result ‡ 32 mg / L among the MRSA-WT, hVISA, and VISA
groups. In contrast, all MRSA-WT and hVISA strains were
inhibited by £ 1 mg / L of DAP, while the VISA strains showed
slightly higher DAP MIC values (range, 0.5–4 mg / L). The
highest DAP MBC result was only 4 mg/L and 93.3% of isolates
showed a DAP MBC at £ 1 mg / L. Eight of 11 DAP MBC
results of 2 mg / L and all 3 MBC results of 4 mg / L were
observed among the VISA strains. DAP MBC / MIC ratio was
not signiﬁcantly affected by VAN susceptibility. All DAP MBC
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results were at the MIC or only 2-fold greater. 17.1% of MRSA-
WT strains, 69.3% of hVISA and all VISA strains showed a VAN
MBC / MIC ratio consistent with tolerance.
Conclusions: VAN showed bacteriostatic activity against the
majority of VISA and hVISA strains. VAN also had high rates of
tolerant MBC/MIC ratios, but DAP was highly bactericidal
against MRSA-WT as well as VISA and hVISA strains.
P979
Genetic basis of fusidic acid resistance in
staphylococci
A.J. O’Neill, G. Kahlmeter, A.S. Henriksen, I. Chopra (Leeds, UK;
Vaxjo, S; Copenhagen, DK)
Objectives: Fusidic acid resistance (fusR) in Staphylococcus
aureus usually results from acquisition of the fusB resistance
determinant, or from mutations in the fusA gene encoding the
drug target (Elongation factor G). Following a recent report of
fusR in S. intermedius, and the detection in our own studies of
fusR S. lugdunensis (unpublished), we have examined whether
resistance in these strains results from fusA / fusB-type mech-
anisms.
Methods: Standard methodology was employed for strain
identiﬁcation, susceptibility testing, Southern hybridization
(SH), PCR ampliﬁcation and DNA sequencing. Primers for
PCR ampliﬁcation of the previously-unsequenced S. intermedi-
us fusA gene were based on portions of the ﬂanking genes
(rpsG, tufA) that are conserved between B. subtilis and S. aureus.
Results: Three fusR S. lugdunensis (fus MIC = 4 ug / ml) and
two fusR S. intermedius (fus MIC = 2 ug / ml) were probed for
the presence of fusB by SH alongside their wild-type, fusS
counterparts (fus MICs of 0.064 and 0.125 ug / ml, respect-
ively). The fusR S. lugdunensis all carried fusB, but this gene
was not detected in S. intermedius, or in the fusS strains.
Furthermore, fusB appeared to be chromosomally-located,
since no hybridization was observed with puriﬁed plasmid
DNA. PCR analysis mapped fusB to a chromosomal region
upstream of the groEL gene, the same locus at which this gene
is carried in the epidemic fusR European S. aureus clone. To
examine whether mutations in fusA are responsible for fusR in
S. intermedius, PCR ampliﬁcation and sequencing of fusA from
the resistant and sensitive strains was performed. Relative to
fusS S. intermedius NCTC 11048, the resistant strains carried six
coding polymorphisms in fusA, although none of these
correspond to reported fusR mutations in the fusA gene of
S. aureus.
Conclusions: Fus resistance in recent strains of S. lugdunensis
results from carriage of the fusB determinant on the chromo-
some, probably acquired horizontally from fusR S. aureus
strains. The fusB gene was not detected in the S. intermedius
strains, although multiple fusA polymorphisms were identi-
ﬁed which may be responsible for the observed fusR pheno-
type.
P980
Analysis of mupA gene loci of high level
mupirocin resistant staphylococci isolated from
tertiary hospitals of Korea
J.I. Yoo, Y.S. Lee, E.S. Shin, J.K. Lee, B.S. Kim (Seoul, KOR)
Objectives: Methicillin-resistant S. aureus (MRSA) and methi-
cillin-resistant coagulase-negative staphylococci (MRCNS) are
the most important pathogens that cause nosocomial infections
worldwide. One of the few antibiotics which is still effective
against MRSA is mupirocin. But mupirocin-resistant S. aureus
has been increased since ﬁrst reported in 1987. And more than
5–10% of S. aureus isolated in tertiary hospitals in Korea was
reported to be high level mupirocin resistant. In this study, we
investigated the restriction fragment length polymorphism
(RFLP) type for mupA gene loci of plasmid DNA and
sequenced mupR plasmid containing mupA gene of high
level mupirocin resistant (MuH) staphylococci from tertiary
hospitals.
Methods: Susceptibility to antimicrobial agents including
mupirocin was tested by the disk diffusion and MIC of
mupirocin was determined by agar dilution method. The
plasmid-encoded mupA gene was detected by PCR. mupA
polymorphisms of plasmid DNA digested by Hind III, EcoR I,
and Cla I restriction enzymes was investigated with southern
hybridization using mupA probe. S. aureus isolate showing the
most prevalent RFLP type was conjugated by ﬁlter mating
method and selected the transconjugant showing only mup-
irocin resistant phenotype. The mupR plasmid of selected
transconjugant was puriﬁed and analysed the plasmid DNA
sequence.
Results: 9 MuH-staphylococci were isolated among the 680
staphylococci from tertiary hospital in Korea. MuH-MRSA
(6 isolates), S. haemolyticus (1 isolates), S. hominis (1 isolates)
and S. epidermidis (1 isolates) were isolated. 1.65kb mupA PCR
product was detected in plasmid of MuH isolate. All isolates
contained more than two plasmid molecules that were repeat-
edly puriﬁed with different efﬁciences. Three different poly-
morphs of the mupA loci were investigated. The most prevalent
mupA polymorph was 4.2kb EcoRI- 8kb HindIII-2.1kb ClaI
hybridizing fragment. The mupirocin resistant plasmid DNA
was about 52kb and IS257-mupA-IS257 sequence was located.
Conclusion: The high-level mupirocin resistant staphylococci
had the multiple plasmids of various size and the diverse RFLP
type suggested the variation of mupA gene loci. The mupR
plasmid contained transferable element such as IS257 with
mupA gene.
P981
Genetic basis of macrolide, lincosamide,
streptogramin resistance in coagulase-negative
staphylococci
S. Gatermann, T. Koschinski, S. Friedrich (Bochum, D)
Objective: In S. aureus erythromycin resistance is almost exclu-
sively caused by ermA or ermC genes whereas export of
macrolide antibiotics by msrA or inactivation of lincosamides by
linA is rare. Resistance may be inducibly (clindamycin appears
susceptible) or constitutively (clindamycin appears resistant)
expressed. During therapy of inducibly resistant strains
with clindamycin mutations may occur that render them
No. of isolates (cumulative %)
VAN
concentration
(mg/L)
VISA (17) hVISA (88) MRSA-WT(105)
MIC MBC MIC MBC MIC MBC
£0.5 - - - - 9 (8.6) 2 (1.9)
1 - - 9 (10.2) 3 (3.4) 84 (88.6) 38 (38.1)
2 - - 61 (79.5) 9 (14.9) 12 (100.0) 23 (60.0)
Susceptible 4 11 (84.7) - 18 (100.0) 5 (19.3) - 9 (68.6)
8 6 (33.3) - - 3 (22.7) - 15 (82.9)
16 - - - 7 (30.7) - 4 (86.7)
Resistant ‡32 - 17 (100.0) - 61 (100.0) - 14 (100.0)
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constitutively resistant. Therefore, in S. aureus, erythromycin
resistant isolates may be considered clindamycin resistant.
Much less is known about the basis of MLSB resistance in
coagulase-negative staphylococci (CoNS) but reportedly resist-
ance mechanisms other than methylation are more common. In
this case unconditional reporting of erythromycin resistant
strains as clindamycin resistant may lead to avoidance of
lincosamides and induce increased usage of glycopeptides. As
automated systems test for resistance to single antibiotics only
but not for induction it is relevant to identify cases that are not
correctly predicted by the software of these machines.
Methods: We tested 494 consecutive non-copy clinical strains of
CoNS. Species were identiﬁed with biochemical techniques;
unclear or equivocal results were resolved by sodA sequencing.
For phenotypic detection the disk approximation test with
erythromycin, clindamycin and lincomycin was used. Multiplex
PCR for erm genes and PCRs for the presence of msrA and linA
were conducted to detect the basis for resistance.
Results: Erythromycin resistance was found in 62% of the
isolates; three (0.6%) were resistant to lincomycin only. Of the
305 erythromycin-resistant strains, 50.8% were constitutively
clindamycin resistant, 24.3% were inducibly resistant, and 76
(24.9%) were non inducible. S. haemolyticus was most often
(91.2%) erythromycin resistant; S. epidermidis in 62.2% and
S. warneri in 53.5%. The ermC gene was most common (68.8%),
msrA (26.5%) was next, followed by ermA (5.5%) and ermB
(2.3%). No signiﬁcant differences in distribution of genes among
resistant species was seen.
Conclusions: Our work extends the data of others who ana-
lysed unspeciated CoNS only. The data indicate that owing to a
relatively high proportion of CoNS that harbour the exporter
unconditional reporting of erythromycin resistant isolates as
clindamycin resistant should not be done but relevant erythro-
mycin isolates should be tested for induction of clindamycin
resistance.
P982
Relationship between lysostaphin susceptibility
and cell wall thickness in a vancomycin-resistant
Staphylococcus aureus isolates
I. Alshami, J.P. Burnie, S.A.H. Awad (Manchester, UK)
Objectives: Lysostaphin is an antibacterial enzyme which is
speciﬁcally capable of cleaving the cross-linking pentaglycine
bridges in the cell walls of staphylococci. S. aureus cell walls
contain high proportions of pentaglycine, making lysostaphin a
highly effective agent against both actively growing and
quiescent bacteria. Relationship between lysostaphin suscepti-
bility, vancomycin susceptibility and cell wall thickness of
passage-selected vancomycin -resistant Staphylococcus aureus
isolates (VRSA) and their parent strains were studied in order
to investigate Characterization of isolates with decreased sus-
ceptibility to vancomycin.
Methods: The susceptibility of lysostaphin for six VRSA and
their parent strains were determined using the spectrophoto-
metric and the macrodilution methods. Spectrophotometric
determination of turbidity was measured as a decrease in
A620 during incubation of the isolates samples at 37C. MICs
were determined by a broth macrodilution method in cation-
adjusted Mueller-Hinton broth according to standards of the
National Committee for Clinical Laboratory Standards. Cell wall
measurement were determined using Transmission Electron
Microscopy.
Results: Determination of lysostaphin activity revealed that
there are signiﬁcant decreases in per cent reduction in turbidity
(activity of lysostaphin) of the VRSA. VRSA shown to be more
resistant to lysostaphin than parent strains. The MICs of
lysostaphin for the VRSA strains also increase. There were
either a 2 or 4 fold increases in the MIC to lysostaphin. Electron
Microscopy of the VRSA showed enhanced cell wall thickness,
uneven surfaces and irregular shape in contrast of the thin and
regular cell wall morphology of the parent strains. Those strains
acquiring the highest thickness in cell wall demonstrating the
highest resistant to lysostaphin.
Conclusion: The mechanism of lysostaphin resistance and its
relationship to vancomycin resistance remains unclear. It is
possible that the increase in cell wall thickness we observed
prevented lysostaphin access to all pentaglycine targets or
increased the number of cross-linkers requiring cleavage before
the strain could lyse.
Typing and epidemiology of MRSA
P983
SeqNet.org: network of laboratories for sequence
based typing of microbial pathogens
A.W. Friedrich, W. Witte, H. de Lencastre, W. Hryniewicz,
J. Scheres, H. Westh and the SeqNet.org participants
Objectives: SeqNet.org is an initiative of currently 27 laborat-
ories from 19 European countries in order to establish a
European network of excellence for sequence based typing of
microbial pathogens. The principle goal of SeqNet.org is to
establish unambiguous, electronic portable, easily comparable
typing data for local infection control and national and Euro-
pean surveillance of sentinel microorganisms. This will be
achieved (i) by harmonization of sequencing methods for
sequence based typing, (ii) by building capacity for DNA
sequencing in diagnostic microbiology, (iii) by establishing
quality control/quality assessment (QC/QA) for DNA sequen-
cing in diagnostic microbiology, (iv) by improving the general
access to sequence based microbial typing results and the
transfer of data at international level and (v) by dissemination of
the projects results through a web-portal.
Methods: Creation and distribution of a consensus document
detailing the needed harmonization of sequencing technology in
diagnostic microbiology will be followed by a certiﬁcation
program for sequence based typing, using methicillin-resistant
S. aureus (MRSA) as a prototype organism.As typingmethod spa-
typing will be used. Five strains, 5 DNAs, and 5 forward and
reverse chromatogram ﬁles of well characterized MRSA strains
will be distributed to all participating laboratories. An annual
proﬁciency testing for sequencebased typingofMRSAisplanned.
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Results: At the kick-off meeting in Mu¨nster, Germany
(November 2004) the participants decided to produce docu-
ments detailing the needed certiﬁcation and annual proﬁciency
tests (external QC) as well as the needed internal quality
procedures for sequence based typing of MRSA. The develop-
ment of a SeqNet.org web-portal and the networking of the
partners by the Ridom StaphTypeTM software was decided.
Thereby, SeqNet.org already achieved a fast cross-border detec-
tion of special clones, e.g. S. aureus harbouring the Panton-
Valentine-Leucocidine (PVL) that are in Europe often associated
with spa t044 and ST80.
Conclusion: The SeqNet.org initiative is a vivid European-wide
network of laboratories for sequence based typing of microbial
pathogens. It generates high quality typing data that are
available on the ﬂy to all participants and the public through
the web- portal. Moreover, the SeqNet.org typing data can
already be used for trend analysis and early warning algorithms.
Other laboratories are welcome to join this initiative.
P984
A prevalence study on carriage of methicillin-
resistant Staphylococcus aureus in a Finnish
nursing home
A.-M. Kerttula, O. Lyytika¨inen, A. Virolainen-Julkunen,
H. Finne-Soveri, N. Agthe, J. Vuopio-Varkila (Helsinki, FIN)
Objectives: Due to the increasing problem of MRSA in Finnish
long-term care facilities, we carried out a prevalence study in the
largest nursing home in Helsinki metropolitan area. Of the
residents, 76 % were females, the mean age was 83 years and
62% suffered from dementia. The objective was to study MRSA
colonization rate in such setting. In addition, the role of
screening sites, and use of broth enrichment culture on sensi-
tivity to detect S. aureus was analysed.
Methods: Of the 25 available wards, 9 such wards were chosen,
where at least one of the residents had either indwelling catheter
or open skin lesions but no previously known MRSA contacts.
The patients volunteered had their nostrils, throats, perineums,
skin lesions, and catheter exit sites swabbed, and catheter urines
cultured. The specimens were cultured onto the non-selective
(blood) and selective (ORSAB) agar, with or without enrichment
in salt-containing trypticase soy broth (TSB). S. aureus was
identiﬁed by routine methods and methicillin-resistance detec-
ted by oxacillin disk diffusion, and MIC E-tests, GenoType
MRSA -test (Hain Lifescience, Germany) was used for MRSA
conﬁrmation. MRSA genotypes were characterized by pulsed-
ﬁeld gel electrophoresis (PFGE).
Results: Total of 663 specimens (210 from nostrils, 197 throats,
207 perineums, 24 skin lesions, 9 catheter exit sites, and 16 from
catheter urines) were obtained from 213 patients. 165 samples
(25%) from 94 patients (44%)were positive for S. aureus, and three
samples (0.4%) from two (0.9%) patients were positive forMRSA.
Two different MRSA strains were found; a non-multiresistant
MRSA strain from the perineum of one patient and a multidrug-
resistant strain both from the nostrils and catheter exit site of
another, respectively. Of 165 S. aureus isolates, 26 (16%) were
found only from other sites than nostrils (25 MSSA, and 1 MRSA
from a total of 25 patients). TSB enrichment detected an
additional 29 (4 %) S. aureus isolates (28 MSSA, and 1 MRSA).
Conclusions: Carriage of S. aureus was high but prevalence of
MRSA low in this long term care facility setting. Omission of
surveillance sampling sites other than nostrils would have
missed 12% (24 MSSA and one MRSA case) of S. aureus carriers.
Addition of the broth enrichment step resulted in ﬁnding 7 (3%)
additional S. aureus-positive carriers.
P985
Molecular epidemiology of an outbreak caused
by methicillin-resistant Staphylococcus aureus in
a health care ward and associated nursing home
A.-M. Kerttula, O. Lyytika¨inen, J. Vuopio-Varkila, N. Agthe,
M. Broas, H. Ja¨gerroos, A. Virolainen-Julkunen (Helsinki,
Rovaniemi, FIN)
Objectives: An outbreak of MRSA with 13 cases occurred in a
health care ward and an associated nursing home of a small
municipality in Northern Finland during autumn 2003. The
MRSA strains were shown to possess a new pulse-ﬁeld gel
electrophoresis (PFGE) and multi-locus sequence typing (MLST)
proﬁle. The molecular epidemiology of MRSA screening results
obtained by the local health authorities during 2003–4 were
compared to the results of a point-prevalence survey in
February 2004.
Methods: Health care ward (34 beds) and nursing home
(46 beds) with 76 participating residents were studied. Infor-
mation on MRSA screening samples from 2003–2004 was asked
from the local clinical microbiology laboratory. In addition, all
the patients had their nostrils, skin lesions, and urinary catheters
swabbed (76. 10, and 4 samples, respectively) for MRSA in
February 2004. The samples were cultivated onto MRSA-
selective and non-selective media. Oxacillin-resistance was
determined by MIC-test, mecA-gene conﬁrmed by PCR, and
S. aureus genotypes characterized by PFGE.
Results: Twenty-four of 76 patients (32%) were S. aureus
carriers; 5 (7%) were positive for MRSA. Two of the MRSA
isolates were from patients recorded positive in autumn 2003,
and 3 from new patients found to be carriers of another Finnish
epidemic MRSA strain. Two of these were also methicillin-
sensitive S. aureus (MSSA) carriers but the MSSA strains were of
another genotype than the MRSA carried by the same person.
All 5 isolates were resistant to oxacillin only, and two isolates,
which expressed oxacillin MIC:s 2 and 4–6 mg / l, did not grow
on the oxacillin screening agar plate having oxacillin 2 mg/l.
A total of 25 MSSA strains were found: from the patients never
found to be positive for MRSA, 3 of the MSSA strains were
genotypically related to the new MRSA outbreak strain, and 3 to
the another epidemic MRSA strain. In addition, 12 MSSA strains
were related to other epidemic MRSA-strains, and 7 were
sporadic strains.
Conclusions: The original MRSA outbreak was found to be
conﬁned, but 3 new MRSA cases not related to the epidemic
were detected by repetitive screening. The current MRSA
screening methods used routinely may not be sensitive
enough for strains possessing low-level oxacillin resistance.
P986
Evaluation of Staphylococcus aureus nasal
carriage rate among patients on haemodialysis -
isolation of community-acquired methicillin-
resistant Staphylococcus aureus
A. Szczepanik, M. Koziol-Montewka, I. Baranowicz, L. Jozwiak,
A. Ksiazek, D. Kaczor, Z. Al-Doori, D. Morrison (Lublin, PL;
Glasgow, UK)
Nasal carriage of Staphylococcus aureus (SA) appears to play a
key role in the pathogenesis of infection, particularly in patients
on haemodialysis. Compounding the problem is dissemination
of methicillin-resistant Staphylococcus aureus (MRSA) and chan-
ging epidemiology of this microorganism. MRSA, besides
having established itself as a major nosocomial pathogen, has
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also begun to appear outside hospital settings as community-
acquired MRSA (CA-MRSA).The aim of the study was evalu-
ation of SA nasal carriage rate in haemodialysed patients and
molecular analysis of cultured isolates.
Methods: Nasal swabs were collected from 43 haemodialysed
patients. SA isolates were identiﬁed using conventional diag-
nostic methods. Antibiotic susceptibility was determined using
the Vitek automated system and the disc diffusion method
according to recommendations given by the National Reference
Centre for Antimicrobial Susceptibility Testing in Poland. SA
isolates were analysed by Pulsed Field Gel Electrophoresis
(PFGE) and PCR assays for staphylococcal cassette chromosome
mec (SCCmec) typing and detection of the nuc and pvl genes.
Results: 12 (27.9%) patients were SA nasal carriers, but only 1
MRSA isolate was identiﬁed. The carrier of MRSA was a
56–year-old male suffering from chronic renal failure and
malignancy (true polycythaemia). The patient had a history of
previous hospitalization. The MRSA strain was resistant only to
B-lactams and tetracycline. The remaining SA isolates were
methicillin-susceptible (MSSA) and demonstrated high rates of
resistance to penicillin (81.8%) and tetracycline (63.6%). Molecu-
lar analysis revealed that the MRSA strain had genetic markers
of CA-MRSA: SCCmec type IV, a PFGE pattern corresponding
to the common European CA-MRSA (MLST Type ST80) and the
pvl locus encoding for Panton-Valentine leukocidin toxin.
Among MSSA isolates, several genotypes were identiﬁed by
PFGE, with the lack of one speciﬁc colonizing strain.
Conclusions: To our knowledge, this is the ﬁrst report of
CA-MRSA in Poland. The results of the study indicate that
colonization and the increased risk of subsequent invasive
infection associated with signiﬁcant pathogenic potential of
CA-MRSA can occur among persons with predisposing risk
factors such as patients on haemodialysis. Although the rate of
MRSA colonization was low among examined patients, the risk
of endogenous infections associated with MSSA carriage must
also be considered.
P987
Expansion of a single multiresistant methicillin-
resistant Staphylococcus aureus clone carrying a
variant of SCCmec type III in a university
hospital
A. Szczepanik, M. Koziol-Montewka, D. Kaczor, Z. Al-Doori,
D. Morrison (Lublin, PL; Glasgow, UK)
The purpose of the study was molecular characterization of
methicillin-resistant Staphylococcus aureus (MRSA) isolates cul-
tured from patients treated in various wards of the University
Hospital in Lublin, Poland.
Methods: 16 MRSA isolates cultured from 11 hospitalized
patients were analysed. Antibiotic sensitivity testing was per-
formed using the Vitek automated system. Phenotypic identi-
ﬁcation of the isolates as S. aureus resistant to methicillin was
conﬁrmed by a multiplex PCR assay (S. aureus PCR diagnostic
kit; DNA Gdansk, Poland) to detect the nuc and mecA genes,
respectively. The MRSA were characterized by Pulsed Field Gel
Electrophoresis (PFGE), 16S-23S rRNA spacer length poly-
morphism analysis and Oliveira and de Lencastre multiplex
staphylococcal cassette chromosome mec (SCCmec) PCR assay.
Results: All MRSA isolates were positive for the nuc and mecA
genes. The isolates were deﬁned as multiresistant - in addition
to resistance to B-lactams, they demonstrated resistance to
ciproﬂoxacin, tetracycline, erythromycin and gentamicin. Resist-
ance to clindamycin and trimethoprim/sulfamethoxazole was
detected in 10 (62.5%) and 1 isolate (6.25%), respectively. The
isolates were susceptible to rifampin and vancomycin. They
were genetically identical and shared common PFGE and 16S–
23S rRNA spacer length polymorphism proﬁles. By SCCmec
typing all MRSA harboured a presumed new variant of SCCmec
type III. The isolates were positive for the 162 - bp internal
fragment of the mecA gene, Locus C (mecI, 209-bp) and Locus G
(303-bp)corresponding to the plasmid pT181 insertion. The
pattern differed from the typical SCCmec type III pattern by the
lack of Locus E (243-bp) and Locus F (414-bp).
Conclusions: The results of the study are indicative of the
expansion of a single, multiresistant MRSA clone in various
wards of the University Hospital. The clone harboured a
presumed new SCCmec type III variant.
P988
Epidemiological typing of MRSA using spa
sequencing and PFGE
A.C. Petersson, S. Haeggman, B. Olsson-Liljequist,
H. Mio¨rner (Lund, Solna, S)
Objectives: The aim of the study was to evaluate the resolution
of spa sequencing and PFGE in epidemiological typing of MRSA
isolated within a low prevalence region.
Methods: MRSA isolates (180 isolates from 180 persons), collec-
ted at CMI in Lund between January 2000 and July 2004, were
subjected to epidemiological typing. For spa typing the poly-
morphic X-region of protein A was ampliﬁed and sequenced
using primers corresponding to nucleotides 1094–1111 and 1492–
1475 or 1533–1516 of GenBank accession no. J01786. The Ridom
StaphType software was used for sequence interpretation. PFGE
was performed on SmaI digested DNA using S. aureus NCTC
8325 as standard reference for gel normalization. The PFGE
patterns were analysed using the BioNumerics software. Dice
coefﬁcient was used for band matching and UPGMA for
dendrograms. Each distinct band pattern was given a speciﬁc
designation. Epidemiological data was obtained from the infec-
tion control unit at Lund University Hospital. The Simpson’s
diversity index with 95 % conﬁdence interval was used to resolve
the resolution of the two typing methods.
Results: Eighty-three isolates (46 %) were most likely acquired
abroad and 58 (32 %) in Sweden (24 of which were considered to
be community-acquired and 34 health care related). For 39 (22
%) of the isolates the origin could not be established. Epidemi-
ological data allocated the 180 isolates to 107 unrelated episodes.
Typing identiﬁed 39 spa types and 61 distinct PFGE patterns.
The number of episodes where epidemiological data and typing
results were concordant is presented in the table. PFGE showed
higher discrimination than spa typing when looking at the
single case episodes (44 % of these episodes were identiﬁed by
unique PFGE patterns and 19 % by unique spa types). Both
techniques correctly identiﬁed a majority of the episodes
including two or more persons (spa typing 97 % (31/32),
PFGE 84 % (27/32)). The resolution of the two typing methods
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was equally high, 98.3–99.3 % for spa typing and 98.4–99.5 % for
PFGE, when combined with epidemiological data.
Conclusion: In the present study spa typing gave equivalent
resolution to PFGE, and is well suited for epidemiological
typing of MRSA in a low prevalence region with a broad
spectrum of strains.
P989
Resistance phenotypes of methicillin resistant
S. aureus in a Greek hospital during 1998–2003
P. Panagiotou, E. Panagiotidou, E. Xatzilakou, A. Tatsiopoulos,
B. Nikolopoulou (Athens, Thessaloniki, GR)
Objective: The prevalence of newmulti-drug resistant strains of
methicillin-resistant S. aureus (MRSA) in recent years, led us to
evaluate the epidemiology and resistance phenotypes of MRSA.
Methods: We studied 900 non-duplicate strains of MRSA of a
total of 2224 strains of S. aureus isolated during the period 1998–
2003 in General University Hospital. The identiﬁcation was
based on the slide-coagulase test and the susceptibility of all
isolates to oxacillin and other antimicrobial agents was tested by
the disk-agar diffusion method as standardized by the NCLLS.
The following antimicrobial disks were used: oxacillin, gentam-
icin(G), erythromycin(E),vancomycin(V),co-trimoxazole(S), cipro-
ﬂoxacin(C), rifampicin(R), fusidic acid(F), clindamycin(L), and
chlorampenicol(H).
Results: We document that the proportion of methicillin resist-
ant isolates had progressively increased from 31% of total
S. aureus in 1998 to 52% in 2003. The majority of MRSA strains
were recovered from wound sites (n = 267), respiratory speci-
mens (n = 219) and blood cultures (n = 116). The highest
proportion of MRSA were observed in intensive care units
(80% S. aureus), in medical (41%) and surgical units(37%). MRSA
strains susceptible to all antibiotics had decreased remarkably
from 35% in 1998 to 14.5% in 2003. Eight main different
antibiotic resistance patterns were identiﬁed among the MRSA,
with the commonest being that exhibiting multiple resistance to
gentamicin, erythromycin, clindamycin, co-trimoxazole, ciproﬂ-
oxacin, rifampicin and fusidic acid (phenotype GELSCRF). This
phenotype had a mean incidence of 40.7% of all MRSA during
the period 1998–2003 and an evolution ranging from only 3% in
1998 and 15% in 2000 to the alarming proportion of 54% in the
last 2 years. The multi-drug resistant pattern was found mainly
in ICU patients (73% of MRSA) and secondly in patients of
medical (47%) and surgical (42%). Resistance to chlorampenicol
was detected only in 3.5% of MRSA and no MRSA strain was
found to be resistant in vancomycin.
Conclusions: A progressive increase of MRSA is well documen-
ted. Since 1999, the predominance of a well-deﬁned multidrug
resistance hospital strain (susceptible only to glycopeptides and
chlorampenicol) is observed. The prevalence of multi resistant
strains leads to an increase in mortality and morbidity and
demands appropriate control, surveillance procedures and
awareness for development of glycopeptide resistance.
P990
Phenotypical differences in antibiotic resistance
between MRSA and MSSA strains isolated from
clinical samples of patients treated at the clinics
of the Semmelweis University
K. Kristo´f, Z. Szabo´, V. Cser, S. Kardos, A´. Ghida´n,
F. Rozgonyi (Budapest, HUN)
Objectives: The aim of this study was to reveal any signiﬁcant
difference in the co-resistance to antistaphylococcal agents
between methicillin-resistant (MRSA) and methicillin-sensitive
(MSSA) strains of S. aureus. In this presentation the results of the
antimicrobial susceptibility testing of a total of 4097 S. aureus
strains isolated from clinical speciments between 1 January 2001
and 31 December 2003 are shown.
Methods: The identiﬁcation of the S. aureus strains was per-
formed by traditional and molecular methods (catalase, coagu-
lase, nucA). The antibiotic susceptibilty tests were carried out by
disc diffusion methods according to the NCCLS recommenda-
tions, and the multiplex PCR method was used for detecting the
mecA gene. The phage typing was carried out with both
conventional and MRSA phages.
Results: In the whole examination period 7.8% of the total
S. aureus isolates proved to be MRSA. A continuous increase in
the incidence of MRSA was found in the period examined (2001:
3.73%, 2002: 7.08%, 2003: 10.59%). The coresistance of MRSA
strains to a variety of antimicrobials was signiﬁcantly higher
than that of the MSSA strains. The ratios of coresistance of
MRSA/MSSA strains were as follows: erythromycin, 92/13;
clindamycin, 90/2; ciproﬂoxacin, 89/1; doxycycline, 98/1; mup-
irocin, 7/1; gentamicin, 69/2; tobramycin, 76/2; amikacin, 65/7;
and netilmicin, 22/1. But the resistance rate was invert to
trimethoprim+sulphamethoxazole, 0.5/98. Neither vancomycin
nor teicoplanin nor linezolid resistant strains were found. Phage
type 623 and 629 predominated the MRSA strains with 53% and
33%, respectively.
Conclusion: During the whole examination period the number
and the proportion of the MRSA isolates increased and also their
resistance against different kinds of antibiotics. There was found
a signiﬁcant difference between the MRSA and MSSA isolates in
the coresistance to antistaphylococcal drugs. Vancomycin, tei-
coplanin and linezolid were fully effective.
P991
Antibiotic resistance of Staphylococcus aureus: a
Tunisian multicentre study 1999–2003
R. Ghozzi, F. Mahjoubi, H. Smaoui, W. Jouahia, A. Hammami,
A. Ke´chrid, A. Ben Hassen, S. Ben Redjeb (Tunis, TN)
Staphylococcus aureus is an important human pathogen related to
its ability to develop resistance to many antimicrobial agents.
Methicillin resistance of S. aureus (MRSA) has become a major
public health problem especially in nosocomial infectious. More
over community acquired MRSA is a growing concern, the rate
of MRSA vary importantly within countries, the highest rates
were reported especially in Southern European countries. A
multicentric study was done to establish antimicrobial resistance
of S. aureus isolated from clinical specimens of hospitalized
patients over ﬁve years period (1999–2003). S. aureus was
identiﬁed by conventional methods and antibiotic susceptibility
testing was performed by disk diffusion method according to
NCCLS standards. A total of 5186 strains of S. aureus were
collected, they were recovered mainly from pus (60%), blood
cultures (15%), respiratory samples (8%) and urines (7%). 34% of
the strains were from in medicine, 18% from surgery, 16% from
orthopaedics, 14% from paediatrics and 13% from intensive care
units. The rates of resistance to different antibiotics was 15% to
oxacilline,9% to gentamicin, 23% to amikacin,8% to oﬂoxacin,
23% to erythromycin and 8% to clindamycin. All isolates were
susceptible to vancomycin. According to this data the rate of
MRSA remained relatively low (< 20%) with no signiﬁcant
change during this time period, however, MRSA presented high
rates of associated resistance to gentamicin (48%), to amikacin,
(91%) to erythromycin (38%), to clindamycin (20%), to oﬂoxacin
(40%) and to trimethoprim- sulfamethoxazole (33%).MRSA were
not of great concern in our country and meticillin remains an
effective antibiotic for treatment of S. aureus infections.
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P992
Characterisation of gentamicin-susceptible
strains of methicillin-resistant Staphylococcus
aureus in two Spanish hospitals
C. Potel, M. Alvarez, C. Lopez-Melendez, I. Otero (Vigo, E)
Objectives: Characterize gentamicin-susceptible methicillin-
resistant Staphylococcus aureus(GS-MRSA)by two molecular
typing methods. Find out whether some GS-MRSA clones are
related to GR-MRSA. Describe the spread of these clones.
Methods: One hundred and twelve SAMR were isolated in two
hospitals between 1997–2001. The epidemiological relatedness
was studied by repetitive element sequence-based PCR and coa
gene restriction fragment length polymorphism. The genes
ant(4´) and aac(6´)-aph(2), that codify two aminoglycoside modi-
fying enzymes, were detected by PCR.We analysed the gentam-
icin consumption and its relation with the emergence of GS-
MRSA.
Results: Thirty nine strains were GS-MRSA. The 80% of these
GS-MRSA belonged to two epidemic clones, the clone A was
tobramycin sensitive and the clone B was tobramycin resistant.
The clone A was only isolated at hospital-I and was replaced by
an epidemic GR-SAMR clone (clone C). The clone B was only
isolated at hospital-II and displaced the clone C.GR and
GS-MRSA strains were not genetically related. The aac(6¢)-
aph(2) gene was detected in the GR-MRSA strains (clon C) but
not the ant(4¢) gene. In the clone B only the ant(4¢) gene was
detected. The gentamicin consumption remained stable in both
hospitals during the studied period.
Conclusions: The GS-MRSA clones were not linked to
GR-MRSA. Therefore, the emergence of GS-MRSA was due to
new MRSA clones that have an epidemic mode of transmision.
Moreover, the clone B (GS-MRSA and tobramycin resistant) did
not come from GR-MRSA by means of the loss of the aac(6¢)-
aph(2) gene. The gentamicin consumption was not related with
the evolution of the different studied clones. *Complejo Hospi-
talario Universitario de Vigo and Clinica Fatima de Vigo
P993
The prevalence of mupirocin resistant MRSA of
long-term care facilities
J.I. Yoo, E.S. Shin, J.O. Cha, J.K. Lee, S.H. Eun, B.S. Kim,
Y.S. Lee (Seoul, KOR)
Objectives: The long-term care facilities (LTCFs) patients are
those with serious underlying disease, poor functional status,
wounds such as pressure sores, invasive devices of urinary
catheters. There is increasing concern about the emergence of
resistance to antimicrobial agents including methicillin resistant
S. aureus in LTCFs and mupirocin has been used in LTCFs to
prevent the occurrence and spread of MRSA. But the prevalence
of mupirocin resistant MRSA in LTCFs has not been known yet
in Korea. In this study, we investigated the prevalence of
mupirocin resistant MRSA from LTCFs and their molecular
epidemiological analysis.
Methods: 749 specimens were obtained from 632 patients of 8
LTCFs from July to August 2002. Specimens were cultered on
staphylococcal medium and species were identiﬁed by PCR and
biochemical test. Antimicrobial susceptibility tests to 12 antibi-
otics were performed by disc diffusion method, MICs of
oxacillin, mupirocin were conﬁrmed by agar dilution method
and E-test method. Mupirocin resistant isolates were divided
into low level mupirocin resistant (MuL) and high level
mupirocin resistant (MuH) by according to criteria £ 256 lg/
ml and ‡ 512 lg / ml, respectively. PFGE and RFLP typing
were performed for molecular epidemiological analysis of
mupirocin resistant isolates.
Results: 365 S. aureus (48.7%) were isolated from the LTCFs
specimens and 259 isolates (70.9%) were identiﬁed resistant to
oxacillin. mecA gene was detected in all tested 259 MRSA
isolates with MICs of 16 - >128 lg / mL. The mupirocin
resistance was 19.3% range from 1.3% to 72.4% of MRSA
depending on LTCFs. In one LTCF, 20 out of 39 MRSA isolates
were MuH including 15 isolates showing the same PFGE
pattern. In the other one LTCF, 19 out of 29 MRSA isolates
were MuL with the same PFGE pattern in 17 isolates. Among 26
MuH MRSA detected in 4 LTCFs of 8 LTCFs, the most
predominant mupA RFLP type was 4.2 kb EcoRI-8 kb HindIII-
2.1 kb ClaI (22 isolates) hybridizing fragments.
Conclusion: Mupirocin resistant MRSA in LTCFs was 19.3%,
range from 1.3 to 72.4%. And it is supposed that there was
mupirocin resistant MRSA outbreak in two LTCFs. This sug-
gests that the mupirocin resistant MRSA is spread in LTCFs and
need the prevention strategy.
P994
Epidemiological relationship of methicillin-
resistant Staphylococcus aureus on an
intensive care unit using staphylococcal
interspersed repeat units
K.J. Hardy, B.A. Oppenheim, F. Gao,
P.M. Hawkey (Birmingham, UK)
Objectives: To establish if variable number tandem repeats
could be used to investigate the epidemiology of endemic MRSA
on an ICU during 2 different study periods.
Methods: During two eight month periods, all patients admit-
ted for > 48 h to a general ICU were screened 3 times a week for
MRSA. Multiple isolates from each patient were then epidem-
iologically typed using 7 previously described variable number
tandem repeats (VNTRs) which have been termed staphylococ-
cal interspersed repeat units (SIRU) The numbers of repeats at
each locus were determined and a 7 digit proﬁle generated. The
ability of SIRU to identify predominant strains and transmission
events was compared with pulse ﬁeld gel electrophoresis
(PFGE). Strains were deﬁned as having >1 band difference
(PFGE) and >1 repeat number at any loci.
Results: During the two eight month periods 56 / 215 (26%)
and 61 / 197 (31%) patients were colonised with MRSA. A total
of 19 different SIRU and 21 different PFGE proﬁles were
observed overall, with 7 SIRU and 9 PFGE proﬁles being present
in the 1st study period only, and 3 SIRU and 4 PFGE only
present in the 2nd. The most predominant SIRU and PFGE
proﬁles were the same during both study periods. Forty eight
patients in the 1st study period and 49 in the 2nd had a high
degree of similarity with the UK EMRSA-15 by both SIRU and
PFGE. Fifteen subtypes of EMRSA-15 were identiﬁed by SIRU
and PFGE. However, within indistinguishable PFGE proﬁles
variation within the SIRU was observed, and similarly within
the same SIRU variation within the PFGE type was observed.
Seven and 13 patients in the 1st and 2nd had a high similarity to
the UK EMRSA-16. Dual colonisation with different MRSA
strains was observed in 7 patients.
Conclusion: SIRU provides a rapid transportable typing
method for typing epidemiologically related isolates within an
endemic ICU setting. It has discriminatory powers similar to
that of PFGE, thereby allowing identiﬁcation of transmission
events.
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P995
Genomic backgrounds of major methicillin-
resistant Staphylococcus aureus epidemic clonal
lineages present in fully susceptible isolates
collected in the 1960s in Denmark
A.R. Gomes, H. Westh, M. Chung, H. de Lencastre
(Oeiras, P; Copenhagen, DK; New York, USA)
Objectives: Most methicillin-resistant Staphylococcus aureus
(MRSA) isolates identiﬁed among blood isolates collected in
Denmark between 1957 and 1970 belonged to either phage
group III or the closely related 83A complex and had a PSTM
antibiotype. Recently, some of these strains were shown to
belong to the same genetic backgrounds as contemporary
epidemic MRSA by MLST and spa typing and Danish MSSA
strains from the 60s with a PST antibiotype were proposed to
have been the recipients of the mecA gene in those lineages.
Among these were strains that belonged to ST247, ST5 and ST30,
a single locus variant of ST36. In this study we sought to
investigate the genetic backgrounds of isolates that were fully
susceptible or resistant to penicillin only from phage group 83A
in order to try to trace the evolutionary trajectory of those MRSA
lineages. We also studied MSSA and MRSA from other phage
groups in order to investigate whether these were associated
with genetic backgrounds that reached an evolutionary dead-
end.
Methods: Eighty-two MSSA and MRSA strains isolated from
the blood between 1957 and 1973 in Denmark were character-
ized by MLST, spa and SCCmec typing.
Results: Most susceptible or P-resistant isolates from phage
groups 83A or III belonged to ST8 or ST5, while four isolates
were ST254, the ﬁrst MSSA strains identiﬁed with this genetic
background. STs 30, 45 and 25 were represented by MSSA
strains from other phage groups, which also included several
singletons. ST250 was the most common genotype among
nontypeable MRSA isolates.
Conclusions: Representatives of some of the current major
epidemic MRSA lineages were identiﬁed among fully suscept-
ible isolates collected in the 60s suggesting that these were
lineages which carried genetic traits important for a superior
epidemicity before acquisition of antibiotic resistance while
singletons may represent less ﬁt genotypes. In particular, ST254
MSSA provided the ﬁrst evidence to the existence of this
derivative of ST8 before the introduction of the mecA gene.
P996
Multidrug resistance among methicillin-resistant
Staphylococcus aureus in long-term care facilities
in Greece
V. Grammelis, G. Tsekes, D. Chalkiadaki, G. Salpigktis,
K. Orlandou, K. Kanellakopoulou, H. Giamarellou,
M.C. Lazanas (Athens, GR)
Objective: A multicentre point-prevalence survey was conduc-
ted in order to determine the prevalence and risk factors for
colonization with multidrug-resistant (MDR) MRSA in residents
of LTCF in Greece estimate the corresponding rates of antimi-
crobial resistance (A´R)
Methods: A total of 28 LTCF were randomly selected from the
public sanitation list of Attica province. Nasopharyngeal and
wound samples were collected from 862 elderly residents. We
chose randomly 30% of the existing population from each LTCF
(minimum sum 35 residents). Cultures and susceptibilities
were performed, following NCCLS guidelines. The minimal
inhibitory concentrations (MICs) of methicillin-susceptible
S. aureus (MSSA) and MRSA to 15 alternative antibiotics were
also compared. Results were analysed using either the Fischer’s
exact or chi-square test. Risk ratios and p values were calculated.
Results: 905 samples were collected and 286 strains of S. aureus
were isolated. From them, 214 (74.8%) were MSSA and 72
(25.2%) MRSA. In contrast to MSSA, most of MRSA isolates
(90% versus 22%) were MDR. Among MDR-MRSA, 49.6% were
resistant to chloramphenicol, 39.4% to erythromycin and 34.2%
to clindamycin. Also, the A´R to gentamicin and ciproﬂoxacin
were 29.5% and 19.2% respectively. The most effective agents
were linezolid and vancomycin, to which no resistant strains
were found, followed by quinupristin/dalfopristin, fucidic acid,
trimethoprim-sulfamethoxazole and rifampicin with A´R lower
than 10%. Overall, MRSA vs. MSSA exhibited a signiﬁcantly
higher incidence of resistance to 10 out of the 15 antibiotics
examined. In multivariate analysis, colonization with MDR-
MRSA was signiﬁcantly associated with recent hospitalization
(p = 0.001), poor functional status (p = 0.001), decubitus ulcers
(p = 0.01) and feeding tube (p = 0.01).
Conclusions: 1. Colonization with MDR-MRSA is worrisome in
Greek LTCF 2. Macrolides and lincosamydes should be used
with caution in case of infections caused by S. aureus, due to
increasing antibiotic resistance. 3. According to our survey,
signiﬁcant risk factors for colonization with MDR-MRSA in
Greek LTCF are recent hospitalization, poor functional status,
decubitus ulcers and usage of feeding tube.
P997
Molecular characterisation of MRSA by
spa-typing, MLST and PFGE in the Cologne
metropolitan area from 1984 to 1998
H. Wisplinghoff, S. Wisplinghoff, B. Ewertz, D. Stefanik,
F. Perdreau-Remington, H. Seifert (Cologne, D)
Background: MRSA continues to be one of the most important
nosocomial pathogens. This study was conducted to evaluate
the molecular evolution of MRSA in a large metropolitan area in
Germany from the beginning of the epidemic in 1984 to 1998.
Methods: MRSA isolates have been prospectively collected at
the IMMIH, University of Cologne, from 1984 to the present day.
Among 800 isolates recovered from different patients hospital-
ized in various teaching and non-teaching hospitals in Cologne,
Germany between 1984 and 1998, 430 strains were characterized
by IS256-PCR and PFGE. Based on the PFGE data, a total of 120
representative isolates were selected for the current study.
MLST and spa-typing proﬁles of all isolates were determined.
Results: Overall, there were 11 MLST sequence-types and 33
spa-types. Most prevalent MLST sequence-types were ST239
(38% of isolates), ST247 (27%) and ST228 (19%). Most prevalent
spa-types were 37 (36%) and 51 (27%). While the same PFGE
pattern was not observed among strains with different MLST-
type, spa-type 8 was seen in strains of 2 different MLST-types,
spa-type 37 was observed in strains of 3 different MLST-types (8.
239. 241). which did belong to the same clonal complex as single
locus variants. Over time. spa-type 37 was the most prevalent
between 1984 and 1990; spa-type 51 between 1991 and 1994 and
spa-types 1. 458 and 143 between 1994 and 1998.
Conclusion: Molecular diversity of MRSA increased from 1984
to 1998. Some of the more prevalent spa-types were shared by
strains with different MLST-types. While between 1984 and 1994
there was one prevalent spa-type. after 1995 three different spa-
types accounted for most of the isolates.
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P998
The incidence and risk factors of MRSA nasal
carriage among healthcare workers in a Turkish
university hospital
S. Hosoglu, M.F. Geyik, S. Akalin, M.K. Celen, C.
Ayaz (Diyarbakir, TR)
Objective: Few data are available concerning the prevalence
and risk factors of MRSA carriers among HCWs. To assess the
prevalence and risk factors of methicillin-resistant Staphylococ-
cus aureus (MRSA) carriage among healthcare workers (HCWs).
Methods: The incidence and risk factors of nasal carriage of
MRSA was evaluated prospectively among HCWs in Dicle
University Hospital, Diyarbakir, Turkey, during an 18-month
period. Epidemiological and clinical data of the HCWs were
evaluated using a standardized data form. At the same time,
nasopharyngeal swab samples were taken for bacterial cultures
of MRSA strains. These swabs were inoculated on blood and
mannitol salt agar plates and incubated at 37oC. The isolate(s)
were identiﬁed as S. aureus on the basis of colony morphology,
Gram staining, catalase and coagulase tests. Sensitivity to
Oxacillin was determined using standard Kirby Bauer tech-
nique.
Results: During the study period, 31 out of 360 (% 8,6) HCWs
were found as MRSA nasal carriers. One hundred and sixty-four
HCWs were employed in the surgical departments. In the last
three months, 123 of the HCWs (34.2%) had used antibiotics. In a
univariate analyses, being a nurse (OR = 0.58, CI = 0.46–0.74,
p = 0.001), working at a surgical department (OR = 0.68,
CI = 0.51–0.91, p = 0.027), and living in a crowded family
(OR = 0.63, CI = 0.46–0.88, p = 0.02) were found to be signiﬁ-
cant factors for MRSA nasal carriage. Besides these signiﬁcant
factors, working at intensive care unit (ICU) (OR = 0.82,
CI = 0.71–0.96, p = 0.065) and female gender (OR = 0.84,
CI = 0.67–1.05, p = 0.179) were included into a multivariate
analyses model. In the multivariate analyses, being a nurse
(OR = 0.29, CI = 0.12–0.68, p = 0.004) and living in a crowded
family (OR = 0.44, CI = 0.20–0.95, p = 0.037) were found to be
independent risk factors for MRSA carriage.
Conclusion: Close contact with patients and some familial
characteristics (being a nurse and living at a crowded family)
could be important factors which identify the status of MRSA
carriage among HCWs.
P999
Methicillin-resistant Staphylococcus aureus:
colonisation and infection of respiratory tract in
cystic ﬁbrosis patients
A. Molina, R. Del Campo, L. Maiz, H. Escobar, F. Baquero,
R. Canto´n (Madrid, E)
Introduction: Cystic ﬁbrosis (CF) is an autosomal recessive
disorder caused by mutation in the cystic ﬁbrosis transmem-
brane conductance regulaor gene on chromosome 7, leading to
recurrent and chronic respiratory infection which is the most
important cause of morbidity and mortality in these patients.
S. aureus is frequently the ﬁrst organism found in the respiratory
tract of CF patients, and an increase in the Methicillin-Resistant
S. aureus (MRSA) pulmonary infection was observed. The aim of
this study was analysed the MRSA infective population in CF
patients.
Material and Methods: A total of 72 MRSA isolates obtained
from 15 CF-patients were included (1–24 isolates per patient).
Susceptibility to different antibiotics was performed by the
microdilution method (Wider system, Francisco Soria Melguizo,
S.A., Madrid, Spain). PFGE-Sma I was applied to analyze genetic
relatedness among the isolates, and the patterns obtained were
compared by the software Phoretrix 5.0, using the Dice coefﬁ-
cient.
Results: All MRSA isolated presented susceptibility to linezolid
and vancomycin, and different resistance levels to other antibi-
otics. Twenty-four different pulsotypes were found among the
72 isolates. Existence of a single clone among all isolated
recovered from the same patient was detected in 8 cases,
whereas the existence of 2 different clones was observed in 5
patients, and ﬁnally 2 patient carried along the time 3 different
MRSA clones. Persistence during ﬁve years of the identical
MRSA clone in an individual that have 24 different isolates was
corroborated. It has been detected clonal relationships among
MRSA isolates of different patients, being much of the strains
closely related.
Conclusion: Although selected MRSA clones were able to
colonized the same patient, a genetic close relation exists
among the different clones of 15 different CF-patients. Addi-
tional studies are needed to understand the colonization /
infections of MRSA in the CF patients, and the role of this
bacteria in the prognostic of this pulmonary disease.
P1000
Emergence of community-acquired MRSA in
Hungary
A´. To´th, E. Ungva´ri, M. Gacs, J. Pa´szti, M. Fu¨zi (Budapest, HUN)
Objectives: The methicillin-resistant Staphylococcus aureus typ-
ically causes infections in inpatients. However, there are MRSA
infections arising also in the community without common risk
factors. These community-acquired MRSA (CA-MRSA) infec-
tions can cause serious or even fatal infections in otherwise
healthy people. Recently, CA-MRSA have been reported in
many European countries (France, Switzerland, Scotland, Ger-
many). The aim of this study was to characterize 6 CA-MRSA
isolates and compare the data of European CA-MRSA isolates.
Methods: The 6 isolates were selected from 2312 MRSA strains
collected between January 2002 and June 2004 on the basis of
epidemiological data and antibiotic resistance proﬁles. Testing
of antimicrobial susceptibility was performed using E-test
according to E-test technical manuel. The presence of the
mecA, lukF-PV and lukS-PV genes was detected by PCR. The
SCCmec type of isolates was determined by a multiplex PCR-
based assay (according to the designation of Oliveira). The
genetic background of the isolates was analysed by pulsed-ﬁeld
gel electrophoresis (PFGE).
Results: All of isolates were resistant to beta-lactams and
kanamycin. Four of the six strains had identical non-beta-
lactam antibiotic resistance pattern, being resistant to fusidic
acid and intermediate resistant to ciproﬂoxacin. All strains
shared the Panton-Valentine Leukocidin (PVL) locus and type
IV SCCmec element that is typical of CA-MRSA isolates.
According to PFGE analyses 5 of 6 strains shared the same
pulsotype and the remaining strain that proved resistant to
tetracyclin was closely related to the others. All six strains
substantially differed from predominant Hungarian hospital-
acquired MRSA (HA-MRSA) strains.
Conclusions: This is the ﬁrst investigation of CA-MRSA in
Hungary. Our results showed that PVL-positive CA-MRSA
strains are present in Hungary and the antibiotic resistance
pattern of the Hungarian isolates is very similar to those
reported from other European countries. The Hungarian
CA-MRSA isolates belonged to a single clonal type.
Abstracts
308
P1001
Community-acquired methicillin-resistant
Staphylococcus aureus nasal carriage: prevalence
and risk factors
M. Kompoti, S. Drimis, K. Kotsomytis, A. Papadaki,
K. Tryﬁnopoulou, M. Kimouli, O. Zarkotou, D. Gianneli,
D. Voutsinas (Athens, GR)
Objective: To assess the prevalence of community-accuired
methicillin-resistant Staphylococcus aureus (MRSA) nasal carriage
at hospital admission among patients of a tertiary-care hospital.
Methods: All patients admitted to our department between
November 2003 and September 2004 were included in the study,
provided that they had not been hospitalized for the previous
three months. Nasal swabs were drawn from both anterior nares
upon admission. Cultures were performed by conventional
methods, identiﬁcation was carried out using the API Staph
system and antimicrobial resistance was evaluated by disk
diffusion method.
Results: Five hundred-forty ﬁve consecutive patients, 278
females (51%) and 267 males (49%), were enrolled in the study
and an equal number of samples were screened for MRSA.
Mean age (± SD) was 69.1±16.8 years. Major comorbidities
included arterial hypertension (41.8%), diabetes mellitus
(23.5%), cerebrovascular disease (17.4%), coronary heart disease
(14.9%), malignancy (10.5%), chronic obstructive pulmonary
disease (6.6%). The prevalence of MRSA nasal carriage was
0.9%, while the overall prevalence of S. aureus was 14.1%. The
most common isolate was S. epidermidis (52.5%), as expected. In
univariable analysis, risk factors for S. aureus nasal carriage
were long-term corticosteroid therapy [odds ratio (OR) = 7.997,
95% conﬁdence intervals (CI) 2.086 – 27.689, p < .001] and
immunosuppression (OR = 1.658, 95% CI 1.091 – 2.518, p =
.022), while in multivariate analysis, only long-term corticoster-
oid therapy attained statistical signiﬁcance [OR = 5.878, 95% CI
1.449 – 23.840, p = .013].
Conclusions: The prevalence of MRSA nasal carriage at hospi-
tal admission in patients referred from a community setting is
low. Long-term corticosteroid therapy is independently associ-
ated with an increased risk of S. aureus nasal carriage.
P1002
Clinical isolates of Staphylococcus aureus in the
Arkhangelsk region, Russia: prevalence of
antimicrobial resistance and molecular
epidemiology of methicillin-resistant strains
V. Vorobieva, T. Bazhukova, N. Semenova, B. Haldorsen,
G. Skov Simonsen, A. Sundsfjord (Tromso, N; Arkhangelsk, RUS)
Objectives: This study was conducted to examine the preval-
ence of antimicrobial resistance in clinical isolates of Staphylo-
coccus aureus from hospitalized and non-hospitalized patients in
the Arkhangelsk region, Russia and to analyze the molecular
epidemiology of methicillin-resistant S. aureus (MRSA).
Material and methods: A total of 130 clinical consecutive
isolates of S. aureus were collected in Arkhangelsk during
June–September 2004; 76(58%) and 54(42%) strains from in- and
out-patients, respectively. Strains were identiﬁed as S. aureus
with standard microbiological methods. Antimicrobial suscep-
tibility testing was performed by agar disc diffusion (AB,
BIODISK, Solna, Sweden) with the following antibiotics: gen-
tamicin (GM), tetracyclin (TC), cefoxitin (FX), ciproﬂoxacin (CI),
fucidic acid (FU), trimethoprim-sulfamethoxazole (TS), and with
the double-disk test (erythromycin (EM) and clindamycin (CM))
for inducible MLS-resistance. Nitroceﬁn discs were used for
beta-laktamase detection after induction with cefoxitin and/or
oxacillin. The oxacillin (4 mg / L) agar method was used for
MRSA screening. MRSA was conﬁrmed by mecA and nuc PCR
and further analysed by SmaI-pulsed-ﬁeld gel electrophoresis
(PFGE).
Results: A total of 102 strains (78%) were beta-lactamase
positive. Other resistance prevalence rates were: TC (29%), EM
(19%), CM (19%), CI (11%), GM (11%), TS (0%) and FU (0%).
Thirteen strains (10%) were MRSA-screen positive, both with the
oxacillin-agar test and the cefoxitin disc, and conﬁrmed MRSA
by mecA and nuc PCR. All MRSA strains were isolated from
hospitalized patients and expressed multiple resistances. PFGE-
analysis revealed that the MRSA-strains belonged three different
PFGE-types. Type 1 consists of 8 strains from the department of
general surgery and ICU. The type 2 group consisted of 3 strains
from general surgery department. Finally, one strain from a
patient at the Department of pulmonary medicine belonged to
the type 3 group. We were not able to type one strain. MLST-
typing of MRSA-strains will be performed.
Conclusion: (i) The high prevalence of resistance to penicillin
(78%), TC (29%) as well as EM/CM (19%) and the low prevalence
of resistance to TS and FU probably reﬂect the pattern of
antibiotic use in the Arkhangelsk region. (ii) The prevalence of
methicillin resistance was 10% and MRSA occurred only in
hospital patients. (iii) MRSA strains expressed a multiple
resistant proﬁle and clustered in three different PFGE-types.
P1003
Validation of the MRSA protocol in a district
health board in New Zealand, which has
remained free of endemic MRSA in its hospitals
M.I. Schousboe, T. Anderson, L. Seaward (Christchurch, NZ)
Objective: Analysis of key variables important for the detection
of MRSA in colonised Health care workers and patients.
Three variables were evaluated:
• Adequacy of specimen collection
• Relevance of sampling multiple body sites for MRSA culture.
• The role of the selective enrichment broth in recovery of MRSA
from swabs.
Material and Methods: The MRSA screening protocol requires
bacterial swab samples from Nose, Groin, Perineum, and any
wounds. The Microbiological procedure for processing of swabs
were: 1. Inoculation onto 5% sheep blood agar (SBA) to detect
presenceofnormalbacterial ﬂora 2.Direct inoculationontoMRSA
selective media 3. Incubation in a selective enrichment broth
whichwas subcultured ontoMRSA selectivemedia. 4. Inoculated
media processed at 24 and 48 hours.Archived computer records
of positive MRSA cultures from 1995–2004 were used to analyse
the relevance of sampling multiple sites. A subset population
(1999–2000) was further analysed for laboratory factors.
Results: During 1999 and 2000, 4500 and 5700 MRSA screens
were submitted respectively per year. 1.2–1.6 % of screens had at
least one body site with no growth on the SBA .The nose swab
represented 0.6–0.7% of such screens while other sites ranged
from 0.2–0.5%.531 persons had positive MRSA cultures in the
period 1995–2004. Of these, 127 (23.9%) had one positive wound
culture on the 1st MRSA screen. The remaining 404 (76.1%)
persons had at least one screening body site positive. The nose
screen was positive in 282 (69.8 %) while an extra 122 (30.2 %)
was detected from other sites only. During 1999 to 2000, 41 new
MRSA positive patients were detected. 18 (44%) were detected
on direct inoculated MRSA selective media but 23 (56%) were
isolated from an enrichment broth only.
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Conclusion: The control ofMRSA is dependent upon the reliable
detection from screening swabs and adequate Infection control
procedures in dealing with colonised persons. This review
documents some of the variables that inﬂuence the Microbiology
Laboratory’s ability to recoverMRSA from colonisedpatients and
staff. It is important not only to sample the nares but to screen
additional sites and samples must be subcultured through an
enrichment broth for maximum sensitivity.
P1004
Comparison of patient and environmental strains
of MRSA using PFGE
E. ONeill, T. Sexton, T. Dillane, P. Clarke, J. OGara, E. Smyth,
H. Humphreys (Dublin, IRL)
Objectives: Environmental cleaning and decontamination of
horizontal surfaces reduces airborne spread of methicillin-
resistant Staphylococcus aureus (MRSA). Failure to eradicate
from environmental sources in clinical areas is recognized as
contributing to persistence and continued spread. We investi-
gated the relationship between the patient and the environment
over time in the rooms of patients in isolation for MRSA.
Methods: Over a two year period we collected environmental
samples in rooms of patients in isolation for MRSA in Beaumont
hospital which is a 600 bed tertiary referral centre in Dublin,
Ireland. Environmental samples were collected by either air
sampling or environmental swabs of horizontal surfaces in the
patient’s room. Using pulsed-ﬁeld gel electrophoresis (PFGE)
we compared patients strain of MRSA with two environmental
strains of MRSA collected from the same room at the beginning
and end of the patients stay. Gel analysis was performed by
visual interpretation of the banding patterns and use of a
computer software programme to generate a dendogram.
Results: A total of 20 patient isolates were compared with their
corresponding environmental isolates. 5 patients had only one
environmental isolate collected due to short duration of stay in
the room or subsequent environmental samples not yielding
MRSA. PFGE was therefore performed on a total of 55 isolates.
PFGE illustrated identical or similar relationships in 14/20 (70%)
of the patient and environmental sub-groups analysed.
Conclusion: The ﬁndings of this study represent an ongoing
potential source of endemic MRSA in our hospital and empha-
sises the importance of enhanced environmental cleaning as part
of an effective programme of MRSA control.
P1005
Methicillin-resistant Staphylococcus aureus
colonisation and its association with infection in
infants hospitalised at neonatal intensive care
units
Y.C. Huang, L.-H. Su, Y.H. Chou, R.I. Lien, T.Y. Lin (Kweishan,
Taoyuan, TW)
Objectives: To assess the association between methicillin-resist-
ant Staphylococcus aureus (MRSA) colonization and infection in
infants hospitalized at MRSA-endemic neonatal intensive care
units (NICUs).
Methods: During March 2003 and February 2004, the infants
admitted to our NICUs-1 and 2 were included in this study and
specimens from the naris, postauricular area, axilla and umbi-
licus were obtained weekly for the detection of MRSA. All the
colonized and clinical isolates from each study infant were
further genotyped with pulsed-ﬁeld gel electrophoresis (PFGE)
with Sma-1 digestion.
Results: A total of 793 infants were included in this study.
MRSA colonization was detected in 331 infants (42%) during
NICU stay and 89%were detected by the ﬁrst 2 samplings. Naris
(71%) and umbilicus (60%) were the 2 most common sites of
colonization. Clinical MRSA isolates were identiﬁed from 92
infants (12%). Among the 92 infants, MRSA colonization, either
preceding or later acquiring, was noted in 84 infants (91%). 121
clinical isolates from 64 infants with 84 episodes of possible
MRSA infection were available for genotyping analysis. Prior
colonization was detected in 68 episodes (81%), among which
both the colonized and clinical isolates were indistinguishable in
63 episodes (93%), highly related in 2 episodes and distinct in 3
episodes. Among the 16 episodes without prior colonization,
colonization was acquired following infection in 9 episodes
(53%), among which indistinguishable or highly related colon-
ized strain was acquired in 6 episodes.
Conclusion: More than 40% of hospitalized infants were col-
onized with MRSA during their stay in MRSA-endemic NICUs.
Most infants with MRSA clinical isolates had prior colonization
of the same strain.
P1006
Phage typing of Belgian MRSA isolates (2003):
two new epidemic phage types
C. Wildemauwe, C. Godard, R. Vanhoof (Brussels, B)
Objectives: In 2002, in Belgium, a methicillin-resistant Staphy-
lococcus aureus (MRSA) frequency of 28% was estimated. Since
several years, the National Reference Centre for Phage Typing
has followed the evolution of the phage type patterns and has
seen a continual evolution among these patterns. In this work,
we show the phage type distribution found in 2003 and newly
recognized epidemic phage types.
Methods: 2169 MRSA isolates of hospitalized patients were
examined. Phage typing was done with the International Typing
Set (ITS) at Routine Test Dilution (RTD) and 100RTD. The
Minimal Inhibitory Concentration (MIC) of oxacillin was done
by plate test.
Results: Of the 2169 isolates, only 73 isolates (3%) were not
typable with the ITS, though a low number (21%) was typable at
RTD.The phage type groups [A] and [C], at RTD, were still
present with 7 (<1%) and 93 (4%) isolates belonging to [A] and
[C] respectively. The majority of the isolates (40%) belonged to
the phage type group [J]* at 100RTD. The phage group [O]* was
detected in 18% of the isolates. The group Other represented
34% and in this group, two phage types were rather signiﬁcant:
29/(42E)/54/(D11)* (123 isolates) and HK2* (55 isolates). The
oxacillin MICs of those two phage types were high (>256mg/L
and 256mg/L respectively). They appeared in 9 and 8 hospitals
respectively.
Conclusions: The increasing importance op MRSA, associated
with hospital outbreaks, has been recognized in many coun-
tries. The determination of MRSA strains remains an important
tool to control MRSA problems. With this in mind, we
followed, in Belgium, during several years, the phage type
patterns of Belgian MRSA isolates.We obtained, until now, a
good typability of our isolates at least at the 100 fold
concentration, whereas low typability of MRSA with the
phage typing technique has been mentioned in other coun-
tries.The high prevalence of phage type groups [J]* and [O]* is
in agreement with the results found in the 2002 survey.
Striking phage types in 2003 were: 29 / (42 E) / 54 / (D 11)*,
already noticed in 2002 but at a rather low frequency, and
HK2*. Both types became epidemic. To follow the local and/or
temporal MRSA epidemiology in Belgium, phage typing
remains a good, cheap and reliable method.
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P1007
Empirical treatment of serious infections due to
health care-related methicillin-resistant
Staphylococcus aureus
J. Rodrı´guez-Ban˜o, A.B. Milla´n , M.A. Domı´nguez, B. Almirante,
E. Cercenado, B. Padilla, M. Pujol on behalf of GEIH/GEMARA/
REIPI
Objectives: To analyze the empirical treatment in a series of
infections due to health care- associated methicillin-resistant
Staphylococcus aureus (MRSA) and the variables associates with
inappropriate empirical treatment.
Methods: Prospective cohort of cases of MRSA infection from
60 hospitals in Spain during June 2003. Cases of MRSA
infections were included in this analysis if the patients presented
with systemic inﬂammatory response syndrome (SIRS) and/or
invasive infection. Empirical treatment was considered inap-
propriate if the patient did not received any active antimicrobial
agent (according to in vitro susceptibility data) during the ﬁrst
48 hours after the onset of the infection. Percentages were
compared by the chi-squared test. Relative risks and their 95%
interval conﬁdence were calculated.
Results: During the study period, there were 370 cases of
colonization/infection due to health-care associated MRSA; 118
cases presented with SIRS and/or had an invasive infection and
were included. The more frequent types of infections were: skin
and soft tissues, 33%; pneumonia, 19%; catheter infection, 17%,
and primary bacteraemia, 10%; 42% of the cases were bacte-
remic; 16% presented with severe sepsis or septic shock. With
regard to the type of units of admission: ICU, 22%; medical
services 41%, and surgical services 37%. Crude mortality was
32%, and infection-related mortality was 23%. The most frequent
empirical antimicrobials were: betalactams, 63%; glycopeptides,
24%, ﬂuorquinolones, 22%; aminoglycosides, 10%. Empirical
treatment was considered inappropriate in 77%. The following
variables were associated with increased risk of receiving
inappropriate empirical treatment: neoplasia (RR = 1.2,
p = 0.04), <7 days of previous stay (RR = 1.2, p = 0.01); the
following variables were associated with diminished risk:
chronic renal disease (RR = 0.5, p = 0.006), hemodialysis
(RR = 0.3, p = 0.03), ICU admission (RR = 0.6, p = 0.006),
central venous catheter (RR = 0.6, p = 0.001), previous antimi-
crobial treatment (RR =0.8, p = 0.05).
Conclusions: Inappropriate empirical antimicrobial treatment
is frequent among patients with serious infections due to
MRSA and is more frequent in patients with neoplasia or
shorter previous stay. ICU patients, renal disease, hemodia-
lysis, central venous catheter and previous antimicrobial use
were associated with diminished risk of inappropriate empir-
ical treatment.
P1008
Correlation of antimicrobial use and MRSA rates:
data from the project Surveillance of
Antimicrobial Use and Antimicrobial Resistance
in Intensive Care Units (SARI)
E. Meyer, F. Schwab, D. Jonas, P. Gastmeier, H. Ru¨den,
F.D. Daschner (Freiburg, Berlin, Hannover, D)
Objectives: To analyse MRSA rates and antimicrobial con-
sumption in intensive care units (ICUs) participating in the
SARI surveillance system from 2000–2003; to look for temporal
changes and to establish differences between ICUs with
increasing and ICUs with decreasing MRSA rates over three
years.
Methods: Prospective unit and laboratory based surveillance in
38 German ICUs from 2000–2003. Antimicrobial use was deﬁned
by deﬁned daily doses per 1000 patient days (pd); temporal
changes in individual ICUs were calculated by Wilcoxon signed
rank test.
Results: From 2/2000–12/2003, 38 ICUs reported data on
499.694 pd, 9.552 S. aureus isolates, including 2.249 MRSA,
and 660.029 DDDs of antimicrobials. Cumulative MRSA rates
ranged from 0% - 64.4% with a mean of 23.6%, the MRSA rate/
1000pd ranged from 0–38.2 with a mean of 2.77. MRSA rates
and imipenem and ciproﬂoxacin use data showed a positive
correlation (p < 0.05). Overall, comparison of the years 2001 and
2003 showed that MRSA rates had increased in 18 (median
13.2%, range 1.6%–38.4%) and decreased in 14 ICUs (median
12%, range 1.0%–48.4%). Increased use of third generation
cephalosporins, glycopeptides or aminoglycosides correlated
signiﬁcantly with the increase in MRSA rates. Cumulative
nosocomial MRSA infections/1000pd in 141 ICUs without
feedback data showed an increase over three years from 0.26
to 0.35 while SARI-ICUs were able to decrease their rate from
0.63 to 0.40.
Conclusion: The MRSA situation in German ICUs is still
heterogeneous. Ciproﬂoxacin and imipenem use correlated
signiﬁcantly with MRSA rates. Increased use of third generation
cephalosporins, glycopeptides or aminoglycosides correlated
signiﬁcantly with the increase in MRSA rates. Further studies
are required to substantiate ﬁndings that no change in MRSA
rate and a decrease in MRSA incidence in SARI-ICUs reﬂect the
impact of an active surveillance system.
P1009
Analysis of epidemiological situation of MRSA
infections in selected hospitals in the Czech
Republic
B. Mackova, P. Urbaskova, O. Melter (Prague, CZ)
Objectives: Infections caused by MRSA (methicillin-resistant
Staphylococcus aureus) have been historically considered as
hospital infections. Nevertheless, MRSA is becoming increas-
ingly involved in community infections as well. The incidence of
MRSA infections in the Czech Republic varies widely with the
regions and population groups.
Methods: Since 2000 the Czech Republic has been taking part in
the European Antimicrobial Resistance Surveillance System
monitoring the incidence of ﬁve pathogens in invasive isolates
from blood and cerebrospinal ﬂuid. One of the causative agents
under surveillance is Staphylococcus aureus. The incidence of
MRSA has been monitored in blood specimens from 95 hospitals
of the Czech Republic. Data on patients, hospitals and pheno-
types of antibiotic resistance in the bacterial strains isolated have
been recorded. We used genetic methods for analysis of selected
strains. Basic statistical methods are used for epidemiological
analysis.
Results: Between 2000–2003, 4144 Staphylococcus aureus
strains were analysed. Out of these strains, 5.7% were MRSA
(see Table). The incidence of MRSA varied with types of
hospitals, hospital wards, age groups and time. Geographical
Year S. aureus MRSA
2000 525 20 (3.8%)
2001 1091 63 (5.8%)
2002 1188 70 (5.9%)
2003 1408 88 (6,2%)
Total 4212 241 (5.7%)
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distribution of MRSA strains in the Czech Republic was
mapped. Thanks to collaboration of 47 laboratories, highly
valid data covering 82 % of the Czech population have been
available.
Conclusion: Surveillance of MRSA strains as a basis for active
antibiotic policy has become of increasing concern to both health
care providers in hospitals and community general practition-
ers. There is a need for better awareness of MRSA infections
among both health care professionals and the public. The
incidence of MRSA infections in last years in the Czech Republic
shows a slightly increasing trend. Very interesting is local
distribution of MRSA strains. The development of the incidence
of MRSA infections in their spread will be the subject of further
study.
P1010
Comparison of phenotypic typing methods and
PFGE of methicillin resistant S. aureus isolated
from two university hospitals in Thailand
C. Chomvarin, K. Chaicumpar, S. Srigulbutr (Khon Kaen, TH)
Objectives: Comparison of phenotypic typing methods and
genotypic typing method to differentiate MRSA isolates
obtained from the two University hospital in Thailand.
Methods: Seventy-four MRSA isolates were randomly collected
from the two University hospital (central and northeastern) in
Thailand. They were conﬁrmed with the presence of mecA gene.
Antibiograms, phage typing and enterotoxin productions were
used for the phenotypic typing analysis. Pulsed-ﬁeld gel
electrophoresis (PFGE) with SmaI digestion of chromosomal
DNA was used for the genotypic typing analysis.
Results: We found 19 distinct proﬁles by phenotypic typing
methods and 18 PFGE types designed as 5 major types (A to E)
and 13 subtypes. The most frequently types and their related
subtypes found in both hospital, were A and C with represented
54.1% and 27%, respectively. All isolates resistant to penicillin,
cephalosporin, erythromycin, gentamicin, kanamycin, tetracyc-
line and oxacillin; and variably resistant to cotrimoxazole,
lincomycin, chloramphenicol, ciproﬂoxacin. All isolates were
susceptible to vancomycin and fosfomycin. Ten (13.5%) MRSA
isolates produced enterotoxin A. Forty-ﬁve (60.8%) isolates were
nontypable by phage typing method. No signiﬁcant correlation
between the phenotypic typing methods and the genotypic
typing method were found.
Conclusions: The phenotypic typing methods were not signi-
ﬁcantly correlated with the genotypic typing (PFGE). Our results
demonstrated that PFGE types A and C were the common
endemic MRSA clone of both hospitals in Thailand.
P1011
Risk factors for intensive care unit – acquired
MRSA infections
N. O¨ztoprak, M.A C¸evik, E. Akinci, M. Korkmaz, A. Erbay,
S.S Eren, N. Balaban, H. Bodur Ankara, TR
Objectives: MRSA infections are frequent in intensive care
units (ICUs) of our hospital. A prospective study was imple-
mented to investigate the risk factors for ICU - acquired MRSA
infections.
Methods: This study was conducted in surgical and neurolog-
ical ICUs from May to October 2003. The patients staying at ICU
more than 48 hours were included in the study. All of
the patients were visited daily and data were recorded on
individual forms for each patient until discharge or death. Nasal
swab cultures were done in 48 hours of ICU admission and
repeated every week until the patients colonizied with MRSA or
discharged. ICU-acquired MRSA infections were deﬁned
according to the criteria of CDC in which MRSA was isolated
as causative agent. SPSS-10 was used for all statistical analyses.
Results: Overall 249 patients were included in the study. Male
patients accounted for 143 (57.4 %) of the patients. Mean age was
52.1 + 23.2 years and mean hospitalization period in ICU was
6.45 + 9.3 days. MRSA infection was detected in 21 (8.4 %) of
these patients. The most frequent infection was primary blood
stream infection (74 %). It was followed by pneumoniae (38 %)
and surgical site infection (14 %). Nasal MRSA colonization was
detected in 58 patients and 12 of them (20.7%) developed MRSA
infection. The following parametres were found signiﬁcant
(p < 0.05) risk factors for MRSA infection in univariate
analysis:Hospitalization period in ICU, intra-abdominal and
orthopedics pathologies, central venous catheter insertion,
entubation, mechanical ventilation, total parenteral nutrition,
previous antibiotic use, nasal MRSA colonization and presence
of more than two patients having nasal colonization in the same
ICU at the same time. In multivariate analysis; hospitalization
period in ICU (OR:1.090, 95%CI:1.038–1.144, p:0.001), central
venous catheter insertion (OR:1.822, 95%CI:1.095–3.033, p:0.021),
previous antibiotic use (OR:2.337, 95%CI:1.326–4.119, p:0.003)
and presence of more than two patients having nasal coloniza-
tion in the same ICU at the same time (OR:1.398, 95%CI:1.020–
1.917, p:0.037) were independently associated with MRSA
infection.
Conclusion: Prolonged hospitalization, central venous catheter
insertion, previous antibiotic use and nasal MRSA colonization
are the risk factors for MRSA infection in ICUs.
P1012
Genotypes of methicillin-resistant
Staphylococcus aureus isolated from neonates:
the same genotypes of well-known CA-MRSA
strains
K.S. Ko, S. Park, S. Kim, W.S. Oh, J.-H. Song, K.R. Peck (Seoul,
KOR)
Objective: To investigate the molecular characteristics of meth-
icillin-resistant Staphylococcus aureus (MRSA) strains isolated
from neonates transferred from primary care obstetric clinics.
Methods: Twelve MRSA strains were isolated from 11 neonates
in 2004. Ten MRSA strains were also isolated from nurses and
facilities in corresponding primary care obstetric clinics.
Molecular features of MRSA strains were analysed by using
multilocus sequence typing (MLST, arcC-aroE-glpF-gmk-pta-
tpi-yqiL), spa typing, and SCCmec typing. Presence of Panton-
Valentine leukocidin (PVL) gene was investigated by PCR
method.
Results: All 22 MRSA strains analysed in this study contained
SCCmec type IVA. Of six isolates from neonates of clinic A,
ﬁve showed ST1 (1–1–1–1–1–1–1) and resistance to only
gentamicin and tetracycline. The remaining one showed
novel ST (25–1–1–1–1–1–1), shared with one isolate from
nurse of clinic A. Four MRSA strains from neonates of clinic
B showed ST1 (1–1–1–1–1–1–1) and resistance to erythromycin
and gentamicin, which is the same characteristics with three
isolates from nurses and environment of clinic B. The other
two MRSA strains from neonates of clinic B showed ST493
(62–1–1–1–1–1–1), which is shared by six strains from nurses
and environment of clinic B. spa type of these 22 MRSA strains
was identical as UJEBKBP and all strains were negative for
PVL gene.
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Conclusion: MRSA strains isolated from neonates, hospital
workers, and environment of the same primary care obstetric
clinics showed genotypes not found commonly in hospital-
acquired MRSA (HA-MRSA) strains, instead represented close
relatedness with those of CA-MRSA strains. This suggests that
CA-MRSA can spread by mediation of primary clinics with low
antibiotic pressure, and there is a possibility that CA-MRSA is
transmitted into hospitals.
P1013
Band-based versus sequence-based typing:
comparison of typing results for Staphylococcus
aureus obtained from PFGE and spa typing
B. Strommenger, C. Kettlitz, B. Pasemann, G. Werner,
J. Rothga¨nger, D. Harmsen, W. Witte (Wernigerode, Wu¨rzburg,
Mu¨nster, D)
Objectives: Over the last years there has been adramatic increase
in the prevalence of methicillin- and multiresistant Staphylococ-
cus aureus (MRSA) leading to a major health problem, especially
in the nosocomial setting. To support infection control measures
typing ofMRSA is essential. The present gold standard for strain
typing is pulsed ﬁeld gel electrophoresis (PFGE), but several
sequence basedmethods including spa typing have recently been
introduced. Therefore this study was initiated to compare typing
results obtained from PFGE with those from spa typing.
Methods: 90 well characterized S. aureus strains of different
evolutionary origin including methicillin sensitive and resistant
isolates were included. Strains were selected from a variety of
clonal groups prevalent in Germany and middle Europe during
the last ten years. The collection comprised hospital derived
strains as well as isolates from the community, including the
recently emerging community acquired MRSA. All isolates were
subjected to PFGE with subsequent cluster analysis; additionally
the polymorphic X-region of the protein A gene was sequenced
and a spa type was assigned using the Ridom StaphType
software. The newly developed algorithm BURP (based upon
repeat patterns) was applied to the spa sequences to cluster the
resulting spa types into different groups. Clustering results were
compared to those obtained from PFGE and MLST.
Results: Overall the results obtained from the different typing
approaches were in agreement. In some cases where PFGE
results were inconsistent despite uniform epidemiological back-
ground spa typing was able to group the corresponding strains
together. Only two strongly related epidemic clones could not be
separated by spa typing.
Conclusion: Spa typing in combination with BURP analysis is
an easy, rapid and reliable method for epidemiological analyses
in S. aureus. It is superior to PFGE in cases where PFGE might be
overdiscriminatory. In rare cases a second discriminatory locus
(for example a single MLST locus) might be helpful for an
ultimate classiﬁcation.
P1014
The antibiotic susceptibility of methicillin-
resistant Staphylococcus aureus
L. Gavriliu, G.A. Popescu, E. Benea, C. Popescu, G. Badea,
M. Ivan, M. Popoiu, S. Botea (Bucharest, RO)
Methicillin-resistant staphylococci (MRSA) are often multidrug
resistant and represent a major problem for the antimicrobial
therapy. Glicopeptides are the golden standard for these infec-
tions but resistance and toxicity concerns limit their usage.MRSA
antibiotic resistance may be divided into two distinctive proﬁles:
multidrug resistance (probably nosocomial infections) and vari-
able resistance, usually to 1 or 2 non-betalactamic antibiotics
(often correlated with community-related MRSA infections).
Objective: To characterize the susceptibility of MRSA to non-
betalactamic antibiotics, in order to evaluate the therapeutical
alternatives when a MRSA infection is suspected.
Methods: A retrospective study of 65 MRSA strains isolated
and drug-susceptibility tested in Matei Bals Institute of Infec-
tious Diseases in 2003.
Results: The most active of all the tested antibiotics proved to
be linezolid (100%), vancomycin (95.48%) and clindamycin
(77.58%) and less active were tetracycline (16.08%) , cloramph-
enycol (33.3%), rifampin (45.65%) and ﬂuorquinolones
(42.3%).25 MRSA isolated strains (38.46%) were sensible to less
than 4 antibiotics; the most active have been linezolid (100%)
and vancomycin (95.48% - two VISA strains).For the 40 MRSA
more sensible strains, the efﬁciency was similar for linezolid,
vancomycin (1 strain VISA), clindamycin (90%) and trimetho-
prim/sulfamethoxazole (77.56%).
Conclusions: The therapeutic alternatives are linezolid and
glicopeptides, for nosocomial or health-related infections, TMP/
SMX and clindamycin, for community-acquirred infections. The
decision to use one of these should be correlated to the clinical
ﬁndings.
P1015
Associated factors and mortality in elderly
patients with methicillin-resistant vs. methicillin-
susceptible Staphylococcus aureus bacteraemia
B. Marı´, G. Serrate, M. Canals, G. Bejarano, M. Bare`, E. Anto´n,
F. Segura (Sabadell, E)
Objectives: To assess the impact of methicillin-resistance on
selected aspects of the infectious process and outcome in
patients over 65 years of age with S. aureus bacteraemia.
Methods: Prospective case-control study of patients older than
65 years with methicillin-resistant S. aureus (MRSA) or methicil-
lin-susceptibleS. aureus (MSSA)bacteraemia,matched for ageand
sex. Microbiologically documented bloodstream infections
between 1997 and 2004 were used to search for patients. Death
was attributed to the infection if it occurred before the resolution
of symptoms or within 7 days of the onset of bacteraemia in the
absence of other explanations. Results: There were 51 patients in
each group. Mean age was 77.2 + 7 and most (68.6%) were male.
Bacteremia was hospital-0acquired in 51%. Differential charac-
teristics of patients are shown in the table 1 A quarter of the
patients in eachgrouphadaBarthel Index<55.Ahigh-risk source
of bacteremiawas observed in 17%of theMRSAgroup and23%of
MSSA (p = NS). No differences were found between groups for
in-hospitalmortality (45%vs41%) or formortality associatedwith
bacteremia (29% vs 27%). The results of the univariate analyses of
the association between clinical variables and associated mortal-
ity are show in the table 2. MRSA was not an independent
predictor of mortality. In the logistic regression analysis, inap-
propriate therapy and high-risk source of bacteraemia were
independently associated with mortality due to bacteraemia.
Clinical characteristic MSSA % MRSA % P
Diabetes 29 49 0.04
COPD 12 39 0.001
Sore 10 37 0.001
Hemodialysis 28 72 0.03
Prior hospitalization 25 51 0.008
Median duration of stay prior to bacteremia (d) 8 19 0.03
Prior antibiotic therapy 31 72 0.0001
Inappropriate empirical therapy 90 62 0.001
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Conclusions: Our results conﬁrm that MRSA bacteraemia is
associated to factors previously reported to predispose to MRSA
infection.In our series of elderly patients, high-risk source of
bacteraemia and inappropriate therapy were related to
increased mortality due to S. aureus bacteraemia, regardless of
whether the bacteria were susceptible or resistant to methicillin.
P1016
Failure to control MRSA in LTCF by restricting
admissions or implementing strict isolation
procedures
C. Petignat, M. Attinger, D. Blanc, P. Francioli (Lausanne, CH)
The optimal strategy to control the circulation of MRSA between
acute care and long-term care facilities (LTCF) is not well deﬁned.
The study region has 2 acute care facilities (ACF)one of which
being a tertiary care centre (CHUV) and over 50 LTCFs. The vast
majority of LTCFs denied admission to MRSA patients until
repeated cultures were negative. The few LTCFs accepting
MRSA patients would implement strict isolation measures. In
2001 this strategy induced increasing problems for the transfer of
patients from ACFs to LTCFs, due to the fact that ACFs
experienced an abrupt increase in the total number of new
MRSA cases (approx 30–40 cases per year until 2001, over 230
cases after 2001). The goal of the study performed in 2003 was to
investigate if the present strategy indeed protected the LTCFs
from MRSA and what was the role of LCFTs as a potential
reservior for MRSA for the ACFs. A prevalence survey per-
formed in 993 residents of 17 LTCFs showed that 39 residents
(5.3%) were MRSA carriers, of which only 5 were previously
identiﬁed. All but 2 LTCFs hosted positive patients. Nine
residents had never previously been hospitalised. None of the
nine MRSA carriers who were observed for one year, developed
MRSA infection. On the other hand, the rate of MRSA carriers on
admission at the ACFs in 2002 was 13 / 418 (3%) for patients
transferred from LTCFs, as compared to 131/30.000 admissions
(0.4%) for those from other health-care facilities or from home.
Molecular typing showed the 5 different genotypes were circu-
lating in the region.
Conclusions: Most of the MRSA carriers in LTCFs were not
previously known, indicating that the control strategy was at
least partially ineffective. The results also indicate that colonised
LTCF residents appear to be at low risk of developing infection,
in the absence of predisposing conditions. This led to the
modiﬁcation of the control strategy for MRSA in the region: no
special MRSA control measures in LTCFs except for standard
precautions unless obvious predisposing factors for infection or
planned hospitalisation, screening of patients transferred from
LTCFs in acute-care hospitals.
Antibiotic-resistant pneumococci and streptococci
P1017
Pneumococcal resistance surveillance in Canada,
1993–2004
K. Green, S. Pong-Porter, D.E. Low for the Canadian Bacterial
Surveillance Network
Objectives: To monitor resistance trends in Canadian isolates of
Streptococcus pneumoniae (SP).
Methods: The Canadian Bacterial Surveillance Network is a
collaborative network of microbiology laboratories from across
Canada that submit bacterial isolates to a central laboratory for
standardized antimicrobial susceptibility testing. Since 1993, 192
laboratories have submitted 22,531 SP isolates to the central
study lab where susceptibility testing was performed according
to NCCLS protocols.
Results: Of the 22,531 SP isolates tested, 37.5% were from
blood/CSF, 33% from sputum, 17.1% from eyes, and 7.2% from
ears. The trends in antimicrobial susceptibility are expressed
below as percentage resistant (R). Rates of ciproﬂoxacin (Cip)
and levoﬂoxacin (Lev) use increased annually since 1993 with
Cip use peaking at 51/1000 popn in 2000 and Lev at 14.3/1000
popn in 2001. Subsequently Cip use has stabilized at 48/1000
popn and Lev use has decreased modestly to 13/1000 popn in
2003. In 2003 we observed the ﬁrst signiﬁcant decrease in Cip
and Lev resistance rates since their introduction to market; (Cip
2.7%–1.8% p = 0.02; Lev 1.9%–1.2%, p = 0.04). Preliminary data
from 2004 show another increase in 2004 (Cip 2.3%, p = ns; Lev
1.8%, p = ns). Despite decreased macrolide use, rates of macro-
lide resistance continue to rise as evidenced by the erythromycin
resistance rates of 14%,16%, and 17.7% (Chisq for trend 10.2,
p = 0.001) in 2002, 2003 and 2004 respectively.
Conclusions: Data from 2004 show no statistically signiﬁcant
changes in rates of resistance for any class of antibiotics with the
exception ofmacrolides. This trend of continued increasing rates of
macrolide resistance is of concern. Although rates of ﬂouroquino-
lone resistance decreased signiﬁcantly in 2003, preliminary analy-
sis of 2004 data suggests that resistance rates may be increasing
again in 2004. These trends need to be monitored further to
determine if these changing patterns of resistance continue.
P1018
Phenotypic and genotypic resistance to
macrolides in S. pneumonia and S. pyogenes – a
nationwide surveillance
K. Ekeund, A.M. Hammerum, B. Gahrn-Hansen,
M. Kaltoft (Copenhagen, Odense, DK)
Objectives: Erythromycin is the second drug of choice used for
treatment of infections caused by Streptococcus pneumoniae
(S. pn) and Streptococcus pyogenes (S. pyo). Knowledge of
Clinical characteristic
Associated-mortality
Yes (n = 29) % No (n = 73) % P
MRSA 48 51 0.82
Barthel index £ 55 43 20 0.02
Median duration of stay prior to
bacteremia (d)
22 10 0.04
High-risk source of bacteremia 34 15 0.08
Inappropriate empirical therapy 39 19 0.03
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Pen NS 5.7 8.1 8.8 12.2 13.4 14.8 13.6 12.6 14.5 15.2 14.6 15.0
Pen R 0.9 1.3 2.2 4.1 6.5 5.6 5.9 5.9 6.9 6.5 6.2 5.6
Eryth R 1.9 3.4 3.1 5.1 6.8 10.5 10.0 11.2 12.9 14.0 16.0 17.7
ClindaR 0 1.7 1.3 2.4 3.6 5.1 4.9 5.6 5.8 6.5 7.4 8.0
Tmp/Smx R 3.8 4.6 9.6 12.6 14.7 12.0 12.0 11.4 11.9 13.2 13.3 14.0
Tet R 1.4 2.3 3.4 2.4 6.3 9.0 7.9 8.1 9.1 9.8 9.7 10.5
Ceftriax R (mening) 0 0.2 0.1 0.7 1.3 2.4 1.5 2.0 2.4 1.5 1.8 2.7
Ceftriax R (non-mening) 0 0.04 0 0.2 0.1 0.1 0.3 0.1 0.1 0.2 0.2 0.1
Cipro R 0.5 0.8 0.7 0.8 1.8 1.8 1.6 1.4 2.4 2.7 1.8 2.3
Levo R 0 0.4 0.1 0.2 0.5 0.3 0.4 0.9 1.2 1.9 1.2 1.8
Moxi R NT NT 0 0 0.3 0.2 0.2 0.4 0.4 0.3 0.4 0.8
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resistance towards the most often used antibiotics is very
important since fast and effective treatment is needed to reduce
morbidity and of course mortality. erm(B) encodes macrolide/
lincomycin/streptogramin resistance in S. pn and S. pyo
whereas erm(A) only can be detected in S. pyo. Resistance
resulting from efﬂux is mediated by a surface protein encoded
by the mef(A) gene both in S. pn and S. pyo.
Methods: Between 1 January 2003 and 30 September 2004, a
total of 2,183 invasive S. pn and 273 invasive S. pyo (mainly
from blood) were collected from hospitals all over Denmark
and send to the National Reference Centre for Streptococcus at
Statens Serum Institut. During the same period, 217 non-
invasive S. pyo isolates (pharyngitis and skin specimens) were
received from the Department of Clinical Microbiology at
Odense University Hospital. All isolates were examined at the
National Reference Centre for Streptococcus at Statens Serum
Institut. Susceptibility to erythromycin was determined by
disc diffusion method for S. pn and S. pyo. In addition, MICs
of erythromycin were determined by E-test for the erythro-
mycin resistant isolates. Clindamycin resistance was deter-
mined by double disc diffusion test. The erythromycin
resistant (ery-res.) isolates were tested for erm(A), erm(B)
and mef(A) by PCR.
Results: In total, 4.5 % (98) of S. pn was resistant to erythro-
mycin and 2.9% (8) of invasive and 4.6% (10) of non-invasive
S. pyo were resistant to erythromycin. None of the isolates were
resistant to clindamycin. Among the ery-res S. pn, the most
frequent gene was mef(A) 83.7%, while erm(B) was found in
13.3%. In two isolates no resistance genes were identiﬁed. 81 out
of 82 mef(A) carrying isolates had serotype 14.erm(A) and
mef(A) was present in 62.5% and 37.5% of the invasive ery-res.
S. pyo isolates. None of the isolates were positive for erm(B). In
non-invasive ery-res. S. pyo isolates 40%, 10%, 50% were PCR-
positive for erm(A), erm(B) and mef(A) respectively.
Conclusion: In contrast to S. pyo, ery-res. S. pn is dominated by
one serotype, carrying mef(A). The overall resistance proﬁle of
S. pn and S. pyo is still favourable, but the resistance to
macrolides is of growing concern in Denmark.
P1019
Resistance in Streptococcus pneumoniae: AUC/
MIC breakpoints differ between gatiﬂoxacin,
gemiﬂoxacin, levoﬂoxacin, and moxiﬂoxacin
K. LaPlante, M. Rybak, B. Tsuji, G. Kaatz (Detroit, USA)
Objective: The potential for resistance development in Strepto-
coccus pneumoniae (SP) secondary to varying exposure to gatiﬂ-
oxacin, gemiﬂoxacin, levoﬂoxacin, and moxiﬂoxacin was
examined at high inoculum (108.5–9 log 10 CFU/ml) over
96 hours in an in vitro pharmacodynamic model.
Methods: Various AUCfree/MIC exposures, 16 through 449 of
the tested ﬂuoroquinolones (FQ), were evaluated against two
clinical (WT) FQ-susceptible isolates of SP (ATCC 49619; BSP
2443). Pharmacokinetics of each drug were simulated to match
various areas under the concentration-time curve (AUCfree) for
each FQ. The QRDR regions of GyrA and ParC of isolates with
raised MICs were sequenced to identify mutations, if any.
Results: Gatiﬂoxacin, gemiﬂoxacin, levoﬂoxacin, and moxiﬂ-
oxacin MICs for ATCC 49619 were 0.19, 0.03, 0.75, and
0.125 mg/L, respectively, and for BSP 2443, the corresponding
results were 0.25, 0.03 0.75, 0.25 mg/L. Simulated free gatiﬂ-
oxacin exposure led to S52G, S79Y, and N91D parC & S81Y
and S114G gyrA mutations at AUCfree/MIC of 35 & 60,
(corresponding to doses of 100 & 198 mg). Gemiﬂoxacin
exposure led to S52G, S79Y, and N91D parC & S114G gyrA
mutations at AUCfree/MIC of 37 (corresponding to a free dose
of 50 mg). Leqwvoﬂoxacin AUCfree/MIC of 55 through 86
(corresponding to doses of 500 mg through 843.5 mg/day) led
to isolation of S79Y parC & S81Y and E85G gyrA mutants as
early as 32 hrs. Moxiﬂoxacin exposure led to S52G, S79Y, and
N91D parC & S81Y gyrA mutations at AUCfree/MIC of 16–32
(corresponding to free doses of 50–75 mg). For each compound
evaluated, a delay of ﬁrst- & second-step mutants was observed
with increasingly higher AUCfree/MIC ratios.
Conclusions: Recovery of topoisomerase mutations in SP was
related to the AUCfree/MIC exposure. Clinical doses of gatiﬂ-
oxacin, gemiﬂoxacin, and moxiﬂoxacin exceed the AUC/MIC-
free resistance breakpoint against WT SP. The cited exposure
breakpoints differed between FQs & may be related to structural
differences within the class.
P1020
Serotype 11A prevalence and clonal diversity
in Streptococcus pneumoniae isolated from
children attending day-care centres in
Lisbon, Portugal
N.G. Sousa, S. Nunes, N. Fraza˜o, R. Sa´-Lea˜o,
H. de Lencastre (Lisbon, P)
Objectives: The characterization of 1172 drug-susceptible Strep-
tococcus pneumoniae (DSPn) isolates from carriage and recovered
from the nasopharynx of children attending eight day-care
centres in the Lisbon area, during 2001–2003, showed that
serotype 11A was the second most prevalent (12.0%) just
preceded by serotype 6A (13.8%). Since serotype 11A was
rarely found (0.2%) among the 2,067 drug-resistant isolates we
have previously characterized from collections recovered
between 1996 and 2003 in the same geographical area, in the
present study, we aimed to assess the genetic diversity of
serotype 11A DSPn isolates.
Methods: Isolates were characterized by pulsed-ﬁeld gel elec-
trophoresis (PFGE) after SmaI restriction of total DNA. PFGE
patterns were analysed with Bionumerics software.
Results: The molecular analysis of one hundred and forty
serotype 11A DSPn isolates revealed six clonal types. However,
the vast majority (95%) belonged to a single clone. The preval-
ence of this dominant clone during the study ranged from 6.3%
to 13.9% and it was disseminated in all day-care centres.
Conclusions: Serotype 11A is not a capsular type with an
important representation in drug-resistant collections which are
the most commonly studied worldwide. However, it seems to be
common among DSPn strains. This serotype 11A collection
showed little genetic variability. In fact, one genotype was found
to be dominant and disseminated successfully in all day-care
centres studied. These ﬁndings suggest that this serotype 11A
clone is frequent in colonization and thus its monitoring is of
importance particularly after the introduction of the seven-
valent pneumococcal conjugate vaccine.
Agent
AUC/MICfree
Breakpoint to
Prevent Resistance
Corresponding
dose
Recommended
Dosages
Gatiﬂoxacin >66 ± 10 175 mg to 235 mg 400 mg qd
Gemiﬂoxacin ‡50.5 ± 2.0 75 mg 320 mg qd
Levoﬂoxacin ‡97 ± 0.0 843.5 to 875 mg 500 –750 mg qd
Moxiﬂoxacin ‡31 ± 0.1 100 mg 400 mg qd
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P1021
New cefotaxime/ceftriaxone NCCLS
susceptibility breakpoints: effect on reported
Streptococcus pneumoniae resistance in European
surveillance
N. Bruinsma, G. Kahlmeter, E. Tiemersma, J.C.M. Monen,
H. Grundmann on behalf of EARSS participants
Objectives: In January 2003, the National Committee for Clin-
ical Laboratory Standards (NCCLS) ﬁnalised new cefotaxime
and ceftriaxone susceptibility breakpoints for S. pneumoniae
(SPN) isolates. The majority (70%) of the laboratories that
participate in the European Antimicrobial Resistance Surveil-
lance System (NCCLS) use NCCLS guidelines.
Methods: Since 1999 EARSS collects routine antimicrobial
susceptibility results of invasive SPN isolates from blood or
cerebrospinal ﬂuid (CSF). According to the EARSS protocol
laboratories report cefotaxime and/or ceftriaxone minimal
inhibitory concentrations (MICs) for penicillin non-susceptible
SPN isolates (PNSP). The former NCCLS criteria of MIC
breakpoints for cefotaxime and ceftriaxone were £ 0.5 (Suscept-
ible), 1 (Intermediate), and ‡ 2 lg/ml (Resistant). The new
criteria of MIC breakpoints for non-CSF isolates (mainly blood
isolates) are £1 (S), 2 (I), and ‡ 4 lg/ml (R). In the present study,
the proportion of cefotaxime resistance based on the MICs
reported to EARSS according to the former and new NCCLS
guidelines were compared.
Results: In the period 1999–2002, cefotaxime MICs were repor-
ted for 2034 of the 2710 PNSP isolates, mostly isolated from
blood (92%). Interpreting the MIC values according to the
former NCCLS guideline resulted in an overall proportion I, and
R of 20.9% and 3.8% respectively. Interpreting the MIC values
according to the new NCCLS guidelines resulted in an overall
proportion I, R of 4.3% and 0.5% respectively.
Conclusions: The proportion of cefotaxime resistance among
PNSP when interpreted by the new NCCLS guideline decreased
almost 7–fold. The rates from those countries that do not use
NCCLS guidelines were unchanged since breakpoints from the
national breakpoints committees in Europe were unchanged.
The effect of change of cefotaxime breakpoints implemented by
NCCLS illustrates that caution is needed when comparing data
according to S, I, R interpretation.
P1022
The International Circumpolar Surveillance
System for population-based surveillance of
invasive pneumococcal disease 1999–2003
M. Bruce, T. Cottle, D. Parks, S.L. Deeks, T. Tam, M. Lovgren,
L. Jette, K.G. Kristinsson, G. Sigmundsdottir, K. Brinklov Jensen,
O. Lovoll, P. Nuorti, E. Herva, A. Koch, T. Hennessy,
A.J. Parkinson (Anchorage, USA; Toronto, Ottawa, Edmonton,
Quebec, CAN; Reykjavik, IS; Nuuk, GRL; Oslo, N; Helsinki, Oulu,
FIN; Copenhagen, DK)
Background: The International Circumpolar Surveillance (ICS)
Project is a population-based surveillance network for invasive
bacterial disease in the US Arctic, Alaska (AK), Northern
Canada (N Can), Greenland (GN), Iceland (IC), Norway (Nor)
and Finland (Fin). Among circumpolar countries, the 7-valent
conjugate vaccine (pcv7) has been used for routine infant
immunization in AK since 2001 and in selected areas in N Can
since 2002.
Methods: We deﬁned a case of invasive pneumococcal disease
(IPD) as illness in a surveillance area resident with isolation of
Streptococcus pneumoniae from a normally-sterile site. We ana-
lysed data on IPD from AK and N Can (Jan 1999–Dec 2003), and
from GN, IC, Nor, Fin (Jan 2000–Dec 2003) to determine: 1)
Common clinical syndromes, 2) Rates of disease by country, 3)
Serotype distribution and 4) Antimicrobial susceptibility pat-
terns.
Results: A total of 7196 cases of laboratory-conﬁrmed IPD were
reported from AK (547), N Can (195), GN (38), IC (183), Nor
(3664), and Fin (2569). Case-fatality ratios varied from 5.0–22.0%.
Pneumonia (46%), septicemia (28%), and meningitis (8%) were
the most common clinical presentations. Rates of IPD in
aboriginals in AK and N Can were 42 and 38 cases per
100,000 persons, respectively. Rates of IPD in children <2 years
of age and persons >2 years of age ranged from 35–144 and 8–24
cases per 100,000 persons, respectively. In AK, the rate of IPD in
children <2 with pcv7 serotypes declined by 85% after routine
vaccination; from 137 in 1999–2000 to 21 in 2001–2003
(p < 0.001). Rates of non-pcv7 serotypes in AK increased from
26 in 1999–2000 to 49 in 2001–2003 in children <2 years of age
(p = 06). Overall, 89% of isolates from persons >2 years of age
were serotypes contained in the 23-valent polysaccharide
vaccine. The proportion of isolates fully-resistant to penicillin
varied by country from <1% in Fin to 7.5% in AK.
Conclusions: Rates of IPD are high in aboriginals and children
<2 years of age residing in Arctic countries. After introduction
of pcv7 in AK, rates of disease in children <2 years of age with
pcv7 serotypes rapidly declined; however, increasing rates of
non pcv7 serotypes are concerning and merit further surveil-
lance. Continued surveillance is needed to determine the impact
of pcv7 in AK and areas of N Can. High IPD rates in children <2
warrant consideration of pcv7 use in other circumpolar
countries.
P1023
Phenotypic and genotypic diversity of penicillin
non-susceptible pneumococci isolated from
nasopharynx of children in Lublin, Poland
I. Korona-Glowniak, A. Malm (Lublin, PL)
Objectives: Currently, the most penicillin non-susceptible
Streptococcus pneumoniae (PNSP) isolates belong to serotypes
6B, 9V, 14, 19F and 23F. Majority of them have also acquired
resistance to other drugs, including erythromycin, chloram-
phenicol, trimethoprim-sulfamethoxazole, and tetracycline. It
was shown that young children have a high carriage rate of
PNSP which suggests the critical role of nasopharynx of
children, particularly those of pre-school age and attending
day care centres (DCCs), in the emergence and spread of
resistant to penicillin and to other drugs S. pneumoniae. Epide-
miological typing of S. pneumoniae is essential to determine
strain relatedness and also to trace resistant clones. The
antimicrobial resistance, serotyping and BOX PCR assay were
used for characterization of the clonal relationship of PNSP
isolates from nasopharynx of children attending 4 DCCs in
Lublin, Poland.
Methods: Nasopharyngeal isolates of 56 PNSP had been isola-
ted from 241 children attending 4 DCCs between May and June
2002. Susceptibility to penicillin (P), erythromycin (E), clinda-
mycin (CC), tetracycline (Te), chloramphenicol (C) or trimeth-
oprim-sulfamethoxazole (SXT), and capsular serotypes were
determined. Clonal relationship between isolates was investi-
gated by BOX PCR assay using the Box A primer.
Results: All of the isolated PNSP strains belonged to paediatric
serotypes 6B (12.5%), 9V (5.4%), 14 (53.6%) and 19F (28. 6%). 9
strains showed high level resistance (PenR) and 47 strains – low
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level resistance (PenI) to penicillin. MIC 50/90 (mg/L) were
determined to penicillin 1.0/1.0 and cefotaxime 0.38/0.5. All of
the strains from serotypes 6B and 19F have the same drug
resistant phenotype PECCTeCSXT, whereas 18 strains of sero-
type 14 were resistant to P and 12 strains – to PSXT. 3 isolates of
serotype 9V have PSXT resistance pattern. When genotypic
method was used 4, 8, 5 and 1 different patterns were identiﬁed
among 14, 19F, 6B and 9V serotypes, respectively. The isolates of
serotype 14 were very clonal irrespective of DCCs, while isolates
of serotypes 19F and 6B showed greater genetic diversity but
within the same DCC higher similarity of genotypes was found.
Conclusions: Clonal spreading of S. pneumoniae among children
attending the same DCC indicates that local PNSP strains can
also easily disseminate in the community. In addition, there is
need to monitor an appearance and extension of the major
international resistant clones of pneumococci in Poland.
P1024
Genetic diversity of Streptococcus pneumoniae
resistant strains isolated in Western Pomeranian
Region of Poland in 2001–2003
M. Nowosiad, M. Mnichowska, S. Giedrys-Kalemba (Szczecin,
PL)
Introduction: Streptococcus pneumoniae is a main causative agent
of upper respiratory tract infections and severe systemic
diseases. An abrupt antimicrobial resistance increase and
clonal spread of resistant pneumococcal strains has resulted in
serious therapeutic problems in recent years. The aim of this
study was to analyze resistance patterns and genetic diversity of
S. pneumoniae resistant strains isolated in our region during three
years (2001–2003).
Methods: Using E-test method and the NCCLS criteria for
benzylpenicillin (P), erythromycin (E), clindamycin (L), tetra-
cycline (T), cotrimoxazole (S), ceftriaxone (C), chloramphenicol
(H), vankomycin (W), imipenem (I), ﬁfty nine resistant or
intermediate to at least one drug strains were obtained. Strains
were submitted to molecular characteristic by PFGE with SmaI
restriction enzyme and computer analysis using Molecular
Analyst software application. For each strain resistance pattern
and PFGE proﬁle was determined.
Results: Resistance to 8 out of 9 determined antibiotics (except
vancomycin) was described. Strains showed 22 different resist-
ance patterns and TSH (13%strains), PSI (11.8%) and ELTS
(10.1%) were the most often. Resistance degree reached 7 drugs
(5% strains) and 69% strains were MDR.We have found 26 PFGE
proﬁles: 15 of them (U 1–15) were unique single isolates, 11
clusters (A-K) were represented by 2–10 strains, which were
more than 78% of similar. The most numerous clusters (A-K)
consists of strains that were isolated over three years of study and
showed the same or very similar resistant patterns: A-TSH (8 of
10 strains), TH (2); B-PSI (7 of 8), S (1); C-PELSHI (3 of 6), PTSHI
(2), PTSCHI (1); D-ELTS (3 of 4), ELS (1); E-SH (2 of 4), TS (1), T
(1). All strains of TSH and PSI resistance patterns were found in
one cluster A(A1–A9) or D (D1–D6) respectively but strains with
ELTS and PELSHI patterns belonged to different (2–3) clusters
and unique PFGE proﬁles. Another clusters (F–K) were repre-
sented by two strains with different resistant patterns each.
Conclusions: Population of S. pneumoniae resistant strains in
our region presents high genetic diversity and numerous
different resistance patterns. The majority of strains with the
same resistance pattern showed different PFGE proﬁles but
there were observed some strains of the same resistance pattern,
which belonged to only one cluster and were isolated over three
years of study.
P1025
Characterisation of penicillin-resistant
Streptococcus pneumoniae circulating in Italy
during 2000–2003
D.L. Rocca, L. Gualco, A. Marchese, G.C. Schito (Genoa, I)
Objective: Recent epidemiological surveys have shown increas-
ing resistance to penicillin in pneumococci circulating in our
Country (from <5% in 1992 to >20% in 2003). This phenomenon
has worsened in the last two years. Because only limited data on
the molecular characterization of these strains are available, the
present study was aimed at providing more information on this
subject.
Methods: 139 S. pneumoniae refractory to penicillin isolated
recently (2000–2003) from 23 centres widely distributed in Italy
and causing respiratory infections have been analysed for
antibiotic susceptibility (broth microdilution method, NCCLS
2004) and chromosomal relatedness (pulsed-ﬁeld gel electro-
phoresis: PFGE). Serotyping was done by the capsular reaction
using commercially available sera.
Results: Lack of susceptibility to other drugs among strains
possessing high-level resistance to penicillin (HLPR) (74/139,
53.2%) was: erythromycin 58.1%, clindamycin 40.5%, tetracyc-
line 43.2%, co-trimoxazole 85.1% and chloramphenicol 49.7%.
Among low-level penicillin resistant isolates (LLPR) (65/139,
46.7%) 63.1, 44.6, 66.1, 38.5 and 23.1% were refractory to
erythromycin, clindamycin, tetracycline, co-trimoxazole and
chloramphenicol respectively. After PFGE analysis, 49 of 74
(66.2%) HLPR strains showed a proﬁle identical or related to
two epidemic clones: Spain23F-1 and Spain9V-3. The remaining
HLPR pneumococci belonged to unique or rare clones. LLPR
isolates were characterised by more variable backgrounds in
terms of PFGE patterns and serotypes than HLPR strains. In fact,
27.7% showed an identical or related proﬁle (arbitrarily called D,
serotype 15A) previously not described in Italy and 10 (15.4%)
exhibited the PFGE patterns typical or related to the Spain23F-1
and Spain9V-3 clones. The remaining 37 LLPR isolates (56.9%)
belonged to 22 different proﬁles and to 11 distinct serotypes. In
this study, the 23F Italian clone circulating in 1993–1996 was
not found.
Conclusions: The recent increase of total penicillin-resistance in
Italy can be ascribed to the emergence of a new clone and to the
diffusion of two well known international clones, whose ability
to spread is higher than that of the autochthonous Italian clone
described in 1996. Changing antibiotic prescribing habits,
including the recent strict limitation to the consumption of
parenteral drugs, may also explain the variations described.
P1026
Characterisation of macrolide-resistant
Streptococcus pneumoniae isolated in Austria
S. Forsthuber, H. Lagler, K. Stich, W. Graninger,
A. Georgopoulos (Vienna, A)
Objectives: The aim of this study was (i) to evaluate the in vitro
activity of antimicrobial agents against erythromycin resistant
Streptococcus pneumoniae (ERSP) and (ii) to detect the genetic
mechanisms of macrolide, penicillin and tetracycline resistance.
Methods: Fifty-seven ERSP were isolated from 20 adults and 37
children between 2002 and 2003. MICs to erythromycin (ERY),
clarithromycin (CLA), azithromycin (AZM), josamycin (JOS),
clindamycin (CLI), telithromycin (TEL), penicillin (PEN), cefp-
odoxime (CPD), cefotaxime (CTX), linezolid (LNZ), quinupris-
tin/dalfopristin (Q-D), ciproﬂoxacin (CIP), levoﬂoxacin (LVX),
gatiﬂoxacin (GAT), moxiﬂoxacin (MXF) and tetracycline (TET)
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were determined by the broth microdilution method according
to NCCLS. Macrolide resistance phenotype (c-MLSB, i-MLSB,
M) was characterized by using a triple-disk test with ERY, JOS
and CLI. Species identiﬁcation (ply, lytA, psaA) and detection of
genes coding for resistance to macrolide (ermB, ermTR, mefE),
penicillin (pbp1A, pbp2B) and tetracycline (tetM, tetO) were
done by PCR.
Results: Following macrolide phenotype/genotype distribution
was found: 24 (42%) with c-MLSB / 16 ermB, 2 ermB + mefE; 8
(14 %) with i-MLSB / 4 ermB, 2 ermB + mefE, 1 ermTR; 25 (44
%) with M / 23 mefE. 20 strains showed reduced susceptibility
to PEN (with altered pbp1A and/or pbp2B) and 29 ERSP were
resistant to TET (24 tetM, 1 tetO). 19 isolates (33%) demonstrated
MDR (multidrug resistance, deﬁned as resistance to three or
more different classes of antimicrobials), however all ERSP were
sensitive (100%) to TEL, LNZ, LVX, GAT, MXF.
Conclusions: (i) MefE was the most common macrolide resist-
ance gene although ermB was also often present. (ii) One third of
ERSP strains were multidrug resistant. (iii) New antibiotics like
TEL have shown excellent activity against these strains.
P1027
Streptococcus pneumoniae invasive disease. Study
of susceptibility to frequently used antimicrobial
drugs over a 4-year period
S. Solis del Ban˜o, A. San Pedro Garrido, A. Sanchez Garcia,
I. Gestoso, J.J. Picazo (Madrid, E)
Objectives: Study the incidence of S. pneumoniae invasive
disease in the health district of our hospital (600,000 inhabitants)
between March 2001 and October 2004, and the prevalence of
resistance to the main antimicrobial drugs (penicillin, cefotaxime
and erythromycin).
Material and methods: Retrospective analysis of 143 isolates of
S. pneumoniae in blood and CSF during the study period at the
Hospital Clı´nico San Carlos, Madrid (1130 beds). We studied the
seasonal and age-group distribution (0–15 years, 16–65,
>65 years). Sensitivity to antimicrobial drugs was measured
following NCCLS criteria.
Results: During the study period, 143 strains of S. pneumoniae
were isolated: 6 (4.2 %) in CSF and 137 (95.8%) in blood. Total
incidence was 6 cases/100,000 inhabitants/year, with maximum
incidence in winter and spring. The largest number of cases, 76
(54 %), were in the over 65s. In children, 11 (7.7 %) were
detected, all in the under 5s. The total number of strains whose
sensitivity to penicillin fell was 43 (30 %), of which 20 (46.5 %)
had an MIC 2 mg/ml. 46.5% of the penicillin-resistant strains
were also resistant to erythromycin. 16 (11%)/ 143 had reduced
sensitivity to cefotaxime, and most of these (63%) had interme-
diate sensitivity. Resistance to erythromycin was detected in 34
(24%). During the study period, resistance to antibiotics
decreased gradually in such a way that the resistance percent-
ages each year were: penicillin 41%, 30%, 27%, 23%; cefotaxime
28%, 14%, 4%, 4%; erythromycin 34%, 19%, 29%, 8%. No
differences were observed in the resistance percentage in the
different age groups.
Conclusions: The prevalence of CSF and blood strains of
S. pneumoniae with reduced sensitivity to penicillin in this
study was 30%. The treatment of choice in S. pneumoniae
invasive disease was third-generation cephalosporins, due to
their low level of resistance. Resistance to the main antimicro-
bials from this type of strain has fallen. During the study period,
resistance to penicillin fell by 43.9 %, 58.5 % for cefotaxime 63.4
% for erythromycin. The fall in resistance among invasive
S. pneumoniae could be due to vaccination in children and the
elderly from 2002 onwards, since the vaccination includes the
most common and resistant serotypes. The low number of
isolates in children could be due to the low number of samples
processed.
P1028
Change in distribution of macrolide-resistant
Streptococcus pneumoniae genotypes over 4 years
– data from PROTEKT 1999–2003
D.J. Farrell on behalf of the PROTEKT Study Group
Objectives: This analysis of data from 39 countries over the ﬁrst
4 years (1999–2003) of the PROTEKT global surveillance study
was undertaken to investigate longitudinal and regional trends
in the distribution of macrolide resistance mechanisms among
Streptococcus pneumoniae, and the susceptibility of these isolates
to antibacterials, including the ketolide telithromycin.
Methods: Isolates were tested centrally for antibacterial sus-
ceptibility using NCCLS methodology; macrolide (erythromy-
cin-resistant [ERY-R; MIC ‡1 mg/L]) isolates were genotyped
using PCR.
Results: Overall, 31.4% (1077/3435) of S. pneumoniae isolates in
Year (Y) 1 (1999–2000), 32.7% (1391/4256) in Y2 (2000–2001),
36.9% (2329/6320) in Y3 (2001–002) and 36.4% (2451/6739) in Y4
(2002–003) were ERY-R. erm(B) alone or mef(A) alone were the
most prevalent macrolide resistance genotypes, accounting for
58.5% and 30.9% of all ERY-R isolates over the 4 years,
respectively. erm(B) was particularly common in France and
Spain (95.3% and 91.2%, respectively, overall), whereas mef(A)
predominated in Latin American countries and the USA. While
the proportion of ERY-R isolates with erm(B) or mef(A) alone
was stable between 1999 and 2003, the proportion positive for
both genes increased from 6.6% in Y1 to 10.5% in Y4 (Y2, 5.0%;
Y3, 10.2%). In Y4, dual erm(B)/mef(A) strains were particularly
prevalent in South Korea (26.0%), South Africa (40.0%) and the
USA (22.3%). Overall, 46.6% of ERY-R isolates were resistant to
penicillin (MIC ‡2 m/L) and a further 22.3% exhibited interme-
diate susceptibility (MIC 0.12–1 mg/L) to this agent. Co-resist-
ance to other antibacterials was markedly high in dual erm(B)/
mef(A) isolates (penicillin, 89.8%; cotrimoxazole, 82.2%; tetra-
cycline, 97.2%). Telithromycin continued to exhibit potent
activity against ERY-R S. pneumoniae, irrespective of their
genotype: 99.1% of erm(B), 100% of mef(A) and 99.2% of
erm(B)/mef(A) isolates collected over the 4 years were fully
susceptible (MIC £1 mg/L) to this antibacterial.
Conclusions: The marked geographic variability in the distribu-
tion of macrolide resistance genotypes among S. pneumoniae
isolates highlights the need for continued international surveil-
lance. Isolates positive for both erm(B) and mef(A) exhibit high
rates of multidrug resistance and are increasing in prevalence in
most regions. Telithromycin remains highly active against
macrolide-resistantS. pneumoniae isolates, regardless of genotype.
P1029
Changes in the global distribution of
Streptococcus pneumoniae serotypes from
paediatric isolates collected in PROTEKT Year 1
(Y1; 1999–2000) compared to Year 4 (Y4; 2002–
2003)
D.J. Farrell, S.G. Jenkins, R.R. Reinert (London, UK; Charlotte,
USA; Aachen, D)
Objectives: The 7-valent formulation of the pneumococcal
conjugate vaccine (PCV7) was introduced in the USA in
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February 2000. There is a general recommendation for its use in
all children <2 years of age, and the vaccine is licensed for
children up to 5 years of age. In Europe, the vaccine is licensed
for children up to 5 years of age, but most countries do not have
a general recommendation for use. PROTEKT – a global,
longitudinal study of the antimicrobial susceptibility of bacterial
respiratory tract pathogens – has now completed its fourth year.
A comparison was made between serotype distribution and
PCV7 coverage between Y1 and Y4.
Methods: Analysis was performed only on Streptococcus pneu-
moniae isolates obtained from paediatric patients at the 31
centres common to both years (Y1, n = 553; Y4, n = 682).
Serotyping was performed by Neufeld’s Quellung reaction
using Statens Serum Institute antisera (SSI, Denmark).
Results: PCV7 coverage decreased from 67.7% and 62.5% in Y1
to 51.0% and 41.0% in Y4 in the USA and Latin America,
respectively (Chi-squared; p = <0.001 and 0.007, respectively).
Serotypes that showed the greatest increase (Y1, Y4) in the USA
were 19A (7.0%, 22.2%), 6A (1.8%, 9.9%), 3 (1.8%, 6.2%), 15
(1.8%, 6.2%), and 11 (0%, 6.2%). In Brazil, a similar pattern was
seen although there was no change in the proportion of isolates
with the 19A serotype. In contrast, no change in serotype
distribution was observed in Canada, Western Europe, and the
Far East, where the PCV7 vaccine is not routinely used for
paediatric vaccination.
Conclusions: Results from this analysis of PROTEKT data
indicate that the proportion of S. pneumoniae isolates from
paediatric patients covered by the PCV7 vaccine has decreased
signiﬁcantly over 4 years in regions where the vaccine is
routinely used. Other serotypes, such as 19A, which is known
to be highly resistant to antimicrobials and is not covered by
PCV7, have increased in these regions. This study demonstrates
the importance of serotyping antimicrobial surveillance study
isolates in order to monitor such changes and any potential
future implications for therapy and vaccine formulations.
P1030
Population structure and MURm gene analysis of
early and contemporary high penicillin resistant
Streptococcus pneumoniae isolates in Spain
R. Del Campo, M.I. Morosini, A. Fenoll, E. Go´mez G-de la
Pedrosa, J. Lin˜ares, F. Caﬁni, F. Baquero, R. Canto´n, J. Prieto on
behalf of the Spanish Pneumococcal Infection Network
Background: Sequential alterations in PBP sequences constitute
the classical mechanism to acquire penicillin resistance in
S. pneumoniae, that is reﬂected in changes in the cell wall
peptidoglycan structure. murM gene controls the addition of the
ﬁrst amino acid of the dipeptide bridge of the pneumococcal
muropeptide. Mutations in this gene are apparently required for
high penicillin and cefotaxime resistance. The aim of this study
was to compare the murM gene sequence within the earlier and
the latest highly penicillin resistant pneumococcal populations
recovered in Spain.
Material and methods: A total of 56 S. pneumoniae isolates (10 of
them from 1987–88 and 46 from 2002–04) with resistance to
penicillin (MIC 2–8 lg/ml) were included. Susceptibility to
different b-lactams, macrolides, tetracycline, levoﬂoxacin, chlo-
ramphenicol, and trimethoprim-sulfamethoxazole (SxT) were
determined by the agar dilution method. All isolates were
grouped according to serotype and pulsotype (PFGE-SmaI
pattern) and the murM gene was sequenced.
Results: A high percentage of resistance (intermediate plus
resistant) was observed for cefotaxime (100%) and SxT (96.6%).
All isolates remained susceptible to telithromycin but not to
levoﬂoxacin (93% of susceptibility). All isolates recovered
during 1987–88 were genetically unrelated and mainly belonged
to serotypes 23F (40%) and 6B (40%). In contrast, the most
frequent serotypes during 2002–04 were 14 (30%), 9V (26%), and
6B (17%). In this period, a predominant Spain9V-3clone was
detected in 10 out of 14 isolates of serotype 14, and in 11 out of
12 isolates of serotype 9V (capsular switch). All 8 isolates of
serotype 6B belonged to a single clone (Spain6B-2). The analysis
of murM sequences of isolates from both periods revealed the
existence of different alleles. Homologous sequences to the
murMA (identical to that described for R6 penicillin susceptible
strain), were replaced in part by murMB5, and murMB6
(different variants of these alleles were detected in our
collection).
Conclusion: Early high penicillin resistant S. pneumoniae iso-
lates in Spain were genetically unrelated and corresponding to
23F and 6B serotypes. On the contrary, recent isolates showed
dissemination of selected clones, particularly Spain9V-3. Many
S. pneumoniae isolates with high-level resistance to penicillin
retain (or reacquired) the murM gene of susceptible strains, but
different allelic variants was also detected.
P1031
mef(E) and mef(A) gene characterisation in
Spanish Streptococcus pneumoniae clinical
isolates
E. Go´mez G-de la Pedrosa, M.I. Morosini, J.C. Gala´n,
R. del Campo, E. Loza, F. Baquero, R. Canto´n (Madrid, E)
Objectives: To determine among 712 S. pneumoniae clinical
isolates recovered from different Spanish hospitals during three
different periods (1999–2000, 2001–2002 and 2002–2003) the
prevalence of erythromycin resistance phenotypes and resist-
ance genes associated to this resistance.
Methods: Susceptibility testing was performed by the standard
microdilution technique (NCCLS). A PCR assay was carried out
to identiﬁed erythromycin resistance genes (erm or mef) and a
multiplex-PCR was designed to distinguish between mef(A) and
mef(E) genes within mef positive isolates. Clonality was studied
using the Sma-I-PFGE technique.
Results: Resistance values (intermediate plus resistant isolates)
during the studied period ranged from 48.3% (ﬁrst studied
period) to 45.2% (third studied period) for penicillin, 39% (ﬁrst
studied period) to 32.9% (third studied period) for erythromy-
cin, and 32% (ﬁrst studied period) to 30.3% (third studied
period) for clindamycin. Levoﬂoxacin resistance was only found
in 2.4% of isolates and were recovered during the third studied
period. M phenotype was observed in 3.2% of all tested isolates.
Considering non-susceptible erythromycin isolates, ermB and
mef genes was found in 87.1% and 9.5% of isolates, respectively,
as a sole erythromycin resistance gene. The concomitant pres-
ence of both determinants was found in 3.3% of isolates.
Interestingly, among the isolates with mef PCR positive result,
only one (3.2%) carried the mef(A) gene whereas the mef(E)
gene was detected in the others (96.8%). An increase in mef
prevalence was observed between the ﬁrst and the second
studied periods (2% to 5.8%) and a slightly decrease (4.9%) in
the third period. PFGE analysis revealed a polyclonal structure
of mef positive isolates.
Conclusions: Prevalence of mef positive isolates among eryth-
romycin-resistant strains remains low in our country (4.3%)
being the mef(E) gene the most prevalent mef determinant
among these isolates (96.8%).
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P1032
Molecular mechanisms of tetracycline resistance
and clonal diversity of Streptococcus pneumoniae
isolated from respiratory tract infections in
Poland
R. Izdebski, E. Sadowy, W. Hryniewicz (Warsaw, PL)
Objectives: The objective of this project was to study molecular
mechanisms of tetracycline resistance and clonal diversity of
tetracycline-resistant Streptococcus pneumoniae isolated in Poland
to clarify which mechanism predominates in the strikingly high
spread of tetracycline resistance in the Polish population of
S. pneumoniae.
Methods: Eight hundred and nineteen clinical isolates of
S. pneumoniae from respiratory tract infections collected in
Poland between 1998 and 2003 were investigated by disk
diffusion method for tetracycline susceptibility as recommended
by the NCCLS. Serotyping of resistant isolates was performed
by capsule swelling reaction (Statens Serum Institut, Denmark)
and PCR. Clonality of the resistant isolates was studied by PFGE
of SmaI-digested bacterial DNA. Selected isolates representing
main PFGE types were analysed by the multilocus sequence
typing (MLST). Resistance determinants (tetM, tetO) were
detected by PCR.
Results: Two hundred and ﬁfty two (30,8%) isolates were non-
susceptible to tetracycline. The majority of isolates (49.6%)
possessed serotype 19F (69 isolates) or 23F (56 isolates). Serotype
19F isolates had 12 PFGE types. The main type in this group (55
isolates) had 8 subtypes. The representatives of the most
numerous subtype (43 isolates – 17% of whole resistant isolates)
had ST423. Isolates of the 23F serotype group had 21 PFGE
types. Among isolates of 23F serotype STs 440 (16 isolates), 81
(Spain 23F-1; 13 isolates) and 173/272 (Poland 23F-16; 5 isolates)
were identiﬁed. All isolates were positive for the tetM gene and
one isolate carried additionally the tetO gene.
Conclusion: The observed high level of resistance to tetracyc-
line among S. pneumoniae isolated in Poland is caused by spread
of relatively few epidemic clones, harbouring the tetM gene as
resistance determinant.
P1033
Streptococcus pneumoniae resistance in
young children: differences between European
countries
N. Bruinsma, W. Hryniewicz, K.G. Kristinsson, E. Tiemersma,
J.C.M. Monen, H. Grundmann on behalf of EARSS participants
Objectives: The highest levels of erythromycin and penicillin
resistance in S. pneumoniae (SPN) are found among isolates from
young children that are most vulnerable to pneumococcal
infections. In the present study,the prevalence of SPN resistance
among young children (less than 5 years of age) reported to the
European Antimicrobial Resistance Surveillance System
(EARSS) was compared between countries.
Methods: The EARSS has been collecting routine antimicrobial
susceptibility results of primary invasive SPN isolates from
blood or cerebrospinal ﬂuid (CSF) since 1999. The eight
countries reporting more than 100 isolates for the under ﬁve-
years-olds for the period 1999–2003 (Belgium, Denmark, Fin-
land, Ireland, Netherlands, Sweden, United Kingdom, and
Spain) were included in the analysis (total number of SPN
isolates = 17,123). The proportion of resistance was described as
the per cent of SPN with single penicillin (PEN) (non-suscept-
ible), single erythromycin (ERY), or dual resistance.
Results: Among young children, single ERY resistance was
most prominent in all countries, (from 6% in Sweden to 38% in
Belgium), except for Spain where the proportion of dual
resistance was highest (33%). For the other countries dual
resistance among young children ranged from 0% in Denmark
to 13% in Belgium. Except for Ireland (12%) and Spain (21%),
single PEN resistance remained below 5%.
Conclusion: Between countries, large differences in the patterns
of S. pneumoniae resistance were found among young children.
ERY resistance was most common among young children,
which may indicate greater use of macrolides in this age group.
In order to assess the effectiveness of interventions like vaccin-
ation, resistance and serotype data should be monitored care-
fully.
P1034
Evolution in the pattern of sensitivity to
penicillin and cefotaxime of Streptococcus
pneumoniae
I. Bonilla, E. Martin, F. Lopez Fabal, A. San Pedro Garrido, F. De
la Torre, J.J. Picazo (Madrid, E)
Background: The increase in resistance to penicillin, and more
recently to cefotaxime, means that it is necessary to study the
prevalence of resistance to these antibiotics, giving them huge
clinical importance. This study compares the sensitivity of
S. pneumoniae to penicillin and cefotaxime during
1991,1995,2000,2001,2002,2003 and 2004.
Methods: A total of 892 strains of S.pneumoniae from signiﬁcant
respiratory tract isolates were studied. These corresponded to
the years 1991(130); 1995(126); 2000(142); 2001(121); 2002(126);
2003(137) and 2004(110). MICs were determined according to
National Committee for Clinical Laboratory Standars (NCCLS)
guidelines. Break points for cefotaxime were established for
non-meningeal infections (sensitivity £ 1, intermediate resist-
ance = 2, resistance 4).
Results: The results are summarized in the following table:
Conclusions: A ﬁve-fold increase in resistance to penicillin was
observed with respect to the year the study started: 4.6% in 1991
to 22.2% in 2002. During the last two years, we observed a slight
resistency decrease. This is probably due to increase of the
vaccine use. The resistance proﬁle of cefotaxime shows a slow
but stable increase. Using breakpoints for meningeal infections,
resistance increases signiﬁcantly.
P1035
Sensitivity to different antimicrobials of
S. pneumoniae isolated in a university hospital
E. Martin, A. San Pedro Garrido, A. Sanchez Garcia, S. Solis del
Ban˜o, F. De la Torre, J.J. Picazo (Madrid, E)
Background: S. pneumoniae is one the most important patho-
gens in respiratory tract infections. The use of the most common
% Penicillin % Cefotaxime
S I R S I R
1991 (n = 130) 64.6 30.8 4.6 98.5 1.5 0
1995 (n = 126) 66.7 30.1 3.2 99.2 0.8 0
2000 (n = 142) 43.7 31.7 24.6 97.9 2.1 0
2001 (n = 121) 51.2 29.8 19 95.1 4.1 0.8
2002 (n = 126) 46.8 31 22.2 95.2 3.8 1
2003 (n = 137) 40.1 55.5 4.4 95 4.4 0.6
2004 (n = 110) 59 30 11 96.2 3.8 0
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antibiotics such as penicillins, cephalosporins and macrolides
has led to an increase in resistance. Consequently, new antimi-
crobial agents are needed.
Methods: We studied 350 strains of S. pneumoniae in clinical
isolates from the respiratory tract during 2002, 2003 and 2004. A
total of 41 strains were resistant to penicillin. The MICs for the
10 antibiotics (including new antimicrobial drugs) were tested
according to National Committee for Clinical Laboratory Stand-
ards (NCCLS) guidelines.
Results: The results are expressed in the following table:
Conclusions: No strains resistant to vancomycin, linezolid or
dalfopristin were found. For dalfopristin there is a 6% rate of
intermediate strains during 2002, and 1% during 2004. Cefotax-
ime maintains a low level of resistance and intermediate
sensitivity. The quinolones analysed may be a good alternative
in the treatment of S. pneumoniae. New antimicrobial agents
seem promising in treating infections caused by this pathogen.
P1036
Characterisation of the ﬁrst telithromycin
resistant pneumococcal isolate in Germany
A. Al-Lahham, N. Neuberger, S. Barbosa, I. Klawiter, M. van der
Linden, C. Heeg, R.R. Reinert (Aachen, D)
Background: S. pneumoniae is a serious infectious agents of the
respiratory tract and its resistance to new antibiotics is increas-
ing worldwide. In this study, the ﬁrst telithromycin resistant
S. pneumoniae isolate in Germany was characterized.
Methods: In a German nationwide study including 16 clinical
microbiological laboratories, a total of 206 S. pyogenes (pharyn-
gitis and wound infections) and 485 S. pneumoniae (respiratory
tract infections) isolates were colleced between January 2003 and
April 2004. MICs of penicillin G (PEN), cefotaxime (CEF),
erythromycin A (ERY), clindamycin (CLI), tetracycline (TET),
quinupristin-dalfopristin (Q-D), telithromycin (TELI), and levo-
ﬂoxacin (LEV) were determined using the microdilution method
according to the latest NCCLS guidelines. Macrolide resistant
genotypes were checked by RT-PCR with the LightCycler and
macrolide resistant phenotypes and sequencing of L4, L22, ermB
and 23S rRNA were performed according to standard methods.
Results: Resistance rates of S. pyogenes isolates were as follows
(I + R): PEN (0%), ERY (7.0%), CLI (0.5%), TET (7.0%), Q-D (0%)
and TELI (1%). S. pneumoniae isolates showed the following
resistance rates (I + R): PEN (7.2%), ERY (18.9%), CLI (5.3%),
TET (11.3%), and TELI (0.2%). The new ketolide telithromycin
was 99.8% active against S. pneumoniae isolates (MIC50 and
MIC90 equal 0.016 mg/L and 0.125 mg/L, respectively). The
telithromycin resistant pneumococcal strain showed 7 mutations
in the 23S rRNA (T107G, A1745T, A1535G, 1513T, T1514A,
A1530T, T1531A) and one amino acid alteration in L4 protein
(T20G). The strain was serotype 15A and MLST 63. It was
resistant to penicillin G, erythromycin A, clindamycin and
tetracycline. 26 macrolide resistant strains of pneumococci
(28.9%) harboured the ermB and 62 isolates (68.9%) had the
mef A resistance determinants. Two macrolide resistant strains
had neither ermB nor mefA. Two macrolide resistant S. pyogenes
isolates (14.3%) had the ermB gene and were telithromycin
resistant. Eleven S. pyogenes isolates (78.6%) contained the mefA
resistance determinant and one strain (7.1%) contained the
ermTR gene. Only two strains of S. pyogenes were inducible
showing the iMLSB-C phenotype.
Conclusions: Telithromycin resistance was observed in a mul-
tiply resistant serotype 15A (ST63)isolate, which may have the
potential for further spread in Germany.
P1037
Characterisation of quinolone-resistant
Streptococcus pneumoniae isolates in Germany
A. Al-Lahham, M. ven der Linden, C. Heeg,
R.R. Reinert (Aachen, D)
Background: S. pneumoniae belongs to the main human infec-
tious agents worldwide. In several nationwide studies on
resistance development in pneumococcal disease pneumococcal
isolates were collected.
Methods: Strains were serotyped using Neufeld’s Quellungre-
action and MICs of penicillin G (PEN), cefotaxime (CEF),
amoxicillen (AMOX), erythromycin A (ERY), clindamycin (CLI),
tetracycline (TET), ciproﬂoxacin (CIP), levoﬂoxacin (LEV), spar-
ﬂoxacin (SPA), grepaﬂoxacin (GRE), clinaﬂoxacin (CLX), moxiﬂ-
oxacin (MOX), gatiﬂoxacin (GAT) and gemiﬂoxacin (GEM) were
determined using the microdilution method according to the
latest NCCLS guidelines. Flouroquinolone resistant genotypes
were checked by PCR followed by DNA-sequencing of gyrA,
gyrB, parC and parE according to standard methods.
Results: Between Jan. 1992 and Dec. 2003 10.700 isolates from
315 laboratories were included in this study. A total of 40
ﬂuoroquinolone resistant strains (MIC CIP >2) were identiﬁed
(0.3–0.8%). The predominant serotypes were 23F (17.5%) and 9N
(10%). The moxiﬂoxacin MIC50 of the resistant strains was
0.5 lg/ml. Most mutations leading to ﬂuoroquinolone resistance
were found in parC (corresponding amino acid positions: 78, 79,
80, 83, 91 and 137), and parE at amino acid positions 460 and 435.
Only one strain was found to possess a gyrB mutation. 20 strains
(50%) were analysed by MLST. Predominant sequence types
were ST81 (10%), ST 9 (10%) and ST 66 (10%). MLST data of the
isolates did not show clonal relatedness of quinolone resistance.
Conclusions: Fluoroquinolone resistant strains remain rare in
Germany. A clonal relatedness of strains could not be afﬁrmed
using MLST.
P1038
Antimicrobial resistance of pneumococci isolated
from the nasopharynx of healthy children and
clinical isolates in Greece in 2004
I. Katsarolis, G. Poulakou, I. Matthaiopoulou, S. Tsiodras,
E. Roilides, D.A. Kafetzis, I. Paraskakis, G.L. Daikos,
V. Syriopoulou, S. Kanavaki, I. Kavaliotis, A. Kansouzidou,
S. Leveidiotou, G. Samonis, I. Pneumatikos, H. Giamarellou on
behalf of the Hellenic Study Group for the Susceptibility of
Streptococcus pneumoniae 2004
Objective: To present data from a nation-wide surveillance
study on the susceptibility of Streptococcus pneumoniae strains
Antibiotic 2002 (n = 103) 2003 (n = 137) 2004 (n = 110)
%S %I %R %S %I %R %S %I %R
Penicillin 46.6 31.1 22.3 39.5 55.5 5 59 30 11
Amoxicilin-
Clavulanic
86.4 12.6 1 94.4 5 0.6 92.5 7.5 0
Cefotaxime 95.2 3.8 1 95 4.4 0.6 96.2 3.8 0
Clarithromycin 58.8 0 41.8 61.3 0 38.7 64.5 1 34.5
Erythromycin 56.9 0 43.1 59.8 1.4 38.8 64.5 0 35.5
Levoﬂoxacin 96 3 1 97.8 0.7 1.5 100 0 0
Moxiﬂoxacin 96 3 1 98.5 0 1.5 100 0 0
Linezolid 100 0 0 100 0 0 100 0 0
Quinupristin-
Dalfopristin
94.2 5.8 0 100 0 0 99 1 0
Vancomycin 100 0 0 100 0 0 100 0 0
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from nasopharyngeal colonization (NPC)and from patients with
pneumococcal infections in year 2004.
Methods: Nasopharyngeal sampling from healthy children (2–
6 years old) attending day-centres was performed from Febru-
ary to May 2004. Clinical strains were also collected during the
same period in the collaborating laboratories. Pneumococci were
identiﬁed by use of optochin sensitivity, bile solubility and slide
agglutination (Pneumolatex) assays. Susceptibility testing was
performed for penicillin (PG), ceftriaxone (CXT), erythromycin
(ERY), tetracycline (TET), cotrimoxazole (COT), levoﬂoxacin and
moxiﬂoxacin by E-test. Ciproﬂoxacin (CIP) MICs were meas-
ured only in the NPC strains. NCCLS methodology and
breakpoints for intermediate resistance (IR) and resistance (R)
were used. The breakpoint used for CIP resistance was ‡4 mg/
L.
Results: A total of 762 NPC pneumococcal strains and 35
clinical strains were studied. For the NPC strains, results for IR
and R respectively per antibiotic (as %) were: PG (20.3/14.8),
CXT (0.8/0.1), ERY (0.8/33), TET (1.6/24.8), COT (18.7/25.6),
CIP (3.7). Twenty-eight NPC PG resistant strains (i.e. 3.7%) had
an MIC‡4 mg/L, (range 4–8). PG and EM R strains account for
10.5% of the total. Susceptibility patterns varied among different
geographic departments. For the clinical isolates, results were as
follows: PG (14.3/11.4), CXT (0/0), EM (5.7/22.9), TET (3/12.1),
COT (14.7/17.6). No resistance to the respiratory ﬂuoroquino-
lones was observed in both groups.
Conclusions: Data suggest an increasing trend in the resistance
rates for both penicillin and erythromycin. Results from the
colonizing and the clinical strains had good correlation,
although clinical strains had lower resistance rates. Respiratory
ﬂuoroquinolones did not display resistance in vitro, but the
emergence of CIP resistant colonizing strains needs further
evaluation and attention. Despite increasing trends in resistance,
the low number of strains beyond clinical resistance cut-offs
(MIC for PG >4 mg/L) render beta-lactams still potent agents
against pneumococcal disease.
P1039
Susceptibility of pneumococci causing meningitis
in England and Wales to recommended
antimicrobials, 2001–2003
N. Potz, M. Warner, U. Gungabissoon, R. George, D. Livermore,
R. Pebody, A. Johnson (London, UK)
Objectives: Streptococcus pneumoniae is the second commonest
cause of bacterial meningitis in the UK after Neisseria meningitis.
The present national recommendations for treatment of pneu-
mococcal meningitis in the UK is cefotaxime, with penicillin
substituted if the isolate proves to be susceptible in laboratory
tests. In cases involving cephalosporin-resistant pneumococci,
cefotaxime should be supplemented with vancomycin or rif-
ampicin. Resistance to these antibiotics was investigated for the
period 2001–2003.
Methods: Cases of pneumococcal meningitis reported routinely
to the Health Protection Agency were reconciled with cases
identiﬁed from reference laboratory submissions of pneumococci
during 2001–2003. Inclusion criteria were cases where S. pneu-
moniae was isolated from CSF, and those where pneumococci
were isolated from blood with meningitis given as a clinical
diagnosis.
Results: A total of 813 cases of pneumococcal meningitis were
identiﬁed in England and Wales. Of the 673 case reports
submitted, 433 were accompanied by penicillin susceptibility
data, with 26 cases (3.9%) indicating reduced penicillin suscep-
tibility. Only one of the 549 isolates (0.2%) with cefotaxime
susceptibility data was reported as resistant. No resistance to
rifampicin or vancomycin was reported. Among the referred
isolates with reduced penicillin susceptibility, the commonest
serotypes were 9V, 14and 6B.
Conclusions: This study provides a reasonably robust estimate
of the prevalence of antibiotic resistance for pneumococcal
meningitis in England and Wales during 2001–2003. Results
obtained show that resistance to cefotaxime, the recommended
empirical treatment for pneumococcal meningitis, was very low
during this period.
P1040
Antibiotic resistance among invasive
pneumococcal isolates from Southwest Sweden
1998–2001
E. Backhaus, S. Berg, B. Trollfors, B.E.B. Claesson,
R. Andersson (Sko¨vde, Go¨teborg, S)
Objectives: Streptococcus pneumoniae is amajor human pathogen.
In Southwest Sweden, with a population of 1.8 million, 200
patients are diagnosed each year with invasive pneumococcal
disease. The rapid emergence of isolates with decreased suscep-
tibility to several antibiotics is an increasing problem in many
parts of theworld. The aim of the present studywas to investigate
the pattern of susceptibility among invasive isolates, in order to
see if the current treatment policies are appropriate, and to see if
there seems to be a trend of increasing antibiotic resistance.
Methods: All clinical isolates of S. pneumoniae from blood,
cerebrospinal and joint ﬂuid were collected at the laboratories in
Go¨teborg, Sko¨vde, Bora˚s, Uddevalla and Halmstad during 1998–
2001. The MIC-values for seven commonly used antibiotics
(penicillin G, erythromycin, clindamycin, tetracycline, moxiﬂ-
oxacin, cotrimoxazole and cefotaxime) were determined with
E-test (AB Biodisk) according to standard methods.
Results: 868 invasive strains were tested. Of these, 808 were
fully susceptible and 60 were classiﬁed as Indeterminate (I) or
Resistant (R) for any of the tested antibiotics, according to the
Swedish Reference Group for Antibiotics system of species
related breakpoints. No isolate had a MIC >1.0 mg/L against
penicillin (R). 15 (1.7%) isolates had MIC ‡0.5 mg/L and 8
isolates had MIC’s between 0.094 and 0.38 mg/L. Among these
23 isolates classiﬁed as I to penicillin (MIC >0.06, £1.0 mg/L), 16
isolates were also I against cefotaxime (MIC <0.12, ‡1.0 mg/L)
(1.8%).The other tested antibiotics showed the following results:
Erythromycin R (MIC >0.5 mg/L) 33 isolates (3.8%), clindamy-
cin R (MIC >0.5 mg/L) 6 isolates (0.7%), tetracycline R (MIC
>2 mg/L) 17 isolates (2.0%), and moxiﬂoxacin R (MIC >2 mg/L)
1 isolate (0.1%). There were no isolates classiﬁed as I for those
antibiotics. There were 23 isolates classiﬁed as I against
cotrimoxazole (MIC >16, £32 mg/L), but no R (MIC >32 mg/L).
Conclusion: The proportion of invasive isolates of pneumococci
with decreased sensitivity to commonly used antibiotics is very
low.
P1041
Antimicrobial susceptibility of Streptococcus
pyogenes isolated in 2004 in Spain, and
comparison with previous studies (1998 and 2001)
J. Tamayo, J.I. Alo´s, J.L. Go´mez-Garce´s on behalf of the Study
Group IAP-SEIMC
Objectives: To examine the susceptibility to penicillin G,
macrolides, clindamycin and telithromycin of Streptococcus
pyogenes isolated in 2004 in Spain, and to compare the results
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with those obtained in previous studies performed in 1998 and
2001 with the same methodology.
Methods: A total of 530 unique isolates of S. pyogenes collected
in 21 laboratories were studied by the agar dilution method, in
accordance with NCCLS guidelines. The number of strains
collected was proportional to the number of inhabitants of each
geographical area. We also determined the different macrolides-
lincosamides-streptogramins phenotypes of resistance.
Results: (See table 1 and table 2) If we compared the results
obtained in 2004 with those obtained in 1998 and 2001, we
observed an statistically signiﬁcant increase in the prevalence of
the MLSB constitutive phenotype (p < 0.001, Chi square test).
Conclusions: In 2004, (1) 14.9 % of the isolates were erythro-
mycin-resistant and clindamycin-and miocamycin susceptible
(M phenotype), a smaller percentage than in previous studies;
(2) There was a signiﬁcant increase in 2004 of isolates with the
MLSB constitutive phenotype; (3) There was a high prevalence
of resistance to telithromycin (88.6 %) in the 35 strains with
MLSB constitutive phenotype.
P1042
Patterns of macrolide resistance determinants
among S. pyogenes and S. pneumoniae isolates in
Saudi Arabia
A. Shibl (Riyadh, SA)
Objective: To characterize the macrolide sensitivity of recent
isolates of S. pyogenes and S. pneumoniae collected from different
hospitals around Saudi Arabia and to investigate the resistance
determinants carried by macrolide-resistant isolates.
Methods: Susceptibility testing was performed using standard
NCCLS methodology on 335 S. pyogenes and 350 S. pneumoniae
isolates. Macrolide resistance mechanism phenotypes were
identiﬁed using double disk diffusion.
Results: All S. pyogenes were penicillin sensitive, while 6.4%
were macrolide resistant, the main mechanism of which was of
M-phenotype (96%). Approximately 51% of S. pneumoniae was
penicillin non-susceptible. Macrolide resistance in S. pneumoniae
accounted for 18.8%, the majority of which was M phenotype
(92%). Low-level resistance mediated by mef-bearing strains
predominated.
Conclusions: Efforts should focus not only on antibiotic resist-
ance surveillance and the development of guidelines but also on
appropriate use of antibiotics. Strategies have been proposed
which include restricting access, compliance promotion and
reduction in our prescriptions and inappropriate use of antibi-
otics. Newer macrolides, including azithromycin, are still
considered drugs of choice for empirical treatment of respirat-
ory infection in such circumstances.
P1043
Tetracycline resistance in erythromycin resistant
beta-haemolytic streptococci of Lanceﬁeld groups
A, B, C and G
M.R. Amezaga, L. Ford, H. McKenzie (Aberdeen, UK)
Objectives: MLSB phenotype erythromycin resistance (EryR) is
often associated with tetracycline resistance (TetR) and in
Streptococci is mediated by the methylase genes erm(B) or
erm(TR). In Streptococcus pneumoniae, erm(B) is carried in
transposons such as Tn1545 which also carry the TetR gene
tet(M). M phenotype EryR is associated with the efﬂux genes
mef(A) or mef(E). These genes are carried in genetic elements
that do not commonly include TetR genes, but the mef(E)
element in S. pneumoniae can be inserted in a transposon that
carries tet(M). Our objective was to investigate TetR in EryR
beta-haemolytic streptococci of groups A, B, C and G.
Methods: 129 EryR beta-haemolytic streptococci of groups A
(26), B (42), C (9) and G (52) were collected over two years. TetR
was determined by disc diffusion and MICs by E-test. PCR was
performed for tet(M), tet(O) and tet(L); EryR genes had been
characterised previously.
Results: The prevalence of TetR amongst EryR MLSB isolates
was high in groups A (73%, 11 of 15), B (92%, 34 of 37) and C
(100%, 2 of 2) but lower in group G (38%, 18 of 47). The range
of MICs in TetR isolates was 4 ‡ 256 (mg/l). The tet(M) gene
was responsible for most TetR in groups A (100%, 11 of 11), B
(85%, 29 of 34), C (100%, 2 of 2) and G (56%, 10 of 18); tet(L)
and tet(M) were both found in the same isolates in groups B
(2) and G (1). At least 80% of erm(B) isolates and 57% of
erm(TR) isolates of groups A, B and C carried tet(M). In
contrast, only 21% of erm(TR) isolates in group G carried
tet(M). Amongst M phenotype isolates, the prevalence of TetR
was high in groups B (100%, 5 of 5) and G (80%, 4 of 5) and
lower in group C (14%, 1 of 7). TetR was not detected in M
phenotypes of group A. In M phenotypes, tet(M) was
responsible for 100% TetR in group B (5 of 5) and 25% in
group G (1 of 4); 1 isolate of group C carried tet(O). tet(M) and
tet(O) were found in mef(E) isolates but not in mef(A) isolates.
There were TetR isolates in groups B (5) and G (11) in which
no TetR gene was identiﬁed.
Conclusions: 1) The prevalence of TetR in EryR beta-haemo-
lytic Streptococci was high in MLSB isolates of groups A, B and C
and in M isolates of groups B and G. 2) tet(M) was the
predominant TetR gene. 3) tet(M) was strongly associated with
erm(B) and to a lesser extent with erm(TR). 4) tet(M) was found
in association with mef(E) but not mef(A).
Table 1. In vitro susceptibilities of 530 recent S. pyogenes isolated
in 2004
Antibiotic MIC range (mg/L) MIC90 (mg/L) %S %R
Penicillin G £ 0.008–0.03 0.015 100 0
Erythromycin £ 0.12–>16 4 78.3 21.7
Azithromycin £ 0.12–>16 4 78.5 21.5
Miocamycin £ 0.12–>16 0.5 93.4 6.6
Clindamycin £ 0.12–>16 £ 0.12 93.2 6.6
Telithromycin £ 0.008–>16 0.25 94.0 5.8
Table 2. Frequency of different phenotypes of resistance in the
studies performed
Year
Phenotype (%)
M MLSB c
a MLSB i
b
1998 22.4 0.8 0.20
2001 28.2 1.3 0.19
2004 14.9 6.6 0.20
aMLSB c: MLSB constitutive
bMLSB i: MLSB inducible
Isolate (no.)
Resistance %
Penicillin Macrolide
S I R
S. pyogenes (335) 100 – – 6.4
S. pneumoniae (350) 49 42 9 18.8
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P1044
Predominance of three emm-types among
Streptococcus pyogenes isolates from invasive
diseases in Greece
A. Stathi, L. Zachariadou, P.T. Tassios, A. Pangalis, N.J. Legakis,
J. Papaparaskevas on behalf of The Hellenic Strep-EURO Study
Group
Objectives: Based on the enhanced surveillance of Streptococcus
pyogenes (group A Streptococci; GAS) invasive disease in Greece
during the period 2003–2004, we aimed to determine the
predominant emm-types and their possible association with
erythromycin resistance and toxin gene production.
Materials and methods: A total of 60 invasive GAS isolates
were collected during the period 1/2003–6/2004 from 10
hospitals in Greece. MIC determination of erythromycin, clin-
damycin and tetracycline was performed using the Etest
method. MLS phenotype detection was performed using the
erythromycin-clindamycin double disk method. PCR was used
for detection of MLS resistance determinants mefA, ermB and
ermTR as well as erythrogenic toxin genes speA, speB and speC.
T-serotyping was performed using commercially available
antisera. OF detection was performed using the agar method.
M-type assignment was performed using the CDC emm-gene
ampliﬁcation and sequencing protocol.
Results: Isolates were from blood, deep tissue infections,
synovial, pleural and cerebrospinal ﬂuid (27, 22, 5, 4 and 2,
respectively). Mean patient age was 19 years (range 1–80 years).
Seven strains (12%) were resistant to erythromycin (EryR; MIC
>0.5 mg/L). Four of these belonged to MLS phenotype M, two
to the IR and one to the CR phenotype. Fifteen strains (25%)
were resistant to tetracycline (MIC >4 mg/L). All four M
phenotype isolates possessed only the mefA gene, both IR
strains possessed only ermTR, whilst the CR strain possessed
only ermB. Twenty isolates possessed only the speB toxin gene,
nineteen possessed both speB and speA, nineteen possessed
both speB and speC, and two possessed all three toxin genes. Of
the 21 emm-types detected, three were predominant: emm1,
emm12 and emm6 (33%, 10% and 6.6% of all isolates, respect-
ively). Erythromycin resistance amongst these types was only
detected in three emm12 strains. Three of the four M phenotype
strains belonged to the emm4 type. All but one of the 20 emm1
type strains possessed the speA toxin gene, whilst only two of
the 40 strains belonging to all other emm-types possessed the
speA toxin gene (p < 0.0001).
Conclusions: A total of 12% of invasive GAS isolates were
resistant to erythromycin, with phenotype M being predomin-
ant. Half of the isolates belonged to three emm types, with the
remaining 30 being distributed among 18 emm-types. Type
emm1 was predominant, and presented a strong association
with the speA toxin gene.
P1045
Distribution of mefA-containing genetic
elements in Italian isolates of Streptococcus
pyogenes
S. DErcole, D. Petrelli, C. Zampaloni, L.A. Vitali, F. Marmocchi,
M.S. Pasquantonio, S. Ripa, M. Prenna (Camerino, I)
Objectives: Erythromycin resistance M phenotype in Group A
Streptococci (GAS, Streptococcus pyogenes) is due to an efﬂux
system coded by the mefA gene, which is carried by a mobile
genetic element, named either Phi10394.4 or Tn1207.3. This
element is essentially composed of a transposon inserted into a
prophage and its chromosomal insertion site has been mapped
into the comEC gene. The aim of the present study was to
analyze the genetic localization of the mefA gene by determin-
ing the general structure variability of the genetic element and
its insertion site into the bacterial chromosome in 124 erythro-
mycin resistant S. pyogenes clinical Italian isolates.
Methods: comEC gene was ampliﬁed in all isolates to test for its
integrity. Negative reaction was taken as an indication of the
insertion of the mobile genetic element. Subsequently, a set of
oligonucleotide primers was constructed and used in PCR
experiments to screen for the presence of distinctive parts along
the entire sequence of the Phi10394.4/Tn1207.3 chimeric element
(i.e. ﬂanking regions and R-6, mefA, ABC-transporter, umuC-
mucB, type II methylase genes).
Results: 20 out of 124 isolates (16.1%) were negative to the
comEC gene ampliﬁcation. The analysis of the insertion point
ﬂanking regions indicated that the Phi10394.4/Tn1207.3 element
is present and inserted into the comEC gene. 9.7% of the
population showed a mixed genotypic pattern, where comEC
gene was ampliﬁed but the prophagic element was still present.
This result was additionally conﬁrmed by sequencing of the
PCR products obtained. The remaining comEC positive popu-
lation (74.2%) was Phi10394.4/Tn1207.3 negative, as none of the
mobile element genes tested was ampliﬁed.
Conclusions: A very low portion of the population (16.1%) has
the mefA gene carried by the Phi10394.4/ Tn1207.3 prophage
element inserted into the comEC gene. About a tenth of the
population contains an intact form of the comEC gene while
presenting a Phi10394.4/ Tn1207.3 positive pattern. Unexpect-
edly, the vast majority of isolates (74.2%) has the mefA gene
vectored by neither forms of the prophagic chimeric element
previously described. However, since it has been largely
demonstrated that streptococci efﬂux mediated resistance can
be transferred among bacteria by means of a transformation
process, other mobile genetic elements should be present in
Streptococcus pyogenes that act as molecular hosting vector for
the mefA gene.
P1046
Prevalence, phenotypes, genotypes and molecular
epidemiology of macrolide resistant clinical
isolates of Streptococcus pyogenes in Norway 1993
and 2002
P. Littauer, M. Sangvik, B. Haldorsen, K. Dahl, D. Caugant,
A. Høiby, A. Sundsfjord, G. Simonsen (Tromsø, Oslo, N)
Background: We have limited knowledge regarding the pre-
valence and molecular epidemiology of macrolide resistant
Streptococcus pyogenes in Norway.
Objectives: i. Examine the prevalence of macrolide resistance in
clinical S. pyogenes–isolates in Norway. ii. Further caution of
macrolide resistant isolates of S. pyogenes strains with regard to
resistance phenotype, genotype and different typing schemes
including T-typing, emm-typing and multilocus sequence
typing (MLST).
Methods: A total of 1657 isolates of S. pyogenes from respiratory
tract and wound specimens were collected in Norway in three
periods in 1993–97 and 2002 by 24 participating laboratories
within the NORM surveillance programme for antimicrobial
resistance in human pathogens. Erythromycin susceptibility
testing was performed by E-test. Further analyses for their
susceptibility to eight different antibiotics by E-test and double-
disk-diffusion as well as opacity factor (OF), T-typing, emm
typing and MLST. Genotypic analyses were performed by erm
and mef speciﬁc PCRs.
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Results: Reduced susceptibility (MIC >1 mg/L) was detected in
44 (2.7%) S. pyogenes isolates. A total of 32 (73%) S. pyogenes
isolates demonstrated a MLSB phenotype resistance. The dom-
inating gene was erm(A) (n = 27), encoding resistance in 27
strains, whereas erm(B) was detected in only ﬁve of the strains
isolates. While one of the cMLSB strains carried both erm(A) and
the mef(A) gene, another cMLSB strain was reproducibly
negative in erm and mef PCR analyses, and will be further
investigated. The remaining 11 (25 %) isolates all carried the
mef(A) gene and showed a consistent with their M phenotype
resistance. Thirty (68%) strains were resistant to tetracycline and
carried the erm-positive strains (n = 30) genes, while all the
Mtype strains were susceptible to tetracycline. Typing analyses
revealed T-type 4 and ST39 dominated in nine 9 out of 10 with
Mtype phenotype, whereas T-type 3 was associated with ST46 in
8 of 9 erm(A)-positive and tetracycline resistant strains. Results
from emm typing supported these clonal observations.
Conclusions: (i) The prevalence of macrolide resistance among
S. pyogenes in Norway is low, and the (ii) MLSB resistance,
erm(A) or erm(B) was the most prevalent resistance type and
co-resistance to tetracycline was frequently observed. (iii) Clonal
observations were discerned in MLSB-strains (T3 and ST46;
n = 8) as well as Mtype isolates (T4 and ST39; n = 9)
P1047
Evaluation of the Phoenix Automated
Microbiology System in identiﬁcation and
antimicrobial susceptibility of clinical isolates of
Streptococci
F. Luzzaro, G. Brigante, F. Meacci, G. Lombardi, B. Pini,
A. Toniolo (Varese, Siena, I)
Objectives: Streptococci are important pathogens causing both
community- and hospital-acquired infections. Prompt and
correct identiﬁcation of clinical isolates at the species level is
essential for therapeutic management and epidemiology. Clas-
sical criteria (colony size, hemolysis, and group carbohydrate
antigens) represent a useful tool for streptococcal identiﬁcation,
but recent taxonomic changes tend to revaluate biochemical
identiﬁcation.
Methods: The PhoenixTM Automated Microbiology System
(Becton Dickinson, Sparks, MD) was evaluated for its capability
of identifying clinical isolates belonging to the genus Strepto-
coccus and quantitatively determining the susceptibility to
antimicrobials. One hundred clinical isolates were investigated:
S. pneumoniae (n = 46), S. agalactiae (n = 15), S. pyogenes (n = 14),
S. dysgalactiae (n = 20), other streptococcal species (n = 5).
Thirteen isolates of S. pneumoniae with reduced susceptibility
to penicillin were included in the study. Species identiﬁcation
obtained by the Phoenix System was evaluated in comparison to
results given by the API System (API 20 STREP; bioMe´rieux sa,
Marcy lE´toile, France). Discrepancies were resolved by direct
sequencing of 16S rDNA. Quantitative antimicrobial suscepti-
bility results for eight clinically relevant drugs (penicillin,
cefotaxime, cefepime, erythromycin, clindamycin, chloramphen-
icol, levoﬂoxacin, and vancomycin) were compared to MIC
values measured by the Etest (AB Biodisk, Solna, Sweden).
Based on NCCLS criteria, a reference broth dilution method was
used to resolve discrepancies.
Results: The Phoenix System correctly identiﬁed 93% test
isolates within 16 hr. When not identiﬁed or misidentiﬁed
organisms were retested, correct identiﬁcation rose to 98%. AST
results interpreted according to current NCCLS guidelines
showed essential and categorical agreement of 92% and 99%,
respectively. No very major or major errors were produced. The
overall percentage of minor errors was approximately 1%. The
average time (±SD) to results was 12.3 ± 2.2 hr and appeared to
depend on the species.
Conclusion: Identiﬁcation and AST results provided by the
Phoenix System appeared to be satisfactory in terms of accuracy
and speed of diagnosis for the therapeutic management of
streptococcal infections.
P1048
Incidence and mechanisms of reistance to
macrolides in S. pyogenes in the West of Ireland
A. Coleman, M. Cormican, D. Kilmartin, M. NiChulain (Galway,
IRL)
Aims and Objectives: Macrolides are an important alternative
to penicillin for treatment of Streptococcus pyogenes infection.
Rates of resistance to macrolides vary from region to region and
these rates are important in deﬁning the role of macrolides in
empiric therapy. Macrolide and lincosamide resistance are
mediated by 3 distinct mechanisms, (1) mefA encodes resistance
to erythromycin but not clindamycin, (2) ermB encodes resist-
ance to erythromycin and clindamycin, (3) ermA encodes
resistance to erythromycin and inducible resistance to clinda-
mycin.
Methods: Consecutive pharyngeal isolates of Streptococcus pyo-
genes isolates were collected between January 2003 and April
2004. Isolates were conﬁrmed as S. pyogenes by Lanceﬁeld
grouping using the Pastorex STREP rapid agglutination kit.
Erythromycin susceptibility testing was performed by NCCLS
disc diffusion. Erythromycin resistant isolates were tested for
susceptibility to erythromycin and azithromycin by Etest. The
mechanisms of resistance was assessed using the erythromycin/
clindamycin disc approximation test and by PCR, with primers
speciﬁc for the ermA, ermB and mefA genes. Positive controls
were kindly provided by Ralf R. Reinert.
Results: Four (4) of 360 consecutive isolates (1%) were resistant
to erythromycin. Erythromycin resistance was conﬁrmed by
Etest and these isolates were also resistant to azithromycin. All 4
erythromycin-resistant study isolates and 3 of 4 previously
collected erythromycin-resistant isolates were conﬁrmed as
ermA positive by PCR and exhibited inducible resistance by
disc approximation. One previously collected isolate was sus-
ceptible to clindamycin and was mefA positive by PCR.
Conclusion: These data show that macrolide resistance in
S. pyogenes is very uncommon in this area and is encoded
primarily by ermA.
P1049
Prevalence of multiresistance among
Streptococcus pneumoniae strains in Finland
M. Rantala, J. Jalava, P. Huovinen (Turku, FIN)
Objectives: Multiresistance among Streptococcus pneumoniae
strains is becoming alarming problem. Aim of this study was
to evaluate the prevalence of multiresistant strains in Finnish
pneumococci.
Materials and methods: Study was based on two groups of
pneumococci: 1007 pneumococcal strains isolated both from non-
invasive and invasive infections in 2002. The other group
consisted all invasive pneumococcal isolates (n = 1011) that had
been reported into National register Infectious Disease Register
at the National Public Health Institute between January 2003
and April 2004. Antimicrobial susceptibility testing was per-
formed by agar plate dilution method. Strain was deﬁned as
multiresistant if it showed resistance to three or more antimi-
crobial classes. Detection of macrolide resistance determinants
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[mef(A/E), erm(B), erm(TR)] was done by multiplex PCR from
erythromycin non-susceptible and multiresistant strains isolated
in 2002. Mef(A) and mef(E) subtypes were differentiated by
separate PCR reactions.
Results: In year 2002 10.5% (106/1007) of pneumococci were
multiresistant. Prevalence of multiresistant strains varied from
2% to 25% in different hospital districts. Non-invasive strains
were more commonly multiresistant compared to invasive
strains (10% vs. 4%). Among invasive strains the proportion of
multiresistance was 5.1% in 2003–2004. Of 106 multiresistant
strains, 91 (86%) strains carried either erm(B) methylase gene
(m = 58) or subtype mef(E) efﬂux gene (n = 33). Double
mechanism was detected in four strains. Most common multi-
resistant phenotype was [MLSB or M]-penicillin-tetracycline-
trimethoprim-sulfomethoxazole (n = 34). Strains from young
children (two years or younger) were more frequently resistant
compared to strains from older patients.
Conclusions: When compared to previous years, the signiﬁcant
increase in multiresistance among invasive strains was detected
between periods 1999–2000 and 2003–2004 (from 0.3% to 5.1%).
The high prevalence of multiresistant pneumococci in Finland is a
matter of concern. Additional studies are on progress to verify
whether the spread of multiresistance is due to horizontal gene
transfer or spread of resistant clones.
Wound and fungal infections
P1050
Does initial choice of antimicrobial therapy affect
length of stay for patients with complicated intra-
abdominal infections?
S. Wilson, R. Turpin, X.H. Hu, E. Mansley (Irvine, West Point,
USA)
Objective: Complicated Intra-abdominal infections (IAIs) often
require surgical intervention and antimicrobial therapy, fre-
quently resulting in lengthy hospital stays. Common diagnoses
include acute appendicitis with peritonitis or abscess (APP),
cholecystitis (CHO), diverticulitis (DIV), acute pancreatitis
(PAN), and post-operative infections (POI). Outcomes are
inﬂuenced by many patient-related factors and aspects of
medical management, including antimicrobial treatment
choice. We studied a multiple hospital database to explore the
length of stay (LOS) associated with initial choice of antimicro-
bial therapy for complicated IAIs.
Methods: We utilized Premier’s Perspective Comparative Data-
base to assess LOS for all 2150 admissions between February
2002 and June 2003 at 33 hospitals. The study population was all
patients ‡18 years with diagnoses described above, receiving 1st
line ampicillin/sulbactam (A/S), ceftriaxone (CEF), ertapenem
(ETP), levoﬂoxacin (LEV), or piperacillin/tazobactam (P/T). A
regression tree using CART software was performed to select
important variables, their interactions, and their order of
importance in explaining LOS. A linear regression model was
then utilized to formally compare the ﬁve treatment groups in
terms of their LOS, controlling for patient variables (diagnosis,
ICU stay, co-morbidities, age, sex and ethnicity) and hospital
variables (region, urban/rural and teaching designation).
Results: Table 1 indicates mean LOS by initial antimicrobial
therapy and diagnosis; italics indicate shortest LOS per diagno-
sis; n’s are in parenthesis (X2 = 186.9; p < 001). Table 2 presents
the adjusted LOS from the linear regression model; n’s are in
parenthesis. Controlling for variables listed above, LOS with
ETP was not signiﬁcantly different from A/S (p = 31). Both ETP
and A/S were signiﬁcantly different from LEV, P/T and CEF
(all p < 05). Adjusting for all other factors, the variables
associated with severity (diagnosis, ICU stay and co-morbid-
ities) had the greatest impact on adjusted LOS (all p < 0.0001).
Conclusion: Findings indicate ETP and A/S were associated
with shorter hospital stays, though this may be explained by
underlying severity of infection. A randomized trial to test a
treatment effect may be warranted.
P1051
Evaluation of surgical prophylaxis in heart
surgery
C. Buke, O. Sipahi, M. Tuncel Basoglu, E. Bascesme,
H. Posacioglu, S. Ulusoy (Izmir, TR)
Objective: Aim of this study was to evaluate antimicrobial
prophylaxis (AP) practice and its cost in Intensive Care Unit of
Heart Surgery Depertment in our hospital.
Method: Study was performed prospectively between January–
December 2002. AP lasting >1 day was considered inappropri-
ate, unless the patient was in high risk group (heart transplan-
tation or repeated by-pass). In addition AP with two beta lactam
agents; beta lactam+aminoglycoside (only beta lactam+gentam-
icin was allowed); 3rd generation cephalosporins; quinolones or
glycopeptides were considered inappropriate. In high risk
patients, AP lasting up to 3 days and AP with glycopeptides
were considered appropriate. Cost of inappropriate AP was
calculated by using August-2004 prices in EURO. Cost of
inappropriate AP in patients who received cefazolin or beta
lactam/beta lactamase inhibitors (ampicillin/sulbactam or am-
oxycillin/clavulanate) was calculated by substraction of cost of
1 day lasting AP from total AP cost. In case of inappropriate
glycopeptide or quinolone or aminoglycoside usage, one day
lasting cefazolin cost was substracted from total AP cost. In high
risk patients cost of inappropriate glycopeptide usage was
calculated by substracting 3 days lasting AP cost from total cost.
Infections were diagnosed according to the criteria of Center for
Diseases Control and Prevention (CDC). Data were analysed
with chi square and Student’s t-tests.
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Results: Among 168 patients (50 females, 118 males, aged
41.2 ± 26) who received AP, only one patient (0.6%) received
appropriate AP. Only 71 patients (42.2%) received £ 3 days AP.
Patients who received (3 days AP developed more nosocomial
infections than patients who received <3 days AP (15/97–15.4%
vs 5/71–5.6%, p < 0.05). Mortality rate was 12.3% (12/97) in
>3 days AP group and 4.2% (3/71) in <3 days AP group
(p > 0.05). Average cost of AP was higher in >3 day group.
(23.68 ± 18.97 EURO vs 217.12 ± 270.62 EURO, p < 0.05). Total
cost of AP was 22.778 EURO, and cost of inappropriate or
>1 day AP was 21.065 EURO.
Conclusion: Although it is not a randomized study, it is seen
that AP longer than known criteria does not mean less
nosocomial infections. Education and other interventions
about AP may be necessary in order to resolve the situation.
P1052
Perioperative anti-infective prophylaxis with
teicoplanin or second generation cephalosporins
in vascular and orthopaedic surgery involving
prosthetic material: a meta-analysis of
randomised control trials
K. Vardakas, E. Soteriades, S. Chrysanthopoulou,
P. Papagelopoulos, M. Falagas (Athens, GR; Boston, USA)
Objective: To evaluate the effectiveness and safety of teicopl-
anin compared to second-generation cephalosporins for periop-
erative anti-infective prophylaxis in orthopedic and vascular
surgery involving prosthetic material.
Design: Meta-analysis of randomized controlled trials (RCTs)
Data sources: Data were obtained from PubMed (1/1950–10/
2004), Current Contents, Cochrane central register of controlled
trials, and references from relevant articles.
Study selection: RCTs comparing teicoplanin with second
generation cephalosporins in vascular and orthopaedic surgery
were included in the study.
Data extraction: Two independent reviewers extracted data
concerning development of infections at the site of operation or
in remote areas, reported adverse effects, and mortality.
Results: Six RCTs were included in the analysis. Publication
bias and statistically signiﬁcant heterogeneity was not observed
among the analysed studies. There were no differences in the
development of infection at the site of operation (OR = 0.95, 95%
CI 0.58–1.56) or in remote areas of the body (OR = 0.94, 95% CI
0.73–1.22) between teicoplanin and cephalosporins. In addition,
there was no signiﬁcant difference in reported adverse effects
(OR = 0.77, 95% CI 0.50–1.18).
Conclusions: Teicoplanin is not more effective than second-
generation cephalosporins as perioperative anti-infective pro-
phylaxis in orthopedic and vascular operations involving
prosthetic material.
P1053
Postoperative infection in posterior spinal fusion
surgery in children
M. Syrou, I. Hager, A. Makri, H. Papavasileiou, G.
Kanellopoulou, D. Demetriades, A Voyatzi (Athens, GR)
Objectives: The aim of the present study was to investigate the
frequency and the type of wound infections, as well as the
bacteria involved, after posterior spinal fusion in children,
especially with spinal deformities, over a 6-year period (1999–
2004).
Materials and methods: A total of 133 spinal fusions were
performed on 110 children, with or without instrumentation,
because of spinal scoliosis (120), spondylolisthesis (4), fractures
(4), and for other reasons (5). The average age at operation was
13 years (range 4–17). Metal instrumentation was used in all the
posterior spinal surgery. Out of 115 posterior spinal fusion cases
15 patients developed deep wound infections. 289 consecutive
specimens were obtained from the infected wounds and
cultured on appropriate media, for aerobic and anaerobic
bacteria. The identiﬁcation was based on conventional methods.
Results: 15 patients (13%) developed an early (2–7 days) or
delayed (6 months–2.5 years) infection after surgery (11 early, 4
delayed). Out of 289 wound specimens, 219 were found positive
for pathogens. From these in 19 (8.6%) were isolated 2 bacteria
and only in 1 three. The most common organisms from 240
isolated bacteria were: coagulase-negative Staphylococci (CNS)
(46.2%), following by Gram negative bacteria(36.2%), Staphylo-
coccus aureus (10.9%), Anaerobes (4.6%),Steptococci spp (1.7% )
and Candida spp (0.4%).25 S. epidermidis slime-producing strains
were isolated from 6 patients with persistent wound infections.
CNS were resistant against penicilline (63. 9%), oxacillin (32.4%),
erythromycin (38.7%), fusidic acid (35.1%), clindamycin (27.9%),
gentamicin (26.1%) and co-trimoxazole ( 21.6%). Low resistance
was recorded against rifampicin (8.1%) and quinolones (9.9%),
while all isolates were sensitive to glycopeptides.
Conclusions: 1. The most predominant pathogens were CNS
and Gram negative bacteria. 22.5% of CNS pathogenic strains
were slime producers. 2. Infection rate after posterior spinal
instrumentation was found 13%. 3. In comparison with the rate
of infection 20% of previous reported study in our hospital, the
reduction to 13% should be correlated with the improvement of
surgical technique and operation room conditions.
P1054
Lucilia sericata: latest results of antibacterial
activity
M. Reinecke, G. Mayer, P. Heisig (Hamburg, Barsbu¨ttel, D)
Objectives: Therapy of chronic wounds with Lucilia sericata
presents a promising alternative to the classical approach with
antibiotics. Larvae are placed in wounds free-roaming or in
biobags. The therapy often stimulates the process of wound
healing. This effect is based on different mechanisms. Maggots
saliva contains collagenases, trypsin and chymotrypsin-like
enzymes which dilute necrotic tissue. Furthermore, an antibac-
terial effect has been described. In our study, we focused on the
question whether this effect could be explained by the ingestion
of bacteria by larvae.
Methods: Free roaming maggots were placed on agar plates
with Escherichia coli. These bacteria had been transformed with
Green ﬂuorescent protein (GFP)-containing plasmids. GFP-free
Escherichia coli XL1 blue served as a control. Two days old
maggots were put on agar plates in groups of ten at room
temperature. Every thirty seconds, a maggot was displaced from
the agar plate and washed with sterile saline (0.9%). Dead larvae
which could not have taken up bacteria served as a control.
Maggots were tested for ﬂourescence under a ﬂuorescence
microscope [Zeiss Axioskop; HPO50/AC, Axiocam MRmZeiss].
Larvae were examined by an independent observer as well.
Results: Maggots that had been placed on GFP-labelled Escheri-
chia coli showed an intensive green ﬂuorescence, especially at
the back of the head and in the intestines. The controls did not
show any ﬂuorescence. After three to four minutes GFP-labelled
Escherichia coli could be detected inside the maggots‘ body. At
this early stage of digestion GFP-ﬂuorescence could mainly be
examined in the area of the head. This ﬂuorescence results of the
ingestion of GFP- labelled Escherichia coli by larvae.
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Conclusion: We have proven that the uptake of bacteria
represents a further mechanism of antibacterial activity of
larvae. Not only diluting necrotic tissue, but also minimizing
the rate of infections, maggot therapy which is also well-known
as biosurgery could be a beneﬁcial alternative to the use of
antibiotics. As the mechanical uptake is a non-speciﬁc process,
there might not be a risk of resistance.
Antibiotic resistance: nosocomial pathogens
P1055
Antimicrobial resistance patterns of bacterial
pathogens from blood culture of cancer patients
in a single cancer institution
M. Faiz, H. Aziz, T. Bashir, S. Asghar (Lahore, PAK)
Objective: The widespread emergence of resistance to antimi-
crobial agents among bacterial pathogens is well known and has
an impact on our ability to treat patients effectively. Blood
stream infections (bacteraemia) among cancer patients that
develop during the course of disease are potentially life
threatening because of suppression in their immune systems.
The changing spectrum in the incidence and epidemiology of
microbial pathogens has resulted in an increase in resistance to
many antibiotic compounds emphasizing the need to monitor
the prevalence of resistance in these strains.
Methods: Susceptibility and resistance pattern of clinically sig-
niﬁcant bacterial isolates from positive blood cultures collected
during 2000–2004 was studied. The isolated strains were tested
against a wide range of antibiotics belonging to cephalosporins,
aminoglycosides, carbapenemsandquinolonesderivativegroups
by disc diffusion method and the results were interpreted
according to British standard for antimicrobial chemotherapy.
Results: A total of 250 bacterial pathogens were isolated with
60% gram positive and 40% gram negative bacteria. The
dominating pathogens were Staphylococcus aureus, Streptococci,
Pseudomonas , Enterobacter and Klebsiella. Among gram negative
strains, highest level of resistance (98%) to third generation
cephalosporins was observed followed by carbapenems and
penicillin (79%, 80%) respectively. Similarly, high resistance to
aminoglycosides were found (69% to ampicillin, 50% to tobra-
mycin and 62% resistant to quinolone derivates group of
antibiotics. However only 29% were resistant to ciproﬂoxacin.
In gram positive bacteria, high resistance to ciproﬂoxacin (40%)
was observed as compared to gram negative bacteria. A still
higher resistance level (100%) was observed for aminoglycosides
and third generation cephalosporins (97%) respectively.
Conclusion: The spectrum of isolates among our patients were
shifting towards gram positive bacteria with high resistance to
different groups of antimicrobial agents limiting few choices for
alternative therapies for infection control. Antimicrobial resist-
ance continues to increase and ongoing surveillance of microbial
pathogens is essential. This study also warrants the need of
infection control measures, rational antibiotic policies and rapid
laboratory detection of resistance to prevent the spread of
resistance among these strains.
P1056
Antimicrobial susceptibility of bloodstream
infections has no impact on outcome in intensive
care unit patients with acute renal failure
E. Hoste, S. Blot, G. Verschraegen, J. De Schuijmer, S. Claus, J. De
Waele, J. Decruyenaere, N. Lameire, R. Vanholder, A. Dhondt,
F. Colardyn (Ghent, B)
Objectives: Bloodstream infections (BSI) have a worse outcome
when the microorganisms involved are antimicrobial resistant
(AM-R), compared to BSI with antimicrobial susceptible (AM-S)
microorganisms. We evaluated whether this is also true in
intensive care unit (ICU) patients with acute renal failure who
are treated with renal replacement therapy (ARF-RRT), a
particular severely ill cohort of ICU patients.
Methods: All ICU patients with ARF-RRT in the period 95–01
(n = 704) were evaluated. A comparison was made between
patients with AM-S BSI and patients with AM-R BSI. Enteroccci
were deﬁned AM-R when R to vancomycin, staphylococci when
R to methicillin, gram-negative bacteria when R to ceftazidim,
Pseudomonas when R to ceftazidim, quinolones, piperacilin, or
imipenem, and Candida when R to ﬂuconazole. Data are
presented as median (IQR) or %.
Results: BSI occurred in 62 patients, incurring 68 microorgan-
isms; BSI was AM-S in 25 and AM-R in 37 patients. AM-S and
AM-R patients had the same age (62 (55–69) vs. 58 (40–66) yr,
P = NS) and APACHE II score (28 (18–37) vs. 28 (20–34),
P = NS). The time between ICU admission and BSI was longer
for AM-R patients (4 (1–16) vs. 13 (6–26) d, P = 0.02). AM-R BSI
involved more gram-positive bacteria and primary BSI com-
pared to AM-S BSI (76% vs. 24% P < 0.01, resp. 54 vs. 12 %,
P < 0.01). More AM-S patients received adequate antimicrobial
therapy (96 vs. 76 %, P = 0.03); the delay of adequate therapy
was equal (0 (0–0) vs. 0 (0–0.8) d, P = NS). Vasopressor use was
equal in both groups (92 vs. 95 %, P = NS), as was mechanical
ventilation (92 vs. 87 %, P = NS). There was no difference in
length of hospital stay and hospital mortality between AM-S and
AM-R patients (29 (15–77) vs. 46 (31–70) d resp 76 vs. 65 %, both
P = NS). Hospital mortality in non-BSI patients with ARF-RRT
was 70 %. In a Cox proportional hazards model only increasing
age (HR 1.3/10 yr, P = 0.04) and secondary BSI (HR 3.2,
P = 0.01) were associated with mortality.
Conclusion: In this cohort of patients with high baseline
mortality, AM-R of BSI had no impact on outcome.
P1057
Antimicrobial-resistant bacteria isolated from
nosocomial bacteraemia
C. Sartor, P. Barthelemy, P. Berger, C. Zandotti, M. Bimar,
B. La Scola (Marseille, F)
Objectives: Although a monthly surveillance of the antimicro-
bial-resistance of bacteria is performed in our institution, the
bacterial resistance in nosocomial infections was unknown. We
focused this study on the nosocomial bacteraemia.
Methods: We studied the bacteria that had been isolated from
the blood cultures collected in our institution, a 3500 bedded
acute care hospital, from January 1st, 2002 to June 30th, 2004. We
also analysed the bacteraemia identiﬁed by the active surveil-
lance of nosocomial infections in our institution, during the
same period. The study concerned the distribution of the
bacteria and the antimicrobial-resistance of Staphylococcus
aureus, Pseudomonas aeruginosa and enterobacteria. The analysis
were performed using VIGIact and SPSS softwares.
Results: During the study period, 8313 blood cultures have
been isolated. Of them, 1214 nosocomial bacteraemia had been
identiﬁed by the surveillance of nosocomial infections, whom
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11% had been acquired out of the hospital. The following
bacteria were more frequently isolated from the nosocomial
bacteraemia: 275 (23%) S. aureus, 166 (14%) Staphylococcus
epidermidis, 165 (14%) Escherichia coli and 84 (7%) P. aeruginosa.
Of the S. aureus, 30% were resistant to oxacillin, and 32% to
oﬂoxacin. Of the P. aeruginosa, 54% were resistant to ticarcillin,
32% to ceftazidime, 31% to imipenem and 36% to ciproﬂoxacine.
Of the 363 enterobacteria, 12% were resistant to third-generation
cephalosporins (C3G), 15% to ciproﬂoxacine and 22% to trim-
ethoprime/sulfamethoxazole.
Conclusion: The results suggest a strong level of the antimi-
crobial-resistance of the bacteria isolated from nosocomial
bacteraemia. This was in accord with the results of the local
laboratories network, although the resistance of P. aeruginosa to
imipenem and enterobacteria to C3G seems greater.
P1058
Antibiotic use and bacterial resistance in German
intensive care units: data from project SARI
(Surveillance of Antibiotic Use and Bacterial
Resistance in German Intensive Care Units) from
2000 to 2004
E. Meyer, F. Schwab, D. Jonas, H. Ru¨den, P. Gastmeier,
F.D. Daschner (Freiburg, Berlin, Hannover, D)
Objective: To study data on antibiotic resistance, prophylactic
or therapeutic use of antibiotics in ICUs, on changes over time,
and on the correlation between antibiotic use and resistance
rates in intensive care units (ICUs) in Germany.
Methods: Prospective, unit-based surveillance in which ICUs
collected data on patient days, antibiotic use (deﬁned daily
doses = DDD according WHO) and resistance rates of selected
non-duplicate pathogens. Antibiotic use density (AD) is calcu-
lated in DDDs/1000 patient days. The data were recorded,
analysed centrally and communicated to the participants every
six months (www.sari-antibiotika.de).
Results: Starting in 02/2000, by 6/2004) SARI had recorded
data provided by 40 ICUs covering a total of 1571 months,
578,760 patient days and 773,306 deﬁned daily doses. On
average, each patient received 1.2 doses of an antibiotic per
ICU-day. Antibiotic usage rates were highest for penicillins with
lactamase inhibitor (AD 297) and chinolones (AD 156). Resist-
ance data were collected on 53,038 isolates of 13 pathogens: S.
aureus (n = 11750; 22.2%), S. pneumoniae (n = 881; 1.7%), coag-
ulase-negative Staphylococci (n = 8373; 15.8), E. faecalis (n = 5463;
10.3%), E. faecium (n = 1888; 3.6%), E. coli (n = 8614, 16.2%), K.
pneumoniae (n = 3310, 6.2%), E. cloacae (n = 3033, 5.7%), Citrob-
acter spp. (n = 970, 1.8%), S. marcescens (n = 1011; 1.9%), P.
aeruginosa (n = 5109; 9.6%), A. baumannii (n = 1247; 2.4%) and S.
maltophilia (n = 1389; 2.6%).
Conclusions: The resistance situation in Germany is still
highly heterogenous: MRSA-rates range from 2.9% to 66.7%
(mean 21.2%); according to DIN testing ciproﬂoxacin resistant
E. coli rates range from 0.8% to 50.0% (mean 12.5%) and
imipenem resistant P. aeruginosa rates range from 0.0% to
47.8% (mean 25.0%). Over a period of three years (2001–2003),
a signiﬁcant increase was only seen in ciproﬂoxacin resistant E.
coli by Wilcoxon sing rank test for paired samples. Antibiotic
use and bacterial resistance rates are still highly heterogenous
in German ICUs. The large differences between ICUs indicate
that initiatives may be most effective when undertaken at the
local level. Over a period of three years (2001–2003), a
signiﬁcant increase was only seen in ciproﬂoxacin resistant
E. coli.
P1059
Klebsiella oxytoca outbreak in the department of
neonatology of a university hospital in Gdansk,
Poland
B. Rybak, E. Czarniak, E. Augustynowicz, A. Nowaczek,
A. Samet, J. Szczapa (Gdansk, Warsaw, PL)
Objective: The aim of this study was to analyse outbreak of
Klebsiella oxytoca in neonatology patients from of the Medical
University of Gdansk.
Materials and methods: Teaching hospital of the Medical
Universityt contains four neonatal wards: Neonatal Intensive
Care Unit [NICU], Pathology Unit [PU], Septic Unit [SU] and
Rooming-in Unit [RU]. This department serves an average of
about 160 of patients per month. We analysed patients recovered
from May 2004. Strains were identiﬁed by classical methods and
VITEK cards (BioMerieux). Sensitivity was determined by the
agar diffusion method according to NCCLS guidelines. Clinical
data were retrospectively collected from the medical records of
patients admitted to the department during the study period.
The following sociodemographic variables and potential risk
factors were assessed: gender, gestational age, mode of delivery,
Apgar score, birth weight, mechanical ventilation, parenteral
nutrition, length of hospital stay, and antimicrobial treatment.
K. oxytoca isolates were analysed by RAPD-PCR method.
Results: We analysed 30 isolates from 18 patients from two
days. Isolates were recovered from urine (9), and epidemiolo-
gical swabs from throat and rectum (21). We found two
susceptibility groups: group 1 (7 patients) resistant to amox/
clavul.acid, pip/tazobactam, aztreonam, cefuroxime, and group
2 (11 patients) susceptible for these antibiotics. RAPD proﬁles
corresponded with the susceptibility testing results. Drug
resistance proﬁle in group 1 could be attributed to overproduc-
tion of chromosomal encoded K1 beta- lactamase. Group 1 was
from RU and group 2 from NICU, PU and SU. Analysis of
sociodemographic variables and potential risk factors showed
differences between analysed groups in mean birth weight,
length of hospital stay, antimicrobial treatment and invasive
therapeutic procedures usage.
Conclusions: The outbreak analysis revealed concurrent isola-
tion of twoK. oxytoca clones, normal and K1 overproducer. RAPD
results were supported antibiotyping results. The epidemic of
K. oxytoca K1 was stopped by strict infection control measures.
P1060
Multi-resistance in K. pneumoniae:
epidemiological results from the GENARS
Project
I. Noll, J. Beer, K. Huppertz, W. Pﬁster, T. Pietzcker, S. Schubert,
T.A. Wichelhaus, S. Ziesing, B. Wiedemann (Bonn, Leipzig, Jena,
Ulm, Kiel, Frankfurt a.M., Hannover, D)
Objectives: Clones of K. pneumoniae were involved in nosoco-
mial infections with fatal consequences in the late 1960s. They
became rare with the introduction of 3rd and 4th generation
cephalosporins. Today this species again seems to play a major
role in nosocomial infection due to resistance to the modern
drugs. The GENARS-project (German Network for Antimicro-
bial Resistance Surveillance) is designed to provide epidemio-
logical data for German university hospitals. Since 2002
resistance data are collected for all clinical relevant pathogens.
Methods: Analysis was based on ﬁrst isolates of K. pneumoniae
from six laboratories, collected from January 2002 to June 2004.
Minimal inhibitory concentrations (MICs) were determined by
broth microdilution method (DIN) for ceftazidime (CAZ),
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cefotaxime (CTX), ciproﬂoxacin (CIP), gentamicin (GEN),
meropenem (MER) and piperacillin (PIP). Resistance patterns
were evaluated by using breakpoints according to DIN, group-
ing resistant and intermediate as non-susceptible; multi-drug
resistance was deﬁned as non-susceptibility to at least four of
the six agents.
Results: A total of 3077 isolates was analysed. 51.4% of these
isolates were non-susceptible to at least one agent, the highest
proportion is due to mono-drug resistance to piperacillin
(39.6%). 4.8% of the strains were classiﬁed as multi-resistant,
the most frequent patterns were PIP/CAZ/CTX/GEN (2.1%)
and PIP/CAZ/CTX/GEN/CIP (1.7%). Two strains were resist-
ant to all six antibiotics. Signiﬁcant differences in multi-drug
resistance rates were associated with ward type with highest
rates for ICU-patients (8.8%). Furthermore, multi-resistance
rates varied signiﬁcantly between the centres involved with a
range from 0.9% to 7.2%. The centres differed not only in respect
to the multi-drug resistance rates, but also in respect to the
dominating phenotype.
Conclusions: The relevance of multi-resistance in K. pneumoniae
as a major clinical problem is proved by an overall rate of almost
ﬁve per cent for German university hospitals and an even higher
proportion for ICU-patients. Among the agents tested pipera-
cillin plays an eminent role in regard to its mono-resistant rate
as well as a component of the most frequent resistance patterns.
Resistance to the combination of PIP with Tazobactam however
is rare.
P1061
The development of antimicrobial resistance
in German hospitals
K. Huppertz, J. Beer, I. Noll, W. Pﬁster, T. Pietzcker, S. Schubert,
T.A. Wichelhaus, S. Ziesing, B. Wiedemann (Bonn, Leipzig, Jena,
Ulm, Kiel, Frankfurt, Hannover, D)
Objectives: Since the end of 2001, six laboratories for medical
microbiology at German university hospitals are taking part in
the GENARS-project (German Network for Antimicrobial
Resistance Surveillance). These laboratories regularly send
data obtained in the laboratory routine to the central ofﬁce of
GENARS in Bonn. Here they are merged in the database and
analysed. The goal of this investigation was to ﬁnd out, if
signiﬁcant trends in the development of antimicrobial resistance
in GENARS-hospitals are detectable.
Methods: MIC-values from species listed were determined for
25 antibiotics, considering all relevant antibiotic classes: E. coli,
E. cloacae, P. mirabilis (ciproﬂoxacin, gentamicin, ampicillin,
piperacillin and cefotaxime), P. aeruginosa (ciproﬂoxacin, imipe-
nem, ceftazidime, gentamicin and piperacillin) and S. aureus
(penicillin, oxacillin, erythromycin, doxycyclin und linezolid).
Only the values of non-copy strains of ﬁve GENARS hospitals
entered the statistics.
Results: For many antibiotic–species-pairs no obvious trends
could be detected. However some species show continuous
changes in their resistance rates. A highly signiﬁcant increase in
ciproﬂoxacin resistant strains of E. coli and P. aeruginosa could be
observed. Detailed percentages of resistant strains for the 1st
half of 2002 and the 1st half of 2004 are shown in Table 1. For
S. aureus strains resistant to Oxacillin (MRSA) increased signi-
ﬁcantly to a level of 11.6 % (Table 1). In means for all GENARS-
hospitals the resistance rate to Oxacillin increased. Nevertheless,
in two of these hospitals a clear decrease was observed. The
level of resistance and resistance development for all species
evaluated can vary considerably from hospital to hospital.
Conclusions: In the time under observation, in GENARS-
hospitals for most of the selected species and antibiotics no
signiﬁcant changes in antimicrobial resistance could be detected.
Nevertheless, as shown for E. coli and P. aeruginosa resistance to
ciproﬂoxacin and for S. aureus resistance to oxacillin increased
signiﬁcantly. This demonstrates that an early detection of any
alterations in antimicrobial resistance by a continuous surveil-
lance is of great importance.
P1062
Staphylococcal bacteraemias in internal medicine
and oncology patients in a university hospital
S.G. Kalpadakis, I.S. Kourbeti, M. Rovithi,
A. Christidou-Stefanaki, G. Samonis (Heraklion, GR)
Objectives: To determine the epidemiology, the clinical pres-
entation and the resistance patterns of Staphylococcus aureus (SA)
and Coagulase Negative Staphylococci (CNS) Blood Stream
Infections (BSI) in Internal Medicine (IM) and Oncology
(ON)wards.
Methods: Medical records of patients >18 years old hospital-
ized over a one year period (2003) in the IM and Oncology ON
wards were retrospectively reviewed.
Results: In the year 2003 there were 11 patients with S. aureus
bacteraemia (SAB) in the IM and 1 the ON ward. During the
same time period there were 2 clinically signiﬁcant CNS BSI in
the IM and 7 in the ON ward. The IM patients with SAB and
CNSBSI had the same average age (59 years). The maximum
temperature upon the diagnosis was in average 38.1 for the SAB
and 37.8 for CNSBSI. The men predominated among the SAB
(72%). The average numbers of the White Blood Cells (WBC)
were 16,020 for the SAB and 9,600 for CNSBSI. The infections
were community acquired (CA) in 54% of the SAB and in 50% of
the CNSBSI. The ON patients with CNSBSI had an average age
of 63 years and the female predominated (71%). The average
WBC was 8,600 and the temperature was 38.6. The infections
were catheter-related in 72% of the cases. The bacteremias were
mixed in 43%. No infection was associated with neutropenia in
the ON population. The infections were more severe in the IM
ward where most of the cases were associated with abscesses or
endocarditis where in the ON wards the infections were mainly
catheter associated. The average length of stay was 11.3 days in
the ON ward where in the IM ward it was 23.7 days. No death
could be attributed to the SAB or the CNSBSI either in the IM or
ONward. The percentage of MRSA in the IM patients was 18.8%
when in Greece the MRSA percentage for the year 2003 in
medical wards was 44%. Among the ON patients, the only SAB
was caused by an MRSA. The CNS BSI were caused by
methicillin R organisms in 57%.
Conclusion: The percentage of MRSA in our IM ward is
considerably lower than in the average percentage in the
national surveillance. This is probably due to the fact that
most cases were community acquired. The SAB comprised only
0.56% of the 2003 IM ward admissions. The staphylococcal
infections in the non-oncologic patients required longer length
of stay. On going prospective surveillance is in progress to
determine the differences in the proﬁle of the staphylococcal
infections in IM and ON patients and the pathogen resistances.
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P1063
A four-year analysis of antimicrobial use and
antimicrobial resistance among Gram-negative
bacilli in an Italian intensive care unit
M. Bassetti, E. Righi, R. Fasce, A. Costa, E. Cantagalli,
B. Rebesco, M. Cruciani, C. Mengoli, F. Bobbio Pallavicini,
D. Bassetti (Genoa, I)
Obiectives: Assess rates of antimicrobial resistance of the
common gram-negative isolates in ICU and to evaluate
the impact of antibiotic use on the emergence of resistant
organisms.
Methods: Retrospective analysis for a four years period (1999–
2002) in a medical and surgical ICU. Duplicate isolates were not
considered. A hospital-acquired infections (HAI) was deﬁned,
according to CDC deﬁnitions. Susceptibility was evaluated for
piperacillin (P), piperacillin/tazobactam (PT), cefotaxime (CX),
ceftazidime (CZ), ciproﬂoxacin (CP), gentamicin (GT) and
imipenem (IM). We analysed resistance patterns and DDDs
per 1000 patient-days. Data were analysed by Chi square for
linear trend and logistic regression, with a level of signiﬁcance
deﬁned as p < 0.05.
Results: 1476 clinical strains were isolated from 1237 patients
with an HAI. A prevalence of Gram-negatives isolates (>60%)
was observed. High resistance rates were observed for almost all
the antibiotic tested. Exceptions were IM (100% strains suscept-
ible) and GT (93–99%) toward K. pneumoniae (Kp), IM toward
Serratia spp. (90–100%), and GT toward Kp (93–99%). Steady
levels of resistance to all the antibiotics tested were observed for
P. aeruginosa (Pa) and Serratia spp. By contrast, a signiﬁcant
trend toward an increase in resistance rate to P, CX, CZ, and CP
was observed for Kp. A linear and signiﬁcant trend toward a
decrease in resistance rate to PT was observed. Overall, we
recorded a continual increase in the antibiotics use from 1999
through 2002. The most remarkable trend in antimicrobial use
was represented by huge increases in utilization of broad
spectrum penicillins, 3rd generation cephalosporins, IM, and
CP. A signiﬁcant drug-usage vs susceptibility relationship was
found with Kp and Proteus spp. (Pr). Increasing use of CX, CZ,
P, and CP was associated with decreased susceptibility of Kp to
themselves. The increase in the consumption of PT was
associated with increasing susceptibility of Kp. Moreover,
increasing use of CX and IP were associated with decreased
susceptibility of Pr to these drugs. No other signiﬁcant relation-
ships were found.
Conclusion: The data demonstrated the correlation between
antimicrobial consumption for extended spectrum cephalospo-
rins, quinolones and carbapenems and selection of resistances in
Kp, Pr and Pa. In contrast, an increased usage of PT was
associated with increasing susceptibility in Kp, suggesting a
protective role of PT for ESBL in Kp.
P1064
Colonisation of long-term care facilities residents
with multidrug-resistant Escherichia coli
in Greece
V. Grammelis, N. Tsogas, M. Mbomboli, A. Kapaskelis,
G. Greka, K. Kanellakopoulou, H. Giamarellou, M.C. Lazanas
(Athens, GR)
Objective: Resistance to antimicrobials of different structural
classes has arisen in a multitude of bacterial species. A survey
was performed to determine the prevalence and resistant rates
of MDR E. coli isolates colonizing the elderly residents of Greek
LTCF.
Methods: A total of 28 LTCF were randomly selected from the
public sanitation list of Attica province. Urine, nasopharyngeal
and wound samples were collected from 668 elderly residents.
We chose randomly 35% of the existing population from each
LTCF (minimum sum 25 residents, age above 65 years). E. coli
isolates were identiﬁed by API strips and underwent antimi-
crobial disk susceptibility testing, following the NCCLS guide-
lines. Conﬁrmation of ESBL-R was done by MIC broth
microdilution and double disk diffusion, as per NCCLS.
Results: The mean age of the residents was 86.2 years. 302
E. coli strains were isolated from 1448 samples (20.8%). 76 MDR
(i.e., those resistant to ‡3 antimicrobial agents including amp-
icillin, ceftazidime, trimethoprim-sulfamethoxazole, gentamicin,
and ciproﬂoxacin) E. coli isolates (25.2%) were recovered. The
majority of them were isolated from urine samples (83%).
Resistance to ampicillin (AMP), trimethoprim- sulfamethoxazole
(TMP/SMX), ampicillin-sulbactam, ciproﬂoxacin (CIP), gentam-
icin (GM), and ceftazidime was found in 57.5%, 47.6%, 33.8%,
22.2%, 9.4% and 2.3% of isolates, respectively. Beta-lactam
resistance phenotypes essentially comprised penicillinase pro-
duction (36.8%), overexpression of chromosomal cephalospori-
nase (5.6%), and synthesis of inhibitor-resistant TEM/OXA
enzymes (5.5%) or ESBL (2.0%). 66.5 % of the previous ESBL-
producing strains were resistant to CIP. Resistance to non-beta-
lactam antibiotics (ST, CIP and GM) was more prevalent in
AMP-resistant strains and ESBL-producing strains. The most
prevalent phenotype was resistance to AMP, TMP/SMX and
CIP, which was detected in 62.5% of MDR resistant isolates and
0.3% of strains overall.
Conclusions: 1. Colonization with MDR-E. coli is relative high
in Greek LTCF. 2. The close relationship between resistance to
non-beta-lactam antibiotics and ESBL-producing E. coli strains is
worrisome. 3. Resistant rates of E. coli to ampicillin, TMP/SMX
and ciproﬂoxacin are relatively high and must be considered in
case of urinary infections in residents of Greek LTCF.
P1065
Colonisation of long-term care facilities residents
with quinolone-resistant Gram-negative bacteria
in Greece
V. Grammelis, G. Tsekes, M. Nikolakopoulou, M. Gika,
D. Katsala, K. Kanellakopoulou, H. Giamarellou, M.C. Lazanas
(Athens, GR)
Objectives: Quinolones (Q) are among the most frequently
used agents for treating LTCF-acquired infections. Conse-
quently, bacteria exhibit increasing resistance to Q. A multi-
centre survey was conducted in order to determine (I) the
prevalence and risk factors for colonization with QRGN in
Greek LTCF (II) the corresponding antimicrobial resistant rates
(A´R).
Methods: A total of 28 LTCF were randomly selected from the
public sanitation list of Attica province. Urine, nasopharyngeal
and wound samples were collected from 668 elderly residents.
We chose randomly 35% of the existing population from each
LTCF (minimum sum 25 residents, age above 65 years). Gram
negative bacteria were identiﬁed by API strips and underwent
antimicrobial disk susceptibility testing, following the NCCLS
guidelines. Data were also collected on resident factors and
institutional variables. Univariate and multivariate analyses
were performed. Odds ratios (OR) and P values were calculated.
Results: 412 Gram negative (GN) strains were isolated from
1448 samples (prevalence rate 28.5%). The majority of them were
recovered from urine samples (86.8%). 53% of the residents had
been taking systemic antibiotics during the preceding month. Q
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were the leading class (38%). A´R of GN to ciproﬂoxacin (CIP)
were estimated (Table). Multi-drug QRGN accounted for 11.5%
of the isolated strains. The most prevalent phenotype was
resistance to ampicilline, CIP and trimethoprim-sulfamethoxaz-
ole. In the multivariate analysis, only prior exposure to antimi-
crobial agents (P < 0.001; OR = 2), speciﬁcally to Q (P < 0.001;
OR = 14), and the presence of a urinary catheter (P < 0.001;
OR = 2) were signiﬁcantly associated with colonization with
QRGN.
Conclusions: 1. Colonization of residents in Greek LTCF with
QRGN is relatively high. 2. Given the high rate of colonization
with QRGN, empiric use of quinolones may not be appropriate.
3. Signiﬁcant risk factors for colonization with QRGN are prior
exposure to antimicrobial agents, speciﬁcally to quinolones, and
the presence of a urinary catheter.
P1066
Colonisation and resistance dynamics of Gram-
negative bacteria during and after hospitalisation
P.M.G. Filius, I.C. Gyssens, A. Ott, A.G. Vulto, H.A. Verbrugh,
H.P. Endtz (Rotterdam, NL)
Objectives: Colonization and resistance dynamics of gram-
negative bacteria in the intestinal and oropharyngeal microﬂora
of patients admitted to intensive care units (ICU) and general
wards (GW) were investigated during and after hospitalization.
Methods: Specimens were obtained on admission, once weekly
during hospitalization, at discharge from the ICU, at discharge
from the hospital and one and three months after discharge from
the hospital. Five colonies per specimen were selected for
identiﬁcation and susceptibility testing by the VITEK 2 system.
Results: A total of 3316 specimens from 411 patients were
collected. In both patient populations, the gram-negative colon-
ization rates in oropharyngeal specimens increased during
hospitalization and did not decrease in the three months after
discharge. In rectal specimens, colonization rates decreased
during hospitalization and increased after discharge. There was
a change in species distribution among the dominant microﬂora
during hospitalization. Klebsiella spp., Enterobacter spp., Serratia
marcescens and Pseudomonas aeruginosa were more often isolated,
whereas the frequency of E. coli declined. The percentage of ICU
patients colonized with ampicillin and/or cephalothin resistant
faecal E. coli was signiﬁcantly increased at discharge from the
hospital and did not change in the three months after discharge.
Emergence of multi-drug resistance was observed in many
gram-negative species during stay on the ICU. Resistance
frequencies in E. coli signiﬁcantly increased with length of stay
on the ICU. For the GW population, no signiﬁcant changes in
resistance frequencies were found during hospitalization.
Conclusion: From a population perspective, the risk of dissem-
ination of resistant gram-negative bacteria into the community
through hospitalized patients appears to be low in GW patients,
but is noticeably higher among ICU patients.
P1067
Association of antibiotic resistance phenotypes
and the presence of class I integrons in a sample
of bacterial isolates from U.S. hospitals
A.N. Rao, M. Barlow, L.A. Clark, F.C. Tenover, J.E. McGowan
Jr. (Atlanta, USA)
Objective: We assessed the association between class 1 integ-
rons and patterns of resistance to aminoglycosides, beta-lactams,
quinolones, and chloramphenicol in Escherichia coli and Klebsiella
species isolates from U.S. hospitals participating in Project
ICARE.
Methods: A convenience sample of 320 E. coli and Klebsiella
species isolates was collected between October 2002 and
December 2003 from 19 U.S. hospitals as part of Phase IV of
Project ICARE and tested for susceptibility to a variety of
antimicrobial agents. These organisms were submitted in
response to a request for organisms resistant to 3rd generation
cephalosporins (ceftazidime, ceftriaxone, cefotaxime) and/or
ﬂuoroquinolones. The isolates were screened for the presence of
class I integrons using sets of primers speciﬁc for 5¢ and 3¢
conserved segment of the integrase gene. We obtained measures
of association between the presence and absence of integrons
and resistance phenotypes.
Results: Of the 320 E. coli and Klebsiella species isolates
screened, 181 (57%) contained a class I integron. A signiﬁcant
association was seen between the presence of the class I integron
and resistance to amikacin, gentamycin, tobramycin, ampillicin,
chloramphenicol, aztreonam, ceftazidime, cefotaxime, and cef-
podoxime. Resistance to ciproﬂoxacin and cefepime was not
signiﬁcantly associated with the presence of an integron.
Conclusions: The presence of class I integrons in 57% of our
convenience sample of E. coli and Klebsiella species isolates,
along with the differential association of those integrons with
resistance to some drugs, but not others, suggests that integrons
may play an important role in determining how the epidemi-
ology of bacterial resistance results from antimicrobial agent
selective pressure.
Species % of isolates % AR to CIP
Escherichia coli 40.2 22.1
Proteus spp. 21.3 25.1
Klebsiella spp. 18.2 27.1
Enterobacter spp. 2.4 21.2
Citrobacter spp. 2.3 5.2
Morganella spp. 5.5 41.5
Acinetobacter spp. 2.2 66.3
Pseudomonas spp. 3.5 35.2
Providencia spp. 1.9 4.3
Serratia spp. 1.5 6.5
Other 1.0 4.2
Total/Mean 100 (412) 21.2
Antimicrobial Integron No Integron X2(p value)* Odds Ratio (95% CI)**
Amikacin S*** 162 136 8.54 (0.0035) 5.32
NS 19 3 (1.54,18.35)
Gentamicin S 81 112 42.15 (<0.0001) 5.12
NS 100 27 (3.07, 8.55)
Tobramycin S 72 109 47.77 (<0.0001) 5.5
NS 109 30 (3.33,9.09)
Ampicillin S 9 21 9.51 (0.002) 3.4
NS 172 118 (1.51,7.69)
Ciproﬂoxacin S 41 43 2.79 (0.0951) 1.53
NS 140 96 (0.93,2.52)
Chloramphenicol S 46 62 12.95 (0.0003) 2.36
NS 135 77 (1.47,3.79)
Ceﬂazidime S 89 91 8.48 (0.0036) 1.96
NS 92 48 (1.24,3.09)
Cefotaxime S 98 94 5.95 (0.0147) 1.77
NS 83 45 (1.12,2.80)
Cefpodoxime S 69 69 4.25 (0.0392) 1.6
NS 112 70 (1.02,2.50)
Cefepime S 161 124 0.005 (0.9415) 1.03
NS 20 15 (0.51,2.09)
Aztreonam S 97 93 5.78 (0.0162) 1.75
NS 84 46 (1.11,2.77)
*from Chi Square
**odd ratios and 95% conﬁdence intervals for non-susceptibility
***NS - not susceptible (resistant plus intermediate where applicable); S - Susceptible
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P1068
Characterisation of the AcrAB locus in two
Citrobacter freundii clinical isolates
J. Sa´nchez-Ce´spedes, S. Marti, M. Ruiz, J. Vila (Barcelona, E)
Objectives: The main purpose of this study was to investigate
the mechanisms of resistance to ﬂuoroquinolones in two
isogenic Citrobacter freundii clinical isolates, which led us to
characterize the acrA and acrB genes of this microorganism.
Methods: Two C. freundii strains (1.44 and 1.38) sequentially
isolated from the same patient were characterized. The relation-
ship was determined by REP-PCR and PFGE. The susceptibility
to ciproﬂoxacin and chloramphenicol was determined by E-test.
Mutations in the quinolone resistance determining region of the
gyrA and parC genes, the outer membrane protein proﬁle and
the accumulation of ciproﬂoxacin was also investigated. The
expression of genes in both strains was analysed using DNA
microarrays for E. coli and the expression of the acrA and acrB
genes was veriﬁed by RT-PCR using the gapA gene as the
control. The acrA gene was cloned and DNA sequenced.
Results: Both C. freundii belong to the same clone by both REP-
PCR and PFGE. The MIC of ciproﬂoxacin was of 8 (strain 1.44)
and 32 mg/L (strain 1.38). The MIC of chloramphenicol was of
16 and 96 mg/L, respectively. The two strains showed the same
substitutions in the GyrA and ParC (Thr-83–Ile and Asp-87–Tyr
in GyrA and Ser-83–Ile in ParC). No major differences were
found between the outer membrane protein proﬁles. However,
differences were observed in the amount of ciproﬂoxacin
accumulated, with strain 1.38 showing less accumulation.
Eleven genes were overexpressed in strain 1.38 compared to
strain 1.44. Among these genes the acrA was overexpressed.
This result was further corroborated by RT-PCR. The nucleotide
similarity between the partially sequenced acrA (1027 bp) and
acrB (420 bp) genes of C. freundii and E. coli was of 81.5% and
86%, respectively.
Conclusion: The acrA and acrB genes of C. freundii are similar
to those described in E. coli and in collaboration with mutations
in the gyrA and parC genes, their overexpression may play an
important role in modulating the ﬁnal MIC of ﬂuoroquinolones.
P1069
High prevalence of aac(3)-II encoding gentamicin
resistance in Escherichia coli obtained from
patients with urinary tract infections in a Danish
hospital
L. Jakobsen, D. Sandvang, D.S. Hansen, H. Westh,
A.M. Hammerum (Copenhagen, Hvidovre, DK)
Background: Aminoglycosides are administered intravenously
and are thus reserved for hospitalized patients in Denmark.
Gentamicin in combination with a Beta-lactam antibiotic is the
recommended empirical therapy for patients with suspected
septicemia in Denmark. Thus, a spread of gentamicin resistance
(gmR) genes is undesirable. The three most common genes
causing gmR in Gram-negative bacteria in Denmark are aac(3)-
II, aac(3)-IV and ant(2)-I. The objective of this study was to
investigate the prevalence of gmR genes among clinical isolates
of Escherichia coli from a hospital collected during a period of
13 months and to determine their clonal relationship.
Methods: Between Sep. 1st 2002 and Sep. 30th 2003, 38 gmR
E. coli were isolated from patients with urine tract infections at
Hvidovre Hospital. Only one isolate from each patient was
included in this study. The gmR isolates were sent to National
Center for Antimicrobials and Infection Control at SSI. Suscep-
tibility to gentamicin (1–32 mg/l) was determined by the micro
broth dilution method and a breakpoint of ‡16 mg/l was used.
GmR isolates were investigated for the presence of aac(3)-II,
aac(3)-IV and ant(2)-I by PCR. To investigate clonal relationship,
the isolates were typed by PFGE using XbaI. The PFGE-types
were analysed by Bionumerics resulting in a dendrogram.
Results: aac(3)-II was detected in 30 (79%) isolates among the 38
tested isolates. Neither aac(3)-IV nor ant(2)-I were detected in
any of the tested isolates. It was not possible to determine the
background for the gmR in eight isolates. Of the 38 isolates, 35
had 33 different PFGE-types and three were not typable. Despite
the many PFGE-types, two clones occurred: One clone consisted
of two isolates from Oct. 2002 and Mar. 2003. The other clone
likewise consisted of two isolates detected in Apr. and Aug.
2003. aac(3)-II was detected in both clones. Furthermore, two
groups of three and six isolates, respectively, obtained in
different months, had related PFGE-types.
Conclusion: The gentamicin resistance was largely due to
aac(3)-II gene. Even though the isolates had many different
PFGE-types, isolates obtained in differentmonths could share the
same PFGE-type. This indicates persistence of aac(3)-II gentam-
icin resistant clones at the hospital up to a six months period.
P1070
Multidrug resistance of Gram-negative bacilli
and consumption of third generation
cephalosporins and imipenem in a Tunisian
hospital
S. Ben Redjeb, M.A. Ben Hadj Kacem, S. Ennigrou, A. Kosontini,
M. Saı¨dani, M. Mediouni (Tunis, TN)
Objectives: Multidrug resistance of gram negative bacilli
(GNB) has become a major public health problem in Tunisia.
Surveillance of both antimicrobial resistance and antimicrobial
consumption has now been recognised as essential for planning
future strategies to control resistance. The aim of our study is to
examine for the whole hospital and wards with risks the
correlation between resistance of GNB and the consumption of
third generation cephalosporins (3rd GC) and imipenem for the
period from January 2003 to September 2004.
Methods: A surveillance of antibiotic resistance and antibiotic
consumption was established respectively by the laboratory and
the department of pharmacy. Data on antimicrobial resistance
and antibiotic consumption were collected quarterly and anti-
biotic consumption was calculated in deﬁned daily doses (DDD)
using ABC Calc. Results were expressed per 1000 bed-days (bd).
Statistical analysis was done using SPSS software for the
calculation of the Spearman rank correlation (rs) with an alpha
risk of 5%.
Results: For the whole hospital, resistance to 3rd GC ranged
from 0.9 to 1.7 GNB/1000 bd. The highest rates were observed in
intensive care unit (ICU: 4.7–12.7 GNB/1000 bd) and the lowest
rates in orthopaedic ward (0–2 GNB/1000 bd). A statistically
signiﬁcant correlation was observed between C3G consumption
and resistance of GNB for the whole hospital (rs = 0.95;
p = 0.001), ICU (rs = 0.82; p = 0.02) and orthopaedic ward
(rs = 0.75; p = 0.05). A parallel variation was observed with
imipenem consumption. Concerning general surgical wards and
urology, there was not a signiﬁcant correlation. For the whole
hospital, during the year 2003, antibiotic consumption cost
reached 26.6% of total drugs; 3rd GC and imipenem consump-
tion cost represented 40.3% of total antibiotics. The highest rate
was observed in ICU (69.8%).
Conclusion: Regarding our results, more effective strategies
may be developed to combat antibio-resistance including the
implementation of an antibiotic policy.
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P1071
Prevalence and risk factors of acquiring MRSA
and ESBL+ Enterobacteriacae vis-a`-vis usage of
antimicrobials
J B. Sarma (North Shield, UK)
Objectives: A point prevalence study performed in a Indian
tertiary hospital (surgery, orthopaedic, medicines, n = 182,
male) in 2001 to ﬁnd the prevalence and risk factors of acquiring
MRSA and ESBL+ Enterobacteriacae vis-a`-vis usage of antimicro-
bials.
Methods: Dry swabs were collected (nose, throat, wounds).
Isolates were carried to the Microbiology department, RVI,
Newcastle, UK where works were done. A subset of S. aureus
was characterised by phage typing. MRSA were typed by PFGE.
A case-control study was performed.
Results: Usage of antimicrobials: 93(surgery), 60 (orthopaedic)
and 53(medicine) DDD/100 bed-days. All MRSA isolates, except
2, belonged to phage group III. Majority of MSSA isolates were
distinct strains. PFGE conﬁrmed that MRSA isolates were
indistinguishable.
Colonization rates: orthopaedic(MRSA, 34%;ESBL, 41%), sur-
gery (MRSA, 18%;ESBL, 23%) medicine (MRSA, 1%;ESBL, 14%).
All MRSA isolates were resistant to multiple classes of anti-
microbials whereas MSSA were sensitive (p < 0.001). All ESBL+
bacteria were resistant to multiple classes but sensitive to
meropenem, colistin, amikacin (82%), cotrimoxazole (50%) and
chloramphenicol (50%). Resistance in non-ESBL+ bacteria was
detected to ampicillin (73%), cefalexin (32%), 2nd/3rd genera-
tion cephalosporin (0%), chloramphenicol (32%), cotrimoxazole
(11%), ciproﬂoxacin (5%), trimethoprim (21%), gentamicin (5%),
netilmicin (53%) and tobramycin (11%). Potentially community
acquired isolates showed lower rates of resistance (0% to
trimethoprim, ciproﬂoxacin, gentamicin, amikacin, tobramycin,
2nd/3rd generation cephalosporin).Duration of hospital stay
was not a risk for acquiring either ESBL+ bacteria or MRSA
whereas having a surgery was associated. Exposure to quino-
lone was a risk factor for MRSA but not ESBL+ bacteria.
Aminoglycoside and cephalosporin were risks for ESBL+
bacteria. Acquiring both MRSA and ESBL+ Enterobacteriacae
together did correlated with the duration of hospital stay in
addition to exposure to aminoglycoside and cephalosporin.
Conclusion: Majority of patients remained free from resistant
bacteria implying that cross-transmission alone was not sufﬁ-
cient in absence of risk factors, particularly exposure to
antimicrobials. Good hand-hygiene and prudent use of anti-
microbials are realistic options for resource poor countries to
reduce the burden of resistant bacteria. There is a unique
opportunity to sequentially introduce speciﬁc infection control
measure and evaluate its effectiveness.
P1072
Antimicrobial resistance in an intensive care unit
before adopting an antibiotic rotation programme
for empiric therapy of ventilator-associated
pneumonia
G. Corti, V. Mangani, P. Pecile, B. Borchi, E. Grilli, P. Nicoletti,
G. Tulli, F. Paradisi (Florence, I)
Objectives: A high prevalence of morbidity, mortality, antibi-
otic use, antimicrobial resistance (AR), and economic costs is
generally encountered in the intensive care unit (ICU). The
adoption of an antibiotic rotation programme (ARP) can
minimize the emergence and spread of AR. Before initiating
an ARP for empiric therapy of ventilator-associated pneumonia
(VAP) in our ICU, we evaluated the AR proﬁle of major bacterial
pathogens that generally cause severe infections in the ICU.
Methods: During a 16–month period, a total of 533 nonrepet-
itive bacterial strains were isolated from clinical samples
(primarily blood, tip of vascular catheters, bronchial aspirate
and/or bronchoalveolar lavage, and urine) of adult patients
admitted to a 7-bed mixed ICU of a 350-bed non-teaching
hospital. Bacterial isolates were identiﬁed by automated meth-
ods (VITEK) and tested for AR using NCCLS guidelines; they
were 175 Staphylococcus aureus, 82 Pseudomonas aeruginosa, 76
coagulase-negative Staphylococci (CNS), 32 Escherichia coli, 24
Enterococcus faecalis, 18 Klebsiella pneumoniae, and other species
with <15 isolates each.
Results: Among gram-negative aerobic bacilli, we found P.
aeruginosa strains to be meropenem and piperacillin/tazobac-
tam-resistant in 22% and 14.6% of cases, respectively; P.
aeruginosa, E. coli and K. pneumoniaewere resistant to ceftazidime
in 29.3%, 6.25%, and 0% of cases, respectively, and resistant to
ciproﬂoxacin in 54.9%, 12.5%, and 5.6% of cases, respectively.
Neither E. coli nor K. pneumoniae were resistant to either
meropenem or piperacillin/tazobactam. Among gram-positive
aerobic cocci, oxacillin-resistant S. aureus and CNS were 55.8%
and 82.7%, respectively; S. aureus isolates were very susceptible
to cotrimoxazole (resistance 7.65%) and rifampin (11%), whereas
resistance exceeded 40% for clindamycin, gentamicin, and
norﬂoxacin. Ampicillin- and penicillin-resistant E. faecalis were
20.8% and 33.3%, respectively. Neither S. aureus nor E. faecalis
were resistant to vancomycin, whereas one CNS strain was
resistant to it (1.3%) and 6 out of 76 to teicoplanin (7.9%).
Conclusion: In our ICU, where a careful policy of antibiotic use
with no predetermined restrictions has been applied for years,
AR among both gram-negative and gram-positive microorgan-
isms is generally lower than in the ICUs of Italy and other
Mediterranean countries. We expect that the institution of an
ARP for empiric therapy of VAP can further minimize AR in our
ICU.
Difﬁcult to treat nosocomial infections
P1073
Cure of post-traumatic recurrent multiresistant
Gram-negative rod meningitis with
intraventricular colistin
S. Kasiakou, P. Rafailidis, K. Liaropoulos, I. Bliziotis,
F. Chelvatzoglou, M. Falagas (Athens, GR)
Background: Although newer antibiotics have been introduced
to the market during the last years, they have not solved the
problems arising in the management of infections due to
multiresistant Gram-negative bacteria. Colistin, an antibiotic
almost forgotten for decades has proved itself helpful, when
used parenterally in patients where a lot of the classic and newer
antibiotics fail.
Methods: We report our experience with the management of
the case of a young patient who, after head trauma, had ﬁve
episodes of meningitis due to multidrug-resistant Gram-negat-
ive microorganisms.
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Results: A 28-year-old patient was admitted in our hospital
because of coma. Three months prior to his admission, he
sustained acute brain injury due to a fall and was hospitalized
elsewhere for this entire period. A computerized tomography
scan of his brain at his admission in the ﬁrst hospital, showed
multiple cerebral contusions, and an intracerebral hematoma
causing deviation of the midline. He underwent a decompres-
sive craniotomy with removal of the hematoma. During his
long-standing hospitalization, he developed 5 episodes of
meningitis, i.e. on day 65, 96, 108, 147, and 165 after head
trauma. The pathogens isolated from each episode of meningitis
were multiresistant strains of Pseudomonas aeruginosa (1st and
2nd episodes), Acinetobacter baumannii (3rd episode), Enterobacter
cloacae (4th episode), and Acinetobacter baumannii (5th episode).
The two episodes of Acinetobacter baumannii meningitis were
managed only when colistin and amikacin were given by the
intraventricular in addition to the intravenous route for long
period of time (six weeks for the last episode) and in high doses
(40,000 IU of colistin and 10 mg of amikacin).
Conclusion: Intraventricular colistin should be considered to be
a life-saving therapeutic intervention in cases of multi-resistant
Gram-negative rod meningitis.
P1074
Intravenous colistin for treatment of infections
due to multidrug-resistant Gram-negative
bacteria in patients without cystic ﬁbrosis
S. Kasiakou, A. Michalopoulos, E. Soteriades, G. Samonis,
G. Sermaides, M. Falagas (Athens, GR; Boston, USA; Iraklion, GR)
Background: Colistin, an antibiotic almost abandoned for intra-
venous administration for many years, due to its reported
toxicity, has been recently reintroduced in clinical practice due
to the emergence of multidrug-resistant Gram-negative bacteria
and the lack of development of new antibiotics to combat them.
Objective: To assess the safety and effectiveness of intravenous
colistin in the treatment of serious infections in patients without
cystic ﬁbrosis.
Design: Retrospective cohort study.
Setting: 450-bed tertiary-care hospital in Athens, Greece.
Patients: Patients who were hospitalized during the period
from 1/October/2000 to 31/January/2004 and received intra-
venous colistin for more than 72 hours.
Measurements: Primary outcome measure was the in-hospital
mortality; secondary end points were the clinical outcome of the
infections and the occurrence of colistin toxicity.
Results: Fifty patients received intravenous colistin with a
median (mean) daily dose of 3 (4.5) million IU for 16.5 (21.3)
days for the management of 54 episodes of infections due to
multidrug-resistant Gram-negative bacteria. The predominant
infections were pneumonia (33.3%), bacteraemia (27.8%), urin-
ary tract infection (11.1%), and intra-abdominal infection
(11.1%). The responsible pathogens were Acinetobacter baumannii
(51.9%), Pseudomonas aeruginosa (42.6%), and Klebsiella pneumonia
(3.7%) strains (no pathogen was isolated from one case). In-
hospital mortality was 24% (12/50 patients). Clinical response
(cure or improvement) of the infection was observed in 66.7% of
episodes (36/54). In the studied group, serum creatinine levels
were decreased, at the end of colistin treatment, by an average of
0.2 ± (1.3) mg/dl compared to baseline levels. Deterioration of
renal function during colistin therapy was observed in 4/50
patients (8%).
Limitations: Co-administration of other antimicrobial agents
with spectrum against Gram-negative microorganisms and the
absence of a control group.
Conclusions: Use of intravenous colistin for the treatment of
infections due to multidrug-resistant Gram-negative bacteria
appears to be safe and effective.
P1075
Aerosolised colistin for the treatment of
nosocomial pneumonia due to multidrug-
resistant Gram-negative bacteria in patients
without cystic ﬁbrosis
A. Michalopoulos, S. Kasiakou, Z. Mastora, K. Rellos,
A. Kapaskelis, M. Falagas (Athens, GR)
Background: The clinical and economical consequences of the
emergence of multidrug-resistant Gram-negative bacteria in the
intensive care unit (ICU) setting in combination with the high
mortality rate among patients with nosocomial pneumonia have
made the medical community to search for alternative thera-
peutic options. The use of adjunctive therapy with aerosolized
colistin represents one of them. Extensive experience with
aerosolized colistin exists in patients with cystic ﬁbrosis.
However, the literature lacks data regarding the use of aeros-
olized colistin in non-cystic ﬁbrotic patients.
Methods: To assess the safety and effectiveness of aerosolized
colistin as an adjunctive to the intravenous antimicrobial
therapy for the treatment of Gram-negative nosocomial pneu-
monia, we retrospectively reviewed the medical records of
patients, who were hospitalized in a 450-bed tertiary-care
hospital during the period from October/2000 to January/
2004, and received aerosolized colistin as an adjunctive therapy
for multidrug-resistant pneumonia.
Results: Eight patients received aerosolized colistin. All were
admitted to the ICU with a mean Acute Physiological and
Chronic Health Evaluation II (APACHE II) score on the day of
ICU admission and on the 1st day of aerosolized colistin
administration of 14.6 and 17.1, respectively. Six of the 8 patients
had ventilator-associated pneumonia. The responsible patho-
gens were Acinetobacter baumannii (7/8 cases) and Pseudomonas
aeruginosa (1/8 cases) strains. Half of the isolated pathogens
were sensitive only to colistin. Daily dosage of aerosolized
colistin ranged from 1.5 to 6 million IU (divided into 3 or 4
doses) and the mean duration of administration was 10.5 days.
Seven out of 8 patients received concomitant intravenous
treatment with colistin or other antimicrobial agents. Clinical
response of pneumonia was observed in 7 out of 8 patients [4
cured, 3 improved (they were transferred to another facility)].
One patient deteriorated and died due to septic shock and
multiple organ failure. Aerosolized colistin was well tolerated
by all patients; no bronchoconstriction or chest tightness was
reported.
Conclusions: Aerosolized colistin may be a beneﬁcial adjunc-
tive treatment in the management of nosocomial pneumonia
(VAP or not) due to multidrug-resistant Gram-negative bacteria.
P1076
Toxicity after prolonged (more than four weeks)
administration of intravenous colistin
M. Falagas, M. Rizos, I. Bliziotis, K. Rellos, S. Kasiakou,
A. Michalopoulos (Athens, GR)
Objective: To study the toxicity of prolonged intravenous
administration of colistin
Design: Observational study of retrospective cohort.
Setting: Henry Dunant Hospital, a 450-bed tertiary care centre
in Athens, Greece.
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Participants: Patients who received intravenous colistin for
more than 4 weeks for the treatment of multidrug resistant
Gram-negative infections.
Main outcome measures: Serum creatinine, blood urea, liver
function tests, symptoms and signs of neurotoxicity.
Results: We present our experience with the use of 19 courses
of prolonged intravenous colistin [mean duration of adminis-
tration (±SD) 43.4 (±14.6) days, mean daily dosage (±SD) 4.4
(±2.1) million IU, mean cumulative dosage (±SD) 190.4 (±91.0)
million IU] in 17 patients. The median creatinine value
increased by 0.25 mg/dl during the treatment compared to
the baseline (p < 0.001) but returned close to the baseline at
the end of treatment (higher by 0.1 mg/dl, p = 0.67). No
apnea or other evidence of neuromuscular blockade was noted
in any of these patients who received prolonged treatment
with colistin.
Conclusions: No serious toxicity was observed in patients
who received prolonged intravenous colistin. Colistin
should be considered as a therapeutic option in patients
with infections due to multidrug resistant Gram-negative
bacteria.
P1077
Colistin-resistant Acinetobacter baumannii: report
of a case
O. Bargiacchi, G. Fucale, F.G. De Rosa, E. Carretto, S. Garazzino,
S. Audagnotto, D. De Vitis, D. Barbarini, G. Di Perri (Torino,
Pavia, I)
Acinetobacter baumannii is an important nosocomial pathogen
and outbreaks by multi-drug resistant (MDR) strains have been
reported worldwide, especially in burn and intensive care units.
The most effective drugs are carbapenems, colistin and new
glicilcyclines, even if reports of carbapenem-resistant strains are
increasing worldwide. To date, susceptibility rates to imipenem
and colistin of nosocomial strains are reported as high as 88%
and >98%, respectively. In particular, resistance to colistin has
been rarely described and the mechanisms of this resistance are
poorly understood. We report a case of colistin resistant
A. baumannii infection in a patient without previous adminis-
tration of colistin.
Case report – methods: A colistin resistant (MIC >2 mcg/ml)
A. baumannii was isolated from 3 sets of blood cultures in a
patient admitted in a burn unit without previous colistin
exposure. The patient was treated with ampicillin/sulbactam
and colistin, despite the documented resistance to all antibi-
otics. MDR A. baumannii was repeatedly isolated from
different sites and the patient died after 61 days of hospital-
ization. Strain identiﬁcation and susceptibility tests were
performed using Phoenix automated microbiology system.
Resistance to ampicillin, ampicillin/sulbactam, ceftazidime,
imipenem, meropenem, cotrimoxazole, amikacin, ciproﬂoxacin
and colistin was conﬁrmed by disk diffusion test and broth
microdilution, in accordance with the NCCLS guidelines. The
susceptibility results were conﬁrmed by a reference laborat-
ory.
Conclusion: Colistin is one of the few effective drug available
against MDR Acinetobacter infections and acquired resistance is
exceptional. Our report points out that colistin resistant
A. baumannii may be found in hospitalized patients without
previous exposure to colistin. Nosocomial infections by colistin-
resistant A. baumannii could represent a new therapeutic
challenge. Programmes of active surveillance cultures and
contact precautions should be implemented to control the
spread of this MDR microorganism.
P1078
Intrathecal colistin treatment of central nervous
system infections due to multi-resistant
Acinetobacter baumannii
C. Sua´rez Ferna´ndez, P. Ferna´ndez-Viladrich, F. Tubau,
L. Corral , A. Mateu, J. Ariza (Barcelona, E)
Objectives: The optimal therapy of CNS infections due to
Multi-Resistant Acinetobacter baumannii (MRAB) is not estab-
lished. In 1999 we published the ﬁrst two cases of ventriculitis
due to MRAB treated with intrathecal (it) colistin. One patient
received 10 mg colistin base/12 hours after delayed CSF steril-
ization was documented with initial dosage of 5 mg/12 hours.
Here we describe our extended experience with this kind of
treatment .
Methods: We retrospectively reviewed all documented CNS
infections due to MRAB diagnosed in our terciary 1000-bed
hospital from 1999 to 2004. MRAB was deﬁned as those strains
with only susceptibility to colistin (MIC < 4 mg/L). CNS
infections were deﬁned as those cases with suggestive clinical
features plus ventricular or lumbar CSF with both characteristic
cytochemical alterations and positive culture.
Results: There were 7 cases with documented nosocomial CNS
infection due to MRAB. Six of them were acquired after
neurosurgical procedure through surgical wound infection or
local catheter infection. One case was caused by hematogenous
spread after urological manipulation. Intrathecal therapy was
administered through a ventricular catheter in ﬁve cases, lumbar
catheter in one case and both ventricular and lumbar catheter in
one case. The usual doses administered was colistin base 10 mg
(equivalent to colistimethate sodium 24 mg) every 12 hours
with CSF continuous drainage being interrupted for about
3 hours. Length of treatment were 8–21 days with any apparent
adverse effect. Six of these patients received simultaneous
intravenous colistin therapy. Culture sterilization was docu-
mented in all patients. Two patients died (one from unclear
cause after initial favorable evolution; one after receiving only
two doses of it colistin). The rest of them cured with sequela
attributable to their previous neurological diseases.
Conclusions: In our experience, combined treatment with both
intrathecal and intravenous colimicin seems safe and effective.
When administered by local route to patients with continuous
CSF drainage we suggest a dosage of colistin base of 10 mg
every 12 hours with temporary interruptions of the drainage.
P1079
Bacillus cereus – the forgotten pathogen. An
unusual infection in an orthopaedic patient
S. Thomas, A. Pillai, J. Arora, A.C. Ogden (Dumfries, UK)
Background: Infection with Bacillus cereus has been well docu-
mented in the literature for over a century. Infection is generally
associated with the gastrointestinal effects of food poisoning and
linked to the consumption of infected rice dishes. However, the
Bacillus genus is extremely heterogenic. It can occupy a wide
variety of ecological niches and bacillus spores are found
ubiquitously in the environment. Even so, Bacillus cereus isolated
from the hospital and clinic setting in any material other than
vomitus or faeces is commonly dismissed since it is a known
contaminant of blood cultures and most bacillus bactereamias
are transient and usually insigniﬁcant.
Case Report: We report a case of Bacillus cereuswound infection
in a previously healthy 31-year-old male admitted to the
orthopaedic ward with a comminuted fracture of the right
distal tibia. He developed compartment syndrome one day later
Abstracts
336
and was taken to theatre for fasciotomy. Within 48 hours, he
developed chest complications and was admitted to the High
Dependency Unit. After three days he was taken back to theatre
for wound inspection and change of dressing. Seven days later
external ﬁxation was applied. Subsequently, the wound site
became red, inﬂamed and tender and was associated with an
acute rise in inﬂammatory markers. Microbiological reports
showed Bacillus cereus growth from the suture sites, sensitive to
ciproﬂoxacin. No source was identiﬁed.
Discussion: This report merits concern, because it highlights
the risk of wound cross infection with this unlikely pathogenic
species. Bacillus cereus has been known to be a contaminant of
dressings, intravenous catheters, theatre scrub suits and linens
pointing to an array of possible infective sources within the
hospital. It emphasizes the need for theatre and hospital sterility
and stresses the importance of vigilance against this infrequent
cause of a potentially serious non-gastrointestinal bacillus
infection. This is of particular importance because alcohol-
based cleaning solutions are known to be ineffective against
bacillus spores and infections dismissed as contaminants may
lead to rapid clinical deterioration.
P1080
Antibacterial effect of phenytoin in wound
healing
S. Abolghasemi, B. Mostanfar (Tehran, IR)
Objectives: Phenytoin is an antiseizure medication, has since
been reported to promote wound healing when applied as a
topical agent. This effect is due to rapid inﬁltration of ﬁbroblasts,
collagen deposition, new vessel formation as well as antibacte-
rial activity. This study was undertaken to evaluate it’s effect on
chronic skin ulcers with different causes and compare it with
normal saline.
Methods: Fifty inpatients with chronic skin ulcers were inclu-
ded in this case-control study: diabetic foot (20%), fracture and
surgery wounds (40%), decubitus ulcers resulting from war-
related (40%). The patients were matched for age, sex, severity
and size of wounds and randomly assigned to two group: 25
phenytoin treated (pht) and 25 control (ctl). Each group included
15 men and 10 women, age range was between 20 and 60.
Surface areas of the ulcers was 12–200 cm2. The ulcers were
debraded of necrotic tissue (if required). Cultures of ulcers were
taken at the beginning of treatment and on day 7, 14. In pht, thin
dusting of phenytoin powder and dry gauze dressing were
applied daily after washing with normal saline. Ctl group
received only daily washing with normal saline and plain
dressing.
Results: Bacteriologic culture in both group conﬁrmed some
strains (Staphylococcus aureus, Kelebsiella, Proteus and Psudomon-
as). At the beginning of treatment, there was 17 culture positive
in pht. 13 case became negative by day 7 and 4 case became
negative by day 14. In ctl, we had 15 culture positive that they
didn’t become negative by day 7 and 14 (seventy-six per cent of
pht had negative cultures by day 7 compared to 0% of ctl). The
mean time for appearance of granulation tissue was 13.48 days
in pht compared with ctl that was 37.5 (p = 0.006). The average
time to complete healing in pht was 24.76 days compared to
43.36 in the ctl (p = 0.0001). In pht only 13 patients required to
analgesics (mean 1/day) compared with ctl that all patients
required to analgesics about 3–4/day (p = 0.0001). Age, sex and
kind of wounds didn’t effect the healing time in both group.
Conclusions: This study with statistical analysis demonstrated
good improvement and efﬁcacy of phenytoin in treatment of
chronic ulcers compared with normal saline. 1. prompt pain
relief, 2. reduction in ulcer size, 3. changing bacterial culture to
negative, 4. more rapid granulation and healing time, charac-
terized the pht group. We recommend wider use of this safe,
inexpensive, readily available and easy to use agent because of
it’s positive effect on wound healing especially in our country
that a lot of patients suffer from decubitus ulcers resulting from
war-related wounds and limited access to more expensive
wound care therapies.
P1081
Recurrent osteomyelitis secondary to different
bacteria
I. Uckay, M. Assal, L. Legout, P. Rohner, R. Stern, D. Lew,
P. Hoffmeyer, L. Bernard on behalf of the Osteomyelitis Group
Study
Objective: Recurrence of osteomyelitis due to the same bacteria
from a prior site of infection without evidence of trauma or
bacteraemia is an entity well-known in the literature and clinical
practice. The objective of this study is to try and determine if all
these reactivations are actually due to the same bacteria, as has
been assumed in previous case reports.
Case reports: We report three cases of osteomyelitis recurring in
the same bone in otherwise healthy patients. In all three
patients, there was no history of illness or trauma to assume
another origin. Surprisingly, the strains were different from the
two infectious episodes.
Conclusion: Reactivation of osteomyelitis can be caused by
different strains of bacteria, many years after the initial episode
without trauma or evident bacteraemia. Former infected and
therefore altered bone surface might be a region of diminished
resistance for a new infection during silent transient bacterae-
mia, reminiscent of the clinical entity of (recurrent) infectious
endocarditis on altered valve surfaces.
P1082
Aetiological factors of vascular grafts infection
and their antimicrobial susceptibility
J. Niedzwiadek, E. Mazur, S. Misztal, B. Ziemba, P. Terlecki,
J. Ligieza, M. Koziol-Montewka, J. Wronski (Lublin, PL)
Objectives: Vascular graft infection proved to be the most
dangerous complication in vascular surgery patients. The aim of
our study was the identiﬁcation of microorganisms causing
vascular graft infections and the evaluation of their antimicro-
bial susceptibility. 25 patients with infected vascular grafts,
treated in Vascular Surgery Department, took part in our
research. In 76% of patients, the late type of infection was
recognized, in 24% of patients the infection was qualiﬁed as
early.
Methods: Purulent discharge obtained from the ﬁstula was
inoculated on the bacteriological media. Antimicrobial suscep-
tibility was assessed by disc-diffusion method.
Results: Staphylococcus aureus and Pseudomonas aeruginosa, pre-
sent in 16,7% of patients, proved to be the most frequently
isolated microorganisms. Staphylococcus epidermidis and E. coli
were isolated in 13.3% and 10% of patients, respectively. Mixed
infection, caused by two distinct bacteria, occurred in 20% of
patients; in all cases one species belonged to Gram-positive, and
the second one to Gram-negative bacteria. In 50% of patients
with early type infection different species of Gram-negative rods
were present, in 37.5% of patients, Staph. aureus and Staph.
epidermidis were isolated, Enterococcus faecalis occurred in 12.5%
of patients. In late type infection Gram-negative rods were
isolated from 54.5% of patients and Gram-positive bacteria from
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31.5% of patients. The most frequently isolated species appeared
to be Pseudomonas aeruginosa. In one patient Candida crusei was
isolated. The isolated species of bacteria varied depending on
the degree of infection (according to Shilagy and Samson). In
IIIA degree of infection Staph. epidermidis and E. coli were
present in 67.7% and 33.0% of patients, respectively. Pseudo-
monas aeruginosa and Staph. aureus were isolated in 21,1% of
patients with IIIB degree of infection. Various species of Gram-
negative rods were isolated from 80% of patients with IIIC
degree of graft infection.
Conclusions: Most isolated bacteria appeared to possess the
resistance patterns typical for hospital ﬂora; among them
methicillin-resistant Staph. aureus (MRSA) and methicillin-resist-
ant coagulase-negative Saphylococci (MRCNS) strains, Gram-
negative rods producing extended spectrum of beta-lactamases
(ESBL) or AmpC beta-lactamases, and Enterococcus faecalis with
high level of aminoglicosides resistance (HLAR).
P1083
Treatment failure due to emergence of resistance
to imipenem during therapy for Shewanella algae
bacteraemia
D.M. Kim, M.-D. Oh (Gwang-Joo, Seoul, KOR)
Objective: We describe here a case of bacteraemia caused by
S. algae, which was initially susceptible to imipenem, but the
bacteria later became resistant during the treatment. In addition,
we investigated the propensity of S. algae to develop resistance
to imipenem by using a serial passage technique.
Method: In vitro test for resistance induction
1. Bacterial strains
Resistant variants selection
(a) single step resistant variants were obtained from clinical
Isolate on Mueller-Hinton agar containing increasing amounts
of imipenem (1xMIC, 2xMIC, 4xMIC, 8xMIC),
(b) serial passage experiment S. algae strain and P. aeruginosa
ATCC 27853 were grown overnight in Mueller–Hinton agar and
then grown overnight in Mueller–Hinton agar and then
swabbed onto Mueller–Hinton agar plates containing one-half
the MIC of imipenem. The surface growth at 24 h was swabbed
to Mueller–Hinton agar containing twice the prior concentration
of imipenem.
Results: Single step resistant variants were selected from Isolate
1 at up to 4 times the MIC, whereas the resistant variant from P.
aeruginosa ATCC 27853 could be selected at up to 2 times the
MIC. All the resistant variants of S. algae selected either by a
single step or by a sequential stepwise passage exhibited at up to
8–16 lg/ml of MIC, whereas those of P. aeruginosa ATCC 27853
showed up to 16 lg/ml of MIC
Conclusion: We documented that S. algae, which was initially
susceptible to imipenem, subsequently became resistant to
imipenem during the treatment. We also demonstrated in
vitro that the initial isolate of S. algae could easily develop
resistance to imipenem when the organism was exposed to
imipenem, suggesting that S. algae organisms have a propensity
toward resistance to imipenem.
P1084
Micro-organisms from peritoneal ﬂuid of patients
on continuous ambulatory peritoneal dialysis
M. Dimoutsos , E. Platsouka, E. Perivolioti, E. Patsouris, C.
Moularogianni, S. Kallia, G. Margariti, O. Paniara (Athens, GR)
Objective: Peritonitis remains a common and serious compli-
cation of peritoneal dialysis. In this study, we evaluated the
frequency of microorganisms isolated from peritoneal ﬂuids of
patients on continuous ambulatory peritoneal dialysis (CAPD).
Methods: During a 2.5 year period, 321 peritoneal ﬂuid samples
were collected from 107 CAPD patients with peritonitis symp-
toms. The specimens were inoculated on appropriate media after
10-min centrifugation. Gram stained smears and aerobic, anaer-
obic and broth cultures were performed. The isolates were
identiﬁed by commercial ID panels. MICs were determined with
a microdilution method according to NCCLS guidelines.
Results: Fifty two out of 321 sampleswere positive (16.2%), six of
the positives were polymicrobial. The following microorganisms
were obtained: Pseudomonas aeruginosa (8), Staphylococcus epider-
midis (7), Escherichia coli (7), Staphylococcus aureus (6), Streptococcus
viridans (6), Klebsiella pneumoniae (4), Enterococcus faecalis (4),
Stenotrophomonas maltophilia (4), Enterobacter aerogenes (2), Acine-
tobacter baumannii (1), Enterococcus faecium (1), Proteus mirabilis (1),
Pseudomonas ﬂuorescens/putida (1), Acinetobacter lwofﬁi (1), Sal-
monella group D (1), Bacteroides spp. (2). Fungi were isolated in
three patients:Candida tropicalis (1),Candida krusei (1) and Candida
parapsilosis (1). Three out of 6 of S. aureus strains and three out of 7
of S. epidermidis isolates were found resistant to methicillin. All
Saphylococci and Enterococci were susceptible to vancomycin and
linezolid. Gram-negative pathogens were sensitive to used
antibiotics.
Conclusion: Thirty ﬁve patients (32.7%) developed peritonitis
The most prevalent etiologic agents of peritonitis on CAPD
patients were Pseudomonas aeruginosa, Staphylococcus epidermidis,
Escherichia coli, Staphylococcus aureus and Streptococcus viridans.
Since CAPD patients are commonly outpatients, the antimicro-
bial resistance in the Gram-negative strains is low compared to
the nosocomial isolates. Appropriate antibiotic therapy based on
microbiologic results needs for the management of peritonitis on
CAPD patients.
Susceptibility surveillance studies
P1085
In vitro activity of cefepime and other broad
spectrum antibiotics against Gram-negative and
Gram-positive pathogens causing severe
infections in hospital patients. Results of a
German surveillance study
F.-J. Schmitz (Minden, D)
Objectives: Cefepime is a fourth generation cephalosporin with
a broader spectrum of activity against Gram-negative and
Gram-positive pathogens in comparison with all other cephalo-
sporins. Due to the excellent antibacterial activity including
Pseudomonas aeruginosa and Enterobacter spp. together with low
rates of resistance and favourable pharmacokinetic and clinical
properties, cefepime is a drug of choice for initial empiric
treatment of severe nosocomial infections. Nevertheless, in
addition to recommendations in guidelines, the surveillance of
local resistance data is important for empiric treatment decisions
in hospitals.
Methods: In this study, the in vitro activity of cefepime (CEP),
imipenem (IMI), piperacillin tazobactam (P/T), ceftazidime
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(CAZ) and cefotaxime (CFT) has been investigated against 1130
bacterial strains, isolated in the year 2004. MICs have been
determined by microdilution method according to DIN 58940.
Reference test strains were E.coli ATCC 25922, S. aureus ATCC
29213, P.aeruginosa ATCC 27853, and S.pneumoniae ATCC 49619.
Results: Highest in vitro activity against Gram negative Entero-
bacteriaceaewere determined for CEP and IMI with susceptibility
rates for Enterobacter spp. 98%,98%,M.morganii 96%,92%, Proteus
spp. 98%,96% and Citrobacter spp. 96%,100% whereas the
susceptibility rates for P/T, CAZ and CFT were much lower
(E.spp. 68%,72%,68%; M.m. 88%,72%,66%; P.spp. 96%,96%,66%;
C.spp. 68%,76%,72%). For Pseudomonas aeruginosa (n = 100),
susceptibility rates were 76% (CEP), 73% (CAZ), 72% (IMI)
and 55% (P/T) with lowest resistance rates for CEP (6%)
followed by CAZ (11%), P/T (14%), IMI (23%). The study
conﬁrmed excellent cefepime activity against Gram positive
isolates (pneumococci, Streptococcus viridans and b-hemolytic
Streptococci) and high cefepime susceptibility rates for Staphylo-
cocci (MSSA 99% and MSSE 98%) on contrary to ceftazidime
(MSSA 44% and MSSE 42%).
Conclusion: Regarding our in vitro data, CEP is a reliable
treatment option for empiric therapy in patients with severe
nosocomial infections, demonstrating high activity against Gram
positive isolates, comparable activity in Gram negative Entero-
bacteriaceae to carbapenems (IMI) and lowest resistance rates in
Pseudomonas aeruginosa.
P1086
Antimicrobial activity and spectrum of cefepime
tested against 65,746 clinical strains from North
American medical centres: report from the
SENTRY Antimicrobial Surveillance Program,
1998–2004
H. Sader, D. Biedenbach, T. Fritsche, R. Jones (North Liberty,
USA)
Objectives: To evaluate antimicrobial spectrum and potency of
cefepime (CPM) and selected comparators against clinical
bacterial strains collected in North America (NA) over a 7-year
period (1998–2004).
Methods: Isolates were consecutively collected from blood-
stream (44%), respiratory tract (41%), urinary tract (6%) and
skin/soft tissue (5%) infections in 48 medical centres. 75% of
isolates were from hospitalized patients. Isolates were suscep-
tibility (S) tested by reference NCCLS broth microdilution
methods in a central laboratory. Oxacillin-resistant (R) Staphy-
lococci (ORS) and Enterococci were excluded.
Results: The activity of CPM against the key organisms tested is
summarized in the Table. Overall, 99.8% of Gram-positive cocci
(GP) tested were S to CPM. Imipenem (IMP; MIC90, 1 mg/L;
99.9% S) was the most active compound tested against ENT,
followed by CPM (MIC90, 0.25 mg/L; 99.5% S) > amikacin
(AMK; 99.4% S) > ceftriaxone (95.6% S) > aztreonam (95.1% S).
The lowest S rate for ENT was observed with ciproﬂoxacin
(CIPRO; 92.8%). IMP was also the most active compound against
ESBL-producing KSP and E. coli (99.3 and 100% S, respectively),
followed by AMK (81.4 and 97.2% S) and CPM (92.5 and 93.8%
S). CPM activity against PSA (85.2% S) was similar to that of IMP
(86.9% S). Against OSSA, CPM was 4-fold more potent than
ceftazidime (CAZ; MIC90, 16 mg/L, 86.4% S) and showed
higher activity than CIPRO (93.2% S). CPM was the most active
compound against SPN after gatiﬂoxacin and levoﬂoxacin
(99.2% S). Against VGS, CPM was 8-fold more potent than
CAZ and 4-fold more potent than piperacillin/tazobactam. The
activity of CPM remained very stable during the period
evaluated with the % S varying from 99.5 to 99.3% among
ENT, 85.2 to 88.4% among PSA, 98.1 to 97.6% among SPN, and
94.4 to 92.6% among VGS.
Conclusions: CPM was very active against ENT, PSA and GP
cocci (except ORS and Enterococci) isolated in NA medical
centres. CPM activity remained stable in the 7-year period of the
study with low level of cross-R to third-generation cephalospo-
rins. Continued R surveillance is necessary to monitor the
effectiveness of widely used antimicrobials.
P1087
The prevalence of multidrug resistance among
Streptococcus pneumoniae in the United States
R. Blosser, G. Tillotson, R.K. Flamm, D.A. Styers, D.F. Sahm,
M. Jones (Herndon, Waltham, USA; Hilversum, NL)
Objectives: In the U.S., recent approval of antimicrobial agents
(e.g. gemiﬂoxacin [GEM]) with indications for multiple drug
resistant (MDR) S. pneumoniae (SP) demonstrates a positive
industry and governmental response to the need for develop-
ment of agents against resistant (R) pathogens. This mandates
the need for surveillance initiatives to track MDR, as opposed to
tracking a single agent’s resistance (e.g. penicillin [PEN]). We
investigated the current status of MDR among recent clinical
isolates of SP distributed throughout USA.
Methods: TSN Database–USA (Jan–Dec, 2003) was used to
evaluate the current prevalence of the MDR SP in nine geo-
graphic urban areas (Atlanta, Baltimore/DC, Carolinas, Central
Florida, Chicago, Dallas, Los Angeles, Ohio, South Florida). MDR
prevalence was also analysed on the basis of specimen source
(upper respiratory [UR], lower respiratory [LR], blood [BL]).
MDR was deﬁned as resistance to ‡2 among PEN, erythromycin
(ERY), and trimethoprim-sulfamethoxazole (SXT). We also selec-
ted 30,2003 MDR SP clinical strains to evaluate the relative in
vitro activities of respiratory ﬂuoroquinolones (GEM, gatiﬂoxa-
cin [GAT], moxiﬂoxacin [MXF], and levoﬂoxacin [LFX]).
Results: AmongSP fromall regions combined, theMDRratewas
19.2%. R to PEN, ERY, and SXTwas themost commonphenotype.
Regionally, MDR ranged from 9.1% in Los Angeles to 32.2% in
South Florida. R to PEN, ERY, and SXT was the most common
MDR phenotype in all regions except Baltimore/DC (R to ERY
and SXTwasmost common). By specimen source, 15.5% of blood,
21.0% of LR, and 29.0% of UR isolates were MDR with R to PEN,
ERY, and SXT being the most common phenotype regardless of
specimen source. For the 30 strains tested, the ﬂuoroquinolone
MIC ranges were: 0.008–0.03 mg/L (GEM), 0.12–0.25 mg/L
(GAT), 0.06–0.25 mg/L (MXF), 0.5–1 mg/L (LFX).
Conclusions: MDR among SP is a phenotype that is widely
dispersed geographically and is likely to be encountered
regardless of the site of infection. Fluoroquinolones show
activity against most MDR isolates. As the use of ﬂuoroquino-
lone compounds increases, surveillance to monitor the preval-
ence of MDR and track the in vitro activity of agents such as
GEM used for these resistant strains must be continued.
MIC (mg/L) Cumulative % inhibited at MIC (mg/L):
Organism (no. tested) 50% 90% £0.5 1 2 4 8 16
E. coli (10,361) £0.12 £0.12 98.5 99.1 99.4 99.6 99.7a 99.18
Klebsiella spp. (KSP; 5,166) £0.12 0.25 94.4 96.0 97.5 98.6 99.3 99.7
Enterobacter spp. (2,836) £0.12 2 85.9 89.9 94.1 97.3 99.0 99.6
Serratte, spp (1,412) £0.12 0.25 95.6 97.2 98.5 99.0 99.3 99.6
P. mirabilis (1, 225) £0.12 £0.12 98.6 98.9 99.0 99.3 99.5 99.7
All Enterobacteriaceae (ENT; 22,860) £0.12 0.25 95.5 97.0 98.1 99.0 99.5 99.7
H. inﬂuenzae (7,975) £0.06 0.12 99.9 100.0 - - - -
P. aeruginosa (PSA; 5,517) 4 16 1.9 13.8 45. 1 67.0 85. 2 94.5
Oxacillin-S S. aureus(OSSA; 10,835) 2 4 0.6 2.4 68.3 99.5 100.0 -
S. pneumoniae (9,249) £0.06 1 85.3 97.4 99.7 99.9 100.0 -
b-haemoytic strept (2,703) £0.12 <0.12 99.9 100.0 - - - -
viridans gr. strept. (VGS; 783) £0.12 1 88.8 94.1 99.7 999 100.0 -
a. Underline values indicate % S.
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P1088
Comparative activity of oral and parenteral
cephalosporins against multi-drug-resistant
Streptococcus pneumoniae: report from the
SENTRY Antimicrobial Surveillance Program
(1997–2003)
S. Pottumarthy, T. Fritsche, H. Sader, R. Jones (North Liberty,
USA)
Background: Multi-drug resistant (MDR) S. pneumoniae strains
are increasing at an alarming rate worldwide. The therapy of
respiratory tract infections due to these strains is challenging
with an urgent need for antimicrobials with reliable activity
against the MDR strains. Comparative activity of oral cephalo-
sporins and parenteral cephalosporins against various pneumo-
coccal MDR phenotypes was analysed in a large, multi-year
international collection of clinical strains of S. pneumoniae.
Methods: S. pneumoniae strains (21,605) collected during 1997–
2003 from worldwide participants of the SENTRY Program were
tested and interpreted using NCCLS (M7-A6, M100-S14) guide-
lines. The antimicrobial agents analysed included penicillin
(PEN), erythromycin (ER), clindamycin (CM), tetracycline (TET)
and trimethoprim/sulfamethoxazole (TS); cephalosporins mon-
itored included oral (cefpodoxime, cefuroxime) and parenteral
(ceftriaxone, cefepime) agents.
Results: The rank order of occurrence rates of the various
resistance phenotypes were: PEN only (32.0%) > PEN and ER
(17.6%) > PEN, ER and CM (8.6%) > PEN, ER, CM and TET
(7.6%) > PEN, ER, CM and TS (6.5%) > all ﬁve drugs (5.7%). The
susceptibility rate of all strains to the orally administered
cephalosporins, cefpodoxime (77.6%) and cefuroxime (77.3%),
dropped to only 16.1% and 14.5% respectively, for the ﬁve-drug
MDR phenotype. The parenteral cephalosporins retained excel-
lent activity for all MDR phenotypes, with resistance rates being
lower for cefepime than ceftriaxone (cefepime, 1.3–1.9%; ceftri-
axone, 3.0–4.4%) or the oral cephalosporins (cefpodoxime, 64.4–
74.1%; cefuroxime, 69.3–79.1%) using respiratory infection
breakpoints (NCCLS).
Conclusions: Our in vitro ﬁndings conﬁrm that the parenteral
cephalosporins, cefepime and ceftriaxone, retain excellent activ-
ity against the MDR phenotypes analysed, and remain useful
drugs in the armamentarium to treat MDR pneumococcal
respiratory tract infections.
P1089
Antibiotic resistance surveillance over a 5-year
period in Spain: results of the MYSTIC
Programme
A. Pascual, E.J. Perea, M. Alvarez , M. Casal, J. Garcı´a-de-Lomas,
J.A. Garcı´a-Rodrı´guez , R. Martin, J. Zapardiel and the Spanish
MYSTIC group
Objective: To monitor resistance trends to meropenem (MEM)
and other broad-spectrum antibiotics among bacteria isolated
over a ﬁve-year period in 7 Spanish hospital units involved in
the MYSTIC programme, a global study providing in-vitro
surveillance data on antimicrobial susceptibility in centres
prescribing meropenem.
Methods: Organisms were tested using National Committee for
Clinical Laboratory Standards (NCCLS) methodology. Mini-
mum inhibitory concentration (MIC) values and percentage
susceptibilities at NCCLS breakpoints (%S) were obtained for
MEM and a range of comparators including imipenem
(IPM),ceftazidime (CAZ), piperacillin + tazobactam (TAZ),
ciproﬂoxacin (CIP) and gentamicin (GM).
Results: Three ICUs, two neutropenia units and two general
wards provided a total of 4.022 Gram-negative and Gram-
positive isolates during the period 1999–2003. The most common
species tested were Escherichia coli (14.3%), methicillin-suscept-
ible Staphylococcus aureus (13.8%) and coagulase-negative Sta-
phylococci (13.5%), Pseudomonas aeruginosa (12.2%), Enterobacter
cloacae (7.2%), Klebsiella pneumoniae (5.7%) and A.baumannii
(5.6%). In general, the carbapenems (MEM and IPM) were the
most active antimicrobial agents tested against the common
organisms (range of %S:100% to 71% and 100% to 67%,respect-
ively). Among Enterobacteriaceae, 100% of Enterobacter spp,
Citrobacter spp and Serratia spp were susceptible to carbapen-
ems. E. coli and K. pneumoniae susceptibility to carbapenems
were 100% and >98% respectively. The %S of MEM was the
same as or higher than IPM against every organism tested. CIP
resistance in E. coli was around 20%. CAZ and TAZ were the
least active antimicrobial agents against Enterobacter sp (74% and
77% S, respectively) and Citrobacter spp (67% and 68% S,
respectively). MEM and TAZ were the most active agents
against P. aeruginosa (89% and 88%S, respectively). A. baumannii
were 61–90% susceptible to carbapenems, but only 6–1%
susceptible to CIP. In this period, around 100% of methicillin-
susceptible Staphylococci were susceptible to MEM.
Conclusion: There was no signiﬁcant decrease in susceptibility
to the carbapenems throughout the ﬁve-year period. MEM and
IMP appear to remain reliable options for the treatment of
serious nosocomial infections. The clinical use of MEM did not
increase bacterial resistance to this agent in the Spanish centres
evaluated.
P1090
Surveillance of antimicrobial susceptibility of
anaerobes in a Belgian University hospital
Y. Glupczynski, H. Nizet, C. Berhin (Yvoir, B)
Background: Antimicrobial resistance is becoming a growing
concern among anaerobes involved in human infections. Since
there are only scarce data on the in vitro susceptibility of
anaerobes in our country, we aimed to determine the suscep-
tibility and resistance proﬁles of anaerobic bacteria isolated in
our hospital.
Methods: Minimum inhibitory concentrations (MICs) of 151
consecutive clinically signiﬁcant isolates of anaerobes recovered
from various anatomical sites between 09/2003 and 10/2004
were determined against penicillin (PEN), amoxicillin-clavula-
nate (AMC), piperacillin-tazobactam (PTZ), imipenem (IMP),
meropenem (MER), clindamycin (CLI), metronidazole (MET)
and moxiﬂoxacin (MOX) by E-test using NCCLS interpretative
guidelines. Referencse strains B.fragilis (ATCC 25285), B. theta-
iotaomicron (ATCC 29711) and E. lentum (ATCC 43055) were
used as quality control reference strains.The organisms were:
B. fragilis group (BFG) (n = 75) including B. fragilis (n = 42),
B. theaiotaomicron (9), B. ovatus (5), B. distasonis (5), B. caccae (6), B.
vulgatus (n = 7), and B. uniformis (n = 1), Prevotella spp. (n = 27),
Clostridium spp. (n = 11), Fusobacterium spp. (n = 9), Peptostrep-
tococcus spp. (n = 18) and other Gram-negative anaerobic spe-
cies (OGNA) (n = 12). They were isolated from blood (8), sterile
body ﬂuids (31), abominal or deep wounds (49) and surgical
biopsies (12).
Results: The overall MIC50, MIC90 and % resistance were as
follows: PEN: 4/>256, 56%, AMC: 0.125/2, 3%; PTZ: 0.064/16,
3%; MER: 0.06/0.25, 1%, IMP: 0.12/1, 1%; CLI: 0.19/>256, 27%;
MTZ: 0.25/1.5, 1%, MOXI: 0.5/8, 3%. Group/species speciﬁc
resistant rates (%) at breakpoint are listed in the Table.
Conclusion: b-lactams-b-lactamases inhibitors, carbapenems,
and MET remain highly active against anaerobes including the
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more resistant BFG of organism. Resistance in CLI actually
almost reaches 30% and is observed among almost all different
species of anaerobes. MOX, as a representative of the newer
ﬂuoroquinolones exhibits a broad spectrum and potent activity
in vitro against all anaerobes tested and looks promising for the
treatment of mixed infections involving anaerobes.
Pharmacokinetics/pharmacodynamics of quinolones
P1091
Retrospective analysis of electrocardiogram
following oral or intravenous garenoxacin in ﬁve
phase I studies
Z. Wang, G. Krishna, D. Wexler, D. Grasela (Kenilworth,
Princeton, USA)
Objective: Garenoxacin (GRN) is a novel des-F(6)-quinolone
effective against a broad spectrum of pathogens, including
anaerobes. Some of the ﬂuoroquinolones have the potential to
prolong QTc. To determine the effect of GRN on QTc, a
retrospective analysis was performed on manually read ECGs
from ﬁve Phase I studies.
Methods: Serial ECGs were collected in 5 randomized, double-
blind, placebo-controlled studies in healthy adult subjects
administered oral (PO) or intravenous (IV) GRN 50- to 1200-
mg doses (therapeutic dose £600 mg) with dosing duration 1 to
28 days (therapeutic duration £14 days). The QT interval was
corrected for heart rate using Bazett’s (QTcB) and Fridericia’s
(QTcF) formulas, and the effect of GRN was assessed by counts
of outliers and linear regressions. Single- and multiple-dose
pharmacokinetics of PO and IV GRN were derived from plasma
concentration versus time data.
Results: A total of 149 subjects received GRN and 55 received
placebo. GRN plasma exposure (AUC and Cmax) increased with
increasing dose. No subjects experienced a prolonged QTcB
interval (>450 msec for males, >470 msec for females). Only one
subject experienced a prolonged (>60 msec) QTcB change from
baseline which occurred on day 7, but not on subsequent days
despite continued dosing. The incidence of borderline QTcB
(change between 30–60 msec) was comparable between placebo
andGRN.Means forQTcBMax,QTcBAvgandQTcBat Tmaxand
their changes from baseline for GRN were similar to those for
placebo,with the exceptionofQTcBMax,QTcB at Tmax, and their
changes for 600mg IVGRN on day 14. Although 1200mg PO and
800 mg IV GRN produced higher plasma exposures than 600 mg
IV on day 14, the means for the derived QTcB values were
comparable to placebo. All 95% conﬁdence intervals for the linear
regression slopes of derived (delta)QTcB on Cavg(0–12 h) were
equal to or less than 0, except for (delta)QTcB at Tmax on day 7,
indicating that GRN had no effect on QTcB. Results obtained for
QTcF were similar to those for QTcB.
Conclusions: GRN does not appear to have dose-, route of
administration- or concentration-dependent effects on QTc
interval in healthy subjects.
P1092
Tissue and ﬂuid penetration of garenoxacin
Z. Wang, C. Edmiston, K.V. Rolston, D. Grasela, D.
Gajjar (Kenilworth, Milwaukee, Houston, Princeton, USA)
Objective: Garenoxacin (GRN) is a novel des-F(6)-quinolone
being developed for a variety of indications because of its
efﬁcacy against a broad spectrum of pathogens, including
anaerobes. The objective of this study was to assess the tissue
or ﬂuid to plasma ratios of GRN following a single oral dose.
Method: An open-label study was conducted in subjects ‡18
years of age with a body mass index £33 kg/m2 undergoing
abdominal surgical procedures that would permit the removal
of tissue or ﬂuid without increased risk to the subject. A single
600 mg oral dose of GRN was administered based on the
scheduled operative time. The tissue or ﬂuid (with correspond-
ing plasma sample) was collected 3 to 5 hours post-dose.
Concentrations of GRN in biological ﬂuids and tissues were
determined using validated LC/MS/MS assays. Safety was
assessed by measurement of vital signs, physical examination,
and electrocardiographic and clinical laboratory evaluations.
Adverse event (AE) monitoring was performed from time of
consent until discharge from the study.
Results: Thirty-one subjects were enrolled in and completed the
study. Mean ﬂuid or tissue GRN concentrations greater than
that found in plasma (mean ﬂuid or tissue to plasma ratio >1)
occurred in large and small bowel tissue, gallbladder, and liver.
Mean ﬂuid or tissue GRN concentrations less than that found in
plasma occurred in adipose tissue, bone, sinus mucosa, striated
muscle, incisional skin, and subcutaneous tissue. Mean GRN
concentrations in bile and lymph node tissue were roughly
similar to that found in plasma. Tissue and ﬂuid concentrations
of GRN exceeded the MIC90 of most target organisms involved
in skin and soft tissue, bone, and intra-abdominal infections and
sinusitis ‡2-fold. No treatment-emergent AEs or serious AEs
were considered to be related to GRN.
Conclusion: A 600 mg oral dose of GRN penetrates well into
most of the tissues and ﬂuids studied, with concentrations
exceeding the MIC90 of most pathogens causing sinusitis, skin
and soft tissue infections, bone infections, and intra-abdominal
infections. These results suggest that adequate concentrations of
GRN can be achieved to treat infections at these sites.
P1093
Penetration of garenoxacin into lung tissues in
patients undergoing lung biopsy or resection
M. Gotfried, K.V. Rolston, Z. Wang, D. Grasela,
D. Gajjar (Phoenix, Houston, Kenilworth, Princeton, USA)
Objective: Garenoxacin (GRN) is a novel des-F(6)-quinolone
effective against a broad spectrum of pathogens, including those
commonly found in the respiratory tract (RT). This study was
conducted to determine the penetration of GRN into lung
parenchyma (LP) and bronchial mucosa (BM) following a single
600 mg oral dose. Penetration of GRN into bone was also
assessed.
Methods: This was an open-label, nonrandomized study in
subjects undergoing an invasive procedure to the lung (other
than percutaneous lung biopsy) which facilitated the removal of
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macroscopically normal healthy lung tissue without exposing
the subject to undue risk. Penetrance of GRN into bone was
determined when removal of rib bone was part of the normal
surgical procedure. A single 600 mg oral GRN dose was
administered based on the scheduled operative time. LP and,
if possible, BM and/or bone samples and corresponding plasma
samples were removed at 2 to 4, 4 to 6, 10 to 12, or 20 to 24 h
post-dose. Concentrations of GRN in these samples were
determined using validated LC/MS/MS assays. Safety was
assessed based on the occurrence of adverse events (AEs) and
changes in physical examinations, vital signs, clinical laboratory
results, and electrocardiographic results.
Results: Twenty-seven subjects were enrolled; samples were
taken from a minimum of 6 patients at each time interval. Mean
GRN concentration in LP increased between the 2–4 and 4–6 h
post-dose, suggesting rapid penetration into LP, then declined
similar to the decrease seen in plasma concentration. Concen-
trations of GRN in LP exceeded the MIC90 of organisms
associated with RT infections by 62- to 466-fold over a 24 h
period. GRN concentrations in BM over a 24 h period exceeded
the MIC90 of respiratory pathogens 51- to 380-fold. Concentra-
tions of GRN in bone exceeded the MIC90 of the organisms
associated with bone infections (except Pseudomonas aeruginosa,
MRSA, Fusobacterium species, and Enterobacter species) by 6- to
101-fold over a 12 h period. Across the 4 time intervals, mean
ratios of tissue to plasma GRN concentration in LP, BM, and
bone reached 2.80, 0.99, and 0.56, respectively, suggesting
adequate penetration. No GRN-related AEs were reported,
indicating that a single 600 mg oral GRN dose was well
tolerated in subjects undergoing invasive procedures.
Conclusions: GRN penetrates rapidly into LP, BM, and bone
tissue, producing sustained concentrations that predict adequate
coverage of GRN-susceptible pathogens at these sites.
P1094
Bioavailability and safety in healthy volunteers
unaltered when crushed garenoxacin tablets are
administered via a nasogastric tube with or
without enteral feeding
R. Noveck, R. Vargas, G. Krishna, D. Grasela (New Orleans,
Kenilworth, Princeton, USA)
Objective: The purpose of this trial was to assess, in healthy
volunteers, the bioavailability and safety of single doses of the
novel des-F(6)-quinolone garenoxacin (GRN) administered as
crushed tablets with and without concomitant enteral feeding
compared with intact tablets.
Methods: In this randomized, crossover, single-dose study,
healthy adult volunteers (aged 18 to 45 y) received GRN 600 mg
(one 200 mg and one 400 mg tablet) orally in 3 regimens: A)
intact tablets; B) crushed tablets suspended in water and
delivered via nasogastric (NG) tube; C) regimen B plus con-
comitant enteral feeding (Osmolite, 600 mL at 100 mL/hr).
Subjects were randomized to receive all 3 regimens in 1 of 6
crossover sequences (ABC, ACB, BAC, BCA, CAB, CBA)
separated by 7-day washout intervals. For each treatment,
subjects entered the facility 1 day before and were conﬁned for
72 hours after drug administration. Subjects were discharged
from the study after ﬁnal assessments on day 4 of the third
treatment. Post-screening assessments included vital signs;
plasma drug levels for PK analysis; and physical, laboratory,
and ECG examinations for drug safety.
Results: 18 male subjects were enrolled (4 white, 14 black; mean
age, 30 y). PK analysis for GRN administered as crushed tablets
with and without concomitant enteral feeding vs intact tablets
showed no differences in the adjusted geometric means for
Cmax (8.5 and 8.3 lg/mL vs 8.3 lg/mL) or AUC(INF) (97.2 and
93.4 lg*hr/mL vs 103.3 lg*hr/mL). The 90% CI for log-
transformed Cmax and AUC(INF) for B and C compared to A
were contained within the protocol-speciﬁed no effects limit of
70% to 143%. Mean GRN half-life was similar among the 3
groups (mean range of 12–13 h). Tmax was 1 hour following
administration of intact tablets compared with 0.5 hour in the
other 2 groups. A single oral 600 mg dose of GRN was well
tolerated whether administered as crushed tablets suspended in
water and delivered via NG tube with or without enteral
feeding, or as intact tablets. Three adverse events (AEs) were
reported; 1 (nausea) was deemed probably related to study
drug. There were no serious AEs, meaningful changes on safety
examinations, or discontinuations due to AEs.
Conclusions: The bioavailability of GRN was similar for
crushed versus intact tablets, regardless of whether an enteral
feeding was given with crushed tablets. These results show that
GRN may be administered as crushed tablets with or without
concomitant feeding.
P1095
Garenoxacin pharmacokinetics in subjects with
severe renal impairment
G. Krishna, T. Marbury, S. Swan, D. Wexler,
D. Grasela (Kenilworth, Orlando, Minneapolis, Princeton, USA)
Objective: Garenoxacin (GRN) is a novel des-F(6)-quinolone
effective against a broad spectrum of pathogens. The absolute
bioavailability of GRN after oral intake is 92% and approxi-
mately 40% of GRN is excreted unchanged in the urine. The
objective of this study was to evaluate the pharmacokinetics of
GRN in subjects with severe renal impairment.
Methods: This non-randomized, open-label study enrolled
patients into 1 of 4 groups: healthy control subjects (HC) with
normal renal function (CLcr > 80 mL/min); subjects with severe
renal impairment (SRI) (CLcr < 30 mL/min) not requiring
dialysis; subjects with SRI receiving hemodialysis (HD); and
subjects with SRI receiving continuous ambulatory peritoneal
dialysis (CAPD). A single 600 mg oral dose of GRN was
administered on day 1 for all groups except HD patients. HD
patients received a single 600 mg oral GRN dose both before
(HD1) and after (HD2) HD, with dosings separated by a 14-day
washout. Blood, urine, and dialysate samples were collected up
to 144 h post-dose and concentrations of GRN were determined
using validated LC/MS/MS assays. Safety was assessed by
physical examination, vital signs, and electrocardiographic and
laboratory evaluations.
Results: Twenty-ﬁve subjects received GRN (HC, n = 6; SRI,
n = 6; HD1, n = 7; CAPD, n = 6). Six subjects in HD2 received
GRN. Mean GRN exposure [AUC(I)] was similar in HC and
HD1 but was 51%, 15%, and 21% higher in SRI, HD2 and CAPD,
respectively, than in HC. However, many of the individual
values were within the range observed for HC, and these
average increases in AUC(I) did not exceed values previously
shown to be well tolerated. Decreases in Cmax were observed in
SRI, HD1, CAPD, and HD2, but were not considered clinically
relevant. Approximately 11%, 1.5%, and 3% of GRN dose was
removed in the dialysate for HD1, HD2, and CAPD, respect-
ively. A total of 34 treatment-emergent adverse events (AEs)
were reported, all mild or moderate in severity; 5 were
considered to be probably or possibly related to GRN. One
treatment-emergent but not treatment-related serious AE was
reported.
Conclusions: A single dose of 600 mg GRN was well tolerated
in patients with SRI, including those requiring HD and CAPD.
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There was no clinically signiﬁcant increase of GRN exposure in
patients with SRI based on the broad therapeutic index of GRN.
Therefore, no GRN dosage adjustment is recommended in
subjects with SRI.
P1096
The effect of omeprazole on the bioavailability
and safety of garenoxacin in healthy volunteers
J. Kisicki, G. Krishna, S. Olsen, D. Grasela (Lincoln, Kenilworth,
Princeton, USA)
Objective: The novel des-F(6)-quinolone garenoxacin (GRN) is
more soluble in acidic conditions than at neutral pH. Therefore,
this study was designed to determine if omeprazole affects the
bioavailability of GRN.
Methods: This non-randomized, open-label pharmacokinetic
study was conducted in healthy adult subjects. On day 1, the
single-dose pharmacokinetics of 600 mg of oral GRN (one 200
and one 400 mg tablet) were determined in fasting subjects, with
serial blood samples obtained through 72 hours post-dose.
Omeprazole 40 mg was administered once daily on days 4 to 7
to achieve steady-state inhibition of gastric acid secretion. On
day 8, single doses of GRN and omeprazole were administered
concomitantly. Omeprazole treatment was continued on days 9
and 10 throughout the period of pharmacokinetic blood samp-
ling. Study assessments included vital signs and physical,
laboratory, and electrocardiographic examinations for safety.
Results: Fourteen subjects (8 male; mean age, 25 years) were
enrolled and 12 completed the study. Concomitant administra-
tion of omeprazole did not affect the AUC (INF) or Cmax of
GRN. The geometric mean (GM) for GRN AUC(INF) was 132.0
mcg.h/mL, compared with 140.4 mcg.h/mL for concomitant
GRN and omeprazole [90% conﬁdence interval (CI) 101–111%].
The GM Cmax value for GRN and GRN/omeprazole
co-administration was 9.6 and 9.3 mcg/mL, respectively, with
90% CI of 90% to 104%. Half-life (mean range 12.9 to 14 h) and
Tmax (median range 1.5 to 1.8 h) were similar after adminis-
tration of GRN either alone or concomitantly with omeprazole.
Concomitant administration of garenoxacin and omeprazole
was well tolerated. Nine of 14 subjects (64%) experienced a total
of 33 adverse events (AEs). The majority of AEs were mild, and
only 12 were deemed possibly or probably related to the study
drug. The most frequently cited AEs, headache, nausea and
abdominal pain, were mild to moderate in severity. Two
subjects withdrew from the study; neither discontinuation was
due to AEs.
Conclusions: The concomitant administration of omeprazole
had no effect on garenoxacin bioavailability. These ﬁndings
indicate that garenoxacin can be administered with omeprazole
or other agents that affect gastric pH to a similar or lesser extent.
P1097
The effect of Maalox on bioavailability and safety
of garenoxacin in healthy volunteers
J. Kisicki, G. Krishna, S. Olsen, D. Grasela (Lincoln, Kenilworth,
Princeton, USA)
Objective: Garenoxacin (GRN) is a novel broad-spectrum des-
F(6)-quinolone antibiotic. Quinolones are known to chelate with
cations such as aluminum, impairing antibiotic absorption. This
study was therefore designed to assess the effect of a 20-mL dose
of Maalox (containing 900 mg aluminum hydroxide and
800 mg magnesium hydroxide) on the pharmacokinetics of
GRN when administered concomitantly with, 2 and 4 hours
before, and 2 and 4 hours after, Maalox.
Methods: This was a randomized, open-label, 6-treatment,
control-balanced, residual effects design pharmacokinetic
study. The 6 oral treatments consisted of 600 mg GRN (one
200 and one 400 mg GRN tablet) given alone, with concomitant
Maalox, 2 h before Maalox, 4 h before Maalox, 2 h after Maalox,
and 4 h after Maalox. Each healthy adult subject received 3 of
the above treatments, with a 7-day washout period between
treatments. In each treatment, serial blood samples for pharma-
cokinetic analysis were collected before and up to 72 h after
GRN dosing. Study assessments included vital signs and
physical, laboratory, and electrocardiographic examinations for
drug safety.
Results: Twenty subjects (12 male, 8 females; mean age, 27
years) were enrolled. Exposure to GRN [AUC(INF)] was
reduced by 58% when coadministered with Maalox. Exposure
to GRN was also reduced when administered 2 or 4 hours after
Maalox, by 22% and 16%, respectively. In contrast, when
administered 4 hours before Maalox, GRN exposure was not
affected. When GRN was administered 2 hours before Maalox, a
small reduction (12%) in GRN exposure was observed that is
unlikely to be clinically relevant. Half-life (mean range 11.5 to
14.2 hours) and Tmax (median range 1.5 to 2 hours) were similar
across treatment groups. A single oral 600 mg dose of GRN was
well tolerated. Mild adverse events were reported by 2 subjects;
1 subject discontinued due to mild abdominal pain and blood in
the stool.
Conclusions: Maalox does not affect GRN bioavailability when
GRN is administered at least 2 h prior to Maalox. However, a
reduction in GRN exposure is observed when GRN is admin-
istered concomitantly or up to 4 h after Maalox. Therefore, GRN
can be administered 2 h before or 4 h after administration of
Maalox or other products containing a high content of cations,
particularly aluminum.
P1098
Mutant prevention concentrations of
ﬂuoroquinolones authorised for use in poultry
against Salmonella enterica serovar Typhimurium
DT 104
L.P. Randall, S.W. Cooles, K. Stapleton, N.G. Coldham,
L.J.V. Piddock, M.J. Woodward (New Haw, Birmingham, UK)
Objectives: It has been demonstrated that ﬂuoroquinolone
treatment of humans and animals can rapidly select for bacteria
with reduced susceptibility to ﬂuoroquinolone antibiotics. In
recent years, there has been considerably interest in the concept
of the mutant prevention concentration (MPC). The MPC has
been deﬁned as that concentration of antibiotic at which no
mutants are selected from 10,000,000,000 organisms. In previous
studies MPCs of ciproﬂoxacin and enroﬂoxacin were deter-
mined in vitro against Salmonella enterica serovar Typhimurium
DT 104. Here the use of a chick model to investigate the MPC of
enroﬂoxacin in vivo is reported.
Methods: Chicks were experimentally infected with S. Typhimu-
rium and treated with Baytril (enroﬂoxacin) at 50 ppm/10mg/kg
for 5 days (recommended therapeutic dose) or 2 days or 125
ppm/25 mg/kg for 2 days or 250 ppm/50 mg/kg for 1 day.
Chicks received the dose in the drinking water (ppm) or by oral
gavage (mg/kg). During and 24 hours after dosing, birds were
killed and tissue samples (caecal contents, liver and sera) were
taken and the levels of enroﬂoxacin and ciproﬂoxacin were
determined in these tissues by HPLC or bio-assay. Caecal
contents were also monitored for the presence of Salmonella
during dosing and for up to 4 weeks after dosing. Selection of
resistance was monitored by replica plating of colonies to media
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containing 4x the ciproﬂoxacin and nalidixic acid MIC of the
strain before treatment.Results: The only conditions where the
antibiotic treatments did not select for reduced susceptibility (e.g.
4xMIC of parent strains) were in birds that received the antibiotic
at 2.5x the dose for 2 days by oral gavage or 4x the dose for 1 day
in the water. This oral gavage treatment also signiﬁcantly
reduced the counts of Salmonella compared to all other oral
gavage treatments. For the oral gavage study, concentrations of
ﬂuoroquinolones in caecal contents were above the MPC for at
least 6 hours after dosing for all treatment regimes.
Conclusion: It was of interest to note that whilst the ﬂuoro-
quinlone antibiotics are regarded as concentration rather time
dependent antibiotics, the 2 day at 2.5x the dose was more
effective at reducing the counts of Salmonella in both experi-
ments than the 1 day at 5x the dose. These results would suggest
that length of treatment as well as dose and route of adminis-
tration, is critical in minimising the selection of ﬂuoroquinolone
resistance in vivo.
P1099
Effect of levoﬂoxacin coadministration on the
international normalised ratios during
acenocumarol therapy
J. de Otero, M. Payeras, C. Carratala, A. Artigues, M. Sanz,
P. Nadal (Manacor, E)
Levoﬂoxacin (L) showed no effect on warfarin pharmacokinetics
in healthy volunteers but several recent descriptions reveal
elevated international normalised ratios (INR) in patients
receiving concurrent L and warfarin. To our knowledge no
cases of L-acenocumarol (A) interaction have been reported.
Objectives: To report 6 cases of hypoprothrombotic response
resulting from addition of L therapy to chronic A therapy.
Methods: A 9-month retrospective analysis of adult patients
receiving A who were admitted to our ward under L prescrip-
tion on the basis of clinical diagnosis and judgement. Descrip-
tive statistical measurements were performed.
Results: Six patients, 74–89 years old (median 81.5), were
included. Four were men (66.6%). They suffered from a
median of 4 (range 2–6) concurrent chronic medical problems
(including coronary heart disease, atrial ﬁbrillation, hyperten-
sion, obstructive pulmonary disease, renal insufﬁciency, cardi-
omyopathy and heart failure) and took a median of 7 (range
4–10) different kind of drugs (including digoxin, furosemide,
antihypertensives and inhaled bronchodilators). Types of infec-
tion for which the patients were treated with L included acute
bronchitis (4 cases) and pneumonia (2 cases). Three patients had
an INR range of 2.0–3.0 and experienced an increase in INR to
5.36, 14.51 and 5.76 on L-treatment days 8, 5 and 2. Two patients
had a low INR (1.84 and 1.86) and experienced an increase to
4.25 and 2.77, on days 5 and 2, despite no changes in A dosage
were performed. The sixth patients had a high INR (4.03) at the
time of admission and, in spite of stopping A administration,
INR increased to 4.66. Two patients experienced minor bleeding
but only one required L stopping. Patient with the highest INR
presented L-related diarrhoea, and it was prescribed L discon-
tinuation and vitamin K. A median of 4 days (1–6) were required
to completely control INR in a therapeutic range of all patients.
Conclusion: We provide some evidence of an increase in INR
observed during concomitant L and A treatment. Further
studies are required to better determine that possible effect.
Due to the demonstrated clinical efﬁcacy of L in many infections
we must recommend its use. But, to our opinion, until the
clinical signiﬁcance of an interaction between these two drugs is
well deﬁned, a patient’s INR values during A therapy should be
closely monitored, during, and after L coadministration.
P1100
Ciproﬂoxacin accumulation and intracellular
activity against L. monocytogenes are reduced in
ciproﬂoxacin-resistant macrophages due to
increased efﬂux
M. Heremans, M.P. Mingeot-Leclercq, P.M. Tulkens, F. Van
Bambeke (Brussels, B)
Objectives: CIP is substrate for an MRP efﬂux pump in J774
mouse macrophages (Michot et al, AAC 48:2673–82), which
reduces its cellular accumulation. We have recently shown that
CIP-resistant macrophages can be selected upon chronical
exposure of these cells to CIP, in which CIP accumulation
becomes negligible because of an increased activity and/or
expression of the efﬂux transporter (ICAAC 2004, abstract
A-1304). We have now examined whether this reduced accu-
mulation affects CIP intracellular activity using a model of
intracellular infection by L. monocytogenes (L.m.) and comparing
resistant cells to the wild type parent cell line.
Methods: Infection was carried out using a bacteria: macroph-
age ratio of 7:1, according to the procedure described in Seral et
al (JAC 51:1167–73). CFU/mg cell protein was determined after
5 h exposure to increasing concentrations of CIP ± 10 mM
probenecid (inhibitor of MRP transporters). CIP cellular con-
centration was measured by ﬂuorimetry (AAC 48:2673–82).
Results: In wild cells, an extracellular concentration corres-
ponding to 3 X the MIC was sufﬁcient to obtain a static effect,
and this value rose to 30 X in CIP-resistant cells. This value was
decreased to 1 X and 1.5 X the MIC, for wild and CIP-resistant
cells respectively, in the presence of probenecid. In cells
incubated with 20 mg/l CIP (10 X MIC), CIP accumulation
was 4.8 ± 0.3 and 0.3 ± 0.1 in wild and CIP resistant cells, but
increased to 21.3 ± 0.8 and 10.6 ± 0.5 in the presence of
probenecid.
Conclusions: Increase in expression and/or activity of the CIP
efﬂux transporter causes a reduction of the antibiotic efﬁcacy
against intracellular infection, which can be reversed upon
inhibition of the efﬂux transporter.
P1101
Quinolone-induced changes in tenocytes are
intensiﬁed by dexamethasone in vitro
J. Sendzik, M. Shakibaei, M. Scha¨fer-Korting,
R. Stahlmann (Berlin, D)
Objectives: Quinolones can cause tendinitis and tendon rup-
tures. Retrospective studies and case reports reveal that an
additional therapy with glucocorticoids increases the risk of
quinolone-induced tendon disorders.
Methods: We investigated possible combination effects of
quinolones and glucocorticoids in an in vitro model with
human tendon cells. Tenocytes were cultured for 1, 2, 3 and 4
days as monolayers and incubated with (a) ciproﬂoxacin or
levoﬂoxacin (3 mg/l), (b) 0.1 nM dexamethasone, and (c)
ciproﬂoxacin or levoﬂoxacin (3 mg/l) plus 0.1 nM dexametha-
sone. Immunoblotting was used to quantify changes in the
amount of beta1-integrin, activated src homology collagen (shc)
and of activated caspase-3 (casp-3). Furthermore, ultrastructural
alterations were analysed by electron microscopy.
Results: At 3 mg/l, ciproﬂoxacin caused a signiﬁcant decrease
of the amount of beta1-integrin from day 3 onwards, while no
effect was seen with 3 mg levoﬂoxacin/l medium or 0.1 nM
dexamethasone compared to the untreated control. The combi-
nation of both quinolones (3 mg/l) with 0.1 nM dexamethasone
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resulted in an earlier onset of the beta1-integrin reduction: for
ciproﬂoxacin + dexamethasone from the ﬁrst day of incubation,
for levoﬂoxacin + dexamethasone from day 3 onwards. Quino-
lone-induced changes in signalling proteins, such as activated
shc, are not fortiﬁed by dexamethasone at the concentration
tested. Interestingly, the time and concentration dependent
increase of the apoptosis marker activated casp-3 was intensiﬁed
with dexamethasone. The results of immunoblotting with
respect to the induction of apoptosis were conﬁrmed by electron
microscopy.
Conclusions: Our results show that quinolone-induced changes
in the amount of the beta1-integrin as well as of the apoptosis
marker activated casp-3 are enhanced by dexamethasone in
vitro. The addition of the glucocorticoid caused an earlier onset
of the quinolone-induced changes. Our results support the
clinical observations that glucocorticoids are an additional risk
factor for quinolone-induced tendopathies.
P1102
Pharmacokinetics and pharmacodynamics of a
novel extended release formulation of
ciproﬂoxacin as compared to levoﬂoxacin against
extended spectrum beta-lactamase producing
Enterobacteriaceae
S. Schubert, H. Stass, U. Ullmann, A. Dalhoff (Kiel,
Wuppertal, D)
Background: An extended release formulation of ciproﬂoxacin
(CIP XR, 1000 mg qd, p.o.) has been developed, delivering peak
concentrations which are 40% to 50% higher than following the
administration of the conventional formulation (CIP IR, 500 mg
bid, p.o.) while the areas under the curve (AUC) were compar-
able.
Objectives: First, CIP is used for the treatment of infections due
to Enterobacteriaceae, frequently being ESBL producers. Thus, the
PK/PD characteristics of CIP XR vs. IR against ESBL strains was
examined. Second, CIP is used in urinary tract infections (UTIs).
Thus, the PK/PD proﬁles of CIP XR vs. IR in serum and urine
were studied. Third, the PK/PD characteristics in either BHI or
artiﬁcial urine were compared.
Methods: Genotypically characterised ESBL producing E. coli
(Ec) and K. pneumoniae (Kpn) and their wild type counterparts
were exposed to the geometric mean plasma and urine concen-
tration proﬁles following CIP 1000 mg XR qd, 500 mg IR bid and
LEV (500 mg qd). The CIP and LEV urine concentrations were
ﬁtted from Phase I study data by compartmental modeling
using TopFit 2.0. Bacteria were cultivated in a modiﬁed Grasso
model at 37C in brain-heart infusion broth as well as artiﬁcial
urine acc. to Grifﬁth et al.; viable counts were quantitated at 0.5,
1, 1.5, 2, 3, 4, 6, 8 and 24 h. The areas under the bacterial kill
curves normalised to the inoculum were calculated.
Results: First, irrespective of the PK proﬁles simulated, the WT
were eliminated rapidly. The ESBL producing Ec and Kpn were
moderately to negligibly affected upon simulation of serum PK
proﬁles of both CIP and LEV. Second, simulation of urine
concentrations by using artiﬁcial urine IR and XR resulted in an
elimination of the ESBL producers from the test system. LEV
eliminated the ESBL producing K. pneumoniae but not the E.coli
strain, which regrew. CIP XR killed the ESBL Kpn strain more
rapidly than CIP IR or LEV. Third, PK/PD surrogates derived
from studies in conventional media or artiﬁcial urine are
signiﬁcantly different.
Conclusions: This model and the use of artiﬁcial urine predicts
a more rapid and pronounced effect of CIP XR as compared to
CIP IR or LEV.
P1103
Moxiﬂoxacin concentrations in plasma and
tonsillar tissue in adult patients
S. Esposito, S. Noviello, G. D’Errico, G. Motta, D. Passali,
C. Aimoni, S. Pilucchi, S. Fallani, M. Cassetta, T. Mazzei,
A. Novelli (Naples, Siena, Ferrara, Florence, I)
Objectives: The antibacterial spectrum of moxiﬂoxacin includes
all the major respiratory pathogens and its pharmacokinetics
demonstrates high peak concentrations in plasma as well as at
respiratory sites. Nevertheless, the tonsillar tissue concentra-
tions have never been investigated. In the present study we
determined the moxiﬂoxacin concentrations in plasma and
tonsils after the administration of three doses of 400 mg to
adult patients with chronic or recurrent tonsillitis undergoing
tonsillectomy.
Methods: This was an uncontrolled, open-label, randomised,
parallel group study including 35 patients randomly assigned to
5 groups of 7 patients each, depending on the time between the
last dose of moxiﬂoxacin and that of plasma and tissue sampling
(2, 3, 6, 12 and 24 h). Moxiﬂoxacin was given orally od for 3
days. Moxiﬂoxacin concentrations were measured by a valid-
ated HPLC assay and ﬂuorescence detection. Each sample was
analysed twice and the mean value obtained used for statistical
analysis. Pharmacokinetic data were analysed by presenting
descriptive statistics of moxiﬂoxacin levels in plasma and
tonsillar tissue.
Results: Cmax occurred at 3h in plasma (mean value 3.20 mg/
L) and in tonsillar tissue (mean 8.96 mg/L). Tonsillar tissue/
plasma ratios (mean values) were constantly >2 mg/L at any
collecting time, ranging between 2.37 mg/L (after 2 h) and 2.93
mg/L (after 24 h), which indicates a prolonged maintenance of
moxiﬂoxacin level in tonsillar tissue compared to plasma.
Variability among pts was present at 6 h, the tonsillar tissue /
plasma ratio ranging between 0.8 and 3.4 mg/L.
Conclusions: Moxiﬂoxacin achieves a good penetration in
tonsillar tissue, which favourably compares with that reported
for other ﬂuoroquinolones. The moxiﬂoxacin concentrations that
we observed exceed the MICs of the usual respiratory tract
pathogens.
P1104
Penetration kinetics of moxiﬂoxacin in human
pancreas: comparison of intravenous vs oral
administration
R. Wacke, S. Fo¨rster, S. Park, R.G. Mundkowski, U. Adam,
W. Schareck, E. Klar, B. Drewelow (Rostock, Freiburg, D)
Objectives: Acute necrotizing pancreatitis is still related to a
high mortality rate, based on local infectious complications,
particularly due to bacterial infections of the necrotic pancreatic
and parapancreatic areas. Limited penetration of antimicrobial
drugs in these areas/compartments is considered to be a major
cause of failure of therapy of severe local pancreatic infections.
However, ﬂuoroquinolones (e.g. ciproﬂoxacin, levoﬂoxacin)
have been shown to penetrate sufﬁciently into pancreatic
tissue. On that score, the value of new quinolones such as
moxiﬂoxacin (MXF) has not been investigated yet. Using a rat
model of acute necrotizing pancreatitis MXF has been demon-
strated to penetrate rapidly and efﬁciently into pancreatic tissue,
also into the inﬂamed and necrotic pancreas.
Methods: Addressing the penetration capability of MXF fol-
lowing intravenous (IV) or oral (PO) administration with respect
to the human pancreas, a prospective clinical trial was designed
using a single IV (20 patients) or PO dose (40 patients) of 400 mg
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MXF for antimicrobial prophylaxis in patients undergoing
pancreas resection. Samples were taken from blood and from
resection area of pancreatic tissue at two time points after
application (1st sample at the beginning, 2nd sample at the end
of resection). Concentrations of MXF were determined by
HPLC/UV using oﬂoxacin as internal standard.
Results: Mean plasma concentrations of MXF IV and PO at ﬁrst
sampling time (3 - 3.7 h) were 1.8 ± 0.5 and 1.2 ± 0.6 lg/ml,
respectively. At the end of resection (4.3–5.3 h) 1.5 ± 0.4 and
1.0 ± 0.5 lg/ml were measured. Corresponding mean concen-
trations of MXF in pancreatic tissue were 2 to 3times higher
(3.1 ± 0.9 and 2.7 ± 1.4 lg/g 1st sample; 3.6 ± 1.5 and 3.1 ± 1.8
lg/g 2nd sample). The MXF concentrations in pancreatic tissue
exceeded the MIC90 s of the relevant pathogens encompassed
by MXF (e.g. E. coli 0.008–0.06 lg/ml, Klebsiella spp. 0.13 lg/ml,
and S. aureus 0.06– 0.12 lg/ml) for at least ﬁve hours at the
dosing interval.
Conclusion: MXF has been demonstrated to penetrate efﬁ-
ciently into human pancreatic tissue following IV as well as PO
administration. In this study MXF concentrations after PO
administration were found to be slightly lower than those
observed in healthy subjects probably due to diminished or
delayed intestinal absorption prior and during surgery.
P1105
Effects of enteral feeding on the oral
bioavailability of moxiﬂoxacin
O. Burkhardt, H. Stass, U. Thuss, K. Borner,
T. Welte (Magdeburg, Wuppertal, Berlin, D)
Objective: In clinical practice on ICU wards moxiﬂoxacin
(MFX) may be occasionally administered through a nasogastric
(NG) feeding tube. In absence of an oral liquid formulation and
since the divalent cations contained in enteral feeds may
potentially impair absorption of MFX given via this way, we
wanted to study the effect of concomitant enteral feeding on the
pharmacokinetics and tolerability of MFX passed as a crushed
tablet through a NG tube, ﬁrstly in healthy volunteers.
Methods: In a randomized 3-way crossover study the oral
bioavailability of MFX was investigated in 12 healthy volunteers
(9 f, 3 m). Each subject received separately an intact 400 mg
MFX tablet (A), a crushed tablet as a suspension through an NG
tube with water (B), and while receiving enteral feeding (C). The
concentrations of MFX in serum were measured by a validated
HPLC. AUC and Cmax were analysed statistically assuming log
normally distributed data using ANOVA.
Results: All MFX treatments were well tolerated. The AUC was
slightly, but not signiﬁcantly decreased in treatments B and C
[geo means (A) 39.6 vs. (B) 36.1 vs.(C) 36.1 mg*h/L; point
estimates (PE) 91% for B/A and C/A and 90% conﬁdence
interval (CI) 86 to 97% for B/A and C/A] indicating equivalence
of the treatments. Likewise the maximum serum concentrations
after MFX administration through NG tube with water (B) and
with tube feed (C) were slightly decreased [Cmax; geo means
(A) 3.20 versus (B) 3.05 and (C) 2.83 mg/L; PE 95%, CI 88 to
103% for B/A and PE 88%, CI 82 to 95% for C/A]. They were
within the range seen in other studies with oral administration
of the drug. No statistically signiﬁcant differences were
observed in time to reach Cmax [Tmax; median (A) 1.75 h
versus (B) 1.00 h and (C) 1.75 h]. Thus, rate of absorption was
not affected by NG tube administration. This route of ingestion
seems to be associated only with a slight loss of bioavailability -
independent of the carrier medium used (water vs. enteral feed).
No clinically relevant interaction with the multivalent cations
contained in the enteral feed was observed indicating that MFX
and enteral nutrition can be administered concomitantly.
Conclusion: There was no clinically relevant effect of enteral
feeding on the pharmacokinetics of oral MFX in healthy volun-
teers. This results has to be evaluated in patients, especially those
from ICU, who are characterised by severe infectious and/or
concomitant diseases, whichmight inﬂuence absorption of MFX.
Pharmacokinetics/pharmacodynamics of antifungals
P1106
Comparison of posaconazole adverse event
proﬁles in healthy volunteers and in patients
with invasive fungal infections
L. Pedicone, A. Ullmann, J. Graybill, A. Sansone, R. Courtney,
M. Laughlin, I. Raad (Kenilworth, USA; Mainz, D; San Antonio,
Houston, USA)
Objectives: To better deﬁne the adverse event (AE) proﬁle of
posaconazole (POS), we compared the safety proﬁles of patients
with invasive fungal infections (IFIs) enrolled in POS clinical
trials with those of healthy volunteers enrolled in clinical
pharmacology studies.
Methods: AE analyses from 428 patients with IFIs from 2 open-
label clinical trials and from 449 healthy volunteers from 18
clinical pharmacology trials were compared. In the healthy
volunteer studies, compliance with dosing regimens was strictly
enforced and participants had no signiﬁcant underlying diseases
or concomitantmedications that could confound interpretation of
safety data. Therefore, for the purpose of this analysis, the healthy
volunteers served as a control group for the patient population. In
both groups, most subjects received POS 800 mg/d in divided
doses.
Results: Treatment-related AEs (TRAEs) occurred in 44% (196/
449) of healthy volunteers; the most common were headache
(17%), dry mouth (9%), and dizziness (6%). In patients, many
AEs were consistent with underlying diseases. TRAEs occurred
in 38% of patients (164/428); the most common were nausea
(8%), vomiting (6%), headache (5%), abdominal pain (4%), and
diarrhoea (4%). Notably, gastrointestinal (GI) TRAEs occurred
in 18% of healthy volunteers and 19% of patients. Treatment-
related abnormal liver function test results were observed in 2%
of healthy volunteers and up to 3% of patients. There were no
clinically signiﬁcant differences in mean QTc interval change
from baseline in either population. Serious AEs (SAE) consid-
ered possibly or probably related to POS occurred in 35 (8%)
patients and 1 healthy volunteer. The most common SAEs in
patients were altered drug level, increased hepatic enzymes,
nausea, rash, and vomiting (1% each). No signiﬁcant trends
related to age, sex, or race were observed in either group.
Additionally, no unique TRAEs were identiﬁed in patients
during long-term exposure (>6 months) compared with those
identiﬁed during shorter-duration therapy.
Conclusion: The safety proﬁle of POS in patients was similar to
that observed in a controlled population of healthy volunteers
and is likely indicative of what will be observed in the clinical
setting. Headache and GI events (nausea, vomiting, abdominal
pain, diarrhoea) were the most common TRAEs observed in
patients. Given its favorable safety proﬁle, POS should provide
an additional treatment option for severely ill patients with IFIs.
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P1107
Evaluation of the drug interaction potential of
posaconazole: summary of 7 clinical
pharmacology studies
A. Sansone, R. Courtney, G. Krishna, D. Wexler, M. Martinho,
M. Laughlin (Kenilworth, New Jersey, USA)
Objective: We evaluated the drug interaction (DI) potential of
posaconazole (POS), an extended-spectrum triazole antifungal
agent, in 7 phase 1 studies. POS is an inhibitor of cytochrome
P450 (CYP) 3A4 activity, but it does not affect the activity of
other CYP enzymes. These studies were conducted to evaluate
potential changes in the pharmacokinetics of POS and the
coadministered medication, when given in combination.
Methods: Seven open-label DI studies were conducted in which
subjects received POS (200–800 mg) for 8 to 14 consecutive days,
alone or in combination with single or multiple doses of
cimetidine, cyclosporine, glipizide, phenytoin, rifabutin, tacrol-
imus, or antiretroviral medications (zidovudine, lamivudine,
ritonavir, and indinavir). In the cyclosporine and antiretroviral
studies, patients received established doses (ED) of these drugs,
and plasma concentrations were presumed to be at steady state
(SS) before POS administration. Bioavailability, based on log-
transformed AUC values, was expressed as the ratio of the
combination treatment to POS or concomitant drug given alone.
Results: The effects of coadministration on the AUC values of
POS and each concomitant medication are summarized in the
table.
Conclusion: No dose adjustments are required for glipizide,
zidovudine, lamivudine, indinavir, or ritonavir when coadmin-
istered with POS, as the small differences in exposure are not
considered clinically signiﬁcant. However, when POS was given
with glipizide, glucose concentrations decreased in some
healthy volunteers more so than after glipizide administered
alone. Monitoring of cyclosporine and tacrolimus blood levels is
warranted with POS coadministration, and dose adjustments of
cyclosporine and tacrolimus should be made accordingly.
Concomitant use of POS with rifabutin, phenytoin, or cimetidine
should be avoided unless the beneﬁts outweigh the risks, due to
the decrease in POS concentrations.
P1108
Posaconazole pharmacokinetics in elderly
healthy volunteers and elderly patients
A. Sansone, R. Courtney, G. Krishna, D. Wexler, M. Martinho,
L. Pedicone (Kenilworth, USA)
Objectives: The pharmacokinetics (PK) of many medications
may be altered in the elderly population. Because alterations in
PK can potentially affect clinical outcomes, the PK parameters of
Posaconazole (POS), an extended-spectrum investigational
triazole antifungal agent, were examined in healthy elderly
persons (‡65 years), and the clinical implications of age-related
PK differences were evaluated.
Methods: We conducted a meta-analysis of POS steady-state
PK data from 5 clinical studies in healthy volunteers. PK data
from elderly healthy volunteers were compared with those of
elderly patients with invasive fungal infections (IFIs) who
participated in an open-label trial that evaluated POS efﬁcacy
and safety. Study participants received POS oral suspension 800
mg/day in divided doses. Because POS plasma concentrations
at steady state are relatively constant, AUC values in healthy
subjects could be directly compared with the average steady-
state plasma concentration in patients.
Results: Out of a total of 174 healthy volunteers in the meta-
analysis, 24 (14%) were ‡ 65 years. POS exposure was approxi-
mately 24% higher in elderly than that in adult (18–64 years)
subjects. Mean AUC values for adult (n = 150) and elderly
subjects were 28.495 and 35.444 ngÆh/mL, respectively. These
observations were consistent with PK data from elderly patients
with IFIs. The IFI study included 330 patients; 33 (10%) were
elderly, ofwhom25were included in thePKanalysis. The average
concentrationvalueswere 1056 ng/mLand817 ng/mL in elderly
patients and patients 18 to 64 years, respectively. Although POS
exposurewasapproximately 29%higher in elderly than that in the
adult patients <65 years, treatment-related adverse event (TRAE)
occurrence rates were similar in elderly patients (48%) and the
overall population (42%). Themost common TRAEswere similar
in both populations: nausea (15% vs 9%), vomiting (9% vs 6%),
and headache (9% vs 5%). Efﬁcacy was evaluated in 31 elderly
patients, and 27 (74%) had successful outcomes.
Conclusion: POS exposure is slightly higher in the elderly
healthy volunteers and patients compared to those <65 years old,
but the difference in exposure is not clinically relevant. Safety
proﬁles between elderly and younger patients were similar, and
POS was well tolerated in both populations. POS may be useful
against IFIs in elderly patients because of its favorable safety
proﬁle and demonstrated clinical activity against IFIs.
P1109
The long-term visual safety of voriconazole
K. Tomaszewski, A. Laties, J.M. Goodrich (Sandwich, UK;
Pennsylvania, New London, USA)
Objectives: Long Term Visual Safety of Voriconazole (VORI) is
an extended-spectrum antifungal agent, with activity against
Candida and moulds such as Aspergillus, Fusarium, and Scedos-
porium. While displaying an overall favorable safety proﬁle,
VORI is associated with transient visual adverse events (VAEs).
In clinical trials, between 23–35% of VORI-treated subjects
reported VAEs, including blurred vision and altered light
perception. Over 28 days of treatment with VORI, the VAE
was non-progressive and fully reversible following discontinu-
ation. The objective of this study was to investigate and better
understand the visual safety of VORI beyond 28 days.
Methods: In a multicentre, open-label, comparative study, 53
patients with paracoccidioidomycosis were randomized to
receive VORI (po 200 mg bid) or itraconazole (ITRA) (po
100 mg bid) in a 2:1 ratio over a period of at least 6 months.
Visual function tests (VFTs) and safety assessments were
performed at baseline, Week 12, Week 24, end of treatment
(EOT) and at 8 weeks post EOT. The VFTs included color vision
(Farnsworth-Munsell 15 Hue), visual acuity (ETDRS), contrast
sensitivity (Pelli-Robson), visual ﬁeld (Humphrey), funduscopy
and slit lamp examination. Other adverse events and laboratory
evaluations were recorded at the same visits as VFTs.
Study N Drug (mg) Duration (d) POS (mg)
Bioavailability (AUC %)
POS Concomitant Drug
1 12 Cimetidine (800) 10 200 qd 61 ND
2 4 Cyclosporine (ED) SS 200 qd ND Doses reduced
)14-29% in 3 of 4
3 12 Glipizide(10) 1 400 bid 91 118
4 36 Phenytoin (200) 10 200 qd 50 115
5 24 Rifabutin (300) 17 200 qd 51 172
6 34 Tacrolimus (0.05a) 1 400 bid ND 458
7 17 Zidovudine (600) SS 200 qd ND 112
17 Lamivudine (300) SS 200 qd ND 107
17 Ritonavir (1200) SS 200 qd ND 130
17 Indinavir (3200) SS 200 qd ND 116
a mg ⁄ kg;
ND ¼ not determined.
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Results: 32/35 VORI and 17/18 ITRA patients completed 3
months treatment, with 14/35 and 11/18 respectively receiving
>6 months treatment. 1 subject receiving VORI prematurely
discontinued due to unrelated sarcoidosis and 2 due to elevated
liver enzymes. 16/35 VORI and 0/18 ITRA subjects experienced
drug-related VAEs; none were considered serious or severe or
resulted in discontinuation. There were 22 separate VAEs in the
16 subjects reporting eye ﬁndings. 19 o 22 VAEs started on day 1
of dosing and had resolved by day 3.No VORI or ITRA subject
had a signiﬁcant deterioration (>2 lines) in visual acuity at
anytime whilst on drug. There were no differences in other VFTs
between the two groups. VORI had no long-term effect on
ocular structure, as assessed by funduscopy and slit lamp. There
was therefore no relationship of visual function to occurrence of
VAEs in either treatment group.
Conclusions: Clinical assessment of the results of VFTs in this
study found no evidence of an effect of VORI on long term
visual function or new concerns about VORI’s effect on the eye.
P1110
Caspofungin bioassay using the hypersusceptible
C. albicans cell wall sensor mutant delta-mid2
A. Pascual, D. Sanglard, J. Bille, T. Calandra,
O. Marchetti (Lausanne, CH)
Background: Caspofungin (CSP) is the ﬁrst member of a new
class of antifungal agents, the echinocandins, approved for
clinical use in patients with candidiasis and aspergillosis. Phar-
macokinetics of CSP may be altered in critically ill patients with
severe invasive mycoses. Blood levels measurement may there-
fore help to monitor antifungal therapy. Available HPLC and
LC-MS methods for measurement of CSP blood levels are labor-
intensive and need sophisticated equipments. A bioassay would
be a useful alternative.
Objective: To develop a bioassay for measurement of CSP
blood levels using the hypersusceptible C. albicans cell wall
sensor mutant delta-mid2.
Methods: The C. albicans mutant delta-mid2 (MIC for CSP:
0.008 mg/L) was constructed by targeted deletion of the gene
encoding for a cell wall sensor putatively involved in the
maintenance of cell wall integrity. The bioassay was validated
according to international guidelines (Shah et al, 2000; FDA,
2001). Standard curve included 8 CSP concentrations over the
range 0.4 to 25 mg/L. Four quality controls were used (0.5, 2, 8,
16 mg/L) to study: i) stability of CSP concentrations over time at
different pre-analytical storage conditions, ii) accuracy (meas-
ured/nominal value x 100, validation range 85–115%), iii)
precision (coefﬁcient of variation: SD/mean of measured
values x 100, validation range 15%). The validation procedure
included 6 intra-run and 6 inter-run measurements.
Results: The limit of detection and quantiﬁcation was 0.2 and
0.4 mg/L (corresponding to 5 and 10 ng of CSP in a sample
volume of 25 ml), respectively. Reproducible standard curves
were obtained over the clinically relevant concentration range
(0.4 to 25 mg/L) (r ‡ 0.99). Analytical time was 16 h. CSP
concentrations with a deviation from nominal values < 15%
were measured: i) over 4 days in plasma, and 3 days in whole
blood, at 4 C, ii) over 3 and 2 days, respectively, at 21 C, iii) over
6 months in plasma at - 80 C, iv) after 5 freeze/thaw cycles.
Intra- and inter-run validation with the four quality controls
(mean % value, ± SD) are shown in table 1.
Conclusions: A rapid bioassay for caspofungin with high
accuracy and precision was developed using the hypersuscep-
tible C. albicans cell wall sensor mutant delta-mid2. This new
analytical tool may offer an easy to use alternative to sophis-
ticated HPLC/LC-MS methods
P1111
In vitro interaction of albumin and of local
anaesthetics with antifungal susceptibility proﬁle
of Aspergillus species
R. Araujo, A.G. Rodrigues, C. Pina-Vaz (Porto, P)
Objectives: To evaluate the effect of combination of drugs
commonly used in critical care patients, like albumin (Alb) and
local anesthetics (lidocaine (Lid) and bupivacaine (Bup)), upon
the susceptibility proﬁle of Aspergillus to antifungals.
Methods: Clinical isolates of A. fumigatus (5 strains), A. ﬂavus (3
strains) and A. niger (3 strains) were used. The checkerboard
dilution method1 was used for determination of minimal
inhibitory concentration (MIC) or minimal effective concentra-
tion (MEC) while testing combinations of drugs. Concentration
of antifungals (amphotericin B (AMB), itraconazole (ITC),
voriconazole (VRC) and caspofungin (CPF)) ranged between
0.03 and 16 lg.ml)1. Alb 2% and 4% was tested. Final Lid
concentrations ranged between 0.125 and 2 mg.ml)1, while Bup
serial ranged between 0.06 and 1 mg.ml)1. Data were compared
at signiﬁcance level of 0.05.
Results: Albwas associated to a systematical increasewithin one
to three dilutions of the MIC of AMB and ITC, in all the three
species of Aspergillus. Such differences were signiﬁcant for both
antifungal agents. However, MIC values to VRC did not change
signiﬁcantly, after 48 hours, in presence of both tested concentra-
tions of human albumin (P > 0.05). The activity of AMB, ITC and
CPF was signiﬁcantly enhanced in presence of both Lid and Bup,
upon all Aspergillus strains. Synergistic activity was found with
the highest concentrations of both local anesthetics (0.5–
2 mg.ml)1 of Lid and 0.25–1 mg.ml)1 of Bup) associated to these
antifungals, upon 2 strains (A. fumigatus). VRC showed a com-
pletely diferent pattern in comparison with the other antifungals.
In fact, in almost all isolates an indifferent effect was found, while
antagonistic effect occurred with Lid (4 strains: 2 of A. ﬂavus, 1 of
A. fumigatus and 1 of A. niger) and Bup (1 strain of A. niger).
Conclusion: The distinct mechanisms of action of antifungal
agents may explain different behaviour of VRC comparing to
AMB, ITC and CPF. Drug interactions should be fully evaluated
and later taken into account when establishing antifungal
therapeutic regimens, particularly in patients receiving multiple
medications, e.g. patients admitted in intensive care units or
neutropenic patients which represent the main targets for such
microbial agents.
1- Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro
synergy of caspofungin and amphotericin B against Aspergillus
and Fusarium spp. AntimicrobAgents Chemother. 46:245–7, 2002.
P1112
Findings of Candida species in critically ill
patients in context with pharmacokinetic-
pharmacodynamic properties of antifungal
therapy
J.D. Knudsen, M.C. Arendrup, J.S. Andersen, T.H. Jensen,
L. Heslet, M. Tvede (Hvidovre, Copenhagen, DK)
Objective: To identify the pharmacokinetic and pharmacody-
namic (PK-PD) parameters of antifungal therapy predictive for
Intra-and inter-run bioassay validation I
Intra (n = 6) Inter (n = 6)
Accuracy 93.1 ± 1.9 96.0 ± 2.5
Precision 1.3 ± 1.7 5.8 ± 3.0
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invasive fungal infections in patients admitted to an intensive
care unit (ICU).
Methods: The medical records of all ptt admitted to a tertiary
hospital ICU in a 6 month period in 2002 were retrospectively
reviewed, and the antifungal therapies were recorded and
correlated to the ﬁndings of fungi from the ptt. The PK-PD-
parameters for each pt was estimated from the treatment given
and the MIC of the isolated Candida, i.e. AUC/MIC-ratio (in h)
for the azoles, and Peak/MIC ratio for the free fraction of
amphotericinB. Candida isolated from various infectious foci, or
from the surveillance samples taken routinely three times a
week, were susceptibility tested using E-tests for ﬂuconazole,
itraconazole and amphotericinB.
Results: In total 120 ptt were included.Among the 14 ptt with
invasive fungal infections, 3 ptt had bloodstream infections at
admission. One of the remaining 11 (9%) received systemic
prophylactic therapy before getting colonized, and 3 ptt (27%)
were prophylactic treated when colonized, 3 ptt with ﬂuconaz-
ole (AUC/MIC: 66–1600), and one pt with liposomal ampho-
tericinB (Peak/MIC = 3). The 1-year survival was 21%. Of the 66
ptt colonised, 7 (11%) received systemic antifungal therapy
before colonisation, in total 27 (41%) received systemic antifun-
gal therapy when the colonization was detected, 21 ptt received
ﬂuconazole (AUC/MIC: median 267, range <1–1600), 3 ptt
received itraconazole (AUC/MIC: 2.500–10,000), 6 ptt received
amphotercinB (Peak/MIC>8), 4 ptt received caspofungin. The
1-year survival was 47%.Among the 40 patients without any
ﬁndings of Candida, systemic antifungal therapies were given in
15%. The 1-year survival was 51%. Statistically signiﬁcant lower
AUC/MIC ratios were found for the prophylactic treatments
with azoles for ptt with invasive fungal infections compared to
ptt only colonized (p < 0.05). A signiﬁcant higher morbidity and
mortality rate was found among ptt with invasive fungal
infections.
Conclusion: An aggressive diagnostic attitude and antifungal
treatment directed against the speciﬁc infecting Candida species
in critical ill patients is highly warranted. The identity and
susceptibility of colonizing Candida strains must be determined
to give a sufﬁcient preemptive therapy for prevention of
invasive fungal infections in patients admitted to intensive
care units.
P1113
Tacrolimus pharmacokinetics are not affected by
concomitant anidulafungin
J.A. Dowell, J. Schranz, M. Buckwalter, M. Stogniew,
D. Krause (King of Prussia, USA)
Background: Fungal infections in transplant recipients are a
major cause of morbidity and mortality. Antifungal drugs have
been shown to be effective in the prevention and treatment of
serious fungal infections, but may interact with immunosup-
pressive agents. Anidulafungin is a novel echinocandin in late-
stage development for the treatment of serious fungal infections.
Tacrolimus is a potent macrolide immunosuppressant for pro-
phylaxis of organ rejection in patients receiving allogeneic liver
or kidney transplants. Drug interactions with tacrolimus have
been observed for caspofungin, another echinocandin. A study
was done to assess a possible pharmacokinetic interaction
following co-administration of tacrolimus and anidulafungin.
Methods: An open-label, single sequence pharmacokinetic
interaction study was conducted in healthy male subjects, ages
18 to 55 years. Subjects received a single oral 5 mg dose of
tacrolimus on Days 1 and 13. Anidulafungin was given
intravenously as 200 mg on Day 4 followed by 100 mg/day
(Days 5–13). Pharmacokinetic parameters were assessed for
tacrolimus alone and in combination with anidulafungin.
Maximum plasma concentration (Cmax) and area under the
plasma concentration versus time curve (AUC) were determined
and compared.
Results: Thirty-six healthy males were enrolled in the study.
Thirty-ﬁve of these subjects completed all treatments. No dose-
limiting toxicities occurred in the study. No differences were
observed in the pharmacokinetic parameters when tacrolimus
was administered alone, compared to concomitant administra-
tion.Mean (standard deviation) tacrolimus pharmacokinetic
parameters are shown in the table.
Conclusions: Anidulafungin and tacrolimus can be adminis-
tered together. The combination was well-tolerated. Pharmaco-
kinetic parameters are not affected when tacrolimus and
anidulafungin are administered concomitantly.
P1114
Prediction of human pharmacokinetic properties
of BAL4815, a new azole antifungal, from animal
data
A.H. Schmitt-Hoffmann, J. Spickermann (Basel, CH)
Objective: To predict the pharmacokinetic properties of
BAL4815 a new azole antifungal, in humans.Methods:
BAL8557 (the water-soluble pro-drug of BAL4815) was incuba-
ted at 10 lg/mL in pooled heparinized rat, cynomolgus monkey
and human plasma for 5 minutes at 37C. BAL4815 was
incubated at 1,10 and 100 lg/mL equivalent BAL4815 with
rat, cynomolgus monkey and human liver microsomes for 120
min at 37C in the presence of 1 mg/mL proteins. The extent of
plasma protein binding of BAL4815 in rat, cynomolgus and
human plasma was measured using the red blood cell parti-
tioning method and 14C-BAL4815. Rats received a single oral
dose of 10 mg/kg equivalent BAL4815 and a single intravenous
dose of 5 mg/kg equivalent BAL4815 as BAL8557. Cynomolgus
monkeys received single oral and intravenous doses of 3 mg/kg
as BAL8557. Serial blood samples were obtained. Plasma
concentrations of BAL4815 and BAL8557 were quantiﬁed
using an HPLC/ﬂuorescence method or a LC-MS/MS assay.
Results: In plasma, BAL8557 is converted within minutes to
BAL4815 in all species investigated. In the presence of rat,
cynomolgus monkey and human liver microsomes, less than
10% of BAL4815 is metabolized during a 120 min period.
BAL4815 is bound to plasma proteins with a free fraction of
3.5%, 3.6% and 2.2% in rat, cynomolgus monkey and human,
respectively. After intravenous administration, the pro-drug
BAL8557 is converted to BAL4815 within minutes. BAL4815 has
a large volume of distribution with values greater than the total
body water: 15 L/Kg and 5 L/kg in rat and cynomolgus
monkey, respectively. BAL4815 is slowly eliminated with half-
lives of 5 h in rat and 10 h in cynomolgus monkey. After oral
administration of the pro-drug, BAL4815 reaches Cmax-values
between 2.0 to 3.5 hours. We observed high bioavailability of
BAL4815: 62% in rat and 87% in cynomolgus monkey.
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Conclusions: Based on these in vitro results and animal data,
we predict that the pro-drug BAL4815 is very rapidly converted
to BAL4815 in man. Due to the protein binding and in vitro
metabolic stability, BAL4815 is expected to behave as a low
intrinsic clearance drug in human (clearance < 10 % of liver
blood ﬂow). This combined with a large volume of distribution
explains the long half-life > 30 hours observed in man. Animal
data suggest a good oral bioavailability as is conﬁrmed in
humans.
P1115
Pharmacokinetics and fungicidal activity of
aminocandin (HMR3270), a novel echinocandin
in healthy volunteers
B. Sandage, G. Cooper, N. Najarian, J. Lowther (Lexington, USA;
Romainville, F)
Objective: Aminocandin (AC), an echinocandin, is being devel-
oped for treatment of systemic fungal infections. A study was
carried out to determine the pharmacokinetic (PK) and fungi-
cidal activity of AC in plasma samples against 2 strains of
C. albicans and 1 strain of A. fumigatus following single IV doses.
Methods: Single IV doses of 75–300 mg of AC were adminis-
tered to 12 healthy, male volunteers in a single-blind, random-
ized, placebo-controlled trial. Individual plasma samples were
collected from active and placebo (PBO) treated volunteers,
serially diluted in 25% control plasma/75% growth medium,
and the fungicidal titre determined on 2 C. albicans strains and
inhibitory titre against 1 A. fumigatus strain. Titres and PK
results are the mean values (n = 3). Due to the dilution factor in
test medium, the limit of detection was a titre of 4.
Results: The Cmax and AUC of AC increased in proportion to
its dose. Mean Cmax was 4.9–16.1 mcg/mL after infusion of
75–300 mg of AC, with respective AUC values of 239–849
mcg*h/mL. The elimination half-life of AC was 48–58 hours, the
volume of distribution was 23.5–26.2 L, and the total systemic
clearance was 0.328–0.358 L/h. Susceptibilities of the strains to
AC were: C. albicans 444 and C. albicans 26, MIC/MFC (mg/L)
0.06, 0.125 and 0.12, 0.5 respectively. A. fumigatus Afu6, MEC /
MFC (mg/L) 0.06 and >128, respectively. Samples from all
subjects dosed with 75–300 mg of AC showed fungicidal concen-
trations against both C. albicans strains. Mean peak titres ranged
from 16 (75 mg) to 128 (300 mg). The duration of measurable
fungicidal titres ranged from 48 hours (75 mg) to 168 hours
(300 mg). Inhibitory titres of plasma samples againstA. fumigatus
Afu6 ranged fromapeak of 8, to 4 at 48 hours (75 mg). For 300 mg,
dose titres ranged from 64 at the peak, to 4 at 168 hours. No
antifungal effect was noted in PBO samples, as expected. ACwas
well tolerated with few reported adverse events.
Conclusion: AC exhibited a long half-life and signiﬁcant dose-
dependent fungicidal titres over the range evaluated. The
300 mg dose retained antifungal activity even up to 168 hours
post administration. Infrequent dosage regimens may be poss-
ible with AC and further studies are warranted.
Infection control: environmental and hand disinfection
P1116
Disinfection of patient rooms, using dry mist of
hydrogen peroxide
B.M. Andersen, M. Rasch, K. Hochlin, J.-E. Fredriksen (Oslo, N)
Background: To control the spread of pathogens in hospital
environments, good hygienic routines based on cleaning and
disinfection of surfaces contaminated with biological materials
are obligatory requirements. Chemicals like chlorine and 5%
chloramine have traditionally been used for surface disinfection
purposes for a ﬁnal room disinfection in Norway. In this study a
patented programmable device which provides a dry mist of
hydrogen peroxide disinfectant is tried for room and surface
decontamination.
Materials and methods: The technology produces hydrogen
peroxide particles of such a small size that they cirkulate freely
in the air-as a mist- making disinfectant accessible to all surfaces
(Sterinis, Gloster Sante Europe). The test room was closed and
all openings taped to control the concentration of the mist. The
concentration of hydrogen peroxide was programmed accord-
ing to the volume of the enclosed room. The robot was placed in
a corner to get the most effective mist concentration ca 2 m in
front. Three preset cycluses of hydrogen peroxide dry, 17.4 ppm,
mist were done. Each time the diffusion time was 26 min,
followed by increasing contact time; 30 min, 60 min and 120 min.
Spores of Bacillus Subtilis Raven 1162282 were placed on a table,
on walls, and outside different medical equipments in the
middle of the room. The spore envelopes were either opened or
unopened before the disinfection test was performed. The
spores were removed after 18–20 hours.
Results: Preliminary results from disinfection of the enclosed
room showed no groth in 6/6 tests. Repetitive tests were done
for 11 days. The hydrogen peroxide treatment disinfected 33/42
spores (78.6%) in opened envelopes, and 94/104 spores (90.4%)
in closed envelopes. The treatment was effective in 127/146
(87%) of all tests.
Conclusion: The use of hydrogen peroxide dry mist pro-
grammed to a preset concentration, may be an effective
method to decontaminate critical enclosed areas, including
isolation units, clean rooms, and general areas contaminated
with pathogens. Further studies are needed.
P1117
Disinfection of ambulances, using dry mist of
hydrogen peroxide
B.M. Andersen, F.-H. Jensen, K. Hochlin, M. Rasch,
J.-E. Fredriksen (Oslo, N)
Ambulances trasporting patients with infectious diseases may
easily be contaminated. Special construction and narrow space
inside, the ventilation system, and all the equipments and
devices present are difﬁcult to disinfect. In this study a patented,
programmable device which provides a dry mist of hydrogen
peroxide disinfectant is tried for decontamination of ambu-
lances.
Materials and methods: Hydrogen peroxide particles of such a
small size that they circulate freely in the air–as a mist- make
disinfectant accessible to all surfaces (Sterinis, Gloster Sante
Europe, www.sterinis.com). The ambulance was placed in closed
garages A and B, with all openings to the garage taped to control
the concentration of the mist, and with the ventilation system
shut down. The doors of the ambulances were open during the
disinfection period and afterwards closed. The concentration of
Abstracts
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hydrogen peroxide was programmed according to the volume of
the enclosed garages. Spores were placed inside and outside the
ambulance, and inside devices, equipment and in drivers cabin.
1) Garage A - three cycluses; diffusion time 29 min, concentration
ca 36 ppm, followed by increasing contact time; 30 min, 60 min
and 120 min. 2) Garage B – one and two cycluses; diffusion time
27 min, concentration ca 42 ppm, followed by contact time;
30 min in ﬁrst cyclus and 60 min in second. 3)Garage B- three
cycluses; diffusion time 27 min, concentration of ca 42 ppm,
contact time; 30 min, 60 min and 120 min.
Results: 1) Garage A – three cycluses: No growth in 24/24 spore
tests from two separate experiments. 2)Garage B- one and two
cycluses: Growth after one and two cycluses in 6/6 and 12/12
spore samples, respectively. 3) Garage B- three cycluses: No
growth in 36/36 spore samples, even after placement inside
equipments and in drivers cabin. The penetration of hydrogen
peroxide into equipment, devices and drivers cabin inside and
outside an ambulance was effective when using three cycluses
of disinfection.
Conclusion: The use of hydrogen peroxide dry mist, pro-
grammed to a preset concentration, may be an effective method
to decontaminate critical enclosed areas and devices that are
difﬁcult to decontaminate, like ambulances. Further studies are
needed, concerning hydrogen peroxide concentration, number
of cycluses and contact time.
P1118
Disinfection of surfaces in hospital isolation
rooms with ultraviolet C (UVC) light, compared
with chloramine
B.M. Andersen, H. Ba˚nrud, E. Bøe, O. Bjordal,
F. Drangsholt (Oslo, Rud, Trondheim, N)
The germicidal effect of ceiling- and wall mounted ultraviolet C
(UVC) light at 254 nm in isolation units with negative pressure
()45 pascal) was examined and compared with disinfection with
chloramine during end-disinfection after patient stay. Microbial
samples were taken from surfaces before and after disinfection
with UVC (33–47 min) and chloramine (5%, 1 h exposure) using
standard contact plates (20cm2). The UVC-distribution in the
isolation units was monitored at 165 positions. The output on
the ﬂoor varied between 0.08 and 3.2 W/m2, with an average
( ± SD) of 2.2 ± 0.5 W/m2 in the patient room, 2.0 ± 0.7 W/m2
in the sluice and 1.4 ± 0.5 W/m2 in the bath/ decontamination
room. On other places, the values varied from 0.08 to 6.82 W/
m2. The units were UVC-disinfected for 33–47 min, correspond-
ing to doses ranging from 160 J/m2 in shadowed area to 19
230 J/m2 at the highest exposed site. According to published
UVC-dosimetry, the survival of bacteria and bacterial spores are
reduced by 90% with doses ranging from 4–120 J/m2 and 100–
365 J/m2, respectively. Thus, UVC doses used in this study
should be high enough to inactivate most bacterial organisms,
including spores, even on surfaces not directly exposed to UVC.
UVC-disinfection signiﬁcantly reduced the bacteria on surfaces
directly or indirectly exposed to UVC to a very low number
(from ca 30 to 1–2 cfu/plate), as did 5% chloramine disinfection
(fom ca 30 to 1–2 cfu per plate) alone; p < 0.001,and p < 0.001,
respectively. Since cleaning before disinfection may be a risk for
the staff in isolation units, disinfection with UVC- or chemicals
should always be performed ﬁrst. The presence of completely
shadowed areas in the isolation unit (the bed rail, lockers,
matresses etc.) still needs disinfection by chemicals before
cleaning. Therefore, UVC may not be used alone, but is a
good additive to chemical disinfection, to lower the biological
burden of infectious agents in isolation units for high risk
infectious patients.
P1119
Disinfection of medical equipment, using dry
mist of hydrogen peroxide
B.M. Andersen, K. Hochlin, P. Wismar, M. Rasch, W. Svendsen,
J.-E. Fredriksen (Oslo, N)
Background: Internal parts of medical equipments, like differ-
ent ventilators, CPAP, and other equipment associated with the
respiratory tract, infusion pumps, suction equipments, etc may
be difﬁcult to disinfect. Most equipments have an air cooled
motor that takes air from the patients room/environment.
Internal parts may then be contaminated. In this study a
programmable device which provides a dry mist of hydrogen
peroxide disinfectant is tried for surface and internal decon-
tamination of medical equipments.
Materials and methods: Hydrogen peroxide particles of small
size circulate freely in the air - as a mist, making disinfectant
accessible to all surfaces (Sterinis, Gloster Sante Europe). The
test room was closed and openings taped to control the
concentration of the mist. The concentration of hydrogen
peroxide was programmed according to the volume of the
room. Three preset cycluses of hydrogen peroxide dry mist were
done. Each time the diffusion time was 12 min, giving a
concentration of 12 ppm, followed by increasing contact time; 30
min, 60 min and 120 min. The medical quipment tested:
Freedom nebulizer, Micro Air U22, compressor CR 60, Walk
boy Pari, pulse oxymeter (SN P 1020601402-N-550), CPAP
(Autoset Sprint), Medela suction apparatus, ventilator (Lifecare
PVL-100), and 571 infusion pump. Spores of Bacillus Subtilis
Raven 1162282 were placed inside and outside different medical
equipments. The medical equipment that had motors were
started and run during the period of disinfection.
Results: The hydrogen peroxide treatment disinfected opened
spores placed inside medical technical equipments in 37/82
(45.1%) cases, and closed (enveloped spores) in 47/88 (53.4%)
cases. The treatment was effective in 84/170 (49.4%) of all tests.
All the spore tests at inside of medical equipment were,
however, negative, when the device was run and ventilated
during the period of disinfection; 27 / 27 tests.
Conclusion: The inside of medical equipment may - by the use
of hydrogen peroxide dry mist, be disinfected in ca 50% of all
cases. The method seems to be effective when the internal parts
are ventilated during disinfection.
P1120
Antimicrobial effect of pine core wood against
organisms causing hospital-acquired infections
M. Strehlein, J. Wirmer, E. Schmidt-Eisenlohr, D. Mlangeni,
F.D. Daschner (Freiburg, D)
Objective: To compare the antimicrobial efﬁcacy before and
after disinfection of pine core wood surfaces with surfaces made
of polyethylene and synthetic laminate against organisms
typically causing hospital-acquired infections.
Methods: S. aureus (MRSA), E. faecium, E. coli, P. aeruginosa.
C.albicans, M. terrae and P camembertii were uses as test
organisms. After inoculation of the test organisms on surfaces
made of pine core wood, polypropylene and synthetic laminate,
samples were collected on RODAC plates before and after
disinfection with commonly used hospital germicides (alcohol,
aldehyde, glucoprotamine and a quaternary ammonium com-
pound). Bacterial colonies were counted after 0 min, 30min, 1 h,
4 h and 24 h, respectively, according to a standardised micro-
biological method.
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Results: Substantially lower colony counts were measured on
pine core wood surfaces before application of the disinfectant
compared with counts on polypropylene and synthetic laminate
surfaces. After bacterial contamination of the surfaces, signiﬁ-
cant colony counts were not observed on the surfaces after
disinfection with alcohol, aldehyde and glucoprotamine. How-
ever, after disinfection with a quaternary ammonium com-
pound, signiﬁcant elevations in colony counts were found on the
pine core wood surfaces in comparison to the polypropylene
and synthetic laminate surfaces.
Discussion: The poor efﬁcacy of quaternary ammonium com-
pound on wooden material might be explained by the interac-
tion between wood and the anionic polyphenols and cationic
surfactants contained in the disinfectant.
Conclusion: The study ﬁndings corroborate the antimicrobial
effect of pine core wood against organisms typically causing
nosocomial infections. With the exception of a quaternary
compound, all the germicides displayed good disinfecting
properties. From a hygienic point of view, pine core wood is
suitable for use in hospitals.
P1121
Survey of the microbiological quality of drinking
water supply in hospitals. Drinking water cooler
vs tap water fed dispenser vs bottled water
S. Adler, M. Eikenberg, D. Mlangeni, F.D. Daschner (Freiburg,
D)
Objectives: Hygienic, economic and ecologic comparison of
drinking water coolers versus tap (mains) water-fed dispensers
versus bottled drinking water.
Methods: Samples were taken from each system without
preﬂow or cleaning of the nozzle. These comprised 2 samples
from 20 drinking water coolers each over 2 months, 1 sample per
week from the tap water dispenser over 6 months, and samples
from 6 different bottles of drinking water. Total colony counts
were analysed at 22C and 36C, respectively. Total P. aerugi-
nosa, E. coli, and coliforms, as well as sulphite-reducing
clostridia were examined according to European Norms (EN
ISO) for compliance with the German Drinking Water Ordin-
ance 2001 (limit value for total colony counts at 22 ± 2C: 100
cfu/ml, at 36 ± 1C: 100 cfu/ml and 20 cfu/ml for bottled
water). Costs per litre were calculated and compared based on
the economic data supplied by the manufacturers. The ecolog-
ical impact of the different systems was evaluated based on
expert opinion.
Results: All the samples from the water cooler system exceeded
German Drinking Water Ordinance threshold values. All the
samples taken from the tap water dispenser, and, with one
exception, all the samples from the bottled water complied with
the German Drinking Water Ordinance. If more than 400 l of
water are consumed per month, the tap water dispensing system
and bottled water are more economical than the water cooler
system ( 0.57 per l for water cooler, 0.45 for month tap water
dispenser, 0.49 per l for bottled water). In economic terms, the
water cooler system can only be recommended for consumption
levels below 400 l per month. From an ecological point of view,
the tap water dispenser is most favourable (expressed in CO2-
emissions per year for 403.720 l at Freiburg University Hospital),
followed by the water cooler system and ﬁnally the bottled
water.
Conclusion: For reasons of hygiene, the use of water cooler
systems cannot be recommended in hospitals. Furthermore,
drinking water cooling systems are only economic for low
consumption rates. Tap (mains) water-fed dispensers feature the
best hygienic, economic and ecologic properties.
P1122
Citrofresh, a revolutionary new, natural, broad
spectrum disinfectant
Z. Nack, R. Narain (North Geelong, AUS)
Objectives: The objective of this presentation is the evaluation
of the effectiveness of Citrofresh- a revolutionary new, organic,
non-toxic, non-carcinogenic, non-irritative, non-rinse, biode-
gradable sanitizer and disinfectant- against the three major
group of multiresistant bacteria; Methicillin Resistant Staphylo-
coccus sp. (MRSA and MRSE), Vancomycin Resistant Enterococcus
sp. (VRE) and Gentamicin Resistant Gram Negative Bac-
teria,(Acinetobacter sp. and Pseudomonas sp.) Citrofresh has
been classiﬁed by the FDA (USA) as a "GRAS" product,-
"Generally Regarded As Safe".
Methods: The investigation was performed using TGA (Thera-
peutic Goods Administration, Australia) Disinfectant test, given
by Kelsey & Maurer, evaluating disinfectant’s performance.The
test consisted of challenging the diluted disinfectant (Citrofresh
4%–6% and 10% in sterile hard water) with bacterial inoculum
(108 to 109 orgs/ml, grown in Wright and Mundy Dextrose
medium), withdrawing a sample after a given time (8 min.) and
culturing it in a suitable recovery medium (5 bottles of Nutrient
Broth). After sampling (takes 2 min), the mixture was challenged
again with a second inoculum for 8 min, (total of 18 min) than
sampled for culturing in other 5 Nutrient Broth, at 37 degree
Celsius for 48 hrs. The test was passed or failed according to the
extent of growth- there is no growth in at least two out of the
ﬁve recoveries broths-shown in the two cultures sampled. The
test was performed with the addition of sterile yeast (organic
soil, dirty condition.For test validation, we used Virkon S -a
registered, broad spectrum disinfectant-in 1% concentration.
Results: The effective concentration against Methicillin Resist-
ant Staphylococcus sp. (MRSA or MRSE)is from 4%. The effective
concentration against Vancomycin Resistant Enterococcus faecium
and Enterococcus faecalis is from 4%. The effective concentration
against Gentamicin Resistant Acinetobacter sp. is from 8%,and
against Gentamicin Resistant Pseudomonas aeruginosa, is from
10%.
Conclusion: The above mentioned testing procedure imitates
the real situation of a cleaning process in a highly contaminated
area or surface. According to our results, Citrofresh can be
regarded a very effective and safe, broad spectrum sanitizer. Its
recommended concentration is minimum 10% (from 4% for
Gram positive cocci only) in hospitals, nursing homes, child care
centres and in any other community or health organizations.
P1123
Comparison assessment of antibacterial
efﬁciency of ﬁnishes used in medical areas
B. Jakimiak, E. Ro¨hm-Rodowald, M. Staniszewska, M. Cieslak,
G. Malinowska, A. Kaleta (Warsaw, Lodz, PL)
Objectives: The application of antimicrobial ﬁnishes to textiles
can prevent bacterial growth and might reduce the risk of
infection resulting from fabrics that are contaminated with
pathogenic microorganisms in hospitals. The main aim of this
study was the determination of the antibacterial activities of
chemical treatments applied to textiles. Comparison of testing
methods assessing antibacterial efﬁciency was conducted. These
studies were performed in order to select the right methods of
evaluating the antibacterial and bacteriostatic activity of ﬁn-
ishes.
Methods: Fibers and fabrics made from cotton (100%) applied
with quaternary ammonium salts were tested. Finishes treated
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with bactericidal agent were compared with samples (not
treated with the disinfectant). The European Standards ISO /
DIS 20645/2002 and AATCC 147/1998 suitable for assessment
of antibacterial activity were applied. The bacterial strains
recommended by the above standards such as: Klebsiella pneu-
moniae (ATCC 4352), Staphylococcus aureus (ATCC 6538), Escheri-
chia coli (ATCC 11229) were tested. Due to its high resistance to
quaternary ammonium salts, additionally P. aeruginosa (ATCC
9027) was examined. Bacterial suspension 1 – 2,9 x 108 cfu/ml
was prepared according to the standards requirement. The
samples impregnated with biocidal products were examined
with agar diffusion plate test. The specimens were located
transversely across the bacterial inoculum on the nutrient agar.
The level of antibacterial activity was assessed by examining the
extent of bacterial growth in the contact zone between agar and
the specimens. Additionally, the extent zone of inhibition
(minimal 1 mm) around the specimens was considerate.
Results: Tested ﬁbers did not show antibacterial activity. The
fabrics showed antibacterial activity against K. pneumoniae and
S. aureus (inhibition zone 4 mm). The examined specimens
showed no bacteriocidal activity against Escherichia coli and
Pseudomonas aeruginosa. The results obtained in two applied
methods were comparable in assessing antibacterial activity of
ﬁnishes. The antymicrobial ﬁnishes did not fulﬁll requirements
of the standards.
Conclusion: Based on the obtained result the tested antimicro-
bial ﬁnishes may not be considered effective in preventing
bacterial transfer at contaminated areas in hospitals.
P1124
A new interactive approch to improve hand
hygiene compliance
J. Holt, E. Tvenstrup Jensen, D. Buhl (Copenhagen, DK)
Introduction: The compliance of guidelines for hand hygiene is
well below 50 % despite several at-tempts to improve. When
planning an educational outline to promote a behavioural
change in the hand hygiene practice in the aim of lowering
the incidence of Nosoco-mial Infections the mapping of critical
factors and implications that affect this practice is of utmost
importance.
Objectives: This study was an empirical investigation of the
aspects of the hand hygienic practice as it takes place in the
Danish health care system today. The study attempted to answer
the question:’’How can the health staff’s lack of compliance with
hand hygiene be explained and understood as basis for planning
an educational material to support a behavioural change.’’
Methods: Literature studies of hand hygiene, a questionnaire
based done survey (1700 per-sons/294 respondents) and qual-
itative interviews (N = 15) was performed in order to uncover
the explanations for this low rate of compliance.The data was
analysed and discussed on the basis of theories on action,
experience, reﬂective thinking, control and rituals in order to
aim for a broader view and under-standing of this ﬁeld.
Results: Both the questionnaire and interviews showed that
hygiene still is a ﬁeld that has great implications on the
interactions between individuals. Furthermore it seemed dif-
ﬁcult for the staff to draw a professional and not a private line
between ’’the clean and the unclean’’ and thereby perform hand
hygiene without compromising each other. Further the inter-
views showed that it is difﬁcult for the staff to react on
something they cannot see and that not gives an immediate
result when staff does not act as pre-scribed.
Conclusions: Hand hygiene training should be targeted using a
new approach which puts focus on the interpersonal relations
and who allows interactivity to build up experience with what
happens when you do not perform hand hygiene. The training
should aim for an open minded dialogue and should be taught
in a media that allows reﬂection, experi-mental learning and
shows the invisible. On the basis of this study a web based train-
ing program in hand hygiene who allows staff and all others
with interest in this ﬁeld has been developed and is now
available in Danish on the Statens Serum Institut web-site
(www.ssi.dk). The training program contains facts on hand
hygiene, latest litera-ture and gives room for visualising,
experiments and testing.
P1125
Spread of a carbapenem-resistant Pseudomonas
aeruginosa associated with contamination of
hand-washing facilities on an intensive care unit
S. Jamdar, J.S. Cargill, R. Catlin, A.O. Qamruddin,
C. Williams (Manchester, UK)
Objectives: An increased rate of isolation of carbapenem-
resistant P. aeruginosa was noted on an intensive care unit
(ICU) between August and September 2004. We here report the
clinical and epidemiological features of this spread.
Methods: A regular six-monthly assessment of the antibiotic
resistance proﬁles is made for our 12-bed ICU, showing that
carbapenem sensitivity (based on BSAC guidelines for disc
diffusion testing) for P. aeruginosa usually runs at at least 85%
(Nov 2003–April 2004, 116 isolates from 41 patients; May–
October 2003, 81 isolates from 25 patients). Between August and
September 2004 18 isolates from 7 patients (from a total of 45
isolates, 10 patients) were shown to be carbapenem resistant. All
7 patients were intubated and were on treatment for pseudo-
monal infections of varying degree. None received carbapenem
treatment during this period. Swabs were taken to exclude the
presence of an environmental source of resistant Pseudomonas. A
selection of isolates from 2 patients and the environmental
isolates were sent to a reference laboratory for PFGE typing.
Results: PFGE typing showed that at least two types of
P. aeruginosa serotype 01 were present within the patient
population. The environmental screening revealed the presence
of carbapenem-resistant Pseudomonas in the drainpipes of some
of the hand basins in the ICU, but not the taps. PFGE typing
showed that this strain was indistinguishable from one patient’s
strain.
Conclusion: This shows that the spread of resistant Pseudomon-
as within a unit may be partly associated with contamination of
the hand washing facilities. Infection control measures were
effective in eradicating the organism from the basins. No further
carbapenem-resistant isolates have been noted from any later
patients.
P1126
Impact of hand hygiene on hospital-acquired
infections in the cardiosurgical department of a
Greek university hospital
S. Metallidis, N. Harokopos, A. Tsona, E. Koumentaki,
G. Batanis, P. Kollaras, P. Nikolaidis (Thessaloniki, GR)
Objective: The purpose of the present study was to estimate the
incidence of Hospital Acquired Infections (HAIs) after increas-
ing the compliance of hand hygiene in the cardiosurgical
department of a Geek University Hospital.
Methods: Data concerning the year 2002 and 2003 were derived
from the database of HAIs of our hospital. The Infectious
Disease Division is responsible for the surveillance of HAIs in a
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daily base. Hand hygiene compliance for the year 2002 was
estimated from questionnaires that were given to all medical
stuff. Hand hygiene compliance during the year 2003 was
estimated from the same questionnaires as well as from random
visits of nurses of infection control committee. The increase of
the hygiene compliance the year 2003 was achieved by monthly
lectures to the personnel of the department and by using pictures
of the proper way to wash hands in many visible places. Between
all beds there were alcoholic solutions for the stuff to use.
Results: In year 2002 1243 patients were hospitalized, 900 of
them had at least one operation. 106 HAIs (8.2 %) were detected
(21 LRIs, 42 SSIs, 32 BSIs, 6 UTIs and 5 others). The hand hygiene
compliance was estimated 38%. In year 2003 1369 patients were
hospitalized, 857 of them had at least one operation. 71 HAIs
(5.1%) were detected (8 LRIs, 25 SSIs, 30 BSIs, 4 UTIs and 4
others).The hand hygiene compliance was estimated 62%.
MRSA infections were also reduced from 27 in year 2002 to 14
in year 2003
Conclusion: The increase of hand hygiene compliance has
signiﬁcantly reduced the incidence of HAIs, especially SSIs
and LRIs and contributed in the reduction of MRSA infections.
We did not observe any reduction in the BSIs.
Exotic infections – II
P1127
Prevalence of Leishmania infantum antibodies in
central northern Spain
M.A. Bratos, M.P. Gutierrez, M.P. Zarzosa, I. Garrote, R. Lo´pez
Izquierdo, S. Garcinun˜o, A. Almaraz, C. Can˜avate, A. Rodriguez
Torres, A. Ordun˜a (Valladolid, E)
Introduction: Leishmaniasis has increased in importance in
recent years as HIV-infected patients have emerged as a risk
group for the disease. However, real prevalence in the general
population is unknown.
Objetive: The objective is to know the antibody seroprevalence
for infection by Leishmania infantum in the general population of
Castilla-Leon (Spain).
Methods: A random sample from the general population (4825
sera) and from HIV-infected patients in the Autonomous
Community of Castilla-Leon was collected in 1996. Seropreva-
lence of antibodies against L. infantum was determined by an
indirect enzymoimmunoanalysis (EIA) test designed in the
laboratory.
Results: Anti-Leishmania infantum antibody seroprevalence in
the general population was 4.9%. There is a signiﬁcant increase
in seroprevalence with age (P = 0.001), from 3.96% in the 14–20
years group up to 7.2% for those over 70 years old. There were
no signiﬁcant differences between women and men (5.0% versus
4.9%; P = 0.9534). Seroprevalence was signiﬁcantly higher in
people from rural areas than in those from cities (6.0% versus
3.4%; P = 0.001). HIV-infected patients had a seroprevalence
against L. infantum of 64.0%. No differences were observed
between women and men, nor was there a prevalence increase
with age.
P1128
Efﬁcacy of intralesional pentavalent antimony in
combination with oral azole for treatment of old-
world cutaneous leishmaniasis
A. Beltrame, A. Arzese, F. Cristini, G. Rorato, C. Romano,
M. Tavio, P. Viale (Udine, I)
Objective: Systemic treatment of Old-world cutaneous leishmani-
asis (CL) lesions is burdened by unacceptable high rate of
adverse events related to pentavalent antimonial compounds
and by unproved efﬁcacy of monotherapy with azoles. We
describe the treatment of 3 cases with combined intralesional
and systemic treatment.
Methods: Diagnosis was histologically and microbiologically
conﬁrmed. Treatment consisted of oral ﬂuconazole (200 mg once
daily) and intralesional injections of meglumine antimoniate
(0.8–1 ml/lesion at alternate days). Clinical follow-up (icono-
graphically documented) was conducted weekly during treat-
ment and 1–3 months afterwards. Cure was deﬁned as complete
healing of all lesions by the end of treatment and by the 3-month
follow-up.
Results: A 30-year-old man presented with a 6-month history of
slowly growing round lesions on his right arm and leg. He had a
history of travel in the Mediterranean area (Including North
African And Middle East Countries) 6 months prior to presen-
tation. Examination showed one nodular lesion (1 · 1 cm) with
margin induration and depressed central ulceration on the right
arm, a second nodular lesion (0.5 · 0.5 cm) on the right leg, and
a red papule (0.5 · 0.5 cm) on the left arm. A 52-year-old man
with an history of a 4-month stay in Iraq until 1 months prior to
presentation, showed 6 lesions, which had grown during the last
three months: two nodular lesions (3.5 · 1 cm, 4.5 · 2 cm) with
erythematous margins and a thick crust on the left arm, 4 round
lesion (2.5 · 2.5 cm) with depressed central ulceration, at the left
arm, right arm, right leg and second ﬁnger of the right hand. A
49-year-old man with a 5-month stay in Iraq until 5 months prior
to presentation, showed two painless conﬂuent nodular lesions
(5.5 · 3.5 cm) with depressed central ulceration at the right
elbow, which had grown over 4 months, two round lesions
(1 · 0.5 cm and 0.8 · 0.7cm) with a thick crust on the left
poplitea fossa and one nodular lesion (1.5 · 1 cm) at right leg.
All patients received 12 alternate-days intralesional injections of
meglumine antimoniate and 6 weeks of oral ﬂuconazole. All
lesions healed completely at the end of therapy and at the
3-month follow-up. None of the patients complained of any
adverse events during treatment or follow up.
Conclusion: Treatment with intralesional pentavalent antimony
in combination with azole is effective and absolutely safe, in that
it reduces the total amount of antimonial exposure.
P1129
Entomological study of sandﬂies (Dipthera:
Psychodidea) in three foci of endemic cutaneous
leishmaniasis in Iran
H. Nekouie, M. Razavi, M. Assmar, S. Nadaf (Tehran, IR)
Human leishmaniasis is a globally widespread parasitic disease
caused by members of the genus leishmania. Currently, leish-
maniasis is considered to be endemic in 82 countries including
Iran. Phlebotomine sandﬂies the vectors of leishmaniasis have
received considerable attention in recent years due to the
resurgence of leishmaniasis in some endemic areas of Iran ,so
extensive studies have been conducted on the ecology of
sandﬂies in different parts of the country in recent years.
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A total 8026 sandﬂies were collected by using funnel traps of
rodent burrows in rural district of the 3 province of Iran (Shiraz,
Yazd, Khozestan). These sandﬂies identiﬁed in 3 Maine croups:
Phlebotomus. papatasi(61%) , P. sergenti (10%) , P. sergentomya
(29%). These ﬁndings indicate that P. papatasi could be a vector
of humans and the gerbils (Merion libycus). The close contact
between vectors and resevoirs have created a very efﬁcient cycle
for the transmission of the disease in these areas and the villages
around these 3 provinces.
P1130
Erysipelas like cutaneous leishmaniasis: a case
report
A. Erdogan, D. Balaban, E. Dervis, G. Sengoz, G. Barut,
A. Karaoglu (Istanbul, TR)
Cutaneous leishmaniasis is an infectious disorder of the skin
caused by leishmania major, tropica, aethiopica and infantum
which are transmitted by phlebotomine sandﬂies. We present
here a patient who demonstrated a morphologically rare form of
erysipelas like cutaneous leishmaniasis. A 74-year-old woman
with a four-month history of erythema and edema on her nasal
and left malar area was referred to our clinic for further
evaluation. Her dermatological examination revealed an erythe-
matous, edematous and ﬁne desquamative plaque on her nose
and left malar region resembling erysipelas. Other physical and
laboratory ﬁndings were normal. Punch biopsy taken from the
lesion and dyed with H.E revealed dense lymphocytic inﬁltra-
tion between the layers of just beneath the epidermis and deep
dermis. In addition, a huge number of amastigots were found in
macrophages and histiocytes that formed granulomas. In light of
these ﬁndings the patient was diagnosed with cutaneous leish-
maniasis and commenced a regimen of meglumin antimonat 425
mg b.i.d. After two weeks of therapy the lesion was gradually
disappeared without any scar formation. In conclusion, cases
with cutaneous leishmaniasis are still observed in our country not
always with usual clinical appearance, but also like the present
case, it may clinically resemble erysipelas and provides difﬁ-
culties in the differential diagnosis.
P1131
Study of human infection of cutaneous
leishmaniasis in a focus of the disease, southern
Iran
A.A. Hanaﬁ-Bojd, M.R. Yaghoobi-Ershadi, R. Jafari, A. Barzekar,
G. Zamani (Tehran, IR)
Objectives: In the last decade cutaneous leishmaniasis (CL) is
reported increasingly from 3 parts of the Hormozgan province,
southern Iran. Hajiabad County is one of the important foci CL
in Hormozgan province. This investigation was conducted to
determine the kind and agent of the disease, and it’s prevalence
in the area.
Methods: For this study, three villages were chose. About one
hundred of each villages and all students of their schools were
visited and related forms were completed with asking and
examination them about the disease. Smears were prepared
from all patients with acute lesions. Also, obtained samples from
lesions of 4 patients were injected at the base of the tail of 12
Balb/c mice. Infected mice were transported to the School of
Public Health, Tehran University of Medical Sciences for
isolation and detection of parasite.
Results: A total of 310 households with 1392 inhabitants (48.4%
male, 51.6% female) were visited. Study of prevalence showed
116 cases (8.3%) with scar and 14 cases (1%) with ulcers. The
mean of acute lesions and scars per infected cases was 1.64 and
1.87, respectively. Totally 129 cases were observedwith sores and
scars, and 122 out of them were infected in the area. The highest
rate of the acute lesion was observed in 0–4 years old age group
(4.5%); meanwhile the highest rate of scars was in 10–14 years old
age group (12.9%). Sores were located on hands (8.7%), foot
(65.2%) face (4.4%) and other parts of body (21.7%). In the study
of schools, 1201 students (53.5% boys, 46.5% girls) were visited.
The infection rate to acute lesion was 0.6% and 22.6% of students
had scar. There is no signiﬁcant difference between males and
females based on the acute infection (P > 0.05), but this difference
was signiﬁcant based on scar (X2 = 9.84, P < 0.05). The highest
infection rate was observed in Tashkooieh village (2.7%). Two
injected mice were developed the acute lesion and the agent of
the disease was identiﬁed as Leishmania major by PCR test.
Conclusion: The infection rate of the sores and scars shows that
the disease is located in the studied area in recent years. The
disease had one peak during 1995–2000 and has been increased
from 2002 up to now. This is the ﬁrst time that the parasite
isolated from human in the area. Therefore, this focus must be
added to the Zoonotic Cutaneous Leishmaniasis foci of Iran. The
disease is endemic in the area because more than 95% of cases
were infected locally.
P1132
Giardia and Cryptosporidium in the Netherlands
L.M. Kortbeek, T.G. Mank (Bilthoven, Haarlem, NL)
Objectives:
• The studies were designed to get an insight into the incidence
of protozoal-, bacterial-, and viral infections in patients with
diarrheal complaints in different groups: patients consulting
their general practioner and the dutch population. Here we
focus on Giardia and Cryptosporidium
• To decrease diagnostic deﬁcit
• Study the risk factors
Methods: Three studies were designed and conducted :
• Haarlemstudy: 1994–1996, general practitioners, Haarlem
region
• NIVEL: Case-control study in sentinel General practitioners
practices (1996–1999)
• SENSOR: prospective population based cohort study with a
nested case-control study in the Dutch population. (1999)The
studies differ in inclusion criteria and the diagnostic laborat-
ory techniques used, esp. virological stool examinations
Results: Incidence of gastroenteritis in the NIVEL (GP) study
(after correction) was 79.5 per 10,000 personyears. This means
that 80.000–130.000 persons will consult a GP annually for
gastroenteritis. Incidence of gastroenteritis in the population-
based study was 283 per 1000 personyears. Giardia was detected
in 14.8% of the cases in Haarlem, in 5.4% of the cases in the
NIVEL study and 3.3% of the controls. For Cryptosporidium this
was resp 3.3%, 2.1% and 0.2%. The diagnostic deﬁcit decrease
substantialy by testing for viral pathogens like NLV. Detection
of pathogens was inﬂuenced by age, season and duration of
symptoms. We were able to construct an algoritm for diagnostic
workup in GI patients.The main riskfactors for Giardia are:
• swimming OR: 6.8 ( 95%CI: 2.4–19.3) multivariate OR: 15.6
(3.2–77.1);
• contacts with person with GE 7.1 (1.8–26.6); Multivar.OR 28.6
(3.2–255.6)
• family member attending primary school: 2.8 (1.4–5.8); multi-
var. OR 2.5 (1.0–6.3) .The population attributable risk fraction
(PARF) for all these factors was 49% in the GP patients and
76% for patients in the general population.
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Conclusion:
• Giardia lamblia and Cryptosporidium are important pathogens
in gastro-enteritis patients in the Netherlands.
• If transmission through water, infected persons and through
school contacts could be eliminated, about 50–76% of Giardia
gastro-enteritis could be prevented.
• Giardia lamblia is the most frequently found potentially
pathogenic intestinal protozoal species in patients with
diarrheal complaints in the Netherlands
P1133
Climate impact on seasonal patterns of diarrhoeal
diseases in a tropical country
A. Teshima, M. Yamada, T. Hayashi (Uji, Kyoto, JP)
Statistical surveys have been made for the effect of the climate
on the epidemic diseases in tropical area, but not so much has
been clariﬁed on the relation between the variations of mete-
orological elements and of the number of patients. In this paper,
we apply EOF analysis method to time series of diarrhoea
patients and meteorological elements in Bangladesh, to under-
stand effects of the meteorological variation to the prevalence of
the diarrhoea disease. The EOF analysis of the time series of
patients and meteorological elements averaged every two weeks
for 21 years from 1981 to 2001 shows that in the dominating
component, the anomaly of the number of the diarrhoea patients
has different signs for the periods before and after June,
corresponding to the two seasonal peaks of the number of the
patients. Higher maximum temperature and more humidity in
the pre-monsoon period are found to have a tendency to
enhance the ﬁrst peak of the diarrheal occurrence. We will also
report the result for the different types of diarrhoea as V. Cholera,
Rota and Etec.
P1134
Serologic evidence for babesiosis in the northern
and eastern Tyrol (Austria) and the southern
Tyrol (Italy)
G. Walder, R. Edelhofer, J. Simeoni, G. Morosetti, D. Scho¨nitzer,
R. Wu¨rzner, P. Kreidl (Innsbruck, Vienna, A; Bozen, I)
Objective: Recently, human infections with Babesia strain EU 1
have been reported from Austria and Italy. The aim of this study
was to assess the percentage of seropositives against Babesia
strain EU 1 among healthy blood donors in the Austrian and
Italian part of the Tyrol.
Methods: 1607 volunteer donors were obtained from the
institutes of transfusion medicine, representing the demogra-
phic situation in the Tyrol regarding gender and residence. Sera
were tested for IgG with an in-house Immunoﬂuorescence assay
coated with an isolate of strain EU 1 obtained from a human
patient. Positive samples were conﬁrmed by a second test with a
different charge. False positve results due to antibodies reactive
to cells were ruled out by testing with uninfected cells. The
proper cut-off was assessed with 120 samples of a low-risk
collective according to the guidelines of the WHO.
Results: The cut-off titre was set at 1:64. over all, 70 samples
were found positive (4,4%). in detail, 38(3,8%) samples from the
Austrian part of the region and 32 (5,2%) samples from the
Italian part of the region were found positive.
Conclusions: Evidence was found for the occurrence of babesi-
osis in all parts of the region, particularly in the lower Inn valley
and te eastern Tyrol. Physicians should be aware of this illness
and consider it in febrile ilnesses following tick-bites.
P1135
Acute leptospirosis: experience at a tertiary care
referral centre
K.K. Sharma, A. Mohan, S. Bollineni, A. Gururajkumar, V. Siva
Kumar, A. Sharma (Tirupati, IND)
Objective: Retrospective study of the epidemiology, clinical
spectrum and laboratory abnormalities in 36 patients (mean age
42.6 ± 17.1 years; 22 males) with acute leptospirosis seen
between January 2001 and April 2004.
Methods: Leptospirosis was diagnosed by leptospiral IgM
enzyme linked immunosorbent assay (ELISA) and the serovar
was conﬁrmed by the microscopic agglutination test (MAT)
using a battery of 12 live leptospiral strains as antigens.
Results: Most of them were outdoors manual workers (52%),
housewives (29%), indoors non-manual workers (16%) and
unknown (3%). Mean duration of symptoms was 12.4±21.2 days.
Majority of the patients presented with fever (89%), jaundice
(55%), chills and rigors, vomiting (47% each), cough (28%),
abdominal pain (25%), diarrhoea, and altered sensorium (19%
each), purpura/bleeding (11%). Salient laboratory abnormalities
included anaemia (50%), leucocytosis (59%), thrombocytopaenia
(64%), elevated erythrocyte sedimentation rate (ESR) (55%),
hyponatremia (50%), hypokalemia (23%). Acute renal failure
occurred in 47%. Hepatic function derangement occurred in
64%. Three patients had pulmonary inﬁltrates and sputum
revealed haemosiderin laden macropahges in them. Two others
manifested exudative pleural effusion which was bilateral and
sequential in one of them. The common serovars encountered
included L. autumnalis (30%), L. hebdomadis (22%), L. grippoty-
phosa (18%), L. icterohaemorrhagiae and L. javanica (11% each),
L. australis (8%). All patients were treated with parenteral
crystalline penicillin, oral doxycycline and were managed
conservatively. Haemodialysis was required in four patients.
Two patients died, both of whom developed multiorgan system
failure.
Conclusions: Leptospirosis is an important cause of acute
febrile illness with renal, hepatic dysfunction and bleeding
abnormalities. A high index of clinical suspicion is required
conﬁrm the diagnosis early as the condition responds well to
conservative management.
P1136
Determination of FR900098, a promising
antimalarial agent, in human serum by capillary
electrophoresis for pharmacokinetic studies
S. Bronner, C. Renault, M. Hintz, J. Wiesner, H. Jomaa,
H. Monteil, F. Jehl (Strasbourg, F; Giessen, D)
The acetyl derivative of fosmidomycin, FR900098, was demon-
strated to be twice as active against Plasmodium falciparum in
vitro and in the Plasmodium vinckei mouse model. FR900098, as
fosmidomycin, is an inhibitor of 1-deoxy-D-xylulose-5-phosphate
(DOXP) reductoisomerase, an essential enzyme of the non-me-
valonate pathway of isoprenoids biosynthesis. The biosynthesis
of isoprenoids in Plasmodium is depending on this DOXP
pathway, as found in eubacteria, algae and plants, but not in
human. In plasmodium, the DOXP pathway is localised inside a
plastid like organelle, the so-called apicoplast. Here, we report on
the development of a high-performance capillary electrophoresis
(HPCE) technique for the determination of FR900098 in serum.
Various instrumental setting for migration (voltage, capillary
temperature) were tested and the buffer properties (pH values,
component molarities) were optimized. The assay was submitted
to standard quality control procedures: within-, between-days
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reproducibility, accuracy, limits of detection (LOD) and quanti-
ﬁcation (LOQ), linearity, short and long term stability. Finally, the
working buffer usedwas 14mMKH2PO4/ 56mMK2HPO4, 15%
methanol, and 0.2 mM hexadecyltrimethylammonium bromide
(HTAB). The pH was adjusted to 10.9. The electroosmotic ﬂow
was modiﬁed by the cationic ion pairing reagent, HTAB. The
assayswere linear over the large concentration range tested, from
0.25 to 100 lg/ml. The recovery of the sample pre-treatments was
higher than 100%. Good precision was obtained, with between-
days reproducibilities resulting in coefﬁcients of variation (CV%)
of 2.1, 2.0 and 3.2%, and within-days reproducibilities of 0.6, 1.8,
and 4.9% (CV%), for 100, 10, and 1 lg/ml, respectively. The LOD
was 0.25 lg/ml, and the LOQwas 0.5 lg/ml. The studies of short
and long-term stability of FR900098 in serum showed a good
stability of the molecule, at room temperature, +4C or )80C.
Moreover, FR900098was resistant to numerous cycles of freezing
and thawing. Indeed, after four freeze-thaw cycles (4 days),
94.9%, 101.0%, and 97.5% of FR900098 were recovered from the
100, 10, and 1 lg/ml samples, respectively. In conclusion, we
have developed a convenient CE technique for the determination
of FR900098 in serum which offers advantages of speed, sensi-
tivity, and accuracy. At present, the procedure is applied for
pharmacokinetic studies in an animal model of Go¨ttingen
mini-pig.
P1137
Present and future of malaria in Kahnouj
endemic area, southern Iran
H. Basseri, H. Moosakazemi (Tehran, IR)
Objective: Kahnouj district is associated with one of the malaria
regions in southeast of Iran. The anopheleine fauna does not
appear to have changed much over several decades.
Methods: Entomological studies and mosquito collection were
performed every 15 days from indoor and out door shelters.
Malaria surveillance was carried out by Health Centers, Minis-
try of Health. Microscopy was performed on out patients with
fever or suspected malaria. Malaria cases detection were mostly
performed passive and rarely actively. The positive cases were
treated with chorolquien/primaquen.
Results: In the present study ﬁve vectors species of malaria
were found in this study which had been previously recorded 3
decades ago. This district like other malaria endemic areas in
Iran has been under pressure of anti malaria programmes
including case ﬁnding and residual spraying insecticide as well
as larviciding against the vectors since 1958. Annual incidence of
malaria declined from 10.27 to 3.86 during ten years. The most
transmission occurred in October to December when the
temperature was suitable for vector activity in Kahnouj area.
Electricity was recently supplied into the rural area where most
malaria cases were found. Therefore, most houses equipped
with air conditioner and the resident keep windows close, so
they are secured from mosquitoes bites during hot season but
not in beginning of spring and autumn when temperature is
mild enough, in order to save the electricity cost, the residents
do not use air conditioners whereas they leave windows open
and no other protection against mosquito bites is provided.
Residual spraying insecticide of indoor shelters have been
stopped for ﬁve years and the most activity of antimalaria
programme set up base on case ﬁnding. Conclusion; In order to
control malaria, indoor residual spraying of insecticide would
not assist effectively, so given knowledge to people to use bed
net particularly in season people are more expose to mosquitoes
bite may be considered as an effective measure in controlling
malaria in Khanouj district. Also development in this area is
effectively pushing back malaria in near future.
P1138
Application of complementary techniques to
diagnosis of malaria
V.M. Martı´nez, A. Amor, A. Morente, N. Portocarrero,
M. Baquero, M. Subirats (Madrid, E)
Objectives: Increase in internacional travels and population
migration from endemic areas of malaria have caused a growth
in the prevalence of cases in our area. Because the diagnosis of
malaria in low parasitemia cases has signiﬁcant limitations, in
suspected samples other techniques may serve as a comple-
mentary diagnostic strategy. The aim of the present study was to
evaluate different approach to routine diagnosis of malaria.
Methods: From January 2003 until September 2004, we carry
out 147 blood samples submited from Pediatric, Tropical
Medicine and Emergency Departments of Hospital Carlos III
to our laboratory. Inclusion criteria were positive sample by
microscopy or negative sample with highly suspicious level
(negative samples with indirect sights of malaria) of patients
with epidemiological risk factors. Each sample was tested by
four diagnostic techniques: microscopical examination of thick
and thin ﬁlms with modiﬁed Field´s stain, two rapid inmunoc-
romatographic tests (OptiMAL-IT, Diamed; and NOW Malaria,
Binax) and in house multiplex PCR assay. Parasitemia levels
was determined by a semiquantitative method in thin ﬁlm.
Results: Of 105 specimens from 96 patients we found 69% of
blood samples were collected of travelers/inmigrants from
Equatorial Guinea. 21% of positive microscopy results had a
parasitemia <0.1%. Microscopy, antigen detection and PCR for
the 105 blood samples had an overall agreement of 65.71%.
Fourty two specimens were negative and twenty seven were
positive with the 4 tests. In the case of PCR-microscopy
correlation, it was 91,42% (96/105). Of seven discordant cases
2 have been treated and 5 no treatment data were collected.
Regarding agreement in species diagnosis, it was 97.6% (41/42)
for P. falciparum, 100% (2/2) for P. ovale, 50%(3/6) for P. vivax. In
three cases direct examination of thick and thin ﬁlm was
inconclusive at the species level.
Conclusions: Only direct view of parasite allows to quantify
parasitemia level aswell as asses response to treatment. Although
molecular techniques may achieve potentially elevated power
detection, thick and thin ﬁlms remain as reference method in
diagnosis of malaria. Nevertheless in selected cases molecular
techniques could be useful as complementary diagnosis.
P1139
Some ecological aspects of Anopheles stephensi
liston, the main malaria vector in an endemic
focus of malaria in Bandar Abbas district, south
of Iran
H. Ladonni, S. Moosakazemi, H. Basseri, A. Podat,
A.A. Hanaﬁ-Bojd (Tehran, IR)
Objectives: Bandar Abbas district is one of the Malaria regions
in south of Iran, Anopheles stephensi is the vector of malaria in
this area. Studies on different aspects of its ecology are essential
for establishing the diseases control programme.
Method: Following the annual report of cases of malaria from
different area of Bandar Abass district, Hormozgan provience,
an investigation on some ecological aspects of this malaria
vectors was carried out from April 2002 to December 2003.
Entomological studies and mosquitoes collection were per-
formed every 15 days from indoor and outdoor shelters as well
as breeding places with the aid of suction tube and dipper.
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Results: Entomological researches were found that ﬁve vectors
species of malaria in this study had been previously recorded 2
decades ago. Anopheles Stephensi was recognized as the main
vector of malaria in this area with two peaks, one in May and the
other in December. The most malaria transmission occurred in
June and December. The larval habitats includes draying river
bed with pools, rocky river pools, stagnant streams, slow foothill
streams, temporary pools, slow moving water with or without
vegetation.
Conclusion: Operational of insecticides for adult and larval
control, as well as surveillance of malaria cases, would not assist
effectively to control of malaria, so given another malaria control
methods as impregnation of bed nets as well as repellent
particularly in seasons that people are more expose to mosqui-
toes bite, may be considered as an effective measure in
controlling malaria in this area .
P1140
Evidence of infection in humans with West Nile
virus in Delta de l’Ebre (a wetland in the south of
Catalonia), Spain
N. Carden˜osa, D. Boﬁll, M. Oviedo, J. Alvarez, J. Zaragoza,
S. Minguell, G. Carmona, F. de Ory, C. Domingo, A. Dominguez,
A. Tenorio and the research network EVITAR (Virus Diseases
Transmitted by Arthropods and Rodents)
Objectives: The objective of this study was to evaluate the
seroprevalence of West Nile Virus (WNV) in the human
population of Delta del Ebre and to determine possible risk
factors associated to exposition to this virus transmitted by
arthropods (mostly by mosquitoes). The Delta del Ebre wetland
is a stopping-off point for birds migrating from Africa and an
area where different WNV vectors and reservoirs have been
found so is a high-risk area as regard this infection, as well as
other arthropod-borne virus infections.
Methods: A total of 952 serum samples from people living in
ﬁve different municipalities of Delta del Ebre were analysed.
IgG (suggesting past infection) and IgM (suggesting recent
infection) were determined by ELISA (Focus Technologies). 128
subjects accepted to answer an epidemiological survey. Varia-
bles surveyed were gender, age, profession, living place, time
living in the actual residence, outdoors activities, mosquitoes
bites, use of insecticides and repellents, and clinical symptoms
related to WNV infection. Statistical analysis was performed
using X2 or Fisher test. Odds ratios and their 95% conﬁdence
intervals were calculated and a p<0.05 was considered signiﬁ-
cant.
Results: Seroprevalence of WNV was 1.3% (12/952) and in one
serum Ig M antibodies were detected suggesting recent infec-
tion. No statistical differences among positive subjects were
found by any of the studied variables but the risk of past
infection in those where mosquitoes bites were more frequent
was higher (OR: 8.62 (0.44–169 Woolf correction). All positive
cases related a background of frequent mosquitoes bites. No
clinical symptoms related to WNV infection were reported by
the IgM positive subject, but he was born in the area, never been
abroad, he was frequently bitten by mosquitoes and he works
outdoors.
Conclusions: These results conﬁrm the presence of past infec-
tions by WNV or other ﬂaviviruses in people from the wetland
of Delta del Ebre in South Catalonia. The detection of one IgM
positive serum could signify the present circulation of WNV or
other ﬂaviviruses in this area. Diagnosis for these viruses should
be also considered in cases of viral meningitis and encephalitis
from this risk area.
P1141
Dengue in the Dutch Caribbean
B. Kesztyus (Willemstad, ANT)
Objectives: Dengue is a mosquito borne arboviral illness
endemic in tropical and subtropical regions. The illness is
characterized by sudden unset of fever, headache, severe
myalgia and athralgia, abdominal discomfort, rash and liver
enzyme abnormalities. In some cases it develops into Dengue
hemorrhagic fever (DHF) or even fatal Dengue Shock Syndrome
(DSS). Dengue is caused by a ﬂavivirus of which four serotyes
can be distinguished: DEN-1- 4. On the Netherlands Antilles
there have been epidemics throughout the year with peaks
during the rainy season, but no severe DHF or DSS have ever
been reported. Most of the cases occur in Curac¸ao, the biggest
island of ﬁve with a population of 130,000 and a surface of 90
square kilometers situated 50 miles offshore Venezuela. Over
the last 10 years all laboratory requests are ﬁled at the health
department and the national laboratory in Curac¸ao, the Analytic
Diagnostic Center (ADC). The purpose of this study is to
describe the incidence of Dengue infections on the Netherlands
Antilles over the last 4 years in order to create an overview of
this emerging disease and its endemic reach.
Methods: Since 2000 all serum samples of suspected cases were
tested by Dengue IgM ELISA in the acute and if available also in
the convalescent phase. If positive IgM was detected, the serum
was send to the Erasmus Medical Center Rotterdam (EMCR) in
The Netherlands for serotyping by Reverse-Transcriptase
Polymerase Chain reaction (RT-PCR). Since 2002 the laboratory
started to use the IgG and IgM ELISA (Focus). The analysis of
the data is based on the ELISA results.
Results: In the year 2000 there were 112 requests for Dengue
testing of which 21 positive. In 2001 there were 666 requests with
173 positive sera. In 2002 752 suspected sera reached the lab in
Curac¸ao of which 277 were positive. In 2003 there were 268
suspected cases of which 50 were positive. In the ﬁrst 10 month
of 2004 522 sera were tested of which 67 positive. Of the 138 sera
which were send on dry ice and )20 degree Celsius to
Rotterdam for RT-PCR, 24 could be serotyped. No Den-1 and
DEN-4 were found, 8 DEN-3 and 15 DEN-2.
Conclusion: Dengue is endemic in the Dutch Caribbean. Diag-
nostic tools as RT-PCR or serospeciﬁc ELISA are not available
yet on the islands. Serotyping of sera done The Netherlands
indicates that only DEN-2 and 3 are endemic on The Nether-
lands Antilles. No severe DHF and DSS occurred in the last 4
years.
P1142
Dengue 3 outbreak in Peru
E. Ca´ceda, J. Perez, A. Huama´n, R. Castillo, C. Guevara,
J. Olson (Lima, PE)
Objectives: Surveillance of febrile illnesses in 7 cities of Peru
provides a means of monitoring newly introduced illnesses as
well as describing their spread. Dengue (DEN) is considered the
most important arboviral disease because of the signiﬁcant
morbidity and mortality it causes worldwide. In 1990, DEN-1
was isolated during an outbreak of dengue fever among
residents of the city of Iquitos in the northeastern Amazon
region of Peru. In 1995, an outbreak was associated with the
introduction of DEN-2 in the same area. Finally, DEN-3
outbreaks occurred during 2002 in Tumbes and Loreto. Multiple
serotypes of dengue virus have circulated in Peru since 1990, but
until now, no DHF or DSS outbreaks have occurred. Although
the percentage of cases has decreased, new conﬁrmed cases
continue to present in the northern regions of our country.
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Methods: Patients with fever >38C and typical symptoms of
dengue fever were included in the study. Dengue virus
etiologies were conﬁrmed by virus isolation and/or serologic
testing.
Results: A total of 7.982 study subjects, ranging from 0 to 85
years of age were enrolled. We conﬁrmed DEN-3 in 1048
patients, 363 (35%) by virus isolation only, 402 (38%) by serology
only, and 283 (27%) by both methods. The prevalence of dengue
was 13% (1048/7982). No signiﬁcant association was found
between age and conﬁrmed cases. DEN-3 was conﬁrmed in
92(29%) of 312 patients in Tumbes, 936(15%) of 6088 in Loreto,
12(3%) of 480 in Junin, 6(1%) of 474 in Piura, and 2(2%) of 128 in
Lima. In the year 2000, DEN-3 cases comprised 1% of the total
(9/609), in 2001 it was 1% (16/1557), in 2002 it was 25% (679/
2694), in 2003 it was 8% (123/1567), and in the ﬁrst 8-months of
2004 DEN-3 accounted for 14% (221/1555).
Conclusion: Virologic cultures and serologic data have con-
ﬁrmed that DEN-3 caused and outbreak of classical dengue
fever in the northern areas of Peru (Tumbes & Loreto). Since the
detection of DEN-3 in 2000, it has spread to other areas of Peru
where it has become the predominant serotype.
P1143
Generalised cowpox infection after exposure to
infected rat
B. Ho¨nlinger, N. Romani, C.P. Czerny, R. Ho¨pﬂ,
H.P. Huemer (Innsbruck, A)
Case report: A 16 year old boy presented with fever and a
generalized exanthema at the local dermatology clinic. The
mixed appearance of pustules and umbilicated non purulent
vesicles led to the suspicion of an Orthopoxvirus infection. The
patient reported that little red dots had occurred 2 weeks earlier
at the extremities after contact with a sick pet rat. 1–2 weeks later
a generalized pustular exanthema appeared, which was associ-
ated with high fever (>39C) and a pronounced feeling of
sickness. Histologically no viral inclusion bodies were found in
pustule material but poxvirus particles were detected by ELMI
in swabs from pustule ground. Following the anamnestic
suspicion of transmission by an infected rat, which unfortu-
nately had perished soon afterwards, and the experience made
at the recent monkeypox outbreak in the USA initiated by
imported rats, one of the major aims was the exclusion of
monkeypoxvirus. This was accomplished by PCR typing, which
like ELMI had been established on occasion of the implemen-
tation of the Austrian plan for poxvirus preparedness (Pocken-
alarmplan) and despite the diagnostic means for detection of
variola vera also included the ability to discriminate between
animal Orthopoxviruses. Additionally serological diagnosis was
performed and presumably due to the protracted course of
infection cowpox speciﬁc IgG antibodies were already present at
admission with a titre of 1:800. Interestingly the humoral
immune response initially seemed to be rather cowpox speciﬁc
as there were no antibodies crossreacting with vaccinia virus
detectable in indirect immunoﬂuorescence. As an exclusive
immune reaction with one species alone would be a very rare
situation observed with orthopoxviruses we did more extensive
testing by western blot analysis. Although not exclusively
directed against cowpoxvirus antigens a very restricted reactiv-
ity of the patient serum was observed in the early course of
infection using different recombinant and virus-derived Ortho-
poxvirus antigens. This would suggest that also serological
methods might be able to give a hint towards rapid determin-
ation of Orthopoxvirus species, which certainly is also the case
with immunological antigen detection methods.
P1144
Crimean-Congo haemorrhagic fever in Eastern
Turkey: clinical features, risk factors, prognostic
factors and efﬁcacy of ribavirin therapy
Z. Ozkurt, I. Kiki, S. Erol, F. Erdem, N. Yilmaz, M. Parlak,
M. Gundogdu, M.A. Tasyaran (Erzurum, TR)
Objective: Crimean-Congo hemorrhagic fever is being epi-
demic in recent years in Turkey. We assessed the clinical
features, risk and prognostic factors of this disease, and efﬁcacy
of ribavirin therapy.
Methods: From 2002 to 2004, 60 cases (26 conﬁrmed and 34
suscepted) admitted to our hospital were included in this study.
The diagnosis was conﬁrmed with ELISA and/or RT-PCR.
Results: Age, farming, handled livestock, to be housewive,
living in rural area, bitten by tick, removing tick from animal
and living in north part of our city (Erzurum) were determined
as the risk factors for the CCHF in our region. Fever during
hospitalization, confusion, bleeding from multiple sites, pres-
ence of petechia or ecchymosis, very high levels of ALT, AST,
LHD and CK, long PTT, high INR and urea level, and severe
thrombocytopenia were poor prognostic factors. The clinical
outcome was better in ribavirin group, and white blood cell
(WBC), PLT, ALT-AST returned to normal levels in a short
period in cases with treated ribavirin (p = 0.001, 0.006, and 0.031
respectively). The need of blood and blood product was not
different between both groups. But, number of patients with
bleeding more in ribavirin group (63% vs. 36%, and p = 0.04).
Mean hospitalization duration was not different (7.7 days in
ribavirin groups vs 10.3 days in the control group). Fatality rates
were 9% (2/22) in ribavirin group vs 10.5% (4/38) in the control
(p = 0.85). Of ribavirin group, diagnosis and therapy were late
in ﬁrst case who died, and absorbsion of the oral drug did not
possible due to massive hematemesis and melana in second
case. The hospital expenditure was not different in both groups.
Conclusion: In Estern part of Turkey the risk and prognostic
factors of the disease were similar in other outbreaks of CCHF.
Ribavirin decrease recovery duration of the disease, but not
hospitalization time and expenditure. Further studies need for
evaluation of ribavirin therapy respect to need of blood or
product and mortality in CCHF.
P1145
Demographic, epidemiological and clinical data
analysis of 81 conﬁrmed cases of Crimean-Congo
haemorrhagic fever in Iran
M. Mardani, MA. Keshtkar Jahromi, K. Holakouie Naieni,
B. Haghighat (Tehran, IR)
Objectives: In order to report epidemiological, demographic and
clinical features of Crimean-Congo Hemorrhagic Fever (CCHF)
cases in Iran, we evaluated 81 conﬁrmed cases that were reported
to the ministry of health since June 1999 up to September 2001.
Methods: Conﬁrmed cases were deﬁned as those who had
signs and symptoms compatible with those of CCHF cases in
association with serological test results that were positive for
IgM and/or IgG by ELISA. Conﬁrmed cases were evaluated for
sex, age, occupation {at risk (physician, butcher or nurse) and
low risk (teacher and household worker)}, place of residence,
animal contact, human contact, clinical ﬁndings and laboratory
data such as fever, hemorrhage and thrombocytopenia.
Results: 72% (59 cases) were male. 51% (42 cases) were 33 year
old or older. 48% (39 cases) were reported from only one
province in the south of Iran (Sistan VA Balouchestan). 79% (64
cases) had history of animal contacted, but only 16% (13 cases)
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had history of contact with a human case of CCHF. 98% (80
cases) were febrile. 98% (80 cases) had hemorrhagic manifesta-
tions and 98% (80 cases) were thrombocytopenic.
Conclusion: Most CCHF cases in Iran were male, 33 year old or
older, with low risk occupation, had history of animal contact
and from a major province that borders upon Afghanistan and
Pakistan which are endemic for CCHF. Nearly all of the cases
were febrile, had hemorrhage and were thrombocytopenic. It
seems that importing infected animals from countries endemic
for CCHF may be a major risk factor for acquiring the disease in
our country. We conclude that in endemic areas, febrile illnesses
with hemorrhagic manifestations and thrombocytopenia should
be evaluated for CCHF. This project has been supported by
Infectious Diseases and Tropical Medicine Research Centre of
Shaheed Beheshti University of Medical Sciences, Tehran, Iran.
P1146
The analysis of occupational Crimean Congo
haemorrhagic fever virus, Brucella spp., and
Coxiella burnetii infections among veterinarians
in Turkey
O¨. Ergonul, H. Zeller, S. Kilic, S. Kutlu, M. Kutlu, S. Cavusoglu,
A. Gozalan, B. Esen, B. Dokuzoguz (Ankara, TR; Lyon, F; Aydin,
Tokat, TR)
Objective: To investigate the prevalence of the infections by
Crimean-Congo Hemorrhagic Fever (CCHF) virus, brucella
spp., Coxiella burnetii among veterinarians.
Methods: The study was conducted in two provinces of Turkey,
one is an endemic region both for CCHF and brucella infections,
and the other is not. The sera from veterinarians were collected
in October 2003, and tested for antibodies to CCHF virus,
Brucella spp, and Coxiella burnetii.
Results: Forty veterinerians from endemic region (Tokat), and
43 from non-endemic region (Aydin) were included. Demogra-
phic characteristics in two groups were similar, whereas
professional activities of veterinarians in non-endemic region
were more intense (p = 0.001). The CCHF IgG positivity (2.5%
vs 0%), brucella agglutination titre of >1/160 (27.5 vs 4.6%) were
more common in endemic region than non-endemic region.
Three veterinarians in Tokat had malaise, myalgia, and fever. In
multivariate analysis to detect the risk factors for serum tube
agglutination of > 160, the veterinarians living in endemic area
were found to have 7.8 times higher risk of brucella infection
than the ones living in non-endemic area (OR; 7.8, Conﬁdence
interval; 1.4–40.9, p = 0.015). The prevalence of Coxiella burnetii
serology was equal in both regions as 7%, and none of the
seropositives had complaints. The history of tick bite was
signiﬁcantly more common in the endemic region than the non-
endemic region (35% versus 12%, p = 0.011).
Conclusions: CCHF and brucellosis compose infection risks for
veterinarians in endemic region, despite the veterinarians in
endemic region perform less riskfull professional activities.
Veterinarians in CCHF endemic regions should be warned to
protect themselves against tick bites according to universal
precautions. The use of masks should be employed to prevent
inhalational transmission of brucellosis in endemic regions.
P1147
Changes in temperature and the Crimean Congo
haemorrhagic fever outbreak in Turkey
O. Ergonul, S. Akgunduz, I. Kocaman, Z. Vatansever,
V. Korten (Ankara, Istanbul, TR)
Objective: To investigate the role of the climatic factors that
could effect the activation of Hyalomma marginatum
marginatum population, and consequently the emergence of
Crimean-Congo Hemorrhagic Fever (CCHF) epidemic.
Methods: The meteorological data were obtained from three
meteorology stations (Tokat, Sivas, and Yozgat), where the
majority of the CCHF cases were reported in the last 2 years.
These 3 provinces are located at the northern parts of eastern
Anatolia and southern parts of Black sea region. Temperature
data have been observed and recorded by the Turkish State
Meteorological Service (TSMS), and were available for 70 years
in Sivas, for 40 years in Tokat, and for 60 years in Yozgat.
Meteorology stations are located at the city centres, not at the
airports. Temperature variations and trends for Turkey were
analysed by using a data set including monthly averages of
daily mean, and minimum temperatures. Annual rainfall, and
the number of days in April with the temperature of > 5C were
also included in the analysis. In order to detect homogeneity in
mean annual series, ﬁrst a homogeneity analysis was performed
by using the non-parametric Kruskal-Wallis (K-W) test. The
non-parametric Mann-Kendall (M-K) rank correlation test (13)
was used to detect any possible trend in temperature series, and
to test whether or not such trends are statistically signiﬁcant.
Statistical signiﬁcance was set as <0.05 in both K-W and M-K
tests.
Results: The monthly mean temperature and the monthly
minimum temperatures over 70 years in Sivas increased
homogenously with a signiﬁcant increasing trend (p < 0.05).
Within a smaller period, from 1990 to 2003, the daily mean
temperature in April, increased signiﬁcantly in these provinces.
The number of days with the temperature of >5 C increased
homogenously in January, February, March, and April in Sivas,
and the trend was signiﬁcant for April. A signiﬁcant increase in
yearly rainfall was detected in Tokat.
Conclusion: Recent climatic changes will inevitably coincide
with any recent epidemiological phenomena, but this does not
necessarily indicate causality. A signiﬁcant increasing trend of
temperature was detected in only one (Sivas), and rainfall in
another (Tokat), of the three provinces where a CCHF epidemic
occurred in 2002–2004. At the same time, changes in biotic
environmental factors, of the sort that could be beneﬁcial for
survival of large numbers of hyalommas, have also occurred.
P1148
Epidemiological measures of Crimean-Congo
haemorrhagic fever infection in Sistan va
Baluchestan province, Iran
K. Holakouie Naieni, S. Izadi, S. Chinikar, A. Nadim (Tehran,
Zahedan, IR)
Objectives: Since 1999, many cases of Crimean-Congo Hemorrha-
gic Fever have been reported from different parts of Iran. This
study intends to deﬁne CCHF seroprevalence, incidence rates,
and the most important risk in Sistan va Baluchestan province,
Iran.
Methods: Using cluster sampling with probability proportional
to size, 310 subjects were selected from various Zahedan and
Zabol districts in the northern part of the province. Blood
samples were drawn from consenting subjects, once at the
beginning of the study and then 6 months later. A total of 18 out
of 285 subjects who consented to give blood samples were
actually positive on IgM and IgG capture ELISA tests.
Results: The calculated seroprevalence was 6.32% (95% CI:
3.24% to 9.40%). Of the subjects who were sampled for the
second time (226 persons), only one had experienced serocon-
version. The calculated incidence rate was 0.48 (95% CI: 0.00% to
1.44%). 14 out of the 18 subjects with deﬁnitely positive IgG or
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IgM were females. In multivariate analysis, age, education, and
history of slaughtering livestock were signiﬁcantly related to the
risk of infection. History of travel to the rural areas was
inversely related to the risk of infection. Only one of the
seropositive subjects had a history of tick bite.
Conclusion: This study shows the importance of subclinical
infections in the epidemiology of this disease in Iran. It also
seems that the risk of infection for housewives is high.
Regardless of the high female to male ratio of seropositive
subjects, it appears that the epidemiologic characteristics of the
infection in this region are not so different compared to other
parts of the world.This investigation received ﬁnancial support
from the WHO’s Eastern Mediterranean Regional Ofﬁce
(EMRO), Division of communicable Diseases (DCD) and the
WHO Special Programme for Research and Training in Tropical
Diseases (TDR): The EMRO DCD/TDR Small Grants Scheme for
Operational Research in Tropical and Other Communicable
Diseases.
Fungal susceptibility testing
P1149
Antibacterial and antifungal activities of some
new acrylate complexes
M. Badea, R. Olar, D. Marinescu, V. Lazar, R. Cernat,
M. Balotescu (Bucharest, RO)
The interest in the coordination properties of acrylate acid
and its homologues was generated by the facile synthesis of
the metal-containing monomers (MCM) materials. These
compounds can be polymerised with a lot of organic
monomers leading to various metal-containing polymers.
Polymeric transformations of MCM led to a new research
ﬁeld of current interest due to the practical importance of the
obtained products which exhibit a number of unique features:
high catalytic activity, unusual magnetic, electro-physical and
biological properties.These polymers are especially appropri-
ate for biological applications (tissue engineering, implanta-
tion of medical devices, dentistry, bone repair etc.) because of
their molecular weight, compositions and architectures which
can be regulated through controlled reactions. We report here
the antibacterial and antifungal activity of new complexes of
type M(phen)(C3H3O2)2(H2O)y ((1) M: Mn, y = 0; (2) M: Ni,
y = 2;(3) M: Cu, y = 1;(4) M: Zn, y = 2; phen = phenantroline
and C3H3O2 is acrylate anion), representing the ﬁrst step
products in the synthesis of polymeric materials. The in vitro
antimicrobial testings were performed by broth microdilution
method, in order to establish the minimal inhibitory concen-
tration (MIC), against Gram-positive (Bacillus subtilis, Listeria
monocytogenes, Staphylococcus aureus), Gram-negative (Psedo-
monas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Salmon-
ella enteritidis), as well as Candida sp., using both reference
and clinical, multidrug resistant strains. Our results showed
that the tested compounds exhibited a speciﬁc antimicrobial
activity, both concerning the microbial spectrum and the MIC
value. The MICs values widely ranged between 4 mg/ml and
16 mcg/ml. All the tested compunds were highly active
against Salmonella and Listeria (MIC = 16 mcg/ml). The
compound no. (2) proved to be very active against Candida
species (MIC 16 mcg/ml). S. aureus and P. aeruginosa were
resistant to all of the metal complexes only compund no.(1)
showing intermediate activity against multidrug resistant
P. aeruginosa (MIC 64 mcg/ml). Our studies demonstrated
that the tested new acrylate complexes exhibit selective and
effective antimicrobial properties that could lead to the
selection and use of these compounds as efﬁcient antimicro-
bial agents, especially for the treatment of multidrug resistant
infections.
P1150
Voriconazole, amphotericin and ﬂuconasole
susceptibility for keratitis and endophthalmitis
fungal pathogens
I. Fedotova (Kharkov, UKR)
Objectives: Investigate in vitro efﬁcacy of voriconazole and
other antifungals.
Methods: Microbiology database was scanned and fungal iso-
lates associated with keratitis (186) and endophthalmitis (97)
were analysed for classiﬁcation and isolate frequency. The
Sensititre YeastOne microdilution antifungal susceptibility test
was used to evaluate susceptibility (MICs) of 34 common fungal
pathogens against viriconazole, amphotericin , ﬂuconazole.
Results: Fusarium species remains the most frequent corneal
fungal pathogen (57.2%). Colletotrichum species (5.4%) has
emerged as the ﬁfth most common mold in keratitis. Top yeast
isolates from cornea included Candida albicans (58.6%) and
Candida parapsilosis (36.8%). Half of the intraocular pathogens
were Candida species. Paecilomyces (3.1%) and Philophora (2.8%)
were unusual pathogens. In vitro susceptibility proﬁles were
voriconazole (100%), amphotericin (71.4%), ﬂuconazole (57,8%).
Voriconazole MIC(90) were lowest for Candida species (0.014
microg/ml) and highest for Fusarium species (1.5 lg/ml).
Reference laboratory MICs correlated 100% for yeast isolates
(0.016 lg/ml) but were fourfold higher for Fusarium species (7
lg/ml). MIC(90) for Aspergillus species was 0.4 lg/ml.
Conclusions: Candida, Fusarium, and Aspergillus species remain
frequent fungal pathogens. Voriconazole may have a role in the
therapeutic management of Candida and Aspergillus ocular
infections. Human use and animal models will determine its
use in the clinical setting.
P1151
Changes in azole susceptibility and
electrophoretic karyotype in sequential
bloodstream isolates from patients with Candida
glabrata candidaemia
J.H. Shin, D.H. Shin, S.I. Jung, B.J. Oh, D. Cho, S.J. Kee,
M.G. Shin, S.P. Suh, D.W. Ryang (Gwangju, KOR)
Objectives: C. glabrata is innately less susceptible to azole than
most other species ofCandida and it acquires azole resistance after
short-term exposure to ﬂuconazole, as recently noted in oropha-
ryngeal isolates. Since C. glabrata has emerged as a signiﬁcant
cause of candidemia, we examined the change in azole MIC and
karyotype in sequential isolates of C. glabrata during the course of
fungaemia, and its relationship to antifungal therapy.
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Methods: Serial bloodstream isolates of C. glabrata were
obtained from 15 patients with fungaemia over periods of up
to 38 days. Forty-seven C. glabrata isolates from 15 patients (6
patients who received antifungal therapy and 9 patients who
did not receive antifungal therapy) were analysed using elec-
trophoretic karyotyping (EK) and tested for antifungal suscep-
tibility to ﬂuconazole, voriconazole, and itraconazole.
Results: The overall rates of resistance to ﬂuconazole
(MIC ‡ 64 lg/mL) and itraconazole (MIC ‡ 1 lg/mL) for all 47
isolates were 8 and 50%, respectively. For most patients, the
sequential strains from each patient exhibited the same or similar
azole susceptibilities. However, sequential isolates from two
patients showed three- or four-fold increases in the MICs of all
three azole antifungals, while they retained the same karyotypes.
Azole-resistant strains were isolated from both patients after
ﬂuconazole therapy was discontinued and the intervals after the
ﬁrst blood isolation were 24 and 38 days, respectively. The isolates
from one of these patients exhibited increased expression of the
CgCDR1efﬂuxpump.The sequential strains fromeachpatient had
identical karyotypes in 10 (67%) patients, but two or four different
karyotypes in 5 (33%) patients. The sequential isolates from these
ﬁve patients exhibited the same or similar antifungal susceptibil-
ities, showed only one or two chromosome band differences, and
had no association with previous antifungal therapy.
Conclusion: This study showed that sequential bloodstream
isolates of C. glabrata were able to acquire azole resistance in
association with ﬂuconazole therapy, and that they developed
two or four different karyotypes in some patients, during the
course of fungaemia.
P1152
Antifungal susceptibility of clinical isolates of
Cryptococcus neoformans
K. Baba, A. Hoosen (Pretoria, ZA)
Crytococosis is a leading mycological cause of morbidity and
mortality among HIV/AIDS patients especially in developing
countries where anti-retroviral therapy is not easily available. In
this study clinical isolates of Cryptococcus neoformans obtained
from blood and cerebrospinal ﬂuid (CSF) cultures from patients
admitted for meningitis were tested for their in-vitro suscepti-
bility to 3 antifungal agents.A total of 50 clinical isolates
obtained from AIDS patients admitted to the George Mukhari
Hospital, Pretoria with a diagnosis of meningitis were available
for analysis. Antifungal analysis were done by microbroth
dilution (M27-A) for amphotericin B and ﬂuconazole. The E test
and the disc diffusion tests were performed for voriconazole and
ﬂuconazole. All isolates tested were fully susceptible to amph-
otericin B and voriconazole. For ﬂuconazole, two isolates were
resistant by the E test and microbroth dilution method. This has
implications for maintenance therapy for the patients who are
HIV positive and have cryptococcal meningitis. Voriconazole
may be an appropriate alternative in this group of patients. The
availability of anti-retroviral therapy may also be beneﬁcial to
this subset of patients.
P1153
Susceptibility to azoles of Cryptococcus
neoformans: pre-HAART and HAART eras
R. Claro, A.I. Aller, F. Colom, M. Ramı´rez, C. Castro,
E. Martı´n-Mazuelos (Seville, Alicante, E)
Objectives: To study the susceptibility to azoles of C. neofor-
mans isolates from HIV patients and establish possible differ-
ences between pre-HAART and HAART eras.
Methods: 76 C. neoformans isolates from HIV patients were
studied. 29 of them were obtained from patients without
HAART from 1994 to 1996; the other 47 were obtained from
patients with HAART from 1997 to 2003. The susceptibility to
ﬂuconazole, voriconazole and itraconazole of the ﬁrst group and
the susceptibility to ﬂuconazole and voriconazole of the second
one were performed by the broth microdilution method accord-
ing to the NCCLS guidelines (M27-A2 document). Fluconazole
and voriconazole were provided by Pﬁzer and itraconazole by
Janssen. Fluconazole was dissolved in sterile distilled water,
whilst voriconazole and itraconazole were dissolved in dime-
thylsulphoxide. RPMI medium (Sigma) was used for all drugs.
Inocula were adjusted to a cell density of 1 McFarland, and
microtiter plates were incubated for 72 h at 35C with agitation
(Ghannoum et al. Susceptibility testing of Cryptococcus neofor-
mans: a microdilution technique. 1992. J Clin Microb. 30, 2881–
2886). The ﬁnal concentrations were 0.12–64 mg/l for ﬂuconaz-
ole and 0.015–8 mg/l for voriconazole and itraconazole. For all
drugs, MIC values were the lowest drug concentration wich
inhibited growth by the 50% (prominent inhibition of growth)
compared with the control.
Results: The next table shows the MICs obtained for the tested
drugs. From the three isolates with voriconazole MIC > 1 mg/l,
two of them had a ﬂuconazole MIC ‡ 16 mg/l. Six isolates with
voriconazole MIC = 1 mg/l were found: the ﬂuconazole MIC
for one of them was 4 mg/l, for another four was 8 mg/l and for
the last one was 32 mg/l.
Conclusions: a. There wasn’t found any ﬂuconazole or voric-
onazole resistant isolate in the HAART era. b. The percentage
(11.84%) of isolates with voriconazole MIC ‡ 1 mg/l is higher
than it has been described in other works. c. The 75% of the
voriconazole resistant isolates were ﬂuconazole resistant too,
so a cross resistance mechanism could be implicated.
P1154
In vitro susceptibiility testing of micafungina
(fk-463) and anidulafungin (ly303366) against
candida spp.
M. Ramirez, C. Castro, E. Lopez, R. Claro, C. Martin, A. Romero,
E. Martin-Mazuelos (Seville, E)
Objectives: The incidence of invasive fungal infections has
increased in the last 20 years also have witnessed an increased
All isolates tested were C. neofermans var neoformans. The anti-
fungal susceptibility test results (according to NCCLS break-
points - M27A) were follows.
Disc Diffusion Etest Broth Dil
S SDD R S SDD R Range Mic 90
Fluconazole 46 1 3 46 2 2 0.125 ‡ 64 8
Voriconazole 50 0 0 50 0 0 0.003–0.38 0.125
Amphotericin B ND ND 0.03–0.25 0.25
Number (%) of isolates
Drug MIC (mg/l)* Pre-HAART HAART
Fluconazole ‡16 (R) 4 (13.8%) 0 (0%)
Voriconazole <16 (S) 25 (86.2%) 47 (100%)
>1(R) 3 (10.3%) 0 (0%)
Itraconazole £1(S) 26 (89.7%) 47 (100%)
>0.5 (R) 5 (17.24%) -
£0.5 (S/SDD) 24 (82.76%) -
*Arbitrary breakpoint were chosen.
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resistance to established antifungal agents. Antifungal drug
resistance is becoming a mayor problem in certain population,
especially in immunosuppressed patients. Micafungin (FK463)
and Anidulafungin LY303366 are a new echinocandins with
in vivo and in vitro antifungal activity against Candida spp.The
aim of these study was to compare the susceptibility of Candida
spp two both antifungal agents.
Methods: A total number of 219 Candida spp.(183 C.albicans, 12
C. glabrata, 11 C. krusei, 10 C. tropicalis, 3 C. parapsilosis) isolated
from different clinical specimens were included in this study.
We determined minimal inhibitory concentration (MIC) of both
antifungal agents by following the NCCLS M27 A-2 broth
microdilution method. Endpoints were deﬁned as the lowest
concentration of drug resulting in prominent inhibition (MIC80)
and total inhibition (MIC100) of visual growth compared with
the growth in the control wells containing no antifungal.
Results: The MIC90–50 determined at 48 hours and total
inhibition (MIC100) are as follows:
FK-463 LY302
Range MC50/90mcg/ml Range
(183) 0.008–1 0.01/0.25 £0.03–‡16
(12) 0.008–4 0.06/1 £0.03–0.5
(1) 0.01–0.5 0.5/0.5 £0.03–0.5
(10) 0.06–0.25 0.06/0.25 £0.03–0.12
basis (3) 2–4 2/4 £0.06–2
(219) 0.008–4 0.03/0.5 £0.03–‡16
Conclusion: These data suggest that both antifungal agents
shows a good in vitro activity against Candida spp. except
Candida parapsilosis.The value of these in vitro results as
predictors of therapeutic outcome is to be established in clinical
trials.
P1155
Synergism of micafungin with voriconazole
against clinical Aspergillus, Fusarium and
Scedosporium spp.
K. Heyn, A. Tredup, S. Salvenmoser, F.-M. Mu¨ller (Heidelberg,
D)
Objectives: The combination of Micafungin (MCF) and Voric-
onazole (VRC) against 100 clinical isolates of Aspergillus fumig-
atus, ﬂavus, niger and nidulans, Fusarium solani as well as
Scedosporium apiospermum and proliﬁcans was analysed by in
vitro checkerboard analysis. As the drugs have a different mode
of action, it can be expected that their combination may be
synergistic.
Methods: The interactions have been evaluated by in vitro
checkerboard analysis with determination of FIC indices. The
spectrophotometric reading has been performed by 50% growth
inhibition (MIC-2) using XTT colorimetric method. The in vitro
drug interactions were calculated on the basis of fractional
inhibitory concentrations (FIC) index.
Results: Synergism, was observed for 64% of all tested isolates.
80% of A. fumigatus strains showed synergism. Also for
S. proliﬁcans, a pathogen with enhancing frequency of occur-
rence, which causes various types of human infections with high
mortality rates, 75% synergistic effects were found. When
synergy was not achieved (36% of the isolates), there was still
a decrease in the MIC-2 of one or both drugs used in the
combination (indifference 0.5 > FIC index < 4). One the basis of
the single drug MIC-2s (VRC 0.35lg/ml, MCF 44.66 lg/ml) for
all ﬁlamentous fungi we observed that in combination just 32%
of VRC (0.11 lg/ml) and 7% of MCF (3.04 lg/ml) is sufﬁciently
to reach the same inhibition. Taking into account the values for
the FIC indices, the majority of all indifferent FIC indices were
close to the cut–off from synergism to indifference. To clarify
this effect, for example F. solani, the FIC index averages 0.5005.
None of the isolates yielded antagonistic effects (FIC index > 4).
We also investigated signiﬁcant reductions in the MIC50 and
MIC90 values. For VRC the MIC50 and MIC90 of all ﬁlamentous
fungi reduced from 0.125 and 0.5 lg/ml to 0.03125 and 0.25 lg/
ml and for MCF from 2 and 256 lg/ml to 0.0625 and 8 lg/ml,
respectively.
Conclusion: Combination of VRC and MCF demonstrated
synergism in the majority of the strains. This study demon-
strates that the in vitro activity of both drugs can be enhanced by
using them in combination. Their relative lack of toxicity also
makes them an attractive option as add-on therapy. Clinical
trials to investigate the effectiveness of MCF combined with
VRC are warranted.
P1156
Effect of media composition and in vitro activity
of new antifungal agents against zygomycetes
C. Gil-Lamaignere, R. Hess, S. Salvenmoser, K. Heyn, R. Kappe,
F.-M. Mu¨ller (Heidelberg, Erfurt, D)
Objectives: Despite antifungal therapy, mortality in dissemin-
ated zygomycosis is still too high. We analysed the in vitro
activity of Posaconazole (POS), Voriconazole (VRC) and Caspo-
fungin (CAS) against 59 strains of the genera Rhizopus, Mucor,
Absidia, and Cunninghamella in different media compositions.
Methods: The following ﬁve media compositions were com-
pared: RPMI 1640 ± 2% glucose, AM3 ± 2 % glucose and HR-
Medium. MICs were determined by microdilution method
following NCCLS guidelines with minor modiﬁcations. Each
well was read visually, the growth in each well was compared
with the growth control. Two endpoints were evaluated for each
drug: an inhibition of growth >90% war recorded as MIC1 and
an inhibition of growth >50% was recorded as MIC 2. The ﬁnal
concentrations of the antifungal agents were 0.015–8 mg/l for
POS and VRC, and 0.03–16 mg/l for CAS.
Results: POS was signiﬁcantly more active than CAS and VOR,
both in R + G and in HR media (P < 0.05 when comparing the
MIC1 of POS in HR medium to that of VRC; P < 0.001 for all
other comparisons). Growth in RPMI and AM3 media supple-
mented with glucose was more robust than in the corresponding
media lacking glucose. Glucose had little inﬂuence on MIC
values. The agreement when comparing the MIC1 evaluated in
AM3 ± glucose was > 85%, while the use of MIC2 endpoint
yielded 100% agreement for all genera. When comparing the
data obtained in RPMI ± glucose to that in HR, the agreement
was good. The percentage agreements using the MIC2 and MIC1
endpoints were 100% and > 70%, In contrast, the agreement
between AM3 ± glucose and the other media was generally
poor. Moreover, the average MICs obtained in AM3 medium
were lower than those obtained in either HR or RPMI which was
due to a difference among genera.
Conclusions: Our results suggest the following: a) POS is active
in vitro against zygomycetes at clinically relevant concentra-
tions. b) within zygomycetes, there are differences between
genera in terms of their antifungal susceptibilies. c) growth
medium is an important variable for MIC determination in
zygomycetes, and the more relevant medium appears to be
RPMI supplemented with 2% glucose.
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P1157
Effect of micafungin against bioﬁlm of six
different Candida spp.
M. Seidler, S. Salvenmoser, F.-M. Mu¨ller (Heidelberg, D)
Objectives: Patients with peripheral vein and implanted cath-
eters (e.g. Hickman catheters) have an increased risk for
development of candidaemia and invasive candidasis. Candida
spp. attach on polymers, create a bioﬁlm protecting the yeast
and pose a reservoir for entering the bloodstream. Candida spp.
in bioﬁlm are less susceptible to the antifungal drugs currently
in use. We investigated the in vitro antifungal activity of
Micafungin (MCF) against bioﬁlms of C. albicans, C. parapsilosis,
C. dubliniensis, C. tropicalis, C. glabrata and C. kefyr.
Methods: Bioﬁlm formation was performed in vitro on poly-
styrene 96-well plates and on Hickman catheter discs with
minor modiﬁcations to Kuhn (1). MCF was tested at six
concentrations (0.25–32 lg/ml). Measurements were done by
XTT reduction assay at 490nm, % inhibition was calculated in
comparison to the growth control. The biphasic structure of
bioﬁlms were imaged by reverse light-through microscopy.
Results: On polystyrene plates and on Hickman catheters all
Candida spp. produced intermediate bioﬁlm after 24–48h incu-
bation. At all concentrations on polystyrene plates Micafungin
reached at maximum 50% inhibition in bioﬁlm against all
Candida spp.: C. albicans (47% at 16 lg/ml), C. parapsilosis (49% at
16 lg/ml), C. dubliniensis (42% at 16 lg/ml), C. tropicalis (28% at
16 lg/ml), except for C. glabrata (73% at 8 lg/ml) and C. kefyr
(53% at 1 lg/ml). At max. concentration (16 lg/ml) on Hick-
man catheter discs Micafungin reached at maximum 80%
inhibition, except for C. glabrata (84% at 8 lg/ml).
Conclusion: Micafungin is in vitro more active against Candida
bioﬁlm on Hickman catheter discs in comparison to polystyrene
plates, but 100% inhibition cannot be reached at all. Further
investigations are required to assess combinations of different
antifungals for increased antifungal activity in bioﬁlm. Ref. 1
Kuhn DM et al. (2002) AAC 46(6):1773–80
P1158
Caspofungin resistant C. glabrata
K.J. Dodgson, A.R. Dodgson, C. Pujol, S.A. Messer, D.R. Soll,
M.A. Pfaller (Iowa City, USA; Manchester, UK)
Objectives: Here we describe ﬁrst clinical case of a caspofungin
resistant C. glabrata infection. The patient was a 43 year old male
withAML.He received amatchedunrelatedHSCT, 9 months prior
to his death. He had a complicated hospital course which included
C. glabrata sepsis. C. glabrata was cultured from his stool, from the
time of transplant to death. Initial blood culture isolates were azole
resistant andAmphotericin Bwas started. Thiswas stopped due to
renal insufﬁciency and caspofunginwas started (MIC 0.12 lg/ml).
He had a prolonged duration of therapy which comprised of
alternating courses of IV voriconazole and caspofungin. Four
months after initial fungaemia C. glabratawas cultured which was
both caspofungin resistant (MIC > 8lg/ml) and azole resistant.
Despite the addition of amphotericin B the patient died 8 weeks
later. C. glabratawas isolated from the bone marrow at autopsy.
Methods: The series of patient isolates, from time of transplant to
death, had susceptibilities performed as per NCCLS document
M27-A. The isolates were typed using Cg6 probe and MLST.
Results: he susceptibilities demonstrated caspofungin resistance
in the blood isolate ( > 8 lg/ml) and azole resistance in all but a
few of the initial stool isolates. All the isolates were shown to be
identical by Cg6 andwere determined to beMLST group 1,which
has previously been shown to be the most prevalent clade of C.
glabrataworldwide.
Discussion: This describes the ﬁrst caspofungin resistant clinical
isolate ofC. glabrata. It has been recently reported inC. albicans. This
data details an isolate that has developed resistance in the presence
of therapy.Resistance to caspofungin is not commonand is thought
to be due to mutations in the beta-1–3-glucan synthase (FKS) gene.
There are 3 FKS genes inC. glabrata. Preliminary sequencingdata of
one of these genes has so far revealed no non-conservative
mutations. The 2 remaining genes are yet to be sequenced and the
presence of other mechanisms cannot be ruled out.
P1159
Deoxycholate amphotericin B and its lipid
formulations enhance antifungal activity of
human neutrophils against hyphae of Apergillus
fumigatus and Fusarium solani
J. Dotis, M. Simitsopoulou, M. Dalakiouridou, T. Konstantinou,
T.J. Walsh, E. Roilides (Thessaloniki, GR; Bethesda, USA)
Objective: Innate immune response is critical in the antifungal
host defense against invasive aspergillosis and fusariosis, and
neutrophils (PMNs) constitute an important component of it.
We studied the effects of deoxycholate amphotericin B (DAMB)
and its lipid formulations liposomal amphotericin B (LAMB), lipid-
complex (ABLC) and colloidal-dispersion (ABCD) on antifungal
activity of human PMNs against hyphae of Aspergillus fumigatus
and Fusarium solani.
Methods: PMNs were isolated from healthy donors by dextran
sedimentation/Ficoll centrifugation. They were incubated with
no drugs, 1 or 5 mg/L DAMB and 5 or 25 mg/L LAMB, ABLC
and ABCD at 37C/5% CO2 for 2h. Hyphae of A. fumigatus and
F. solani germinated after incubation of conidial suspensions in
YNB for 17 h at 32C and 25C respectively, were added at an
effector:target (E:T) ratio 5:1 or 10:1. After 2 h, PMN-induced
hyphal damage was assessed using the XTT colorimetric assay
at 450 nm. Statistical analysis was performed using ANOVA
with Dunnett test for multiple comparisons.
Results: They are summarized in the table (*p < 0.05, **p < 0.01).
No decrease of PMN viability was induced by the drugs at the
concentrations used. All amphotericin B formulations at both
concentrations resulted in signiﬁcant increases of PMN-induced
damageofA. fumigatus hyphaeat 5:1 and10:1E:T ratios as compared
tountreatedPMNs (p < 0.01). Similar increaseswere inducedbyall
Table for 1159
% damage of A. fumigatus hyphae (n = 6)
(mg/L) DAMB LAMB ABLC ABCD
E:T ratio PMNs only 1 5 5 25 5 25 5 25
5:1 19.04 ± 2.33 58.31 ± 10.06** 86.84 ± 2.44** 43.99 ± 4.76** 68.88 ± 3.7** 65.43 ± 2.98** 77.69 ± 3.33** 62.11 ± 3.88** 75.53 ± 2.83**
10:1 23.75 ± 2.52 66.37 ± 5.79** 90.35 ± 1.18** 58.54 ± 1.69** 78.23 ± 3.48** 73.07 ± 2.89** 79.22 ± 2.33** 70.36 ± 2.9** 77.14 ± 2.05**
%damage of F. solani hyphae (n = 8)
5:1 12.18 ± 2.51 47.68 ± 5.91** 90.69 ± 2.12** 34.85 ± 4.88** 66.41 ± 3.94** 41.77 ± 5.92** 43.73 ± 5.33** 32.79 ± 5.26 47.75 ± 2.82**
10:1 22.26 ± 4.09 51.60 ± 3.38** 96.05 ± 1.96** 42.99 ± 3.37* 84.24 ± 2.72** 58.71 ± 3.52** 60.34 ± 4.83** 43.36 ± 6.96* 59.73 ± 5.91**
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amphotericin B formulations when pre-treated PMNs were
incubated with F. solani hyphae (p < 0.05), except for ABCD-
pretreated PMNs at 5 mg/L and 5:1 ratio where a tendency of
increasewas shown.DAMB5 mg/Lexerted thehighest increase in
PMN-induced hyphal damage against both fungi (p < 0.01).
Conclusion: Both deoxycholate and lipid amphotericin B for-
mulations enhance the damage induced by human PMNs on
hyphae of A. fumigatus and F. solani. DAMB appears to show the
highest enhancement among them. These immunomodulatory
effects of amphotericin B formulations on PMN antifungal
activities against the two ﬁlamentous fungi may be important in
the antifungal therapy of invasive aspergillosis and fusariosis in
immunocompromised patients.
P1160
Species distribution and antifungal susceptibility
in yeast isolated from peritoneal ﬂuid over a
period of 17 years
J. Martı´nez-Alarco´n, M.J. Goyanes, T. Pela´ez, L. Alcala´,
J.V. Guinea, M.A. Ferna´ndez-Chico, E. Bouza (Madrid, E)
Background: Yeast pathogens are uncommon isolates in the
setting of peritonitis. Most cases of fungal peritonitis due to
yeasts are caused by Candida species, although other yeasts have
occasionally been reported.
Objectives: To study the evolution of peritonitis due to yeasts,
its distribution by species and its antifungal susceptibility in our
hospital over the last 17 years.
Methods: Retrospective study for the period January 1988 to
October 2004 of all the episodes of yeast peritonitis diagnosed in
our microbiology lab. The in vitro activities of amphotericin B
(AB), ﬂuconazole (FZ), itraconazole (IZ), ketoconazole (KZ),
voriconazole (VZ), and ﬂucytosine (FC) were determined by the
broth microdilution method following NCCLS criteria.
Results: A total of 510peritoneal ﬂuids, from349 patients, showed
positive yeast growth (560 isolates). Theperitonitis rates per 100.000
patient admissions during the two periods of study were respect-
ively: 32.8 (1988–1995) and 50.6 (1996–2004) (p < 0.005). Globally,
Candida albicanswas themost frequently isolated yeast (313. 55.9%)
followed by C. glabrata (78; 13.9%), C. parapsilosis (63; 11.3%), C.
tropicalis (44. 7.9%), C. krusei (19. 3.4%) and others (43. 7.7%). The
speciesdistribution inboth theadult andpaediatric populationwas
respectively as follows: C. albicans (59.2% / 39.1%), C. glabrata
(16.5% / 1.1%), C. tropicalis (7.1% / 12%), C. parapsilosis (5.1% /
42.4%),C. krusei (4.1%/ 0%) and others (8.1%/ 5.4%).C. parapsilosis
was the specie most frequently isolated from paediatric patients
(42.4%),whereas C. albicanswas themost isolated in adult patients
(59.2%).Numberof isolates tested, andMIC90ofAB, FZ, IZ,KZ,VZ
and FC (mcg/mL) were as follows: 102 C. albicans (0.06, 0.25, 0.06,
0.016, 0.008, 0.125), 29 C. glabrata (0.125, 16, 1, 1, 0.5, 0.06), 30
C. parapsilosis (0.125, 1, 0.125, 0.125, 0.016, 0.125), 19 C. tropicalis
(0.125, 1, 0.25, 0.25, 0.06, 0.25) and 6C. krusei (0.125, 64, 0.5, 1, 0.25, 8).
Conclusions: In our hospital, peritonitis due to yeasts increased
signiﬁcantly during the study period. The species distribution
was different between the adult and paediatric population. In
adult patients, C. albicans was the most isolated species, with C.
parapsilosis as the most important in children.
P1161
Bioﬁlm production and antifungal susceptibility
patterns of Candida species isolated from
hospitalised patients
M. Demirbilek, F. Timurkaynak, F. Can, O. Kurt Azap,
H. Arslan (Ankara, TR)
Objectives: The aim of this study was to investigate the
production of slime factor among Candida species which were
isolated from hospitalized patients. Another aim of this study
was to see in vitro activities of antifungal agents and to compare
these results with slime production.
Methods: Total 116Candida spp (79 C. albicans and 37 nonalbicans
Candida spp) isolated from various specimenswere included to the
study. Fluconazole, itraconazole, amphotericin B and caspofungin
susceptibilities of these strains were determined by broth microdi-
lution method according to NCCLS M27-A2 standards. Bioﬁlm
production of Candida spp. was determined bymicroplate method
on polystyrene microtiter plates using Brain Heart Infusion broth
supplemented with 0.25% Glucose as a growth medium.
Results: Caspofungin and amphotericin B was the most active
agents which MIC90 values 1mg/ml and 0.5 mg/ml respect-
ively. Fluconazole resistance (MICs > 64) was obtained from 24
of the isolates (21%). Bioﬁlm formation was detected in 33 of the
total strains (28%). Statistically important difference (p < 0.05)
was determined between the bioﬁlm production of C. albicans
(21.5%) and nonalbicans species (%48.4). Signiﬁcant correlation
between bioﬁlm production and amphotericin B MIC values
was established (p < 0.05)
Conclusion: Candida species are one of the most important
etiologic agents of catheter related infections especially biolﬁlm
producing strains. This study showed us bioﬁlm production
rates are too high particularly in non-albicans strains. This will
explain the rising incidences of non albicans strains especially C.
parapsilosis in serious infections. Our study also implicated that
the MIC values amphotericin B which was one of the most active
agent against Candida infections had a signiﬁcant correlation
with slime production. This will be a problem in treatment of
slime producing Candida infections with this drug.
P1162
Update on susceptibility proﬁle of clinical
isolates of Scedosporium species, Spain 2004
M. Cuenca-Estrella, A. Gomez-Lopez, E. Mellado, A. Monzon,
J. Rodriguez-Tudela (Majadahonda, E)
Objectives: Scedosporium spp. are quite common as agents of
invasive mycoses at Spain. Mycology Reference Laboratory has
conducted retrospective surveillance for Scedosporium infec-
tions during last ﬁve years. We have analysed the antifungal
drug susceptibility proﬁles of these species and proportion of
resistance among the isolates.
Methods: Acollectionof 135 clinical isolateswas tested.All strains
were recovered during a period of ﬁve years (2000–2004) from 38
Spanish hospitals. Each clinical isolate represented an unique
isolate from a patient. Clinical isolates were identiﬁed by routine
procedures.Abrothmicrodilution testwasperformedby following
the NCCLS reference method, document M-38A. Antifungal drug
tested were amphotericin B (AMB), itraconazole (ITC), voriconaz-
ole (VRC), posaconazole (POS) and terbinaﬁne (TBF). Aspergillus
ﬂavus ATCC 204304 and Aspergillus fumigatus ATCC 204305 were
used as reference strains for susceptibility testing.
Results: Table displays MIC ranges, MIC geometric means
(GM), and MICs including 50% (MIC50) and 90% (MIC90) of
isolates in mg/L, classiﬁed per species:
Species (No of isolates) AMB ITC VRC POS TBF
S. apiospermum (N = 69) Range 1.0–32.0 0.5–16.0 0.12–16.0 0.25–16.0 8.0–32.0
GM 4.7 3.7 0.9 1.3 17.1
MIC50 4.0 8.0 1.0 1.0 8.0
MIC90 16.0 16 0 8.0 8.0 32.0
S. proliﬁcans (N = 66) Range 2,0–32.0 8.0–16.0 8.0–16.0 8.0–16.0 8.0–32.0
GM 12.8 9.6 9.4 10.5 19.2
MIC50 16.0 8.0 8.0 16.0 16.0
MIC90 32.0 16.0 16.0 16.0 32.0
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Conclusions: (i) Scedosporium spp. carry on with high MICs of
antifungal agents, even for new antifungal agent as POS.
(ii) S. proliﬁcans is a multi-resistant organism. (iii) S. apiosper-
mum is resistant to ITC and TBF, but 15% of strains are
susceptible in vitro to AMB (MIC < 2 mg/L), 75% to VRC
(MIC < 2 mg/L), and 60% to POS (MIC < 2 mg/L). (iv) These
ﬁndings reinforced the need of continued surveillance
programmes that analyze antifungal susceptibility proﬁles of
medically important fungal isolates.
P1163
Assessing susceptibility of fungi isolated from
hospital environment to disinfectants
M. Staniszewska, B. Tadeusiak, W. Kurztkowski, B. Jakimiak,
E. Rohm-Rodowald (Warsaw, PL)
Objectives: The hospital infection control including prevention
and killing of environmental pathogenic microorganisms with
the application of properly designed disinfecting procedures
and adequate chemical disinfectants, belongs to basic duties of
hospital management. In this study the sensitivity of yeasts and
dermatophytes to disinfectants was determined. Two agents
were assayed through out the study as following: I (99% sodium
dichloroisocyanurate: 1.5 g active chlorine in tablet); II (9.5 %
glutaraldehyde, 7.5% glyoxal, 9.6 % didecylodimethylammoni-
um chloride). Seventeen clinical strains of Candida albicans and
Epidermophyton ﬂoccosum, Microsporum canis, Trichophyton
rubrum, Trichophyton mentagrophytes, Scopulariopsis spp. were
used.
Methods: Phase I – qualitative suspension test method
(National Institute of Hygiene, Poland) was used. Antifungal
activity on C. albicans and dermatophytes was evaluated by
determination of the MIC. Observation of the inhibition or
destruction of invasive form development and spores were
studied with the use of phase – contrast microscopic techniques.
Phase II – carrier test methods: qualitative (NIH) and quantita-
tive European Standard EN 13697 were applied.
Results: MIC values assessed in this study were independent of
places where the disinfectants were applied. Noticeable inhibi-
tion of the growth of dermatophytes was observed with MIC
values ranging (mg/l): I–100 to 120; II – 0.012 to 0.02. In case of
C. albicans MIC values ranging (mg/l): I–140 to 160; II–0.0005 to
0.012 were obtained. The comparison of fungal suspension
treated with chemical agents and control suspension at direct
microscopic count showed signiﬁcant reduction of the amount
of cells. The investigation of the second phase showed the
activity of disinfectants: I (1000 mg/l, 15 min) and II (1% and
2%, 15 min) to fungal pathogens. Disinfectants in used param-
eters showed activity to fungi in the place of application.
Conclusion: Those studies revealed that investigated strains
showed different susceptibility to disinfectants. Strains of
Candida albicans demonstrated signiﬁcantly higher resistance to
chlorine compounds than dermatophytes but more sensitivity to
aldehydes. Using proper disinfectant in clinical environment is
an essential tool in eradication of fungal infection.
Skin and soft tissue infections
P1164
Bacteriologic efﬁcacy of meropenem versus
imipenem-cilastatin for the treatment of patients
with complicated skin and skin structure
infections
J. Iaconis, N. Soto, P.J. Turner (Waltham, Wilmington, USA;
Macclesﬁeld, UK)
Objectives: In a recent multicentre, double-blind study, the
broad-spectrum carbapenem, meropenem (MEM), had compar-
able efﬁcacy to imipenem-cilastatin (IPM) in patients with
complicated skin and skin structure infections (cSSSI). This
study presents the clinical and bacterial response rates for MEM
and IPM in the subgroup of microbiologically documented
infections.
Methods: This multicentre, randomized, double-blind study
compared MEM with IPM (both 500 mg IV every 8 hours) in
patients hospitalized with cSSSI. The primary efﬁcacy endpoints
were clinical and bacteriological responses at follow-up in the
fully evaluable (FE) patient population (all patients meeting
eligibility criteria and who had an identiﬁed pathogen prior to
treatment). Subgroup analysis was conducted in patients with
polymicrobial infections.
Results: Of the 1037 patients enrolled and treated in the trial,
440 comprised the FE population. Of all the pretreatment
pathogens isolated, the majority were aerobic Gram-positive
organisms (827/1444; 57%) followed by aerobic Gram-negative
organisms (378/1444; 26%) and anaerobic organisms (239/1444;
17%). Polymicrobial infections were seen in 38% of all docu-
mented infection. Gram-positive pathogens included 402
Staphylococcus aureus isolates, (284 methicillin-susceptible [S;
100% to MEM and IPM], 118 methicillin-resistant [excluded
from FE analyses]), Streptococcus pyogenes (n = 89, 100% S to
MEM and IPM), S. agalactiae (n = 59; 100% S to MEM and IPM),
and E. faecalis (n = 52; 82% S toMEMand 100% S to IPM). Aerobic
Gram-negative and anaerobic organisms included Escherichia coli
(n = 64, 100% S toMEM and IPM), Proteus spp. (n = 52; 100% S to
MEM and IPM), Pseudomonas aeruginosa (n = 53; 94% S to MEM
and 92% S to IPM), Bacteroides spp. (n = 74; 97% S to MEM and
100% S to IPM), and Peptostreptococcus spp. (n = 63; 100% S to
MEM and IPM). Satisfactory clinical (cure or improvement)
response rates were 88.5% (MEM) and 83.1% (IPM) in the FE
group, and 87.3% (MEM) and 81.2% (IPM) in patients with
polymicrobial infections; bacteriological (documented or pre-
sumed eradication, colonization) response rates were 79.4%
(MEM) and 79.2% (IPM) in the FE group, and 78.5% (MEM) and
72.9% (IPM) in the polymicrobial infection group.
Conclusion: In patients with cSSSI and documented infection
(including polymicrobial infections), MEM (500 mg IV every
8 hours) had comparable clinical and bacteriological efﬁcacy to
IPM (500 mg IV every 8 hours).
P1165
Molecular typing of Hungarian Streptococcus
pyogenes isolates
B. Krucso´, K. Csisza´r, M. Gacs, J. Pa´szti (Budapest, Salgo´tarja´n,
HUN)
Objectives: The aim of the authors was the examination of the
genetic relatedness of the Hungarian Streptococcus pyogenes
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clinical isolates by emm amplicon characterisation and PFGE
analysis, as well as the determination of the prevalent emm
types among the strains originated from different infections.
Methods: From 2003 to 2004 40 S. pyogenes strains were isolated
from two Hungarian counties. Out of the isolates, 15 originated
from respiratory, 17 from superﬁcial pyogen, and 8 from
invasive infections, like Streptococcal shock syndrome (STSS),
meningitis and sepsis. emm gene detection and restriction
analysis of the emm amplicon (with HincII and HaeIII; DdeI
enzymes) was performed in all strains.The sequence of the emm
amplicon from all invasive isolates and from one strain of all
RFLP groups was determined, and macrorestriction chromoso-
mal analysis by PFGE (Pulsed Field Gel Electrophoresis) method
for these isolates was also performed.
Results: As a result of the restriction analysis of the emm
amplicons 17 restriction patterns were differentiated. Most emm
types were standard types: emm 1.0, emm12.0, emm 28.0,
emm59.0, emm66.0, emm75.0, emm76.0, emm77.0, emm 80.0,
emm 81.1, emm84.0, emm110.1, emm118.0, plus one new allelic
variant (emm 110.2) was identiﬁed. Moreover, two GAS strains
had a type (stg6 and stg485) previously found in group G
streptococci. The emm types varied among the isolates originated
from different sources. The next emm types were identiﬁed
among the invasive isolates: emm 1.0, emm 28.0, emm 66.0, emm
80.0, emm 81.1, emm84.0, stg6. Some emm type could be further
differentiated into several PFGE genotypes, and within a PFGE
genotype different emm types could be observed.
Conclusions: This report provides epidemiological information
from a geographic area has not been examined by emm
characterisation. PFGE and emm type analysis showed high
genetic diversity among the 40 GAS strains. The most frequent
emm types were emm1.0, emm28.0, emm 81.1 and emm84.0 in
the two counties.
P1166
Molecular characterisation of group A
streptococci from invasive disease episodes in
Poland
K. Szczypa, E. Sadowy, R. Izdebski, L. Strakova,
W. Hryniewicz (Warsaw, PL; Prague, CZ)
Objectives: The past decade has witnessed a worldwide
increase in serve invasive GAS infections. These rapidly pro-
gressive infections are associated with high mortality rates
despite prompt antimicrobial therapy. The aim of this study was
to characterize GAS isolates causing severe invasive disease in
different regions of Poland by emm-typing, multilocus sequence
typing (MLST), PFGE, virulence genes distribution and their
susceptibility to antimicrobial agents.
Methods: A total of 42 GAS isolates from blood (54.7%), pus
(33.3%), sputum (7.1%), peritoneum ﬂuid (4.7%) and other
sources were examined. Susceptibility to penicillin, erythromy-
cin, clindamycin, telithromycin, tetracycline, levoﬂoxacin, chlo-
ramphenicol, quinupristin/dalfopristin and linezolid was
determined by the microdilution method according to the
NCCLS guidelines. Clonality of all isolates was studied by
emm typing, PFGE of Sma I-restricted bacterial DNA as well as
MLST. The strains were also tested for the presence of speA,
speB, speC, speF and ssa genes by PCR.
Results: Resistance to erythromycin was found in four isolates
(9.5%), two of them exhibited the iMLSB and two the cMLSB
phenotype. Twenty-one (50%) and ﬁve (11.9%) were resistant to
tetracycline and chloramphenicol, respectively. All tested isolates
were fully susceptible to penicillin, levoﬂoxacin, quinupristin/
dalfopristin and linezolid. Twenty different emm types were
detected, of which emm1 (23.8%) and emm12 (21.4%) were most
common, followed by emm85, emm60 and emm81. All emm1
types and emm12 types corresponded to the ST28 and ST36,
respectively. Altogether, 24 different PFGE patterns, designated
A–Y were discerned among the isolates, with two predominant
proﬁles A (n = 10) and B (n = 9). Our study showed that all
isolates possessed speB and speF genes, while the frequencies of
speC and speA were 59.5% and 26%, respectively.
Conclusion: Two clones predominated among GAS strains
causing severe invasive disease in Poland; these clones were
of emm type 1 and 12.
P1167
Characterisation of methicillin-resistant
Staphylococci in Ulaanbaatar, Mongolia
D. Orth, K. Grif, L. Erdenichemeg, B. Strommenger, C. Cuny,
G. Walder, C. Lass-Flo¨rl, M.P. Dierich, W. Witte (Innsbruck, A;
Ulaanbaatar, MNG; Wernigerode, D)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA)
has become one of the most prevalent nosocomial pathogen
throughout the world, capable of causing a wide range of
hospital infections. This study was aimed to characterize the
Mongolian MRSA by antibiotic susceptibility patterns and
molecular genotyping.
Methods: Strains of S. aureus were collected from various sites
of patients from four different medium-sized university hospi-
tals of Ulaanbaatar city (Mongolia), in 2000–2002. The study
included two hundred seven strains of S. aureus. Susceptibility
testing was performed by disk diffusion according to National
Committee for Clinical Laboratory Standards guidelines. All
strains were screened by polymerase chain reaction for the
presence of the mecA gene. Molecular genotyping was per-
formed using automated ribotyping with EcoRI as restriction
enzyme and PFGE with SmaI as restriction enzyme.
Results: Among the 207 S. aureus 6 isolates (2.9%) were positive
for the mecA gene by PCR. All of the 6 MRSA strains were
resistant to oxacillin, susceptible to amikacin, vancomycin,
teicoplanin, fucidic acid and rifampicin. Only one isolate was
intermediate-resistant to gentamicin, tobramycin and trimetho-
prim-sulfamethoxazole. Three of the 6 MRSA strains were
intermediate resistant to ciproﬂoxacin. Five of the 6 isolates were
resistant to erythromycin and all were resistant to tetracycline
and chloramphenicol. Three of the 6 MRSA isolates were of
MLST St 154, possessed a SCC-mec element of type IV c and the
determinant for Panton-Valentine Leukocidin (lukS-lukF). The
remaining 3 MRSA isolates exhibited MLST ST 239, contained a
SCC-mec element of type III and were lukS-lukF negative.
Automated ribotyping as well as PFGE divided the 6 MRSA
strains into 4 different types, three strains showed unique
patterns using both typing methods.
Conclusion: The limited use of antibiotics in Mongolia is
assumed to be the reason for the low rate of MRSA found in
Mongolian hospitals and for their susceptibility against most
antibiotics. Molecular typing indicates that on one hand
oldMRSA (ST 239) are still prevailing in Mongolia and that a
cMRSA until now described for Sweden had been spread to
Mongolia (ST 154).
P1168
First report of Staphylococcus aureus with
reduced susceptibility to vancomycin (VISA) in
Denmark
A. Sandberg, A. Bolmstro¨m, R. Skov (Copenhagen, DK; Solna, S)
Objective: Are VISA / hVISA isolates present among MRSA
isolates in Denmark?
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Methods: All MRSA isolates in Denmark are referred to the
Staphylococcus reference laboratory at Statens Serum Institute.
From January 1st 2003 to October 31st 2004 a total of 576 isolates
were screened by the Etest macromethod for VISA/hVISA. i.e.
each isolate was plated on Brain Heart Infusion agar (BHI,
Difco) using a McFarland 2.0 inoculum, vancomycin (VA) and
teicoplanin (TP), Etest was applied and the isolates were
incubated for 48 h in ambient air (Walsh et al, JCM, 2001). VA
and TP MIC > 6 mg/L or TP MIC > 8 mg/L was used as the
screen interpretive criteria for hVISA/VISA phenotype. Screen
positive isolates were veriﬁed by population analysis proﬁles
(PAP) using BHI with 0, 0.5, 1, 2, 2.5, 4, 8 and 16 mg/L VA.
These isolates were also MIC tested by the standard Etest
method, and NCCLS broth microdilution (BMD). Agar screen
with 4 and 6 mg/L VA and betalactam+VA antagonism for
ampicillin, cefoxitin, cefaclor, cefo-taxime, ceftazidime and
imipenem using Etest on BHI plate ± VA 2 mg/L was also
done. Presence of the vanA and vanB gene was investigated by
PCR.
Results: 15 potential hVISA/VISA isolates were found by the
Etest macro-method. Four isolates had hVISA and one had VISA
phenotype by PAP and none of them were positive for the vanA
and vanB gene. The betalactam+VA antagonism test was
positive for all four isolates. Agar screen, BMD and standard
Etest did not reliably detect the hVISA isolates. Four patients
acquired the isolates outside Denmark and it appears that cross
infection occurred in Denmark in the ﬁfth case.
Conclusion: This is the ﬁrst report of VISA and hVISA isolates
in Scandinavia. Standard MIC methods including the NCCLS
reference do not reliably detect these isolates and specialised
VISA/hVISA phenotypic tests are necessary. Etest macrometh-
od was easy to perform and efﬁciently detected the VISA/
hVISA strains. In one hVISA case, there is evidence for cross
infection in Denmark.
P1169
Actinomyces spp.: a disregarded pathogen?
S. Palombarani, M. Almuzara, K. Bombicino, H. Rodriguez,
E. Bertona, A. Famiglietti, C. Vay (Buenos Aires, RA)
We present 45 Actinomyces spp isolations, their identiﬁcation to a
species level and their clinical sources. In addition, we perform
susceptibility testing of 23 of those strains to 13 drugs. The
identiﬁcation of Actinomyces spp was done taking into account
their cultural features, growths atmosphere and biochemical
and enzimatical tests, according to schemes proposed by
Sarkonen N., Funke G., Moncla B.,Hillier S., and Bernard K.
We studied too, the clinical sources of Actinomyces spp, if they
were isolated lonely or in association with mucosa’s normal
ﬂora. The susceptibility testing was performed by the agar
dilution method, with Mueller Hinton agar supplemented with
5% sheep blood. The reading of minimum inhibitory concen-
tration (MICs) were done after 48 hours incubation at 37C in at
atmosphere enriched with CO2. All strains were grown at 37C
on sheep blood agar plates with CO2 added. A. radingae,
A. europaeus, and A. odontolyticus were the most frequent
isolated species ( 7 each one) followed by A. israelii, A.
graevenitzii, A. turicensis and A. viscosus. In 27 isolations,
Actinomyces spp were recovered as sole microorganism, and in
the 18 remainder, in association with mucosa’s normal ﬂora.
There were not relations between Actinomyces species and the
clinical sources of the samples. MICs for penicilin, ampicilin and
cefotaxime were from <0.016 to 0.25 lg/ml. There was a
bimodal behaviour with macrolides : erythromycin, azithromy-
cin and clarithromycin (MICs from 0.032 to 128 lg/ml) and the
same was observed with quinolones: levoﬂoxacin, ciproﬂoxacin
and moxiﬂoxacin (MICs from 0.032 to 8 lg/ml). All isolations
presented MICs for vancomycin <0.125 lg/ml. The identiﬁca-
tion of the Actinomyces genus presents diagnostic difﬁculties due
to its growth requirements. Some species are not so infrequent,
and the sources from which they are recovered suggest that they
may be of clinical relevance, for they are often isolated as sole
pathogen.
P1170
Isotretinoin versus tetracycline: a comparative
study with regard to efﬁciency in the treatment of
acne vulgaris
C. Oprica, L. Emtestam, C.E. Nord (Stockholm, S)
Tetracyclines are most commonly used for treatment of moder-
ate and severe inﬂammatory acne, and systemically adminis-
tered isotretinoin has proved to be the most efﬁcient treatment,
used in patients with moderate or severe acne that fails to
respond to other therapies.
Objectives: A randomized clinical trial was conducted to
compare the clinical efﬁcacy and the antimicrobial susceptibility
of Propionibacterium acnes strains isolated before, during and
after treatment with either tetracycline or isotretinoin in patients
with acne vulgaris.
Methods: 52 male and female patients, 15–35 years of age, with
moderate or severe acne, were randomized into two groups of
26 patients each. They received oral tetracycline hydrochloride
1 gram/day together with topical retinoid (differine gel 0.1%) or
isotretinoin (Roaccutane) 1 mg/kg/day. The therapy was given
for a 6-month period. Clinical evaluation (Leeds acne grading
system and lesions counting) and bacterial samples were taken
before the treatment started, during the treatment and 2 months
after the treatment had stopped. Dermatology Life Quality
Index questionnaire was completed by patients before and after
treatment, in order to determine impairment of life quality.
Results: Acne severity was signiﬁcantly reduced by both regi-
mens during therapy, and patients in the isotretinoin group
continuously improved the acne scores after the treatment had
stopped. After 6 months of treatment, isotretinoin produced
greater lesion reductions than tetracycline. The mean per cent
reduction in the different lesion counts was as follows: 83%
versus 45% for non-inﬂammatory lesions (p < 0.01) and 80%
versus 56% for inﬂammatory lesions (p < 0.01) in isotretinoin or
tetracycline group, respectively. In the drug-free period, the
group of patients treated with isotretinoin presented signiﬁ-
cantly less inﬂammatory lesions compared to the group treated
with tetracycline (p < 0.001). Both treatments had improved the
life quality (p < 0.01), independent of acne severity. Resistant
P. acnes strains were isolated after treatment in both the
tetracycline group (53%) and isotretinoin group (25%).
Conclusions: Both treatments were effective during treatment
period. More resistant strains were recovered from the tetracyc-
line group.
P1171
Psoas abscesses. Differences between pyogenic
and tuberculous abscess
F.J. Ferna´ndez-Ferna´ndez, J. de la Fuente-Aguado, S. Pe´rez-
Ferna´ndez, L. Va´zquez-Tun˜as, B. Sopen˜a-Pe´rez Argu¨elles,
C. Martı´nez-Va´zquez (Vigo, E)
Objectives: To compare the demographic characteristics, clin-
ical features, laboratory, microbiologic and imaging data, thera-
peutic options and outcome of pyogenic and tuberculous psoas
abscesses.
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Patients and methods: Retrospective descriptive study of the
medical records of the patients diagnosed of psoas abscess in
our institution, in the period between January/1994 and
october/2004.
Results: In this period 14 patients were diagnosed of psoas
abscess, all of them secondary to a adjacent source of infection.
Nine patients had pyogenic abscess, and M. tuberculosis was the
causal microorganism in 5 patients. In 3 patients there were
bilateral involvement, and all three were tuberculous abscess.
An underlying disease was present in 67% patients of pyogenic
abscess, and only in 20% of tuberculous abscess. These one were
malignancy, intravenous drug use, cirrhosis, use of steroids, and
3 with inﬂammatory bowel disease. Patients with tuberculous
abscess were younger (37 vs 49 years), and they presented with
a longer duration of symptoms from presentation to diagnosis
(145 vs 15 days) than patients with pyogenic abscess. Abdom-
inal pain was the most frequent symptom at diagnosis in
pyogenic abscess (78%), whereas lumbar pain (80%) was in
tuberculous abscess. Other clinical manifestations were similar
in both groups. The source of infection in pyogenic abscess was
gastrointestinal in 7 patients (4 polymicrobial), and in 1 patient
infection of an aortobifemoral bypass and sacroilitis (both
caused by S. aureus). All tuberculous abscess were secondary
to spondilitis. There were no differences between both groups in
analysis or imaging alterations. Culture of the abscess was
positive in all cases practised. Drainage was performed in 12
patients (7 percutaneous), without differences in both groups.
Clinical improvement was more delayed in patients with
tuberculous abscess than in patients with pyogenic abscess (18
vs 10 days). There were no deaths in any group.
Conclusions: Tuberculous psoas abscesses presents in younger
patients with lesser underlying diseases and a more prolonged
clinical presentation than pyogenic abscesses. These tuberculous
abscesses are secondary to spondilitis, usually with bilateral
involvement.
P1172
Prevalence of micro-organisms isolated from
wounds of inpatients versus outpatients in a
Spanish teaching hospital
E. Garcı´a-Pen˜uela, A. Pe´rez de Ayala, D. Domingo, E. Aznar,
T. Alarco´n, M. Lo´pez-Brea (Madrid, E)
Objective: To study the prevalence of microorganisms isolated
from wounds of in-patients and out-patients (emergency,
consultation and primary care) in a Spanish University Hospital
of 500 beds.
Methods: Descriptive retrospective study performed from in-
formatics data obtained in the Microbiology Department of
Hospital de la Princesa during January 2000 to December 2003.
Culture, isolation, identiﬁcation and susceptibility were per-
formed following standard recommendations.
Results: The total number of wounds during this period was
3753. From these, 1981 were obtained from in-patients, being
positives 1510 (76.22%) resulting a total of 2154 microorganisms.
Polimicrobian infection was detected in 543 samples. The
specimens of out-patients were 1772, being positives 1328
(74.9%) resulting a total of 1762 microorganisms. In 470 samples
more than one microorganisms were detected. Frequency of
isolation from in-patient and out-patient were as follows:
Staphylococcus aureus (18.1% and 27%), Escherichia coli (13.13%
and 7.71%) and Pseudomonas sp. (8.45% and 10%) respectively
(p < 0.05). Less frequent microorganisms isolated were Entero-
coccus faecalis (7.28% and 2.78%), Streptococcus sp. (3.94% and
7.38%), fungi (2.36% and 1.3%) and anaerobes (1.3% and 0.79%)
from in-patients and out-patients, respectively.
Conclusions: Positive rates of wounds cultures were similar in
both groups.
- Staphylococcus aureus was the most prevalent microorganism,
being most frequent in out-patients.
- Among enterobacteria Escherichia coli was the most frequent,
followed by Proteus mirabilis.
P1173
Vitamin E as an adjuvant for the therapy of
patients with hidradenitis suppurativa
A. Antonopoulou, M. Mouktaroudi, M. Kyriakopoulou,
M. Raftogiannis, F. Baziaka, D. Plachouras, H. Giamarellou,
E.J. Giamarellos-Bourboulis (Athens, GR)
Objectives: Hidradenitis suppurativa (HD) is a chronic disor-
der characterized from dilatation of sweat glands and recurrent
bacterial infections. Vitamin E was administered in several
patients as an antioxidant in an attempt to relieve tissue function
probably altered by the locally increased oxidant status.
Methods: Twenty nine patients with HD, 15 male and 19
female, were enrolled over a period of twelve months. All have
presented with more than three episodes of bacterial exacerba-
tions for at least two years. A detailed medical history was taken
upon ﬁrst evaluation and patients were examined for areas
affected by the disease. They were asked to self-evaluate the
severity of their condition on a scale of 1 to 10 (1 representing
intact skin and 10 maximum severity). Patients were divided
into three groups of treatment: A (n = 6), controls; B (N = 8),
vitamin E orally 200 mg bid; and C (N = 15), vitamin E 200 mg
tid orally. Patients were withhold from any antimicrobial
regime. Patients were followed-up at three-month intervals;
they were asked to re-evaluate their condition, and to provide
details regarding frequency of relapses before and after the
initiation of treatment.
Results: Mean ± SE duration of the disease was 11.7 ± 1.9)
years and of involved areas 3.84 ± 035, with axillas and groin
being involved in the majority of cases. Mean interval between
exacerbations before initiation of therapy with vitamin E was
33.98 ± 9.43 days and after initiation of therapy
91.35 ± 21.64 days (p: 0.042). For group B, mean ± SE time
interval between exacerbations before initiation of treatment
was 45.00 ± 27.39 days and after initiation of treatment
69.00 ± 38.42 days. For group C, respective values were
36.30 ± 9.42 days and 132 ± 12 days. Mean ± SE of self-evalua-
tion scores before therapy with vitamin E was 9.00 ± 0.71 and
4.33 ± 1.76 for patients of groups B and C respectively. They
were 4.75 ± 1.31 and 2.75 ± 1.55 respectively after twelve
months of follow-up. The latter changes constituted a signiﬁcant
improvement (p: 0.027).
Conclusion: Vitamin E seems to improve the overall clinical
condition of patients with HD substantially. Further placebo-
controlled studies are necessary to conﬁrm these results.
P1174
Clonal diversity and toxin genes of
Staphylococcus aureus causing infections in a
clinical ward over a 12-year period (1992–2003)
S. Pollini, G. Zanelli, A. Sansoni, S. Cresti, C. Cellesi,
G.M. Rossolini (Siena, I)
Objectives: S. aureus remains one of the leading bacterial
pathogens worldwide, representing a major challenge for
antimicrobial chemotherapy. The aim of this study was to
evaluate the molecular epidemiology of S. aureus infections
observed in an Infectious Disease ward during the past 12 years.
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Methods: 38 nonreplicate S. aureus isolates were collected from
patients with staphylococcal infections (including food-borne
infections, osteomyelitis, skin and soft tissue infections [SSTI],
pneumonia, meningitis and bacteraemia/endocarditis; mostly
community-acquired) at the Infectious Diseases Clinic, Univer-
sity of Siena, during the period 1st Feb 1992–31st March 2003.
All isolates were analysed for antimicrobial resistance, clonal
diversity and toxin genes (sea-e, eta-d, tst, lukS-PV and lukF-
PV). Susceptibility testing was performed according to the
NCCLS guidelines. Clonal diversity was determined by PFGE
and by analysis of the coagulase (coa) and protein A (spa) genes
polymorphism. Toxin genes were analysed by PCR and restric-
tion mapping.
Results: Most isolates (35, 92%) were methicillin-susceptible
(MSSA), while 2 were methicillin-resistant (MRSA, mecA-
positive) and 1 borderline. Genotyping revealed a single
MRSA clone and remarkable clonal diversity among the MSSA
isolates (at least 20 distinct clonal lineages). Several clones
(including 6 MSSA and the MRSA clone) were detected over
prolonged times (2–8 years). The most prevalent clone was
detected over a 8-year period and was exclusively associated
with SSTI (mostly bullous impetigo). Toxin genes were overall
detected in 87% of isolates, the most frequent being sea (45%), tst
(32%) and eta and/or etb genes (29%). Six isolates (all MSSA)
harboured the lukS-PV and lukF-PV genes.
Conclusions: MRSA were rare and appeared only since 1997.
Signiﬁcant clonal diversity was observed within MSSA. A
signiﬁcant relationship was observed between toxin production
and some infections (e.g. SSTI).
P1175
Severe group A streptococcal infections in
Romania. A surveillance within the Strep-EURO
project
B. Luca, M. Straut, V. Ungureanu, C. Schalen, A. Jasir On behalf
of the Strep-EURO study group
Objectives: In the last 20 years, severe invasive streptococcal
infections, often afﬂicting otherwise healthy subjects and yield-
ing high mortality rates, have been increasingly recorded in
Europe and other areas. Our main objective was to investigate
the situation in Romania lacking earlier data in the ﬁeld.
Methods: The strains used in this study were clinical isolates
from nine regions in Romania. The strains were mainly blood
isolates, but some were from other sterile sites. The in vitro
susceptibility to antibiotics was tested by disk diffusion on PDM
agar following the standard instruction. T-typing was per-
formed by slide agglutination using sera from Sevapharma,
Prague. Spe gene detection and emm sequence typing was
performed according to provious publications.
Results: During eighteen months 33 cases were reported. Most
prevalent T-type was 3,13 followed by types 12 and 1. More than
ﬁfteen different emm types were recognised, most of them
unusual types; only four were type 1. Half of the reported cases
were from children below 12 years. Out of all strains, 50%
harboured speC gene, and 25 harboured speA. Erythromycin
resistance was uncommon (one isolate), whereas an overall high
rate of tetracycline resistance was found (54%).
Conclusion: This is the ﬁrst report on severe invasive strepto-
coccal infections since no surveillance has been previously done
in Romania. The population covered was from eight out of 42
provinces. The emm type distribution might be of concern since
many unusual types, not previously associated with severe
disease, were found. This may be partly related to the dissem-
ination of new types in populations immune to classical types.
Since tetracycline is not used in the treatment of streptococcal
infections the level of tetracycline resistance among clinical
isolates, appeared comparatively high. In contrast to several
European countries, macrolide resistance seems not to be
common among invasive group A streptococci in Romania.
Acknowledgment: The Strep-EURO project is funded by the
European Commission.
P1176
Severe soft tissue infection and secondary
bacteraemia due to community-acquired MRSA
in a traveller returning from the Congo
R. Padmanabhan, R. Shrestha, G. Hall, S. Gordon,
L. Saravolatz (Cleveland, Detroit, USA)
Objectives: Community acquired MRSA is increasingly becom-
ing a global problem. These isolates possess the Staphylococcal
cassette chromosome (SCC) mec type IV in their genome and a
different pattern of antibiotic susceptibilities than hospital
acquired strains. They are frequently virulent and cause pre-
dominantly skin and soft tissue infections by virtue of a Panton
Valentine Leukocidin (PVL) toxin gene. A returning traveler,
who had spent the preceding four weeks in Congo, presented
with a staphylococcal bacteraemia and a large cutaneous ulcer of
the right lower extremity that progressed to extensive soft tissue
necrosis. He ﬁrst experienced symptoms in Kinshasa Interna-
tional Airport, while awaiting his return ﬂight to the United
States, approximately 48 hours prior to presentation at our
facility.
Methods: MRSA that was isolated from blood was susceptible
to vancomycin, clindamycin, erythromycin, tetracycline, trim-
ethoprim-sulfamethoxazole and gentamicin. Pulse Field Gel
Electrophoresis (PFGE) analysis was performed using Sma1 on
the patient’s isolate along with another strain from our hospital
and compared to other strains isolated from the Midwestern
United States. PCR ampliﬁcation of the genes encoding Panton–
Valentin Leukocidin (PVL) was performed using primers
described elsewhere.
Results: PFGE demonstrated that the Congo strain was differ-
ent from any of the other Midwestern United States strains. SCC
mec typing of this isolate revealed that this strain was type IV.
PCR analysis did not detect sequences speciﬁc for the PVL gene.
Conclusions: The differential diagnosis of an ulcer in a return-
ing traveler is large and includes bacterial, fungal, helminthic,
protozoal, viral and arthropod borne causes. MRSA should be
added to this list. The widespread occurrence of CA-MRSA in
many parts of the world would support the ﬁnding of this
organism on the African continent. To our knowledge, this
represents the ﬁrst CA-MRSA with the SCC type IV mec gene
reported from Congo.
P1177
Ten-year of community-acquired methicillin-
resistant Staphylococcus aureus ST80-IV clone
in Denmark
A.R. Larsen, R.V. Goering, L.V. Pallesen, R. Skov (Copenhagen,
DK; Omaha, USA)
Objectives: To determine the epidemiology in Denmark of the
pandemic European CA-MRSA clone ST80-IV with respect to
subtypes, dissemination, acquisition and types of infection.
Methods: All methicillin resistant Staphylococcus aureus (MRSA)
isolated in Denmark between 1999–2003 were referred to and
stored at the Staphylococcus Laboratory, Statens Serum Institut
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(N = 617). The isolates were characterized by macro-restriction
(SmaI) analysis using PFGE, SCCmec typing, dru sequence
typing, antibiotic susceptibility testing and PCR ampliﬁcation of
the Panton Valentine Leukocidin gene (pvl). Clinical and
epidemiological information from all patients were obtained
from discharge summaries and registered.
Results: Between 1999 and 2003, the MRSA ST80-IV clone
accounted for 28% (172/617) of the total number of MRSA in
Denmark and 30% (146/490) of Infections due to ST80-IV had
primarily community onset (122/146) and thereby ST80-IV
accounted for 67% of all community onset MRSA in the period.
More than 80% of the ST80-IV infections were skin and soft
tissue infections. By comparing the antibiogram of ST80-IV
(streptomycin-, kanamycin-, tetra-cycline- and fusidic acid -
resistant and gentamicin sensitive) with the isolates stored in
our S. aureus bacteraemia collection, we traced the ST80-IV clone
back to 1993. Before 1999 one to ﬁve ST80-IV isolates were
encountered pr. year, which increased to 25, 26, 50, 26 and 45
isolates in the years after. By PFGE, the ST80-IV isolates
exhibited nine different patterns (A1–9), of which 60% were
type A1. Nine Type A1 isolates, isolated 1993–2003 were
subjected to dru typing, which has earlier enabled separation
of PFGE clones into subtypes. This was however not possible for
the ST80-IV isolates.
Conclusions: ST80-IV isolates cause a large proportion of the
MRSA infections in Denmark and in particular among the
infections with a community onset. The success of ST80-IV as an
infective clone outside the hospital environment may in part be
due to its small SCCmec type IV and its ability to cause skin and
soft tissue infections probably associated with the expression of
PVL. The dru sequence typing could not subdivide the major
type of ST80-IV found in Denmark pointing out the strict
clonality of this clone, which may indicate that it is a very well
adapted pathogen.
P1178
Epidemiology and management of pressure
ulcers in an acute care hospital
F. Barbut, B. Parzybut, R. Farid, D. Neyme, M. Kosmann,
L. Luquel (Paris, F)
Objectives: The aims of the study were to determine pressure
ulcer prevalence in an acute care hospital, to identify risk
factors, to evaluate the medical and non medical management of
pressure ulcers and to study the microbiological contamination
of pressure ulcers.
Methods: For each patient, a standardized questionnaire was
completed. The questionnaire included demographic data (age,
sex, previous hospitalizations…) and the risk factors of the
Braden scale. Detection of pressure ulcer was performed by skin
examination of patients by two experts in skin care. Manage-
ment of ulcer pressure was evaluated by reviewing the clinical
charts of each patient with pressure ulcer. Each pressure ulcer
was swabbed and inoculated on selective media. All the data
were entered and analysed with EpiInfo 6.04d (CDC, Atlanta,
Ga).
Results: A total of 549 patients (59 ± 19 years old) were
included : 75 ulcer pressures were observed in 37 patients
(prevalence = 6.9%). Heel anckle was the most frequent local-
ization (40%), followed by sacrum (20%), elbow (11%), spinous
processes (7%) and ischial tuberosities (7%). Pressure ulcers
were stage I (24%), stage II (29%), stage III (31%) and stage IV
(16%). Eighty percents of pressure ulcers were acquired within
the hospital. Using univariate analysis, risk factors signiﬁcantly
associated with pressure ulcer were : Braden cutoff < 15
(OR = 6.56, p < 0.0001), neurological disorders (OR = 2.30,
p = 0.009), previous ulcer pressures (OR = 6.36, p < 0.0001),
and hospitalization in an intensive care unit (p = 0.0003).
Among the criteria used for Braden scale, humidity, activity,
motility, nutrition friction and shear were signiﬁcantly asso-
ciated with ulcer pressures (p < 0.05). Among the 75 pressure
ulcers, 9.3% were diagnosed only by the experts in skin care and
83.8% were treated. Treatment was considered inappropriate in
31.5% (mostly in stage I and III) according to the French
guidelines. Microbiological results showed that 24.5 % of ulcer
pressures, mostly from stage III and IV were colonized with
multiple resistant bacteria (i.e. methicillin resistant Staphylococ-
cus aureus, extended spectrum beta-lactamase Enterobacteria-
ceae).
Conclusion: This prospective prevalence study led to a better
awareness of patients at risk for pressure ulcer. This surveillance
also contributed to a better knowledge of the mobile unit of
geriatrics recently created within the hospital.
P1179
Suction drainage culture in the management of
musculoskeletal infection
L. Legout, R. Stern, M. Assal, P. Rohner, P. Hoffmeyer,
L. Bernard Osteomyelitis Study Group
Background: Following surgery for a musculoskeletal infection
(MI), a positive suction drainage culture (SDC) is consistent with
persistent sepsis and an unfavorable evolution in the majority of
cases. The objective of this study was to determine the effect of a
negative SDC obtained in a subsequent operation or repeated
operations on the outcome of MI.
Methods: One hundred patients treated surgically for MI
utilizing suction drainage for 24–48 hours postoperative and
appropriate antimicrobial therapy were enrolled in this pros-
pective study. Surgical treatment consisted of the routine
practice developed for the treatment of MI, consisting of
drainage of purulent material, de´bridement, and prosthetic
exchange or implant removal. The accumulated drainage ﬂuid
in the reservoir was cultured. SDC was considered negative if all
bottles resulted in negative cultures. Patients were placed into
one of three possible MI treatment groups according to the SDC
results identiﬁed after the ﬁrst surgical procedure, as follows:
(I) Patients with a negative SDC and no new operation was
performed; (II) Patients with a positive SDC and a new
operation(s) was performed until the SDC was negative; and
(III) Patients with a positive SDC and there was no new
operation. The duration of antibiotic therapy for those with
osteomyelitis ranged from 6 to 12 weeks, while others with MI
(soft tissue infection) were treated for 10–21 days.
Results: The 3 groups were similar with regards to gender, age,
underlying conditions, MI, bacterial organism, surgery, and
antibiotic therapy. The majority of patients (84%) had osteomy-
elitis in the presence of an implant. At ﬁnal review, a cure was
obtained in 90% of patients (45 of 50) in group I, 87% of patients
(20 of 23) in group 2, and 44% of patients (4 of 9) in group 3.
Conclusion: A negative SDC following MI surgery is a strong
indication as to the eventual outcome of the infectious process.
P1180
Microbial aetiology of osteomyelitis of the foot in
diabetic patients
L. Legout, M. Assal, R. Stern, P. Rohner, P. Hoffmeyer,
L. Bernard (Geneva, CH)
Foot infections in diabetic patients (pts) are often accompagnied
by osteomyelitis and they are the leading cause of diabetes-
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related hospitalization and lower-extremity amputation.Acute
infections in pts who have not recently received antibiotic
therapy are predominantly caused by aerobic gram-positive
cocci, often as a monomicrobial infection. Although chronic
wounds tend to develop polymicrobial ﬂora.
Objective: To know the microbial etiology of osteomyelitis of
the foot in diabetic pts, to determine the best choice empirical
antibiotics combination.
Methods: Diabetic pts with osteomyelitis of the foot admitted in
our unit between 2002 and 2004 were included. The infection
was documented with intraoperative samples and osteomyelitis
was histolopathologically prouved. Clinical and biological data
were collected.
Results: 87 diabetics pts (64 males, 23 females) with a median
age 65 years(23–94) were included.The co-morbidities were
chronic renal failure (n = 35), arteriopathy (n = 34), obesity
(n = 13), alcoholism (n = 10), immunodepression (n = 10). The
clinical data were fever (40%), shock (2%), local signs as
erythema (90%), ﬁstula (86%), necrosis (43%) and foul odor
(54%). The median rates of neutrophils polynuclear, C-reactive
protein and erythrocyte sedimentation were respectively
9.7 G/L, 131 mg/l, 82 mm. 59 pts (68%) had a polymicrobial
infection.The intra-operative samples (n = 87) yieled a majority
of gram positive cocci [MSSA:n = 30;MRSA:n = 15; CNS:n = 15;
Streptococcus sp:n = 34; Enterococcus sp: n = 15], following with
gram negative bacteria [ Pseudomonas sp: n = 12; Proteus sp:
n = 11;Morganella sp: n = 11; E. coli: n = 8; Klebsiella sp: n = 6; E.
cloacae: n = 6; Citrobacter sp: n = 4; Serratia sp: n = 3, others:
n = 3] and anaerobes (n = 17). 10 pts had positive blood
samples. S. aureus is the most frequent pathogen isolated
especially in monomicrobial infections and infections with
positive blood samples. Pseudomonas spp. seems to be correlated
with chronic renal failure and immunodepression. No clinical
data was signiﬁcantly associated with a special bacteria , except
necrosis and foul odor with gram negative bacteria or anaerobes.
Conclusion: Our results are according with clinical studies in
the literature. The major difﬁculty to treat osteomyelitis of
diabetics foot is to well documented the infection. Selecting an
appropriate antibiotic to treat is particularly important because
of the prolonged duration of therapy required and potential
resistance of pathogens.
P1181
The duration of hospitalisation (length of stay) in
patients hospitalised with complicated skin and
skin structure infections: identifying clinical and
microbiologic risk factors in a comparison of
tigecycline with vancomycin/aztreonam
R. Mallick, S. Solomon (Collegeville, USA)
Objectives: Despite therapeutic advances in the treatment of
complicated skin and skin structure infections (cSSSI), pro-
longed hospital stays are a major cost driver and highlight the
need for expanded broad-spectrum therapies that enable faster
cure and discharge.
Methods: We pooled data from 2 double-blind, randomized,
multinational clinical studies in patients with cSSSI. Patients
were randomly assigned to receive tigecycline (100-mg dose,
then 50 mg twice daily [BID]) or vancomycin with aztreonam
(1 g vancomycin + 2 g aztreonam BID) administered intraven-
ously for 5 to 14 days. Formal test of cure was assessed at least
12 days after antibiotic termination (which was based on clinical
assessments). Length of stay (LOS) reﬂects comorbidities and
disease severity as well as therapy duration. We used a Cox
proportional hazard (CPH) model adjusting for potential clinical
and microbiologic risk factors, to evaluate LOS.
Results: Among the 1116 modiﬁed intent-to-treat patients, the
most common infection diagnoses at baseline were cellulitis
(58.9%) and major abscess (27.9%). The most common underly-
ing etiologies were spontaneous infection (52.3%) and trauma
(27.6%). About 20.2% of patients had diabetes; 6.9% had
peripheral vascular disease. Staphylococcus aureus was the most
common causative pathogen (about 50% of patients) among 540
patients with conﬁrmed microbiology and complete hospital-
ization data. However, about 18% of patients had a gram-
negative causative pathogen, primarily Escherichia coli. About
half the patients were polymicrobial. Overall, there were no
differences between the treatment groups in LOS (p = 0.794).
The estimated CPH model identiﬁed diabetes, trauma, a gram-
negative causative pathogen, absence of cure, use of concomit-
ant medications, infected ulcer, ICU and non-US hospital setting
for treatment initiation as risk factors for signiﬁcantly higher
LOS. Adjusting for all of these factors, treatment with tigecycline
was associated with faster discharge (hazard ratio = 1.22;
p = 0.019 [~1 day shorter LOS]). This difference was almost
entirely attributable to the subgroup of patients in which the
causative pathogen was gram-negative.
Conclusions: Diabetes, gram-negative pathogen, and infected
ulcers are risk factors for prolonged LOS. Tigecycline, the ﬁrst
glycylcycline antibiotic, was associated with shorter LOS in
those patients with a primary gram-negative pathogen, consis-
tent with its expanded broad-spectrum activity.
P1182
Global variations in infection diagnoses,
aetiologies, co-morbidities, and causative
microbiology in hospitalised patients with
complicated skin and skin structure infections:
evidence from a pooled clinical database
R. Mallick, S. Solomon (Collegeville, USA)
Objectives: Given heterogeneous clinical presentation of com-
plicated skin and skin structure infections (cSSSI), we used a
large multinational, pooled clinical database to examine global
differences in etiologies, comorbidities, infection subtypes, and
causative pathogen distributions.
Methods: Data were pooled from 2 double-blind, randomized,
multinational clinical trials for patients with cSSSI treated with
tigecycline (100-mg dose, then 50 mg twice a day [BID]) or
vancomycin with aztreonam (1 g vancomycin + 2 g aztreonam,
BID) administered intravenously for 5 to 14 days. We compared
key baseline clinical and microbiological characteristics across
regions: United States (US), Canada, Europe, Latin America,
Asia, South Africa and Australia using the chi-square test of
proportions.
Results: Among 1,116 modiﬁed intent-to-treat patients with
cSSSI, regions varied by subdiagnoses, etiologies and co-morbi-
dities (p < 0.0001). Although deep/extensive cellulitis was the
most common sub-diagnosis overall (~59%), it was most
common in South Africa (91%); major abscess was the most
common cSSSI subdiagnosis in the US (46%). Spontaneous
infections were the most common etiology overall (52%),
reported most commonly in Asia (69%); trauma (28%) was the
2nd most common, reported most commonly in South Africa
(40%). About 20% of all patients presenting with cSSSI had
diabetes; this proportion was highest in Asia and Canada (~34%
each) and in the US (~30%). Among 540 patients with conﬁrmed
microbiology, Staphylococcus aureus was the most common
causative pathogen but varied signiﬁcantly in prevalence
across regions (about 50% of patients overall, 82% in the US,
67 to 68% in Europe and Asia, and 39% in South Africa). About
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42% of patients had polymicrobial infections. About 18% had a
gram-negative causative pathogen, mostly Escherichia coli.
Gram-negative causative pathogen prevalence was greatest in
Asia (39%).
Conclusions: This analysis showed signiﬁcant global variations
in cSSSI subdiagnoses, etiologies, comorbidities and causative
pathogens. Consistent with ﬁndings of the SENTRY Antimicro-
bial Surveillance Program, S. aureus was identiﬁed as the
predominant pathogen in cSSSI, especially in the US. Gram-
negative pathogens were also identiﬁed as causative in a
substantial proportion of complicated skin infections. These
ﬁndings may offer guidance in selecting effective empiric
therapy, especially regarding newer agents with expanded
broad-spectrum activity.
P1183
A novel approach for evaluating the
microbiological efﬁcacy of tigecycline in patients
with complicated skin and skin-structure
infections
A. Meagher, P. Ambrose, J. Passarell, B. Cirincione,
T. Babinchak, E.J. Ellis-Grosse (Buffalo, Albany, Collegeville, USA)
Objectives: Tigecycline (T) is a glycylcycline in development
for the treatment of patients (pts) with serious infections,
including complicated skin and skin-structure infections
(cSSSI). While cSSSI can be caused by a mixture of Gram-
positive and -negative bacteria, Staphylococcus aureus and strep-
tococci are the predominant pathogens. Previous analyses
combining all pathogens have failed to identify an exposure-
response (ER) relationship. A method was developed to create
more homogenous pt populations for the microbiological (M)
ER analysis of T in the treatment of cSSSI.
Methods: Pts from 3 cSSSI clinical trials (one Phase 2 & two
Phase 3) with T pharmacokinetic data and classiﬁed as both
clinically and M evaluable, were pooled for analysis. Pts
received 100 mg loading dose (LD)/50 mg q12h (100/50) or
50 mg LD/25 mg q12h (50/25). At the test of cure visit, M
(eradication or persistence) response was evaluated. Indeter-
minate responses were excluded. Non pathogenic baseline
isolates were excluded. Five homogeneous pt cohorts (C) were
created based on baseline pathogens: S. aureus only (C1);
S. aureus or streptococci (C2); 2 Gram-positive pathogens (C3);
polymicrobial (C4); other monomicrobial infections (C5). Pros-
pective step-wise procedures for combining C to increase
sample size were used. Logistic regression was used to evaluate
steady-state 24 hr area under the concentration-time curve
(AUC) to MIC ratio (AUC/MIC) to predict response.
Results: The dataset included 58 pts with 88 observations. C1
(n = 20) and C2 (n = 9) could not be evaluated due to small
sample size. Analysis began with pooled C2 + C3. Continuous
AUC/MIC ratio was marginally signiﬁcant (p = 0.1130); a pt
was 5.1% more likely to have successful response for every one-
unit increase in AUC/MIC. Adding C4, including pathogens
with MIC values up to 16 mcg/mL, decreased AUC/MIC,
added cures to the lower end of the distribution, and added
signiﬁcant noise to the analysis. Adding C5 increased sample
size and further decreased the ability to detect a relationship.
Conclusion: Analysis of all pathogens combined could not
identify an ER relationship. Polymicrobial infections with Gram-
negative and anaerobic pathogens, associated with high MIC
values, added noise to the analysis and decreased the predictive
capability of the model. The approach of creating homogenous
populations based on two key pathogens in cSSSI, S. aureus and
streptococci, was critical for identifying signiﬁcant ER relation-
ships.
P1184
Exposure-response analysis of the efﬁcacy of
tigecycline in patients with complicated skin and
skin-structure infections
A. Meagher, J. Passarell, B. Cirincione, S. Van Wart, K. Liolios,
T. Babinchak, E.J. Ellis-Grosse, P. Ambrose (Buffalo, Collegeville,
Albany, USA)
Objectives: Tigecycline (T), the ﬁrst glycylcycline to reach
clinical trials, is in development for the treatment of patients
(pts) with serious infections, including complicated skin and
skin-structure infections (cSSSI). Pharmacokinetic-pharmacody-
namic (PK-PD) relationships, including pt covariates, for micro-
biological (M) & clinical (C) efﬁcacy of T were evaluated in pts
with cSSSI.
Methods: Pts from 3 cSSSI clinical trials (one Phase 2 & two
Phase 3), with PK data and classiﬁed as both C & M evaluable,
were pooled for analysis. Only those pts with infections due to
Staphylococcus aureus and/or streptococci, the predominant
pathogens in cSSSI, were prospectively evaluated. Pts received
100 mg loading dose (LD)/50 mg q12h (100/50) or 50 mg LD/
25 mg q12h (50/25). At the test of cure visit, M (eradication or
persistence) & C (cure or failure) outcomes were assessed.
Indeterminate responses were excluded. Steady-state 24 hr area
under the concentration-time curve (AUC) and AUC/MIC ratio
were evaluated as predictors of response. Pt covariates included:
age, weight, country, baseline Pseudomonas aeruginosa or anaer-
obes, & comorbidities (diabetes, peripheral vascular disease).
Classiﬁcation and regression tree (CART) analyses determined
AUC/MIC breakpoints (BP). Logistic regression (one observa-
tion/pt) was performed to determine predictors of efﬁcacy.
Results: The dataset included 35 pts with 40 S. aureus and/or
streptococcal baseline pathogens. MIC values ranged from 0.06
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to 0.5 mcg/mL. Clinical cure was achieved in 30 (85.7%) pts and
35 (87.5%) pathogens were successfully eradicated. The median
AUC/MICratiowas13.5 and29 for the 25 and50 mgdosegroups,
respectively. Covariates were not signiﬁcant predictors of efﬁc-
acy. CART identiﬁed a signiﬁcant AUC/MIC BP of 12.5
(p = 0.0177 for M and 0.0341 for C). The continuous AUC/MIC
ratio was marginally signiﬁcant based on sample size (p = 0.0563
for M & 0.1960 for C) and was deemed the most informative
model. For each unit increase in AUC/MIC, within the observed
range, pts were 3.7% more likely to have a successful C response
and 17.1% more likely to have a successful M response.
Conclusion: Pts with AUC/MIC ratios ‡12.5 were 13.5 times
more likely to have successful M response. At the median AUC/
MIC ratio of 13.5 & 29 for the 50/25 & 100/50 dose groups, the
model-predicted probability of C success was 0.66 & 0.96,
respectively. T is likely to be an important treatment option for
cSSSI.
P1185
Streptococcus pneumoniae spinal infection
L. Cuadra, E. Calbo, R. Pallare´s, J.M. Aguado, E. Pe´rez-Trallero,
M. Xercavins, J. Garau (Terrassa, Barcelona, Madrid,
San Sebastian, E)
Introduction: Vertebral osteomyelitis and/or sacroiliitis due to
Streptococcus pneumoniae are extremely rare. Although it is one of
the most common pathogen isolated in blood cultures, there are
only about 30 cases reported in the literature. In the main series
of vertebral osteomyelitis (VO) SPSI represents less than 1% of
cases (1/587).
Material and methods: We report 6 cases of spinal infection
due to S. pneumoniae (5 VO and 1 SI with psoas abscess) seen
between 1999 and 2004 at 4 different acute care hospitals.
Results: The 6 cases reported were part of a total of 1227
episodes of pneumococcal bacteraemia (0.48%).Mean age of the
patients was 57.1 years (range 37–82); there were 4 men. Alcohol
abuse 2/6, immunosupression 2/6 and smoking 4/6 were the
most common comorbilities. Blood cultures were positive in all
cases, epidural pus and vertebral biopsy were also positive in 3/
6. All strains were susceptible to penicillin. Diagnoses were
made by MRI in 4 and CT scanning 2. All patients recived
betalactam agents during a mean of seven weeks (3.8–10.7) in
monotherapy (cefotaxime 4/6, ampicillin 1/6) or in combination
(with vancomicin+gentamicin in 1 case). One case needed
surgery, because of progression of a psoas abscess. Other foci
were found in three cases (psoas and paravertebral abscesses
and acromio-clavicular arthritis).
Conclusions: SPSI is a rare presentation of invasive pneumo-
coccal disease. Underlying disease is comnmon and other
territories are frequently involved. Infective endocarditis must
be ruled out. Its course appears to be benign. Beta-lactam
antibiotics are a good option, and surgery is occasionally
indicated for progressive disease despite appropriate antimi-
crobial therapy.
P1186
Lumbar spine spondylitis due to Staphylococcus
schleiferi following coronary angioplasty:
isolation of the pathogen in peripheral blood
cultures
A. Karakolios, C. Karagiannidou, T. Kallinikidis, F. Markou,
V. Kontos, G. Tsinopoulos (Serres, GR)
A 70-year old man presented with acute, severe lower back pain
3 weeks after having been subjected to coronary angioplasty for
ischaemic heart disease. He was treated with NSAIDs but not
antibiotics without any improvement. CT scan of the lumbar
spine showed changes in L5-S1 vertebrae that were consistent
with spondylitis. MRI imaging, as well as conﬁrming spondy-
litis at L5-S1, it also revealed the presence of a left paravertebral
abscess. On admission to hospital, low grade fever was
documented. Clinical examination of the lower limbs was
normal. Staphylococcus schleiferi, sensitive to several antibiot-
ics, was isolated from 3 sets of blood cultures taken from both
arms. Initially, Ciproﬂoxacin 200 mg bd IV was administered for
4 weeks. Despite continuous clinical improvement, MRI ima-
ging 8 weeks after the commencement of antibiotic treatment
showed no improvement of the radiological ﬁndings. Thus,
Levoﬂoxacin 500 mg bd p.o. Rifampicin 300 mg bd p.o. were
given for further 16 weeks. At the end of the treatment, the
patient was symptom-free, resumed full activity and MRI
imaging showed considerable improvement. Multiple blood
cultures taken from both arms at different time points can help
isolate pathogens causing spondylitis averting thus the need for
difﬁcult, interventional sampling of the focus of infection.
P1187
Diabetes and use of topical ocular antibiotics: a
population-based case-control study
A.K. Hansen, R.W. Thomsen, H.H. Hundborg, L.L. Knudsen,
H.C. Schønheyder (Aalborg, Aarhus, DK)
Objectives: We conducted this population-based case-control
study to examine whether patients with diabetes mellitus have
an increased relative risk of being treated with topical ocular
antibiotics, as compared with population controls.
Methods: Incident cases were deﬁned as 24,559 individuals
who redeemed a prescription for a topical ocular antibiotic in
1999 in North Jutland County, Denmark. Ten gender- and age-
matched population controls per case were selected, using a
unique personal identiﬁer. Diabetes prior to the topical ocular
antibiotic prescription was determined by record-linkage with
the County Prescription Database and Hospital Discharge
Registry. We did conditional logistic regression to estimate
odds ratios (ORs) for ocular antibiotic use among diabetic
individuals and population controls, with adjustment for a
range of comorbid diseases.
Results: Among individuals treated with topical ocular antibi-
otics, 2.5% had diabetes as compared with 2.0% among control
subjects. The overall adjusted OR for use of ocular antibiotics in
diabetic individuals was 1.24 (95% conﬁdence interval [CI]:
1.13–1.35). Stratiﬁed analyses showed that children between 3
and 15 years with diabetes had a 60% increased relative risk for
ocular antibiotic use, whereas the effect of diabetes as a risk
factor was low in individuals over 65 years and in those with
presence of other diseases.
Conclusions: These results suggest that diabetes is a risk factor
for the use of topical ocular antibiotics, especially in younger
individuals.
P1188
Bacterial pathogens and their antibiotic
susceptibility in infectious conjunctivitis in
general practice
R.P. Rietveld, J.H. Sloos, P.J.E. Bindels,
H.C.P.M. van Weert (Amsterdam, Alkmaar, NL)
Objectives: Determination of bacterial species and their sus-
ceptibility to antibiotics in infectious conjunctivitis in general
practice.
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Methods: 179 patients suspected of having infectious conjunc-
tivitis were included from 25 general care centres in the
Netherlands. From both eyes a swab was taken and pathogens
found in the bacterial cultures were tested for their susceptibility
using the Etest for chloramphenicol, fusidic acid, trimethoprim,
ciproﬂoxacin, and gentamicin (MICs according to Dutch
national criteria).
Results: 80/220 affected eyes were culture positive. Streptococ-
cus pneumoniae (n = 55) was the most predominant pathogen,
followed by Haemophilus inﬂuenzae (n = 19), and Staphylococcus
aureus (n = 18). Only for chloramphenicol and ciproﬂoxacin the
MIC90s were in the susceptible or intermediate susceptible
range for all three pathogens, whereas this was not the case for
the other antibiotics tested, of which at least one MIC90 was in
the resistant range.
Conclusion: In only one thirdth of the patients suspected of
infectious conjunctivis in general practice a bacterial pathogen
was found. Although the prescription of antibiotics can be
debated on the basis of our results, chloramphenicol and
ciproﬂoxacin seems to be superior above fusidic acid, trimeth-
oprim, and gentamicin.
P1189
Investigation of the aetiology of a trachoma-like
condition in a rural population in Guangxi
province, PRC
P. Cho, M.V. Boost, W. Ng (Hong Kong, HK)
Objectives: To determine the presence of trachoma in primary
school children of the Zhuang and Yiao ethnic minority groups
in Du¡an county in Guangxi, China.
Method: Primary school children were examined using a slit
lamp and several were noted to display follicular/papillary
conjunctivitis suggestive of trachoma. To conﬁrm the etiology of
the condition, children were examined on a follow-up visit. For
each subject, after examination with the slit lamp, the upper lid
was everted after the application of a topical anesthetic (Nove-
sin), and a dacron swab was passed along the upper tarsal
lengthwise four times. Strict aseptic precautions were employed
to prevent cross-contamination during sample collection. Swabs
were placed in DNA-free tubes, transported to Hong Kong, and
tested using the Roche Amplicor kits for detection of Chlamydia
trachomatis following the manufacturer¡s instructions. Twenty
children displayed signiﬁcant conjunctival signs and photo-
graphs of the everted upper lids were taken to determine if these
visual signs correlated with presence of trachoma as conﬁrmed
by PCR.
Results: Sixty-ﬁve of 120 primary school students were willing
to be tested, and 29% of these were positive for trachoma by
PCR. Comparison of photographs and PCR result indicated that
not all children who showed signs of conjunctivitis were positive
for trachoma. In addition, some children whose eyelids dis-
played milder form for conjunctivitis were positive by PCR. No
obvious corneal involvement was observed for these children.
Conclusions: It was conﬁrmed that hyper-epidemic levels of
trachoma can be found among ethnic minority children in Du¡an
county. This may be related to the poor hygiene standards and
the scarcity of water in this limestone region. PCR was not
positive for all children showing signs of follicular/papillary
conjunctivitis, which may indicate that some cases were in a
dormant stage. It is also possible that failure to detect the
organism was due to sampling error or delay in PCR analysis.
Nevertheless, the high level of infection is a cause for concern as
trachoma remains one of the leading causes of blindness, and
further investigation and treatment are warranted.
P1190
Clinical and epidemiological considerations
about anthrax in Constanta county, Romania
S. Rugina, I.M. Dumitru, C.N. Rugina, E. Dumea, E. Basca
(Constanta, RO)
Introduction: Anthrax is by primarily a disease of herbivores
but humans can become infected as they come into contact with
infected animals or their products.
Objective: To study the cases of human anthrax diagnosed in
the last twelve years and their characteristics: epidemiology,
clinical forms and evolution.
Material and method: It is a retrospective study on a period of
twelve years performed in Infectious Diseases Clinical Hospital.
The diagnosis was based by smear, and culture of vesicular ﬂuid
or CSF.
Results: During this period ﬁfteen cases of anthrax in humans
were identiﬁed. The repartition of cases according to sex groups
revealed a high predominance of male cases (13 cases). The
disease was most prevalent in 35–44 age group and after 55–
years old (6 cases), although anthrax can be observed between
15 years and 65 years. In all cases anthrax was occupational
disease and the provenience of patients was rural area. The
annual incidence of anthrax was characterized by a low value
and irregular frequency of the disease. The most cases were in
1994 (6 cases) and 2004 (5 cases). According to the seasonal
repartition, anthrax was most prevalent in the summer months
(11 cases). The most frequent clinical form of anthrax was the
cutaneous anthrax (14 cases), and only one patient achieved
anthrax meningitis. Under speciﬁc treatment with penicillin G,
all the patients with cutaneous anthrax recovery complete, only
the patient with anthrax meningitis died.
Conclusions: In Constantza County, anthrax remained sporadic
in the last years. After a free period (2001–2003) 5 cases of
coutaneous anthrax were registered in 2004. A good cooperation
between veterinary and physicians and individual awareness of
the materials is the key to prevention of anthrax.
P1191
Microbiological characteristics of anthrax strains
L. Lukhnova, G. Temiraliyeva, T. Meka-Mechenko, Y. Pazylov,
S. Zakaryan, J. Denissov (Almaty, KAZ)
Objectives: The Kazakh Science Center for Quarantine and
Zoonotic Diseases (KSCQZD) has a collection of pathogens of
especially dangerous infections that have been isolated in
Kazakhstan. By Kazakh government resolution, the KSCQZD’s
collection is the ofﬁcial collection of pathogenic bacteria for
Kazakhstan. KSCQZD has 71 strains of B. anthracis that were
isolated in various years (1952–2004).
Methods: We studied the biological properties of 30 anthrax
strains from our collection: 16 from humans, 4 from soil, 5 from
sheepskins, 2 from sheep organs, and 3 from the external
environment. We tested the anthrax strains using standard
identiﬁcation tests.
Results: The growth of the Bacillus anthracis strains on the
Hottinger’s agar was typical (R – form), and no distinctions
based on the origin of the strains were noted. All of the strains
form spores and are immobile. When stained with speciﬁc
antibody directed toward anthrax antigens, all strains stained
positive. Three of the B. anthracis strains did not have capsules
when originally studied, but after 7 cultures on the Hottinger’s
agar, the strains’ ability to form capsules in a CO2 atmosphere
was restored. The anthrax strains are sensitive to anthrax
bacteriophage and penicillin. The strains have lipolytic and
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hemolytic activity. All of the 30 strains tested have hemopeptic
activity, which is indirect evidence of their virulence. The strains
have no phosphatase enzymes or lecithinase. The strains we
studied ferment glucose, sucrose, glycerin, and rhamnose, and
they form acid without gas. The strains all grew in synthetic "A"
medium, although growth was weak. When L-tyrosine, L-
tryptophan, L-threonine, and L-methionine were added to the
synthetic "A" medium, the pathogen grows in the typical
manner. Two anthrax strains are moderately resistant to
rifampicin (MIC 1.5–16), and three are not sensitive. The anthrax
strains are highly sensitive to tetracycline, benzylpenicillin,
gentamycin, and oxacillin.
Conclusions: Regardless of their source of isolation and time of
storage, the anthrax strains isolated during outbreaks are
virulent, spore-forming, and capsule-forming cultures. This
study conﬁrms that virulent forms of B. anthracis are still
circulating in Kazakhstan. The research described in this
abstract was made possible in part by support provided by
the U.S. Defense Threat Reduction Agency under the project
«KB0-1950-AL-03» and administered by U.S. CRDF.
P1192
The importance of laboratory methods in
diagnosing anthrax in humans
L. Lukhnova, A. Aikimbayev, T. Meka-Mechenko,
G. Temiraliyeva, S. Zakaryan, M. Sagatova (Almaty, KAZ)
Objectives: Isolation of anthrax bacillus using bacteriological
methods is slow and frequently misleading. The literature
suggests anthrax bacillus is isolated in 13% to 48% of patients
infected with Bacillus anthracis. The pathogen quickly perishes
or transforms into atypical forms. The number of bacilli in a
clinical specimen is often low or below the sensitivity of
culture. This suggests other methods would be useful in
establishing the diagnosis of anthrax, speciﬁcally; serological
methods would be beneﬁcial in diagnosing infection with
Bacillus anthracis.
Methods: We conducted studies to assess various methods for
diagnosis of Bacillus anthracis infection in patients. We
reviewed archival data and our own results on pathological
material from patients infected with Bacillus anthracis in the
Southern and Eastern Kazakhstan oblasts.
Results: The most informative test for detection of anthrax in
patients was the delayed type hypersensitivity (DTH) or
dermatoallergic test with anthraxin. Eighty one per cent of
patients with signs and symptoms of anthrax gave a positive
reaction with anthraxin. The Ascoli reaction complete with scab
was positive in 72.1% of patients, and the indirect hemeagglu-
tination (IHA) test was positive in 65.6% of patients. The clinico-
epidemiological diagnosis of anthrax was conﬁrmed with
culture in 44% of cases. Serum samples from patients diagnosed
with anthrax in the Eastern Kazakhstan oblast were evaluated
using IHA in 2001–2004. High titres of speciﬁc antibodies (1:640-
1:5120) were detected in patients with dermatologic anthrax
lesions from which anthrax was isolated.
Conclusion: Our data suggest the anthraxin DTH test and IHA
are good methods for establishing a diagnosis of anthrax.
Cultures for anthrax bacillus were the least efﬁcient method for
establishing the diagnosis. When results of laboratory tests are
negative or inconclusive, one still has to rely on the clinicoep-
idemiological diagnosis. The research described in this abstract
was made possible in part by support provided by the U.S.
Defense Threat Reduction Agency (DTRA) under the project
«KB0-1950-AL-03» and administered by U.S. Civilian Research
and Development Foundation (CRDF).
Fluroquinolones, in vitro studies
P1193
Comparative bactericidal activity of moxiﬂoxacin
and levoﬂoxacin against viridans streptococci at
simulated salivary concentrations
R. Davidson, C. Howley, S. Campbell (Halifax, CAN)
Objectives: The ﬂuoroquinolones are bactericidal agents fre-
quently used in the treatment of respiratory tract infections. The
viridans Streptococci (VGS), although associated with disease,
generally exist as part of the normal human oral ﬂora. As such,
they may exposed to antibiotics with greater frequency than
oppurtunistic pathogens. Preliminary data suggest that the VGS
may act as a reservoir for ﬂuoroquinolone resistance in S.pneu-
moniae through horizontal transfer. Here, we compared the
killing kinetics of moxiﬂoxacin (MXF) and levoﬂoxacin (LEV),
against VGS at simulated saliva concentrations.
Methods: Eight strains of VGS, 4 S. mitis (2 with parC mutation)
and 4 S.oralis, (2 with parC mutation) were challenged with MXF
and LEV in a pharmacodynamic model utilizing Mueller–
Hinton broth supplemented with 5% lysed horse blood. Cul-
tures were inoculated at a density of 1 · 108 cfu/ml, incubated
at 35ordm;C, and examined for viable growth at 0, 1, 2, 4, 6, 12,
and 24 hrs after exposure to the antibiotics at concentrations
simulating salivary levels. Salivary concentrations of MXF
(400 mg), and LEV (500 mg) were 3.19 and 3.71 lg/ml respect-
ively. Protein binding of MFX and LEV were taken to be 50%
and 30%. Adjusted salivary levels were 1.6 (MXF) and 2.6
(LEV) ug/ml. PCR was used to amplify parC and gyrA, and
mutations detected by DNA sequencing.
Results: Both MXF and LEV were highly bactericidal against
susceptible strains of VGS at salivary concentrations. MFX
typically eradicated the VGS by 6 hours and LEV by
12–24 hours. For parC mutants, both MXF and LEV were
consistently bactericidal resulting in eradication after12 hours
for MXF and 24 hours for LEV. Regrowth was observed in both
strains of S.mitis (parC) exposed to LEV (2 of 10 experiments).
The MIC of these strains to LEV increased 4 fold and DNA
sequencing revealed the selection of a gyrA mutation in each
strain. No regrowth was detected in the S. oralis strains.
Conclusions: Both MXF and LEV are extremely active against
susceptible VGS at concentrations of drug found in saliva,
however, superior killing kinetics were consistently observed
with MXF. MXF consistently eradicated strains with a parC
mutation, however, regrowth was observed on 2 occasions
with LEV suggesting that MXF may be less likely to drive
resistance among VGS. Again, this may have implications due
to the ability of VGS to exchange its genetic determinants with
S. pneumoniae.
Abstracts
376
P1194
Moxiﬂoxacin and ciproﬂoxacin uptake by human
neutrophils and their inﬂuence on viability,
phagocytosis, oxidative burst, and chemotaxis
A.M. Berg, J. Altrichter, B. Drewelow,
R.G. Mundkowski (Rostock, D)
Objectives: The inﬂuence of antibiotics on the immune defence
is of increasing interest. The purpose of this study was to set up
a cellular model for correlating the intracellular concentrations
of the ﬂuorochinolones Moxiﬂoxacin and Ciproﬂoxacin with
selected cell functions of early immune response. A human
promyelotic cell line which is used for sepsis treatment by the
Extracorporeal Immune Support System (EISS, Teraklin
GmbH) was chosen to establish the model. The second stage
involved native human polymorphonuclear neutrophiles
(PMNs) as target cells.
Methods: The promyelotic model cell line was differentiated
towards neutrophils with all-trans retinoic acid, human PMNs
were isolated using dextran sulfate sedimentation and density
gradient centrifugation. The cells were incubated with antibiotic
concentrations within the therapeutic range and above (0.5–2
Cmax) for time periods up to 8 hours. The extra- and intracel-
lular concentrations were determined by HPLC-UV. The viab-
ility of the cells was controlled using the Trypanblue-exclusion
assay. Phagocytosis and oxidative burst were assessed by a
combined ﬂow cytometric assay after stimulation of the cells
with serum-opsonised ﬂuorescein-isothiocyanate-conjugated
E. coli in the presence of dihydroethidium as an indicator of
superoxid production. A two-compartement chamber system
was used to study the inﬂuence of either ﬂuorochinolone on the
chemotaxis.
Results: With either cell type, Moxiﬂoxacin accumulated rap-
idly with peak concentrations within 15 min whereas intracel-
lular maximum concentrations of Ciproﬂoxacin were achieved
after 2 h. The accumulation rate of both antibiotics inside the
native PMNs was more than twice as high as in differentiated
EISS cells. Neither Moxiﬂoxacin nor Ciproﬂoxacin showed a
signiﬁcant inﬂuence on viability and the immune response
parameters phagocytosis and oxidative burst of native PMNs;
chemotaxis ability was reduced to a minor degree.Viability and
phagocytosis of the diffentiated EISS-cells remain unaffected
whereas the oxidative burst appeared decreased. Chemotactic
acticity of EISS-cells could not be stimulated.
Conclusions: A signiﬁcant accumulation of Moxiﬂoxacin and
Ciproﬂoxacin was determined in both cell types. However, no
relevant inﬂuence on viability, phagocytosis, oxidative burst,
and chemotaxis was observed. Hence no hints were found
suggesting a restricted use of Moxiﬂoxacin and Ciproﬂoxacin for
immunocompromised patients.
P1195
Prospective, multicentre in vitro study to
determine resistance rates and comparative
activity of moxiﬂoxacin vs. clinical bacterial
isolates from patients with respiratory tract
infections (MOXIAKTIV study)
A. Dalhoff, G. Korfmann, E. Jacobs (Kiel, Leverkusen, Dresden, D)
Objective: To determine the prevalence of resistance in current
clinical isolates of S. pneumoniae, H. inﬂuenzae, M. catarrhalis,
S. aureus and K. pneumoniae as well as the in vitro susceptibility
to moxiﬂoxacin and other iv antibiotics in Germany.
Methods: Up to 20 isolates of each of the above-mentioned
species were cultured on standard media and tested for in vitro
susceptibility using Etest in each of the 29 study centres in
Germany. For validation, an ATCC control strain was included
for each species. Drugs tested were moxiﬂoxacin, levoﬂoxacin,
amoxicillin/clavulanate, cefuroxime, clarithromycin and peni-
cillin G. The latter twowere not tested forKlebsiellae. S. aureuswas
additionally tested for oxacillin resistance and K. pneumoniaewas
tested for production of extended spectrum beta-lactamases
(ESBL). DIN breakpoints were used where applicable.
Results: Overall, 1859 pathogens of 1,811 hospitalised patients
with respiratory tract infections were analysed. Results for
moxiﬂoxacin are summarized in table 1. Of S. pneumoniae
isolates 93.3% were susceptible to penicillin G and 85.7% to
clarithromycin. With an MIC90 of 1 mg/l, the in vitro activity of
levoﬂoxacin was markedly lower than that of moxiﬂoxacin.
H. inﬂuenzae showed almost 100% susceptibility to ﬂuoroquino-
lones, but only 4.5% to clarithromycin (MIC90 32 mg/l). As
beta-lactamase production is common among H. inﬂuenzae
isolates in Germany, amoxicillin/clavulanate showed far
higher susceptibility rates than penicillin G (87.9% vs. 1.0%).
Due to a high rate of beta-lactamase production only 9.8% of
Moraxella isolates were susceptible to penicillin G, compared
with 99.1% to amoxicillin/clavulanate. Moraxella isolates were
fully susceptible to the ﬂuoroquinolones. Overall, 13.0% of
Klebsiella isolates produced an ESBL. Interestingly, ESBL pre-
valence was 38.8% in Eastern Germany, but below 10% in
Western Germany. ESBL producers of Klebsiella were less
susceptible to antibiotics other than cefotaxime or ceftazidime
than non-ESBL producers.
Conclusion: For all species tested, the ﬂuoroquinolones
achieved the highest overall susceptibility rate (92.8%) com-
pared to the other antibiotics (penicillin G: 36.9%, clarithromy-
cin: 60.5%, ampicillin/clavulanate: 85.7%, cefuroxime: 89.6%).
Moxiﬂoxacin showed a high activity against current respiratory
pathogens in Germany and was the most active ﬂuoroquino-
lone, in particular against Gram-positive pathogens.
P1196
Double and triple combinations of ciproﬂoxacin
with other antipseudomonal drugs against
multidrug resistant isolates of Pseudomonas
aeruginosa in vitro
B. Henkle, M. El-Azizi, A. Entabi, F. Malal,
N. Khardori (Springﬁeld, USA)
Objectives: Drug combinations have become the best choice in
treatment of serious infections with resistant microorganisms
including P. aeruginosa (PA). We tested Ciproﬂoxacin (CIP) in
double and triple combinations with ceftazidime (CAZ), imipe-
nem (IMP), piperacillin (PIP), and amikacin (AMK) against 20
MDR clinical isolates of PA.
Methods: The MIC for each drug alone was determined by
broth microdilution technique described by NCCLS. Double and
triple combinations of CIP with other drugs were tested by
using 96-well plates and by time–kill assay. Rows A to G were
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assigned for the drugs as follows: row A for CIP alone, B for
second drug, C for third drug, D for CIP + second drug, E for
CIP + third drug, F for second drug + third drug and G for the
three drugs together. Row H was left for drug-free control.
Brieﬂy, all wells were ﬁlled with 50 ll of cation adjusted Muller
Hinton broth. The drugs at 2X of the highest tested concentra-
tions in 50 ll of the medium (alone, in double or in triple
combinations) were delivered to wells A1–G1. Two-fold serial
dilutions were made by using multichannels pipettes. Bacterial
suspensions (5 ll) were added to bring the initial inoculum size
to 5 · 105 cfu/ml and the plates were incubated at 37C for 24 h.
Synergy was considered only in triple combinations if the
growth-free wells with lowest concentration of the most potent
drug were at least 2-fold less than the growth-free wells
containing the most potent drug alone or in double combina-
tions with the two other drugs.
Results: The best synergistic effects were observed in combi-
nation of AMKwith CAZ (80%) or PIP (80%) and in combination
of CAZ with PIP (60%) or CIP (60%). Antagonism was observed
in combination of IMP with CAZ (60%) or PIP (50%). In triple
combinations of AMK-CAZ-CIP, synergy was observed in all
isolates (100%). Good results were also observed in combination
of AMK-PIP-CIP (70%) and CAZ-PIP-CIP (70%). No antagonism
was observed in any of the triple combinations tested.
Conclusion: Our data show that triple combination of anti-
pseudomonal drugs is better than using one or two drugs in
treating PS infections
P1197
Determination of the mutant prevention
concentration and minimal inhibitory
concentration of gemiﬂoxacin against penicillin
susceptible and resistant clinical isolates of
Streptococcus pneumoniae
J. Blondeau, S. Borsos, C. Hesje, L. Blondeau (Saskatoon, CAN)
Objective: While MIC measurements determine the in vitro
drug concentrations required to inhibit the growth of
100,000 organisms/ml, it may not detect resistant subpopula-
tions that are detected at higher inoculums (‡1 billion organ-
isms) as used in the MPC assay. As quinolones are widely used
for treating SP infections and quinolone resistance is a concern,
we tested GM–a newly approved compound–by MIC and MPC
against PS and PRSP.
Methods: MIC testing was by microbroth dilution in accord-
ance with NCCLS guidelines. For MPC testing, 10 billion
organisms were applied to agar plates containing drug and
read at 24 and 48 hours following incubation. The lowest
concentration preventing any growth was the MPC. Organisms
with high MPC values (‡2 lg/ml) were screened for amino
acid substitution in the quinolone resistance determining
region.
Results: A total of 402 clinical SP isolates were tested: 320 PS, 69
penicillin intermediate (PI) and 13 PR. The following represents
the MIC50/90 (lg/ml) and range (lg/ml) respectively against
PR, PI, PS strains: 0.031/0.063, £0.002–2; 0.031/0.063, £0.002–0.5;
0.031/0.063, 0.016–0.125. MPC50/90 and range values respect-
ively were: 0.125/0.25, 0.031–8; 0.125/0.5, 0.031–2; 0.25/0.5,
0.063–0.5. By MIC < 1% of isolates had values ‡1 lg/ml as
compared to 4.5% by MPC. The modal MIC was 0.031 lg/ml
and 0.125 lg/ml for the MPC. Eight isolates had MPCs ‡2 lg/
ml and had amino acid substitution in either of gyrA, parC or
both. For 74 isolates with MPCs to levoﬂoxacin ‡ 4 lg/ml, all
had MPCs to GM of £0.25 lg/ml and for 58% £ 0.125 lg/ml.
Conclusion: GM is a new ﬂuoroquinolone with low MIC and
MPC values against SP and 95% of strains–regardless of
penicillin susceptibility–had MPCs £ 0.5 lg/ml and 91% £
0.25 lg/ml. This data suggests that GM is highly efﬁcacious in
vitro against SP and with low MPC values is less likely to select
for quinolone resistant SP following drug exposure. No differ-
ences were seen in MIC or MPC values between PS, PI, PR
strains suggesting no co-resistance with GM. GM retained low
MPC values against some organisms with high MPC values to
other quinolones.
P1198
In vitro activities of moxiﬂoxacin and
ciproﬂoxacin against Staphylococcus aureus
isolates
A. Azap, S. O¨zkan, H. Aygu¨n, S. Gu¨l, D. Yagci, O.K. Memikoglu,
E. Tekeli (Ankara, TR)
Objective: To determine the in-vitro activities of moxiﬂoxacin
and ciproﬂoxacin against methicillin-susceptible S. aureus
(MSSA) and methicillin-resistant S. aureus (MRSA) strains.
Methods: The study was conducted in a University Hospital in
Turkey. A total of 440 non-repeat isolates (196 MSSA and 244
MRSA) from various clinical specimens were included in the
study. All isolates were identiﬁed as S. aureus by phenotypic
characteristics, Gram staining, catalase and tube coagulase tests.
MICs of the drugs were determined by an agar dilution method,
according to the NCCLS criteria. The drugs were obtained from
their manufacturer (Bayer Inc). S. aureus ATCC 29213 was used
as quality control strain.
Results: Twenty-seven (14%) of 196 MSSA strains and 239
(98%) of 244 MRSA strains were resistant to ciproﬂoxacin.
MIC50 and MIC90 values of 27 ciproﬂoxacin-resistant MSSA
strains for moxiﬂoxacin were 0.25 mg/L and 4 mg/L, respect-
ively. MIC50 and MIC90 values of ciproﬂoxacin-susceptible
MSSA strains for moxiﬂoxacin were £0.125 mg/L and
0.250 mg/L, respectively. Moxiﬂoxacin was 4-fold more active
than ciproﬂoxacin against MSSA strains. There was not any
difference between these two quinolones against MRSA strains
(MIC90s: ‡16 mg/L).
Conclusion: MRSA strains are major causes of nosocomial
infections. Despite advances in antibacterial therapy, treatment
of infections caused by MRSA is still troublesome. New
quinolone-derived compounds such as moxiﬂoxacin are repor-
ted to have improved activities against S. aureus including
MRSA. In this ﬁrst study on in-vitro activity of moxiﬂoxacin
against S. aureus from Turkey, the moxiﬂoxacin MICs were
higher than those reported from different countries. This may be
due to excessive quinolone use in our country. According to our
ﬁndings we conclude that moxiﬂoxacin should not be used in
MRSA infections in our setting, but it can be a good alternative
to ciproﬂoxacin in treatment of infections caused by MSSA.
P1199
BIVEMOX III: results of the Belgian in vitro
evaluation of moxiﬂoxacin (winter 2003–2004)
J. Verhaegen, M.J. Struelens, H. Goossens, Y. Glupczynski,
S. Lauwers, G. Verschraegen, P. De Mol, D. Govaerts,
G. Mascart, J. Frans, A. Bousse, S. Vingerhoedt (Leuven, Brussels,
Antwerp, Mont-Godinne, Ghent, Montigny-Le-Tilleul, Bonheiden, B)
Objectives: A multicentric study during the winter period of
2003–2004 was performed in Belgium to assess the in-vitro
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activity of moxiﬂoxacin on S. pneumoniae (Sp), H. inﬂuenzae (Hi)
and M. catarrhalis (Mc) clinical isolates collected from the
respiratory tract by determination of the MIC’s using the E-
test and to compare these results against 9 other antimicrobial
agents.These results were also compared for Sp versus those of
the previous study (winter periods 2000–2002) for interpretive
criteria S – I – R (according the NCCLS – breakpoints).
Methods: 10 Belgian university and non-university medical
microbiology laboratories participated during the past winter
period in this multicentre in-vitro evaluation of moxiﬂoxacin.
Each laboratory included 40 strains of Sp and 20 strains of Hi
and Mc. The total number of evaluable strains (with the
exclusion of duplicate isolates) was 758. Testing conditions:
Method and antibiotics: susceptibility testing was performed in
the participating centres by using the E-test. The antibiotics
tested were penicillin, ampicillin, amoxi/clav., doxycycline,
clarithromycin, cefuroxime, ceftriaxone, ciproﬂoxacin, levoﬂoxa-
cin and moxiﬂoxacin.Medium : Sp and Mc : Mueller–Hinton
agar with 5% blood; Hi : HTM agar. Inoculum : direct
suspension and 0.5 Mc Farland standard.Incubation : 35C for
24 hours in 5% CO2. Quality control was performed using
ATCC reference strains (S. pneumoniae ATCC 49619 ; H.
inﬂuenzae ATCC 49766).
Results: See graphs 1 and 2.
Conclusions: This follow-up Belgian multicentre study con-
ﬁrms the excellent in-vitro potency of moxiﬂoxacin against
clinical isolates of Sp, Hi and Mc and it demonstrates that it is
the most potent ﬂuoroquinolone available in Belgium for the
treatment of lower respiratory tract infections. According the
NCCLS – breakpoints, there are no major S – I – R differences
for Sp between these results (2003–2004) and the results of the
previous study (2000–2002). This means that the use of new
ﬂuoroquinolones like moxiﬂoxacin and levoﬂoxacin has not
led, to date, to an increase of resistance in Sp. However,
repeated follow-up surveys will continue to be needed in order
to assess the activity of ﬂuoroquinolones and to monitor the
ecological impact of the recently increased ﬂuoroquinolone
usage for respiratory tract infections in Belgium in the
forthcoming years.
P1200
Moxiﬂoxacin as an alternative antibiotic in
treatment of Porphyromonas gingivalis
associated periodontitis – conclusions from in
vitro studies
W. Pﬁster, E. Straube, K.-H. Schmidt, A. Schmitt, T. Seltmann,
S. Eick (Jena, D)
Objectives: The objective of several experiments was to evalu-
ate the in vitro activity of moxiﬂoxacin against Porphyromonas
gingivalis (P.g.).
Methods: MICs of moxiﬂoxacin against 16 strains of P.g. were
determined by E-test (AB Biodisk, Solna, Sweden). Furthermore
the spontaneous mutation rate and the induction of resistant
strains by the 0.25-fold MIC of the antibiotic were determined.
To ﬁnd the target of resistance fragments of gyrA and gyrB were
sequenced. Finally the efﬁcacy of moxiﬂoxacin against P. gingi-
valis ATCC 33277 considering special conditions such as effects
on the strain in a bioﬁlm or within epithelial cells (KB cells) was
evaluated.
Results: Moxiﬂoxacin had very low MIC values (ranging from
0.006–0.032 lg/ml), but subinhibitory concentrations of the
ﬂuoroquinolone induced very fast mutations. The spontaneous
mutation rate was up to 5 · 10)8 after the two-fold MIC and
1.2 · 10)8 after the eight-fold MIC. Often the mutants exhibited
a high resistance MICs >32 mg/L. All these mutants bore Ser-
83–>Phe substitution in gyrA. The 5-fold MIC eliminated P.g.
ATCC 33277 within bioﬁlms after 24 h, and the 100-fold MIC
was able to kill all intracellular P. gingivalis within KB cells.
Conclusions: Moxiﬂoxacin showed a very good activity against
planctonic P. gingivalis and P.g. within a bioﬁlm. This antibiotic
in a higher concentration was also efﬁcient to intracellular
bacteria. But a rapid development of resistance was observed in
laboratory. Moxiﬂoxacin might be an alternative in the antibiotic
treatment of P. gingivalis associated periodontitis, nevertheless
clinical studies should focus not only on improvement of clinical
parameters but also on occurrence of resistant strains.
P1201
Levoﬂoxacin activity on respiratory isolates of
Streptococcus pneumoniae with decreased
susceptibility to ciproﬂoxacin in Spain
J. Garcı´a-de-Lomas, J.L. Juan-Ban˜o´n, C. Garcı´a-Rey,
R. Dal-Re´ On behalf of the Spanish Surveillance Group for
Respiratory Pathogens
Objectives: To test the activity of levoﬂoxacin against recent
respiratory isolates of S. pneumoniae with reduced susceptibility
to ciproﬂoxacin (MIC ‡ 2 mg/L; n = 607) belonging to the
national surveillance SAUCE-3 (n = 2721; Nov01–Oct02) and
to identify chromosomal mutations in isolates with a levoﬂoxa-
cin MIC ‡ 4 mg/L.
Methods: The activity of levoﬂoxacin was tested by broth
microdilution following NCCLS recommendations. Genotypic
sequenciation of the QRDR (gyrA, gyrB, parC and pare) was
done on all the strains with a levoﬂoxacin MIC ‡ 4 mg/L.
Results: Levoﬂoxacin MIC distribution, MIC50 and MIC90 (in
bold) are given in the Table for the whole sample and broken
into ciproﬂoxacin MIC categories. Mutations in gyrA (E85K)
were found in 8 (18.6%) strains. No gyrB mutations were found.
Mutation in parC occurred in 100% these strains (26 S79F; 12
S79Y; 2 S79I; 1 S79R; 1 D831; 1 D83N). Finally, mutation of parE
was found in 17 (39.5%) strains and all of them had the change
I460V. One single parC mutation occurred in 24 (55.8%) strains,
Sp Sp Mc Mc Hi Hi
Antibiotic mg/L MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
penicillin G 0.03 0.5 64 64 1 64
ampicillin 0.015 0.25 1 4 0.5 128
amoxi/clav 0.008 0.25 0.12 0.25 1 2
cefuroxime 0.03 1 1 4 1 4
ceftriaxone 0.03 0.25 0.5 1 0.008 0.03
doxycycline 0.12 8 0.12 0.25 1 1
clarithromycin 0.25 256 0.25 0.25 32 32
ciproﬂoxacin 1 2 0.06 0.06 0.03 0.03
levoﬂoxacin 1 1 0.03 0.06 0.03 0.03
moxiﬂoxacin 0.12 0.25 0.06 0.12 0.06 0.06
Antibiotic mg/L
Sp
R (%) I (%) S (%)
penicillin G 0.7 18.1 81.2
ampicillin
amoxi/clav 0.5 1.1 98.4
cefuroxime 7.8 2.7 89.5
ceftriaxone 0 4.4 95.6
doxycycline 19 10.2 70.8
clarithromycin 37.3 0.3 62.4
ciproﬂoxacin
levoﬂoxacin 0.8 0.3 98.8
moxiﬂoxacin 0.5 0 99.5
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two mutations in 15 (34.8%) (3 parC+gyrA and 13 parC+parE),
and 3 mutations in parC+parE+gyrA in 5 (11.6%) strains.
Conclusions: 1) Levoﬂoxacin MIC50 and MIC90 for pneumo-
coccal strains with decreased susceptibility to ciproﬂoxacin were
0.5 and 1 mg/L, respectively. Resistance to levoﬂoxacin
(MIC ‡ 8) occurred in 32 isolates (1.2% of the SAUCE-3
collection). 2) Activity of levoﬂoxacin was negatively affected
only among pneumococcal isolates with a very high MIC of
ciproﬂoxacin (‡8 mg/L). In this case, levoﬂoxacin MIC50 and
MIC90 were 4 and 8, respectively, and 44.4% of these strains
were resistant to levoﬂoxacin. 3) All sequenced strains with a
levoﬂoxacin MIC ‡ 4 mg/L had a mutation in the parC gene
(single in 56% strains), but none of them in the gyrB. The most
common mutations identiﬁed were parC/S79F, parE/I460V,
parC/S79Y and gyrA/E85K. 4) One single parC mutation was
found in 62% and 22% strains with a levoﬂoxacin MIC £8 and
‡16 mg/L, respectively.
P1202
Application of PK/PD modelling and simulation
(M+S) to deﬁne pharmaco-dynamic breakpoints
for ﬂuoroquinolones
H. Stass, A. Bauernfeind, I. Schneider, A. Dalhoff (Wuppertal,
Munich, D)
Background: We studied the application of PK/PD modeling
techniques as an alternative method to deﬁne pharmacodynam-
ic breakpoints complementary to conventional microbiological
breakpoints for ﬂuoroquinolones (FQs).
Methods: 8 Staphylococcus aureus strains with MICs ranging
from 0.03–8 mg/L were exposed to ﬂuctuating concentrations of
Levo- (LFX) Gati- (GFX) and Moxiﬂoxacin (MFX) mimicking
their total serum concentration proﬁles following oral doses of
400 mg MFX, 400 mg GFX, 500 and 750 mg LFX over 24 h using
the sedimentation model. Strains were cultivated in Brain Heart
infusion broth at 37C. Viable counts were quantitated at 14
sampling points. As PD-measure the AUBKCnorm (i.e. Area
Under the Bacterial Kill Curve normalized to the initial
inoculum [h]; AUBKCnorm <24 indicates a bactericidal activity,
>24 bacterial growth) was determined for the time kill
experiment and plotted as a function of MIC for each treatment.
Results: The AUBKCnorm vs MIC function was similar for all
treatments following a bimodal proﬁle. While the slope of all
FQs studied was shallow for MICs below 1 mg/L with AU-
BKCnorm <5 h, AUBKCnorm started increasing steeply beyond
this point. It intercepted the 24 cut off line at concentrations of
1.5 mg/L for LFX 500 mg, 2 mg/L for GFX, 2.4 mg/L for MFX
and 3.1 mg/L for LFX 750 mg. This indicates that S. aureus with
susceptibilites beyond these MICs would no longer be eradi-
cated by the corresponding treatments. Thus, according to our
investigations a breakpoint for FQs integrating both microbio-
logical and clinical pharmacokinetic relation-ships results in a
value of 1 mg/L for LFX 500 mg, and 2 mg/L for MFX, GFX,
and LFX 750 mg.
Conclusion: Pharmacodynamic breakpoints determined by
PK/PD M+S which are taking into respect the ﬂuctuating
concentration time proﬁles encountered in patients are suitable
surrogates complementing the data obtained in microbiological
experiments.
P1203
A multicentre agar and broth dilution
susceptibility testing study of ﬂuoroquinolones
against the Bacteroides fragilis group
K.E. Aldridge, D. Snydman, D. Hecht, C. Edlund,
J. Herrington (New Orleans, Boston, Chicago, USA; Stockholm, S;
West Haven, USA)
Objectives: The development of ﬂuoroquinolones (FQ) anti-
microbials has resulted in effective therapy for a variety of
infections due to aerobic and facultatively anaerobic gram-
positive and -negative pathogens. FQ activity against anaerobes
has not been as promising with only trovaﬂoxacin receiving
FDA approval for anaerobic infections. Moreover, more recent
reports of increased resistance to FQ among the B. fragilis group
has prompted interested to determine if these increases are due
to susceptibility testing methodology problems. This study was
designed to compare the susceptibility results from ﬁve labor-
atories that tested the same 70 isolates against FQ using agar
dilution(AD) and broth microdilution (BMD) testing.
Methods: Seventy clinical isolates of the B. fragilis group
identiﬁed by only a sequential number were distributed to
each of the ﬁve participating laboratories. Four of the laborat-
ories performed AD and one laboratory performed BMD
susceptibility testing using NCCLS recommendations including
breakpoints where appropriate. Serial two-fold dilutions of
moxiﬂoxacin (MOX), gatiﬂoxacin (GATE), trovaﬂoxacin
(TROV), and metronidzaole (METRO) were prepared in the
test medium within a range of 0.03 to 64 mg/L. Plates were
inoculated with 1 · 105 CFU per spot or well, incubated anaer-
obically for 48 hours and the MIC read. QC was performed
using NCCLS-recommended ATCC strains.
Results: MIC values for each antimicrobial were collated as
MIC90 and per cent (%) of isolates inhibited at £2 and £4 mg/L:
Conclusions: These data indicate that inter-laboratory testing of
the same test isolates gave very similar results for each antimi-
crobial. BMDgave slightly lowerMIC results thanADbutwasnot
signiﬁcantly different. We conclude that susceptibility methodo-
logy is not responsible for unusually high resistance rates.
P1204
Global evaluation of gemiﬂoxacin activity tested
against community-acquired respiratory tract
pathogens, Haemophilus inﬂuenzae and
Moraxella catarrhalis (1999–2004)
J. Ross, D. Biedenbach, T. Fritsche, H. Sader, R. Jones
(North Liberty, USA)
Objectives: Chronic lower respiratory tract disease and pneu-
monia are among the top ten leading causes of death in the
Cipro MIC
Levoﬂoxacin MIC
£0.125 0.25 0.5 1 2 4 8 16 32 %R
‡2 (n = 607) 5 (0.8) 37 (6.9) 344 (63.6) 164 (90.6) 12 (92.6) 13 (94.5) 23 (98.5) 8 (99.8) 1 (100) (5.3)
‡4 (n = 127) 3 (2.4) 22 (19.7) 46 (55.9) 11 (64.6) 13 (74.8) 23 (92.9) 8 (99.2) 1 (100) (25.2)
2 (n = 480) 5 (1.0) 34 (8.1) 322 (75.2) 118 (99.8) 1 (100) (0.0)
4 (n = 55) 1 (1.8) 17 (30.9) 32 (90.9) 1 (92.7) 4 (100) (0.0)
‡8 (n = 72) 2 (2.8) 5 (9.7) 14 (29.2) 10 (43.1) 9 (55.6) 23 (87.5) 8 (98.6) 1 (100) (44.4)
MOX TROV GATE METRO
MIC90 2 4 MIC90 2 4 MIC90 2 4 MIC90 2 4
Lab 1 16 56 64 8 66 87 16 43 60 1 100 100
Lab 2 16 57 67 4 63 91 32 49 56 2 96 100
Lab 3 16 50 67 8 43 77 32 39 59 1 100 100
Lab 4 16 50 64 8 49 64 16 43 59 1 100 100
Lab 5 8 64 74 4 60 34 16 54 63 2 100 100
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United States. As resistance (R) to commonly used drug classes
continues to increase, the newer generation ﬂuoroquinolones
(FQs) have provided an excellent therapeutic alternative for
community-acquired respiratory tract infections (CARTI). The
potency of gemiﬂoxacin(GEMI) against H. inﬂuenzae and
M. catarrhalis isolates was determined over a period of six years.
Methods: A total of 12,152 isolates of H. inﬂuenzae (9,411),
M. catarrhalis (2,741) and other Haemophilus spp. (66; not
presented) were collected during 1999–2004 from North Amer-
ica, Latin America and Europe. Reference NCCLS test methods
were utilized and MIC results were interpreted by current
breakpoint criteria M100-S15 (2005). Comparison agents inclu-
ded: ciproﬂoxacin (CIPRO), levoﬂoxacin (LEVO), gatiﬂoxacin
(GATI), and moxiﬂoxacin (MOXI).
Results: H. inﬂuenzae and M. catarrhalis susceptibilities (S) to
GEMIhave not changedover the last six years.GEMI had equal or
greater potency when compared to other FQs. H. inﬂuenzae
isolates tested showed >99.9% S to GEMI (MIC90 from on-scale
values, 0.004 mg/L). In 2003 and 2004, CIPRO, GATI, LEVO, and
MOXI showed complete S amongH. inﬂuenzae isolates, but some
had higher MIC values indicating single-step QRDR mutations
(MIC ‡ 0.12 mg/L). One H. inﬂuenzae isolate was R to all FQs
tested (MICvalues:GEMI 2, CIPRO>4, LEVO>4,GATI >4,MOXI
>4 mg/L) and had multiple QRDR mutations. The number of
beta-lactamase (BL)-negative/ampicillin-R isolates recovered in
this study was only 7 or 0.1% overall. GEMI shows similarly high
potency against M. catarrhalis with the highest observed MIC at
2 mg/L (1999–2002); >99.9% were at £0.12 mg/L
Conclusions: GEMI continues to be a highly potent FQ when
tested against the two most commonly isolated Gram-negative
CARTI pathogens; H. inﬂuenzae and M. catarrhalis. This potency
and spectrum was consistent across six years and three
continents.
P1205
Norﬂoxacin as a marker of decreased
susceptibility to ﬂuoroquinolones in
enterobacteria using the Vitek 2 system
L. Lo´pez, J. Alcala, F. Torres, E.J. Perea, A. Pascual (Seville, E)
Objective: The detection of Nalidixic acid resistance acquires
importance in enterobacteria since already resistant strains
develop more frequently resistance to ﬂuorquinolones than
susceptible strains. Many clinical laboratories have incorporated
the VITEK 2 system because their beneﬁt in routine, but
Nalidixic testing is not included for enterobacteria cards. The
aim of this study was the use of Norﬂoxacin VITEK MICs value
as alternative marker to detect Nalidixic acid resistant entero-
bacteria strains.
Material and methods: A total of 1013 isolates of Enterobacte-
riaceae were analyzed and routinely inoculated into the VITEK 2
ID-GNB and AST-N020 cards (bioMe´rieux) and then loaded into
the VITEK 2 system, as recommended by the manufacturer.
Ninety-six strains with a higher Norﬂoxacin VITEK MIC value
(1–4 mg/L), but still within the susceptibility range established
by the NCCLS breakpoints, and 100 strains with a Norﬂoxacin
VITEK MIC £0.5 mg/L were selected. They were further tested
with a 30 microg-Nalidixic acid-disk (Nal) (Oxoid) according to
NCCLS reference.
Results: The Norﬂoxacin 1–4 mg/L and susceptible to ciproﬂ-
oxacin phenotype represented the 9% of total isolates loaded in
the VITEK system during the study, similar to the prevalence
observed in previous analysis in Spain. Both selected groups,
one with the highest and the other with the lowest Norﬂoxacin
VITEKMIC value, included 60% and 58% E. coli isolates, 8% and
20% S. enterica isolates, respectively. Among the Norﬂoxacin
VITEK MIC 1–4 mg/L strains 93 isolates (98%) were Nal
resistant, and 76 (79%) were ciproﬂoxacin susceptible. The
agreement between Norﬂoxacin VITEK MIC £0.5 mg/L and Nal
susceptibility was foun in 97 (97%) strains. Two isolates (one
E. cloacae and one K. pneumoniae) with Norﬂoxacin VITEK MIC
1–4 mg/L were Nal-S and 3 isolates (two E. coli and one
P. mirabilis) withNorﬂoxacin VITEKMIC £0.5 mg/LwereNal-R.
Conclusion: When using VITEK 2 system for enterobacteria, the
consideration of MIC of norﬂoxacin >0.5 mg/L could be an
alternative marker of nalidixic acid resistance (and decreased
susceptibility to ﬂuoroquinolones).
Antibacterial susceptibility studies – I
P1206
Ceftazidime, glycopeptides and azithromycin in
combination against P. aeruginosa
B. Repetto, S. Roveta, E.A. Debbia, D.L. Rocca,
A. Marchese (Genoa, I)
Objectives: P. aeruginosa is an important nosocomial pathogen,
which causes serious and often lethal infections in immuno-
compromised hosts. This pathogen is intrinsically resistant to
many antibiotics and can easily develop resistance towards
many currently available agents. Natural resistance can be
attributed to the low permeability of the P.aeruginosa outer
membrane to a variety of antibiotics including glycopeptides
(GLYs). Since GLYs are powerful antibiotics against gram-
positive bacteria and resistance is very rarely develop, it seemed
interesting to evaluate the effect of combining these antimicro-
bial agents with antibiotics that might disorganize the structure
of the outer membrane allowing the entrance of glicopeptides
into the gram-negative cells. In order to verify this hypothesis,
ceftazidime (CAZ) has been tested in association with vanco-
mycin (VAN) or teicoplanin (TEI). The same experiments have
been carried out also in the presence of azithromycin (AZI),
which is normally a non anti-pseudomonal agents but has been
shown to interfere with some virulence factors.
Methods: A bacterial suspension of about 109 CFU/ml was
seeded on plates containing a ﬁxed concentration of GLYs
(500 mg/l) and increasing doses (2x,4x,8x,16x) of CAZ. Survi-
vors were counted after 48 hr at 37C. Results were interpreted
as synergism (99%), additivity (90%), and indifference (10%) of
the CFU/ml reduction found in the drugs combination in
MIC 50/100 in mg/L (%S)
Organism/year (no. tested) GEMI CIPRO LEVO GATI MOXI
H. inﬂuenzae
1999–2002 (6213) £.008/2 (>99) £.03/4 (>99) £.03/>4 (>99) £.03/>4 (>99) £.03/>4 (>99)
2003 (1854) £.002/.12 (100) £12/.5 (100) £.03/.12 (100) £.03/.12 (100) £.03/.12 (100)
2004 (1344) £.016/.03 (100) £.03/.25 (100) £.03/.25 (100) £.03/.12 (100) £.03/.25 (100)
BL-Negative
1999–2002 (4841) £.008/2 (>99) £.03/4 (>99) £.03/>4 (>99) £.03/>4 (>99) £.03/>4 (>99)
2003 (1423) £.002/.12 (100) £12/.5 (100) £.03/.12 (100) £.03/.12 (100) £.03/.12 (100)
2004 (1037) £.016/.03 (100) £.03/.25 (100) £.03/.25 (100) £.03/.12 (100) £.03/.25 (100)
BL-Positive
1999–2002 (1286) £.008/25 (>99) £.03/.25 (100) £.03/.25 (100) £.03/.12 (100) £.03/.25 (100)
2003 (402) £.002/.03 (100) £12/£.12 (100) £.03/.06 (100) £.03/£.03 (100) £.03/.06 (100)
2004 (307) £.016/.03 (100) £.03/.06 (100) £.03/.06 (100) £.03/£.03 (100) £.03/.25 (100)
M. catarrhalis
1999–2002 (2473) .008/2 (NA) £.03/.5 (NA) £.03/1 (NA) £.03/.25 (NA) .06/.12 (NA)
2003 (268) £.12/£.12 (NA) £.03/£.12 (NA) £.03/.06 (NA) £.03/.06 (NA) .06/.12 (NA)
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comparison to the drug alone.The same experiments have been
repeated adding AZI (16 mg/l) and using GLYs at concentra-
tions ranging from 500 to 300 mg/l.
Results: CAZ in combination with GLYs reacted synergically in
20 out of 59 cases, additivity was found in 31/59 interactions
and indifference was noted in 8/59 tests. Preliminary results (12
tests performed) indicated that the addition of AZI increased the
incidence of synergisms and additivities even when using GLYs
concentration of 300 mg/l.
Conclusions: CAZ combined with GLYs gave additive or
synergistic results in the great majority of experiments, while
the simultaneous combination of AZI, CAZ and a GLY always
produce an additive or synergistic effect against P. aeruginosa.
These data, given the high concentration of GLYs employed,
could be of particular interest in clinical situations where the
drugs could be topically administered.
P1207
A multicentre correlation study of VITEK 2 with
reference methods for telithromycin, mupirocin,
and daptomycin against Staphylococcus spp.
K.E. Aldridge, A. Dizney, K. Thomson, G. Procop (New Orleans,
Omaha, Cleveland, USA)
Objective: Clinical studies have shown that appropriate anti-
microbial therapy based on in vitro susceptibility data correlates
with better patient outcome. VITEK 2 is a fully automated
susceptibility testing methodology providing rapid(6–8 h)
results for a variety of aerobic and facultatively anaerobic
Gram-positive and -negative pathogens which have been shown
to correlate to established reference methods. The objective of
this study was to correlate the susceptibility results of Vitek 2
testing of telithromycin, mupirocin, and daptomycin against
Staphylococcus spp. with those from reference methodology.
Methods: Three geographically distinct clinical microbiology
laboratories participated in the testing with each site testing 100
consecutive clinical islates and 84 blinded challenge isolates of
staphylococci sent to each site.VITEK 2 testing was performed
according to the manufacturer’s recommendations. The chal-
lenge isolates were also tested using a manual preparation of the
inoculum. NCCLS recommended reference agar and broth
microdilution methods were used to test telithromycin, mup-
irocin, and daptomycin. MIC results were collated to determine
the per cent (%) of isolates susceptible(S), intermediate(I), and
resistant(R) based on CA-SFM, BSAC, and NCCLS recommen-
ded breakpoints. Essential(EA) and categorical(CA) agreements
were then determined.
Results: For telithromycin the MIC values indicated S,I,&R %s
of 79.5,0.6,and 20.9 for clinical isolates and 76.2, 1.2, and 22.6 for
the challenge isolates.EA and CA with reference methods were
100% for clinical isolates and 97.6% and 98.8% for challenge
isolates.Overall for telithromycin the EA and CA were 99.5%
and 99.7%. For mupirocin the MIC values indicated S and R %s
of 88.5 and 11.5 for clinical isolates and 98.8 and 1.2 for the
challenge isolates. EA and CA were 99.7% and 99% for clinical
isolates and 100% for the challenge isolates. Overall the EA and
CA for mupirocin were 99.7% and 99.2% respectively. 100% of
isolates were S to daptomycin. EA was 98% for clinical isolates;
99.1% for challenge isolates; and overall was 98.2% for dapto-
mycin.
Conclusion: Using both clinical and challenge isolates of
Staphylococcus spp. VITEK 2 results showed a high correlation
with reference method results for each agent. EA and CA
signiﬁcantly exceeded regulatory requirements for equivalence
between VITEK 2 and reference methodologies.
P1208
In vitro efﬁcacy of tigecycline tested against
community-acquired respiratory tract infection
and nosocomial pneumonia pathogens
R. Jones, M. Stilwell, H. Sader, T. Fritsche (North Liberty, USA)
Objective: To compare and contrast the pathogens involved in
CARTI and NP cases when tested against tigecycline, a novel
glycylcycline (formerly GAR936). All MIC tests were performed
by reference broth microdilution methods to determine suscep-
tibility (S) and resistance (R).
Methods: The organisms numbered 9,347, a total of 2,004 from
NP and 7,343 from CARTI. The most frequent CARTI pathogens
were: S. pneumoniae (SPN; 2,865), H. inﬂuenzae (HI; 4,011) and
M. catarrhalis (MCAT; 607). The rank order of NP isolates was:
S. aureus (SA; 56.9%), P. aeruginosa (PSA; 13.9%), SPN (5.8%),
Klebsiella spp. (KSP; 3.4%), Enterobacter spp. (ENT; 3.1%), Acine-
tobacter spp. (AC; 2.6%),E. coli (EC; 2.4%),S.maltophilia (SM; 1.6%),
beta-streptococci (BST; 1.5%) and Serratia spp. (SER; 1.2%). All tests
were NCCLS (M7-A7) interpreted using M100-S14.
Results: The characteristics of the organism collection were
(CARTI/NP isolates): SPN PEN-R (34/41%); HI AMP-R (22/
19%) and clarithromycin-R (13%/ND); and MCAT beta-lacta-
mase-positive (96%/ND). Tigecycline MIC results are found in
the table: PSA was less tigecycline-S (MIC90, 16 mg/L), but all
ESBL-producing KSP and EC had tigecycline MICs at £2 mg/L
and tetracycline-R strains were also tigecycline-S.
Conclusions: Tigecycline in vitro activity against CARTI and
NP pathogens was high, showing potency against R phenotypes
of SP, HI, Enterobacteriaceae and some difﬁcult to treat non-
fermentative Gram-negative bacilli. Empiric parenteral applica-
tion of tigecycline for serious pneumonia cases appears prudent
for patients less likely to have PSA as the causative pathogen or
as directed therapy of S organisms.
P1209
Activity of tigecycline tested against an
international collection (1999–2003) of resistant
bacterial pathogens
T. Fritsche, H. Sader, R. Jones (North Liberty, USA)
Objective: To evaluate the activity and potency of tigecycline
(TIG) when tested against a large international collection of
common bacterial pathogens displaying increasing and worri-
some resistance (R) proﬁles. TIG is a novel glycylcycline
derivative of minocycline that has demonstrated activity against
a variety of Gram-positive and -negative pathogens, making it
an attractive candidate for treatment of community-acquired
pneumonia, mixed aerobic/anaerobic infections and SSTI.
Organism (CARTI/NP)
MIC50/90 (mg/L)
CARTI NP %£2/£4 mg/L
SPN (2.748/117) £0.12/£0.12 £0.12/£0.12 100/100
HI (3.995/16) 0.5/1 0.5/1 100/100
MCAT (600/7) £0.12/0.25 0.25/- 100/100
SA (-/1.140) – 0.25/0.5 100/100
KSP (-/69) – 0.5/1 96/100
ENT (-/63) – 0.5/2 98/100
AC (-/53) – 1/4 85/100
EC (-/49) – 0.25/0.5 100/100
SM (-/32) – 1/2 88/100
b St (-/30) – £0.12/£0.12 100/100
SER (-/24) – 1/4 75/92
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Methods: Non-duplicate clinically-signiﬁcant bacterial isolates
(10,275 strains) were collected from 2000 to 2004 in >70 medical
centres participating in the global TIG surveillance program.
Isolates originated from North America (39%); Europe (41%);
Latin America (18%); and the Asia-Australia (2%). All isolates
were tested using NCCLS broth microdilution methods against
TIG and representative comparator agents including ciproﬂoxa-
cin (CIP) and tetracycline (TET).
Results: TIG results for the R organism subsets are in the
Table: TIG was highly active (MIC50 and 90, £0.25 and
£0.5 mg/L, respectively) against all resistant SA, CoNS, ESP,
SPN and VGS with >99% of strains inhibited by £2 mg/L. While
potency of TIG against R subsets of ENT was less (MIC50 and
90, £0.5 and £4 mg/L, respectively), the vast majority of TET-R
isolates remained S to TIG (>98% of isolates were inhibited by
£4 mg/L). No geographic differences in TIG potency among
ESBL-producing, CIP-R or TET-R ENT strains were noted.
Conclusions: Among R subsets of commonly occurring patho-
gens, 97% were inhibited by £2 mg/L of TIG and >99% were
inhibited by £4 mg/L (the current NCCLS breakpoint for TET).
TIG is highly stable to most TET-R determinants, including
protected ribosomes and efﬂux mechanisms, and may represent
a superior choice among parenteral agents for broad-spectrum
coverage, including the most commonly occurring- and prob-
lematic-R phenotypes.
P1210
Determination of the minimum inhibitory and
mutant prevention concentration of telithromycin
against clinical isolates of Streptococcus
pneumoniae
S. Borsos, C. Hesje, L. Blondeau, J. Blondeau Saskatoon, CAN
Objective: Telithromycin (TL) is a novel ketolide antimicrobial
agent that has recently been approved for use inNorthAmerica for
respiratory tract infections ofwhich SP is a principal pathogen. The
global escalationof penicillin (P) andmacrolide (M) resistantSPhas
compromised theuse of beta-lactamandmacrolide compounds.TL
was reported to be active against P and M resistant SP. The MPC
deﬁnes the antimicrobial drug concentration required to prevent
the outgrowth of resistant subpopulations from high density
bacterial cultures. We tested TL by both MIC and MPC against
clinical isolates of SP – including P and M resistant strains.
Methods: MIC testing was by microbroth dilution (utilizing
100,000 cfu/ml) with Todd-Hewitt broth in accordance with
NCCLS guidelines. For MPC testing ‡1 billion organisms were
applied to agar plates containing 2 fold concentration incre-
ments of TL and incubated at 35–37C and 5% CO2 and screened
for growth at 24 and 48 hours. The lowest drug concentration
preventing growth was recorded as either the MIC or MPC
depending on the assay.
Results: To date, 372 clinical SP isolates were tested by MIC and
245 byMPC. By MIC testing the MIC50/90 and range values were
0.008/0.063 lg/ml and 0.002–1 lg/ml respectively. The modal
MIC value was 0.08 lg/ml and 88% of strains were inhibited by
£0.016 lg/ml. For MPC testing, MPC50/90 and range values were
0.031/0.25 lg/ml and £0.008– ‡0.5 lg/ml respectively. Themodal
MPC value was 0.031 lg/ml and 84% of strains were inhibited by
£0.125 lg/ml and 97% by £0.5 lg/ml. Both MIC and MPC values
were elevated against strains that were macrolide resistant–
MIC50/90 0.063/0.25 lg/ml; 0.25–0.5/‡ 0.5 lg/ml. Achievable
TL drug concentration in serum, epithelial lining ﬂuid, white
blood cells, alveolar macrophages and bronchial mucosa would
exceed the MPC90 values by 9x, 5x, 56x, 164x, 3x respectively and
MIC90 values by 36x, 18x, 223x, 651x, 12x respectively.
Conclusion: TL is highly active against SP – including strains
that are macrolide resistant. By MPC testing, TL was highly
active with 90% of strains having MPCs £0.25 lg/ml. This data
suggests that TL is useful for treating SP infections and has a
lower propensity to select for resistant subpopulations and
achieves drug concentrations in various compartments that
exceed the MPC90 values by 3 to 164x.
P1211
Determination of the minimum inhibitory
concentration and mutant prevention
concentration of garenoxacin against over 500
clinical isolates of Streptococcus pneumoniae
J. Blondeau, S. Borsos, P. Hedlin, G. Hansen,
M. Brandt (Saskatoon, CAN)
Objectives: Garenoxacin (GRN) is an investigational des-F(6)-
quinolone with enhanced in vitro activity against gram-positive
cocci. The global escalation in antimicrobial resistance amongst
respiratory tract pathogens –particularly SP-has highlighted the
importance of quinolone compounds for treating SP infections.
The mutant prevention concentration (MPC) is a novel in vitro
measurement that deﬁnes the drug concentration threshold that
would require an organism to simultaneously acquire two or
more resistance mutations for growth in the presence of the
drug. We measured the MICs and MPCs for GRN against
clinical isolates of SP, including multidrug resistant strains and
those with elevated MPCs to levoﬂoxacinGRN.
Methods: Microbroth dilution in accordancewithNCCLSguide-
lines was followed for MIC testing using Todd-Hewitt broth and
two-fold concentration drug increments. For MPC testing, ‡1 bil-
lion organisms were applied to agar plates containing GRN,
incubated at 35–37Cand 5%CO2 and screened for colony growth
at 24 and 48 hours. The MPC was the lowest drug concentration
that completely prevented growth. Select organisms with GRN
MPC values >2 lg/ml were screened for amino acid substitution
in the quinolone resistance determining region.
Results: For 524 strains the MIC50/90 and range values,
respectively were 0.063/0.125 lg/ml and £0.008–2 lg/ml and
not different against penicillin or macrolide resistance strains.
For 99% of strains, MICs were £0.25 lg/ml. For the 516 strains
tested by MPC, the MIC50/90 and range values respectively
were 0.125/0.5 lg/ml and £0.031– ‡2 lg/ml. For 97% of strains,
MPC values were £0.5 lg/ml. MIC and MPC values were not
impacted by SP resistance to beta-lactams, macrolides, tetracyc-
line or trimethoprim/sulfamethoxazole. For 98 isolates that had
MPC values to levoﬂoxacin ‡4 lg/ml, 92 (94%) had GRN MPCs
GRN of £0.5 lg/ml and of these, 73 (75%) were £0.25 lg/ml.
Based on achievable and sustainable serum drug concentration,
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GRN drug concentrations in serum would be expected to remain
above the MPC90 value for >24 hours.
Conclusion: GRN exhibits potent activity against SP, as meas-
ured by both MIC and MPC, and is active against strains with
high MIC/MPC values for other quinolones. GRN is less likely
to select for quinolone resistant SP isolates and may be useful for
therapy in patients infected with an organism resistant to other
quinolones.
P1212
Killing of Streptococcus pneumoniae by
azithromycin, clarithromycin, telithromycin and
gemiﬂoxacin using the minimum inhibitory and
mutant prevention drug concentrations
J. Blondeau, S. Borsos (Saskatoon, CAN)
Objective: SP continues to be a signiﬁcant respiratory pathogen&
increasing antimicrobial resistance has compromised the use of
beta-lactam & macrolide compounds. Bacterial eradication
impacts on clinical outcome & as bacterial load at the site of
infection exceeds the inoculumused in standardized susceptibility
testing, elimination of higher organism numbers is necessary for
successful therapy. We determined the killing of macrolide &
quinolone susceptible SP by Az, CL, TL & GM against a range of
bacterial inoculums using the MIC &MPC drug concentrations.
Method: The MICs were determined by microbroth dilution in
accordance with NCCLS guidelines. For MPC testing, ‡1 billion
organisms were inoculated to agar plates containing drug &
incubated & read at 24 & 48 hours. The MIC & MPC were
recorded as the lowest concentration showing no growth. For
kill experiments, 1million–1billion colony forming units (cfu/
ml) were exposed to drug & sampled at 0, 30 min, 1, 2, 3, 4, 6, 12
& 24 hours following drug exposure & log10 reduction & %
reduction in viable cells recorded.
Results: The MIC/MPC (lg/ml) values for Az, CL, TL & GM
were 0.063/0.5, 0.031/0.5, 0.008/0.016 & 0.031/0.25 respectively.
Exposure of 1 million–1 billion cfu/ml to the MIC drug
concentration resulted in +0.38 to )0.65 log10 reduction by
6 hours with Az as compared to +0.12 to )1.11 for CL, +0.43 to
)0.74 for TL & +0.07 to )4.64 for GM (biggest decrease over
6 hours). Signiﬁcant log10 reductions occurred by 12 & 24 hours
for all drugs. Following exposure of 1 million–1 billion cfu/ml
to MPC drug concentration resulted in the following log10
reduction by 6 hours of drug exposure: Az )0.10 to )3.72; CL
)0.02 to )3.77; TL +0.36 to )0.89; GM )0.30 to )5.03 (biggest
decrease over 6 hours). A ‡3 log10 reduction in viable cells was
seen for all drugs following 12–24 hours of drug exposure.
Conclusion: Bacterial loadat the site of infectionmay range from1
million–1 billion organisms & kill experiments utilizing higher
bacterial inoculumsprovidedamoreaccuratemeasureof antibiotic
performance in high biomass situations. It has been previously
established that a 3 log10 reduction in viable cells is indicative of
bactericidal activity.All agents tested achieved ‡3 log reduction by
12–24hours&killwasgreater& fastestwithMPCversusMICdrug
concentrations.Thisdata suggests thatdosing toachieveMPCdrug
concentration results is more rapid & thorough killing.
P1213
Effect of the efﬂux pump inhibitors on the MIC of
quinolones for MDR strains of non-fermentative
Gram-negative rods
A.E. Laudy, I. Wojtal, E. Witkowska, B.J. Starosciak (Warsaw, PL)
Fluoroquinolones are a therapeutic option in treatment of
infections caused by non-fermentative Gram-negative bacteria.
However, resistance to these antibiotics rapidly increase in
clinical isolates. The efﬂux mechanism is the most common
cause of multidrug resistance of strains P. aeruginosa, A. baumanii
and S. maltophilia. These MDR pumps belonging to the RND
family are inhibited by Phe-Arg-beta-naphthylamide
[MC207,110]. However, different results of reserpine effect on
the activity of RND pumps was established. In our study, we
searched for effect of the efﬂux pump inhibitors (MC207,110,
reserpine and rescinnamine) on the MIC of quinolones for MDR
clinical isolates of P. aeruginosa, A. baumanii and S. maltophilia.
We looked for a interdependence between structure of quino-
lones and ability of tested inhibitors to inhibit efﬂux of these
antibiotics.
Results: The MDR strains were resistant to all tested quinolones
(nalidixic acid-NAL, pipemidic acid-KP, norﬂoxacin-NOR, ci-
proﬂoxacin-CIP and oﬂoxacin-OF). Among studied inhibitors
only MC207,110 affected the susceptibility of all tested strains to
quinolones, ﬁrst of all to NAL. Effect of MC207,110 on the MIC
depended on its concentration, but did not depend on the
temperature. For majority of P. aeruginosa and A. baumanii strains
the MIC of all quinolones decreased in the presence of
MC207,110. The highest decrease of the MIC of quinolones was
obtained for P. aeruginosa (4–512-fold). For A. baumanii strains the
MIC of KP, NOR, CIP and OF decreased only from 2- to 4-fold
but theMIC of NAL decreased to 16-fold.Moreover, the presence
of this inhibitor increased the sensitivity of 80% of S. maltophilia
only to NAL (4- to 16-fold). Reserpine and rescinnamine did not
effect on the MIC of quinolones for all studied MDR strains.
However, reserpine alkaloides showed inhibitors activity against
control strains of S. aureus (decrease MIC of NOR).
Conclusions: Our data conﬁrm that MC207,110 inhibited efﬂux
pumps not only in P. aeruginosa but also in A. baumanii and
S. maltophilia strains. Additionally, obtained results suggested
possibility that for quinolones, depending on their structure, are
different binding sites in efﬂux pumps. Furthermore, probably
also MC207,110 binds to speciﬁc site of pumps depending on the
efﬂux systems. So, the effect of this inhibitor on MIC of
quinolones depends on genus of bacteria, kind of pumps and
structure of agents.
P1214
In vitro activity of fucidic acid against
Staphylococcus aureus strains
A. Azap, H. Aygun, S. O¨zkan, G.Y. Bozkurt, H. Sahintu¨rk,
A. Genc, O.K. Memikoglu, E. Tekeli (Ankara, TR)
Objective: This study was undertaken to investigate the in vitro
susceptibility of Staphylococcus aureus strains to fusidic acid.
Methods: A total of 440 S. aureus [244 methicillin-susceptible
S. aureus (MSSA) and 196 methicillin-resistant S. aureus (MRSA)]
strains isolated from various clinical specimens were included in
the study. All isolates were identiﬁed as S. aureus by phenotypic
characteristics, Gram staining, catalase and tube coagulase tests.
Minimal inhibitory concentrations (MICs) were determined by
agar dilution method, according to the NCCLS criteria. The drug
was obtained from the manufacturer. S. aureus ATCC 29213 was
used as quality control strain. Strains with MIC value of ‡2 mg/
L were interpreted as resistant to fusidic acid according to the
British and French guidelines.
Results: None of the MSSA strains were found to be resistant
while 2 (0.8%) of 244 MRSA strains were resistant and 4 (1.6%)
were intermediate to fusidic acid. MIC50 and MIC90 values
were £0.125 mg/L for both MSSA and MRSA.
Conclusions: Staphylococci cause both community acquired
and nosocomial infections. Methicillin resistance makes this
organism difﬁcult-to-treat. Community acquired MRSA is a
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great concern nowadays because the therapeutical alternatives
are limited. Fusidic acid inhibits protein synthesis. It has only a
few side effects and is usually well-tolerated by patients as an
oral drug. Fusidic acid can be considered as an alternative drug
for the treatment of infections due to both methicillin susceptible
and resistant S. aureus strains.
P1215
Evaluation of synergy between glycopeptides,
levoﬂoxacin and beta-lactams against methicillin-
resistant Staphylococcus aureus
L. Drago, E. De Vecchi, L. Nicola, L. Tocalli,
M.R. Gismondo (Milan, I)
Objectives: Aim of the study was in vitro evaluation of
different combinations of antibiotics used in the treatment of
hospital acquired pneumonia caused by methicillin resistant
Staphylococcus aureus (MRSA).
Methods: Double drugs combinations [levoﬂoxacin (LVX) and
cefotaxime (CTX) with VA/TP and triple combinations
(LVX + amikacin (AMK) + VA/TP, LVX + ceftazidime
(CAZ) + VA/TP, LVX + cefepime (CPM) + VA/TP, LVX + im-
ipenem (IMI) + VA/TP, LVX + piperacillin/tazobactam
(PTZ) + VA/TP] were considered. Synergy was evaluated by
means of checkerboard assay against 50 (double combinations)
and 25 (triple combination) MRSA strains isolated from respir-
atory tract infections and by means of time kill curves (5 strains).
In checkerboard assay synergy was deﬁned as fractional
inhibitory concentration index (FICi) of <0.5, additivity as FICi
>0.5 and >1, indifference as FICi >1 and antagonism as FICi >2,
while in time kill studies synergy was deﬁned as a >2 log
decrease in bacterial count of combinations in respect to the
most active single drug. Moreover, mutational rates of single
and combined drugs at antimicrobial concentrations equal to the
resistance breakpoints were calculated in 10 strains
Results: Synergy and additivity were the prevalent effects,
while no antagonism was observed in checkerboard assay. In
particular, LVX + VA/TP and CTX + TP/VA gave synergy in
16/50, 9/50, 43/50 and 23/50 strains, respectively. Combina-
tions of LVX + VA + CAZ/CPM/PTZ and of
LVX + TP + CAZ/CPM/PTZ yielded synergy or additivity in
all the tested strains, with combinations of LVX + TP + CAZ /
PTZ giving synergy in 20/25 strains. Time kill curves evidenced
synergy for LVX/CTX + VA/TP after 12 and 24 h of incubation.
Synergistic triple combinations occurred more frequently with
LVX + TP than with LVX + VA after 12 and 24 h. For single
antibiotics, mutational frequencies ranged between 10–5 and
<10–9 for LVX, CTX, AMK and IMI, and <10–9 for VA and TP.
When tested in double and triple combinations, mutational
frequencies fell below 10–9 for all the combinations.
Conclusion: The study provide in vitro evidence of synergy
between glycopeptides with ﬂuoroquinolones, cephalosporins
and beta-lactams and of limitations of occurrence of mutations
in MRSA strains responsible of respiratory infections, thus
underlining a potential role in therapy of such infections.
P1216
Comparative activity (MIC and MBC) of
daptomycin, quinupristin/dalfopristin, linezolid,
vancomycin and teicoplanin against a large
worldwide collection of VISA/hVISA
A. Bolmstro¨m, A. Engelhardt, A˚. Karlsson, E. Edling,
P. Ho (Solna, S)
Objective: The worldwide emergence and possible dissemin-
ation of vancomycin (VA) resistance in staphylococci involving
vanA (VRS), VISA and hetero-VISA phenotypes comprise
formidable clinical threats. Comparisons of the in vitro activity
of newer Gram positive agents using larger worldwide collec-
tions of VISA strains become increasingly important both for
individual therapy guidance and for epidemiologic purposes.
Method: A 10 country collection of 243 staphylococci (217
MRSA, 26 MSSA), of which 150 were VISA (E-test macromethod
and PAP-AUC, Walsh et al, JCM 2001) was assessed. MIC of DP,
QD, LZ, VA and TP were determined using the NCCLS broth
microdilution (BMD) and E-test. MBC for all agents for a subset
of 46 VISA and non-VISA strains were determined using an E-
test MBC procedure and BMD.
Results: Inter-method agreement (n = 2430) for all antibiotics
were ±95% ±1 dilution for MIC and ±80% for MBC results. The
continuous gradient format in E-test allowed detection of subtle
upward shifts in MIC and MBC distributions of VISA, as well as
the detection of persister colonies in MBC assays seen with the
less bactericidal compounds.
Conclusion: MIC distributions showed that daptomycin and
linezolid maintained potency against the large collection of
VISA while quinupristin/dalfopristin and glycopeptides
showed a shift towards reduced activity. MBC results showed
daptomycin to be superior to linezolid (bacteriostatic) and the
other agents. The potential usefulness of newer agents for VISA
should be continually assessed with respect to both their static
and cidal activities in order to detect subtle shifts in suscepti-
bility as early as possible.
P1217
Performance of a unique E-test Daptomycin
gradient + calcium gradient on Isosensitest
compared to NCCLS broth microdilution in
Mueller Hinton
A. Bolmstro¨m, A. Engelhardt, A˚. Karlsson, P. Ho, A. Wanger,
R.A. Howe (Solna, S; Houston, USA; Bristol, UK)
Objective: Daptomycin (DP) requires physiologic levels of free
calcium ions (Ca2+) for expression of adequate activity. Suscep-
tibility testing methods can be signiﬁcantly inﬂuenced by Ca2+
variations in agar and broth. NCCLS broth microdilution (BMD)
uses a ﬁnal physiologic level of 50 lg/mL calcium for DP
testing. E-test DP is a unique gradient which incorporates a
constant level of calcium. E-test DP has been shown to be
equivalent to BMD when tested with commercially available
Mueller Hinton (MH) agar. Since Isosensitest (ISO) is used in
some parts of Europe, and has an inherently low level of calcium
(approximately 5–10 lg/mL), it is important to evaluate the
performance of E-test DP on ISO in comparison to BMD.
Method: A 3 lab study compared E-test DP on ISO to NCCLS
BMD. A total of 760 clinical and stock strains comprising
Clinical Microbiology and Infection, Volume 11, Supplement 2, 2005
385
E. faecalis (180), S. aureus MR (172), S. aureus MS (69), S. pyogenes
(190), S. agalactiae (119) and S. dysagalactiae (30) were used. Inter-
laboratory reproducibility was evaluated using 25 bias/preci-
sion strains tested at all sites and 3 NCCLS QC strains were used
to compare E-test DP on ISO values to NCCLS MH values. The
various methods were used according to standard recommen-
dations. NCCLS susceptible breakpoints ‡1 lg/mL for staphy-
lococci and streptococci and ‡4 lg/mL for enterococci were
used as is and as adjusted upwards by 1 dilution.
Results: Percentage essential agreement (EA), Category agree-
ment (CA) and Inter-Laboratory Reproducibility (REP):
*ISO adjusted breakpoints (BP)
Conclusions: E-test DP on ISO were 1–2 dilutions higher for
staphylococci and enterococci due to the lower CA level.
Clustering of elevated ISO MICs around the NCCLS breakpoints
gave lower CAT and this improved to 99% with adjusted
breakpoints. Results for streptococci on ISO agreed with BMD.
To achieve equivalence to NCCLS, E-test DP values for
Gram + aerobes on ISO should be adjusted upwards by 1
dilution to ‡2 lg/mL for staphylococci and streptococci and
‡8 lg/mL for enterococci.
P1218
Four years experience of using E-tests for
antibiotic combination testing of isolates from
cystic ﬁbrosis
I.M. Gould, K.E. Milne, F.M. Mackenzie (Aberdeen, UK)
Objectives: Between April 1999 and March 2003 cystic ﬁbrosis
(CF) centres from around Scotland submitted multi-resistant
Gram-negative isolates from CF patients to our laboratory for
assessment of MICs and Fractional Inhibitory Concentration
Indices (FICI). We present the results of the combination testing.
Methods: E test strips were used to establish the FICI of the
antibiotic combination pairs. Combination testing was carried
out on 125 strains of Pseudomonas aeruginosa (PA), 69 strains of
Burkholderia cepacia (BC) and 29 strains of Stenotrophomonas
maltophilia (SM) from 96 CF patients. 19, 13 and 6 combination
pairs were tested between 10 and 69 times against PA, BC and
SM respectively. The FICI results were categorised as synergistic
(FICI £ 0.5), additive (FICI = 0.5 to £1.0), indifferent (FICI = 1.0
to £2.0) and antagonistic (FICI > 2.0).
Results: 1107 combinations were tested. Synergy was found in
3.1% of PA, 9.7% of BC and 8.6% of SM. 31.6%, 32.6% and 25.8%
of PA, BC and SM respectively demonstrated an additive effect.
64.2% of PA, 54.5% of BC and 62.4% of SM demonstrated an
indifferent effect. Antagonism was found in 1.1%, 3.2% and 3.2%
of PA, BC and SM respectively. The top synergistic combina-
tions for PA, BC and SM were amikacin~ceftazidime (AK~TZ),
tobramycin(TM)~TZ and levoﬂoxacin~ticarcillin/clavulanate
(LE~TLC) respectively. The top additive combinations for PA
and BC were TM~TLC, ciproﬂoxacin~meropenem (CI~MP)
respectively. LE~piperacillin/tazobactam (PTC) and LE~TLC
were joint top additive combinations for SM. 7, 11 and 3
combinations demonstrated antagonism against PA, BC and SM
respectively. The overall rate of synergy was 5.6%, the additive
rate was 31.4%, the indifferent rate was 61.1% and antagonism
was 1.9%
Conclusions: Overall very little antagonism was demonstrated
(1.9%). The level of demonstrable synergy was 5.6%. Some
combinations clearly give lower FICIs than others but this is
species speciﬁc.
P1219
Study of comparative activities of quinupristin–
dalfopristin and linezolid against macrolide-
resistant viridans group streptococci by using
time-kill methodology
C. Rodriguez-Avial, I. Rodriguez-Avial, J.J. Picazo (Madrid, E)
Objectives: Viridans group streptococci (VGS) resistant to
penicillin, macrolides and other antimicrobial are increasingly
found. Linezolid and quinupristin–dalfopristin exert their
mechanism of action by protein synthesis inhibition and are
agents with activity against multidrug resistant gram-positive
cocci. This study was aimed to determine, by time-kill curves,
the activity of linezolid and quinupristin–dalfopristin against
ﬁve VGS expressing various degrees of resistance to erythro-
mycin and harbouring different erythromycin resistance deter-
minants
Methods: The species, erythromycin MICs (mg/l) and the
erythromycin resistance genes present for each of the ﬁve isolates
tested were: S. anginosus/0.06/none, S. sanguis/4/mef(A),
S. sanguis/64/erm(B), S. mitis/256/erm(B) +mef(A), S. angino-
sus/256/erm(B) +mef(A). Quinupristin–dalfopristin and linezo-
lid MICs for all strains were 1 and 0.5 mg/l respectively. Strains
were incubated in cation-adjusted Mueller–Hinton broth supple-
mented with 5% lysed horse blood. Each of the ﬁve isolates were
exposed to linezolid and quinupristin–dalfopristin for 24 hours
in a shacking water bath in presence of 2 · MIC. Colony counts
were performed at 0, 4, 8 and 24 hours.
Results: Time-kill studies showed that for linezolid, the antibi-
otic concentration of 2 · MIC was bacteriostatic for each strain
irrespectively of the resistance to erythromycin and the genes
harboured, showing a 90% of killing at 24 h. The in vitro activity
of quinupristin–dalfopristin was predominantly bactericidal
with a 99.9% of killing at 3 h. The exception were the 2 strains
with erm(B) + mef(A) determinants, in one of them, a S. milleri,
the bactericidal activity was delayed to 24 h, and in the other
strain, a S. mitis, the activity was bactericidal at 3 h but with
regrowth at 24 h.
Conclusions: When VGS are implicated in infections in neu-
tropenic patients and in cases of endocarditis where bactericidal
activity is usually considered mandatory, we have to considered
that: linezolid was bacteriostatic, at the concentration tested,
against all strains and the rapid killing of quinupristin–dalfopr-
istin against VGS was lost when the strain presented the erm(B)
and mef(A) genes together.
P1220
Comparative antimicrobial susceptibility patterns
in different groups of species of viridans group
streptococci and Streptococcus bovis isolated fom
blood cultures
I. Rodriguez-Avial, C. Rodriguez-Avial, J.J Picazo (Madrid, E)
Objectives: Viridans group Streptococci (VGS) and S. bovis are
part of the normal human microbiota and are implicated as a
cause of endocarditis and sepsis in neutropenic patients.
Because of their resident nature are frequently exposed to the
antimicrobial agents. This study was performed to study the
resistance phenotypes to penicillin (P), erythromycin (E),
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clindamycin (Cc), ciproﬂoxacin (C) and tetracycline (T) and also
to determine whether there are any differences in the antimi-
crobial susceptibility patters among the difference species of the
VGS and S. bovis.
Methods: The 145 VGS and 10 S. bovis were isolated from blood
and identiﬁed at species level by ID 32-Strep system (68 S. mitis,
44 S. anginosus, 25 S. sanguis, 7 S. salivarius and 1 S. mutans).
MICs were determined by the agar dilution method and the
percentages of resistance determined according to NCCLS
criteria for streptococci other than S. pneumoniae.
Results: Overall, 64.5% of the streptococci were resistant at least
to one of the antibiotic tested and of these, 32% was resistant to 3
or more. The most susceptible species were S. anginosus and
S. salivarius (57% susceptibility to all antibiotics tested). The only
S. mutans strain was susceptible to all the antibiotics tested. The
resistance phenotypes for the different species are shown in the
table.
Conclusions: As expected Cc resistance was always associated
with E resistance. Overall, the phenotype most frequently
founded was ECcT in 24 strains (15.5%) and it was present in
the 70% of S. bovis and 27% of S. anginosus. The pattern ECcPT
was the second more common phenotype (12.3%) and the most
frequent in S. sanguis and S. mitis with 20% and 17.6% respect-
ively. S. mitis was the specie that showed more number of
phenotypes (17). Heterogeneity in the susceptibility patterns in
the species of VGS indicates the need for accurate identiﬁcation.
P1221
In vitro antibacterial activity of temocillin against
extended spectrum beta-lactamases
Enterobacteriaceae producing clinical isolates
H. Rodriguez-Villalobos, A. Cardentey-Reyes, S. Cuvelier,
J. Frankard, V. Malaviolle, C. Nonhoff, R. De Mendonc¸a,
M.J. Struelens (Brussels, B)
Objectives: Temocillin is a methoxy-derivative of ticarcillin,
active on Enterobacteriaceae and stable against b-lactamases,
including AmpC and extended spectrum b-lactamases (ESBL).
However data concerning its activity on ESBL producing strains
are limited. The aim of this study was describe the range of
minimal inhibitory concentration (MIC) of temocillin in different
species of ESBL producing Enterobacteriaceae from a single
tertiary care centre in Belgium .
Methods: ESBL producing Enterobacteriaceae (172 E. aerogenes,
164 E. coli, 104 E. cloacae, 58 K. pneumoniae and 35 other ) strains
from patients hospitalised in our institution during the period of
1 January 2000 to 31 December 2003. ESBL production was
screened by double-disk test and conﬁrmed by Oxoid combined
disk method. Characterisation of enzymes was performed by
multiplex PCR for bla TEM, bla SHV and bla CTX-M gene
families detection and by DNA sequencing and/or Iso-electric
focusing. MICs (mg/L) were determined by agar dilution
method according to NCCLS guidelines. Susceptibility was
determined according to breakpoints provided by Fuchs et al:
Susceptible MIC £ 16 mg/L. (Eur J Clin Microbiol 1985)
Results: Isolates originated from screening rectal swabs (28%),
urinary tract (25%), respiratory tract (19%), wound (10%), blood
(6%), gastrointestinal tract (4%), or other sites (8%) from 135
male and 233 female patients with a mean age of 61 (range, 0–94)
years. The antimicrobial activity of temocillin against ESBL
producing Enterobacteriaceae is summarised in the table.
Conclusions: This study conﬁrmed the good in vitro activity of
temocillin against multiresistant ESBL-producing clinical iso-
lates of Enterobacteriaceae. Its activity included Enterobacter
AmpC depressed mutant strains that co-produced multiple
ESBL. These data suggest that temocillin could be a valuable
drug to be considered in the treatment of infections by some
ESBL-producing Enterobacteriaceae.
P1222
In vitro activity of ertapenem against
cefpodoxime-resistant Gram-negative bacilli
from urine
F. M’Zali, M. Wilcox, C. Oliviera, S. Wallis, M. Wallis,
M. Denton (Leeds, UK)
Introduction: Resistance to commonly used antibiotics for
urinary tract infection (UTI) is of growing concern. This is due
to the emergence of extended-spectrum beta-lactamase (ESBL)
producing bacteria in the community with reports from differ-
ent parts of the world. The appearance and dissemination of
these resistant bacteria cause serious concerns for the treatment
of urinary tract infections (UTIs).
Objectives: Ertapenem is the latest member of the carbapenem
class of antimicrobials. The aim of this study was to assess the
activity of ertapenem against a collection of cefpodoxime-
resistant Gram-negative bacilli isolated from urine samples of
community and hospital-based patients.
Materials and Methods: Between June and October 2004, our
laboratory received 10,234 urine samples. Of these 2246 gave a
positive culture, of which 446 from hospitalised patients and
1800 from the community. Of these 258 were gram negative
bacilli resistant to cefpodoxime 1 mg/l. The identity of the
isolates was conﬁrmed using API 20E or API 20NE (Biomerieux,
France). ESBL production was sought using the MASTDD and
the identity of the resistant determinant(s) was carried out using
a combination of PCR and nucleotide sequence analysis tech-
Phenotype No. of strains
No. of strains
S. mitis S. anginosus S. sanguis S. salivarius S. bovis
Susceptible 54 18 25 6 4 1
P 10 6 1 1 2 –
E 3 1 1 1 – –
T 2 2 – – – –
C 1 1 – – – –
ECc 1 – 1 – – –
EP 15 10 – 4 1 –
ET 2 – 1 1 – –
EC 4 3 1 – – –
ECcP 2 1 1 – – –
ECcT 24 4 12 1 – 7
ECcPT 19 12 1 5 – 1
ECcTC 3 1 – 1 – 1
ECcPTC 1 1 – 4 – –
EPT 6 2 – – – –
EPTC 1 1 – – – –
PT 1 1 – – – –
PC 3 2 – 1 – –
TC 2 2 – – – –
Total 154 68 44 25 7 10
Table 1 Percentage of susceptibility, MIC 50, MIC 90 and prin-
cipal enzyme type by species
Species
Temocillin%
susceptibility
MIC50
(mg/L)
MIC90
(mg/L) ESPL type enzymes
Enterobacter aerogenes 93 4 16 82%TEM
Enterobacter cloacae 99 2 8 90% SHV12+TOHO2
Escherichia coli 92 8 16 43%TEM 37%TEM+CTX-M
Klebsiella pneumoniae 95 2 16 47%THM+SHV+CTX-M
All species 94 4 16
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nology. The minimum inhibitory concentration (MIC) to ertape-
nem was determined using E-test strips (AB Biodisk, Sweden).
Results: Of the 258 isolates resistant to cefpodoxime, 83 were
positive for ESBL production and the enzymes produced were:
TEM-1, SHV-5, SHV-12, CTX-M-15, CTX-M3 and CTX-M9 singly
or in combination. Ertapenem proved active against all Entero-
bacteriaceae regardless of production of ESBLs (MIC range
0.003–0.125 mg/l). For Acinetobacter sp. Pseudomonas sp. and
Stenotrophomonas sp the MIC were higher (range between 038
and 4 mg/l).
Conclusion: This study conﬁrmed the in vitro activity of
ertapenem against cefpodoxime resistant Gram-negative bacilli
regardless of the presence or absence of ESBL production or the
type of ESBL produced. Ertapenem was less active against non-
Enterobacteriaceae. Identiﬁcation of Gram-negative organisms
to species level is an important predictor of likely susceptibility
to ertapenem.
P1223
In vitro activity of telithromycin against
erythromycin-susceptible and resistant
pneumococci
G. Poulakou, I. Katsarolis, I. Matthaiopoulou, P. Panagopoulos,
A. Avlamis, C. Antachopoulos, D. Soﬁanou, C. Skevaki,
M. Kazantzi, L. Ftika, V. Papatolis, E. Kastrisiou, A. Pangalis,
K. Konstantopoulos, C. Koubaniou, H. Giamarellou on behalf of
the Hellenic Study Group for the susceptibility of streptococcus
pneumoniae 2004 HSSSP-2004
Objectives: To assess the in vitro activity of telithromycin (TEL)
against erythromycin-sensitive (Ery S) and resistant (Ery R)
isolates of Streptococcus pneumoniae isolated from the nasophar-
ynx of healthy children in Greece 2004.
Methods: The strains studied were isolated by nasopharyngeal
sampling in healthy children, aged 2–6 y, attending day-care
centres and were collected during a nation-wide surveillance
study for the susceptibility of pneumococci. Ery MICs were
determined by E-test according to NCCLS methodology. TEL
MICs were determined by agar dilution. NCCLS breakpoints
(Jan 2004) were applied for Ery and TEL: for susceptibility (0.5
and 1 mg/L, respectively; ‡1 and 4 mg/L for resistance. For
macrolide resistance phenotype, the double disk diffusion test
was used and 3 phenotypes identiﬁed: M, constitutive and
inducible MLSB (cMLSB and iMLSB, respectively).
Results: Of the 275 strains studied, 76 were Ery S and 159 were
Ery R. All strains but two (MIC 4 and 8 mg/L) were susceptible
to TEL. In particular, results for telithromycin for the Ery S
strains, showed an MIC range for TEL between 0.008–0.5, with
MIC50 of 0.015 and MIC90 of 0.06. For Ery R in total, MIC50 and
MIC90 were 0.125 and 0.5 (range 0.008–8). With respect to
macrolide resistance phenotype, the distribution per type was:
M 54.5% (Ery MIC range 1–32), and cMLSB and iMLSB (Ery MIC
range 4 to (256) 39% and 6.5% respectively. The two strains
resistant to TEL displayed the cMLSB phenotype (Ery
MIC ( 256). For each different macrolide resistance phenotype,
MIC50/MIC90 of TEL had the following values: M phenotype
0.25/0.5 – cMLSB 0.06/1 – iMLSB 0.03/0.06.
Conclusions: TEL is active against both Ery S and R strains,
irrespective of macrolide resistance mechanisms, although MICs
for resistant strains are higher. This ﬁnding along with the very
low-level of pneumococci resistance to TEL (<1%), in accordance
to other European and global surveillance data, render TEL an
alternative potent agent for the treatment of respiratory tract
infections caused by pneumococci, especially in the setting of
macrolide resistance.
Mechanisms of resistance to macrolides
P1224
Mechanisms of macrolide resistance in
Streptococcus pneumoniae nasopharyngeal
isolates in Athens, Greece in 2003
K. Volonakis, M. Souli, I. Galani, E. Koratzanis,
H. Giamarellou (Chaidari, GR)
Background: The constant increase in macrolide consumption
has been known to raise macrolide resistance of S. pneumoniae
strains. Annual surveillance of resistance rates of S. pneumoniae,
which is the most common cause of upper and lower respiratory
tract infections in the community is warranted.
Methods: A total of 485 S. pneumoniae isolates were collected
from 1396 healthy children, with ages 1–6 years, attending day
care centres during the winter months of 2003 in Athens
(nasopharyngeal carriage 34.7%). Four-hundred-and-forty-
seven of these were evaluated for antimicrobial susceptibilities
using the E-test (AB Biodisk, Sweden) and agar dilution
methods. Macrolide-non-susceptible isolates reached the
number of 135 (30.2%), whereas all were telithromycin suscept-
ible. A hundred-thirty-seven isolates were available for further
testing for phenotypic and genotypic resistance patterns. Phen-
otypic resistance was studied by disk diffusion using 2 lg
clindamycin, 15 lg erythromycin and 7.5 lg quinopristin disks.
Genotypes were studied by PCR for the presence of ermAM and
mefE genes known to prevail in this area.
Results: Fifty-one isolates (38.3%) were assigned to the constitu-
tive macrolide-lincosamine-streptogrammin B resistance pheno-
type (cMLSB). No isolates demonstrated an inducible MLSB
phenotype by thismethod. Forty-nine of these carried the ermAM
gene (34.3%) and three carried both ermAM and mefE genes
(2.18%). Eighty-seven isolates (63.5%) had the M phenotype
(macrolide resistance) and all of these contained the mefE gene.
Conclusions: Our ﬁndings are in contrast to European studies
and to previousGreek studies, where the ermgene prevailed or at
least equaled the prevalence of mef gene. This is the ﬁrst report of
isolates carrying both ermAM and mef genes in Greece. Know-
ledge of the resistant mechanisms to macrolides is crucial for the
empiric antibiotic treatment of community acquired infections.
P1225
Antibiotic susceptibility, mechanisms of
macrolide resistance and clonal relationship in
group B streptococci
J.J. Gonza´lez, A. Andreu, P. Alomar, M.A. Blanco, A. Bordes,
J. Bosch, J. Cacho, A. Cid, A. Coira, M. de Cueto, E. Dopico,
J.M. Garcı´a-Arenzana, A. Gil-Setas, C. Gimeno, C. Guardia,
S. Illescas, T. Juncosa, J. Lite, R. Martı´nez, B. Orden,
M. Pere´z-Pascual, M. Rebollo, M. de la Rosa, M. Rodriguez-
Mayo, I. Sanfeliu, F. Sanz, P. Villanueva, L. Vin˜as Spanish Group
of Perinatal Infection. Spanish Society for Clinical Microbiology and
Infectious Diseases
Objectives: (1) To study the antimicrobial susceptibility among
group B streptococci (GBS) strains of vertical transmission to
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different antibiotics in order to evaluate alternatives for intra-
partum chemoprophylaxis to women allergic to penicillin and
colonized by a GBS strain resistant to macrolides and/or
lincosamides; (2) characterize the mechanisms of resistance to
macrolides and lincosamide; (3) evaluate the clonal relationship
between these strains.
Methods: A total of 610 strains collected in a multicentre
study: 131 isolated between 1997 and 2002 from newborns
diagnosed of early-onset GBS disease and 479 strains collected
in 2002 from vagina or rectum of pregnant women. Microdi-
lution method was used to study the antimicrobial susceptibil-
ity and disk diffusion to deﬁne the macrolide-lincosamide
resistance phenotype. PCR was performed to determine the
presence of ermB, ermTR and mefA resistance genes. To
evaluate the clonal relationship, PFGE of total DNA was done
using SmaI.
Results: All the strains were susceptible to penicillin, ampicil-
lin, vancomycin, quinupristin/dalfopristin, levoﬂoxacin and
teicoplanin. The 12.45% were resistant to erythromycin and
azithromycin, 11.80% to josamycin, 11.31% to clindamycin,
1.80% to telithromycin and 0.32% to fosfomycin. Among the
macrolide resistant strains, the 90.8% presented a constitutive
MLSb phenotype (cMLSB), 5.26% an inducible MLSb phenotype
(iMLSB) and the remaining 3.94% a M phenotype. Three strains
were susceptible to macrolides and resistant to clindamycin. The
ermB, ermTR and mefA genes were presented in 63.2%, 30.3%
and 3.9% of the macrolide resistant strains. Two strains did not
ampliﬁed none of the studied genes. The 100% of the strains
harbouring the ermB gene showed a constitutive phenotype. All
the strains showing an inducible phenotype harboured the
ermTR gene. The 11 telithromycin resistant strains presented a
cMLSB phenotype; of them 10 posses the ermB gene and one the
ermTR.
Conclusion: In Spain, there is a high rate of resistance to
macrolides and lincosamides that makes mandatory to perform
susceptibility testing to GBS strains isolated from pregnant
women allergic to penicillin. In our region ErmB methilase is the
main cause of macrolide resistance, followed by the ErmTR and
the macrolide eﬂux pump in a low proportion. There is a wide
clonal diversity among resistant strains to macrolides, lincosa-
mides and telithromycin.
P1226
Detection of the ermX determinant of macrolide
resistance in clinical strains of Corynebacterium
urealyticum
A. Ortiz, J.I. Garcı´a-Cı´a, R. Ferna´ndez-Roblas,
J. Esteban (Madrid, E)
Objectives: To detect the presence of the ermX macrolide
resistance gene in clinical isolates of C. urealyticum.
Methods: 57 C. urealyticum strains were isolated from clinical
samples in the Fundacio´n Jime´nez Dı´az hospital. The strains
were maintained frozen until the studies to evaluate macrolide
resistance were performed. Antibiotic susceptibility testing was
performed by agar dilution assay in 14 cases and by disc
diffusion assay in 43 cases. Detection of ermX gene was
performed by using primers Cerm-1 and Cerm-2 according to
the protocol described by Rosato et al. DNA was extracted by
boiling a suspension of bacteria in distilled water. Ampliﬁcation
products were analysed by agarose gel electrophoresis and
molecular weight of the amplicons were calculated by using the
PhotoCapt software (BioGene, USA).
Results: 46 strains were resistant to erythromycin and clinda-
mycin, and 11 were susceptible to both antimicrobials. We
detected the gen ermX in 34 cases (all of them resistant). 12
macrolide-resistant strains gave negative results for ermX
detection. The susceptible strains did not show any ampliﬁca-
tion product.
Conclusions: The ermX gene is detected in 73.9 % of macrolide-
resistant Corynebacterium urealyticum strains. However, there
were 26.1 % macrolide-resistant strains in which ermX gene was
not detected. Other resistance determinants must be involved in
macrolide resistance among Corynebacterium urealyticum.
P1227
Characterisation of phenotype and genotype of
macrolide-resistant Streptococcus pyogenes
C.K. Lee, S.Y. Bae, S.W. Ryu, J.A. Kwon, Y.J. Cho, Y.K. Kim,
K.N. Lee (Seoul, KOR)
Objectives: The resistance of Streptococcus pyogenes to macrolide
is a world wide problem. The aim of present study was to
determine the prevalence of antibiotic resistance rate of eryth-
romycin (EM) resistant isolates from Korea, and evaluate their
genetic mechanism, phenotype distribution and clonal relation-
ship.
Methods: Total 51 EM resistant S. pyogenes from clinical
specimens from 1996 to 2003 were studied; agar dilution
method to determine minimal inhibitory concentrations (MICs)
to 9 antimicrobial agents was performed. Resistance phenotypes
were determined by triple-disc test and resistance induction
experiment with sub- inhibitory concentration of erythromycin
(0.05 lg/ml). Their genetic mechanisms of resistance were
determined by PCR. The genetic relatedness of them was also
investigated by means of emm genotyping and random ampli-
ﬁed polymorphic DNA (RAPD) analysis.
Results: An average EM resistance rate was 23% and their
cross-resistance rate to clarithromycin, azithromycin, and spir-
amycin were 100%, 98%, and 67%, respectively. The most
common resistance phenotype was inducible MLS (iMLS; 51%),
followed by constitutive MLS (cMLS;31%), and M type (18%). 18
of 26 iMLS isolates (69% ) showed novel iMLSd phenotype,
which had small (9–12 mm) inhibition zones around all three
discs on triple-disc test and high level resistance to clinamycin
and spiramycin after erythromycin induction. All isolates of the
cMLSa and iMLSd harboured ermB gene, while iMLSc and M
isolates harboured ermA and mefA gene, respectively. All
iMLSd isolates were emm12 except one while all multidrug
resistance cMLSa isolates were emm28 genotype. iMLSd isolates
made a tight cluster on phylogenetic tree and 78% of them
showed a common pattern by RAPD analysis.
Conclusion: iMLSd was most common macrolide resistance
phenotype in Korea and emm gene and RAPD analysis was
suggestive of its clonal relationship.
P1228
Detection of inducible clindamycin resistance in
cutaneous staphylococci clinical isolates by
phenotypic and genotypic method
L. Merino, M.J. Torres, A. Cantos, M. Ruiz, J. Aznar (Seville, E)
Objectives: To study the inducible clindamycin resistance in
Staphylococcus aureus and Coagulase-Negative Staphylococci by
phenotypic and genotypc methods.
Material and methods: A group of 117 erythromycin-resistant
clinical isolates [(57 S. aureus and 60 coagulase-negative staphy-
lococci (CNS)] from cutaneous samples were selected from
recent (December 2003 to June 2004) 536 clinical isolates of
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Staphylococcus spp. (401 S. aureus and 135 CNS). Identiﬁcation
and susceptibility testing of the isolates were performed with
the MicroScan instrument. The standard NCCLS disk diffusion
test was performed on each isolate using unsupplemented
Mueller–Hinton agar (Becton Dickinson Microbiology Systems,
Cockeysville, Md.) and standard 15-lg erythromycin disks and
2-lg clindamycin disks (Becton Dickinson). On the same agar
plates, two additional pairs of disks were placed by hand to
provide distances of 15 and 20 mm between the respective
erythromycin-clindamycin disk pairs to detect inducible clinda-
mycin resistance. Real-time PCR was performed with oligonu-
cleotide primers speciﬁc for the ermA, ermB, ermC and mrsA
genes as described by Martineau et al (AAC.2000), using
Faststart DNA MasterPlus SYBR Green I.
Results: Twenty-nine (24.8%) S. aureus and 31 (26.5%) CNS of
the 117 erythromycin-resistant clinical isolates were susceptible
to clindamycin, and the remaining 57 (48.7%) isolates were
clindamycin resistant, 40 (34.2%) with inducible resistance (21
S. aureus and 19 CNS), and 17 (14.5%) isolates with constitutive
clindamycin resistance (7 S. aureus and 10 coagulase-negative
staphylococci). The mrsA gene was present in all the clindamy-
cin susceptible isolates except for 1 CNS. Among the 40 isolates
with clindamycin inducible resistance, 37 isolates possess either
ermA or ermC while 1 CNS isolate possess both ermC and
mrsA. One CNS and 1 S. aureus isolates were negative for all the
genes tested. All 17 isolates with constitutive clindamycin
resistance ampliﬁed to any of the genes tested. Among the S.
aureus isolates, 2 have the ermA gene, 4 the ermC and 1 both
ermC and mrsA genes. All the CNS isolates possess the ermC
but 3 of them possess also the mrsA gene (Table 1).
Conclusions: The disk-diffusion test detected all the clindamy-
cin resistant strains, and none of the clindamycin inducible
resistant strains was detected by the Microscan. The ermC gen
was the most prevalent among the clindamycin resistant, in both
CNS and S. aureus isolates.
P1229
Ribosomal protein L22 mutations in Bacillus
anthracis associated with cross-resistance
between macrolide, lincosamide, streptogramin
and ketolide antibiotics
D.J. Farrell, A. Athamna, M. Athamna, D.J. Bast,
E. Rubinstein (London, UK; Kfar-Qaraa, IL; Toronto, CAN;
Tel Hashomer, IL)
Objectives: In vitro selection of resistance and cross-resistance
between macrolide, lincosamide, streptogramin and ketolide
(MLSK) antibiotics in the Sterne and ST-1 strains of B. anthracis
have recently been demonstrated (Athamna A et al., J Antimic-
rob Chemother 2004; 54: 424). The aim of this study was to
determine ribosomal mutations associated with this resistance.
Methods: Primers were designed and used to amplify and
sequence the L4, L22 riboprotein genes and the 11 copies of the
23S rRNA gene using B. anthracis str. Ames complete genome
(GenBank Accession No. NC_003997).
Results: (MICs in mg/L) Two signiﬁcant mutations associated
with resistance were found. A 4 amino acid (AA) insertion (a
tandem duplication of 90MGRA93) into the L22 gene at position
94 was found in the ST-1 strain with a quinupristin/dalfopristin
(Q/D) MIC of 128 selected after 18 passages in Q/D. This strain
was cross-resistant to telithromycin, erythromycin, clarithromy-
cin and clindamycin with MICs of 16, 64, 16 and 8 respectively.
An 8 amino acid insertion (MGRAMGRA) into the L22 gene
(also at position 94) was found in the Sterne strain with a
clarithromycin MIC of 64 after 18 passages in clarithromycin.
This strain was cross-resistant to telithromycin, Q/D, erythro-
mycin and clindamycin with MICs of 16, 8, 32 and 1 respect-
ively.
Conclusions: Tandem duplications of L22 90MGRA93 were
found to be important in MLSK resistance in 2 separate strains
of B. anthracis demonstrating that this locus is important for
resistance development under selective pressure of Q/D and
clarithromycin. Importantly, these mutations were also associ-
ated with cross-resistance to other MLSK antibiotics.
P1230
Horizontal transfer of the MLSB resistance gene
erm(B) between the human pathogen Clostridium
difﬁcile and the ruminal anaerobe Butyrivibrio
ﬁbrisolvens
P. Mastrantonio, F. Barbanti, P. Spigaglia (Rome, I)
Objectives: The aim of this study was to investigate the
possibility of in vitro transfer of the MLSB resistance gene,
erm(B) between the human pathogen Clostridium difﬁcile and the
ruminal commensal Butyrivibrio ﬁbrisolvens.
Methods: The erm(B)-positive C. difﬁcile strain CD51 was used
in ﬁlter matings as donor, whereasthe B. ﬁbrisolvens strain 1.230,
tetracycline resistant, and the B. ﬁbrisolvens strain 2221R,
rifampicin resistant, were used as recipients. The strains were
cultured in M2GSC broth, with 30% of sterile rumen, in
anaerobic conditions and the ﬁlter matings were performed on
sheep blood agar plates, supplemented with hemin (0.1%) and
vitamin K (0.1%). The same medium, supplemented with
erythromycin (20 mcg/ml) and tetracycline (10 mcg/ml), were
used to select the transconjugants. MIC values were assessed by
E-tests. The erm(B) transfer was conﬁrmed by PCR and by
hybridisation assays, using an erm(B) probe on transconjugant
genomes digested with PvuII and with SmaI (PFGE).
Results: The transfer average frequency was 5 · 10)7. MIC
values for erythromycin were >256 mg/l both in donor and
transconjugants. An internal fragment of the erm(B) gene
(730 bp) was ampliﬁed in all the transconjugants and a speciﬁc
band was visualised in hybridisation assays on transconjugant
genomes digested with both PvuII and SmaI. The re-transfer of
the erm(B) gene from B. ﬁbrisolvens transconjugants to C. difﬁcile
1977, an erythromycin susceptible strain, was also obtained.
Conclusion: The in vitro transfer of the MLSB resistance gene
erm(B) from C. difﬁcile to B. ﬁbrisolvens and vice-versa, is an
important result supporting the possibility that horizontal
transfer of resistant genes between human pathogenic bacteria
and animal commensal microorganisms could occur, under
natural conditions, more easily than expected.
Table 1. Resistance genotype of 117 erythromycin resistant
cutaneous isolates of S. aureus and CNS
No. of isolates with genotype
Organims and phenotype no. of isolates ermA ermB ermC mrsA ermC/mrsA others
S. aureus 57 4 0 22 29 1 1
CS 29 0 0 0 29 0 0
CRind 21 2 0 18 0 0 1
CRconst 7 2 0 4 0 1 0
CNS 60 0 0 24 30 4 2
CS 31 0 0 0 30 0 1
CRind 19 0 0 17 0 1 1
CRconst 10 0 0 7 0 3 0
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